Physical O O
mapping O O
220 O O
kb O O
centromeric O O
of O O
the O O
human B B_GENE/B_LOCATION
MHC I I_GENE/I_LOCATION
and O O
DNA O O
sequence O O
analysis O O
of O O
the O O
43 O O
- O O
kb O O
segment O O
including O O
the O O
RING1 B B_GENE
, O O
HKE6 B B_GENE/B_BACTERIUM[BIO]
, O O
and O O
HKE4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

DNA O O
elements O O
recognizing O O
NF B B_GENE
- I I_GENE
Y I I_GENE
and O O
Sp1 B B_GENE
regulate O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
multidrug I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resistance I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

As O O
tat B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
itself O O
dramatically O O
increases O O
HIV O O
- O O
1 O O
gene O O
expression O O
, O O
it O O
too O O
is O O
presumably O O
regulated O O
in O O
the O O
latent O O
state O O
, O O
and O O
may O O
also O O
be O O
activated O O
by O O
mitogenic O O
stimulation O O
. O O

To O O
clarify O O
the O O
difference O O
, O O
both O O
the O O
Crk B B_GENE/B_BIO
II I I_GENE/I_BIO
and O O
Crk B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
23 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
proteins O O
were O O
expressed O O
in O O
E O O
. O O
coli O O
and O O
examined O O
their O O
binding O O
capacity O O
in O O
vitro O O
. O O

CONCLUSIONS O O
: O O
Systemic O O
factors O O
that O O
increase O O
bone O O
mineral O O
density O O
appear O O
to O O
be O O
involved O O
in O O
the O O
pathogenesis O O
of O O
ossification O O
of O O
the O O
posterior O O
longitudinal O O
ligament O O
, O O
and O O
these O O
factors O O
may O O
be O O
activated O O
after O O
middle O O
age O O
. O O

Thus O O
, O O
in O O
V O O
. O O
furnissii O O
, O O
the O O
E B B_GENE/B_BACTERIUM[BIO]
. I I_GENE/I_BACTERIUM[BIO]
coli I I_GENE/I_BACTERIUM[BIO]
manX I I_GENE/I_BACTERIUM[BIO]
equivalent I I_GENE/I_BACTERIUM[BIO]
comprises O O
two O O
genes O O
, O O
which O O
are O O
separated O O
in O O
the O O
genome O O
by O O
two O O
other O O
genes O O
of O O
the O O
ptsM B B_PROTEIN[GENE]/B_BIO
complex I I_PROTEIN[GENE]/I_BIO
. O O

Id B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1H I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Id B B_PROTEIN[GENE]
- I I_PROTEIN[GENE]
2H I I_PROTEIN[GENE]
seem O O
to O O
be O O
human O O
homologues O O
of O O
mouse B B_GENE/B_DISEASE
Id I I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
and O O
Id B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
2 I I_PROTEIN[GENE]/I_MEASURE
, O O
respectively O O
, O O
and O O
have O O
potential O O
to O O
encode O O
154 O O
and O O
135 O O
amino O O
acid O O
proteins O O
. O O

Characterization O O
of O O
insertion O O
mutations O O
in O O
the O O
Saccharomyces B B_GENE/B_DISEASE
cerevisiae I I_GENE/I_DISEASE
MSH1 I I_GENE/I_DISEASE
and O O
MSH2 B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
: O O
evidence O O
for O O
separate O O
mitochondrial O O
and O O
nuclear O O
functions O O
. O O

Transcription O O
of O O
FN B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
chloramphenicol B B_GENE/B_DISEASE
acetyltransferase I I_GENE/I_DISEASE
fusion O O
genes O O
carrying O O
the O O
base O O
substitution O O
in O O
one O O
or O O
more O O
of O O
these O O
G O O
- O O
rich O O
sequences O O
both O O
in O O
vivo O O
and O O
in O O
vitro O O
revealed O O
that O O
the O O
base O O
substitution O O
in O O
any O O
G O O
- O O
rich O O
sequence O O
results O O
in O O
reduction O O
of O O
promoter O O
activity O O
, O O
although O O
the O O
downstream O O
GC O O
box O O
( O O
GCd O O
) O O
plays O O
a O O
primary O O
role O O
. O O

Morphologically O O
, O O
corrugation O O
of O O
the O O
internal O O
elastic O O
lamina O O
of O O
vessels O O
was O O
often O O
observed O O
in O O
the O O
vehicle O O
- O O
treated O O
group O O
, O O
but O O
was O O
not O O
prominent O O
in O O
the O O
GLNVA O O
- O O
treated O O
groups O O
or O O
healthy O O
controls O O
. O O

A O O
GT O O
- O O
rich O O
sequence O O
binding O O
the O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
Sp1 I I_GENE/I_LOCATION
is O O
crucial O O
for O O
high O O
expression O O
of O O
the O O
human B B_GENE
type I I_GENE
VII I I_GENE
collagen I I_GENE
gene I I_GENE
( O O
COL7A1 B B_GENE/B_LOCATION
) O O
in O O
fibroblasts O O
and O O
keratinocytes O O
. O O

Each O O
received O O
20 O O
mL O O
of O O
one O O
of O O
three O O
test O O
solutions O O
: O O
levobupivacaine O O
control O O
, O O
levobupivacaine O O
and O O
fentanyl O O
2 O O
microg O O
/ O O
mL O O
, O O
or O O
levobupivacaine O O
and O O
fentanyl O O
3 O O
microg O O
/ O O
mL O O
. O O

The O O
XPR2 B B_GENE
gene I I_GENE
from O O
Yarrowia O O
lipolytica O O
encodes O O
an O O
inducible O O
alkaline B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
extracellular I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protease I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

CONCLUSIONS O O
: O O
This O O
study O O
shows O O
that O O
the O O
annual O O
rate O O
of O O
de O O
novo O O
aneurysm O O
formation O O
is O O
relatively O O
high O O
( O O
0 O O
. O O
89 O O
% O O
) O O
and O O
that O O
the O O
cumulative O O
risk O O
becomes O O
significant O O
after O O
9 O O
years O O
. O O

It O O
was O O
found O O
that O O
Nopp140 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binds O O
primarily O O
to O O
the O O
CK2 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
regulatory I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
subunit I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
beta I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Juvenile O O
idiopathic O O
inflammatory O O
myopathies O O
: O O
the O O
value O O
of O O
magnetic O O
resonance O O
imaging O O
in O O
the O O
detection O O
of O O
muscle O O
involvement O O
. O O

Combined O O
chemotherapy O O
with O O
VM O O
26 O O
and O O
BCNU O O
for O O
recurrent O O
malignant O O
gliomas O O
after O O
operation O O
and O O
irradiation O O
. O O

Like O O
other O O
IAPs B B_BIO/B_GENE
, O O
ch B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
IAP1 I I_GENE/I_DISEASE
contains O O
the O O
N B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
terminal I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
baculovirus I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
IAP I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
repeats I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
and O O
C O O
- O O
terminal O O
RING O O
finger O O
motifs O O
. O O

Effects O O
of O O
long O O
- O O
term O O
use O O
of O O
raloxifene O O
, O O
a O O
selective O O
estrogen B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modulator O O
, O O
on O O
thyroid O O
function O O
test O O
profiles O O
. O O

The O O
donors O O
of O O
10 O O
patients O O
were O O
ABO O O
- O O
incompatible O O
, O O
and O O
for O O
five O O
pairs O O
the O O
ABO O O
incompatibility O O
was O O
major O O
. O O

Alternative O O
splicing O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
serotonin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Interestingly O O
, O O
basal O O
MAPK B B_GENE
, O O
but O O
not O O
Raf B B_GENE
- I I_GENE
1 I I_GENE
, O O
activity O O
was O O
constitutively O O
enhanced O O
in O O
Jak1 B B_GENE
- O O
deficient O O
HeLa O O
cells O O
. O O

This O O
case O O
report O O
describes O O
the O O
treatment O O
of O O
a O O
patient O O
with O O
periodontosis O O
. O O

The O O
aim O O
of O O
this O O
work O O
was O O
to O O
organize O O
chemical O O
data O O
in O O
a O O
client O O
- O O
server O O
environment O O
using O O
Database O O
Management O O
System O O
and O O
Web O O
fashion O O
for O O
the O O
client O O
interface O O
. O O

Cerumen O O
management O O
in O O
hearing O O
conservation O O
: O O
the O O
Dallas O O
( O O
Texas O O
) O O
Independent O O
School O O
District O O
program O O
. O O

Lactate O O
, O O
pyruvate O O
and O O
actual O O
pH O O
values O O
in O O
the O O
venous O O
blood O O
of O O
newborn O O
calves O O

This O O
article O O
focuses O O
on O O
a O O
general O O
approach O O
to O O
the O O
use O O
of O O
ARV O O
agents O O
. O O

Platelets O O
and O O
RBCs O O
from O O
each O O
animal O O
were O O
labeled O O
with O O
51Cr O O
and O O
99mTc O O
, O O
respectively O O
, O O
and O O
were O O
rapidly O O
injected O O
into O O
the O O
right O O
atrium O O
while O O
blood O O
was O O
sampled O O
from O O
the O O
ascending O O
aorta O O
. O O

Protection O O
levels O O
of O O
33 O O
. O O
3 O O
% O O
, O O
36 O O
. O O
6 O O
% O O
and O O
37 O O
. O O
0 O O
% O O
were O O
achieved O O
in O O
groups O O
which O O
had O O
received O O
, O O
respectively O O
, O O
1000 O O
20 O O
- O O
krad O O
cercariae O O
, O O
1000 O O
10 O O
- O O
krad O O
cercariae O O
, O O
2000 O O
40 O O
- O O
krad O O
cercariae O O
and O O
2000 O O
60 O O
- O O
krad O O
cercariae O O
. O O

Thus O O
, O O
primate O O
vs O O
. O O
rodent O O
promoter O O
selectivity O O
mediated O O
by O O
the O O
TBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
TAFI B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex O O
is O O
likely O O
to O O
be O O
the O O
result O O
of O O
cumulative O O
subtle O O
differences O O
between O O
individual O O
subunits O O
that O O
lead O O
to O O
species O O
- O O
specific O O
properties O O
of O O
RNA B B_GENE/B_BIO
polymerase I I_GENE/I_BIO
I I I_GENE/I_BIO
transcription O O
. O O

When O O
gene O O
conversion O O
is O O
initiated O O
by O O
a O O
double O O
- O O
strand O O
break O O
( O O
DSB O O
) O O
, O O
any O O
nonhomologous O O
DNA O O
that O O
may O O
be O O
present O O
at O O
the O O
ends O O
must O O
be O O
removed O O
before O O
new O O
DNA O O
synthesis O O
can O O
be O O
initiated O O
. O O

In O O
this O O
reconstituted O O
system O O
, O O
RNAP B B_GENE
IIA I I_GENE
, O O
but O O
not O O
RNAP B B_PROTEIN[GENE]/B_LOCATION
IIB I I_PROTEIN[GENE]/I_LOCATION
, O O
can O O
transcribe O O
from O O
the O O
DHFR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

FTF O O
( O O
Joint O O
Council O O
of O O
Civil O O
Servants O O
and O O
Functionaries O O
) O O
: O O
clarification O O
about O O
membership O O
in O O
the O O
main O O
organizations O O

Synergy O O
between O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gamma I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
transcriptional O O
activation O O
is O O
mediated O O
by O O
cooperation O O
between O O
signal B B_GENE
transducer I I_GENE
and I I_GENE
activator I I_GENE
of I I_GENE
transcription I I_GENE
1 I I_GENE
and O O
nuclear B B_GENE
factor I I_GENE
kappaB I I_GENE
. O O

1H O O
and O O
15N O O
magnetic O O
resonance O O
assignments O O
, O O
secondary O O
structure O O
, O O
and O O
tertiary O O
fold O O
of O O
Escherichia B B_GENE/B_BACTERIUM[BIO]
coli I I_GENE/I_BACTERIUM[BIO]
DnaJ I I_GENE/I_BACTERIUM[BIO]
( I I_GENE/I_BACTERIUM[BIO]
1 I I_GENE/I_BACTERIUM[BIO]
- I I_GENE/I_BACTERIUM[BIO]
78 I I_GENE/I_BACTERIUM[BIO]
) I I_GENE/I_BACTERIUM[BIO]
. O O

A O O
cDNA O O
for O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
microfibril I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycoprotein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAGP B B_GENE
- I I_GENE
2 I I_GENE
) O O
was O O
used O O
to O O
screen O O
a O O
human O O
leukocyte O O
genomic O O
DNA O O
library O O
in O O
EMBL O O
- O O
3 O O
vector O O
. O O

Furthermore O O
, O O
ERK B B_GENE
phosphorylation O O
was O O
substantially O O
prolonged O O
in O O
LC O O
/ O O
BRY O O
- O O
treated O O
cells O O
compared O O
to O O
those O O
exposed O O
to O O
BRY O O
alone O O
, O O
and O O
pretreatment O O
with O O
the O O
highly O O
specific O O
MEK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitors O O
, O O
PD98059 O O
, O O
U0126 O O
, O O
and O O
SL327 O O
, O O
opposed O O
ERK B B_GENE
activation O O
while O O
protecting O O
cells O O
from O O
LC O O
/ O O
BRY O O
- O O
induced O O
lethality O O
. O O

The O O
cholesterol B B_GENE
7alpha I I_GENE
- I I_GENE
hydroxylase I I_GENE
gene I I_GENE
( O O
CYP7A B B_GENE/B_LOCATION
) O O
is O O
transcriptionally O O
regulated O O
by O O
a O O
number O O
of O O
factors O O
, O O
including O O
hormones O O
, O O
bile O O
acids O O
, O O
and O O
diurnal O O
rhythm O O
. O O

CNS O O
preventive O O
treatment O O
without O O
cranial O O
irradiation O O
was O O
effective O O
in O O
all O O
the O O
groups O O
of O O
ALL O O
patients O O
. O O

Additionally O O
, O O
the O O
members O O
of O O
this O O
family O O
display O O
strong O O
sequence O O
homologies O O
between O O
their O O
larger O O
C O O
- O O
terminal O O
effector O O
binding O O
/ O O
oligomerization O O
domains O O
. O O

Aspartame O O
is O O
a O O
synthetic O O
sweetener O O
commonly O O
used O O
in O O
soft O O
drinks O O
and O O
many O O
foods O O
. O O

The O O
rat O O
anococcygeus O O
muscle O O
was O O
used O O
in O O
postsynaptic O O
studies O O
. O O

The O O
purpose O O
of O O
this O O
presentation O O
is O O
to O O
review O O
the O O
current O O
state O O
of O O
knowledge O O
regarding O O
5 O O
, O O
8 O O
, O O
11 O O
, O O
14 O O
- O O
eicosatetraynoic O O
acid O O
( O O
ETYA O O
, O O
Ro O O
3 O O
- O O
1428 O O
) O O
and O O
its O O
effects O O
on O O
lipid O O
metabolism O O
. O O

A O O
Meis1 B B_GENE/B_DISEASE
cDNA I I_GENE/I_DISEASE
clone O O
that O O
encoded O O
a O O
novel O O
member O O
of O O
the O O
homeobox B B_GENE/B_BIO
gene I I_GENE/I_BIO
family I I_GENE/I_BIO
was O O
identified O O
. O O

The O O
levels O O
of O O
soluble O O
L B B_GENE
- I I_GENE
selectin I I_GENE
and O O
ICAM B B_GENE
- I I_GENE
1 I I_GENE
in O O
the O O
serum O O
were O O
determined O O
by O O
the O O
ELISA O O
method O O
. O O

On O O
the O O
other O O
hand O O
hypokalemia O O
, O O
induced O O
by O O
diuretics O O
, O O
may O O
also O O
be O O
accompanied O O
by O O
a O O
significant O O
depletion O O
of O O
total O O
body O O
K O O
, O O
bringing O O
about O O
more O O
general O O
consequences O O
. O O

Glutathione B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reductase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activities O O
in O O
liver O O
, O O
kidney O O
, O O
lung O O
, O O
and O O
brain O O
were O O
not O O
affected O O
by O O
diet O O
. O O

Here O O
, O O
we O O
describe O O
the O O
nucleotide O O
( O O
nt O O
) O O
sequence O O
and O O
genomic O O
organization O O
of O O
ipiB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
ipiO B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Vancomycin O O
and O O
tetracycline O O
eliminated O O
toxin O O
in O O
stools O O
and O O
delayed O O
death O O
. O O

Comparison O O
to O O
the O O
murine O O
homologues O O
of O O
these O O
molecules O O
reveals O O
a O O
high O O
degree O O
of O O
conservation O O
between O O
the O O
products O O
of O O
one O O
of O O
these O O
genes O O
, O O
Fc B B_GENE
gamma I I_GENE
RIIb I I_GENE
, O O
and O O
the O O
murine B B_GENE/B_MEASURE
beta I I_GENE/I_MEASURE
gene I I_GENE/I_MEASURE
in O O
primary O O
sequence O O
, O O
splicing O O
pattern O O
, O O
and O O
tissue O O
distribution O O
. O O

Acidosis O O
provoked O O
by O O
30 O O
% O O
CO2 O O
irreversibly O O
increased O O
the O O
BDRT O O
, O O
however O O
the O O
TRT O O
were O O
not O O
changed O O
. O O

Others O O
as O O
for O O
example O O
C O O
- O O
11 O O
labeled O O
short O O
chain O O
fatty O O
acids O O
are O O
on O O
the O O
horizon O O
. O O

The O O
average O O
progression O O
was O O
11 O O
. O O
6 O O
( O O
SD O O
9 O O
. O O
0 O O
) O O
. O O

80 O O
bp O O
) O O
surrounding O O
the O O
site O O
of O O
transcription O O
initiation O O
. O O

Ultrastructure O O
and O O
toxin O O
formation O O
of O O
Cor O O
. O O
diphtheriae O O
PW O O
- O O
8 O O
cultured O O
in O O
the O O
presence O O
of O O
penicillin O O

EMT B B_GENE/B_DISEASE
was O O
localized O O
to O O
chromosome O O
5q31 O O
- O O
32 O O
, O O
a O O
region O O
that O O
contains O O
the O O
genes O O
for O O
several O O
growth O O
factors O O
and O O
receptors O O
as O O
well O O
as O O
early O O
activation O O
genes O O
, O O
particularly O O
those O O
involved O O
in O O
the O O
hematopoietic O O
system O O
. O O

Tbx6 B B_GENE/B_DISEASE
maps O O
to O O
chromosome O O
7 O O
and O O
does O O
not O O
appear O O
to O O
be O O
linked O O
to O O
any O O
known O O
mutation O O
. O O

Kaposi O O
' O O
s O O
eruptive O O
disease O O
. O O

It O O
is O O
not O O
tested O O
yet O O
, O O
whether O O
the O O
extent O O
of O O
glaucoma O O
damage O O
should O O
be O O
better O O
quantified O O
using O O
reference O O
plane O O
1 O O
or O O
2 O O
. O O

Importin B B_GENE/B_LOCATION
beta I I_GENE/I_LOCATION
mediates O O
nuclear O O
translocation O O
of O O
Smad B B_GENE
3 I I_GENE
. O O

The O O
encoded O O
protein O O
contains O O
an O O
amino O O
terminal O O
PDZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
domain O O
, O O
followed O O
by O O
a O O
predicted O O
coiled O O
- O O
coil O O
region O O
, O O
a O O
PEST O O
domain O O
, O O
and O O
a O O
carboxy O O
- O O
terminal O O
SAM O O
domain O O
. O O

Using O O
lasers O O
, O O
PRK O O
involves O O
reshaping O O
the O O
cornea O O
so O O
that O O
its O O
refractive O O
power O O
is O O
increased O O
. O O

However O O
, O O
sphincter O O
length O O
decreased O O
with O O
age O O
from O O
24 O O
. O O
3 O O
to O O
14 O O
. O O
8 O O
mm O O
. O O
, O O
maximal O O
urethral O O
pressure O O
from O O
88 O O
. O O
7 O O
to O O
55 O O
cm O O
. O O
water O O
and O O
maximal O O
urethral O O
pressure O O
during O O
voluntary O O
contraction O O
from O O
221 O O
. O O
4 O O
to O O
166 O O
. O O
3 O O
cm O O
. O O
water O O
. O O

Transcription O O
initiation O O
from O O
this O O
region O O
was O O
also O O
detected O O
in O O
vivo O O
, O O
when O O
the O O
cloned O O
rRNA O O
gene O O
cluster O O
was O O
present O O
on O O
a O O
multi O O
- O O
copy O O
plasmid O O
. O O

The O O
results O O
of O O
the O O
transient O O
- O O
transfection O O
assay O O
showed O O
that O O
the O O
Sp1 B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
element I I_GENE/I_LOCATION
located O O
in O O
the O O
core O O
region O O
( O O
positions O O
- O O
- O O
64 O O
to O O
+ O O
1 O O
) O O
of O O
the O O
alpha2 B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
integrin I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
plays O O
an O O
essential O O
role O O
in O O
the O O
alpha2 B B_GENE
- I I_GENE
integrin I I_GENE
promoter I I_GENE
activity O O
and O O
its O O
downregulation O O
by O O
Erb B B_GENE/B_DISEASE
- O O
B2 B B_PROTEIN[GENE]
. O O

Principal O O
component O O
analysis O O
using O O
psychosocial O O
factors O O
in O O
women O O
showed O O
two O O
psychosocial O O
structures O O
, O O
i O O
. O O
e O O
. O O
the O O
second O O
principal O O
( O O
high O O
SOC O O
, O O
high O O
lifestyle O O
, O O
and O O
low O O
stress O O
) O O
and O O
the O O
4th O O
principal O O
components O O
( O O
high O O
supernatural O O
HLC O O
, O O
and O O
high O O
PHLC O O
) O O
. O O

Expression O O
of O O
FNCAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O O
on O O
serum O O
treatment O O
indicating O O
that O O
the O O
region O O
of O O
the O O
FN B B_GENE
gene I I_GENE
between O O
positions O O
+ O O
69 O O
and O O
- O O
510 O O
bp O O
mediated O O
serum O O
responsiveness O O
. O O

Interaction O O
of O O
the O O
v B B_GENE
- I I_GENE
rel I I_GENE
protein I I_GENE
with O O
an O O
NF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
kappa I I_GENE/I_LOCATION
B I I_GENE/I_LOCATION
DNA I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
. O O

This O O
increase O O
is O O
not O O
the O O
result O O
of O O
alterations O O
in O O
the O O
deposition O O
of O O
inhaled O O
particles O O
of O O
capsaicin O O
brought O O
about O O
by O O
volume O O
restriction O O
. O O

Providing O O
appropriate O O
care O O
to O O
both O O
sexes O O
. O O

In O O
the O O
green O O
unicellular O O
alga O O
Chlamydomonas O O
eugametos O O
, O O
cellular O O
division O O
is O O
readily O O
synchronized O O
by O O
light O O
/ O O
dark O O
cycles O O
. O O

SHBG B B_GENE
concentrations O O
in O O
women O O
were O O
also O O
significantly O O
higher O O
at O O
T O O
- O O
2 O O
and O O
T O O
- O O
3 O O
when O O
compared O O
to O O
T O O
- O O
1 O O
values O O
. O O

The O O
more O O
severe O O
the O O
CRF O O
, O O
the O O
more O O
likely O O
that O O
total O O
HDL B B_GENE
and O O
HDL2 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cholesterol I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
low O O
. O O

They O O
are O O
growth O O
- O O
inhibited O O
by O O
TGF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

To O O
investigate O O
the O O
in O O
vivo O O
role O O
of O O
this O O
chimeric B B_GENE/B_MEASURE
bZIP I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
in O O
oncogenic O O
transformation O O
, O O
its O O
expression O O
was O O
directed O O
to O O
the O O
lymphoid O O
compartments O O
of O O
transgenic O O
mice O O
. O O

This O O
is O O
consistent O O
with O O
the O O
need O O
for O O
a O O
nuclear O O
retinoid B B_GENE
receptor I I_GENE
function O O
in O O
RA O O
- O O
induced O O
ERK2 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
. O O

In O O
the O O
virus O O
- O O
infected O O
cells O O
, O O
translation O O
of O O
the O O
M1 B B_GENE
protein I I_GENE
was O O
reduced O O
to O O
10 O O
to O O
20 O O
% O O
of O O
that O O
of O O
the O O
wild O O
- O O
type O O
virus O O
; O O
however O O
, O O
the O O
translation O O
of O O
neither O O
the O O
nucleoprotein O O
nor O O
NS1 B B_GENE/B_BIO
was O O
significantly O O
interfered O O
with O O
, O O
indicating O O
the O O
important O O
role O O
of O O
NS1 B B_GENE/B_BIO
in O O
translational O O
stimulation O O
of O O
the O O
M1 B B_GENE/B_BIO
protein I I_GENE/I_BIO
. O O

Some O O
cells O O
were O O
excited O O
, O O
others O O
inhibited O O
by O O
, O O
and O O
only O O
some O O
were O O
directionally O O
sensitive O O
to O O
the O O
optomotor O O
stimulus O O
. O O

LT B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
beta I I_GENE/I_DISEASE
transcription O O
is O O
maximal O O
in O O
the O O
thymic O O
medulla O O
and O O
in O O
splenic O O
white O O
pulp O O
. O O

Interactions O O
were O O
also O O
detected O O
between O O
full O O
- O O
length O O
HSF1 B B_GENE
and O O
the O O
small O O
subunit O O
( O O
gamma O O
) O O
of O O
TFIIA B B_GENE
. O O

We O O
report O O
that O O
Nim1 B B_GENE
possesses O O
intrinsic O O
serine B B_ENZYME[GENE]
- I I_ENZYME[GENE]
kinase I I_ENZYME[GENE]
, O O
threonine B B_ENZYME[GENE]
- I I_ENZYME[GENE]
kinase I I_ENZYME[GENE]
and O O
tyrosine B B_ENZYME[GENE]
- I I_ENZYME[GENE]
kinase I I_ENZYME[GENE]
activities O O
. O O

A O O
short O O
conserved O O
motif O O
is O O
required O O
for O O
repressor O O
domain O O
function O O
in O O
the O O
myeloid O O
- O O
specific O O
transcription O O
factor O O
CCAAT B B_GENE/B_LOCATION
/ I I_GENE/I_LOCATION
enhancer I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
epsilon I I_GENE/I_LOCATION
. O O

Androgen O O
ablation O O
- O O
- O O
50 O O
years O O
later O O
. O O

In O O
conclusion O O
, O O
ORCA3 B B_GENE
regulates O O
jasmonate O O
- O O
responsive O O
expression O O
of O O
the O O
Str B B_GENE/B_BIO
gene I I_GENE/I_BIO
via O O
direct O O
interaction O O
with O O
the O O
JERE O O
. O O

Also O O
, O O
the O O
absence O O
of O O
PdNi O O
between O O
the O O
segments O O
reduces O O
the O O
heat O O
production O O
of O O
the O O
seed O O
. O O

Theoretical O O
mechanisms O O
of O O
hyperuricemia O O
. O O

ORF3 O O
encodes O O
a O O
putative O O
periplasmic B B_ENZYME[GENE]
c I I_ENZYME[GENE]
- I I_ENZYME[GENE]
type I I_ENZYME[GENE]
cytochrome I I_ENZYME[GENE]
with O O
a O O
molecular O O
mass O O
of O O
94 O O
, O O
000 O O
Da O O
and O O
contains O O
seven O O
c O O
- O O
heme O O
- O O
binding O O
motifs O O
but O O
shows O O
no O O
sequence O O
homology O O
to O O
occ B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
ORF1 O O
. O O

Doxazosin O O
produced O O
increases O O
in O O
both O O
mean O O
and O O
maximum O O
urinary O O
flow O O
rates O O
of O O
1 O O
. O O
01 O O
ml O O
/ O O
s O O
and O O
3 O O
. O O
2 O O
ml O O
/ O O
s O O
respectively O O
, O O
compared O O
with O O
0 O O
. O O
21 O O
ml O O
/ O O
s O O
and O O
2 O O
. O O
2 O O
ml O O
/ O O
s O O
on O O
placebo O O
. O O

Hypoxia O O
decreased O O
the O O
rate O O
of O O
spontaneous O O
impulse O O
initiation O O
in O O
SA O O
nodal O O
fibers O O
by O O
decreasing O O
the O O
slope O O
of O O
diastolic O O
depolarization O O
. O O

TFEC B B_GENE/B_BIO
RNA I I_GENE/I_BIO
is O O
found O O
in O O
many O O
tissues O O
of O O
adult O O
rats O O
, O O
but O O
the O O
relative O O
concentrations O O
of O O
TFEC B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
TFE3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
vary O O
considerably O O
in O O
these O O
different O O
tissues O O
. O O

Studies O O
of O O
HS2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gamma I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gene I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
reporter I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
constructs I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
carrying O O
CACCC O O
box O O
deletions O O
revealed O O
that O O
the O O
CACCC O O
box O O
sequence O O
of O O
the O O
gamma O O
gene O O
promoter O O
mediates O O
the O O
activation O O
of O O
the O O
gamma O O
gene O O
by O O
FKLF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Advisory O O
Committee O O
report O O
recommends O O
that O O
US O O
make O O
amends O O
for O O
human O O
radiation O O
experiments O O
. O O

Animals O O
were O O
divided O O
into O O
six O O
equal O O
groups O O
as O O
follows O O
: O O
( O O
1 O O
) O O
no O O
oral O O
drug O O
( O O
water O O
) O O
, O O
no O O
hemodilution O O
, O O
no O O
IV O O
drug O O
( O O
saline O O
) O O
; O O
( O O
2 O O
) O O
oral O O
water O O
, O O
hemodilution O O
, O O
IV O O
saline O O
; O O
( O O
3 O O
) O O
oral O O
water O O
, O O
no O O
hemodilution O O
, O O
IV O O
propranolol O O
; O O
( O O
4 O O
) O O
oral O O
water O O
, O O
hemodilution O O
, O O
IV O O
propranolol O O
; O O
( O O
5 O O
) O O
oral O O
propranolol O O
, O O
no O O
hemodilution O O
, O O
IV O O
saline O O
; O O
and O O
( O O
6 O O
) O O
oral O O
propranolol O O
, O O
hemodilution O O
, O O
IV O O
saline O O
. O O

First O O
, O O
a O O
GATA B B_GENE
- I I_GENE
1 I I_GENE
motif I I_GENE
was O O
found O O
to O O
bind O O
nuclear O O
factor O O
( O O
s O O
) O O
, O O
presumably O O
the O O
GATA B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
, O O
present O O
in O O
K O O
- O O
562 O O
cell O O
extracts O O
and O O
in O O
living O O
K O O
- O O
562 O O
cells O O
. O O

BPN O O
can O O
be O O
experimentally O O
produced O O
by O O
intratracheal O O
inoculation O O
of O O
microorganisms O O
in O O
high O O
concentrations O O
and O O
ventilator O O
- O O
associated O O
BPN O O
by O O
ventilating O O
baboons O O
with O O
oleic O O
- O O
acid O O
lung O O
injury O O
. O O

A O O
mouth O O
asymmetry O O
study O O
. O O

Additionally O O
, O O
these O O
findings O O
have O O
important O O
implications O O
for O O
the O O
understanding O O
of O O
the O O
mechanisms O O
of O O
HIV O O
- O O
1 O O
latency O O
and O O
reactivation O O
. O O

Diet O O
imbalances O O
and O O
aflatoxicosis O O

48 O O
. O O
35 O O
+ O O
/ O O
- O O
5 O O
. O O
07 O O
mg O O
/ O O
l O O
in O O
R3 O O
; O O
p O O
< O O
0 O O
. O O
05 O O
) O O
and O O
in O O
the O O
AUC O O
( O O
0 O O
. O O
50 O O
h O O
) O O
( O O
1429 O O
. O O
92 O O
+ O O
/ O O
- O O
284 O O
. O O
23 O O
in O O
PR O O
vs O O
. O O

As O O
part O O
of O O
a O O
large O O
Dutch O O
prospective O O
multicenter O O
study O O
( O O
Netherlands O O
Cooperative O O
Study O O
on O O
the O O
Adequacy O O
of O O
Dialysis O O
- O O
2 O O
) O O
, O O
we O O
consecutively O O
included O O
all O O
new O O
patients O O
with O O
end O O
- O O
stage O O
renal O O
disease O O
for O O
whom O O
residual O O
renal O O
function O O
could O O
be O O
obtained O O
0 O O
to O O
4 O O
weeks O O
before O O
the O O
start O O
of O O
dialysis O O
therapy O O
. O O

In O O
murine O O
cells O O
, O O
FPGS B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
is O O
controlled O O
by O O
two O O
promoters O O
that O O
, O O
as O O
we O O
show O O
here O O
, O O
vary O O
substantially O O
in O O
their O O
efficiency O O
, O O
at O O
least O O
in O O
the O O
context O O
of O O
a O O
reporter O O
gene O O
assay O O
. O O

Should O O
we O O
use O O
thiazide O O
diuretics O O
in O O
hypertensive O O
patients O O
with O O
non O O
- O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O O
diabetes O O
mellitus O O
? O O

Reduced O O
glutathione O O
in O O
whole O O
blood O O
decreases O O
within O O
a O O
blood O O
Se O O
range O O
of O O
1 O O
. O O
01 O O
to O O
2 O O
. O O
28 O O
micrograms O O
in O O
the O O
high O O
Se O O
area O O
. O O

Sucrose O O
produced O O
in O O
source O O
leaves O O
is O O
the O O
predominant O O
carbon O O
source O O
for O O
developing O O
sink O O
tissues O O
in O O
most O O
higher O O
plants O O
. O O

A O O
personal O O
view O O
of O O
future O O
trends O O
in O O
the O O
field O O
of O O
immunoassay O O
concludes O O
this O O
review O O
. O O

Numerous O O
genes O O
of O O
this O O
family O O
have O O
been O O
identified O O
in O O
animals O O
, O O
with O O
the O O
largest O O
number O O
found O O
in O O
vertebrates O O
. O O

The O O
GST B B_GENE/B_BIO
- O O
CBL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
LZIP B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion O O
protein O O
contains O O
a O O
binding O O
site O O
for O O
the O O
SH2 B B_PROTEIN[GENE]
domain I I_PROTEIN[GENE]
of O O
the O O
p85 B B_ENZYME[GENE]/B_PERSON
subunit I I_ENZYME[GENE]/I_PERSON
of O O
phosphatidylinositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
mapped O O
to O O
Tyr731 O O
, O O
which O O
is O O
present O O
in O O
the O O
sequence O O
YEAM O O
. O O

We O O
have O O
previously O O
shown O O
that O O
UNC B B_GENE
- I I_GENE
4 I I_GENE
expression O O
in O O
the O O
VA O O
motor O O
neurons O O
specifies O O
the O O
wild O O
- O O
type O O
pattern O O
of O O
presynaptic O O
input O O
. O O

Significant O O
differences O O
were O O
observed O O
in O O
the O O
composition O O
of O O
nuclear O O
transcription O O
factors O O
bound O O
to O O
cis O O
- O O
elements O O
within O O
the O O
LDH B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proximal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
somatic O O
versus O O
germ O O
cells O O
. O O

Above O O
this O O
transition O O
temperature O O
the O O
calcium O O
antagonist O O
lowers O O
fm O O
more O O
pronouncedly O O
than O O
below O O
. O O

( O O
1986 O O
) O O
described O O
optic O O
nerve O O
degenerations O O
in O O
patients O O
with O O
Alzheimer O O
' O O
s O O
disease O O
and O O
Sadun O O
published O O
a O O
dropout O O
of O O
retinal O O
ganglion O O
cells O O
that O O
range O O
from O O
30 O O
% O O
to O O
60 O O
% O O
. O O

It O O
has O O
become O O
clear O O
that O O
there O O
is O O
not O O
one O O
mediator O O
responsible O O
for O O
ALI O O
, O O
but O O
rather O O
a O O
complex O O
interplay O O
exists O O
between O O
diverse O O
proinflammatory O O
( O O
e O O
. O O
g O O
. O O
, O O
lipopolysaccharide O O
, O O
complement O O
products O O
, O O
cytocains O O
, O O
chemocains O O
, O O
reactive O O
oxygen O O
species O O
and O O
arachidonic O O
acid O O
products O O
) O O
and O O
anti O O
- O O
inflammatory O O
( O O
IL B B_GENE
- I I_GENE
10 I I_GENE
, O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
PGI2 O O
) O O
mediators O O
. O O

We O O
then O O
supplemented O O
these O O
spliceosomes O O
with O O
purified O O
proteins O O
or O O
yeast O O
extract O O
fractions O O
as O O
a O O
functional O O
assay O O
for O O
second O O
- O O
step O O
splicing O O
factors O O
. O O

Contrast O O
radiography O O
appears O O
to O O
be O O
an O O
especially O O
inaccurate O O
method O O
to O O
document O O
PUD O O
in O O
CF O O
because O O
the O O
duodenal O O
mucosa O O
typically O O
appears O O
nodular O O
and O O
distorted O O
with O O
poor O O
definition O O
of O O
the O O
mucosal O O
folds O O
. O O

A O O
Brassica O O
cDNA O O
clone O O
encoding O O
a O O
bifunctional O O
hydroxymethylpyrimidine B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
thiamin B B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pyrophosphorylase I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involved O O
in O O
thiamin O O
biosynthesis O O
. O O

Differential O O
decay O O
of O O
a O O
polycistronic O O
Escherichia O O
coli O O
transcript O O
is O O
initiated O O
by O O
RNaseE B B_GENE/B_BIO
- O O
dependent O O
endonucleolytic O O
processing O O
. O O

By O O
means O O
of O O
early O O
detection O O
and O O
correction O O
of O O
the O O
possible O O
causes O O
, O O
the O O
goal O O
of O O
increasing O O
therapeutic O O
efficacy O O
can O O
be O O
achieved O O
. O O

We O O
have O O
previously O O
described O O
the O O
partial O O
purification O O
of O O
Ap4A B B_GENE
hydrolase I I_GENE
from O O
S O O
. O O
pombe O O
[ O O
Robinson O O
, O O
de O O
la O O
Pena O O
and O O
Barnes O O
( O O
1993 O O
) O O
Biochim O O
. O O

Effect O O
of O O
a O O
new O O
positive O O
inotropic O O
agent O O
( O O
OPC O O
- O O
8212 O O
) O O
on O O
intracellular O O
potential O O
of O O
isolated O O
canine O O
ventricular O O
papillary O O
muscle O O

Thirty O O
- O O
seven O O
patients O O
with O O
severe O O
temporal O O
lobe O O
epilepsy O O
were O O
studied O O
interictally O O
with O O
[ O O
18F O O
] O O
fluorodeoxyglucose O O
- O O
PET O O
in O O
each O O
of O O
three O O
conditions O O
: O O
resting O O
, O O
during O O
emotional O O
speech O O
, O O
and O O
while O O
performing O O
a O O
visual O O
recognition O O
task O O
. O O

SYC1 B B_PROTEIN[GENE]/B_DISEASE
( O O
suppressor B B_PROTEIN[GENE]
of I I_PROTEIN[GENE]
yeast I I_PROTEIN[GENE]
cbf5 I I_PROTEIN[GENE]
- I I_PROTEIN[GENE]
1 I I_PROTEIN[GENE]
) O O
was O O
identified O O
as O O
a O O
multicopy O O
suppressor O O
of O O
cbf5 B B_GENE/B_SPECIES[BIO]
- I B_GENE/I_SPECIES[BIO]
1 I B_GENE/I_SPECIES[BIO]
and O O
subsequently O O
was O O
found O O
to O O
be O O
identical O O
to O O
RRN3 B B_GENE
, O O
an O O
RNA B B_GENE/B_TIME[MEASURE]
polymerase I I_GENE/I_TIME[MEASURE]
I I I_GENE/I_TIME[MEASURE]
transcription I I_GENE/I_TIME[MEASURE]
factor I I_GENE/I_TIME[MEASURE]
. O O

Newly O O
hatched O O
F1 O O
nymphs O O
of O O
Aiolopus O O
thalassinus O O
( O O
Fabr O O
. O O
) O O
were O O
fed O O
on O O
food O O
treated O O
with O O
various O O
concentrations O O
of O O
HgCl2 O O
, O O
CdCl2 O O
, O O
and O O
PbCl2 O O
until O O
the O O
end O O
of O O
adult O O
life O O
. O O

Both O O
sequence O O
analysis O O
and O O
restriction O O
fragment O O
length O O
polymorphism O O
analysis O O
revealed O O
a O O
high O O
degree O O
of O O
sequence O O
( O O
97 O O
% O O
homology O O
) O O
and O O
structural O O
similarity O O
among O O
members O O
of O O
the O O
ART B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
CH B B_GENE/B_DISEASE
family O O
, O O
indicating O O
their O O
common O O
origin O O
and O O
recent O O
penetration O O
into O O
chicken O O
DNA O O
. O O

Three O O
of O O
these O O
positions O O
are O O
novel O O
in O O
that O O
they O O
had O O
not O O
been O O
identified O O
to O O
be O O
important O O
for O O
binding O O
PC O O
by O O
previous O O
crystallographic O O
analysis O O
. O O

The O O
elevated O O
levels O O
of O O
inositol O O
phosphates O O
resulting O O
from O O
N B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epi I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
qQ209L I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
were O O
similar O O
to O O
those O O
obtained O O
with O O
carbachol O O
activation O O
of O O
the O O
M1 B B_GENE/B_LOCATION
muscarinic I I_GENE/I_LOCATION
acetylcholine I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
. O O

In O O
addition O O
, O O
wild O O
- O O
type O O
and O O
mutated O O
DNA O O
templates O O
were O O
used O O
as O O
probes O O
in O O
DNase B B_GENE
I I I_GENE
protection O O
experiments O O
to O O
determine O O
sites O O
of O O
protein O O
- O O
DNA O O
interaction O O
. O O

We O O
tested O O
the O O
hypothesis O O
that O O
PEH O O
is O O
associated O O
with O O
reductions O O
in O O
TPR O O
and O O
sympathetic O O
nerve O O
activity O O
( O O
SNA O O
) O O
. O O

Salt O O
wars O O
. O O

In O O
the O O
latter O O
, O O
the O O
cells O O
and O O
adjacent O O
matrix O O
had O O
several O O
characteristics O O
of O O
fibrocartilage O O
, O O
including O O
chondrocytes O O
. O O

Mannich O O
bases O O
of O O
vanillin O O
oxime O O
. O O

All O O
exon O O
/ O O
intron O O
splice O O
junctions O O
follow O O
the O O
GT O O
/ O O
AG O O
rule O O
. O O

Previous O O
work O O
has O O
shown O O
that O O
glucose O O
repression O O
of O O
PRB1 B B_GENE
transcription O O
is O O
not O O
mediated O O
by O O
HXK2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
by O O
the O O
SNF1 B B_GENE/B_DISEASE
, O O
SNF4 B B_GENE/B_DISEASE
, O O
and O O
SNF6 B B_GENE
genes I I_GENE
( O O
C O O
. O O

Comparison O O
of O O
the O O
encoded O O
ERCC3Dm B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
homologous O O
proteins O O
of O O
mouse O O
and O O
man O O
shows O O
a O O
strong O O
amino O O
acid O O
conservation O O
( O O
71 O O
% O O
identity O O
) O O
, O O
especially O O
in O O
the O O
postulated O O
DNA O O
binding O O
region O O
and O O
seven O O
' B B_GENE/B_LOCATION
helicase I B_GENE/I_LOCATION
' I B_GENE/I_LOCATION
domains I B_GENE/I_LOCATION
. O O

The O O
pyridostigmine O O
inhibited O O
AChE B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
recovered O O
only O O
in O O
the O O
100 O O
mumol O O
kg O O
- O O
1 O O
kg O O
oxime O O
groups O O
at O O
the O O
end O O
of O O
the O O
experiment O O
. O O

In O O
the O O
case O O
of O O
a O O
moderate O O
buccal O O
Class O O
II O O
tendency O O
, O O
55 O O
% O O
of O O
the O O
molars O O
were O O
in O O
a O O
Class O O
I O O
relationship O O
when O O
evaluated O O
from O O
the O O
lingual O O
side O O
, O O
whereas O O
45 O O
% O O
belonged O O
to O O
mild O O
( O O
1st O O
degrees O O
) O O
Class O O
II O O
with O O
molar O O
rotations O O
present O O
in O O
81 O O
% O O
of O O
the O O
cases O O
. O O

Mutation O O
of O O
this O O
threonine O O
to O O
isoleucine O O
had O O
no O O
observable O O
effect O O
on O O
either O O
nuclear O O
localization O O
of O O
E1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
DNA O O
replication O O
of O O
the O O
intact O O
viral O O
genome O O
. O O

This O O
suggests O O
that O O
the O O
duration O O
of O O
varicocele O O
per O O
se O O
could O O
affect O O
DHT O O
seminal O O
plasma O O
levels O O
. O O

Left O O
ventricular O O
responses O O
to O O
dopamine O O
in O O
dilated O O
cardiomyopathy O O
as O O
assessed O O
by O O
two O O
- O O
dimensional O O
echocardiography O O
and O O
compared O O
with O O
findings O O
of O O
thallium O O
- O O
201 O O
scintigraphy O O
. O O

Detailed O O
comparison O O
of O O
the O O
urinary O O
excretion O O
of O O
purines O O
in O O
a O O
patient O O
with O O
the O O
Lesch O O
- O O
Nyhan O O
syndrome O O
and O O
a O O
control O O
subject O O
. O O

This O O
enzyme O O
is O O
distinct O O
from O O
other O O
known O O
E3s B B_GENE/B_BIO
, O O
including O O
E3 B B_GENE
alpha I I_GENE
/ O O
UBR1 B B_PROTEIN[GENE]
, O O
E3 B B_GENE
beta I I_GENE
, O O
and O O
E6 B B_GENE
- I I_GENE
AP I I_GENE
. O O

This O O
evidence O O
, O O
together O O
with O O
the O O
ability O O
of O O
a O O
carboxyl O O
- O O
terminal O O
coding O O
sequence O O
starting O O
from O O
the O O
BamHI B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
complement O O
a O O
shy1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
suggests O O
that O O
the O O
Shy1p B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contains O O
two O O
domains O O
that O O
can O O
be O O
separately O O
expressed O O
to O O
form O O
a O O
functional O O
protein O O
. O O

The O O
zinc B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
finger I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
A20 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
tumor B B_DISEASE/B_GENE
necrosis I B_DISEASE/I_GENE
factor I B_DISEASE/I_GENE
( O O
TNF B B_GENE/B_LOCATION
) O O
- O O
and O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IL B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
) O O
- O O
inducible O O
protein O O
that O O
negatively O O
regulates O O
nuclear B B_GENE
factor I I_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
( O O
NF B B_GENE
- I I_GENE
kappaB I I_GENE
) O O
- O O
dependent O O
gene O O
expression O O
. O O

A O O
visibly O O
distinct O O
muscular O O
hypertrophy O O
( O O
mh O O
) O O
, O O
commonly O O
known O O
as O O
double O O
muscling O O
, O O
occurs O O
with O O
high O O
frequency O O
in O O
the O O
Belgian O O
Blue O O
and O O
Piedmontese O O
cattle O O
breeds O O
. O O

For O O
the O O
population O O
of O O
patients O O
with O O
melanoma O O
levels O O
III O O
and O O
IV O O
significant O O
differences O O
in O O
survival O O
rate O O
were O O
associated O O
with O O
thickness O O
( O O
less O O
than O O
2 O O
mm O O
or O O
greater O O
than O O
or O O
equal O O
to O O
2 O O
mm O O
; O O
p O O
less O O
than O O
0 O O
, O O
001 O O
) O O
, O O
though O O
not O O
with O O
level O O
. O O

At O O
least O O
one O O
such O O
complex O O
is O O
eliminated O O
by O O
preincubating O O
the O O
nuclear O O
extract O O
with O O
an O O
antibody O O
with O O
broad O O
cross O O
- O O
reactivity O O
with O O
Ets B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Ets B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
thus O O
confirming O O
that O O
an O O
ETS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
s I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
recognizes O O
the O O
- O O
12 O O
motif O O
. O O

Mutant O O
beta2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
adrenergic I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
receptors I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
with O O
a O O
Tyr O O
- O O
to O O
- O O
Phe O O
substitution O O
at O O
Tyr O O
- O O
350 O O
do O O
not O O
display O O
agonist O O
- O O
induced O O
desensitization O O
, O O
Src B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
recruitment O O
, O O
or O O
Src B B_GENE
activation O O
. O O

Immunoblot O O
analysis O O
of O O
purified O O
and O O
protease O O
- O O
digested O O
intracellular O O
mature O O
virus O O
( O O
IMV O O
) O O
and O O
extracellular O O
enveloped O O
virus O O
( O O
EEV O O
) O O
showed O O
that O O
the O O
A36R B B_GENE
proteins I I_GENE
were O O
present O O
on O O
the O O
surface O O
of O O
EEV O O
with O O
type O O
II O O
membrane O O
topology O O
, O O
but O O
were O O
absent O O
from O O
IMV O O
. O O

Here O O
we O O
demonstrate O O
that O O
several O O
genes O O
associated O O
with O O
NHEJ O O
perform O O
essential O O
functions O O
in O O
the O O
repair O O
of O O
endonuclease O O
- O O
induced O O
DSBs O O
in O O
vivo O O
. O O

The O O
failure O O
suggests O O
that O O
these O O
assembly O O
competent O O
but O O
complementation O O
- O O
negative O O
alpha O O
mutants O O
lack O O
an O O
as O O
yet O O
unidentified O O
function O O
( O O
s O O
) O O
. O O

Psychopathological O O
, O O
vegetative O O
, O O
and O O
vital O O
parameters O O
were O O
assessed O O
every O O
hour O O
. O O

RESULTS O O
: O O
Considering O O
an O O
inulin O O
clearance O O
of O O
less O O
than O O
80 O O
ml O O
/ O O
min O O
/ O O
1 O O
. O O
73 O O
m2 O O
, O O
the O O
cut O O
- O O
off O O
value O O
for O O
serum O O
creatinine O O
was O O
11 O O
. O O
5 O O
mumol O O
/ O O
liter O O
for O O
men O O
and O O
90 O O
mumol O O
/ O O
liter O O
for O O
women O O
. O O

These O O
data O O
may O O
indicate O O
redundancy O O
between O O
members O O
of O O
the O O
NGFI B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Nurr1 B B_GENE
/ O O
Nor1 B B_GENE
subfamily O O
and O O
could O O
explain O O
why O O
no O O
phenotypic O O
disturbances O O
have O O
yet O O
been O O
found O O
in O O
mice O O
in O O
which O O
the O O
NGFI B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
inactivated O O
. O O

Manual O O
sample O O
clean O O
- O O
up O O
procedures O O
as O O
well O O
as O O
the O O
addition O O
of O O
an O O
internal O O
standard O O
are O O
not O O
needed O O
. O O

To O O
directly O O
address O O
this O O
issue O O
, O O
we O O
used O O
a O O
tetracycline O O
- O O
regulated O O
system O O
in O O
human O O
U2OS O O
osteosarcoma O O
cells O O
and O O
thus O O
found O O
that O O
BCL6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediates O O
growth O O
suppression O O
associated O O
with O O
impaired O O
S O O
phase O O
progression O O
and O O
apoptosis O O
. O O

TAAG O O
sites O O
that O O
serve O O
as O O
functional O O
late O O
promoters O O
in O O
OpMNPV O O
were O O
found O O
to O O
mediate O O
transcription O O
initiation O O
at O O
only O O
basal O O
levels O O
in O O
the O O
context O O
of O O
the O O
AcMNPV O O
genome O O
, O O
suggesting O O
that O O
late O O
promoter O O
activation O O
may O O
be O O
virus O O
specific O O
within O O
the O O
family O O
Baculoviridae O O
. O O

In O O
absence O O
of O O
i O O
. O O
m O O
. O O
medication O O
, O O
levels O O
over O O
1 O O
, O O
000 O O
U O O
must O O
be O O
carefully O O
screened O O
in O O
order O O
to O O
rule O O
out O O
SNM O O
or O O
organic O O
pathology O O
associated O O
. O O

Paclitaxel O O
caused O O
a O O
rapid O O
and O O
transient O O
increase O O
in O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NH2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
JNK B B_GENE/B_LOCATION
) O O
activity O O
, O O
a O O
proposed O O
mediator O O
of O O
stress O O
activation O O
pathways O O
. O O

These O O
results O O
indicate O O
that O O
H B B_GENE
- I I_GENE
2RIIBP I I_GENE
( O O
i O O
) O O
is O O
a O O
member O O
of O O
the O O
superfamily O O
of O O
nuclear B B_GENE/B_BIO
hormone I I_GENE/I_BIO
receptors I I_GENE/I_BIO
and O O
( O O
ii O O
) O O
may O O
regulate O O
not O O
only O O
MHC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
but O O
also O O
genes O O
containing O O
the O O
ERE O O
and O O
related O O
sequences O O
. O O

Two O O
courses O O
of O O
chemotherapy O O
( O O
CBCDA O O
+ O O
VDS O O
) O O
failed O O
to O O
gain O O
any O O
improvement O O
, O O
and O O
the O O
pain O O
resulting O O
from O O
recurrent O O
bone O O
metastases O O
was O O
managed O O
mainly O O
by O O
the O O
administration O O
of O O
the O O
best O O
supportive O O
care O O
. O O

We O O
show O O
here O O
that O O
Spb1p B B_GENE/B_LOCATION
is O O
able O O
to O O
bind O O
[ O O
( O O
3 O O
) O O
H O O
] O O
AdoMet O O
in O O
vitro O O
, O O
suggesting O O
that O O
it O O
is O O
a O O
novel O O
methylase O O
, O O
whose O O
possible O O
substrates O O
will O O
be O O
discussed O O
. O O

RESULTS O O
: O O
Lateral O O
PF O O
OA O O
was O O
more O O
common O O
than O O
medial O O
PF O O
OA O O
( O O
P O O
< O O
0 O O
. O O
0001 O O
) O O
. O O

CONCLUSION O O
: O O
Urbanisation O O
is O O
associated O O
with O O
an O O
increase O O
in O O
the O O
prevalence O O
rates O O
of O O
some O O
risk O O
behaviours O O
. O O

However O O
, O O
additional O O
studies O O
on O O
cell O O
lines O O
and O O
whole O O
animals O O
are O O
required O O
to O O
understand O O
GnRH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
signaling O O
in O O
the O O
context O O
of O O
other O O
hormones O O
during O O
the O O
reproductive O O
cycle O O
of O O
mouse O O
and O O
human O O
. O O

Serum B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
angiogenin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
concentrations O O
in O O
young O O
patients O O
with O O
diabetes O O
mellitus O O
. O O

This O O
duplicated O O
genomic O O
region O O
is O O
also O O
linked O O
tightly O O
to O O
D1Z2 B B_GENE/B_DISEASE
, O O
a O O
genetic O O
marker O O
containing O O
a O O
highly O O
polymorphic O O
VNTR O O
( O O
variable O O
number O O
tandem O O
repeat O O
) O O
consisting O O
of O O
an O O
unusual O O
40 O O
- O O
bp O O
reiterated O O
sequence O O
. O O

ATF6 B B_GENE
, O O
a O O
basic B B_GENE
- I I_GENE
leucine I I_GENE
zipper I I_GENE
protein I I_GENE
, O O
was O O
isolated O O
by O O
binding O O
to O O
SRF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
in O O
particular O O
to O O
its O O
transcriptional O O
activation O O
domain O O
. O O

Cetn1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possesses O O
the O O
sequence O O
features O O
of O O
an O O
expressed O O
retroposon O O
: O O
the O O
gene O O
lacks O O
introns O O
, O O
the O O
open O O
reading O O
frame O O
is O O
not O O
interrupted O O
by O O
stop O O
codons O O
, O O
and O O
the O O
coding O O
region O O
is O O
flanked O O
by O O
a O O
pair O O
of O O
direct O O
repeats O O
. O O

The O O
largest O O
one O O
probably O O
corresponds O O
to O O
the O O
precursor O O
form O O
of O O
PS2 B B_GENE
in O O
E O O
. O O
coli O O
. O O

On O O
average O O
these O O
maximum O O
potency O O
estimates O O
were O O
within O O
one O O
order O O
of O O
magnitude O O
of O O
the O O
inverse O O
maximum O O
dose O O
tested O O
. O O

VAV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
SOCS1 B B_GENE/B_DISEASE
form O O
a O O
protein O O
complex O O
through O O
interactions O O
between O O
the O O
VAV B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
NH I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
regulatory I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
region I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
SH2 B B_GENE/B_MEASURE
domain I I_GENE/I_MEASURE
of O O
SOCS1 B B_GENE
in O O
a O O
phosphotyrosine O O
- O O
independent O O
manner O O
. O O

The O O
originally O O
embryonic B B_GENE/B_BIO
gamma I I_GENE/I_BIO
- I I_GENE/I_BIO
globin I I_GENE/I_BIO
locus I I_GENE/I_BIO
duplicated O O
and O O
acquired O O
a O O
novel O O
( O O
fetal O O
) O O
pattern O O
of O O
expression O O
in O O
a O O
defined O O
time O O
period O O
( O O
55 O O
- O O
40 O O
million O O
years O O
ago O O
) O O
during O O
primate O O
phylogeny O O
. O O

Clostridium O O
botulinum O O
in O O
marine O O
sediment O O

Northern O O
blot O O
analysis O O
with O O
GPR37 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
probes O O
revealed O O
a O O
main O O
3 O O
. O O
8 O O
- O O
kb O O
mRNA O O
and O O
a O O
less O O
abundant O O
8 O O
- O O
kb O O
mRNA O O
, O O
both O O
expressed O O
in O O
human O O
brain O O
tissues O O
, O O
particularly O O
in O O
corpus O O
callosum O O
, O O
medulla O O
, O O
putamen O O
, O O
and O O
caudate O O
nucleus O O
. O O

Our O O
studies O O
indicate O O
no O O
single O O
trans O O
- O O
acting O O
factor O O
is O O
absolutely O O
essential O O
for O O
enhancer O O
activity O O
, O O
and O O
that O O
the O O
enhancer O O
activity O O
of O O
MerI B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
mediated O O
via O O
a O O
combinatorial O O
and O O
additive O O
mechanism O O
. O O

In O O
human O O
WI38 O O
cells O O
, O O
the O O
E1B B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
19K I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gene I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutant I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
viruses O O
had O O
a O O
substantial O O
growth O O
advantage O O
over O O
the O O
wild O O
- O O
type O O
virus O O
, O O
yielding O O
500 O O
- O O
fold O O
- O O
higher O O
titers O O
. O O

To O O
elucidate O O
the O O
mechanism O O
of O O
these O O
hormonal O O
effects O O
, O O
we O O
have O O
studied O O
the O O
regulatory O O
regions O O
of O O
the O O
PFK B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
transfection O O
experiments O O
. O O

Furthermore O O
, O O
disruption O O
of O O
pcr1 B B_GENE
reduced O O
expression O O
of O O
fbp1 B B_GENE
, O O
a O O
glucose O O
- O O
repressible O O
gene O O
negatively O O
regulated O O
by O O
PKA B B_GENE
. O O

In O O
solution O O
, O O
[ O O
( O O
125 O O
) O O
I O O
] O O
- O O
labeled O O
ankyrin B B_GENE/B_BACTERIUM[BIO]
was O O
found O O
by O O
ND O O
- O O
PAGE3 O O
to O O
enhance O O
the O O
affinity O O
of O O
spectrin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
self O O
- O O
association O O
by O O
10 O O
- O O
fold O O
. O O

Transcription O O
analysis O O
of O O
the O O
EcoRI B B_GENE
D I I_GENE
region I I_GENE
of O O
the O O
baculovirus O O
Autographa O O
californica O O
nuclear O O
polyhedrosis O O
virus O O
identifies O O
an O O
early O O
4 O O
- O O
kilobase O O
RNA O O
encoding O O
the O O
essential O O
p143 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Anesthesia O O
in O O
the O O
radical O O
surgery O O
of O O
arteriosclerotic O O
coronary O O
disease O O

5 O O
Intravenous O O
prizidilol O O
hydrochloride O O
decreases O O
resting O O
blood O O
pressure O O
and O O
left O O
ventricular O O
area O O
, O O
increases O O
pulse O O
rate O O
and O O
has O O
virtually O O
no O O
effect O O
on O O
left O O
ventricular O O
ejection O O
fraction O O
. O O

In O O
this O O
study O O
, O O
the O O
subcellular O O
location O O
, O O
domain O O
structure O O
, O O
and O O
biochemical O O
function O O
of O O
metaxin B B_GENE/B_BACTERIUM[BIO]
were O O
investigated O O
. O O

Our O O
aim O O
was O O
to O O
evaluate O O
this O O
technique O O
by O O
cross O O
- O O
calibrating O O
the O O
DXA O O
method O O
with O O
the O O
carcass O O
chemical O O
analysis O O
in O O
a O O
heterogeneous O O
population O O
of O O
nondiabetic O O
Wistar O O
and O O
diabetic O O
GK O O
rats O O
( O O
21 O O
animals O O
were O O
used O O
for O O
precision O O
error O O
and O O
reproducibility O O
determinations O O
and O O
26 O O
were O O
used O O
for O O
accuracy O O
studies O O
) O O
. O O

Flux O O
of O O
the O O
paramyxovirus O O
hemagglutinin B B_PROTEIN[GENE]/B_BIO
- O O
neuraminidase B B_PROTEIN[GENE]
glycoprotein O O
through O O
the O O
endoplasmic O O
reticulum O O
activates O O
transcription O O
of O O
the O O
GRP78 B B_PROTEIN[GENE]/B_DISEASE
- O O
BiP B B_GENE
gene O O
. O O

Small O O
cell O O
tumors O O
in O O
children O O
: O O
contribution O O
to O O
the O O
solution O O
of O O
the O O
problem O O
of O O
differential O O
diagnosis O O
with O O
immunohistochemistry O O
and O O
electron O O
microscopy O O

Detonation O O
- O O
traumatic O O
load O O
during O O
military O O
service O O

In O O
static O O
conditions O O
, O O
body O O
sway O O
was O O
assessed O O
using O O
a O O
conventional O O
force O O
platform O O
with O O
eyes O O
open O O
and O O
with O O
eyes O O
closed O O
. O O

Soggy B B_GENE/B_BIO
, O O
a O O
spermatocyte O O
- O O
specific O O
gene O O
, O O
lies O O
3 O O
. O O
8 O O
kb O O
upstream O O
of O O
and O O
antipodal O O
to O O
TEAD B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
a O O
transcription O O
factor O O
expressed O O
at O O
the O O
beginning O O
of O O
mouse O O
development O O
. O O

Teratospermia O O
is O O
therefore O O
an O O
important O O
factor O O
in O O
evaluating O O
fertilization O O
capacity O O
. O O

Results O O
of O O
the O O
study O O
suggest O O
that O O
Chinese O O
medicine O O
use O O
among O O
this O O
population O O
depends O O
on O O
health O O
conditions O O
, O O
and O O
that O O
having O O
a O O
regular O O
source O O
of O O
care O O
for O O
Chinese O O
medicine O O
as O O
well O O
as O O
a O O
preference O O
for O O
Chinese O O
medicine O O
are O O
two O O
predictors O O
for O O
its O O
use O O
. O O

The O O
greatest O O
risk O O
of O O
preterm O O
prelabour O O
rupture O O
of O O
membranes O O
( O O
PPROM O O
) O O
is O O
preterm O O
delivery O O
. O O

DISCUSSION O O
: O O
The O O
higher O O
absolute O O
knee O O
extension O O
strength O O
measures O O
of O O
leg O O
and O O
the O O
similar O O
extension O O
strength O O
of O O
the O O
trunk O O
in O O
the O O
obese O O
sample O O
compared O O
to O O
the O O
lean O O
might O O
be O O
explained O O
by O O
the O O
training O O
effect O O
of O O
weight O O
bearing O O
and O O
support O O
of O O
a O O
larger O O
body O O
mass O O
. O O

In O O
pituitary O O
GH3 O O
cells O O
, O O
vitamin O O
D O O
increases O O
the O O
levels O O
of O O
PRL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
stimulates O O
the O O
PRL B B_GENE
promoter I I_GENE
. O O

METHODS O O
: O O
We O O
retrospectively O O
analyzed O O
the O O
data O O
of O O
20 O O
patients O O
who O O
underwent O O
both O O
gated O O
fluorine O O
18 O O
deoxyglucose O O
( O O
FDG O O
) O O
- O O
PET O O
and O O
equilibrium O O
radionuclide O O
angiography O O
( O O
ERNA O O
) O O
. O O

However O O
, O O
it O O
is O O
now O O
suggested O O
that O O
the O O
use O O
of O O
more O O
slowly O O
digested O O
starchy O O
foods O O
may O O
have O O
positive O O
health O O
benefits O O
. O O

Northern O O
blot O O
analysis O O
demonstrated O O
that O O
the O O
genes O O
are O O
transcribed O O
separately O O
. O O

Complete O O
activation O O
of O O
signal B B_GENE
transducer I I_GENE
and I I_GENE
activator I I_GENE
of I I_GENE
transcription I I_GENE
1 I I_GENE
( O O
STAT1 B B_GENE
) O O
requires O O
phosphorylation O O
at O O
both O O
Y701 O O
and O O
a O O
conserved O O
PMS O O
( O O
727 O O
) O O
P O O
sequence O O
. O O

Over O O
half O O
of O O
the O O
children O O
initially O O
unresponsive O O
to O O
H O O
. O O
influenzae O O
type O O
b O O
meningitis O O
subsequently O O
developed O O
specific O O
antibodies O O
. O O

It O O
is O O
important O O
to O O
understand O O
the O O
etiology O O
of O O
HITT O O
because O O
of O O
its O O
devastating O O
clinical O O
consequences O O
. O O

Five O O
sequence O O
variants O O
were O O
identified O O
. O O

The O O
Ras B B_ENZYME[GENE]/B_LOCATION
GTPase I I_ENZYME[GENE]/I_LOCATION
- I I_ENZYME[GENE]/I_LOCATION
activating I I_ENZYME[GENE]/I_LOCATION
- I I_ENZYME[GENE]/I_LOCATION
protein I I_ENZYME[GENE]/I_LOCATION
- I I_ENZYME[GENE]/I_LOCATION
related I I_ENZYME[GENE]/I_LOCATION
human I I_ENZYME[GENE]/I_LOCATION
protein I I_ENZYME[GENE]/I_LOCATION
IQGAP2 B I_ENZYME[GENE]/I_LOCATION
harbors O O
a O O
potential O O
actin B B_GENE
binding I I_GENE
domain I I_GENE
and O O
interacts O O
with O O
calmodulin B B_GENE/B_DISEASE
and O O
Rho B B_GENE
family I I_GENE
GTPases I I_GENE
. O O

We O O
anticipated O O
SNS O O
function O O
after O O
CVA O O
to O O
be O O
asymmetric O O
and O O
selected O O
null O O
hypotheses O O
of O O
bilaterally O O
symmetric O O
SSR O O
latencies O O
and O O
amplitudes O O
irrespective O O
of O O
side O O
of O O
stimulation O O
and O O
/ O O
or O O
recording O O
. O O

Partial O O
hepatectomy O O
in O O
metastatic O O
Wilms O O
' O O
tumor O O
. O O

The O O
adoption O O
of O O
a O O
twisted O O
structure O O
of O O
importin B B_GENE
- I I_GENE
beta I I_GENE
is O O
essential O O
for O O
the O O
protein O O
- O O
protein O O
interaction O O
required O O
for O O
nuclear O O
transport O O
. O O

The O O
presence O O
of O O
a O O
short O O
( O O
70 O O
bp O O
) O O
intron O O
near O O
the O O
N O O
- O O
terminus O O
of O O
the O O
atX B B_GENE
gene I I_GENE
was O O
predicted O O
that O O
contains O O
the O O
canonical O O
GT O O
and O O
AG O O
dinucleotides O O
at O O
its O O
5 O O
' O O
- O O
and O O
3 O O
' O O
- O O
splicing O O
junctions O O
. O O

Tc O O
- O O
99m O O
HMPAO O O
brain O O
SPECT O O
compared O O
to O O
CT O O
and O O
EEG O O
after O O
seizures O O
in O O
childhood O O
. O O

We O O
show O O
that O O
the O O
upstream O O
region O O
of O O
the O O
beta B B_GENE/B_BIO
- I I_GENE/I_BIO
MyHC I I_GENE/I_BIO
gene I I_GENE/I_BIO
( O O
- O O
5518 O O
to O O
- O O
2490 O O
relative O O
to O O
the O O
transcriptional O O
start O O
site O O
) O O
directed O O
high O O
levels O O
of O O
transcriptional O O
activity O O
only O O
when O O
stably O O
integrated O O
, O O
but O O
not O O
when O O
expressed O O
extrachromosomally O O
in O O
transient O O
assays O O
. O O

DNase B B_GENE
I I I_GENE
protection O O
analysis O O
as O O
well O O
as O O
oligonucleotide O O
competition O O
experiments O O
indicate O O
that O O
this O O
binding O O
is O O
sequence O O
specific O O
. O O

Plasmid O O
pSP64E6E7 O O
which O O
contains O O
the O O
reading O O
frames O O
of O O
both O O
E6 B B_PROTEIN[GENE]
and O O
E7 B B_PROTEIN[GENE]
was O O
constructed O O
in O O
order O O
to O O
study O O
the O O
expression O O
of O O
both O O
proteins O O
in O O
a O O
coupled O O
transcription O O
/ O O
rabbit O O
reticulocyte O O
translation O O
system O O
. O O

These O O
findings O O
suggest O O
that O O
PGE1 O O
is O O
effective O O
in O O
increasing O O
PVF O O
in O O
the O O
liver O O
transplanted O O
condition O O
; O O
however O O
, O O
the O O
hepatic O O
circulatory O O
improvement O O
attributed O O
to O O
this O O
agent O O
would O O
be O O
limited O O
to O O
the O O
first O O
few O O
days O O
following O O
transplantation O O
. O O

Nearly O O
1 O O
. O O
5 O O
million O O
American O O
men O O
age O O
65 O O
and O O
older O O
have O O
osteoporosis O O
, O O
and O O
another O O
3 O O
. O O
5 O O
million O O
are O O
at O O
risk O O
. O O

Both O O
viruses O O
express O O
the O O
mil B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
raf B B_GENE/B_DISEASE
oncogene O O
product O O
as O O
a O O
gag B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
fusion I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
polyprotein O O
, O O
while O O
the O O
myc B B_GENE/B_SPECIES[BIO]
oncogene O O
of O O
MH2 O O
is O O
expressed O O
via O O
a O O
subgenomic O O
mRNA O O
. O O

CONCLUSION O O
: O O
DaunoXome O O
has O O
an O O
improved O O
pharmacokinetic O O
profile O O
compared O O
with O O
free O O
daunorubicin O O
, O O
and O O
is O O
well O O
tolerated O O
. O O

This O O
regimen O O
may O O
be O O
considered O O
front O O
- O O
line O O
therapy O O
when O O
autologous O O
stem O O
cell O O
transplantation O O
is O O
not O O
feasible O O
and O O
when O O
a O O
rapid O O
response O O
is O O
particularly O O
important O O
. O O

Recombinant O O
protein O O
encoded O O
by O O
ESX B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
for O O
epithelial B B_GENE
- I I_GENE
restricted I I_GENE
with I I_GENE
serine I I_GENE
box I I_GENE
) O O
exhibits O O
Ets B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
like I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DNA O O
binding O O
specificity O O
in O O
electrophoretic O O
mobility O O
shift O O
assays O O
and O O
, O O
in O O
transient O O
transfection O O
assays O O
, O O
transactivates O O
Ets B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
responsive I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
including O O
that O O
found O O
in O O
the O O
HER2 B B_GENE
/ O O
neu B B_GENE/B_LOCATION
oncogene O O
. O O

The O O
revaluation O O
at O O
the O O
end O O
of O O
the O O
study O O
showed O O
a O O
good O O
compliance O O
for O O
the O O
proposed O O
diet O O
scheme O O
by O O
children O O
, O O
but O O
a O O
poor O O
compliance O O
by O O
their O O
families O O
. O O

The O O
delta O O
G O O
values O O
of O O
these O O
regions O O
were O O
higher O O
, O O
i O O
. O O
e O O
. O O
potential O O
secondary O O
structural O O
elements O O
were O O
fewer O O
, O O
than O O
in O O
TIR O O
of O O
genes O O
from O O
E O O
. O O
coli O O
. O O

Two O O
closely O O
related O O
groups O O
of O O
transcripts O O
, O O
Sagrp1 B B_GENE
and O O
Sagrp2 B B_PROTEIN[GENE]
, O O
controlled O O
by O O
a O O
circadian O O
rhythm O O
have O O
been O O
isolated O O
. O O

Of O O
921 O O
specimens O O
, O O
95 O O
yielded O O
non O O
- O O
albicans O O
species O O
, O O
mainly O O
from O O
patients O O
with O O
low O O
CD4 B B_GENE/B_MEASURE
lymphocyte O O
counts O O
and O O
extensive O O
previous O O
azole O O
exposure O O
. O O

These O O
findings O O
suggest O O
that O O
eIF5 B B_GENE
- O O
eIF2beta B B_GENE
interaction O O
plays O O
an O O
essential O O
role O O
in O O
eIF5 B B_GENE
function O O
in O O
eukaryotic O O
cells O O
. O O

Three O O
simple O O
methods O O
of O O
detecting O O
malnutrition O O
on O O
medical O O
wards O O
. O O

Compared O O
with O O
controls O O
, O O
patients O O
in O O
the O O
unmedicated O O
state O O
had O O
low O O
smooth O O
pursuit O O
gain O O
, O O
had O O
a O O
higher O O
rate O O
of O O
corrective O O
catch O O
- O O
up O O
saccades O O
, O O
and O O
tended O O
to O O
spend O O
less O O
time O O
engaged O O
in O O
the O O
tracking O O
task O O
. O O

Cytokine O O
- O O
mediated O O
I B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kappa I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reappearance O O
was O O
completely O O
blocked O O
by O O
the O O
protein O O
synthesis O O
inhibitor O O
cycloheximide O O
. O O

Development O O
of O O
P O O
carinii O O
pneumonia O O
was O O
associated O O
with O O
the O O
stage O O
of O O
Kaposi O O
' O O
s O O
sarcoma O O
, O O
B O O
subtype O O
disease O O
, O O
and O O
the O O
presence O O
of O O
0 O O
. O O
20 O O
X O O
10 O O
( O O
9 O O
) O O
/ O O
L O O
( O O
200 O O
/ O O
mm3 O O
) O O
or O O
fewer O O
CD4 B B_GENE/B_DISEASE
cells O O
at O O
study O O
entry O O
. O O

The O O
effects O O
of O O
tilmicosin O O
administration O O
in O O
the O O
feed O O
at O O
400 O O
mg O O
/ O O
kg O O
and O O
an O O
injection O O
therapy O O
of O O
clinically O O
diseased O O
pigs O O
with O O
long O O
- O O
acting O O
oxytetracycline O O
( O O
Terramycine O O
LA O O
) O O
at O O
20 O O
mg O O
/ O O
kg O O
bodyweight O O
were O O
compared O O
. O O

Those O O
participating O O
in O O
this O O
investigation O O
( O O
65 O O
centers O O
= O O
79 O O
% O O
) O O
received O O
a O O
series O O
of O O
computer O O
disks O O
containing O O
50 O O
99mTc O O
- O O
DMSA O O
studies O O
. O O

Pathogenesis O O
of O O
fever O O
. O O

Two O O
full O O
- O O
length O O
clones O O
( O O
pBCH1 O O
and O O
pBCH2 O O
) O O
were O O
isolated O O
. O O

Childbirth O O
and O O
authoritative O O
knowledge O O
. O O

The O O
ends O O
of O O
the O O
barrel O O
are O O
capped O O
by O O
short O O
helices O O
. O O

Non O O
- O O
finger O O
- O O
coding O O
modules O O
conserved O O
among O O
members O O
of O O
subfamilies O O
of O O
zinc B B_BIO/B_GENE
finger I I_BIO/I_GENE
genes I I_BIO/I_GENE
have O O
been O O
described O O
in O O
the O O
murine O O
genome O O
( O O
finger O O
- O O
associated O O
boxes O O
, O O
or O O
FAX O O
domain O O
) O O
and O O
the O O
human O O
genome O O
( O O
Kruppel B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
associated I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
boxes I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
or O O
KRAB B B_GENE/B_DISEASE
domain I I_GENE/I_DISEASE
) O O
. O O

This O O
combination O O
is O O
considered O O
pathognomonic O O
for O O
factitious O O
hyperinsulinism O O
. O O

Comparison O O
of O O
the O O
5 O O
' O O
flanking O O
regions O O
of O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
J I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
the O O
conserved O O
putative O O
recombination O O
target O O
sequences O O
, O O
shows O O
no O O
obvious O O
differences O O
consistent O O
with O O
the O O
variation O O
in O O
recombinational O O
efficiency O O
, O O
so O O
we O O
conclude O O
that O O
, O O
although O O
the O O
consensus O O
heptamer O O
and O O
nonamer O O
signals O O
may O O
be O O
sufficient O O
to O O
identify O O
a O O
recombination O O
site O O
, O O
the O O
probability O O
that O O
that O O
site O O
will O O
be O O
used O O
depends O O
also O O
on O O
other O O
determinants O O
. O O

The O O
melanoma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stimulatory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
CXCL1 B B_GENE/B_LOCATION
, O O
is O O
constitutively O O
expressed O O
at O O
high O O
levels O O
during O O
inflammation O O
and O O
progression O O
of O O
melanocytes O O
into O O
malignant O O
melanoma O O
. O O

Twelve O O
( O O
92 O O
% O O
) O O
showed O O
cognitive O O
dysfunction O O
including O O
impairments O O
in O O
memory O O
, O O
attention O O
, O O
and O O
affective O O
disturbances O O
( O O
anxiety O O
, O O
depression O O
, O O
irritability O O
, O O
and O O
poor O O
frustration O O
tolerance O O
) O O
. O O

To O O
clarify O O
the O O
mechanisms O O
that O O
regulate O O
transcription O O
of O O
the O O
GTP B B_GENE
cyclohydrolase I I_GENE
I I I_GENE
gene I I_GENE
and O O
to O O
generate O O
multiple O O
species O O
of O O
mRNA O O
, O O
we O O
isolated O O
genomic O O
DNA O O
clones O O
for O O
the O O
human O O
and O O
mouse O O
GTP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cyclohydrolase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
present O O
study O O
deals O O
with O O
the O O
screening O O
of O O
11 O O
of O O
these O O
plants O O
against O O
the O O
opportunistic O O
pathogen O O
fungus O O
Candida O O
albicans O O
. O O

Negative O O
modulation O O
of O O
alpha1 B B_GENE
( I I_GENE
I I I_GENE
) I I_GENE
procollagen I I_GENE
gene I I_GENE
expression O O
in O O
human O O
skin O O
fibroblasts O O
: O O
transcriptional O O
inhibition O O
by O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

On O O
the O O
basis O O
of O O
this O O
homology O O
, O O
we O O
examined O O
the O O
potential O O
role O O
of O O
c B B_GENE
- I I_GENE
Rel I I_GENE
in O O
controlling O O
IL B B_GENE
- I I_GENE
2R I I_GENE
alpha I I_GENE
transcription O O
. O O

Expression O O
of O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentiated O O
HS2 O O
- O O
mediated O O
transactivation O O
. O O

We O O
next O O
developed O O
a O O
rapid O O
purification O O
method O O
for O O
bacterial B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
recombinant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MyoD I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
affinity O O
chromatography O O
using O O
a O O
calmodulin B B_GENE
- O O
Sepharose O O
column O O
and O O
investigated O O
the O O
phosphorylation O O
of O O
that O O
peptide O O
by O O
PKC B B_GENE
and O O
its O O
interactions O O
with O O
calmodulin B B_GENE
and O O
S100a B B_GENE
. O O

According O O
to O O
the O O
penetration O O
of O O
Ca O O
- O O
45 O O
, O O
the O O
microleakage O O
level O O
was O O
scored O O
for O O
each O O
section O O
. O O

HL B B_GENE/B_DISEASE
is O O
hypothesized O O
to O O
directly O O
couple O O
HDL B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
lipid O O
metabolism O O
to O O
tissue O O
/ O O
cellular O O
lipid O O
metabolism O O
. O O

Epstein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Barr I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exerts O O
its O O
transactivating O O
function O O
through O O
interaction O O
with O O
recombination B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
J I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
homologue O O
of O O
Drosophila B B_GENE
Suppressor I I_GENE
of I I_GENE
Hairless I I_GENE
. O O

Maduromycosis O O
in O O
Italy O O

Two O O
patient O O
groups O O
were O O
studied O O
: O O
Type O O
I O O
- O O
- O O
with O O
a O O
new O O
ePTFE O O
graft O O
; O O
and O O
Type O O
II O O
- O O
- O O
with O O
thrombectomy O O
and O O
/ O O
or O O
revision O O
of O O
a O O
previously O O
placed O O
ePTFE O O
graft O O
. O O

The O O
author O O
describes O O
the O O
technique O O
in O O
detail O O
and O O
presents O O
the O O
findings O O
for O O
25 O O
patients O O
( O O
10 O O
men O O
and O O
15 O O
women O O
) O O
examined O O
for O O
suspected O O
ileostomy O O
dysfunction O O
, O O
recurrent O O
Crohn O O
' O O
s O O
disease O O
or O O
ileal O O
obstruction O O
remote O O
from O O
the O O
stoma O O
. O O

Increased O O
susceptibility O O
of O O
aphasics O O
to O O
a O O
distractor O O
task O O
in O O
the O O
recall O O
of O O
verbal O O
commands O O
. O O

Lasting O O
paraplegia O O
caused O O
by O O
loss O O
of O O
lumbar O O
spinal O O
cord O O
interneurons O O
in O O
rats O O
: O O
no O O
direct O O
correlation O O
with O O
motor O O
neuron O O
loss O O
. O O

The O O
existence O O
of O O
universal O O
non O O
- O O
specific O O
mechanism O O
of O O
action O O
of O O
external O O
factors O O
upon O O
the O O
living O O
tissue O O
based O O
on O O
the O O
DEL O O
- O O
reaction O O
is O O
suggested O O
. O O

We O O
constructed O O
a O O
stable O O
, O O
doubly O O
transfected O O
cell O O
line O O
( O O
TIS O O
- O O
10 O O
) O O
carrying O O
a O O
chromosomally O O
integrated O O
ptetO7 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CMV I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reporter O O
construct O O
and O O
expressing O O
the O O
TetR B B_GENE/B_DISEASE
- O O
KRAB B B_GENE/B_MEASURE
protein O O
. O O

We O O
suggest O O
that O O
electrical O O
stimulation O O
of O O
the O O
NTS O O
in O O
rats O O
undergoing O O
such O O
surgical O O
preparation O O
to O O
observe O O
the O O
pressor O O
response O O
and O O
/ O O
or O O
increase O O
in O O
pVP O O
, O O
represents O O
a O O
rapid O O
approach O O
for O O
screening O O
the O O
neurosecretory O O
function O O
of O O
the O O
central O O
neural O O
integration O O
to O O
release O O
vasopressin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

To O O
study O O
adaptive O O
processes O O
following O O
spinal O O
cord O O
injury O O
, O O
unstructured O O
audiotaped O O
interviews O O
were O O
conducted O O
on O O
an O O
almost O O
daily O O
basis O O
with O O
a O O
30 O O
- O O
year O O
- O O
old O O
divorced O O
male O O
during O O
the O O
first O O
3 O O
months O O
of O O
his O O
initial O O
comprehensive O O
inpatient O O
rehabilitation O O
. O O

Melioidosis O O
in O O
Sika O O
deer O O
( O O
Cervus O O
nippon O O
nippon O O
) O O
. O O

Enterobius O O
vermicularis O O
eggs O O
were O O
demonstrated O O
during O O
microscopic O O
examination O O
of O O
a O O
smear O O
taken O O
from O O
the O O
posterior O O
fornix O O
of O O
the O O
vagina O O
. O O

Together O O
with O O
previous O O
work O O
our O O
results O O
suggest O O
that O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
a O O
general O O
cooperation O O
partner O O
for O O
v B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Myb I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
myelomonocytic O O
cells O O
. O O

When O O
medical O O
aid O O
was O O
sought O O
a O O
false O O
history O O
was O O
given O O
and O O
the O O
true O O
nature O O
of O O
the O O
child O O
' O O
s O O
illness O O
, O O
heat O O
stroke O O
, O O
was O O
not O O
determined O O
until O O
after O O
death O O
. O O

Both O O
DMP2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
DMP3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
closely O O
localized O O
on O O
mouse O O
chromosome O O
5q21 O O
, O O
corresponding O O
to O O
human O O
chromosome O O
4q21 O O
. O O

This O O
article O O
expands O O
the O O
analysis O O
of O O
a O O
numeric O O
example O O
included O O
in O O
the O O
SAS O O
GLM O O
procedure O O
to O O
cover O O
several O O
crucial O O
statistical O O
aspects O O
relevant O O
to O O
ANCOVA O O
, O O
and O O
to O O
highlight O O
the O O
meaning O O
of O O
the O O
statistical O O
results O O
obtained O O
. O O

A O O
novel O O
alternative O O
spliced O O
variant O O
of O O
the O O
transcription O O
factor O O
AP2alpha B B_GENE
is O O
expressed O O
in O O
the O O
murine O O
ocular O O
lens O O
. O O

Fig1p B B_GENE/B_PERSON
and O O
Fig2p B B_PROTEIN[GENE]/B_LOCATION
are O O
likely O O
to O O
act O O
at O O
the O O
cell O O
surface O O
as O O
Fig1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
: O O
: O O
beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gal I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Fig2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
: O O
: O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fusion I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
localize O O
to O O
the O O
periphery O O
of O O
mating O O
cells O O
. O O

Crystals O O
of O O
the O O
triple O O
mutant O O
A42D B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
D47P B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
A63L B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
are O O
stable O O
for O O
days O O
in O O
its O O
oxidized O O
form O O
, O O
were O O
grown O O
from O O
ammonium O O
sulfate O O
, O O
with O O
the O O
cell O O
constants O O
a O O
= O O
b O O
= O O
34 O O
. O O
3 O O
A O O
and O O
c O O
= O O
111 O O
. O O
8 O O
A O O
belonging O O
to O O
space O O
group O O
P3 O O
( O O
2 O O
) O O
21 O O
. O O

Nevertheless O O
, O O
PEG O O
influenced O O
in O O
vitro O O
drug O O
availability O O
considerably O O
, O O
by O O
increasing O O
both O O
drug O O
solubility O O
and O O
dissolution O O
rate O O
. O O

Normal O O
replication O O
of O O
DNA B B_BIO/B_GENE
A I I_BIO/I_GENE
still O O
carrying O O
the O O
AC3 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
ORF I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation O O
was O O
found O O
in O O
extracts O O
from O O
these O O
plants O O
. O O

Such O O
saturation O O
often O O
occurs O O
for O O
several O O
recording O O
sweeps O O
after O O
large O O
amplitude O O
signals O O
such O O
as O O
eye O O
blinks O O
are O O
rejected O O
. O O

Muscle O O
and O O
liver O O
biopsies O O
demonstrated O O
the O O
same O O
anomalies O O
, O O
again O O
without O O
branching B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
enzyme I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
deficiency O O
in O O
the O O
liver O O
. O O

Possibility O O
of O O
using O O
gynecologic O O
nurses O O
in O O
the O O
independently O O
administered O O
health O O
centers O O

Airborne O O
rabies O O
encephalitis O O
: O O
demonstration O O
of O O
rabies O O
virus O O
in O O
the O O
human O O
central O O
nervous O O
system O O
. O O

By O O
cloning O O
genes O O
encoding O O
benzene O O
- O O
degradative O O
enzymes O O
, O O
we O O
found O O
that O O
strain O O
JS150 O O
also O O
carries O O
genes O O
for O O
a O O
toluene B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
benzene I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
monooxygenase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Our O O
data O O
suggest O O
that O O
association O O
of O O
TBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
TATA O O
box O O
may O O
be O O
regulated O O
, O O
directly O O
or O O
indirectly O O
, O O
by O O
a O O
substrate O O
of O O
Snf1 B B_GENE
. O O

Fusion O O
proteins O O
were O O
isolated O O
by O O
affinity O O
chromatography O O
on O O
APTG O O
- O O
Sepharose O O
. O O

It O O
differed O O
from O O
cued O O
recall O O
only O O
in O O
the O O
instructions O O
, O O
which O O
directed O O
subjects O O
away O O
from O O
the O O
memory O O
aspects O O
of O O
the O O
test O O
and O O
asked O O
them O O
to O O
complete O O
each O O
three O O
- O O
letter O O
cue O O
with O O
the O O
first O O
word O O
that O O
came O O
to O O
mind O O
. O O

Real O O
- O O
time O O
two O O
- O O
dimensional O O
echocardiographic O O
studies O O
of O O
the O O
mitral O O
valve O O
in O O
short O O
- O O
axis O O
view O O
were O O
obtained O O
from O O
10 O O
normal O O
subjects O O
. O O

RESULTS O O
: O O
Sixty O O
- O O
one O O
percent O O
of O O
the O O
patients O O
had O O
damage O O
within O O
7 O O
years O O
of O O
onset O O
( O O
mean O O
3 O O
. O O
8 O O
yrs O O
) O O
. O O

The O O
map O O
is O O
based O O
on O O
the O O
CEPH O O
reference O O
pedigrees O O
and O O
includes O O
over O O
4000 O O
new O O
genotypes O O
, O O
our O O
previously O O
reported O O
data O O
plus O O
29 O O
allele O O
systems O O
from O O
the O O
published O O
CEPH O O
version O O
5 O O
database O O
, O O
and O O
was O O
constructed O O
using O O
the O O
program O O
package O O
CRI O O
- O O
MAP O O
. O O

To O O
identify O O
the O O
GRK6 B B_GENE/B_LOCATION
homologue I I_GENE/I_LOCATION
on O O
chromsome O O
13 O O
, O O
several O O
sets O O
of O O
closely O O
- O O
spaced O O
primers O O
were O O
designed O O
based O O
on O O
the O O
GRK6 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cDNA I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequence I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
then O O
used O O
to O O
amplify O O
human O O
genomic O O
DNA O O
by O O
PCR O O
. O O

In O O
the O O
absence O O
of O O
Mg2 O O
+ O O
, O O
the O O
extent O O
of O O
destabilization O O
of O O
tRNAPhe B B_GENE
is O O
greater O O
but O O
appears O O
to O O
be O O
confined O O
to O O
internal O O
regions O O
of O O
the O O
acceptor O O
and O O
T O O
psi O O
C O O
helices O O
, O O
as O O
evidenced O O
by O O
the O O
selectively O O
enhanced O O
exchange O O
rates O O
for O O
imino O O
protons O O
associated O O
with O O
these O O
base O O
pairs O O
. O O

Studies O O
in O O
26 O O
patients O O
. O O

Serum B B_MEASURE/B_GENE
alpha I I_MEASURE/I_GENE
- I I_MEASURE/I_GENE
amylase I I_MEASURE/I_GENE
, O O
trypsin B B_ENZYME[GENE]
, O O
trypsin B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lipase B B_ENZYME[GENE]
and O O
total O O
protease O O
activity O O
in O O
the O O
pancreatic O O
tissue O O
was O O
studied O O
as O O
indicator O O
of O O
the O O
treatment O O
efficacy O O
with O O
5 O O
- O O
fluorouracil O O
electro O O
- O O
cumulation O O
. O O

1 O O
The O O
effects O O
of O O
high O O
doses O O
of O O
piretanide O O
, O O
a O O
new O O
diuretic O O
agent O O
chemically O O
related O O
to O O
frusemide O O
and O O
bumetanide O O
were O O
evaluated O O
in O O
twelve O O
patients O O
with O O
severe O O
chronic O O
renal O O
insufficiency O O
( O O
creatinine O O
clearance O O
below O O
25 O O
ml O O
/ O O
min O O
) O O
. O O

Synthesis O O
of O O
22 O O
- O O
oxavitamin O O
D3 O O
analogues O O
. O O

Consistent O O
with O O
the O O
large O O
pocket O O
of O O
Rb B B_GENE
binding O O
to O O
TAF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
250 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
large O O
pocket O O
domains O O
of O O
both O O
p107 B B_GENE/B_DISEASE
and O O
p130 B B_GENE
are O O
able O O
to O O
bind O O
to O O
TAF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
250 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O O
. O O

50 O O
- O O
nucleotide O O
) O O
intron O O
to O O
AA O O
. O O

The O O
educational O O
program O O
was O O
the O O
significant O O
factor O O
that O O
influenced O O
the O O
change O O
of O O
concern O O
trajectories O O
, O O
and O O
the O O
recurrent O O
/ O O
non O O
- O O
recurrent O O
factor O O
influenced O O
the O O
change O O
of O O
concern O O
only O O
in O O
pamphlet O O
group O O
. O O

Amplification O O
of O O
4q21 O O
- O O
q22 O O
and O O
the O O
MXR B B_GENE/B_MEASURE
gene I I_GENE/I_MEASURE
in O O
independently O O
derived O O
mitoxantrone O O
- O O
resistant O O
cell O O
lines O O
. O O

Activation O O
of O O
the O O
receptor O O
induces O O
Ret B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphorylation O O
that O O
leads O O
the O O
survival O O
- O O
promoting O O
effects O O
. O O

This O O
paper O O
describes O O
a O O
course O O
of O O
therapy O O
with O O
an O O
agoraphobic O O
female O O
patient O O
. O O

A O O
previously O O
developed O O
kinetic O O
model O O
was O O
used O O
to O O
identify O O
major O O
chemical O O
reaction O O
pathways O O
involving O O
PAH O O
in O O
the O O
afterburner O O
. O O

Henry O O
Quastler O O
brought O O
experience O O
from O O
an O O
actual O O
x O O
- O O
ray O O
treatment O O
, O O
and O O
Dr O O
. O O

DSS4 B B_GENE/B_PERSON
- I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
is O O
a O O
dominant O O
suppressor O O
of O O
sec4 B B_GENE/B_BACTERIUM[BIO]
- I B_GENE/I_BACTERIUM[BIO]
8 I B_GENE/I_BACTERIUM[BIO]
that O O
encodes O O
a O O
nucleotide O O
exchange O O
protein O O
that O O
aids O O
Sec4p B B_GENE
function O O
. O O

These O O
findings O O
indicate O O
that O O
KCTG O O
can O O
contribute O O
to O O
improved O O
monitoring O O
in O O
high O O
- O O
risk O O
pregnancies O O
. O O

The O O
MI O O
site O O
is O O
predictive O O
of O O
hemodynamic O O
left O O
ventricular O O
dysfunction O O
both O O
at O O
rest O O
and O O
during O O
exercise O O
: O O
anterior O O
MIs O O
are O O
more O O
impaired O O
than O O
inferior O O
MIs O O
. O O

The O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IL B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
2R I I_PROTEIN[GENE]/I_LOCATION
alpha I I_PROTEIN[GENE]/I_LOCATION
) O O
chain O O
gene O O
contains O O
a O O
sequence O O
similar O O
to O O
the O O
immunoglobulin B B_GENE
( I I_GENE
Ig I I_GENE
) I I_GENE
kappa I I_GENE
( O O
kappa O O
) O O
enhancer O O
NF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
kappa I I_GENE/I_LOCATION
B I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
. O O

Comparison O O
of O O
the O O
derived O O
amino O O
acid O O
sequence O O
with O O
that O O
of O O
the O O
HCMV B B_GENE/B_PERSON
UL99 I I_GENE/I_PERSON
gene I I_GENE/I_PERSON
product I I_GENE/I_PERSON
reveals O O
34 O O
. O O
8 O O
% O O
identity O O
in O O
an O O
overlap O O
of O O
66 O O
amino O O
acids O O
. O O

Although O O
mutant B B_SPECIES[BIO]/B_GENE
pex5delta I I_SPECIES[BIO]/I_GENE
cells O O
expressing O O
a O O
yeast B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tobacco I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Pex5p I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chimaera I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failed O O
to O O
import O O
a O O
GFP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
Eci1p B B_GENE
reporter O O
protein O O
, O O
they O O
were O O
able O O
to O O
grow O O
on O O
oleic O O
acid O O
. O O

Consistent O O
with O O
this O O
observation O O
, O O
introduction O O
of O O
Smad B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
into O O
a O O
TGFbeta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
insensitive O O
LEF1 B B_GENE/B_LOCATION
/ O O
TCF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O O
gene O O
confers O O
cooperative O O
TGFbeta B B_GENE/B_DISEASE
and O O
Wnt B B_GENE
responsiveness O O
to O O
the O O
promoter O O
. O O

In O O
analogy O O
to O O
human B B_GENE
CD70 I I_GENE
, O O
mCD70 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcript I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
are O O
strongly O O
but O O
transiently O O
up O O
- O O
regulated O O
during O O
lymphocyte O O
activation O O
, O O
which O O
is O O
in O O
line O O
with O O
a O O
role O O
for O O
the O O
CD27 B B_GENE
- I I_GENE
CD70 I I_GENE
receptor I I_GENE
pair O O
early O O
in O O
the O O
immune O O
response O O
. O O

Serum B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IgM I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
showed O O
a O O
highly O O
significant O O
increase O O
in O O
all O O
types O O
of O O
brain O O
tumour O O
when O O
compared O O
to O O
controls O O
. O O

Beyond O O
the O O
first O O
year O O
post O O
- O O
renal O O
transplantation O O
there O O
was O O
no O O
difference O O
in O O
C O O
( O O
IO O O
) O O
between O O
LRD O O
and O O
CAD O O
allografts O O
. O O

The O O
phenomena O O
of O O
nursing O O
are O O
deeply O O
rooted O O
in O O
the O O
human O O
condition O O
. O O

Clinical O O
findings O O
plaque O O
index O O
, O O
PI O O
; O O
gingival O O
index O O
, O O
GI O O
; O O
bleeding O O
on O O
probing O O
, O O
BOP O O
; O O
pus O O
discharge O O
, O O
pus O O
; O O
and O O
probing O O
depth O O
, O O
PD O O
at O O
both O O
PT O O
- O O
01 O O
and O O
control O O
sites O O
were O O
measured O O
at O O
every O O
visit O O
for O O
4 O O
weeks O O
. O O

One O O
of O O
these O O
elements O O
resembles O O
the O O
binding O O
site O O
of O O
a O O
previously O O
identified O O
cellular O O
" O O
transcription O O
" O O
factor O O
. O O

NER O O
was O O
also O O
measured O O
by O O
a O O
plasmid O O
host O O
cell O O
re O O
- O O
activation O O
assay O O
using O O
a O O
vector O O
containing O O
a O O
luciferase B B_GENE
reporter I I_GENE
gene I I_GENE
. O O

Plasma O O
Pi O O
, O O
tibia O O
breaking O O
strength O O
, O O
and O O
percentage O O
of O O
tibia O O
ash O O
were O O
increased O O
by O O
raising O O
dietary O O
Pav O O
in O O
the O O
presence O O
of O O
. O O
392 O O
% O O
A1 O O
with O O
either O O
level O O
of O O
Ca O O
. O O

In O O
the O O
fungus O O
Neurospora O O
crassa O O
, O O
nit B B_GENE
- I I_GENE
2 I I_GENE
, O O
the O O
major O O
nitrogen O O
regulatory O O
gene O O
, O O
activates O O
the O O
expression O O
of O O
unlinked O O
structural O O
genes O O
that O O
specify O O
nitrogen O O
- O O
catabolic O O
enzymes O O
during O O
conditions O O
of O O
nitrogen O O
limitation O O
. O O

During O O
an O O
observation O O
period O O
of O O
12 O O
weeks O O
after O O
halving O O
atenolol O O
from O O
a O O
mean O O
dose O O
of O O
82 O O
mg O O
to O O
41 O O
mg O O
, O O
no O O
significant O O
changes O O
in O O
systolic O O
and O O
diastolic O O
blood O O
pressure O O
or O O
in O O
response O O
rate O O
( O O
defined O O
as O O
a O O
diastolic O O
blood O O
pressure O O
of O O
95 O O
mm O O
Hg O O
or O O
less O O
) O O
were O O
observed O O
. O O

Comparative O O
volumetric O O
analysis O O
is O O
defined O O
as O O
the O O
difference O O
between O O
mean O O
corpuscular O O
erythrocyte O O
volume O O
in O O
peripheral O O
blood O O
( O O
MCVB O O
) O O
diluted O O
in O O
urine O O
supernatant O O
after O O
centrifugation O O
and O O
mean O O
corpuscular O O
volume O O
of O O
urinary O O
erythrocytes O O
( O O
MCVU O O
) O O
. O O

PATIENTS O O
: O O
33 O O
HIV O O
- O O
infected O O
, O O
zidovudine O O
- O O
experienced O O
patients O O
with O O
serum O O
HIV O O
RNA O O
levels O O
of O O
at O O
least O O
20 O O
, O O
000 O O
copies O O
/ O O
mL O O
and O O
CD4 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
counts O O
ranging O O
from O O
50 O O
to O O
400 O O
cells O O
/ O O
mm3 O O
. O O

Within O O
the O O
last O O
few O O
years O O
, O O
the O O
WWW O O
has O O
grown O O
enormously O O
. O O

On O O
the O O
basis O O
of O O
8 O O
cases O O
, O O
the O O
authors O O
report O O
different O O
clinical O O
pictures O O
all O O
caused O O
by O O
cardiac O O
toxicity O O
of O O
5FU O O
. O O

The O O
sequence O O
of O O
Vac1p B B_GENE/B_BIO
contains O O
two O O
putative O O
zinc O O
- O O
binding O O
RING O O
motifs O O
, O O
a O O
zinc O O
finger O O
motif O O
, O O
and O O
a O O
coiled O O
- O O
coil O O
motif O O
. O O

Although O O
cardiac O O
output O O
decreased O O
slightly O O
with O O
PCF O O
, O O
hemodynamic O O
changes O O
due O O
to O O
PCF O O
were O O
unlikely O O
to O O
account O O
for O O
the O O
observed O O
fall O O
in O O
PaO2 O O
. O O

S O O
. O O
aureus O O
leakage O O
into O O
the O O
totally O O
submerged O O
test O O
specimens O O
was O O
detected O O
in O O
1 O O
of O O
5 O O
samples O O
incubated O O
for O O
4 O O
weeks O O
, O O
while O O
no O O
leakage O O
was O O
detected O O
in O O
specimens O O
incubated O O
for O O
3 O O
, O O
5 O O
, O O
6 O O
, O O
7 O O
, O O
and O O
8 O O
weeks O O
. O O

We O O
examined O O
the O O
contribution O O
of O O
a O O
cryptic O O
plasmid O O
, O O
pRmeGR4b O O
, O O
to O O
the O O
nodulation O O
of O O
Medicago O O
sativa O O
by O O
strain O O
GR4 O O
of O O
Rhizobium O O
meliloti O O
. O O

It O O
also O O
appears O O
that O O
in O O
patients O O
with O O
laboratory O O
diagnosis O O
of O O
prerenal O O
acute O O
renal O O
failure O O
( O O
i O O
. O O
e O O
. O O
, O O
a O O
RFT O O
less O O
than O O
1 O O
. O O
0 O O
) O O
, O O
the O O
response O O
to O O
treatment O O
is O O
unpredictable O O
and O O
in O O
fact O O
may O O
have O O
a O O
worse O O
prognosis O O
than O O
in O O
those O O
with O O
a O O
RFI O O
greater O O
than O O
1 O O
. O O
0 O O
( O O
5 O O
/ O O
7 O O
deaths O O
vs O O
10 O O
/ O O
48 O O
deaths O O
) O O
. O O

Paraplegia O O
associated O O
with O O
intraaortic O O
balloon O O
pump O O
counterpulsation O O
. O O

CTP O O
, O O
GDP O O
, O O
GTP O O
, O O
ITP O O
) O O
did O O
not O O
affect O O
the O O
response O O
. O O

The O O
anaesthetic O O
management O O
of O O
41 O O
patients O O
who O O
underwent O O
cardiac O O
transplantation O O
during O O
a O O
40 O O
month O O
period O O
at O O
Clinica O O
Puerta O O
de O O
Hierro O O
is O O
reviewed O O
. O O

Acute O O
respiratory O O
distress O O
syndrome O O
. O O

To O O
investigate O O
the O O
step O O
of O O
spliceosome O O
assembly O O
at O O
which O O
Snu17p B B_GENE
acts O O
, O O
we O O
have O O
used O O
nondenaturing O O
gel O O
electrophoresis O O
. O O

We O O
also O O
show O O
that O O
an O O
internal O O
fragment O O
of O O
U24 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
methylation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
guide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
snoRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
encompassing O O
the O O
upstream O O
antisense O O
element O O
and O O
the O O
D O O
' O O
and O O
C O O
' O O
box O O
motifs O O
, O O
can O O
support O O
the O O
site O O
- O O
specific O O
methylation O O
of O O
rRNA O O
. O O

Mammalian O O
ribonucleotide B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reductase I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shows O O
S O O
- O O
phase O O
specific O O
expression O O
and O O
consists O O
of O O
two O O
non O O
- O O
identical O O
subunits O O
, O O
proteins B B_PROTEIN[GENE]/B_DISEASE
R1 I I_PROTEIN[GENE]/I_DISEASE
( O O
large O O
subunit O O
) O O
and O O
R2 B B_PROTEIN[GENE]
( O O
small O O
subunit O O
) O O
. O O

Effects O O
of O O
dexamethasone O O
on O O
the O O
development O O
of O O
radiation O O
nephropathy O O
in O O
the O O
rat O O
. O O

We O O
previously O O
demonstrated O O
that O O
AKT2 B B_GENE
, O O
a O O
member O O
of O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
activated O O
by O O
a O O
number O O
of O O
growth O O
factors O O
via O O
Ras B B_GENE/B_DISEASE
and O O
PI B B_GENE
3 I I_GENE
- I I_GENE
kinase I I_GENE
signaling O O
pathways O O
. O O

So O O
it O O
is O O
sometimes O O
more O O
convenient O O
to O O
use O O
the O O
back O O
Radon O O
transform O O
R O O
- O O
1 O O
and O O
then O O
to O O
correct O O
the O O
result O O
, O O
taking O O
into O O
account O O
attenuation O O
. O O

Before O O
flecainide O O
, O O
all O O
patients O O
had O O
easily O O
inducible O O
VT O O
that O O
was O O
morphologically O O
identical O O
to O O
their O O
spontaneously O O
occurring O O
arrhythmia O O
. O O

An O O
additional O O
dose O O
of O O
20 O O
- O O
25 O O
Gy O O
was O O
delivered O O
to O O
the O O
site O O
of O O
original O O
involvement O O
using O O
an O O
implant O O
when O O
feasible O O
. O O

The O O
expected O O
products O O
of O O
the O O
cloned O O
bph B B_GENE
genes I I_GENE
, O O
except O O
bphA3 B B_GENE/B_BIO
, O O
were O O
observed O O
in O O
E O O
. O O
coli O O
in O O
an O O
in O O
vitro O O
transcription O O
- O O
translation O O
system O O
. O O

It O O
is O O
our O O
conclusion O O
that O O
Sonoclot O O
coagulation O O
analysis O O
is O O
unlikely O O
to O O
identify O O
patients O O
with O O
prolonged O O
bleeding O O
time O O
in O O
whom O O
platelet O O
count O O
and O O
other O O
coagulation O O
factors O O
are O O
normal O O
. O O

Salts O O
of O O
these O O
four O O
metal O O
ions O O
may O O
be O O
added O O
to O O
the O O
growth O O
medium O O
to O O
facilitate O O
selective O O
isolation O O
of O O
Acinetobacter O O
. O O

The O O
consensus O O
mammalian O O
ER O O
stress O O
response O O
element O O
( O O
ERSE O O
) O O
conserved O O
among O O
grp B B_SPECIES[BIO]/B_GENE
promoters I I_SPECIES[BIO]/I_GENE
consists O O
of O O
a O O
tripartite O O
structure O O
CCAAT O O
( O O
N9 O O
) O O
CCACG O O
, O O
with O O
N O O
being O O
a O O
strikingly O O
GC O O
- O O
rich O O
region O O
of O O
9 O O
bp O O
. O O

Acute O O
toxicity O O
tests O O
were O O
conducted O O
to O O
measure O O
the O O
response O O
of O O
first O O
instar O O
Toxorhynchites O O
splendens O O
to O O
commonly O O
used O O
mosquito O O
adulticides O O
: O O
malathion O O
, O O
naled O O
and O O
resmethrin O O
. O O

A O O
positive O O
correlation O O
was O O
also O O
established O O
between O O
the O O
level O O
of O O
FP9C B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
and O O
the O O
degree O O
of O O
cell O O
differentiation O O
in O O
vitro O O
. O O

Effects O O
of O O
acute O O
exposure O O
to O O
cold O O
on O O
pulmonary O O
arterial O O
blood O O
pressure O O
in O O
awake O O
rats O O
. O O

When O O
labeled O O
by O O
the O O
described O O
method O O
, O O
99mTc O O
on O O
DTPA O O
coupled O O
antibodies O O
shows O O
instability O O
in O O
serum O O
but O O
superior O O
stability O O
than O O
99mTc O O
on O O
antibodies O O
without O O
the O O
attached O O
DTPA O O
. O O

Unlike O O
CSK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
SH3 B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
domain I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
HYL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
unique O O
since O O
the O O
ALYDY O O
motif O O
was O O
absent O O
. O O

As O O
the O O
mechanism O O
of O O
the O O
intractability O O
, O O
cell O O
function O O
involved O O
in O O
the O O
defense O O
against O O
infection O O
was O O
evaluated O O
. O O

88 O O
, O O
3739 O O
- O O
3743 O O
) O O
) O O
. O O

OBJECTIVE O O
: O O
To O O
report O O
a O O
case O O
of O O
fulminant O O
neuropathy O O
with O O
severe O O
quadriparesis O O
associated O O
with O O
vincristine O O
chemotherapy O O
. O O

The O O
median O O
survival O O
time O O
was O O
18 O O
months O O
. O O

Hemorrheological O O
evaluation O O
and O O
proposed O O
pharmacological O O
uses O O
. O O

Its O O
phosphorylation O O
strongly O O
potentiates O O
its O O
ability O O
to O O
activate O O
transcription O O
of O O
the O O
c B B_GENE
- I I_GENE
fos I I_GENE
promoter I I_GENE
through O O
a O O
ternary O O
complex O O
assembled O O
on O O
the O O
c B B_GENE
- I I_GENE
fos I I_GENE
serum I I_GENE
response I I_GENE
element I I_GENE
. O O

Consistent O O
with O O
our O O
observation O O
that O O
AP B B_GENE
- I I_GENE
1 I I_GENE
binding O O
does O O
not O O
contribute O O
to O O
c B B_GENE
- I I_GENE
Jun I I_GENE
coactivation O O
is O O
the O O
observation O O
that O O
the O O
activation O O
of O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
c B B_GENE
- I I_GENE
Jun I I_GENE
is O O
blocked O O
by O O
overexpression O O
of O O
c B B_GENE
- I I_GENE
Fos I I_GENE
. O O

A O O
possible O O
correlation O O
between O O
mandibular O O
growth O O
retardation O O
and O O
palatal O O
clefting O O
is O O
discussed O O
. O O

Time O O
dependence O O
of O O
frequency O O
potentiation O O
in O O
the O O
isolated O O
guinea O O
- O O
pig O O
' O O
s O O
atrium O O
. O O

We O O
found O O
4 O O
highly O O
conserved O O
regions O O
to O O
vertebrate B B_LOCATION/B_ENZYME[GENE]
Hsp90 I I_LOCATION/I_ENZYME[GENE]
exclusively O O
and O O
27 O O
amino O O
acids O O
conserved O O
among O O
but O O
differing O O
between O O
Hsp90 B B_SPECIES[BIO]/B_GENE
alpha I I_SPECIES[BIO]/I_GENE
and O O
Hsp90 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Characterization O O
of O O
trinucleotide O O
- O O
and O O
tandem O O
repeat O O
- O O
containing O O
transcripts O O
obtained O O
from O O
human O O
spinal O O
cord O O
cDNA O O
library O O
by O O
high O O
- O O
density O O
filter O O
hybridization O O
. O O

We O O
present O O
here O O
the O O
complete O O
primary O O
structure O O
of O O
human B B_GENE
gp330 I I_GENE
, O O
the O O
human O O
variant O O
of O O
the O O
principal O O
kidney O O
autoantigen O O
causing O O
Heymann O O
membranous O O
glomerulonephritis O O
in O O
rats O O
. O O

The O O
platelet B B_GENE
membrane I I_GENE
glycoprotein I I_GENE
IIb I I_GENE
/ I I_GENE
IIIa I I_GENE
receptor I I_GENE
inhibitor O O
abciximab O O
is O O
used O O
for O O
the O O
treatment O O
of O O
patients O O
undergoing O O
high O O
- O O
risk O O
percutaneous O O
coronary O O
interventions O O
and O O
is O O
used O O
in O O
approximately O O
one O O
third O O
of O O
coronary O O
interventions O O
in O O
the O O
United O O
States O O
and O O
a O O
growing O O
number O O
of O O
procedures O O
in O O
Europe O O
. O O

In O O
the O O
conscious O O
animals O O
the O O
increase O O
reached O O
statistical O O
significance O O
when O O
the O O
animals O O
were O O
exposed O O
to O O
12 O O
% O O
oxygen O O
in O O
nitrogen O O
, O O
which O O
produced O O
a O O
fall O O
in O O
arterial O O
PaO2 O O
of O O
44 O O
. O O
7 O O
+ O O
/ O O
- O O
5 O O
. O O
0 O O
% O O
. O O

Prenatal O O
diagnosis O O
of O O
genetic O O
diseases O O
. O O

Human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
epidermal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EGF B B_GENE/B_DISEASE
) O O
, O O
a O O
naturally O O
occurring O O
protein O O
, O O
has O O
been O O
implicated O O
in O O
the O O
protection O O
of O O
gastrointestinal O O
mucosal O O
integrity O O
. O O

A O O
ready O O
- O O
made O O
prosthesis O O
is O O
placed O O
on O O
the O O
external O O
side O O
of O O
the O O
ribs O O
vertically O O
bridging O O
the O O
flailed O O
chest O O
segment O O
, O O
and O O
fixed O O
to O O
the O O
first O O
upper O O
and O O
first O O
lower O O
intact O O
rib O O
as O O
well O O
as O O
to O O
the O O
mobile O O
segments O O
of O O
the O O
affected O O
ribs O O
. O O

DESIGN O O
: O O
Prospective O O
case O O
study O O
( O O
Canadian O O
Task O O
Force O O
classification O O
II O O
- O O
2 O O
) O O
. O O

Site O O
- O O
directed O O
mutagenesis O O
of O O
the O O
T4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
endonuclease I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
V I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
role O O
of O O
lysine O O
- O O
130 O O
. O O

A O O
minimal O O
pheromone O O
induction O O
domain O O
, O O
delineated O O
as O O
residues O O
301 O O
to O O
335 O O
of O O
Ste12p B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
dependent O O
on O O
the O O
pheromone O O
mitogen B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activated I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
protein I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
MAP I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kinase I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
pathway O O
for O O
induction O O
activity O O
. O O

The O O
library O O
will O O
thus O O
be O O
useful O O
for O O
the O O
selection O O
of O O
cosmid O O
clones O O
which O O
carry O O
CDC B B_GENE
genes I I_GENE
from I I_GENE
yeast I I_GENE
by O O
complementing O O
first O O
, O O
with O O
the O O
vectorial O O
yeast B B_GENE/B_BIO
gene I I_GENE/I_BIO
URA1 I I_GENE/I_BIO
, O O
the O O
pyrimidine O O
auxotrophy O O
of O O
most O O
cdc B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
strains O O
and O O
then O O
, O O
with O O
the O O
respective O O
CDC B B_GENE/B_MEASURE
wild I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
type I I_GENE/I_MEASURE
genes I I_GENE/I_MEASURE
, O O
of O O
the O O
temperature O O
- O O
sensitive O O
mutant O O
alleles O O
. O O

These O O
mutant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
rps7 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leaders O O
were O O
ligated O O
into O O
an O O
aadA O O
expression O O
cassette O O
and O O
transformed O O
into O O
the O O
chloroplast O O
of O O
C O O
. O O
reinhardtii O O
and O O
into O O
E O O
. O O
coli O O
. O O

In O O
addition O O
, O O
both O O
activated O O
Ral B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GDS I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O O
and O O
Raf B B_GENE/B_DISEASE
stimulate O O
cyclin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcription O O
and O O
E2F B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
and O O
act O O
in O O
synergy O O
with O O
PI B B_GENE
3 I I_GENE
- I I_GENE
kinase I I_GENE
. O O

From O O
the O O
present O O
results O O
a O O
concept O O
of O O
hormone O O
- O O
dependent O O
AR B B_GENE/B_DISEASE
activation O O
is O O
proposed O O
, O O
which O O
requires O O
a O O
functional O O
, O O
direct O O
or O O
indirect O O
intramolecular O O
interaction O O
between O O
the O O
TAD O O
and O O
the O O
LBD O O
. O O

Down O O
- O O
regulation O O
of O O
Id1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
correlated O O
with O O
mitogenesis O O
and O O
occurred O O
when O O
quiescent O O
cells O O
were O O
treated O O
with O O
growth O O
factors O O
that O O
activate O O
G B B_GENE
protein I I_GENE
- I I_GENE
coupled I I_GENE
receptors I I_GENE
and O O
receptor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
but O O
not O O
with O O
a O O
non O O
- O O
mitogenic O O
cAMP O O
analog O O
. O O

Secretogranin B B_GENE
II I I_GENE
( O O
SgII B B_GENE/B_LOCATION
) O O
is O O
a O O
secretory O O
polypeptide O O
stored O O
in O O
large O O
dense O O
core O O
vesicles O O
of O O
neuroendocrine O O
and O O
neuronal O O
cells O O
. O O

CONCLUSIONS O O
: O O
In O O
the O O
results O O
of O O
this O O
study O O
, O O
SDB O O
, O O
even O O
snoring O O
, O O
was O O
independently O O
associated O O
with O O
hypertension O O
in O O
both O O
men O O
and O O
women O O
. O O

The O O
electron O O
spin O O
resonance O O
study O O
also O O
demonstrated O O
that O O
the O O
formation O O
of O O
superoxide O O
- O O
DMPO O O
spin O O
adduct O O
was O O
strongly O O
inhibited O O
by O O
a O O
selective O O
cyclooxygenase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
, O O
etodolac O O
, O O
in O O
a O O
concentration O O
- O O
dependent O O
manner O O
. O O

Embryonal O O
mortality O O

Interestingly O O
, O O
unlike O O
PAK65 B B_GENE
, O O
HPK1 B B_GENE/B_LOCATION
does O O
not O O
contain O O
the O O
small B B_GENE
GTPase I I_GENE
Rac1 B I_GENE
/ O O
Cdc42 B B_GENE
- O O
binding O O
domain O O
and O O
does O O
not O O
bind O O
to O O
either O O
Rac1 B B_GENE
or O O
Cdc42 B B_GENE
, O O
suggesting O O
that O O
HPK1 B B_PROTEIN[GENE]/B_DISEASE
. O O
activation O O
is O O
Rac1 B B_GENE
/ O O
Cdc42 B B_GENE
- O O
independent O O
. O O

The O O
results O O
were O O
compared O O
with O O
the O O
findings O O
in O O
pair O O
- O O
fed O O
non O O
- O O
treated O O
animals O O
( O O
Control O O
Group O O
) O O
. O O

Tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
were O O
measured O O
by O O
enzyme O O
- O O
linked O O
immunoabsorbent O O
assay O O
in O O
plasma O O
samples O O
obtained O O
from O O
the O O
hyperthermic O O
isolated O O
limb O O
perfusion O O
circuit O O
and O O
systemic O O
circulation O O
. O O

However O O
, O O
only O O
plasma B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibrinogen I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O O
showed O O
statistically O O
significant O O
positive O O
associations O O
with O O
IMT O O
in O O
both O O
groups O O
. O O

Without O O
a O O
team O O
, O O
there O O
is O O
little O O
hope O O
for O O
fetal O O
survival O O
; O O
mortality O O
will O O
be O O
80 O O
- O O
100 O O
% O O
. O O

Analysis O O
of O O
deletion O O
and O O
substitution O O
mutations O O
in O O
the O O
MER2 B B_GENE/B_BIO
5 I I_GENE/I_BIO
' I I_GENE/I_BIO
exon I I_GENE/I_BIO
demonstrates O O
that O O
the O O
unusually O O
large O O
size O O
of O O
this O O
exon O O
plays O O
an O O
important O O
role O O
in O O
splicing O O
regulation O O
. O O

To O O
study O O
the O O
signaling O O
pathways O O
that O O
regulate O O
cytoskeletal O O
rearrangements O O
in O O
T O O
lymphocytes O O
, O O
we O O
set O O
up O O
a O O
conjugate O O
formation O O
assay O O
using O O
Jurkat O O
T O O
cells O O
as O O
effectors O O
and O O
cell O O
- O O
sized O O
latex O O
beads O O
coated O O
with O O
various O O
antibodies O O
as O O
artificial O O
APCs O O
. O O

Reexamination O O
of O O
the O O
cdc4 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutant I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
revealed O O
that O O
, O O
in O O
addition O O
to O O
being O O
defective O O
in O O
the O O
onset O O
of O O
S O O
phase O O
, O O
it O O
is O O
also O O
defective O O
in O O
G O O
( O O
2 O O
) O O
/ O O
M O O
transition O O
when O O
released O O
from O O
hydroxyurea O O
- O O
induced O O
S O O
- O O
phase O O
arrest O O
. O O

All O O
such O O
polypeptides O O
containing O O
263 O O
or O O
more O O
residues O O
derived O O
from O O
the O O
C O O
- O O
terminus O O
of O O
P130gag B B_MEASURE/B_GENE
- O O
fps B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
i O O
. O O
e O O
. O O
residues O O
920 O O
- O O
1182 O O
) O O
were O O
enzymatically O O
active O O
as O O
tyrosine B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
kinases I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
. O O

A O O
structural O O
model O O
for O O
Vpu B B_GENE/B_BACTERIUM[BIO]
is O O
proposed O O
in O O
which O O
the O O
membrane O O
anchor O O
precedes O O
a O O
region O O
comprising O O
two O O
amphipathic O O
alpha O O
- O O
helices O O
of O O
opposed O O
polarity O O
, O O
joined O O
by O O
a O O
strongly O O
acidic O O
turn O O
that O O
protrudes O O
into O O
the O O
cytoplasm O O
and O O
contains O O
the O O
CK B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
2 I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
phosphorylation I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
sites I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
recombinant O O
containing O O
the O O
full O O
- O O
length O O
polyhedrin B B_PROTEIN[GENE]/B_BIO
leader O O
sequence O O
gave O O
levels O O
of O O
N B B_GENE
mRNA I I_GENE
comparable O O
to O O
those O O
of O O
AcNPV B B_GENE/B_BIO
polyhedrin I I_GENE/I_BIO
mRNA I I_GENE/I_BIO
. O O

Immune O O
and O O
clinical O O
impact O O
of O O
Lactobacillus O O
acidophilus O O
on O O
asthma O O
. O O

A O O
proposed O O
method O O
. O O

A O O
model O O
for O O
the O O
SMase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
sphingomyelin O O
complex O O
structure O O
was O O
built O O
to O O
investigate O O
how O O
the O O
SMase B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
specifically O O
recognizes O O
its O O
substrate O O
. O O

Two O O
estimates O O
of O O
the O O
fractal O O
exponent O O
are O O
considered O O
which O O
do O O
not O O
suffer O O
from O O
this O O
limit O O
: O O
one O O
derived O O
from O O
the O O
Allan O O
variance O O
, O O
which O O
was O O
developed O O
by O O
the O O
authors O O
, O O
and O O
one O O
based O O
on O O
the O O
periodogram O O
. O O

Births O O
, O O
marriages O O
, O O
divorces O O
, O O
and O O
deaths O O
for O O
July O O
1997 O O
. O O

In O O
conclusion O O
, O O
in O O
coronary O O
artery O O
disease O O
patients O O
, O O
exercise O O
- O O
redistribution O O
201Thallium O O
cardiac O O
imaging O O
with O O
reinjection O O
at O O
rest O O
can O O
identify O O
severely O O
ischemic O O
but O O
still O O
viable O O
myocardium O O
and O O
may O O
be O O
particularly O O
useful O O
in O O
the O O
prognosis O O
of O O
such O O
patients O O
. O O

However O O
, O O
the O O
recovery O O
curve O O
of O O
the O O
R2 O O
component O O
of O O
the O O
blink O O
reflex O O
diminished O O
in O O
patients O O
with O O
tension O O
- O O
type O O
headache O O
compared O O
with O O
the O O
other O O
groups O O
. O O

Transforming B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TGF B B_GENE
- I I_GENE
beta I I_GENE
) O O
inhibits O O
cell O O
cycle O O
progression O O
, O O
in O O
part O O
through O O
up O O
- O O
regulation O O
of O O
gene O O
expression O O
of O O
the O O
p21 B B_GENE
( O O
WAF1 B B_PROTEIN[GENE]/B_LOCATION
/ O O
Cip1 B B_PROTEIN[GENE]/B_MEASURE
) O O
( O O
p21 B B_GENE/B_DISEASE
) O O
cell O O
cycle O O
inhibitor O O
. O O

The O O
results O O
suggest O O
that O O
both O O
superficial O O
and O O
deep O O
cortical O O
venous O O
drainage O O
of O O
the O O
cat O O
kidney O O
should O O
be O O
considered O O
when O O
measuring O O
renal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
renin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
release O O
. O O

CONCLUSION O O
: O O
Detection O O
of O O
recurrent O O
head O O
and O O
neck O O
cancer O O
is O O
feasible O O
with O O
FDG O O
PET O O
. O O

There O O
were O O
no O O
differences O O
in O O
the O O
incidence O O
of O O
fractured O O
zonas O O
. O O

DSIP O O
was O O
found O O
to O O
significantly O O
increase O O
slow O O
- O O
waves O O
( O O
delta O O
sleep O O
) O O
in O O
the O O
sleep O O
EEG O O
. O O

Accuracy O O
and O O
predictive O O
value O O
of O O
ultrasound O O
in O O
acute O O
rejection O O
. O O

7 O O
- O O
Nitroindazole O O
( O O
7NI O O
) O O
, O O
a O O
relatively O O
selective O O
neuronal O O
nitric B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
synthase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
nNOS B B_GENE/B_LOCATION
) O O
inhibitor O O
. O O
was O O
intraperitoneally O O
administered O O
to O O
the O O
guinea O O
pigs O O
30 O O
minutes O O
before O O
the O O
onset O O
of O O
local O O
anoxia O O
. O O

Mutations O O
that O O
extend O O
the O O
specificity O O
of O O
the O O
endonuclease O O
activity O O
of O O
lambda B B_GENE
terminase I I_GENE
. O O

The O O
gene O O
set O O
in O O
this O O
mitochondrial O O
genome O O
is O O
a O O
subset O O
of O O
that O O
of O O
Reclinomonas O O
americana O O
, O O
an O O
amoeboid O O
protozoan O O
. O O

An O O
evaluation O O
of O O
a O O
positive O O
control O O
for O O
platelet O O
neutralization O O
procedure O O
testing O O
with O O
seven O O
commercial O O
activated O O
partial O O
thromboplastin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
time O O
reagents O O
. O O

The O O
prosomal B B_GENE/B_BIO
RNA I I_GENE/I_BIO
- I I_GENE/I_BIO
binding I I_GENE/I_BIO
protein I I_GENE/I_BIO
p27K I I_GENE/I_BIO
is O O
a O O
member O O
of O O
the O O
alpha B B_GENE/B_PERSON
- I I_GENE/I_PERSON
type I I_GENE/I_PERSON
human I I_GENE/I_PERSON
prosomal I I_GENE/I_PERSON
gene I I_GENE/I_PERSON
family I I_GENE/I_PERSON
. O O

A O O
single O O
clone O O
, O O
which O O
was O O
conserved O O
and O O
had O O
near O O
- O O
perfect O O
homology O O
to O O
eight O O
human O O
/ O O
rodent O O
expressed O O
sequence O O
tags O O
, O O
was O O
used O O
as O O
template O O
for O O
5 O O
' O O
and O O
3 O O
' O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
and O O
SPICE O O
( O O
system O O
for O O
polymerase O O
chain O O
reaction O O
amplification O O
of O O
cDNA O O
ends O O
) O O
reactions O O
to O O
obtain O O
the O O
3 O O
. O O
6 O O
- O O
kb O O
cDNA O O
, O O
LGL2 B B_PROTEIN[GENE]/B_LOCATION
( O O
Genbank B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
110195 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
encoding O O
a O O
deduced O O
polypeptide O O
( O O
lgl2 B B_GENE
) O O
of O O
963 O O
amino O O
acids O O
. O O

These O O
tiny O O
premature O O
infants O O
also O O
received O O
PN O O
for O O
significantly O O
longer O O
periods O O
of O O
time O O
, O O
and O O
the O O
longer O O
the O O
infusions O O
were O O
administered O O
the O O
greater O O
was O O
the O O
risk O O
of O O
cholestasis O O
developing O O
. O O

The O O
SM O O
- O O
specific O O
selection O O
of O O
exon O O
2 O O
results O O
from O O
the O O
inhibition O O
of O O
exon O O
3 O O
. O O

It O O
is O O
always O O
present O O
and O O
has O O
a O O
discrete O O
origin O O
and O O
insertion O O
. O O

Medical O O
management O O
of O O
early O O
- O O
stage O O
breast O O
cancer O O
. O O

In O O
6 O O
patients O O
( O O
9 O O
kidneys O O
) O O
irrigation O O
with O O
Solution O O
G O O
in O O
the O O
renal O O
pelvis O O
was O O
performed O O
for O O
the O O
dissolution O O
of O O
their O O
infectious O O
stones O O
. O O

The O O
use O O
of O O
sigma B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
54 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoters I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
known O O
to O O
require O O
cognate O O
binding O O
proteins O O
, O O
could O O
allow O O
the O O
fine O O
- O O
tuning O O
that O O
provides O O
the O O
temporal O O
ordering O O
of O O
flagellar O O
gene O O
transcription O O
. O O

The O O
association O O
of O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
92 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
p92 B B_GENE
, O O
p84 B B_GENE/B_MEASURE
, O O
p75 B B_GENE/B_MEASURE
, O O
p73 B B_GENE/B_MEASURE
, O O
p69 B B_GENE/B_MEASURE
, O O
and O O
p57 B B_GENE
was O O
completely O O
reversible O O
after O O
treatment O O
with O O
the O O
detergent O O
deoxycholate O O
( O O
DOC O O
) O O
. O O

To O O
our O O
knowledge O O
no O O
transcription O O
factors O O
have O O
previously O O
been O O
identified O O
that O O
exhibit O O
androgen O O
- O O
dependent O O
expression O O
in O O
the O O
epididymis O O
. O O

Focal O O
or O O
regional O O
8 O O
- O O
to O O
20 O O
- O O
Hz O O
low O O
- O O
voltage O O
epileptiform O O
paroxysms O O
in O O
either O O
hippocampus O O
( O O
10 O O
patients O O
) O O
, O O
amygdala O O
( O O
1 O O
patient O O
) O O
, O O
or O O
both O O
( O O
1 O O
patient O O
) O O
preceded O O
initial O O
motionless O O
staring O O
. O O

The O O
lack O O
of O O
heterozygous O O
positions O O
essentially O O
facilitates O O
on O O
the O O
one O O
hand O O
the O O
data O O
analysis O O
and O O
on O O
the O O
other O O
hand O O
the O O
detection O O
of O O
new O O
alleles O O
. O O

Epithelial O O
cell O O
- O O
specific O O
activation O O
is O O
achieved O O
by O O
the O O
cooperative O O
interaction O O
of O O
apparently O O
ubiquitous O O
transcriptional O O
factors O O
. O O

The O O
effectiveness O O
and O O
pathogenetic O O
expediency O O
of O O
correcting O O
disorders O O
of O O
lipid O O
metabolism O O
in O O
atherosclerosis O O
with O O
enterosorbents O O
is O O
substantiated O O
. O O

To O O
prevent O O
section O O
wrinkles O O
usually O O
encountered O O
with O O
the O O
use O O
of O O
coated O O
single O O
- O O
hole O O
grids O O
, O O
a O O
simple O O
method O O
was O O
developed O O
. O O

The O O
Cryotherapy O O
for O O
Retinopathy O O
of O O
Prematurity O O
Study O O
has O O
shown O O
that O O
this O O
number O O
can O O
be O O
halved O O
with O O
treatment O O
. O O

Ultrasound O O
- O O
guided O O
fine O O
- O O
needle O O
aspiration O O
biopsy O O
( O O
US O O
- O O
FNAB O O
) O O
revealed O O
normal O O
- O O
looking O O
squamous O O
cells O O
. O O

Bleeding O O
was O O
successfully O O
prevented O O
in O O
28 O O
patients O O
with O O
the O O
use O O
of O O
a O O
combined O O
treatment O O
incorporating O O
IV O O
desmopressin O O
, O O
an O O
antifibrinolytic O O
agent O O
( O O
tranexamic O O
acid O O
) O O
, O O
and O O
local O O
methods O O
( O O
surgical O O
glue O O
and O O
compression O O
techniques O O
) O O
. O O

Hetero O O
- O O
oligomerization O O
of O O
Smad4 B B_GENE
with O O
the O O
pathway O O
- O O
restricted O O
SMAD B B_GENE/B_LOCATION
proteins I I_GENE/I_LOCATION
is O O
essential O O
for O O
Smad4 B B_GENE
- O O
mediated O O
transcription O O
. O O

One O O
of O O
them O O
is O O
its O O
limited O O
sensitivity O O
to O O
weak O O
interactions O O
, O O
which O O
are O O
common O O
in O O
the O O
mammalian O O
cerebral O O
cortex O O
. O O

The O O
cerebellar O O
cortical O O
vessels O O
: O O
they O O
are O O
compared O O
to O O
the O O
cerebral O O
vessels O O
. O O

Transesophageal O O
echocardiography O O
risk O O
factors O O
for O O
stroke O O
in O O
nonvalvular O O
atrial O O
fibrillation O O
. O O

22 O O
- O O
Veneto O O
Region O O
) O O

Preventive O O
health O O
counseling O O
tailored O O
to O O
the O O
needs O O
of O O
this O O
group O O
may O O
be O O
most O O
beneficial O O
. O O

Strains O O
lacking O O
a O O
functional B B_GENE
RPL16A I I_GENE
gene I I_GENE
grow O O
as O O
rapidly O O
as O O
wild O O
type O O
, O O
whereas O O
those O O
containing O O
a O O
null O O
allele O O
of O O
RPL16B B B_GENE/B_DISEASE
grow O O
more O O
slowly O O
than O O
wild O O
type O O
. O O

Neonatal O O
hyperthyroidism O O

After O O
Northern O O
blot O O
hybridization O O
, O O
two O O
Cx31 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
detected O O
in O O
total O O
RNA O O
of O O
the O O
human O O
keratinocyte O O
cell O O
line O O
HaCaT O O
and O O
two O O
transcripts O O
of O O
2 O O
. O O
2 O O
and O O
1 O O
. O O
9 O O
kb O O
in O O
total O O
RNA O O
of O O
E6 B B_PROTEIN[GENE]
/ O O
E7 B B_MEASURE/B_PROTEIN[GENE]
transfected O O
human O O
keratinocytes O O
( O O
HEK O O
cells O O
) O O
. O O

In O O
an O O
effort O O
to O O
identify O O
factors O O
involved O O
in O O
the O O
expression O O
of O O
this O O
important O O
erythroid O O
- O O
specific O O
regulatory O O
protein O O
, O O
we O O
have O O
isolated O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
EKLF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
systematically O O
analyzed O O
the O O
promoter O O
region O O
. O O

Their O O
main O O
representatives O O
are O O
the O O
American O O
diagnostic O O
and O O
statistical O O
manual O O
of O O
mental O O
disorders O O
, O O
DSM O O
- O O
III O O
, O O
its O O
revised O O
version O O
DSM O O
- O O
III O O
- O O
R O O
and O O
the O O
new O O
international O O
classification O O
of O O
mental O O
disorders O O
iCD O O
- O O
10 O O
. O O

Any O O
opacity O O
on O O
a O O
chest O O
radiograph O O
has O O
a O O
wide O O
differential O O
diagnosis O O
. O O

At O O
the O O
same O O
acoustic O O
power O O
, O O
the O O
rate O O
of O O
chloride O O
formation O O
with O O
20 O O
kHz O O
ultrasound O O
was O O
greater O O
when O O
a O O
probe O O
with O O
a O O
larger O O
tip O O
area O O
was O O
used O O
, O O
but O O
significantly O O
less O O
than O O
the O O
rate O O
with O O
900 O O
kHz O O
. O O

In O O
contrast O O
to O O
Torpedo O O
, O O
where O O
only O O
a O O
single O O
transcript O O
is O O
seen O O
, O O
the O O
mouse O O
expresses O O
several O O
mRNAs O O
encoding O O
different O O
isoforms O O
. O O

Four O O
families O O
of O O
homing B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
endonucleases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
have O O
been O O
identified O O
, O O
including O O
the O O
LAGLIDADG B B_GENE/B_LOCATION
, O O
the O O
His B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
Cys I I_GENE/I_DISEASE
box I I_GENE/I_DISEASE
, O O
the O O
GIY B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
YIG I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
H B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
N I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
H I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
endonucleases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
GvpE B B_GENE/B_LOCATION
protein I I_GENE/I_LOCATION
involved O O
in O O
the O O
regulation O O
of O O
gas O O
vesicles O O
synthesis O O
in O O
halophilic O O
archaea O O
has O O
been O O
identified O O
as O O
the O O
transcriptional O O
activator O O
for O O
the O O
promoter O O
located O O
upstream O O
of O O
the O O
gvpA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O O
the O O
major O O
gas O O
vesicle O O
structural O O
protein O O
GvpA B B_GENE/B_MEASURE
. O O

Nosographic O O
problems O O

In O O
early O O
midgestation O O
embryos O O
it O O
is O O
expressed O O
in O O
telencephalic O O
, O O
diencephalic O O
and O O
mesencephalic O O
regions O O
but O O
from O O
day O O
11 O O
. O O
75 O O
of O O
gestation O O
its O O
expression O O
disappears O O
from O O
dorsal O O
telencephalon O O
and O O
is O O
confined O O
to O O
diencephalic O O
and O O
mesencephalic O O
regions O O
. O O

The O O
training O O
programs O O
had O O
a O O
duration O O
of O O
30 O O
days O O
, O O
5 O O
days O O
/ O O
week O O
, O O
and O O
was O O
performed O O
on O O
a O O
motor O O
- O O
driven O O
treadmill O O
. O O

Using O O
probes O O
from O O
these O O
regions O O
, O O
rearrangements O O
have O O
been O O
identified O O
in O O
each O O
of O O
nine O O
cases O O
of O O
t O O
( O O
8 O O
; O O
21 O O
) O O
AML O O
examined O O
. O O

Cloning O O
and O O
nucleotide O O
sequence O O
analysis O O
reveals O O
that O O
BUR6 B B_PERSON/B_GENE
encodes O O
a O O
homolog O O
of O O
DRAP1 B B_GENE/B_DISEASE
( O O
also O O
called O O
NC2alpha B B_GENE
) O O
, O O
a O O
mammalian O O
repressor O O
of O O
basal O O
transcription O O
. O O

BRAP2 B B_GENE/B_PERSON
also O O
shares O O
significant O O
homology O O
with O O
a O O
hypothetical O O
protein O O
from O O
yeast O O
Saccharomyces O O
cerevisiae O O
, O O
especially O O
in O O
the O O
zinc O O
finger O O
region O O
. O O

Earlier O O
published O O
data O O
, O O
indicating O O
Sp1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O O
to O O
the O O
R1 B B_PROTEIN[GENE]/B_LOCATION
alpha I I_PROTEIN[GENE]/I_LOCATION
/ I I_PROTEIN[GENE]/I_LOCATION
beta I I_PROTEIN[GENE]/I_LOCATION
regions I I_PROTEIN[GENE]/I_LOCATION
, O O
could O O
not O O
be O O
confirmed O O
, O O
suggesting O O
that O O
the O O
R1 O O
initiator O O
element O O
may O O
function O O
independent O O
of O O
Sp1 B B_GENE
. O O

In O O
addition O O
, O O
reduced O O
metabolism O O
to O O
cotinine O O
from O O
the O O
proliposomes O O
and O O
MP O O
was O O
apparently O O
responsible O O
for O O
the O O
sustained O O
plasma O O
nicotine O O
levels O O
. O O

Activation O O
of O O
HIV O O
- O O
1 O O
requires O O
the O O
binding O O
of O O
host O O
cell O O
transcription O O
factors O O
to O O
cis O O
elements O O
in O O
the O O
proviral O O
long O O
terminal O O
repeat O O
( O O
LTR O O
) O O
. O O

The O O
yeast B B_GENE/B_PERSON
mitochondrial I I_GENE/I_PERSON
Hsp70 I I_GENE/I_PERSON
, O O
Ssc1p B B_GENE/B_LOCATION
, O O
functions O O
as O O
a O O
molecular O O
chaperone O O
with O O
its O O
partner O O
proteins O O
, O O
Mdj1p B B_GENE
( O O
DnaJ B B_GENE
homologue I I_GENE
) O O
and O O
Yge1p B B_GENE
( O O
GrpE B B_GENE/B_PERSON
homologue I I_GENE/I_PERSON
) O O
. O O

Increased O O
TRE O O
DNA O O
binding O O
failed O O
to O O
lead O O
to O O
increased O O
transactivation O O
correlating O O
with O O
the O O
inability O O
of O O
SB O O
203580 O O
to O O
increase O O
phosphorylation O O
of O O
these O O
AP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
rice O O
gene O O
consists O O
of O O
four O O
exons O O
. O O

Methodological O O
considerations O O
limiting O O
causal O O
assertions O O
permissible O O
with O O
nonexperimental O O
data O O
are O O
discussed O O
. O O

In O O
contrast O O
, O O
postmitotic O O
neurons O O
possessed O O
extremely O O
low O O
levels O O
of O O
E2F1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
assessed O O
by O O
the O O
electrophoretic O O
mobility O O
shift O O
assay O O
and O O
Western O O
blotting O O
. O O

Recurrence O O
of O O
the O O
hepatic O O
cyst O O
after O O
partial O O
excision O O
and O O
drainage O O
was O O
complicated O O
by O O
fistula O O
formation O O
between O O
the O O
cyst O O
and O O
the O O
duodenum O O
. O O

Reversal O O
of O O
mefloquine O O
resistance O O
in O O
rodent O O
Plasmodium O O
. O O

Possible O O
consequences O O
of O O
such O O
binder O O
distribution O O
through O O
powder O O
aggregates O O
are O O
discussed O O
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
parvalbumin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
the O O
putative O O
polyadenylation O O
signal O O
AATAAA O O
13 O O
nucleotides O O
upstream O O
from O O
the O O
polyadenylation O O
site O O
. O O

The O O
delta O O
Mo O O
+ O O
SV O O
tumor O O
DNAs O O
from O O
B O O
- O O
lineage O O
tumors O O
were O O
typically O O
rearranged O O
at O O
the O O
immunoglobulin B B_GENE
gene I I_GENE
loci I I_GENE
and O O
contained O O
germ O O
line O O
configurations O O
of O O
the O O
T B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
experimental O O
results O O
suggest O O
equilibrium O O
complex O O
formation O O
between O O
OTC O O
and O O
PVP O O
, O O
it O O
being O O
mainly O O
the O O
complex O O
which O O
is O O
i O O
. O O
v O O
. O O
injected O O
when O O
both O O
products O O
are O O
combined O O
in O O
an O O
injection O O
formulation O O
. O O

We O O
conclude O O
that O O
the O O
MMF O O
lesion O O
is O O
secondary O O
to O O
intramuscular O O
injection O O
of O O
aluminium O O
hydroxide O O
- O O
containing O O
vaccines O O
, O O
shows O O
both O O
long O O
- O O
term O O
persistence O O
of O O
aluminium O O
hydroxide O O
and O O
an O O
ongoing O O
local O O
immune O O
reaction O O
, O O
and O O
is O O
detected O O
in O O
patients O O
with O O
systemic O O
symptoms O O
which O O
appeared O O
subsequently O O
to O O
vaccination O O
. O O

Whereas O O
the O O
sequence O O
of O O
alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
actinin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Noegel O O
, O O
A O O
. O O
, O O
W O O
. O O

By O O
contrast O O
, O O
clonidine O O
( O O
1 O O
micrograms O O
/ O O
kg O O
) O O
elicited O O
an O O
immediate O O
and O O
prolonged O O
fall O O
in O O
blood O O
pressure O O
and O O
heart O O
rate O O
when O O
given O O
into O O
the O O
vertebral O O
artery O O
, O O
but O O
not O O
intravenously O O
. O O

The O O
shift O O
from O O
complex O O
I O O
to O O
complex O O
II O O
seen O O
only O O
in O O
SCM B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
- O O
producer O O
T O O
cell O O
lines O O
upon O O
activation O O
was O O
completely O O
suppressed O O
by O O
cyclosporin O O
A O O
. O O

( O O
We O O
observed O O
a O O
ferritin B B_GENE/B_MEASURE
value O O
as O O
high O O
as O O
47 O O
mg O O
/ O O
L O O
in O O
one O O
patient O O
. O O
) O O
Results O O
with O O
all O O
these O O
kits O O
did O O
not O O
inter O O
- O O
compare O O
well O O
for O O
ferritin B B_PROTEIN[GENE]
concentrations O O
greater O O
than O O
300 O O
micrograms O O
/ O O
L O O
, O O
a O O
finding O O
that O O
casts O O
further O O
doubt O O
on O O
the O O
controversial O O
use O O
of O O
serum B B_MEASURE/B_PROTEIN[GENE]
ferritin I I_MEASURE/I_PROTEIN[GENE]
measurement O O
in O O
cases O O
of O O
iron O O
overload O O
. O O

Post O O
- O O
CPB O O
cardiac O O
index O O
was O O
superior O O
in O O
group O O
B O O
( O O
3 O O
. O O
9 O O
+ O O
/ O O
- O O
0 O O
. O O
3 O O
vs O O
. O O

ER B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
less O O
potent O O
than O O
ER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O O
activating O O
E2 O O
- O O
stimulated O O
ERELuc B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
( O O
4 O O
- O O
vs O O
. O O

The O O
expression O O
pattern O O
of O O
LjEmx B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changed O O
dramatically O O
during O O
embryogenesis O O
; O O
expression O O
was O O
seen O O
initially O O
in O O
the O O
entire O O
neural O O
tube O O
and O O
mesoderm O O
, O O
which O O
were O O
secondarily O O
downregulated O O
, O O
and O O
secondarily O O
in O O
cranial O O
nerve O O
ganglia O O
and O O
in O O
the O O
craniofacial O O
mesenchyme O O
. O O

Disruption O O
of O O
PML B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
subnuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
the O O
acidic B B_GENE
IE1 I I_GENE
protein I I_GENE
of O O
human O O
cytomegalovirus O O
is O O
mediated O O
through O O
interaction O O
with O O
PML B B_GENE/B_DISEASE
and O O
may O O
modulate O O
a O O
RING O O
finger O O
- O O
dependent O O
cryptic O O
transactivator O O
function O O
of O O
PML B B_GENE/B_DISEASE
. O O

Furthermore O O
, O O
the O O
GC O O
- O O
rich O O
sequences O O
could O O
confer O O
Sp1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O O
transactivation O O
to O O
a O O
heterologous O O
prolactin B B_GENE/B_LOCATION
minimal I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
. O O

Twelve O O
patients O O
of O O
leprosy O O
with O O
arthritis O O
and O O
161 O O
patients O O
without O O
arthritis O O
were O O
studied O O
for O O
immunological O O
parameters O O
like O O
immunoglobulins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
IgG B B_GENE/B_LOCATION
, O O
IgM B B_PROTEIN[GENE]/B_LOCATION
, O O
IgA B B_GENE/B_LOCATION
) O O
, O O
C B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
reactive I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proteins I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
rheumatoid B B_GENE/B_DISEASE
factor I I_GENE/I_DISEASE
. O O

Zonography O O
in O O
urology O O
( O O
author O O
' O O
s O O
transl O O
) O O

( O O
i O O
) O O
p60 B B_MEASURE/B_GENE
bound O O
fast O O
- O O
migrating O O
, O O
underprocessed O O
wild B B_GENE
- I I_GENE
type I I_GENE
ICP22 I I_GENE
and O O
ICP22 B B_GENE/B_MEASURE
lacking O O
the O O
carboxyl O O
- O O
terminal O O
24 O O
amino O O
acids O O
but O O
not O O
ICP22 B B_TIME[MEASURE]/B_GENE
lacking O O
the O O
carboxyl O O
- O O
terminal O O
40 O O
amino O O
acids O O
, O O
whereas O O
the O O
previously O O
identified O O
cellular B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
p78 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
R O O
. O O

Stress O O
thallium O O
- O O
201 O O
myocardial O O
imaging O O
was O O
used O O
in O O
two O O
angina O O
- O O
free O O
patients O O
with O O
severe O O
congestive O O
heart O O
failure O O
to O O
identify O O
clinically O O
silent O O
areas O O
of O O
ischemic O O
myocardium O O
and O O
to O O
distinguish O O
between O O
scar O O
and O O
reversibly O O
ischemic O O
myocardium O O
as O O
a O O
cause O O
for O O
akinesia O O
of O O
left O O
ventricular O O
wall O O
segments O O
. O O

The O O
community O O
- O O
acquired O O
bacteremia O O
was O O
mainly O O
due O O
to O O
E O O
. O O
coli O O
. O O

Low O O
plasma O O
glucose O O
concentrations O O
that O O
may O O
or O O
may O O
not O O
be O O
sufficiently O O
low O O
to O O
result O O
in O O
symptoms O O
can O O
be O O
observed O O
as O O
a O O
concomitant O O
of O O
several O O
diverse O O
diseases O O
. O O

Developmentally O O
- O O
regulated O O
interaction O O
of O O
a O O
transcription O O
factor O O
complex O O
containing O O
CDP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
cut B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
early B B_GENE
histone I I_GENE
H3 I I_GENE
gene I I_GENE
promoter I I_GENE
of I I_GENE
the I I_GENE
sea I I_GENE
urchin I I_GENE
Tetrapygus I I_GENE
niger I I_GENE
is O O
associated O O
with O O
changes O O
in O O
chromatin O O
structure O O
and O O
gene O O
expression O O
. O O

Procedures O O
with O O
perfected O O
method O O

After O O
a O O
shift O O
to O O
37 O O
degrees O O
C O O
, O O
the O O
mutant O O
Rat7 B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1p I I_GENE/I_LOCATION
/ O O
Nup159 B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1p I I_GENE/I_MEASURE
is O O
lost O O
from O O
the O O
nuclear O O
rim O O
of O O
rat7 O O
- O O
1 O O
cells O O
and O O
NPCs O O
, O O
which O O
are O O
clustered O O
together O O
in O O
these O O
cells O O
grown O O
under O O
permissive O O
conditions O O
become O O
substantially O O
less O O
clustered O O
. O O

The O O
mRNA O O
for O O
this O O
protein O O
is O O
expressed O O
in O O
the O O
T O O
- O O
ALL O O
cell O O
line O O
Jurkat O O
and O O
has O O
been O O
designated O O
HUG1 B B_GENE/B_SPECIES[BIO]
, O O
for O O
HOX11 B B_TIME[MEASURE]/B_GENE
Upstream I I_TIME[MEASURE]/I_GENE
Gene I I_TIME[MEASURE]/I_GENE
. O O

The O O
STS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
WI I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
14920 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
in O O
fact O O
derived O O
from O O
the O O
3 O O
' O O
- O O
untranslated O O
region O O
of O O
the O O
human B B_GENE
PUNC I I_GENE
gene I I_GENE
. O O

Its O O
activity O O
was O O
twice O O
that O O
of O O
a O O
construct O O
where O O
the O O
CAT B B_GENE
gene I I_GENE
was O O
driven O O
by O O
the O O
H B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2Kb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
H2TF1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
KBF1 B B_PROTEIN[GENE]/B_LOCATION
site O O
) O O
and O O
comparable O O
to O O
that O O
of O O
pRSVCAT O O
construct B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
carrying I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
the I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
strong I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Rous I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sarcoma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

ORF3 O O
appears O O
to O O
encode O O
the O O
homologue O O
of O O
the O O
well O O
- O O
conserved O O
proteasomal B B_GENE/B_LOCATION
26S I I_GENE/I_LOCATION
regulatory I I_GENE/I_LOCATION
subunit I I_GENE/I_LOCATION
. O O

The O O
tam B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Aspergillus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nidulans I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O O
a O O
739 O O
- O O
amino O O
acid O O
protein O O
with O O
similarity O O
to O O
Uga35p B B_LOCATION/B_GENE
/ O O
Dal81p B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
DurLp B B_MEASURE/B_GENE
of O O
Saccharomyces O O
cerevisiae O O
. O O

Little O O
honoured O O
in O O
his O O
own O O
country O O
: O O
statues O O
in O O
recognition O O
of O O
Edward O O
Jenner O O
MD O O
FRS O O
. O O

A O O
pharmacokinetic O O
interaction O O
between O O
LY354740 O O
and O O
diazepam O O
, O O
leading O O
to O O
the O O
lowering O O
of O O
the O O
plasma O O
level O O
of O O
free O O
diazepam O O
, O O
was O O
also O O
demonstrated O O
. O O

The O O
promoter O O
of O O
this O O
methyltransferase O O
gene O O
lacks O O
an O O
identifiable O O
TATA O O
box O O
but O O
is O O
characterized O O
by O O
a O O
CpG O O
island O O
which O O
begins O O
approximately O O
723 O O
nucleotides O O
upstream O O
of O O
the O O
major O O
transcriptional O O
start O O
site O O
and O O
extends O O
through O O
exon O O
1 O O
and O O
into O O
the O O
first O O
intron O O
. O O

No O O
promoter O O
activity O O
could O O
be O O
detected O O
with O O
various O O
mouse B B_GENE
Fli I I_GENE
- I I_GENE
1 I I_GENE
promoter I I_GENE
- O O
CAT B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
constructs O O
containing O O
600 O O
bp O O
of O O
the O O
5 O O
' O O
flanking O O
region O O
, O O
the O O
complete O O
exon O O
1 O O
, O O
the O O
5 O O
' O O
end O O
of O O
intron O O
1 O O
and O O
/ O O
or O O
retroviral O O
LTR O O
sequence O O
. O O

An O O
81 O O
- O O
nt O O
tandem O O
duplication O O
of O O
the O O
C O O
- O O
terminal O O
coding O O
region O O
is O O
located O O
adjacent O O
to O O
the O O
termination O O
codon O O
of O O
the O O
CyIIIb B B_GENE
gene I I_GENE
, O O
a O O
potential O O
relic O O
of O O
a O O
slipped O O
mispairing O O
and O O
replication O O
event O O
. O O

Only O O
53 O O
% O O
of O O
all O O
injuries O O
and O O
12 O O
. O O
5 O O
% O O
of O O
serious O O
injuries O O
involved O O
children O O
, O O
and O O
in O O
contrast O O
to O O
the O O
1950s O O
and O O
early O O
1960s O O
, O O
young O O
adults O O
appear O O
at O O
greatest O O
risk O O
in O O
the O O
1980s O O
. O O

The O O
method O O
was O O
tested O O
on O O
7 O O
rats O O
with O O
48 O O
- O O
hr O O
- O O
old O O
myocardial O O
infarction O O
and O O
4 O O
sham O O
- O O
operated O O
controls O O
. O O

Here O O
we O O
examine O O
the O O
population O O
of O O
gammaS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
adult O O
human O O
lens O O
and O O
the O O
structure O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CRYGS I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
slope O O
of O O
QD O O
versus O O
QEMF O O
for O O
the O O
four O O
tubes O O
was O O
near O O
unity O O
. O O

The O O
extent O O
of O O
the O O
odontoblast O O
process O O
in O O
human O O
dentin O O
. O O

Mouse B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
macrophage I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CD11b I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
CR3 B B_GENE/B_DISEASE
complement I I_GENE/I_DISEASE
receptor I I_GENE/I_DISEASE
/ O O
Mac B B_GENE
- I I_GENE
1 I I_GENE
antigen I I_GENE
. O O

Enoxacin O O
has O O
been O O
shown O O
to O O
be O O
an O O
effective O O
well O O
tolerated O O
and O O
convenient O O
treatment O O
for O O
gonorrhoea O O
. O O

We O O
assessed O O
cardiovascular O O
variables O O
and O O
blood O O
O2 O O
contents O O
in O O
order O O
to O O
characterize O O
O2 O O
transport O O
in O O
ponies O O
during O O
treadmill O O
exercise O O
. O O

The O O
findings O O
are O O
discussed O O
with O O
reference O O
to O O
possible O O
mechanisms O O
by O O
which O O
parasite O O
development O O
might O O
be O O
controlled O O
. O O

The O O
80 O O
kb O O
preceding O O
the O O
expression O O
site O O
has O O
few O O
, O O
if O O
any O O
, O O
functional O O
ORFs O O
, O O
but O O
contains O O
50 O O
bp O O
repeats O O
, O O
INGI B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
retrotransposon I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
like I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
elements I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
and O O
novel O O
4 O O
- O O
12 O O
kb O O
repeats O O
found O O
near O O
other O O
telomeres O O
. O O

The O O
predicted O O
proteins O O
show O O
strong O O
homology O O
to O O
an O O
ABA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inducible I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rich I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
maize O O
embryos O O
and O O
to O O
the O O
mammalian B B_GENE/B_PERSON
RNA I I_GENE/I_PERSON
- I I_GENE/I_PERSON
binding I I_GENE/I_PERSON
protein I I_GENE/I_PERSON
A1 I I_GENE/I_PERSON
of O O
the O O
heterogeneous O O
nuclear O O
ribonucleoprotein O O
complex O O
involved O O
in O O
pre O O
- O O
mRNA O O
splicing O O
. O O

Increase O O
in O O
[ O O
Ca O O
+ O O
+ O O
] O O
counteracted O O
the O O
effects O O
of O O
verapamil O O
on O O
RAD O O
. O O

We O O
compared O O
the O O
quantities O O
collected O O
with O O
both O O
pollen O O
traps O O
during O O
February O O
, O O
March O O
and O O
April O O
1988 O O
and O O
1989 O O
. O O

Cbl B B_GENE
is O O
a O O
signaling O O
molecule O O
with O O
multiple O O
functional O O
domains O O
: O O
an O O
SH2 B B_GENE
domain I I_GENE
which O O
binds O O
phosphotyrosine O O
residues O O
, O O
a O O
RING O O
finger O O
domain O O
which O O
acts O O
as O O
a O O
ubiquitin B B_LOCATION/B_ENZYME[GENE]
ligase I I_LOCATION/I_ENZYME[GENE]
, O O
a O O
proline O O
- O O
rich O O
region O O
which O O
serves O O
as O O
a O O
docking O O
site O O
for O O
SH3 B B_GENE/B_BIO
- I I_GENE/I_BIO
containing I I_GENE/I_BIO
proteins I I_GENE/I_BIO
, O O
phosphotyrosine O O
residues O O
which O O
serve O O
as O O
docking O O
sites O O
for O O
SH2 B B_BIO/B_GENE
- I I_BIO/I_GENE
containing I I_BIO/I_GENE
proteins I I_BIO/I_GENE
such O O
a O O
CrkL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
p85 B B_ENZYME[GENE]/B_LOCATION
subunit I I_ENZYME[GENE]/I_LOCATION
of O O
PI B B_GENE
3 I I_GENE
- I I_GENE
kinase I I_GENE
, O O
and O O
a O O
nuclear O O
localization O O
signal O O
. O O

Surprisingly O O
, O O
apo B B_GENE
- I I_GENE
iso I I_GENE
- I I_GENE
1 I I_GENE
- I I_GENE
cytochrome I I_GENE
c I I_GENE
is O O
absent O O
in O O
cyc3 B B_GENE/B_PERSON
- I I_GENE/I_PERSON
strains O O
, O O
although O O
apo B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
iso I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
cytochrome I I_GENE/I_LOCATION
c I I_GENE/I_LOCATION
is O O
present O O
at O O
approximately O O
the O O
same O O
level O O
at O O
which O O
holo B B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
iso I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytochrome I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
c I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
found O O
in O O
CYC3 B B_GENE/B_NUMBER[MEASURE]
+ I I_GENE/I_NUMBER[MEASURE]
strains O O
. O O

Here O O
, O O
we O O
identify O O
the O O
analytical O O
form O O
of O O
the O O
PDF O O
of O O
one O O
such O O
measure O O
, O O
the O O
order O O
parameter O O
in O O
the O O
low O O
temperature O O
phase O O
of O O
the O O
2D O O
XY O O
model O O
. O O

The O O
ventricular O O
demand O O
pacemaker O O
( O O
VVI O O
) O O
was O O
implanted O O
three O O
years O O
ago O O
and O O
because O O
of O O
further O O
impairment O O
of O O
cardiac O O
performance O O
an O O
av O O
- O O
sequential O O
pacemaker O O
( O O
DDD O O
) O O
was O O
used O O
to O O
restore O O
atrio O O
- O O
ventricular O O
synchronisation O O
. O O

It O O
was O O
predicted O O
that O O
the O O
Stroop O O
task O O
would O O
trigger O O
greater O O
consumption O O
of O O
ice O O
cream O O
than O O
a O O
fearful O O
film O O
, O O
and O O
that O O
this O O
effect O O
would O O
be O O
more O O
pronounced O O
for O O
binge O O
- O O
eaters O O
than O O
non O O
- O O
binge O O
- O O
eaters O O
. O O

Our O O
data O O
are O O
in O O
line O O
with O O
the O O
hypothesis O O
that O O
E2F B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions O O
as O O
a O O
growth O O
- O O
and O O
cell O O
cycle O O
regulated O O
tethering O O
factor O O
between O O
Sp1 B B_GENE
and O O
the O O
basic O O
transcription O O
machinery O O
. O O

There O O
was O O
a O O
positive O O
correlation O O
between O O
change O O
from O O
baseline O O
in O O
parietal O O
lobe O O
gray O O
- O O
matter O O
cytosolic O O
choline O O
, O O
expressed O O
in O O
terms O O
of O O
choline O O
/ O O
creatine O O
resonance O O
ratios O O
, O O
and O O
cognitive O O
performance O O
as O O
measured O O
with O O
the O O
Alzheimer O O
' O O
s O O
Disease O O
Assessment O O
Scale O O
Cognitive O O
Subscale O O
. O O

Colonization O O
increased O O
with O O
level O O
of O O
care O O
: O O
from O O
9 O O
per O O
cent O O
in O O
independent O O
residents O O
of O O
apartments O O
to O O
60 O O
per O O
cent O O
in O O
patients O O
on O O
an O O
acute O O
hospital O O
ward O O
( O O
P O O
less O O
than O O
0 O O
. O O
0001 O O
) O O
. O O

IRA2 B B_GENE/B_MEASURE
, O O
a O O
second O O
gene O O
of O O
Saccharomyces O O
cerevisiae O O
that O O
encodes O O
a O O
protein O O
with O O
a O O
domain O O
homologous O O
to O O
mammalian O O
ras B B_GENE/B_LOCATION
GTPase I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
activating I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
. O O

Exon O O
A1a O O
encodes O O
most O O
of O O
the O O
5 O O
' O O
- O O
untranslated O O
region O O
. O O

These O O
alterations O O
occurred O O
at O O
both O O
the O O
mRNA O O
and O O
protein O O
levels O O
but O O
did O O
not O O
significantly O O
affect O O
the O O
subcellular O O
distribution O O
of O O
any O O
of O O
the O O
four O O
isoforms O O
. O O

Suspected O O
pelvic O O
endometriosis O O
was O O
prospectively O O
evaluated O O
in O O
31 O O
women O O
with O O
T1 O O
- O O
and O O
T2 O O
- O O
weighted O O
conventional O O
spin O O
- O O
echo O O
( O O
CSE O O
) O O
magnetic O O
resonance O O
imaging O O
alone O O
and O O
in O O
combination O O
with O O
T1 O O
- O O
weighted O O
fat O O
- O O
suppressed O O
( O O
T1FS O O
) O O
and O O
gadolinium O O
- O O
enhanced O O
T1FS O O
( O O
Gd O O
- O O
T1FS O O
) O O
spin O O
- O O
echo O O
techniques O O
. O O

Seroconversion O O
after O O
hepatitis O O
B O O
vaccination O O
. O O

A O O
case O O
of O O
bilateral O O
testicular O O
germ O O
cell O O
tumors O O
in O O
a O O
23 O O
- O O
year O O
- O O
old O O
male O O
is O O
reported O O
. O O

Total O O
body O O
BMD O O
( O O
r O O
= O O
0 O O
. O O
30 O O
; O O
P O O
= O O
0 O O
. O O
02 O O
) O O
and O O
femoral O O
neck O O
BMD O O
( O O
r O O
= O O
0 O O
. O O
39 O O
; O O
P O O
= O O
0 O O
. O O
002 O O
) O O
were O O
positively O O
correlated O O
with O O
weight O O
- O O
bearing O O
activity O O
but O O
not O O
with O O
non O O
- O O
weight O O
- O O
bearing O O
activity O O
. O O

The O O
effects O O
of O O
castor O O
oil O O
, O O
alone O O
, O O
as O O
well O O
as O O
in O O
combination O O
with O O
PGI2 O O
and O O
indomethacin O O
on O O
gastrointestinal O O
functions O O
have O O
been O O
examined O O
in O O
rats O O
. O O

Checking O O
for O O
patient O O
compliance O O
, O O
samples O O
( O O
n O O
= O O
10 O O
) O O
with O O
a O O
FK O O
I O O
concentration O O
of O O
0 O O
ng O O
/ O O
mL O O
were O O
re O O
- O O
analyzed O O
. O O

K O O
. O O

The O O
hematopoietic O O
form O O
of O O
PTPN6 B B_GENE
transcript I I_GENE
is O O
initiated O O
at O O
a O O
downstream O O
promoter O O
separated O O
by O O
7 O O
kb O O
from O O
the O O
first O O
. O O

Extra O O
dose O O
due O O
to O O
extravehicular O O
activity O O
during O O
the O O
NASA4 O O
mission O O
measured O O
by O O
an O O
on O O
- O O
board O O
TLD O O
system O O
. O O

Unconventional O O
mRNA O O
processing O O
in O O
the O O
expression O O
of O O
two O O
calcineurin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Dictyostelium O O
. O O

The O O
deduced O O
amino O O
acid O O
sequence O O
of O O
this O O
open O O
reading O O
frame O O
is O O
significantly O O
homologous O O
to O O
the O O
HSV B B_GENE/B_BIO
1 I I_GENE/I_BIO
UL49 I I_GENE/I_BIO
. I I_GENE/I_BIO
5 I I_GENE/I_BIO
gene I I_GENE/I_BIO
product I I_GENE/I_BIO
, O O
and O O
as O O
with O O
UL49 B B_GENE/B_BIO
. I I_GENE/I_BIO
5 I I_GENE/I_BIO
, O O
it O O
contains O O
a O O
potential O O
signal O O
sequence O O
and O O
transmembrane O O
domain O O
characteristic O O
of O O
membrane O O
- O O
associated O O
proteins O O
. O O

It O O
has O O
been O O
demonstrated O O
that O O
stimulation O O
of O O
the O O
pontomesencephalic O O
parabrachial O O
region O O
( O O
PBR O O
) O O
by O O
microinjection O O
of O O
cholinergic O O
drugs O O
or O O
electricity O O
in O O
the O O
cat O O
produces O O
potent O O
pain O O
suppression O O
which O O
is O O
not O O
antagonized O O
by O O
the O O
opiate O O
antagonist O O
, O O
naloxone O O
. O O

GAGA B B_GENE
factor I I_GENE
is O O
known O O
to O O
remodel O O
the O O
chromatin O O
structure O O
in O O
concert O O
with O O
nucleosome B B_GENE
- I I_GENE
remodeling I I_GENE
factor I I_GENE
NURF B I_GENE
in O O
a O O
Drosophila O O
embryonic O O
S150 O O
extract O O
. O O

Also O O
, O O
like O O
TUB B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
it O O
has O O
a O O
wider O O
pattern O O
of O O
tissue O O
expression O O
than O O
either O O
TULP1 B B_GENE
or O O
TULP2 B B_GENE
. O O

After O O
nine O O
months O O
GFR O O
improved O O
spontaneously O O
to O O
32 O O
ml O O
/ O O
min O O
/ O O
1 O O
. O O
73 O O
m2 O O
despite O O
no O O
improvement O O
in O O
his O O
hypertension O O
. O O

First O O
, O O
ste12Delta B B_PERSON/B_GENE
cells O O
differ O O
from O O
cells O O
with O O
disruptions O O
of O O
the O O
upstream O O
signaling O O
elements O O
( O O
e O O
. O O
g O O
. O O
, O O
ste4Delta B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ste20Delta B B_GENE/B_DISEASE
, O O
ste5Delta B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ste11Delta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
ste7Delta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
or O O
fus3Delta B B_PERSON/B_GENE
kss1Delta B I_PERSON/I_GENE
cells O O
) O O
in O O
that O O
they O O
clearly O O
retain O O
some O O
capacity O O
for O O
inducing O O
Ste3p B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphorylation O O
. O O

Herein O O
, O O
we O O
report O O
that O O
CRE O O
- O O
decoy O O
oligonucleotide O O
treatment O O
results O O
in O O
an O O
increase O O
in O O
the O O
p53 B B_GENE
protein I I_GENE
level O O
in O O
MCF O O
- O O
7 O O
human O O
breast O O
cancer O O
cells O O
that O O
express O O
wild O O
- O O
type O O
p53 B B_GENE
. O O

The O O
selective O O
5 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT2 I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocker O O
ketanserin O O
was O O
found O O
to O O
reduce O O
maximal O O
urethral O O
pressures O O
in O O
healthy O O
females O O
by O O
about O O
40 O O
% O O
without O O
reducing O O
blood O O
pressure O O
. O O

It O O
thus O O
seems O O
likely O O
that O O
genistein O O
affects O O
a O O
common O O
pathway O O
downstream O O
of O O
these O O
signals O O
. O O

The O O
electrocardiogram O O
in O O
tachycardia O O
. O O

Identification O O
of O O
a O O
putative O O
chromosomal O O
replication O O
origin O O
from O O
Helicobacter O O
pylori O O
and O O
its O O
interaction O O
with O O
the O O
initiator B B_GENE
protein I I_GENE
DnaA I I_GENE
. O O

The O O
primary O O
structure O O
of O O
cholesterol B B_GENE
esterase I I_GENE
displayed O O
no O O
significant O O
homology O O
with O O
other O O
lipases B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
although O O
the O O
putative O O
lipid O O
interfacial O O
recognition O O
site O O
of O O
G O O
- O O
X O O
- O O
S O O
- O O
X O O
- O O
G O O
is O O
present O O
in O O
the O O
cholesterol B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
esterase I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
essential O O
questions O O
about O O
hepatitis O O
C O O

The O O
transcriptional O O
initiation O O
site O O
of O O
RAG1 B B_GENE
was O O
localized O O
at O O
A O O
, O O
26 O O
bp O O
upstream O O
of O O
the O O
putative O O
translational O O
initiation O O
codon O O
, O O
ATG O O
, O O
by O O
the O O
primer O O
extension O O
assay O O
. O O

Coronary O O
arteriographies O O
and O O
ventriculographies O O
corresponding O O
to O O
274 O O
consecutive O O
patients O O
( O O
January O O
, O O
1975 O O
- O O
October O O
, O O
1978 O O
) O O
with O O
significant O O
coronary O O
lesions O O
are O O
reviewed O O
. O O

Visualization O O
of O O
the O O
cells O O
by O O
phase O O
contrast O O
microscopy O O
indicated O O
that O O
murine B B_GENE
PKCepsilon I I_GENE
expression O O
in O O
the O O
presence O O
of O O
glycerol O O
resulted O O
in O O
a O O
significant O O
increase O O
in O O
the O O
number O O
of O O
yeast O O
cells O O
exhibiting O O
very O O
small O O
buds O O
. O O

Sonography O O
depicted O O
the O O
true O O
morphology O O
of O O
these O O
cystic O O
lesions O O
more O O
clearly O O
than O O
CT O O
, O O
and O O
the O O
sonographic O O
findings O O
virtually O O
excluded O O
uncomplicated O O
hepatic O O
cyst O O
as O O
a O O
diagnosis O O
. O O

A O O
24 O O
- O O
year O O
- O O
old O O
pregnant O O
woman O O
started O O
to O O
have O O
hyperemesis O O
gravidarum O O
6 O O
weeks O O
before O O
admission O O
. O O

Highly O O
significant O O
similarities O O
were O O
detected O O
between O O
the O O
N O O
- O O
terminal O O
region O O
of O O
P30 B B_GENE/B_LOCATION
and O O
those O O
of O O
GENA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
[ O O
the O O
product O O
of O O
another O O
unidentified O O
gene O O
( O O
geneA B B_GENE/B_LOCATION
) O O
located O O
upstream O O
of O O
the O O
aceEF B B_DISEASE/B_GENE
- O O
lpd B B_PROTEIN[GENE]/B_MEASURE
operon O O
] O O
, O O
and O O
GNTR B B_GENE/B_LOCATION
( O O
a O O
putative O O
transcriptional O O
repressor O O
of O O
the O O
gluconate B B_GENE/B_BACTERIUM[BIO]
operon I I_GENE/I_BACTERIUM[BIO]
of O O
Bacillus O O
subtilis O O
) O O
. O O

In O O
vitro O O
DNA O O
binding O O
assays O O
indicate O O
that O O
the O O
elements O O
identified O O
can O O
specifically O O
interact O O
with O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ets I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

They O O
elicit O O
similar O O
regional O O
cerebral O O
blood O O
flow O O
( O O
rCBF O O
) O O
patterns O O
, O O
even O O
though O O
sign O O
language O O
is O O
dependent O O
on O O
spatial O O
information O O
. O O

The O O
availability O O
of O O
a O O
commercial O O
program O O
( O O
PCNONLIN O O
) O O
is O O
needed O O
to O O
carry O O
out O O
matrix O O
handling O O
calculations O O
. O O

The O O
introduction O O
gives O O
also O O
the O O
history O O
of O O
Research O O
Programme O O
MZ O O
- O O
XVII O O
and O O
its O O
implementation O O
in O O
several O O
regions O O
of O O
Poland O O
. O O

The O O
fecal O O
excretion O O
is O O
found O O
to O O
be O O
only O O
one O O
third O O
of O O
that O O
measured O O
in O O
urine O O
. O O

In O O
this O O
technique O O
, O O
the O O
posterior O O
wall O O
of O O
the O O
neopharynx O O
consists O O
only O O
of O O
the O O
prevertebral O O
tissue O O
, O O
while O O
the O O
flap O O
forms O O
the O O
anterior O O
and O O
lateral O O
walls O O
. O O

The O O
most O O
common O O
hosts O O
were O O
equines O O
( O O
31 O O
% O O
) O O
, O O
bovines O O
( O O
25 O O
% O O
) O O
and O O
raccoons O O
( O O
19 O O
% O O
) O O
. O O

Both O O
claR B B_PROTEIN[GENE]/B_DISEASE
and O O
car B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
expressed O O
as O O
monocistronic O O
transcripts O O
; O O
the O O
level O O
of O O
transcript O O
declined O O
rapidly O O
after O O
48h O O
in O O
complex O O
media O O
, O O
but O O
low O O
sustained O O
levels O O
of O O
both O O
transcripts O O
were O O
observed O O
in O O
defined O O
GSPG O O
medium O O
until O O
96h O O
. O O

The O O
hepatic O O
isoform O O
of O O
6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
phosphofructo I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
kinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
/ O O
fructose B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
bisphosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PF2K B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Fru B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BPase I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
transcriptionally O O
stimulated O O
by O O
glucocorticoids O O
, O O
whereas O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
blocks O O
this O O
stimulatory O O
effect O O
. O O

Being O O
implicated O O
in O O
insulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
GK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
regulations O O
as O O
a O O
common O O
transcription O O
factor O O
, O O
IPF1 B B_GENE/B_DISEASE
/ O O
STF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
/ O O
PDX B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
1 I I_MEASURE/I_GENE
is O O
likely O O
to O O
play O O
an O O
essential O O
role O O
in O O
maintaining O O
normal O O
beta O O
- O O
cell O O
functions O O
. O O

The O O
Caenorhabditis B B_GENE/B_LOCATION
elegans I I_GENE/I_LOCATION
NK I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
class I I_GENE/I_LOCATION
homeoprotein I I_GENE/I_LOCATION
CEH I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
22 I I_GENE/I_LOCATION
is O O
involved O O
in O O
combinatorial O O
activation O O
of O O
gene O O
expression O O
in O O
pharyngeal O O
muscle O O
. O O

Mouse O O
embryo O O
cells O O
( O O
C57BL O O
/ O O
6 O O
, O O
H O O
- O O
2b O O
) O O
transformed O O
by O O
the O O
E1A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
E1B B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes O O
of O O
adenovirus O O
type O O
5 O O
( O O
Ad5E1 O O
MEC O O
) O O
are O O
highly O O
immunogenic O O
. O O

The O O
largest O O
age O O
adjusted O O
differences O O
between O O
men O O
with O O
low O O
and O O
normal O O
mood O O
were O O
for O O
the O O
AH4 O O
( O O
3 O O
points O O
, O O
t O O
= O O
5 O O
. O O
6 O O
, O O
p O O
< O O
0 O O
. O O
0001 O O
) O O
and O O
the O O
CAMCOG O O
( O O
2 O O
points O O
, O O
t O O
= O O
5 O O
. O O
8 O O
, O O
p O O
< O O
0 O O
. O O
0001 O O
) O O
. O O

Our O O
findings O O
suggest O O
that O O
resting O O
Tl O O
- O O
201 O O
scintigraphy O O
has O O
limited O O
value O O
in O O
the O O
detection O O
of O O
coronary O O
artery O O
disease O O
in O O
patients O O
with O O
Hurler O O
syndrome O O
. O O

We O O
demonstrate O O
that O O
the O O
WRM B B_GENE
- I I_GENE
1 I I_GENE
protein I I_GENE
binds O O
to O O
LIT B B_GENE
- I I_GENE
1 I I_GENE
in O O
vivo O O
and O O
that O O
WRM B B_GENE/B_PERSON
- I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
can O O
activate O O
the O O
LIT B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
when O O
coexpressed O O
in O O
vertebrate O O
tissue O O
culture O O
cells O O
. O O

RESULTS O O
: O O
All O O
primary O O
tumors O O
were O O
positive O O
for O O
CAM5 B B_GENE
. I I_GENE
2 I I_GENE
. O O

On O O
the O O
sixth O O
postirradiation O O
day O O
the O O
absorption O O
of O O
phenobarbitone O O
, O O
sulphafurazole O O
and O O
mecamylamine O O
had O O
returned O O
to O O
the O O
control O O
level O O
, O O
but O O
the O O
absorption O O
of O O
quinidine O O
and O O
isoniazid O O
was O O
still O O
retarded O O
. O O

To O O
determine O O
the O O
transactivation O O
potential O O
of O O
each O O
of O O
the O O
four O O
Ahr B B_GENE/B_LOCATION
Sp1 B I_GENE/I_LOCATION
sites I I_GENE/I_LOCATION
, O O
we O O
fused O O
the O O
Ahr B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
to O O
a O O
luciferase B B_GENE
( O O
LUC B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
reporter O O
gene O O
and O O
transfected O O
the O O
construct O O
into O O
the O O
Drosophila O O
cell O O
line O O
Schneider O O
- O O
2 O O
, O O
which O O
contains O O
no O O
Sp1 B B_GENE/B_DISEASE
or O O
Sp1 B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
like I I_GENE/I_LOCATION
factors I I_GENE/I_LOCATION
. O O

We O O
determined O O
that O O
Hop B B_GENE/B_MEASURE
( I I_GENE/I_MEASURE
T42 I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
contains O O
a O O
glutamic O O
acid O O
- O O
to O O
- O O
lysine O O
substitution O O
at O O
amino O O
acid O O
residue O O
695 O O
( O O
E695K O O
) O O
. O O

The O O
organotins O O
. O O

The O O
psh3 B B_GENE/B_MEASURE
( I I_GENE/I_MEASURE
+ I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
gene I I_GENE/I_MEASURE
encodes O O
a O O
protein O O
of O O
215 O O
amino O O
acids O O
, O O
which O O
shares O O
a O O
high O O
degree O O
of O O
structural O O
and O O
functional O O
similarity O O
with O O
Shr3p B B_GENE/B_BIO
. O O

Thus O O
, O O
the O O
antibody O O
class O O
switch O O
appears O O
to O O
be O O
directed O O
by O O
induction O O
of O O
accessibility O O
, O O
as O O
assayed O O
by O O
transcription O O
of O O
germ O O
line O O
CH B B_DISEASE/B_GENE
genes O O
. O O

This O O
growth O O
- O O
inhibitory O O
effect O O
was O O
suppressed O O
by O O
the O O
mpk1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
delta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutation O O
, O O
suggesting O O
that O O
hyperactivation O O
of O O
the O O
Mpk1 B B_GENE
pathway O O
is O O
toxic O O
to O O
cells O O
. O O

The O O
chicken O O
genome O O
contains O O
two O O
functional O O
nonallelic O O
beta1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosyltransferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Homodimers O O
of O O
RIP60 B B_GENE/B_DISEASE
( O O
replication B B_PROTEIN[GENE]
initiation I I_PROTEIN[GENE]
- I I_PROTEIN[GENE]
region I I_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
60 I I_PROTEIN[GENE]
kDA I I_PROTEIN[GENE]
) O O
purified O O
from O O
nuclear O O
extract O O
bind O O
two O O
ATT O O
- O O
rich O O
sites O O
in O O
oribeta O O
and O O
foster O O
the O O
formation O O
of O O
a O O
twisted O O
720 O O
bp O O
DNA O O
loop O O
in O O
vitro O O
. O O

Endodontic O O
treatment O O
of O O
deciduous O O
teeth O O
using O O
the O O
formocresol O O
amputation O O
method O O

Some O O
of O O
these O O
physiological O O
responses O O
are O O
regulated O O
via O O
activation O O
of O O
transcription O O
factors O O
such O O
as O O
activator B B_GENE
protein I I_GENE
1 I I_GENE
( O O
AP B B_GENE
- I I_GENE
1 I I_GENE
) O O
. O O

To O O
test O O
the O O
role O O
of O O
myb B B_GENE
family I I_GENE
members I I_GENE
in O O
progression O O
through O O
the O O
cell O O
cycle O O
, O O
we O O
comicroinjected O O
c B B_GENE
- I I_GENE
myc I I_GENE
and O O
myb B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
vectors O O
into O O
serum O O
- O O
deprived O O
quiescent O O
SMCs O O
. O O

Overall O O
graft O O
and O O
patient O O
survival O O
after O O
HAT O O
were O O
33 O O
. O O
3 O O
% O O
and O O
75 O O
% O O
, O O
respectively O O
. O O

LAC9 B B_GENE
is O O
a O O
DNA O O
- O O
binding O O
protein O O
that O O
regulates O O
transcription O O
of O O
the O O
lactose B B_GENE/B_BIO
- I I_GENE/I_BIO
galactose I I_GENE/I_BIO
regulon I I_GENE/I_BIO
in O O
Kluyveromyces O O
lactis O O
. O O

We O O
determined O O
the O O
complete O O
nucleotide O O
sequence O O
of O O
the O O
gypsy B B_GENE/B_BACTERIUM[BIO]
element I I_GENE/I_BACTERIUM[BIO]
present O O
at O O
the O O
forked B B_GENE
locus I I_GENE
of O O
Drosophila O O
melanogaster O O
in O O
the O O
f1 O O
allele O O
. O O

The O O
same O O
high O O
degree O O
of O O
sequence O O
homology O O
between O O
the O O
two O O
F O O
. O O
diplosiphon O O
PC B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
PC B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
85 O O
and O O
77 O O
% O O
, O O
respectively O O
) O O
was O O
found O O
at O O
both O O
the O O
nucleotide O O
and O O
amino O O
acid O O
levels O O
, O O
and O O
similar O O
results O O
were O O
obtained O O
for O O
interspecies O O
comparisons O O
. O O

A O O
group O O
of O O
factors O O
known O O
as O O
activating B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
have O O
been O O
found O O
to O O
bind O O
to O O
the O O
latter O O
and O O
related O O
sequences O O
found O O
upstream O O
of O O
early O O
adenovirus O O
promoters O O
induced O O
by O O
E1A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
these O O
factors O O
are O O
highly O O
homologous O O
to O O
the O O
CREB B B_GENE/B_TIME[MEASURE]
protein I I_GENE/I_TIME[MEASURE]
. O O

In O O
addition O O
to O O
these O O
cases O O
, O O
patients O O
w O O
with O O
high O O
Loa O O
microfilaremia O O
also O O
developed O O
milder O O
neurologic O O
manifestations O O
causing O O
functional O O
impairment O O
lasting O O
for O O
at O O
least O O
one O O
week O O
after O O
treatment O O
. O O

The O O
vertebrate B B_GENE
transcription I I_GENE
factors I I_GENE
TCF I I_GENE
( O O
T B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
LEF B B_LOCATION/B_GENE
( O O
lymphocyte B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
enhancer I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
binding I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
factor I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
interact O O
with O O
beta B B_GENE
- I I_GENE
catenin I I_GENE
and O O
are O O
hypothesized O O
to O O
mediate O O
Wingless B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
Wnt B B_GENE/B_LOCATION
signaling O O
. O O

Some O O
of O O
these O O
DNA O O
: O O
protein O O
complexes O O
were O O
also O O
present O O
, O O
but O O
at O O
lower O O
levels O O
, O O
in O O
nuclear O O
extracts O O
from O O
untransformed O O
rat O O
cells O O
suggesting O O
the O O
possible O O
involvement O O
of O O
cellular O O
factors O O
in O O
the O O
mechanism O O
of O O
down O O
- O O
regulation O O
mediated O O
by O O
Ad12 B B_GENE/B_DISEASE
E1A I I_GENE/I_DISEASE
. O O

Activity O O
was O O
reconstituted O O
, O O
however O O
, O O
by O O
combining O O
fractions O O
that O O
were O O
enriched O O
in O O
the O O
two O O
components O O
. O O

If O O
failure O O
to O O
solve O O
invisible O O
displacements O O
was O O
due O O
to O O
increased O O
memory O O
requirements O O
, O O
then O O
the O O
primates O O
should O O
perform O O
at O O
chance O O
level O O
on O O
all O O
3 O O
problems O O
. O O

Mineralized O O
bone O O
nodule O O
formation O O
in O O
vitro O O
by O O
cell O O
populations O O
from O O
young O O
adult O O
rabbit O O
alveolar O O
bone O O
. O O

Mouse B B_GENE/B_PERSON
GRK6 I I_GENE/I_PERSON
- I I_GENE/I_PERSON
C I I_GENE/I_PERSON
displays O O
none O O
of O O
these O O
motifs O O
. O O

Comparisons O O
of O O
the O O
efficacy O O
of O O
benazepril O O
and O O
hydrochlorothiazide O O
alone O O
and O O
in O O
combination O O
have O O
shown O O
that O O
benazepril O O
20 O O
mg O O
once O O
daily O O
is O O
as O O
effective O O
as O O
or O O
more O O
effective O O
in O O
lowering O O
diastolic O O
blood O O
pressure O O
than O O
hydrochlorothiazide O O
25 O O
mg O O
once O O
daily O O
and O O
that O O
the O O
combination O O
of O O
benazepril O O
20 O O
mg O O
and O O
hydrochlorothiazide O O
25 O O
mg O O
has O O
a O O
possibly O O
synergistic O O
effect O O
on O O
diastolic O O
blood O O
pressure O O
. O O

1988 O O
) O O
. O O

Sequences O O
within O O
the O O
UAS2 O O
element O O
of O O
the O O
ENO2 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
bound O O
a O O
second O O
protein O O
which O O
corresponded O O
to O O
the O O
ABFI B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
autonomously B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
replicating I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
protein O O
. O O

Steady O O
- O O
state O O
levels O O
of O O
murine B B_GENE
MMR I I_GENE
mRNA I I_GENE
were O O
measured O O
in O O
the O O
macrophage O O
cell O O
line O O
J774E O O
, O O
which O O
is O O
known O O
to O O
express O O
the O O
protein O O
at O O
the O O
cell O O
surface O O
. O O

Discriminant O O
function O O
analysis O O
suggests O O
that O O
AUDIT O O
scores O O
can O O
successfully O O
identify O O
SAT O O
- O O
positive O O
and O O
SAT O O
- O O
negative O O
patients O O
; O O
the O O
analysis O O
accounted O O
for O O
42 O O
. O O
5 O O
% O O
of O O
the O O
variance O O
and O O
correctly O O
classified O O
84 O O
. O O
6 O O
% O O
of O O
the O O
sample O O
. O O

Both O O
the O O
5 O O
' O O
and O O
3 O O
' O O
untranslated O O
regions O O
also O O
show O O
significant O O
similarity O O
to O O
the O O
murine O O
gene O O
, O O
with O O
79 O O
and O O
70 O O
% O O
sequence O O
identity O O
, O O
respectively O O
. O O

One O O
patient O O
exhibited O O
a O O
non O O
- O O
sense O O
mutation O O
( O O
codon O O
388 O O
) O O
, O O
which O O
changed O O
a O O
glutamine O O
codon O O
( O O
CAG O O
) O O
to O O
a O O
stop O O
codon O O
( O O
TAG O O
) O O
. O O

The O O
transcriptional O O
activity O O
of O O
P B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
450 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
11 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
studied O O
with O O
an O O
in O O
vitro O O
transcription O O
system O O
using O O
nuclear O O
extracts O O
prepared O O
from O O
bovine O O
adrenal O O
cortex O O
. O O

Renal O O
dysplasia O O
with O O
multisystem O O
malformation O O
- O O
- O O
a O O
study O O
of O O
9 O O
cases O O
. O O

This O O
bud O O
morphology O O
results O O
at O O
least O O
in O O
part O O
from O O
a O O
cell O O
cycle O O
delay O O
imposed O O
by O O
the O O
Cdc28p B B_GENE/B_DISEASE
- O O
inhibitory O O
kinase O O
Swe1p B B_LOCATION/B_GENE
. O O

Eleven O O
of O O
the O O
12 O O
exons O O
have O O
complete O O
sequence O O
homology O O
with O O
the O O
RBM B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
sequence I I_GENE/I_MEASURE
. O O

Copyright O O
1998 O O
Academic O O
Press O O
. O O

Laparoscopic O O
examination O O
1 O O
year O O
after O O
surgery O O
revealed O O
an O O
enlarged O O
, O O
thin O O
- O O
walled O O
, O O
and O O
fluid O O
- O O
filled O O
uterine O O
segment O O
cranial O O
to O O
the O O
midcornus O O
occlusion O O
sites O O
in O O
all O O
animals O O
. O O

The O O
three O O
proteins O O
copurified O O
through O O
several O O
biochemical O O
fractionation O O
steps O O
and O O
could O O
be O O
coimmunoprecipitated O O
by O O
using O O
antibodies O O
against O O
GCD1 B B_GENE
or O O
GCD2 B B_GENE/B_DISEASE
. O O

Cellular O O
fractionation O O
and O O
Percoll O O
gradient O O
centrifugation O O
combined O O
with O O
immunoblotting O O
show O O
that O O
p67 B B_GENE/B_LOCATION
cofractionates O O
with O O
nuclei O O
and O O
is O O
enriched O O
in O O
resistant O O
structure O O
that O O
is O O
insoluble O O
in O O
2 O O
M O O
NaCl O O
, O O
25 O O
mM O O
lithium O O
3 O O
, O O
5 O O
' O O
- O O
diiodosalicylate O O
, O O
and O O
1 O O
% O O
Triton O O
but O O
is O O
soluble O O
in O O
8 O O
M O O
urea O O
. O O

Elimination O O
of O O
brush O O
border O O
as O O
well O O
as O O
of O O
glomerular O O
marker O O
proteins O O
was O O
significantly O O
lower O O
after O O
intravenous O O
injection O O
of O O
low O O
- O O
osmolar O O
CM O O
iopamidol O O
370 O O
( O O
832 O O
mOsm O O
/ O O
kg O O
) O O
than O O
after O O
meglumine O O
diatrizoate O O
76 O O
( O O
2100 O O
mOsm O O
/ O O
kg O O
) O O
. O O

Raman O O
scattering O O
from O O
VO2 O O
single O O
crystals O O
: O O
A O O
study O O
of O O
the O O
effects O O
of O O
surface O O
oxidation O O
. O O

Combination O O
chemotherapy O O
in O O
advanced O O
ovarian O O
cancer O O
. O O

Making O O
sense O O
out O O
of O O
oxygen O O
sensor O O
. O O

In O O
comparison O O
to O O
a O O
silent O O
baseline O O
, O O
CBF O O
increases O O
were O O
observed O O
in O O
auditory O O
cortex O O
bilaterally O O
and O O
in O O
the O O
right O O
superior O O
parietal O O
, O O
right O O
dorsolateral O O
frontal O O
, O O
and O O
right O O
premotor O O
regions O O
, O O
with O O
no O O
modulation O O
as O O
a O O
function O O
of O O
attentional O O
condition O O
. O O

In O O
vitro O O
, O O
c B B_GENE
- I I_GENE
Src I I_GENE
phosphorylated O O
FAK B B_GENE
Tyr I I_GENE
- I I_GENE
925 I I_GENE
in O O
a O O
glutathione B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
S I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
FAK B B_GENE
C O O
- O O
terminal O O
domain O O
fusion O O
protein O O
, O O
whereas O O
FAK O O
did O O
not O O
. O O

The O O
essential O O
oil O O
composition O O
of O O
three O O
Zingiberaceae O O
widely O O
used O O
as O O
medicinal O O
aromatic O O
plants O O
from O O
S O O
. O O

Gel O O
shift O O
analysis O O
of O O
protein O O
binding O O
from O O
nuclear O O
extracts O O
to O O
these O O
caveolin B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
together O O
with O O
DNase B B_GENE
I I I_GENE
footprinting O O
, O O
confirmed O O
nucleoprotein O O
binding O O
to O O
the O O
SRE O O
- O O
like O O
elements O O
as O O
part O O
of O O
the O O
transcriptional O O
response O O
to O O
LDL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
FC I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

A O O
new O O
model O O
for O O
objective O O
assessment O O
of O O
cervical O O
ripening O O
: O O
the O O
effect O O
of O O
prostaglandin O O
E2 O O
and O O
prelabor O O
contractility O O
. O O

CONCLUSIONS O O
: O O
The O O
MC O O
/ O O
UA O O
ratio O O
improves O O
the O O
sensitivity O O
for O O
the O O
prediction O O
of O O
poor O O
perinatal O O
outcome O O
when O O
it O O
is O O
combined O O
with O O
the O O
NST O O
. O O

Evaluation O O
of O O
materials O O
and O O
technics O O
in O O
vascular O O
surgery O O
using O O
111 O O
- O O
Indium O O

The O O
claustrocortical O O
connection O O
was O O
investigated O O
in O O
13 O O
cats O O
with O O
selective O O
injections O O
of O O
30 O O
% O O
HRP O O
in O O
the O O
three O O
subdivisions O O
of O O
the O O
auditory O O
cortex O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O

The O O
phP1 B B_GENE/B_MEASURE
mutation O O
was O O
induced O O
by O O
insertion O O
of O O
a O O
1 O O
. O O
2 O O
- O O
kb O O
P B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
into O O
the O O
5 O O
' O O
transcribed O O
nontranslated O O
region O O
of O O
the O O
proximal O O
polyhomeotic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

METHOD O O
: O O
Six O O
instruments O O
were O O
reviewed O O
: O O
the O O
Berg O O
Balance O O
Scale O O
( O O
Berg O O
) O O
, O O
the O O
Clinical O O
Test O O
of O O
Sensory O O
Interaction O O
and O O
Balance O O
( O O
CTSIB O O
) O O
, O O
the O O
Functional O O
Reach O O
Test O O
, O O
the O O
Tinetti O O
Balance O O
Test O O
of O O
the O O
Performance O O
- O O
Oriented O O
Assessment O O
of O O
Mobility O O
Problems O O
( O O
Tinetti O O
) O O
, O O
the O O
Timed O O
" O O
Up O O
and O O
Go O O
" O O
Test O O
( O O
TU O O
& O O
GT O O
) O O
, O O
and O O
the O O
Physical O O
Performance O O
Test O O
( O O
PPT O O
) O O
. O O

Genome O O
timeline O O
. O O

Initial O O
computer O O
based O O
similarity O O
searches O O
identified O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
retinoblastoma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
RBP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
) O O
, O O
Drosophila B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
melanogaster I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
male I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
specific I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lethal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Msl B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
S B B_GENE/B_SPECIES[BIO]
. I B_GENE/I_SPECIES[BIO]
pombe I B_GENE/I_SPECIES[BIO]
altered I B_GENE/I_SPECIES[BIO]
polarity I B_GENE/I_SPECIES[BIO]
- I B_GENE/I_SPECIES[BIO]
13 I B_GENE/I_SPECIES[BIO]
( O O
Alp13 B B_GENE/B_MEASURE
) O O
and O O
S B B_GENE/B_SPECIES[BIO]
. I I_GENE/I_SPECIES[BIO]
cerevisiae I I_GENE/I_SPECIES[BIO]
Eaf3p I I_GENE/I_SPECIES[BIO]
, O O
a O O
component O O
of O O
the O O
yeast B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NuA4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HAT B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex O O
( O O
Galarneau O O
et O O
al O O
. O O
, O O
2000 O O
. O O

The O O
pressure O O
measurements O O
under O O
steady O O
flow O O
conditions O O
showed O O
that O O
the O O
hemodynamic O O
performance O O
( O O
including O O
pressure O O
gradient O O
and O O
effective O O
orifice O O
area O O
) O O
of O O
SPAB O O
is O O
superior O O
to O O
that O O
of O O
its O O
stented O O
counterpart O O
, O O
especially O O
in O O
the O O
smaller O O
sizes O O
. O O

Serum O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
rapidly O O
decreased O O
after O O
institution O O
of O O
treatment O O
, O O
with O O
actual O O
normalization O O
( O O
less O O
than O O
20 O O
ng O O
/ O O
ml O O
) O O
by O O
the O O
3rd O O
month O O
. O O

Moist O O
healing O O
versus O O
wet O O
- O O
to O O
- O O
dry O O
. O O

In O O
this O O
report O O
, O O
we O O
identify O O
Tyr319 O O
as O O
a O O
functionally O O
important O O
phosphorylation O O
site O O
in O O
the O O
ZAP B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
70 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
interdomain I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
B I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

These O O
findings O O
suggest O O
that O O
low O O
- O O
power O O
laser O O
irradiation O O
can O O
be O O
used O O
for O O
promotion O O
of O O
vascularization O O
and O O
take O O
of O O
tissue O O
transplants O O
. O O

RESEARCH O O
DESIGN O O
AND O O
METHODS O O
: O O
A O O
total O O
of O O
26 O O
IDDM O O
patients O O
with O O
normoalbuminuria O O
were O O
randomized O O
into O O
two O O
groups O O
, O O
with O O
one O O
group O O
receiving O O
placebo O O
( O O
n O O
= O O
13 O O
, O O
age O O
36 O O
+ O O
/ O O
- O O
3 O O
years O O
, O O
BMI O O
24 O O
. O O
5 O O
+ O O
/ O O
- O O
1 O O
. O O
1 O O
kg O O
/ O O
m2 O O
) O O
and O O
the O O
other O O
group O O
receiving O O
an O O
average O O
of O O
15 O O
mg O O
lisinopril O O
daily O O
( O O
n O O
= O O
13 O O
, O O
age O O
34 O O
+ O O
/ O O
- O O
2 O O
years O O
, O O
BMI O O
24 O O
. O O
4 O O
+ O O
/ O O
- O O
0 O O
. O O
9 O O
kg O O
/ O O
m2 O O
) O O
. O O

Previously O O
, O O
a O O
cDNA O O
( O O
GT2 B B_GENE/B_LOCATION
) O O
encoding O O
this O O
protein O O
was O O
isolated O O
from O O
a O O
mouse O O
3T3 O O
- O O
L1 O O
adipocyte O O
library O O
and O O
was O O
sequenced O O
. O O

Expression O O
of O O
human B B_GENE
complement I I_GENE
receptor I I_GENE
type I I_GENE
2 I I_GENE
( O O
CR2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
CD21 B B_PROTEIN[GENE]/B_MEASURE
) O O
is O O
primarily O O
restricted O O
to O O
mature O O
B O O
cells O O
and O O
follicular O O
dendritic O O
cells O O
. O O

The O O
6 O O
. O O
5 O O
- O O
kb O O
genomic O O
fragment O O
contains O O
the O O
complete O O
coding O O
region O O
of O O
MyoD B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
distributed O O
over O O
three O O
exons O O
, O O
plus O O
2 O O
. O O
3 O O
kb O O
of O O
5 O O
' O O
- O O
noncoding O O
sequence O O
and O O
1 O O
. O O
4 O O
kb O O
of O O
3 O O
' O O
- O O
noncoding O O
sequence O O
. O O

Synthetic O O
studies O O
on O O
furan O O
derivatives O O
by O O
the O O
wittig O O
reaction O O

Phenotypic O O
screening O O
of O O
mutations O O
in O O
Pmr1 B B_GENE
, O O
the O O
yeast B B_ENZYME[GENE]/B_PERSON
secretory I I_ENZYME[GENE]/I_PERSON
pathway I I_ENZYME[GENE]/I_PERSON
Ca2 I I_ENZYME[GENE]/I_PERSON
+ I I_ENZYME[GENE]/I_PERSON
/ I I_ENZYME[GENE]/I_PERSON
Mn2 I I_ENZYME[GENE]/I_PERSON
+ I I_ENZYME[GENE]/I_PERSON
- I I_ENZYME[GENE]/I_PERSON
ATPase I I_ENZYME[GENE]/I_PERSON
, O O
reveals O O
residues O O
critical O O
for O O
ion O O
selectivity O O
and O O
transport O O
. O O

Molecular O O
cloning O O
of O O
cDNAs O O
encoding O O
alpha O O
- O O
subunits O O
of O O
guanine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulatory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
G B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
has O O
revealed O O
the O O
existence O O
of O O
nine O O
species O O
of O O
alpha O O
- O O
subunits O O
. O O

No O O
transactivation O O
of O O
the O O
ovalbumin B B_GENE
promoter I I_GENE
( O O
pLovTATA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
template O O
control O O
was O O
observed O O
. O O

Pros O O
and O O
cons O O
of O O
selective O O
inhibition O O
of O O
cyclooxygenase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
versus O O
dual O O
lipoxygenase B B_GENE
/ O O
cyclooxygenase B B_ENZYME[GENE]
inhibition O O
: O O
is O O
two O O
better O O
than O O
one O O
? O O

At O O
11 O O
. O O
5 O O
years O O
of O O
follow O O
- O O
up O O
, O O
521 O O
major O O
coronary O O
disease O O
events O O
had O O
occurred O O
, O O
261 O O
fatal O O
and O O
260 O O
non O O
- O O
fatal O O
. O O

The O O
etiology O O
was O O
established O O
in O O
73 O O
( O O
76 O O
. O O
8 O O
% O O
) O O
out O O
of O O
95 O O
cases O O
. O O

Morphometry O O
of O O
the O O
intestine O O
of O O
the O O
pig O O
. O O

Serum O O
zinc O O
and O O
copper O O
levels O O
and O O
urine O O
copper O O
concentrations O O
in O O
men O O
were O O
significantly O O
lower O O
than O O
in O O
women O O
, O O
while O O
there O O
were O O
no O O
differences O O
in O O
serum O O
or O O
urinary O O
zinc O O
and O O
copper O O
levels O O
with O O
age O O
. O O

HDE B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
to O O
be O O
exclusively O O
targeted O O
to O O
and O O
imported O O
into O O
peroxisomes O O
in O O
both O O
heterologous O O
expression O O
systems O O
. O O

GeneCalling O O
analysis O O
was O O
successful O O
in O O
detecting O O
members O O
of O O
complex O O
metabolic O O
pathways O O
and O O
uncovering O O
novel O O
genes O O
that O O
were O O
either O O
coincidentally O O
regulated O O
or O O
directly O O
involved O O
in O O
such O O
pathways O O
. O O

Transformations O O
with O O
circular O O
plasmids O O
yielded O O
slowly O O
and O O
irregularly O O
growing O O
geneticin O O
- O O
resistant O O
mycelia O O
in O O
which O O
1 O O
% O O
of O O
nuclei O O
contained O O
plasmid O O
sequences O O
. O O

CONCLUSION O O
: O O
In O O
these O O
patients O O
control O O
of O O
ventricular O O
response O O
rate O O
with O O
either O O
HBA O O
+ O O
VVIR O O
pacemaker O O
or O O
atrioventricular O O
modifying O O
drugs O O
+ O O
VVI O O
pacemaker O O
will O O
lead O O
to O O
a O O
significant O O
improvement O O
in O O
exercise O O
duration O O
and O O
quality O O
of O O
life O O
. O O

The O O
other O O
regions O O
include O O
potential O O
binding O O
sites O O
for O O
transcription O O
factors O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
NF1 B B_GENE/B_DISEASE
, O O
and O O
a O O
CCAAT B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
binding I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
. O O

Both O O
purH B B_GENE/B_DISEASE
and O O
purD B B_GENE/B_LOCATION
genes I I_GENE/I_LOCATION
constitute O O
a O O
single O O
operon O O
and O O
are O O
coregulated O O
in O O
expression O O
by O O
purines O O
as O O
other O O
purine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genes I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O O
. O O

The O O
patient O O
demographics O O
( O O
means O O
+ O O
/ O O
- O O
standard O O
deviations O O
) O O
were O O
as O O
follows O O
: O O
age O O
, O O
57 O O
+ O O
/ O O
- O O
12 O O
years O O
; O O
sex O O
, O O
nine O O
males O O
and O O
three O O
females O O
; O O
APACHE O O
II O O
score O O
, O O
15 O O
+ O O
/ O O
- O O
3 O O
; O O
diagnosis O O
, O O
9 O O
of O O
12 O O
patients O O
with O O
pneumonia O O
. O O

In O O
situ O O
hybridization O O
reveals O O
strong O O
signals O O
for O O
Zep B B_GENE
mRNA I I_GENE
in O O
the O O
cerebellum O O
and O O
olfactory O O
bulb O O
with O O
moderate O O
signals O O
detected O O
in O O
the O O
hippocampus O O
and O O
cortex O O
. O O

UV O O
- O O
cross O O
- O O
linking O O
studies O O
suggested O O
that O O
these O O
two O O
complexes O O
represent O O
one O O
and O O
two O O
molecules O O
of O O
ADR1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bound O O
to O O
DNA O O
. O O

The O O
M O O
- O O
phase O O
induction O O
activity O O
of O O
Cdc2 B B_PROTEIN[GENE]/B_LOCATION
- O O
Cdc13 B B_MEASURE/B_GENE
is O O
inhibited O O
by O O
Wee1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tyrosine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
which O O
phosphorylates O O
Cdc2 B B_GENE
on O O
tyrosine O O
- O O
15 O O
. O O

Nucleotide O O
sequencing O O
revealed O O
a O O
2076 O O
- O O
base O O
pair O O
open O O
reading O O
frame O O
encoding O O
a O O
692 O O
- O O
amino O O
acid O O
protein O O
. O O

But O O
it O O
is O O
possible O O
that O O
the O O
two O O
hemispheres O O
differ O O
in O O
the O O
manner O O
in O O
which O O
they O O
make O O
use O O
of O O
semantic O O
structures O O
: O O
the O O
left O O
hemisphere O O
in O O
a O O
selective O O
manner O O
, O O
appropriate O O
for O O
the O O
solution O O
of O O
a O O
specific O O
task O O
, O O
and O O
the O O
right O O
hemisphere O O
in O O
a O O
more O O
diffuse O O
and O O
global O O
manner O O
. O O

Supportive O O
therapy O O
with O O
xenogenous O O
peptides O O
in O O
patients O O
with O O
metastatic O O
breast O O
cancer O O
undergoing O O
aggressive O O
chemotherapy O O
( O O
modified O O
AC O O
- O O
protocol O O
) O O
: O O
a O O
prospective O O
, O O
randomized O O
double O O
- O O
blind O O
study O O

The O O
pregnancies O O
were O O
terminated O O
at O O
19 O O
and O O
12 O O
weeks O O
of O O
gestation O O
, O O
respectively O O
. O O

Single O O
substitutions O O
of O O
three O O
highly O O
conserved O O
phenylalanine O O
residues O O
( O O
Phe O O
- O O
15 O O
, O O
Phe O O
- O O
17 O O
, O O
Phe O O
- O O
27 O O
) O O
by O O
alanine O O
and O O
substitution O O
of O O
one O O
histidine O O
( O O
His O O
- O O
29 O O
) O O
by O O
glutamine O O
, O O
all O O
located O O
within O O
the O O
putative O O
RNA O O
- O O
binding O O
sites O O
RNP B B_PROTEIN[GENE]/B_DISEASE
- I I_PROTEIN[GENE]/I_DISEASE
1 I I_PROTEIN[GENE]/I_DISEASE
and O O
RNP B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
abolished O O
the O O
nucleic O O
acid O O
- O O
binding O O
activity O O
of O O
CspB B B_GENE/B_BACTERIUM[BIO]
. O O

The O O
cases O O
with O O
terminal O O
forces O O
of O O
left O O
ventricular O O
activation O O
in O O
the O O
same O O
direction O O
as O O
the O O
delta O O
wave O O
, O O
superiorly O O
and O O
to O O
the O O
left O O
at O O
- O O
60 O O
degrees O O
or O O
inferiorly O O
and O O
to O O
the O O
right O O
at O O
+ O O
120 O O
degrees O O
, O O
forming O O
a O O
single O O
deflection O O
of O O
over O O
0 O O
, O O
12 O O
seconds O O
' O O
duration O O
, O O
are O O
the O O
result O O
of O O
delayed O O
activation O O
of O O
the O O
anterior O O
or O O
posterior O O
fascicle O O
of O O
the O O
left O O
bundle O O
after O O
a O O
long O O
delay O O
. O O

The O O
genes O O
encoding O O
these O O
carotenoids O O
in O O
E O O
. O O
herbicola O O
Eho13 O O
are O O
clustered O O
in O O
a O O
7 O O
kb O O
DNA O O
fragment O O
. O O

The O O
results O O
show O O
that O O
while O O
a O O
larger O O
polypeptide O O
substrate O O
carrying O O
the O O
HD1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3C I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
processed O O
more O O
efficiently O O
than O O
a O O
polypeptide O O
substrate O O
carrying O O
the O O
POL B B_LOCATION/B_PROTEIN[GENE]
/ I B_LOCATION/I_PROTEIN[GENE]
Zn I B_LOCATION/I_PROTEIN[GENE]
site I B_LOCATION/I_PROTEIN[GENE]
, O O
cleavage O O
of O O
the O O
synthetic O O
peptide O O
substrates O O
containing O O
these O O
two O O
cleavage O O
sites O O
occurred O O
at O O
similar O O
efficiencies O O
. O O

Using O O
transgenic O O
lines O O
a O O
detailed O O
analysis O O
of O O
the O O
Hoxa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
7 I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer O O
- O O
directed O O
expression O O
during O O
embryogenesis O O
was O O
performed O O
. O O

lacZ B B_GENE/B_PERSON
expression O O
was O O
first O O
detected O O
in O O
the O O
allantois O O
at O O
day O O
7 O O
. O O
5 O O
p O O
. O O
c O O
. O O
and O O
in O O
mesoderm O O
and O O
ectoderm O O
at O O
day O O
8 O O
. O O
5 O O
of O O
gestation O O
. O O

An O O
ERp60 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
like I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
filarial O O
parasite O O
Dirofilaria O O
immitis O O
has O O
both O O
transglutaminase O O
and O O
protein O O
disulfide O O
isomerase O O
activity O O
. O O

At O O
promoters O O
that O O
initiate O O
with O O
+ O O
1 O O
GGG O O
, O O
T7 B B_GENE/B_SPECIES[BIO]
RNAP I I_GENE/I_SPECIES[BIO]
synthesizes O O
a O O
ladder O O
of O O
poly O O
( O O
G O O
) O O
products O O
as O O
a O O
result O O
of O O
slippage O O
of O O
the O O
transcript O O
on O O
the O O
three O O
C O O
residues O O
in O O
the O O
template O O
strand O O
from O O
+ O O
1 O O
to O O
+ O O
3 O O
. O O

The O O
UL3 B B_GENE
ORF I I_GENE
of O O
204 O O
amino O O
acids O O
shows O O
significant O O
homology O O
to O O
UL3 B B_PROTEIN[GENE]/B_LOCATION
( O O
nuclear O O
phosphoprotein O O
) O O
of O O
HSV O O
- O O
1 O O
( O O
62 O O
% O O
) O O
and O O
PRV O O
( O O
53 O O
% O O
) O O
. O O

For O O
routine O O
medical O O
applications O O
, O O
no O O
sophisticated O O
adjustment O O
of O O
the O O
CHESS O O
pulse O O
is O O
needed O O
, O O
as O O
reported O O
in O O
previous O O
methods O O
. O O

The O O
10 O O
eyes O O
injected O O
with O O
human O O
RPE O O
cells O O
showed O O
STAGE O O
2 O O
or O O
less O O
in O O
4 O O
weeks O O
. O O

This O O
report O O
establishes O O
that O O
the O O
effect O O
of O O
homozygous O O
sickle O O
cell O O
disease O O
on O O
growth O O
patterns O O
in O O
childhood O O
is O O
apparent O O
before O O
the O O
age O O
of O O
6 O O
years O O
. O O

The O O
remaining O O
77 O O
nucleotides O O
at O O
the O O
3 O O
' O O
end O O
of O O
domain O O
II O O
and O O
all O O
of O O
domains O O
III O O
( O O
655 O O
nucleotides O O
) O O
and O O
IV O O
( O O
770 O O
nucleotides O O
) O O
are O O
not O O
present O O
in O O
DIssE B B_BIO/B_GENE
RNA I B_BIO/I_GENE
. O O

The O O
biological O O
actions O O
of O O
VHR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
oocytes O O
clearly O O
distinguish O O
it O O
from O O
other O O
dual O O
specificity O O
phosphatases O O
, O O
which O O
have O O
shown O O
inhibitory O O
effects O O
when O O
tested O O
in O O
oocytes O O
. O O

The O O
presence O O
of O O
chloroquine O O
in O O
saliva O O
from O O
seven O O
healthy O O
volunteers O O
for O O
21 O O
days O O
after O O
a O O
single O O
600 O O
mg O O
oral O O
dose O O
of O O
the O O
drug O O
was O O
established O O
by O O
chromatographic O O
and O O
spectroscopic O O
methods O O
. O O

The O O
gp41 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Glu I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Leu I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Asp I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Lys I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Trp I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ala I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fused O O
to O O
the O O
C O O
- O O
terminus O O
of O O
Sj B B_GENE/B_DISEASE
GST I I_GENE/I_DISEASE
forms O O
a O O
loop O O
stabilized O O
by O O
symmetry O O
- O O
related O O
GSTs B B_GENE/B_LOCATION
. O O

Comparison O O
of O O
bioreactive O O
and O O
immunoreactive O O
gastrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

A O O
score O O
( O O
APACHE O O
II O O
) O O
was O O
calculated O O
to O O
assess O O
the O O
severity O O
of O O
disease O O
. O O

We O O
tested O O
several O O
growth O O
regulatory O O
genes O O
that O O
are O O
repressed O O
in O O
senescent O O
cells O O
for O O
ability O O
to O O
restore O O
activity O O
to O O
T B B_GENE/B_PERSON
[ I I_GENE/I_PERSON
K1 I I_GENE/I_PERSON
] I I_GENE/I_PERSON
. O O

We O O
analyzed O O
the O O
contribution O O
of O O
the O O
three O O
different O O
types O O
of O O
UV O O
- O O
inducible O O
mitogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MAP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ERK B B_GENE
, O O
JNK B B_GENE/B_LOCATION
/ O O
SAPK B B_MEASURE/B_GENE
, O O
and O O
p38 B B_GENE/B_LOCATION
) O O
to O O
the O O
activation O O
of O O
the O O
murine O O
uPA B B_GENE
promoter O O
by O O
UV O O
. O O

The O O
high O O
degree O O
of O O
sequence O O
conservation O O
together O O
with O O
the O O
ability O O
to O O
direct O O
nucleolar O O
protein O O
transport O O
supports O O
the O O
hypothesis O O
that O O
MAK16 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
play O O
a O O
key O O
role O O
in O O
the O O
biogenesis O O
of O O
60S B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
subunits I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Characterization O O
of O O
a O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
deformed I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
epidermal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
autoregulatory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DEAF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
related O O
( O O
NUDR B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
transcriptional O O
regulator O O
protein O O
. O O

Here O O
we O O
show O O
that O O
the O O
sck1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
cloned O O
as O O
a O O
high O O
copy O O
number O O
suppressor O O
of O O
a O O
mutation O O
in O O
git3 B B_SPECIES[BIO]/B_GENE
, O O
is O O
able O O
to O O
suppress O O
the O O
defects O O
conferred O O
by O O
a O O
mutation O O
in O O
any O O
of O O
these O O
git B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hamdija O O
Karamehmedovic O O
; O O
Ibn O O
al O O
- O O
Nefis O O
, O O
" O O
Mudzez O O
al O O
- O O
Kanum O O
" O O
, O O
Republicki O O
zavod O O
za O O
zdravstvenu O O
zastitu O O
Sarajevo O O
, O O
1961 O O
, O O
1 O O
- O O
219 O O
; O O
Mr O O
ph O O
Samuel O O
Elazar O O
, O O
Ajnija O O
Omanic O O
: O O
" O O
Bibliografija O O
medicinskih O O
djela O O
u O O
SR O O
BiH O O
do O O
1895 O O
. O O
" O O
Medicinska O O
knjiga O O
Beograd O O
- O O
Zagreb O O
1984 O O
; O O
Besides O O
, O O
the O O
great O O
contribution O O
in O O
bibliography O O
was O O
given O O
by O O
dr O O
Lujo O O
Taler O O
, O O
prof O O
. O O

dr O O
. O O

The O O
longest O O
cDNA O O
insert O O
identified O O
was O O
2 O O
. O O
2 O O
kb O O
and O O
encoded O O
the O O
entire O O
462 O O
- O O
amino O O
acid O O
open O O
reading O O
frame O O
of O O
rat B B_GENE/B_BACTERIUM[BIO]
CgA I I_GENE/I_BACTERIUM[BIO]
including O O
an O O
18 O O
- O O
amino O O
acid O O
hydrophobic O O
signal O O
peptide O O
. O O

We O O
have O O
used O O
systemic O O
application O O
of O O
the O O
ototoxic O O
drug O O
amikacin O O
, O O
to O O
induce O O
total O O
cochlear O O
haircell O O
loss O O
in O O
the O O
chinchilla O O
, O O
in O O
order O O
to O O
create O O
an O O
animal O O
model O O
of O O
profound O O
deafness O O
. O O

Cotransfection O O
with O O
C B B_GENE/B_LOCATION
/ I I_GENE/I_LOCATION
EBPbeta I I_GENE/I_LOCATION
and O O
GATA B B_GENE
- I I_GENE
1 I I_GENE
expression O O
vectors O O
produced O O
a O O
5 O O
- O O
fold O O
increase O O
compared O O
with O O
cotransfection O O
with O O
the O O
C B B_GENE/B_LOCATION
/ I I_GENE/I_LOCATION
EBPbeta I I_GENE/I_LOCATION
or O O
GATA B B_GENE
- I I_GENE
1 I I_GENE
expression O O
vectors O O
individually O O
. O O

Among O O
the O O
different O O
epithelial O O
cell O O
lines O O
tested O O
, O O
only O O
RTS3b O O
cells O O
allowed O O
an O O
expression O O
pattern O O
similar O O
to O O
that O O
observed O O
in O O
naturally O O
infected O O
benign O O
condylomas O O
. O O

In O O
contrast O O
to O O
the O O
p16 B B_GENE
- O O
mediated O O
G1 O O
block O O
, O O
G1 O O
arrest O O
mediated O O
by O O
the O O
cdk B B_GENE/B_DISEASE
inhibitors O O
p21Cip1 B B_GENE
or O O
p27Kip1 B B_GENE
cannot O O
be O O
bypassed O O
either O O
by O O
inactivation O O
of O O
pRb B B_GENE
or O O
overexpression O O
of O O
E2F B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
addition O O
, O O
the O O
authors O O
found O O
one O O
an3 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
allele I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
an3 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
W138A I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
which O O
a O O
dTph1 B B_GENE
element I I_GENE
had O O
inserted O O
30 O O
bp O O
upstream O O
the O O
translation O O
start O O
, O O
without O O
inactivating O O
the O O
gene O O
. O O

Case O O
of O O
nephrotic O O
syndrome O O
caused O O
by O O
gold O O
preparations O O

To O O
investigate O O
the O O
role O O
of O O
bHLH B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
MC3T3 O O
- O O
E1 O O
osteoblasts O O
, O O
which O O
undergo O O
a O O
developmental O O
sequence O O
in O O
vitro O O
, O O
we O O
analyzed O O
the O O
transcriptional O O
control O O
of O O
osteocalcin B B_GENE
gene I I_GENE
expression O O
by O O
stable O O
transfection O O
of O O
an O O
osteocalcin B B_GENE
promoter I I_GENE
- O O
luciferase B B_GENE
chimeric O O
gene O O
( O O
p637OC B B_PROTEIN[GENE]/B_BIO
- I I_PROTEIN[GENE]/I_BIO
luc I I_PROTEIN[GENE]/I_BIO
) O O
and O O
assessed O O
the O O
role O O
of O O
E O O
- O O
box O O
cis O O
- O O
acting O O
elements O O
in O O
osteocalcin B B_GENE
promoter I I_GENE
by O O
DNA O O
binding O O
assays O O
. O O

In O O
summary O O
, O O
the O O
only O O
treatment O O
- O O
related O O
effect O O
noted O O
in O O
this O O
study O O
was O O
hydrocarbon O O
nephropathy O O
in O O
male O O
rats O O
, O O
which O O
is O O
not O O
considered O O
relevant O O
for O O
human O O
health O O
. O O

In O O
this O O
study O O
, O O
we O O
show O O
that O O
HNF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
member O O
of O O
the O O
steroid B B_GENE/B_PERSON
hormone I I_GENE/I_PERSON
receptor I I_GENE/I_PERSON
superfamily I I_GENE/I_PERSON
, O O
binds O O
the O O
AF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
on O O
the O O
apoB B B_GENE
promoter I I_GENE
and O O
through O O
it O O
activates O O
transcription O O
in O O
transient O O
transfection O O
assays O O
in O O
both O O
liver O O
and O O
non O O
- O O
liver O O
cell O O
lines O O
, O O
HepG2 O O
and O O
HeLa O O
, O O
respectively O O
. O O

Gastrointestinal O O
accumulation O O
of O O
indium O O
- O O
111 O O
labelled O O
granulocytes O O
in O O
reactive O O
arthritis O O
. O O

Acute O O
intoxication O O
with O O
cypermethrin O O
( O O
NRDC O O
149 O O
) O O
. O O

We O O
have O O
previously O O
shown O O
that O O
the O O
transcriptional O O
activator O O
CREM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
highly O O
expressed O O
in O O
postmeiotic O O
cells O O
. O O

No O O
interaction O O
with O O
epidural O O
anesthesia O O
was O O
observed O O
. O O

In O O
late O O
October O O
, O O
1974 O O
, O O
Staphylococcus O O
aureus O O
postoperative O O
wound O O
infection O O
was O O
recorded O O
in O O
a O O
nonhuman O O
primate O O
( O O
Macaca O O
mulatta O O
) O O
which O O
had O O
recently O O
undergone O O
surgical O O
operation O O
. O O

Twenty O O
- O O
six O O
calves O O
were O O
subjected O O
to O O
a O O
technique O O
of O O
cryoablation O O
in O O
order O O
to O O
establish O O
an O O
animal O O
model O O
of O O
complete O O
cardiac O O
denervation O O
. O O

Our O O
current O O
study O O
aims O O
at O O
clarifying O O
the O O
role O O
of O O
myristoylation O O
in O O
caveolar O O
targeting O O
using O O
well O O
- O O
characterized O O
acylation O O
mutants O O
of O O
two O O
model O O
proteins O O
, O O
namely O O
Gi1 B B_GENE
alpha I I_GENE
and O O
c B B_GENE
- I I_GENE
Src I I_GENE
. O O

The O O
effect O O
of O O
deferoxamine O O
B O O
on O O
the O O
blood O O
sugar O O
behavior O O
in O O
intravenous O O
glucose O O
loading O O
in O O
healthy O O
persons O O

We O O
infer O O
that O O
RecA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
mediated O O
cleavage O O
of O O
UmuD B B_GENE/B_BIO
is O O
another O O
role O O
for O O
RecA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
SOS O O
mutagenesis O O
, O O
probably O O
activating O O
UmuD B B_GENE/B_BIO
for O O
its O O
mutagenic O O
function O O
. O O

The O O
prevalence O O
of O O
microalbuminuria O O
, O O
defined O O
as O O
an O O
UAER O O
in O O
the O O
range O O
of O O
15 O O
- O O
150 O O
micrograms O O
min O O
- O O
1 O O
in O O
an O O
overnight O O
urine O O
sample O O
, O O
was O O
3 O O
% O O
( O O
95 O O
% O O
C O O
. O O
I O O
. O O
interval O O
: O O
1 O O
. O O
9 O O
- O O
4 O O
. O O
0 O O
) O O
. O O

The O O
Rep B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
adeno O O
- O O
associated O O
virus O O
type O O
2 O O
( O O
AAV O O
) O O
are O O
known O O
to O O
bind O O
to O O
Rep B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
recognition I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
RRSs B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
the O O
AAV O O
inverted O O
terminal O O
repeats O O
( O O
ITRs O O
) O O
, O O
the O O
AAV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
the O O
preferred O O
AAV O O
integration O O
site O O
in O O
human O O
chromosome O O
19 O O
, O O
called O O
AAVS1 O O
. O O

LIP O O
and O O
DIP O O
are O O
less O O
common O O
IIPs O O
, O O
both O O
characterized O O
by O O
ground O O
- O O
glass O O
attenuation O O
. O O

The O O
levels O O
of O O
TPAR1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
dramatically O O
down O O
- O O
regulated O O
in O O
regenerating O O
rat O O
liver O O
when O O
compared O O
to O O
normal O O
adult O O
liver O O
. O O

Copyright O O
1999 O O
Academic O O
Press O O
. O O

Southern O O
hybridization O O
analysis O O
of O O
BenR B B_DISEASE/B_PROTEIN[GENE]
and O O
BenS B B_LOCATION/B_GENE
transformants I I_LOCATION/I_GENE
suggested O O
that O O
plasmid O O
integration O O
occurred O O
most O O
frequently O O
at O O
the O O
chromosomal O O
bens B B_LOCATION/B_GENE
locus I I_LOCATION/I_GENE
, O O
however O O
evidence O O
for O O
gene O O
conversion O O
and O O
heterologous O O
recombination O O
was O O
also O O
observed O O
. O O

The O O
analysis O O
of O O
the O O
effects O O
of O O
eight O O
signaling O O
molecules O O
in O O
the O O
TGFbeta B B_GENE/B_LOCATION
, O O
FGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Hh B B_GENE/B_LOCATION
, O O
Wnt B B_GENE/B_LOCATION
, O O
and O O
EGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
families I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
tooth O O
explant O O
cultures O O
revealed O O
that O O
the O O
expression O O
of O O
edar B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
induced O O
by O O
activinbetaA B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
Wnt6 B B_GENE
induced O O
ectodysplasin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
. O O

Single O O
oblique O O
- O O
view O O
mammography O O
for O O
periodic O O
screening O O
for O O
breast O O
cancer O O
in O O
women O O
. O O

Radiative O O
corrections O O
to O O
pi O O
l2 O O
decays O O
. O O

This O O
deletion O O
disrupts O O
the O O
PU B B_GENE
. I I_GENE
1 I I_GENE
Ets B I_GENE
domain I I_GENE
. O O

In O O
turn O O
, O O
production O O
of O O
sufficient O O
amounts O O
of O O
TraR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
apparently O O
is O O
sensitive O O
to O O
a O O
cellular O O
function O O
requiring O O
RNase B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
predicted O O
product O O
exhibits O O
91 O O
% O O
amino O O
acid O O
identity O O
to O O
the O O
murine B B_GENE/B_PERSON
voltage I I_GENE/I_PERSON
- I I_GENE/I_PERSON
gated I I_GENE/I_PERSON
potassium I I_GENE/I_PERSON
channel I I_GENE/I_PERSON
protein I I_GENE/I_PERSON
Kv1 I I_GENE/I_PERSON
. I I_GENE/I_PERSON
7 I I_GENE/I_PERSON
( O O
Kcna7 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
which O O
plays O O
an O O
important O O
role O O
in O O
the O O
repolarization O O
of O O
cell O O
membranes O O
. O O

This O O
dynamic O O
nature O O
may O O
be O O
relevant O O
to O O
the O O
ability O O
of O O
E47 B B_GENE
both O O
to O O
homodimerize O O
and O O
to O O
heterodimerize O O
with O O
MyoD B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
Id B B_GENE/B_DISEASE
, O O
and O O
Tal1 B B_GENE
. O O

Among O O
these O O
, O O
four O O
patients O O
had O O
the O O
AIDS O O
syndrome O O
, O O
while O O
42 O O
individuals O O
were O O
HIV O O
carriers O O
. O O

Subjects O O
were O O
73 O O
male O O
and O O
female O O
employees O O
of O O
the O O
Xerox O O
Corporation O O
joining O O
a O O
newly O O
developed O O
health O O
fitness O O
program O O
. O O

Overexpression O O
of O O
p50 B B_GENE
in O O
transient O O
cotransfection O O
studies O O
using O O
the O O
proximal O O
CRP B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
( O O
- O O
125 O O
/ O O
+ O O
9 O O
) O O
linked O O
to O O
a O O
luciferase B B_GENE
reporter I I_GENE
caused O O
a O O
3 O O
- O O
fold O O
increase O O
of O O
luciferase B B_GENE/B_LOCATION
activity O O
, O O
while O O
C B B_GENE
/ I I_GENE
EBPbeta I I_GENE
overexpression O O
caused O O
an O O
18 O O
- O O
fold O O
increase O O
; O O
simultaneous O O
overexpression O O
of O O
both O O
transcription O O
factors O O
increased O O
luciferase B B_GENE/B_MEASURE
activity O O
approximately O O
600 O O
- O O
fold O O
. O O

Our O O
results O O
suggest O O
that O O
it O O
might O O
be O O
possible O O
to O O
augment O O
IN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function O O
in O O
vivo O O
through O O
a O O
heterologous O O
domain O O
. O O

While O O
differential O O
expression O O
of O O
the O O
two O O
transcripts O O
was O O
not O O
found O O
, O O
the O O
promoter O O
controlling O O
LT1 B B_GENE
/ O O
LT2 B B_PROTEIN[GENE]/B_MEASURE
transcription O O
is O O
regulated O O
in O O
a O O
cell O O
cycle O O
- O O
dependent O O
manner O O
. O O

Fetal O O
PaO2 O O
fell O O
somewhat O O
during O O
the O O
recovery O O
stages O O
in O O
both O O
NIT O O
and O O
control O O
groups O O
. O O

Genetic O O
analyses O O
indicate O O
that O O
most O O
of O O
the O O
dominant O O
mutants O O
are O O
cis O O
- O O
acting O O
and O O
that O O
the O O
recessive O O
mutants O O
define O O
a O O
minimum O O
of O O
three O O
complementation O O
groups O O
, O O
indicating O O
that O O
defects O O
in O O
several O O
different O O
genes O O
can O O
restore O O
higher O O
levels O O
of O O
HIS4C B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
. O O

Rat B B_ENZYME[GENE]
cholesterol I I_ENZYME[GENE]
side I I_ENZYME[GENE]
- I I_ENZYME[GENE]
chain I I_ENZYME[GENE]
cleavage I I_ENZYME[GENE]
cytochrome I I_ENZYME[GENE]
P I I_ENZYME[GENE]
- I I_ENZYME[GENE]
450 I I_ENZYME[GENE]
( O O
P B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
450scc I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
gene O O
. O O

Histopathologic O O
studies O O
displaying O O
spongiform O O
changes O O
in O O
the O O
gray O O
matter O O
, O O
neuronal O O
loss O O
, O O
and O O
atrogliosis O O
confirmed O O
the O O
clinical O O
diagnosis O O
of O O
Creutzfeldt O O
- O O
Jakob O O
disease O O
. O O

Pig O O
uPA B B_SPECIES[BIO]/B_GENE
promoter O O
- O O
CAT B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
constructs O O
were O O
more O O
active O O
than O O
mouse O O
constructs O O
in O O
this O O
assay O O
. O O

Cloning O O
the O O
cDNA O O
for O O
a O O
new O O
human B B_PROTEIN[GENE]/B_BIO
zinc I I_PROTEIN[GENE]/I_BIO
finger I I_PROTEIN[GENE]/I_BIO
protein I I_PROTEIN[GENE]/I_BIO
defines O O
a O O
group O O
of O O
closely O O
related O O
Kruppel B B_GENE/B_BIO
- I I_GENE/I_BIO
like I I_GENE/I_BIO
transcription I I_GENE/I_BIO
factors I I_GENE/I_BIO
. O O

By O O
computed O O
homology O O
search O O
, O O
we O O
noticed O O
significant O O
similarities O O
between O O
US3 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PK I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
p21 B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
activated I I_GENE/I_LOCATION
kinase I I_GENE/I_LOCATION
( O O
PAK B B_GENE/B_PERSON
) O O
, O O
which O O
is O O
activated O O
by O O
the O O
Cdc42 B B_GENE
or O O
Rac B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
mean O O
amount O O
of O O
blood O O
loss O O
prior O O
to O O
time O O
of O O
injection O O
was O O
4 O O
. O O
5 O O
units O O
( O O
a O O
range O O
of O O
3 O O
to O O
10 O O
units O O
) O O
. O O

These O O
8 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oxoguanine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycosylases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
hOgg1 B B_GENE/B_DISEASE
( O O
human O O
) O O
and O O
mOgg1 B B_GENE
( O O
murine O O
) O O
, O O
are O O
homologous O O
to O O
each O O
other O O
and O O
to O O
yeast B B_SPECIES[BIO]/B_GENE
Ogg1 I I_SPECIES[BIO]/I_GENE
. O O

The O O
CHED B B_ENZYME[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein I I_ENZYME[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
includes O O
the O O
consensus O O
ATP O O
binding O O
and O O
phosphorylation O O
domains O O
characteristic O O
of O O
kinases O O
, O O
displays O O
34 O O
- O O
42 O O
% O O
identically O O
aligned O O
amino O O
acid O O
residues O O
with O O
other O O
cdc2 B B_GENE/B_BIO
- I I_GENE/I_BIO
related I I_GENE/I_BIO
kinases I I_GENE/I_BIO
, O O
and O O
is O O
considerably O O
longer O O
at O O
its O O
amino O O
and O O
carboxyl O O
termini O O
. O O

CONCLUSIONS O O
: O O
These O O
results O O
suggest O O
that O O
, O O
by O O
interacting O O
with O O
cellular O O
transcription O O
factors O O
and O O
cofactors O O
, O O
vIRF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
may O O
modulate O O
the O O
expression O O
of O O
the O O
early O O
inflammatory O O
genes O O
and O O
potentially O O
deregulate O O
the O O
immune O O
system O O
. O O

However O O
, O O
in O O
7 O O
patients O O
with O O
normal O O
CT O O
results O O
the O O
latter O O
method O O
showed O O
areas O O
of O O
cerebral O O
activity O O
anatomically O O
correlated O O
with O O
neurological O O
signs O O
or O O
vascular O O
lesions O O
. O O

We O O
report O O
that O O
Gcn5 B B_GENE
, O O
a O O
histone B B_GENE
H3 I I_GENE
acetylase I I_GENE
, O O
plays O O
a O O
central O O
role O O
in O O
initiation O O
of O O
meiosis O O
via O O
effects O O
on O O
IME2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
. O O

The O O
carboxy O O
- O O
proximal O O
regions O O
of O O
the O O
VP1 B B_GENE/B_SPECIES[BIO]
, O O
which O O
contain O O
very O O
low O O
amino O O
acid O O
homology O O
, O O
displayed O O
evidence O O
of O O
conservation O O
in O O
structural O O
features O O
such O O
as O O
a O O
hydrophilic O O
, O O
highly O O
basic O O
domain O O
. O O

DESIGN O O
- O O
- O O
A O O
randomised O O
double O O
blind O O
placebo O O
controlled O O
parallel O O
arm O O
trial O O
. O O

Genealogical O O
analysis O O
suggested O O
mainly O O
a O O
mother O O
- O O
to O O
- O O
offspring O O
transmission O O
of O O
this O O
STLV O O
- O O
1 O O
. O O

These O O
back O O
mutations O O
led O O
to O O
a O O
modest O O
decrease O O
in O O
kinase O O
activity O O
, O O
decreased O O
tumorigenic O O
potential O O
in O O
chickens O O
, O O
and O O
an O O
unexpected O O
increase O O
in O O
transforming O O
activity O O
in O O
rat O O
cells O O
. O O

Pretoria O O
Pasteurisation O O
is O O
feasible O O
and O O
reliable O O
under O O
a O O
range O O
of O O
conditions O O
. O O

In O O
the O O
present O O
study O O
we O O
use O O
a O O
tnaC B B_GENE/B_BACTERIUM[BIO]
- O O
UGA O O
- O O
' B B_GENE
lacZ I I_GENE
construct O O
lacking O O
the O O
tnaC B B_GENE/B_BACTERIUM[BIO]
- O O
tnaA B B_GENE/B_BACTERIUM[BIO]
spacer O O
region O O
to O O
analyze O O
the O O
effect O O
of O O
TnaC B B_GENE/B_BACTERIUM[BIO]
synthesis O O
on O O
the O O
behavior O O
of O O
the O O
ribosome O O
that O O
translates O O
tnaC B B_GENE/B_BACTERIUM[BIO]
. O O

The O O
in O O
vitro O O
activity O O
of O O
KP O O
- O O
103 O O
, O O
a O O
novel O O
triazole O O
derivative O O
, O O
against O O
pathogenic O O
fungi O O
that O O
cause O O
dermatomycoses O O
and O O
its O O
therapeutic O O
efficacy O O
against O O
plantar O O
tinea O O
pedis O O
and O O
cutaneous O O
candidiasis O O
in O O
guinea O O
pigs O O
were O O
investigated O O
. O O

Serum O O
triglycerides O O
also O O
showed O O
an O O
increase O O
from O O
birth O O
to O O
6 O O
months O O
of O O
age O O
, O O
but O O
a O O
decrease O O
from O O
6 O O
months O O
to O O
1 O O
years O O
of O O
age O O
. O O

Female O O
Wistar O O
rats O O
receiving O O
alcohol O O
( O O
5 O O
% O O
) O O
in O O
drinking O O
water O O
during O O
lactation O O
( O O
N O O
= O O
7 O O
) O O
were O O
compared O O
to O O
normal O O
controls O O
fed O O
ad O O
libitum O O
( O O
N O O
= O O
6 O O
) O O
. O O

Antisense O O
oligonucleotides O O
complementary O O
to O O
the O O
5 O O
' O O
end O O
of O O
PKC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
zeta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
significantly O O
reduced O O
the O O
collagen B B_GENE/B_DISEASE
lattice O O
- O O
stimulated O O
alpha2 O O
and O O
MMP B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
. O O

Overexpression O O
of O O
a O O
HIF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1alpha I I_GENE/I_DISEASE
construct O O
with O O
deletions O O
of O O
the O O
basic O O
domain O O
and O O
carboxy O O
terminus O O
blocked O O
reporter O O
gene O O
activation O O
by O O
endogenous O O
HIF B B_GENE
- I I_GENE
1 I I_GENE
in O O
hypoxic O O
cells O O
. O O

We O O
hypothesized O O
that O O
conjugated O O
estrogens O O
, O O
which O O
contain O O
several O O
vasoactive O O
estrogenic O O
compounds O O
, O O
may O O
favorably O O
influence O O
the O O
vasomotor O O
response O O
to O O
acetylcholine O O
in O O
men O O
. O O

In O O
Experiment O O
2 O O
, O O
levels O O
were O O
: O O
amprolium O O
and O O
ethopabate O O
, O O
. O O
02 O O
% O O
; O O
salinomycin O O
, O O
55 O O
mg O O
/ O O
kg O O
; O O
monensin O O
, O O
99 O O
mg O O
/ O O
kg O O
; O O
and O O
lasalocid O O
, O O
110 O O
mg O O
/ O O
kg O O
. O O

Residues O O
crucial O O
for O O
Ras B B_GENE/B_DISEASE
interaction O O
with O O
GDP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GTP I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exchangers I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

4 O O
. O O

Searching O O
the O O
human O O
DNA O O
data O O
base O O
of O O
expressed O O
sequence O O
tags O O
( O O
EST O O
) O O
revealed O O
novel O O
partial O O
sequences O O
similar O O
to O O
, O O
but O O
distinct O O
from O O
, O O
the O O
sequences O O
of O O
the O O
previously O O
known O O
PEF B B_GENE/B_BIO
proteins I I_GENE/I_BIO
. O O

Under O O
control O O
conditions O O
and O O
in O O
the O O
presence O O
of O O
3 O O
micromol O O
/ O O
kg O O
MIB O O
and O O
VER O O
the O O
maximal O O
effect O O
of O O
noradrenaline O O
was O O
reached O O
at O O
0 O O
. O O
1 O O
micromol O O
/ O O
kg O O
whereas O O
in O O
the O O
presence O O
of O O
10 O O
micromol O O
/ O O
kg O O
MIB O O
and O O
VER O O
it O O
was O O
reached O O
at O O
a O O
dose O O
of O O
1 O O
micromol O O
/ O O
kg O O
. O O

It O O
is O O
also O O
affected O O
by O O
the O O
HAP2 B B_GENE/B_DISEASE
/ I I_GENE/I_DISEASE
3 I I_GENE/I_DISEASE
/ I I_GENE/I_DISEASE
4 I I_GENE/I_DISEASE
transcription I I_GENE/I_DISEASE
factor I I_GENE/I_DISEASE
complex I I_GENE/I_DISEASE
and O O
by O O
SNF1 B B_GENE/B_DISEASE
and O O
SSN6 B B_GENE
. O O

Two O O
different O O
genes O O
( O O
polA B B_GENE/B_BIO
and O O
polB B B_PROTEIN[GENE]/B_BIO
) O O
encoding O O
family B B_ENZYME[GENE]
B I I_ENZYME[GENE]
DNA I I_ENZYME[GENE]
polymerases I I_ENZYME[GENE]
were O O
cloned O O
from O O
the O O
organism O O
by O O
PCR O O
using O O
degenerated O O
primers O O
based O O
on O O
the O O
two O O
conserved O O
motifs O O
( O O
motif O O
A O O
and O O
B O O
) O O
. O O

The O O
effects O O
on O O
survival O O
of O O
adjuvant O O
treatments O O
, O O
including O O
pre O O
- O O
or O O
postoperative O O
systemic O O
or O O
postoperative O O
intra O O
- O O
arterial O O
chemotherapy O O
, O O
are O O
currently O O
under O O
evaluation O O
. O O

Structure O O
and O O
regulation O O
of O O
the O O
luteinizing B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hormone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
disease O O
processes O O
that O O
affect O O
transplant O O
patients O O
both O O
before O O
and O O
after O O
transplantation O O
are O O
not O O
seen O O
frequently O O
in O O
the O O
general O O
practice O O
of O O
gastroenterology O O
. O O

METHODS O O
: O O
Single O O
white O O
flash O O
ERG O O
, O O
photopic O O
ERG O O
, O O
scotopic O O
ERG O O
and O O
flicker O O
ERG O O
were O O
recorded O O
in O O
30 O O
cases O O
of O O
unilateral O O
CRVO O O
. O O

However O O
, O O
to O O
encourage O O
good O O
contact O O
between O O
the O O
farmers O O
and O O
the O O
inseminating O O
personnel O O
, O O
it O O
is O O
beneficial O O
that O O
herdsmen O O
are O O
present O O
when O O
cows O O
are O O
inseminated O O
. O O

Soft O O
independent O O
modelling O O
of O O
class O O
analogy O O
( O O
SIMCA O O
) O O
is O O
applied O O
to O O
identify O O
near O O
- O O
infrared O O
( O O
NIR O O
) O O
spectra O O
of O O
ten O O
excipients O O
used O O
in O O
the O O
pharmaceutical O O
industry O O
. O O

Multiple O O
organ O O
failure O O
( O O
MOF O O
) O O
following O O
major O O
trauma O O
occurs O O
in O O
response O O
to O O
perfusion O O
deficits O O
, O O
a O O
persistent O O
inflammatory O O
focus O O
, O O
or O O
a O O
persistent O O
focus O O
of O O
dead O O
and O O
/ O O
or O O
injured O O
tissue O O
. O O

Western O O
immunoblot O O
analysis O O
detected O O
p55gag B B_GENE
and O O
its O O
cleavage O O
products O O
p39 B B_GENE
and O O
p27 B B_GENE/B_MEASURE
in O O
purified O O
particles O O
derived O O
by O O
expression O O
of O O
gag B B_GENE
and O O
gag B B_PROTEIN[GENE]/B_DISEASE
- O O
pol B B_GENE/B_DISEASE
, O O
respectively O O
. O O

Cefminox O O
shows O O
greater O O
in O O
vivo O O
activity O O
than O O
that O O
expected O O
for O O
the O O
MICs O O
, O O
excellent O O
efficacy O O
and O O
safety O O
. O O

3 O O
- O O
5 O O
- O O
fold O O
increases O O
in O O
EGF B B_GENE
receptor I I_GENE
but O O
not O O
p185 B B_GENE
( O O
neu B B_GENE/B_DISEASE
) O O
tyrosine O O
phosphorylation O O
occur O O
following O O
Gi B B_GENE
- I I_GENE
coupled I I_GENE
receptor I I_GENE
stimulation O O
. O O

Next O O
, O O
to O O
examine O O
the O O
regulation O O
mechanism O O
of O O
CD44 B B_GENE
/ O O
ERM B B_LOCATION/B_GENE
interaction O O
in O O
vivo O O
, O O
we O O
reexamined O O
the O O
immunoprecipitated O O
CD44 B B_GENE/B_LOCATION
/ O O
ERM B B_LOCATION/B_GENE
complex O O
from O O
BHK O O
cells O O
and O O
found O O
that O O
it O O
contains O O
Rho B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GDP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dissociation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GDI B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
a O O
regulator O O
of O O
Rho B B_GENE
GTPase I I_GENE
. O O

The O O
results O O
showed O O
a O O
significant O O
group O O
effect O O
only O O
on O O
the O O
active O O
task O O
. O O

To O O
determine O O
cis O O
- O O
acting O O
elements O O
controlling O O
the O O
rat O O
B B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
GAP B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
43 I I_GENE/I_MEASURE
gene O O
expression O O
, O O
the O O
genomic O O
DNA O O
encoding O O
exon O O
1 O O
and O O
the O O
5 O O
' O O
flanking O O
sequence O O
was O O
isolated O O
. O O

In O O
this O O
paper O O
, O O
the O O
authors O O
used O O
measured O O
weight O O
for O O
1 O O
, O O
259 O O
white O O
women O O
aged O O
65 O O
- O O
74 O O
years O O
from O O
the O O
Epidemiologic O O
Follow O O
- O O
up O O
Study O O
of O O
the O O
First O O
National O O
Health O O
and O O
Nutrition O O
Examination O O
Survey O O
to O O
examine O O
the O O
effect O O
of O O
overweight O O
on O O
coronary O O
heart O O
disease O O
incidence O O
( O O
mean O O
length O O
of O O
follow O O
- O O
up O O
, O O
14 O O
years O O
) O O
. O O

Through O O
genomic O O
library O O
screening O O
and O O
PCR O O
- O O
based O O
genomic O O
walking O O
we O O
have O O
now O O
cloned O O
the O O
mouse B B_GENE
E I I_GENE
- I I_GENE
Tmod I I_GENE
gene I I_GENE
, O O
whose O O
coding O O
region O O
spans O O
approximately O O
60kb O O
containing O O
nine O O
exons O O
and O O
eight O O
introns O O
. O O

The O O
data O O
obtained O O
included O O
1 O O
) O O
the O O
mean O O
frequency O O
of O O
abnormal O O
teased O O
myelinated O O
fibers O O
and O O
its O O
upper O O
limit O O
value O O
of O O
95 O O
% O O
confidence O O
interval O O
, O O
and O O
2 O O
) O O
the O O
mean O O
densities O O
of O O
total O O
, O O
large O O
and O O
small O O
myelinated O O
fibers O O
and O O
of O O
unmyelinated O O
fibers O O
and O O
their O O
lower O O
limit O O
value O O
of O O
95 O O
% O O
confidence O O
interval O O
for O O
each O O
decade O O
. O O

Fusions O O
between O O
the O O
GAL B B_GENE
DNA I I_GENE
binding I I_GENE
domain I I_GENE
and O O
full B B_GENE
- I I_GENE
length I I_GENE
mSin3 I I_GENE
were O O
also O O
capable O O
of O O
repression O O
. O O

None O O
of O O
the O O
19 O O
women O O
with O O
probable O O
RA O O
and O O
100 O O
of O O
the O O
116 O O
women O O
with O O
definite O O
RA O O
met O O
the O O
1987 O O
criteria O O
. O O

The O O
initial O O
oral O O
administration O O
of O O
the O O
1 O O
and O O
2 O O
mg O O
/ O O
kg O O
doses O O
of O O
enoximone O O
improved O O
central O O
hemodynamic O O
parameters O O
with O O
apparent O O
preferential O O
reduction O O
of O O
limb O O
vascular O O
resistance O O
and O O
augmentation O O
of O O
blood O O
flow O O
to O O
the O O
limb O O
region O O
( O O
peripheral O O
musculoskeletal O O
system O O
) O O
. O O

Antibodies O O
against O O
REAP B B_GENE
- I I_GENE
1 I I_GENE
inhibit O O
in O O
vitro O O
RNA O O
editing O O
reactions O O
confirming O O
its O O
role O O
in O O
RNA O O
editing O O
. O O

The O O
full O O
- O O
length O O
cDNA O O
was O O
cloned O O
and O O
sequenced O O
, O O
and O O
the O O
inferred O O
amino O O
acid O O
sequence O O
was O O
found O O
to O O
encode O O
a O O
novel O O
protein O O
, O O
which O O
we O O
named O O
cystatin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
M I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
40 O O
% O O
homology O O
to O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cystatins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
similar O O
overall O O
structure O O
. O O

42nd O O
annual O O
meeting O O
of O O
the O O
American O O
Academy O O
of O O
Oral O O
Pathology O O
. O O

The O O
side O O
effect O O
of O O
pulmonary O O
fibrosis O O
occurs O O
in O O
20 O O
to O O
30 O O
percent O O
of O O
patients O O
receiving O O
this O O
drug O O
. O O

These O O
larger O O
sizes O O
, O O
however O O
, O O
are O O
consistent O O
with O O
predictions O O
from O O
the O O
DNA O O
sequence O O
of O O
the O O
pol B B_BIO/B_GENE
gene I I_BIO/I_GENE
. O O

Primary O O
care O O
programs O O
for O O
the O O
indigent O O
. O O

In O O
serial O O
recall O O
from O O
short O O
- O O
term O O
memory O O
, O O
repeated O O
items O O
are O O
recalled O O
well O O
when O O
close O O
together O O
( O O
repetition O O
facilitation O O
) O O
, O O
but O O
not O O
when O O
far O O
apart O O
( O O
repetition O O
inhibition O O
; O O
the O O
Ranschburg O O
effect O O
) O O
. O O

In O O
addition O O
, O O
two O O
cis O O
- O O
acting O O
elements O O
direct O O
the O O
first O O
zygotic O O
expression O O
of O O
Kr B B_GENE
in O O
a O O
striped O O
subpattern O O
within O O
the O O
central O O
region O O
of O O
the O O
blastoderm O O
embryo O O
. O O

Two O O
hundred O O
and O O
eighty O O
- O O
three O O
patients O O
, O O
217 O O
females O O
( O O
median O O
age O O
24 O O
years O O
, O O
range O O
0 O O
. O O
5 O O
- O O
73 O O
) O O
and O O
66 O O
males O O
( O O
median O O
age O O
20 O O
years O O
, O O
range O O
0 O O
. O O
75 O O
- O O
72 O O
) O O
, O O
were O O
examined O O
. O O

The O O
Robert O O
Wood O O
Johnson O O
Foundation O O
: O O
billion O O
dollar O O
force O O
for O O
health O O
- O O
care O O
change O O
. O O

We O O
have O O
isolated O O
a O O
unique O O
murine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
FLT3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cDNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
codes O O
for O O
a O O
variant O O
isoform O O
of O O
FLT3 B B_GENE
, O O
devoid O O
of O O
the O O
fifth O O
Ig B B_GENE
- I I_GENE
like I I_GENE
domain I I_GENE
, O O
by O O
comparison O O
with O O
the O O
prototypic O O
form O O
. O O

( O O
1993 O O
) O O
8 O O
, O O
94 O O
- O O
99 O O
) O O
. O O

Particle O O
bombardment O O
of O O
barley O O
aleurone O O
with O O
a O O
B22EL8 B B_GENE
promoter I I_GENE
- O O
GUS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
beta B B_PROTEIN[GENE]/B_BIO
- I I_PROTEIN[GENE]/I_BIO
glucuronidase I I_PROTEIN[GENE]/I_BIO
) O O
construct O O
demonstrates O O
that O O
the O O
promoter O O
( O O
3 O O
kb O O
) O O
is O O
active O O
in O O
developing O O
barley O O
grains O O
. O O

Changes O O
in O O
BHR O O
were O O
found O O
to O O
correlate O O
significantly O O
with O O
changes O O
in O O
the O O
levels O O
of O O
24 O O
h O O
mean O O
SO2 O O
, O O
NO2 O O
and O O
smoke O O
; O O
48 O O
h O O
mean O O
NO2 O O
and O O
smoke O O
; O O
24 O O
h O O
lag O O
NO2 O O
; O O
although O O
the O O
effect O O
was O O
only O O
small O O
, O O
accounting O O
for O O
approximately O O
10 O O
% O O
of O O
the O O
variability O O
in O O
within O O
- O O
subject O O
BHR O O
between O O
visits O O
. O O

Characterization O O
of O O
regions O O
of O O
fibronectin B B_GENE/B_BIO
besides O O
the O O
arginine O O
- O O
glycine O O
- O O
aspartic O O
acid O O
sequence O O
required O O
for O O
adhesive O O
function O O
of O O
the O O
cell O O
- O O
binding O O
domain O O
using O O
site O O
- O O
directed O O
mutagenesis O O
. O O

The O O
clinical O O
effects O O
of O O
valproate O O
and O O
ethosuximide O O
can O O
be O O
related O O
to O O
this O O
differential O O
modulation O O
of O O
thalamocortical O O
excitability O O
. O O

Elements O O
regulating O O
cell O O
- O O
and O O
stage O O
- O O
specific O O
expression O O
of O O
the O O
C O O
. O O
elegans O O
MyoD B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family O O
homolog O O
hlh B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

An O O
analysis O O
of O O
the O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kit I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
flanking I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O O
the O O
bacterial B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloramphenicol I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetyltransferase I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CAT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assay O O
) O O
in O O
human O O
erythroleukemia O O
HEL O O
cells O O
, O O
which O O
express O O
the O O
endogenous O O
c B B_GENE
- I I_GENE
kit I I_GENE
mRNA I I_GENE
at O O
high O O
levels O O
, O O
showed O O
that O O
a O O
region O O
from O O
- O O
180 O O
to O O
- O O
22 O O
is O O
important O O
for O O
the O O
expression O O
of O O
the O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kit I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

OAT O O
has O O
become O O
safer O O
in O O
recent O O
years O O
, O O
particularly O O
if O O
monitored O O
in O O
special O O
anticoagulation O O
clinics O O
. O O

However O O
, O O
the O O
relative O O
substrate O O
specificity O O
of O O
RSK3 B B_GENE/B_BIO
differed O O
from O O
that O O
reported O O
for O O
other O O
isoforms O O
. O O

Our O O
data O O
indicate O O
that O O
the O O
various O O
subunits O O
of O O
the O O
human O O
P B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TEFb I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex O O
may O O
play O O
distinct O O
roles O O
at O O
multiple O O
stages O O
to O O
mediate O O
Tat B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
activation O O
of O O
HIV O O
- O O
1 O O
transcription O O
elongation O O
. O O

Corresponding O O
oligonucleotides O O
were O O
used O O
to O O
screen O O
a O O
rat O O
liver O O
cDNA O O
library O O
constructed O O
in O O
the O O
plasmid O O
cloning O O
vector O O
, O O
pcDV O O
. O O

In O O
fifty O O
non O O
selected O O
ductal O O
carcinomas O O
of O O
the O O
breast O O
we O O
found O O
that O O
a O O
marked O O
tumoral O O
inflammatory O O
infiltrate O O
( O O
P O O
less O O
than O O
0 O O
. O O
025 O O
) O O
, O O
perinodal O O
tumoral O O
infiltrate O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
, O O
sinus O O
catarrh O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
, O O
follicular O O
hyperplasia O O
( O O
P O O
less O O
than O O
0 O O
. O O
025 O O
) O O
, O O
mixed O O
pattern O O
in O O
lymph O O
nodes O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
and O O
with O O
54 O O
years O O
of O O
age O O
or O O
younger O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
correlated O O
significantly O O
with O O
lymph O O
node O O
metastases O O
and O O
/ O O
or O O
high O O
histologic O O
grade O O
. O O

Capillary O O
tortuosity O O
was O O
a O O
function O O
of O O
sarcomere O O
length O O
in O O
all O O
animals O O
and O O
this O O
relationship O O
was O O
not O O
changed O O
by O O
hypoxia O O
. O O

Sox8 B B_GENE/B_PERSON
maps O O
to O O
the O O
t B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
mouse O O
chromosome O O
17 O O
and O O
to O O
human O O
chromosome O O
16p13 O O
. O O
3 O O
, O O
a O O
region O O
associated O O
with O O
the O O
microphthalmia O O
- O O
cataract O O
syndrome O O
CATM O O
and O O
the O O
alpha O O
- O O
thalassemia O O
/ O O
mental O O
retardation O O
syndrome O O
ATR O O
- O O
16 O O
. O O

The O O
TCR B B_GENE
beta I I_GENE
enhancer I I_GENE
was O O
active O O
on O O
both O O
the O O
minimal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
simian I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
40 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
TCR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
variable I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
both O O
TCR B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
/ I I_GENE/I_LOCATION
beta I I_GENE/I_LOCATION
+ O O
and O O
TCR B B_GENE/B_LOCATION
gamma I I_GENE/I_LOCATION
/ I I_GENE/I_LOCATION
delta I I_GENE/I_LOCATION
+ O O
T O O
cells O O
. O O

U O O
. O O

Recently O O
, O O
we O O
demonstrated O O
that O O
platelet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
derived I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
growth I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PDGF I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation O O
, O O
but O O
not O O
various O O
other O O
growth O O
factors O O
, O O
inhibits O O
transcription O O
of O O
alpha1D B B_PROTEIN[GENE]/B_LOCATION
- O O
, O O
but O O
not O O
alpha1A B B_PROTEIN[GENE]/B_LOCATION
- O O
or O O
alpha1B B B_GENE
- I I_GENE
ARs I I_GENE
, O O
resulting O O
in O O
reduced O O
norepinephrine O O
- O O
mediated O O
SMC O O
growth O O
. O O

Southern O O
blot O O
analysis O O
following O O
reverse O O
transcription O O
and O O
PCR O O
showed O O
that O O
B2R B B_GENE
is O O
expressed O O
in O O
most O O
mouse O O
tissues O O
, O O
except O O
the O O
liver O O
and O O
spleen O O
, O O
which O O
is O O
consistent O O
with O O
the O O
wide O O
distribution O O
of O O
B2R B B_GENE
activity O O
as O O
deduced O O
from O O
pharmacological O O
studies O O
. O O

Long O O
- O O
term O O
renal O O
function O O
in O O
on O O
- O O
heart O O
- O O
beating O O
donor O O
kidney O O
transplantation O O
: O O
a O O
single O O
- O O
center O O
experience O O
. O O

The O O
study O O
of O O
the O O
intensity O O
of O O
pain O O
evoked O O
by O O
heat O O
is O O
relatively O O
exhaustive O O
: O O
the O O
influence O O
of O O
various O O
local O O
, O O
stimulus O O
- O O
dependent O O
or O O
general O O
factors O O
upon O O
threshold O O
values O O
has O O
been O O
well O O
studied O O
, O O
as O O
has O O
the O O
relation O O
between O O
pain O O
and O O
stimulus O O
intensities O O
. O O

The O O
vaccine O O
was O O
at O O
least O O
80 O O
% O O
efficacious O O
against O O
Chlamydia O O
and O O
Campylobacter O O
spp O O
and O O
appeared O O
to O O
be O O
protective O O
. O O

Pneumatic O O
dilation O O
of O O
the O O
lower O O
esophageal O O
sphincter O O
was O O
accomplished O O
by O O
endoscopic O O
visualization O O
and O O
positioning O O
of O O
a O O
modified O O
polyurethane O O
dilator O O
( O O
90 O O
F O O
diameter O O
) O O
without O O
fluoroscopy O O
in O O
17 O O
consecutive O O
patients O O
with O O
advanced O O
symptomatic O O
achalasia O O
. O O

The O O
second O O
system O O
( O O
VacFix O O
) O O
uses O O
a O O
0 O O
. O O
15 O O
mm O O
thick O O
plastic O O
bag O O
loosely O O
filled O O
with O O
1 O O
mm O O
polysterol O O
spheres O O
. O O

Mean O O
24 O O
h O O
urinary O O
excretion O O
values O O
confirmed O O
this O O
observation O O
. O O

However O O
, O O
the O O
safety O O
of O O
design O O
4 O O
was O O
assured O O
as O O
long O O
as O O
all O O
patients O O
received O O
three O O
courses O O
of O O
chemotherapy O O
, O O
which O O
is O O
unusual O O
in O O
phase O O
I O O
studies O O
in O O
Japan O O
. O O

The O O
results O O
indicate O O
that O O
the O O
RNA O O
in O O
T7 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RNA I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymerase I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
free O O
of O O
steric O O
interactions O O
in O O
the O O
ternary O O
complex O O
and O O
not O O
available O O
for O O
structure O O
formation O O
until O O
it O O
is O O
at O O
least O O
10 O O
bases O O
away O O
from O O
the O O
site O O
of O O
polymerization O O
. O O

The O O
STP1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
located O O
on O O
chromosome O O
IV O O
close O O
to O O
at O O
least O O
two O O
other O O
genes O O
involved O O
in O O
RNA O O
splicing O O
: O O
PRP3 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
SPP41 B B_GENE/B_DISEASE
. O O

An O O
ICU O O
length O O
of O O
stay O O
shorter O O
than O O
24 O O
h O O
was O O
not O O
related O O
to O O
the O O
frequency O O
of O O
group O O
C O O
errors O O
. O O

In O O
vitro O O
, O O
SHIP B B_GENE
catalyzes O O
the O O
conversion O O
of O O
the O O
phosphoinositide B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI3K B B_GENE
) O O
product O O
phosphatidylinositol O O
3 O O
, O O
4 O O
, O O
5 O O
- O O
trisphosphate O O
( O O
PIP3 O O
) O O
into O O
phosphatidylinositol O O
3 O O
, O O
4 O O
- O O
bisphosphate O O
. O O

To O O
confirm O O
the O O
data O O
obtained O O
using O O
the O O
HPLC O O
- O O
ESI O O
- O O
MS O O
procedure O O
, O O
fractions O O
of O O
the O O
glycosides O O
from O O
four O O
berries O O
were O O
separated O O
, O O
hydrolyzed O O
, O O
silylated O O
and O O
the O O
sugars O O
were O O
analyzed O O
using O O
gas O O
chromatography O O
- O O
mass O O
spectrometry O O
. O O

The O O
WEB2 B B_GENE/B_MEASURE
gene I I_GENE/I_MEASURE
encodes O O
a O O
1 O O
, O O
522 O O
- O O
amino O O
- O O
acid O O
protein O O
with O O
homology O O
to O O
nucleic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ATPases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Evidence O O
that O O
the O O
AT1A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates O O
transcription B B_GENE
factor I I_GENE
- I I_GENE
Stat91 I I_GENE
and O O
/ O O
or O O
a O O
related O O
protein O O
. O O

The O O
two O O
complexes O O
were O O
detected O O
with O O
a O O
similar O O
activation O O
kinetics O O
upon O O
IL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
4 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation O O
. O O

These O O
results O O
suggest O O
that O O
dauricine O O
and O O
verapamil O O
have O O
a O O
salutary O O
effect O O
in O O
extracorporeal O O
circulation O O
. O O

These O O
results O O
demonstrate O O
the O O
preferential O O
endometrial O O
cell O O
- O O
type O O
expression O O
of O O
BTEB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
suggest O O
its O O
regulatory O O
role O O
in O O
pregnancy O O
- O O
associated O O
endometrial O O
epithelial O O
gene O O
expression O O
. O O

Spen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
the O O
only O O
known O O
homeotic B B_GENE/B_BIO
protein I I_GENE/I_BIO
with O O
RNP O O
binding O O
motifs O O
, O O
which O O
indicates O O
that O O
splicing O O
, O O
transport O O
, O O
or O O
other O O
RNA O O
regulatory O O
steps O O
are O O
involved O O
in O O
the O O
diversification O O
of O O
segmental O O
morphology O O
. O O

Long O O
- O O
term O O
follow O O
- O O
up O O
of O O
kidney O O
donors O O
: O O
a O O
longitudinal O O
study O O
. O O

Recent O O
research O O
on O O
lipolysis O O
. O O

CONCLUSIONS O O
: O O
The O O
present O O
study O O
showed O O
it O O
is O O
possible O O
to O O
use O O
a O O
modified O O
Stroop O O
task O O
as O O
a O O
measure O O
of O O
implicit O O
processing O O
of O O
alcohol O O
stimuli O O
. O O

Six O O
patients O O
( O O
24 O O
% O O
) O O
developed O O
sepsis O O
and O O
only O O
one O O
survived O O
. O O

None O O
of O O
the O O
10 O O
sequences O O
has O O
hitherto O O
been O O
recognized O O
as O O
part O O
of O O
the O O
p53 B B_GENE
signaling O O
pathway O O
. O O

The O O
Prompt O O
and O O
Praise O O
condition O O
was O O
superior O O
to O O
the O O
other O O
two O O
conditions O O
in O O
encouraging O O
participation O O
in O O
low O O
- O O
interest O O
recreational O O
activities O O
. O O

The O O
majority O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ig I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heavy I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IgH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
cloned O O
and O O
mapped O O
. O O

A O O
. O O

We O O
analyzed O O
right O O
ventricular O O
size O O
and O O
function O O
and O O
201Tl O O
uptake O O
to O O
determine O O
if O O
there O O
was O O
a O O
relationship O O
between O O
201Tl O O
uptake O O
and O O
systolic O O
function O O
in O O
19 O O
patients O O
with O O
pulmonary O O
artery O O
hypertension O O
who O O
were O O
being O O
evaluated O O
for O O
heart O O
- O O
lung O O
transplantation O O
. O O

The O O
transcriptional O O
start O O
site O O
( O O
s O O
) O O
of O O
the O O
IA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
mapped O O
by O O
5 O O
' O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
to O O
97 O O
bp O O
upstream O O
of O O
the O O
translational O O
start O O
site O O
. O O

The O O
RAG B B_GENE
- I I_GENE
2 I I_GENE
gene I I_GENE
encodes O O
a O O
component O O
of O O
the O O
V B B_GENE
( I I_GENE
D I I_GENE
) I I_GENE
J I I_GENE
recombinase I I_GENE
which O O
is O O
essential O O
for O O
the O O
assembly O O
of O O
antigen O O
receptor O O
genes O O
in O O
B O O
and O O
T O O
lymphocytes O O
. O O

The O O
lamina O O
densa O O
was O O
always O O
interrupted O O
by O O
numerous O O
small O O
gaps O O
and O O
in O O
some O O
areas O O
the O O
basement O O
membrane O O
could O O
not O O
be O O
identified O O
over O O
a O O
long O O
distance O O
. O O

We O O
have O O
characterized O O
21 O O
mutations O O
in O O
the O O
type B B_GENE
VII I I_GENE
collagen I I_GENE
gene I I_GENE
( O O
COL7A1 B B_GENE/B_DISEASE
) O O
encoding O O
the O O
anchoring O O
fibrils O O
, O O
18 O O
of O O
which O O
were O O
not O O
previously O O
reported O O
, O O
in O O
patients O O
from O O
15 O O
unrelated O O
families O O
with O O
recessive O O
dystrophic O O
epidermolysis O O
bullosa O O
( O O
RDEB O O
) O O
. O O

The O O
data O O
when O O
used O O
to O O
stimulate O O
the O O
collection O O
of O O
the O O
information O O
at O O
antenatal O O
or O O
postnatal O O
visits O O
, O O
nonetheless O O
provide O O
an O O
accurate O O
description O O
of O O
under O O
- O O
3 O O
mortality O O
trends O O
and O O
differences O O
for O O
the O O
two O O
periods O O
examined O O
- O O
- O O
before O O
1984 O O
and O O
before O O
1989 O O
. O O

There O O
is O O
a O O
good O O
correlation O O
between O O
the O O
occurrence O O
in O O
any O O
particular O O
vascular O O
segment O O
of O O
the O O
transient O O
contractile O O
response O O
and O O
intrinsic O O
tone O O
as O O
assessed O O
by O O
relaxation O O
to O O
papaverine O O
( O O
10 O O
( O O
- O O
6 O O
) O O
M O O
) O O
. O O

Both O O
atracurium O O
1 O O
- O O
100 O O
mumol O O
litre O O
- O O
1 O O
and O O
laudanosine O O
1 O O
- O O
50 O O
mumol O O
litre O O
- O O
1 O O
enhanced O O
the O O
release O O
of O O
3H O O
- O O
NA O O
evoked O O
by O O
field O O
stimulation O O
( O O
2 O O
Hz O O
, O O
24 O O
stimuli O O
) O O
, O O
but O O
did O O
not O O
affect O O
resting O O
release O O
. O O

S16 O O
, O O
16 O O
. O O
8 O O
% O O
, O O
P O O
= O O
0 O O
. O O
001 O O
) O O
. O O

The O O
Zn B B_GENE/B_BIO
- I I_GENE/I_BIO
15 I I_GENE/I_BIO
DNA I I_GENE/I_BIO
- I I_GENE/I_BIO
binding I I_GENE/I_BIO
domain I I_GENE/I_BIO
comprises O O
three O O
zinc O O
fingers O O
separated O O
by O O
unusually O O
long O O
linker O O
sequences O O
that O O
would O O
be O O
expected O O
to O O
interrupt O O
specific O O
DNA O O
site O O
recognition O O
. O O

Replication O O
regions O O
from O O
plant O O
- O O
pathogenic O O
Pseudomonas O O
syringae O O
plasmids O O
are O O
similar O O
to O O
ColE2 O O
- O O
related O O
replicons O O
. O O

There O O
has O O
been O O
no O O
significant O O
toxicity O O
associated O O
with O O
repeated O O
5 O O
- O O
FU O O
instillation O O
into O O
the O O
airway O O
. O O

Twenty O O
male O O
volunteers O O
were O O
studied O O
during O O
almokalant O O
infusion O O
aiming O O
at O O
plasma O O
concentrations O O
( O O
Cpl O O
) O O
of O O
20 O O
, O O
50 O O
, O O
100 O O
, O O
and O O
150 O O
nmol O O
/ O O
l O O
. O O

Consistently O O
, O O
we O O
show O O
that O O
phosphorylation O O
by O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
inhibits O O
Sfl1 B B_GENE/B_PERSON
DNA O O
binding O O
in O O
vitro O O
, O O
and O O
that O O
a O O
tpk2Delta B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation O O
increases O O
the O O
levels O O
of O O
Sfl1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
specific O O
promoter O O
elements O O
in O O
vivo O O
. O O

The O O
response O O
sequences O O
were O O
localized O O
between O O
- O O
67 O O
and O O
+ O O
30 O O
in O O
the O O
simian O O
cytomegalovirus O O
IE94 B B_GENE
promoter I I_GENE
and O O
upstream O O
of O O
position O O
+ O O
9 O O
in O O
the O O
HCMV B B_GENE/B_BIO
IE68 I I_GENE/I_BIO
promoter I I_GENE/I_BIO
. O O

Some O O
CHOP B B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimers O O
apparently O O
bind O O
to O O
alternative O O
DNA O O
sequence O O
and O O
thereby O O
regulate O O
the O O
transcription O O
of O O
other O O
genes O O
. O O

To O O
identify O O
and O O
determine O O
the O O
function O O
of O O
Ino2p B B_GENE
in O O
yeast O O
cells O O
, O O
we O O
raised O O
antibodies O O
to O O
a O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
Ino2 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion O O
protein O O
. O O

Northern O O
blot O O
analyses O O
were O O
used O O
to O O
examine O O
the O O
regulated O O
expression O O
of O O
the O O
cys B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
14 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Typicality O O
is O O
probably O O
a O O
better O O
representation O O
of O O
Alexander O O
, O O
Dunbar O O
and O O
others O O
' O O
conclusions O O
than O O
specificity O O
, O O
which O O
was O O
always O O
too O O
absolute O O
a O O
term O O
. O O

Additions O O
of O O
NH4 O O
+ O O
up O O
to O O
200 O O
micrograms O O
1 O O
( O O
- O O
1 O O
) O O
were O O
not O O
stimulatory O O
, O O
whereas O O
at O O
1 O O
. O O
0 O O
mg O O
1 O O
( O O
- O O
1 O O
) O O
levels O O
, O O
Ke O O
was O O
50 O O
% O O
greater O O
than O O
for O O
NO3 O O
- O O
enriched O O
medium O O
. O O

Cardiovascular O O
drug O O
use O O
and O O
hospitalizations O O
attributable O O
to O O
type O O
2 O O
diabetes O O
. O O

The O O
arrangement O O
of O O
amino O O
acids O O
in O O
the O O
helix O O
1 O O
and O O
helix O O
2 O O
regions O O
is O O
quite O O
similar O O
to O O
those O O
of O O
Mxi B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Mad B B_PROTEIN[GENE]/B_BIO
, O O
but O O
different O O
from O O
those O O
of O O
E2F B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
1 I I_PROTEIN[GENE]/I_LOCATION
and O O
DP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
. O O

They O O
contain O O
a O O
large O O
( O O
0 O O
. O O
9 O O
X O O
10 O O
( O O
3 O O
) O O
to O O
1 O O
. O O
88 O O
X O O
10 O O
( O O
3 O O
) O O
base O O
- O O
pairs O O
) O O
intron O O
in O O
the O O
middle O O
of O O
the O O
gene O O
and O O
are O O
further O O
interrupted O O
close O O
to O O
the O O
5 O O
' O O
end O O
of O O
the O O
gene O O
. O O

The O O
present O O
study O O
also O O
emphasizes O O
the O O
need O O
of O O
establishing O O
dose O O
- O O
response O O
curves O O
to O O
correctly O O
assess O O
the O O
relative O O
contribution O O
of O O
the O O
different O O
regions O O
of O O
steroid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
activation O O
of O O
transcription O O
. O O

Routine O O
and O O
default O O
retrieval O O
home O O
visits O O
were O O
given O O
to O O
ensure O O
maximal O O
drug O O
compliance O O
. O O

D O O
. O O
, O O
and O O
Long O O
, O O
C O O
. O O

By O O
contrast O O
with O O
ama B B_GENE/B_BIO
- I I_GENE/I_BIO
1 I I_GENE/I_BIO
, O O
rpc B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
was O O
not O O
deleted O O
by O O
mDf4 O O
or O O
larger O O
deficiencies O O
examined O O
, O O
indicating O O
that O O
these O O
genes O O
are O O
no O O
closer O O
than O O
150 O O
kb O O
. O O

Anovulatory O O
cycles O O
with O O
an O O
apparently O O
normal O O
level O O
of O O
blood O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

By O O
differential O O
screening O O
of O O
a O O
Xenopus O O
laevis O O
egg O O
cDNA O O
library O O
, O O
we O O
have O O
isolated O O
a O O
2 O O
, O O
111 O O
bp O O
cDNA O O
which O O
corresponds O O
to O O
a O O
maternal O O
mRNA O O
specifically O O
deadenylated O O
after O O
fertilisation O O
. O O

Similar O O
immunological O O
disturbances O O
were O O
observed O O
in O O
SCI O O
but O O
not O O
in O O
the O O
PC2 O O
subgroup O O
, O O
i O O
. O O
e O O
. O O
patients O O
examined O O
later O O
than O O
6 O O
months O O
after O O
injury O O
. O O

This O O
study O O
demonstrates O O
that O O
Fluosol O O
significantly O O
attenuates O O
neutrophil O O
adherence O O
, O O
cytotoxicity O O
, O O
and O O
enzyme O O
release O O
in O O
an O O
in O O
vitro O O
model O O
of O O
microvascular O O
injury O O
. O O

We O O
further O O
examined O O
the O O
interaction O O
of O O
JAK2 B B_GENE
with O O
the O O
GHR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytoplasmic O O
domain O O
by O O
two O O
lines O O
of O O
investigation O O
. O O

These O O
p21 B B_PROTEIN[GENE]/B_LOCATION
- O O
E2F B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes O O
, O O
while O O
present O O
in O O
young O O
G1 O O
cells O O
at O O
very O O
low O O
levels O O
, O O
were O O
elevated O O
in O O
senescent O O
cells O O
. O O

There O O
is O O
little O O
similarity O O
among O O
the O O
sequences O O
upstream O O
from O O
the O O
CAP O O
site O O
of O O
the O O
Spec2 B B_GENE
genes I I_GENE
except O O
the O O
TATA O O
consensus O O
sequence O O
and O O
a O O
repeating O O
trinucleotide O O
, O O
AAC O O
. O O

The O O
study O O
drugs O O
( O O
combination O O
vinblastine O O
- O O
CCNU O O
and O O
single O O
- O O
agent O O
triazinate O O
or O O
dactinomycin O O
) O O
failed O O
to O O
provide O O
any O O
meaningful O O
antitumor O O
activity O O
for O O
these O O
patients O O
with O O
advanced O O
renal O O
cell O O
cancer O O
. O O

Our O O
results O O
indicate O O
that O O
GCN4 B B_GENE
contains O O
two O O
activation O O
domains O O
of O O
similar O O
potency O O
that O O
can O O
function O O
independently O O
to O O
promote O O
high O O
- O O
level O O
transcription O O
of O O
the O O
target O O
genes O O
HIS3 B B_GENE
and O O
HIS4 B B_GENE
. O O

Those O O
diagnosed O O
as O O
having O O
affective O O
disorder O O
( O O
n O O
= O O
96 O O
) O O
, O O
according O O
to O O
DSM O O
- O O
IIIR O O
criteria O O
, O O
were O O
compared O O
with O O
the O O
other O O
non O O
- O O
affective O O
suicide O O
attempters O O
( O O
n O O
= O O
161 O O
) O O
. O O

Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
demonstrated O O
to O O
interact O O
directly O O
with O O
CREB1 B B_GENE
but O O
not O O
with O O
other O O
bZIP B B_GENE/B_BIO
proteins I I_GENE/I_BIO
, O O
including O O
CREB2 B B_GENE/B_LOCATION
and O O
Jun B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Anxiogenic O O
effects O O
of O O
pentagastrin O O
in O O
patients O O
with O O
social O O
phobia O O
and O O
healthy O O
controls O O
. O O

Ischaemia O O
and O O
reperfusion O O
injury O O
in O O
the O O
kidney O O
: O O
current O O
status O O
and O O
future O O
direction O O
. O O

We O O
also O O
demonstrate O O
that O O
a O O
p110RB1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutant I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
which O O
is O O
refractory O O
to O O
cell O O
cycle O O
phosphorylation O O
but O O
intact O O
in O O
E1a B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
large B B_GENE/B_LOCATION
T I I_GENE/I_LOCATION
antigen I I_GENE/I_LOCATION
- O O
binding O O
properties O O
, O O
represses O O
EIIaE B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
50 O O
- O O
to O O
80 O O
- O O
fold O O
greater O O
efficiency O O
than O O
wild B B_GENE/B_TIME[MEASURE]
- I I_GENE/I_TIME[MEASURE]
type I I_GENE/I_TIME[MEASURE]
p110RB1 I I_GENE/I_TIME[MEASURE]
. O O

Subgroup O O
analysis O O
failed O O
to O O
show O O
any O O
benefit O O
for O O
etoposide O O
in O O
patients O O
with O O
monocytic O O
or O O
myelomonocytic O O
disease O O
, O O
or O O
in O O
any O O
other O O
diagnostic O O
subgroup O O
. O O

The O O
IGFBP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
IRS B I_GENE/I_DISEASE
and O O
PEPCK B B_LOCATION/B_GENE
IRS B I_LOCATION/I_GENE
both O O
bind O O
the O O
alpha O O
and O O
beta O O
forms O O
of O O
hepatic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HNF B B_GENE
- I I_GENE
3 I I_GENE
) O O
, O O
although O O
the O O
latter O O
does O O
so O O
with O O
a O O
sixfold O O
- O O
lower O O
relative O O
affinity O O
. O O

Polyglutamine O O
- O O
containing O O
protein O O
fragments O O
have O O
been O O
shown O O
to O O
accumulate O O
as O O
aggregates O O
in O O
the O O
nucleus O O
and O O
in O O
the O O
cytoplasm O O
, O O
and O O
to O O
induce O O
cell O O
death O O
when O O
expressed O O
in O O
cultured O O
cells O O
, O O
leading O O
to O O
the O O
proposal O O
that O O
polyglutamine O O
aggregation O O
is O O
an O O
important O O
step O O
in O O
the O O
pathogenesis O O
. O O

It O O
is O O
suggested O O
that O O
on O O
presentation O O
of O O
tail O O
tip O O
necrosis O O
in O O
kittens O O
a O O
diagnosis O O
of O O
neonatal O O
isoerythrolysis O O
or O O
isoagglutination O O
should O O
be O O
considered O O
. O O

Microscopically O O
, O O
cartilage O O
showed O O
markedly O O
stunted O O
and O O
disorganized O O
endochondral O O
ossification O O
. O O

Our O O
data O O
provide O O
the O O
first O O
evidence O O
that O O
differential O O
splicing O O
in O O
the O O
extracellular O O
region O O
of O O
a O O
receptor O O
gene O O
generates O O
receptor O O
variants O O
with O O
different O O
ligand O O
- O O
binding O O
specificities O O
. O O

Sucrose O O
- O O
specific O O
signalling O O
represses O O
translation O O
of O O
the O O
Arabidopsis B B_GENE
ATB2 I I_GENE
bZIP I I_GENE
transcription I I_GENE
factor I I_GENE
gene I I_GENE
. O O

Wolf O O
- O O
Hirschhorn O O
syndrome O O
( O O
WHS O O
) O O
is O O
a O O
malformation O O
syndrome O O
associated O O
with O O
a O O
hemizygous O O
deletion O O
of O O
the O O
distal O O
short O O
arm O O
of O O
chromosome O O
4 O O
( O O
4p16 O O
. O O
3 O O
) O O
. O O

Our O O
aim O O
was O O
to O O
check O O
whether O O
, O O
during O O
PG O O
- O O
DS O O
administration O O
, O O
serum O O
lipase B B_ENZYME[GENE]
activity O O
changes O O
simultaneously O O
with O O
serum O O
amylase B B_GENE
activity O O
, O O
and O O
, O O
if O O
so O O
, O O
what O O
the O O
reason O O
is O O
for O O
the O O
detected O O
change O O
. O O

A O O
long O O
- O O
term O O
follow O O
- O O
up O O
study O O
of O O
a O O
children O O
' O O
s O O
psychiatric O O
day O O
treatment O O
center O O
. O O

Sequencing O O
and O O
restriction O O
enzyme O O
analysis O O
demonstrated O O
that O O
this O O
single O O
- O O
copy O O
gene O O
contains O O
11 O O
exons O O
and O O
spans O O
9596 O O
base O O
pairs O O
. O O

In O O
phase O O
II O O
studies O O
, O O
MDL O O
72 O O
, O O
974A O O
is O O
proving O O
to O O
be O O
a O O
useful O O
adjunct O O
to O O
conventional O O
therapy O O
. O O

However O O
, O O
no O O
consensus O O
on O O
indications O O
exists O O
and O O
, O O
according O O
to O O
the O O
literature O O
, O O
results O O
are O O
contradictory O O
. O O

The O O
effect O O
of O O
the O O
NMDA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonist O O
( O O
+ O O
/ O O
- O O
) O O
- O O
CPP O O
on O O
the O O
conditioned O O
- O O
reflex O O
activation O O
of O O
an O O
operant O O
reaction O O
in O O
the O O
brain O O
electrical O O
self O O
- O O
stimulation O O
test O O
in O O
rats O O

Within O O
any O O
cell O O
line O O
, O O
several O O
Tcfs B B_GENE/B_BACTERIUM[BIO]
and O O
TLEs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
are O O
co O O
- O O
expressed O O
. O O

Constructs O O
containing O O
fragments O O
of O O
the O O
upstream O O
region O O
of O O
the O O
cytotactin B B_GENE
gene I I_GENE
fused O O
to O O
a O O
promoterless O O
gene O O
for O O
chloramphenicol B B_GENE/B_TIME[MEASURE]
acetyltransferase I I_GENE/I_TIME[MEASURE]
were O O
transiently O O
transfected O O
into O O
chicken O O
embryo O O
fibroblasts O O
to O O
define O O
functional O O
promoter O O
sequences O O
. O O

We O O
investigated O O
the O O
pattern O O
of O O
evolution O O
of O O
bronchial O O
albumin B B_GENE/B_DISEASE
, O O
IgA B B_GENE
, O O
and O O
IgG B B_GENE
levels O O
in O O
ventilated O O
ICU O O
patients O O
in O O
relation O O
to O O
nosocomial O O
pneumonia O O
. O O

Mortality O O
among O O
patients O O
with O O
CAVB O O
is O O
still O O
high O O
and O O
has O O
not O O
declined O O
within O O
the O O
last O O
decade O O
. O O

Mutations O O
away O O
from O O
splice O O
site O O
recognition O O
sequences O O
might O O
cis O O
- O O
modulate O O
alternative O O
splicing O O
of O O
goat O O
alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
s1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
casein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

SETTING O O
: O O
A O O
private O O
office O O
- O O
based O O
fertility O O
program O O
. O O

Promoter O O
, O O
spliced O O
leader O O
, O O
and O O
coding O O
sequence O O
for O O
BICP4 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
largest O O
of O O
the O O
immediate B B_GENE/B_NUMBER[MEASURE]
- I I_GENE/I_NUMBER[MEASURE]
early I I_GENE/I_NUMBER[MEASURE]
proteins I I_GENE/I_NUMBER[MEASURE]
of I I_GENE/I_NUMBER[MEASURE]
bovine I I_GENE/I_NUMBER[MEASURE]
herpesvirus I I_GENE/I_NUMBER[MEASURE]
1 I I_GENE/I_NUMBER[MEASURE]
. O O

The O O
limb O O
defects O O
, O O
oligodactyly O O
and O O
syndactyly O O
, O O
have O O
been O O
traced O O
to O O
improper O O
differentiation O O
of O O
the O O
apical O O
ectodermal O O
ridge O O
( O O
AER O O
) O O
and O O
shortening O O
of O O
the O O
anteroposterior O O
limb O O
axis O O
. O O

There O O
was O O
no O O
correlation O O
between O O
starting O O
platelet O O
- O O
associated O O
IgG B B_GENE
levels O O
or O O
changes O O
in O O
platelet O O
- O O
associated O O
IgG B B_GENE
levels O O
with O O
therapy O O
and O O
the O O
increment O O
in O O
the O O
patient O O
' O O
s O O
platelet O O
count O O
. O O

We O O
investigated O O
whether O O
two O O
WT1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
splice I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
variants I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
lacking O O
or O O
including O O
a O O
three O O
- O O
amino O O
- O O
acid O O
( O O
KTS O O
) O O
insertion O O
between O O
the O O
third O O
and O O
fourth O O
zinc O O
finger O O
in O O
the O O
DNA O O
- O O
binding O O
domain O O
could O O
repress O O
the O O
IR B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
in O O
vitro O O
. O O

An O O
oligomer O O
synthesized O O
to O O
this O O
region O O
of O O
homology O O
produced O O
two O O
DNA O O
- O O
protein O O
complexes O O
with O O
oviduct O O
nuclear O O
proteins O O
. O O

In O O
contrast O O
translocation O O
of O O
G1 B B_PROTEIN[GENE]
to O O
the O O
Golgi O O
was O O
not O O
observed O O
when O O
G1 B B_PROTEIN[GENE]
was O O
coexpressed O O
with O O
NSm B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
although O O
NSm B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
itself O O
was O O
still O O
detected O O
in O O
the O O
Golgi O O
. O O

Since O O
simian B B_GENE/B_DISEASE
virus I I_GENE/I_DISEASE
40 I I_GENE/I_DISEASE
( I I_GENE/I_DISEASE
SV40 I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
large I I_GENE/I_DISEASE
T I I_GENE/I_DISEASE
antigen I I_GENE/I_DISEASE
and O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
papillomavirus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
16 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HPV16 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E7 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O O
bind O O
host O O
regulatory O O
factors O O
, O O
we O O
investigated O O
whether O O
these O O
viral O O
proteins O O
can O O
complement O O
E1A B B_DISEASE/B_GENE
mutants I I_DISEASE/I_GENE
which O O
are O O
defective O O
in O O
early O O
gene O O
activation O O
. O O

We O O
further O O
showed O O
a O O
significant O O
repression O O
of O O
promoter O O
activity O O
( O O
> O O
40 O O
fold O O
) O O
by O O
E2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
lacking O O
the O O
amino O O
acid O O
sequence O O
RSRS O O
) O O
when O O
the O O
E47 B B_GENE
reporter I I_GENE
construct I I_GENE
, O O
containing O O
a O O
hexameric O O
E O O
- O O
box O O
site O O
, O O
was O O
used O O
. O O

Similar O O
observations O O
were O O
obtained O O
when O O
these O O
mutated O O
versions O O
of O O
site O O
A O O
were O O
evaluated O O
by O O
transient O O
cotransfection O O
assays O O
in O O
CV1 O O
cells O O
. O O

The O O
shear O O
bond O O
strength O O
recorded O O
for O O
the O O
Novabond O O
system O O
was O O
significantly O O
lower O O
( O O
17 O O
MPa O O
) O O
. O O

A O O
400 O O
- O O
bp O O
fragment O O
( O O
bp O O
- O O
339 O O
through O O
+ O O
71 O O
) O O
of O O
the O O
CD22 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
subcloned O O
into O O
a O O
pGEM O O
- O O
chloramphenicol B B_PROTEIN[GENE]/B_MEASURE
acetyltransferase I I_PROTEIN[GENE]/I_MEASURE
vector O O
and O O
after O O
transfection O O
into O O
B O O
and O O
T O O
cells O O
was O O
found O O
to O O
be O O
active O O
in O O
both O O
B O O
and O O
T O O
cells O O
. O O

Electrophoretic O O
mobility O O
- O O
shift O O
assays O O
between O O
viral O O
RNA O O
and O O
BMV B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CP I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptides I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
either O O
proline O O
or O O
alanine O O
substitutions O O
revealed O O
that O O
the O O
interaction O O
is O O
nonspecific O O
. O O

Thus O O
, O O
over O O
a O O
wide O O
range O O
of O O
arterial O O
dimensions O O
, O O
results O O
obtained O O
with O O
caliper O O
estimates O O
of O O
luminal O O
area O O
and O O
diameter O O
are O O
comparable O O
to O O
those O O
obtained O O
with O O
videodensitometry O O
using O O
the O O
XR O O
- O O
70 O O
system O O
. O O

CONCLUSIONS O O
: O O
Neurodevelopmental O O
assessment O O
at O O
1 O O
year O O
is O O
predictive O O
of O O
school O O
performance O O
and O O
outcome O O
in O O
the O O
adolescent O O
period O O
. O O

We O O
reviewed O O
the O O
different O O
published O O
cases O O
of O O
acute O O
high O O
dose O O
methotrexate O O
neurotoxicity O O
and O O
the O O
different O O
underlying O O
mechanisms O O
. O O

Drug O O
therapy O O
of O O
AAPMC O O
is O O
directed O O
at O O
reducing O O
the O O
amount O O
of O O
Cl O O
. O O
difficile O O
in O O
the O O
colon O O
and O O
promoting O O
normalization O O
of O O
intestinal O O
flora O O
. O O

The O O
yield O O
of O O
endocervical O O
cells O O
and O O
the O O
incidence O O
of O O
dysplasia O O
was O O
determined O O
for O O
both O O
the O O
prenatal O O
and O O
the O O
postpartum O O
Pap O O
smears O O
performed O O
for O O
this O O
group O O
of O O
patients O O
. O O

No O O
significant O O
difference O O
in O O
plasma O O
ET B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
was O O
found O O
between O O
cardiac O O
and O O
peripheral O O
sampling O O
sites O O
( O O
pulmonary O O
artery O O
; O O
1 O O
. O O
07 O O
+ O O
/ O O
- O O
0 O O
. O O
28 O O
, O O
right O O
atrium O O
; O O
1 O O
. O O
02 O O
+ O O
/ O O
- O O
0 O O
. O O
28 O O
, O O
peripheral O O
artery O O
; O O
1 O O
. O O
12 O O
+ O O
/ O O
- O O
0 O O
. O O
23 O O
, O O
peripheral O O
vein O O
; O O
1 O O
. O O
14 O O
+ O O
/ O O
- O O
0 O O
. O O
38 O O
fmol O O
/ O O
ml O O
: O O
N O O
. O O
S O O
. O O
) O O
, O O
or O O
among O O
patients O O
with O O
uncomplicated O O
MI O O
, O O
unstable O O
angina O O
( O O
1 O O
. O O
00 O O
+ O O
/ O O
- O O
0 O O
. O O
32 O O
fmol O O
/ O O
ml O O
) O O
, O O
and O O
healthy O O
subjects O O
( O O
1 O O
. O O
01 O O
+ O O
/ O O
- O O
0 O O
. O O
29 O O
fmol O O
/ O O
ml O O
) O O
. O O

Dose O O
- O O
dependent O O
pharmacokinetics O O
: O O
emphasis O O
on O O
phase O O
I O O
metabolism O O
. O O

Inhibition O O
of O O
DNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
topoisomerase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
by O O
the O O
p53 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tumor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppressor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Activation O O
of O O
HIV O O
gene O O
expression O O
by O O
UV O O
must O O
therefore O O
involve O O
additional O O
cellular O O
processes O O
, O O
such O O
as O O
those O O
triggered O O
by O O
DNA O O
damage O O
, O O
for O O
generation O O
of O O
a O O
full O O
gene O O
expression O O
response O O
. O O

4 O O
. O O

Microsporum O O
persicolor O O
, O O
an O O
easily O O
misinterpreted O O
dermatophyt O O

We O O
propose O O
that O O
, O O
while O O
Y O O
. O O
lipolytica O O
CEN O O
DNA O O
is O O
essential O O
for O O
plasmid O O
maintenance O O
, O O
this O O
function O O
can O O
be O O
supplied O O
by O O
several O O
sub O O
- O O
fragments O O
which O O
, O O
together O O
, O O
form O O
the O O
active O O
chromosomal O O
centromere O O
. O O

In O O
this O O
second O O
clinical O O
paper O O
, O O
the O O
genetic O O
features O O
of O O
the O O
case O O
of O O
microphthalmia O O
in O O
sheep O O
reported O O
by O O
Wagenaar O O
is O O
discussed O O
in O O
greater O O
detail O O
. O O

Our O O
study O O
reveals O O
a O O
consequence O O
of O O
adhesion O O
receptor O O
- O O
mediated O O
signaling O O
in O O
T O O
cells O O
, O O
which O O
is O O
potentially O O
important O O
in O O
the O O
regulation O O
of O O
T O O
cell O O
activation O O
, O O
including O O
production O O
of O O
cytokines O O
and O O
expression O O
of O O
proto O O
- O O
oncogenes O O
, O O
many O O
of O O
which O O
are O O
controlled O O
through O O
3 O O
' O O
AU O O
- O O
rich O O
elements O O
. O O

The O O
family O O
histories O O
were O O
obtained O O
from O O
the O O
parents O O
. O O

The O O
DW O O
directions O O
uniformly O O
sampled O O
the O O
diffusion O O
ellipsoid O O
surface O O
. O O

Here O O
we O O
demonstrate O O
that O O
CD40 B B_GENE
or O O
IgM B B_GENE
receptor I I_GENE
stimulation O O
of O O
primary O O
B O O
cells O O
results O O
in O O
transactivation O O
of O O
this O O
enhancer O O
. O O

This O O
cell O O
line O O
expresses O O
productively O O
rearranged O O
immunoglobulin B B_GENE
genes I I_GENE
as O O
well O O
as O O
the O O
Oct B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
at O O
high O O
levels O O
which O O
are O O
comparable O O
to O O
those O O
observed O O
in O O
activated O O
murine O O
splenic O O
B O O
cells O O
. O O

Both O O
RNA14 B B_GENE/B_BIO
and O O
RNA15 B B_PROTEIN[GENE]
wild I I_PROTEIN[GENE]
- I I_PROTEIN[GENE]
type I I_PROTEIN[GENE]
genes I I_PROTEIN[GENE]
, O O
when O O
cloned O O
on O O
a O O
multicopy O O
plasmid O O
, O O
are O O
able O O
to O O
suppress O O
the O O
temperature O O
- O O
sensitive O O
phenotype O O
of O O
strains O O
bearing O O
either O O
the O O
rna14 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
the O O
rna15 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
suggesting O O
that O O
the O O
encoded O O
proteins O O
could O O
interact O O
with O O
each O O
other O O
. O O

It O O
is O O
very O O
probable O O
that O O
this O O
change O O
was O O
due O O
to O O
mechanical O O
effects O O
induced O O
by O O
injecting O O
a O O
hypertonic O O
solution O O
of O O
MT O O
- O O
141 O O
at O O
a O O
rate O O
of O O
70 O O
- O O
- O O
130 O O
ml O O
/ O O
dog O O
. O O

It O O
is O O
not O O
well O O
known O O
that O O
giant O O
cell O O
arteritis O O
can O O
cause O O
fatal O O
complications O O
due O O
to O O
rupture O O
of O O
aortic O O
aneurysms O O
or O O
cerebral O O
and O O
myocardial O O
infarctions O O
. O O

Basal O O
urinary O O
17 O O
- O O
hydroxycorticoid O O
( O O
17 O O
- O O
OHCS O O
) O O
values O O
were O O
elevated O O
in O O
9 O O
/ O O
12 O O
patients O O
and O O
low O O
dose O O
dexamethasone O O
suppression O O
test O O
favoured O O
Cushing O O
' O O
s O O
syndrome O O
in O O
8 O O
/ O O
9 O O
patients O O
. O O

Like O O
the O O
human O O
gene O O
, O O
the O O
Drosophila O O
gene O O
encodes O O
at O O
least O O
three O O
isoforms O O
of O O
full B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
length I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dystrophin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
dmDLP1 B B_PROTEIN[GENE]/B_DISEASE
, O O
dmDLP2 B B_GENE
and O O
dmDLP3 B B_GENE
, O O
) O O
, O O
regulated O O
by O O
different O O
promoters O O
located O O
at O O
the O O
5 O O
' O O
end O O
of O O
the O O
gene O O
, O O
and O O
a O O
smaller O O
product O O
regulated O O
by O O
an O O
internal O O
promoter O O
( O O
dmDp186 B B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

Accordingly O O
, O O
infection O O
of O O
IFN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
pretreated O O
HeLa O O
S3 O O
cells O O
with O O
an O O
E3L O O
- O O
deficient O O
VV O O
( O O
VVDeltaE3L O O
) O O
resulted O O
in O O
increased O O
phosphorylation O O
levels O O
of O O
both O O
PKR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
eIF2alpha B B_GENE
. O O

The O O
goal O O
of O O
our O O
work O O
was O O
to O O
determine O O
hearing O O
thresholds O O
in O O
patients O O
with O O
hearing O O
impairment O O
due O O
to O O
hereditary O O
motor O O
and O O
sensory O O
neuropathy O O
( O O
HMSN O O
I O O
) O O
. O O

Influence O O
of O O
dietary O O
supplementation O O
with O O
Streptococcus O O
faecium O O
M O O
- O O
74 O O
on O O
broiler O O
body O O
weight O O
, O O
feed O O
conversion O O
, O O
carcass O O
characteristics O O
, O O
and O O
intestinal O O
microbial O O
colonization O O
. O O

The O O
results O O
reveal O O
preferences O O
for O O
particular O O
initiating O O
nucleotides O O
( O O
ATP O O
> O O
or O O
= O O
GTP O O
> O O
UTP O O
> O O
> O O
CTP O O
) O O
and O O
for O O
starting O O
positions O O
downstream O O
of O O
the O O
Pribnow O O
box O O
( O O
7 O O
> O O
> O O
6 O O
and O O
8 O O
> O O
9 O O
> O O
10 O O
) O O
. O O

Trimethylcolchicinic O O
acid O O
methyl O O
ether O O
d O O
- O O
tartrate O O
( O O
TMCA O O
; O O
NSC O O
- O O
36351 O O
) O O
was O O
administered O O
daily O O
by O O
mouth O O
to O O
71 O O
patients O O
with O O
malignant O O
lymphomas O O
. O O

Gene O O
transcripts O O
are O O
detected O O
on O O
tissues O O
such O O
as O O
bovine O O
liver O O
, O O
kidney O O
, O O
lung O O
, O O
and O O
brain O O
. O O

Assessment O O
of O O
ammonia O O
and O O
urea O O
blood O O
content O O
in O O
metabolic O O
acid O O
- O O
base O O
disorders O O
in O O
white O O
rats O O
. O O

The O O
immediate O O
and O O
remote O O
results O O
of O O
surgical O O
treatment O O
of O O
renal O O
adenocarcinomas O O
. O O

Vibrio O O
cholerae O O
iron O O
transport O O
: O O
haem O O
transport O O
genes O O
are O O
linked O O
to O O
one O O
of O O
two O O
sets O O
of O O
tonB B B_GENE/B_BACTERIUM[BIO]
, O O
exbB B B_PROTEIN[GENE]/B_LOCATION
, O O
exbD B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
predicted O O
amino O O
- O O
acid O O
sequence O O
includes O O
an O O
N O O
- O O
terminal O O
signal O O
sequence O O
of O O
27 O O
amino O O
acids O O
, O O
a O O
27 O O
amino O O
- O O
acid O O
pro O O
- O O
region O O
, O O
a O O
251 O O
amino O O
- O O
acid O O
catalytic O O
domain O O
typical O O
of O O
a O O
serine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protease I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
trypsin B B_ENZYME[GENE]
- O O
like O O
specificity O O
, O O
and O O
a O O
C O O
- O O
terminal O O
hydrophobic O O
extension O O
which O O
is O O
predicted O O
to O O
function O O
as O O
a O O
membrane O O
anchor O O
. O O

To O O
examine O O
the O O
biochemical O O
mechanism O O
of O O
Tax1 B B_GENE/B_ORGANIZATION
transactivation O O
, O O
we O O
have O O
developed O O
an O O
in O O
vitro O O
transactivation O O
assay O O
in O O
which O O
wild O O
- O O
type O O
Tax1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
able O O
to O O
specifically O O
transactivate O O
a O O
polymerase B B_GENE/B_SPECIES[BIO]
II I B_GENE/I_SPECIES[BIO]
promoter O O
through O O
upstream O O
Tax1 B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
responsive I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
elements I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O O

Interestingly O O
, O O
PMA O O
- O O
, O O
PDGF B B_GENE
- O O
, O O
and O O
serum O O
- O O
induced O O
GHR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteolysis O O
was O O
associated O O
with O O
substantial O O
decreases O O
in O O
GH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
activation O O
of O O
Janus B B_GENE
kinase I I_GENE
- I I_GENE
2 I I_GENE
, O O
which O O
were O O
also O O
prevented O O
by O O
IC3 O O
. O O

Thus O O
, O O
IF O O
- O O
laser O O
therapy O O
has O O
a O O
certain O O
antioxidative O O
effect O O
by O O
increasing O O
SOD B B_GENE
activity O O
in O O
RA O O
patients O O
' O O
blood O O
cells O O
and O O
reducing O O
the O O
production O O
of O O
highly O O
reactive O O
oxygen O O
and O O
nitrogen O O
forms O O
. O O

Reactive O O
mesothelial O O
cells O O
, O O
usually O O
seen O O
as O O
exfoliated O O
cells O O
, O O
were O O
consistently O O
strongly O O
positive O O
for O O
alpha B B_GENE
1 I I_GENE
- I I_GENE
antichymotrypsin I I_GENE
and O O
more O O
variably O O
for O O
alpha B B_GENE
1 I I_GENE
- I I_GENE
antitrypsin I I_GENE
and O O
lysozyme B B_GENE
. O O

Recombinant O O
propeptides O O
containing O O
mutations O O
of O O
one O O
of O O
the O O
three O O
tryptophan O O
residues O O
were O O
three O O
orders O O
of O O
magnitude O O
less O O
effective O O
as O O
inhibitors O O
of O O
mature B B_ENZYME[GENE]
cathepsin I I_ENZYME[GENE]
S I I_ENZYME[GENE]
than O O
the O O
wild O O
- O O
type O O
propeptide O O
. O O

The O O
highest O O
incidence O O
was O O
observed O O
for O O
V O O
. O O
alginolyticus O O
( O O
92 O O
- O O
100 O O
% O O
) O O
, O O
followed O O
by O O
V O O
. O O
parahaemolyticus O O
( O O
67 O O
- O O
92 O O
% O O
) O O
, O O
V O O
. O O
fluvialis O O
( O O
34 O O
- O O
67 O O
% O O
) O O
, O O
V O O
. O O
vulnificus O O
( O O
8 O O
- O O
17 O O
% O O
) O O
, O O
V O O
. O O
furnissii O O
( O O
0 O O
- O O
17 O O
% O O
) O O
, O O
V O O
. O O
mimicus O O
( O O
0 O O
- O O
17 O O
% O O
) O O
and O O
V O O
. O O
cholerae O O
non O O
- O O
O1 O O
( O O
0 O O
- O O
8 O O
% O O
) O O
. O O

Acute O O
morphine O O
treatment O O
did O O
not O O
increase O O
the O O
locomotor O O
activity O O
of O O
mice O O
withdrawn O O
for O O
1 O O
day O O
, O O
after O O
withdrawal O O
for O O
3 O O
days O O
the O O
increase O O
was O O
similar O O
to O O
that O O
in O O
controls O O
, O O
and O O
after O O
5 O O
days O O
the O O
increase O O
was O O
clearly O O
larger O O
than O O
in O O
controls O O
. O O

In O O
patients O O
with O O
active O O
TB O O
, O O
cytokines O O
that O O
were O O
elevated O O
in O O
serum O O
were O O
IFN B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
IL B B_GENE
- I I_GENE
10 I I_GENE
. O O

Isolation O O
and O O
properties O O
of O O
Drosophila B B_GENE
melanogaster I I_GENE
ferritin I I_GENE
- O O
- O O
molecular O O
cloning O O
of O O
a O O
cDNA O O
that O O
encodes O O
one O O
subunit O O
, O O
and O O
localization O O
of O O
the O O
gene O O
on O O
the O O
third O O
chromosome O O
. O O

We O O
show O O
that O O
Fos B B_GENE
down O O
regulates O O
several O O
immediate B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
early I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
genes I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
c B B_GENE
- I I_GENE
fos I I_GENE
, O O
Egr B B_GENE
- I I_GENE
1 I I_GENE
, O O
and O O
Egr B B_GENE
- I I_GENE
2 I I_GENE
) O O
after O O
mitogenic O O
stimulation O O
. O O

This O O
study O O
demonstrates O O
a O O
novel O O
link O O
between O O
alterations O O
in O O
platelet B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
derived I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PDGF B B_GENE/B_LOCATION
) O O
regulation O O
of O O
ornithine B B_ENZYME[GENE]
decarboxylase I I_ENZYME[GENE]
( O O
ODC B B_GENE/B_DISEASE
) O O
expression O O
during O O
malignant O O
conversion O O
. O O

Circulating O O
immune O O
complexes O O
were O O
determined O O
by O O
the O O
method O O
of O O
phagocytosis O O
and O O
immunofluorescence O O
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IFI16 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
member O O
of O O
an O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
inducible O O
family O O
of O O
mouse O O
and O O
human O O
genes O O
closely O O
linked O O
on O O
syntenic O O
regions O O
of O O
chromosome O O
1 O O
. O O

In O O
agreement O O
with O O
this O O
model O O
, O O
elimination O O
of O O
the O O
ADAM13 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytoplasmic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
increased O O
developmental O O
alterations O O
attributable O O
to O O
ADAM13 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proteolytic O O
activity O O
. O O

Diabetic O O
osteopathy O O
. O O

A O O
third O O
GEF B B_GENE/B_LOCATION
, O O
GRP3 B B_GENE
( O O
KIAA0846 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
activated O O
both O O
Ras B B_GENE/B_DISEASE
and O O
Rap1 B B_GENE
and O O
shared O O
significant O O
sequence O O
homology O O
with O O
the O O
calcium O O
- O O
and O O
diacylglycerol O O
- O O
activated O O
GEFs B B_GENE/B_ORGANIZATION
, O O
GRP1 B B_GENE
and O O
GRP2 B B_GENE
. O O

Comparisons O O
of O O
defective O O
HTLV O O
- O O
I O O
proviruses O O
predict O O
the O O
mode O O
of O O
origin O O
and O O
coding O O
potential O O
of O O
internally O O
deleted O O
genomes O O
. O O

Previous O O
studies O O
have O O
shown O O
that O O
the O O
IME1 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
required O O
for O O
sporulation O O
and O O
the O O
expression O O
of O O
meiosis O O
specific O O
genes O O
in O O
Saccharomyces O O
cerevisiae O O
. O O

A O O
case O O
comparison O O
of O O
acquired O O
immune O O
deficiency O O
syndrome O O
( O O
AIDS O O
) O O
in O O
homosexual O O
males O O
with O O
spindle O O
- O O
endothelial O O
cell O O
abnormalities O O
and O O
with O O
recrudescent O O
melioidosis O O
. O O

Intrathecal O O
injections O O
of O O
small O O
volumes O O
of O O
the O O
alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
adrenoceptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
agonists O O
, O O
xylazine O O
and O O
clonidine O O
, O O
into O O
the O O
cervical O O
region O O
of O O
the O O
spinal O O
cord O O
of O O
conscious O O
unrestrained O O
sheep O O
produced O O
a O O
dose O O
- O O
dependent O O
analgesia O O
of O O
the O O
forelimbs O O
as O O
measured O O
using O O
a O O
mechanical O O
pressure O O
device O O
. O O

In O O
the O O
absence O O
of O O
c B B_GENE
- I I_GENE
fos I I_GENE
gene I I_GENE
expression O O
, O O
c B B_GENE
- I I_GENE
Fos I I_GENE
protein I I_GENE
appears O O
to O O
be O O
replaced O O
by O O
proteins O O
of O O
Fos B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Fra B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
1 I I_PROTEIN[GENE]/I_LOCATION
) O O
and O O
ATF B B_PERSON/B_GENE
family I I_PERSON/I_GENE
( O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ATFa B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
dopamine B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D1 I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dopamine I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist O O
SCH O O
23390 O O
dose O O
dependently O O
( O O
7 O O
. O O
5 O O
- O O
30 O O
micrograms O O
/ O O
kg O O
s O O
. O O
c O O
. O O
) O O
antagonized O O
the O O
stimulant O O
locomotor O O
effect O O
on O O
both O O
drugs O O
but O O
did O O
not O O
prevent O O
their O O
antiimmobility O O
effect O O
on O O
the O O
behavioral O O
despair O O
test O O
. O O

The O O
results O O
obtained O O
show O O
that O O
expression O O
of O O
the O O
gene O O
is O O
low O O
at O O
23 O O
degrees O O
C O O
and O O
is O O
induced O O
rapidly O O
at O O
37 O O
degrees O O
C O O
. O O

Characterization O O
of O O
Chlamydomonas O O
reinhardtii O O
zygote O O
- O O
specific O O
cDNAs O O
that O O
encode O O
novel O O
proteins O O
containing O O
ankyrin B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
repeats O O
and O O
WW O O
domains O O
. O O

Adenomas O O
in O O
the O O
upper O O
gastrointestinal O O
tract O O
were O O
found O O
in O O
all O O
of O O
the O O
patients O O
: O O
Vater O O
' O O
s O O
papilla O O
- O O
- O O
12 O O
, O O
duodenum O O
- O O
- O O
nine O O
, O O
and O O
gastric O O
antrum O O
- O O
- O O
seven O O
. O O

A O O
total O O
of O O
64 O O
uncomplicated O O
Type O O
- O O
2 O O
diabetic O O
individuals O O
of O O
higher O O
middle O O
class O O
to O O
rich O O
socio O O
- O O
economic O O
status O O
were O O
studied O O
. O O

Basic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
helix I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loop I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
helix I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
act O O
at O O
the O O
E O O
- O O
box O O
within O O
the O O
serum O O
response O O
element O O
of O O
the O O
c B B_GENE
- I I_GENE
fos I I_GENE
promoter I I_GENE
to O O
influence O O
hormone O O
- O O
induced O O
promoter O O
activation O O
in O O
Sertoli O O
cells O O
. O O

Using O O
yeast O O
two O O
- O O
hybrid O O
screening O O
, O O
we O O
isolated O O
histone B B_GENE
H3 I I_GENE
as O O
an O O
interacting O O
factor O O
of O O
CIA B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Concentrations O O
of O O
Co O O
, O O
Cu O O
, O O
Fe O O
, O O
Hg O O
, O O
Mn O O
, O O
Sb O O
, O O
Se O O
and O O
Zn O O
in O O
IAEA O O
milk O O
( O O
dry O O
) O O
standard O O
A O O
- O O
11 O O
were O O
re O O
- O O
evaluated O O
with O O
the O O
help O O
of O O
instrumental O O
and O O
radiochemical O O
neutron O O
activation O O
analysis O O
( O O
NAA O O
) O O
. O O

Gallstone O O
- O O
formation O O
has O O
traditionally O O
been O O
attributed O O
to O O
supersaturation O O
of O O
bile O O
with O O
cholesterol O O
. O O

Sixteen O O
patients O O
on O O
maintenance O O
hemodialysis O O
underwent O O
dialysis O O
with O O
either O O
cuprophane O O
( O O
n O O
= O O
8 O O
) O O
or O O
polymethylmethacrylate O O
( O O
PMMA O O
; O O
n O O
= O O
8 O O
) O O
membranes O O
for O O
1 O O
week O O
and O O
then O O
switched O O
to O O
the O O
opposite O O
membrane O O
during O O
the O O
second O O
week O O
. O O

Gene O O
expression O O
is O O
in O O
part O O
controlled O O
by O O
chromatin O O
remodeling O O
factors O O
and O O
the O O
acetylation O O
state O O
of O O
nucleosomal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histones I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Each O O
patient O O
was O O
seen O O
for O O
5 O O
to O O
13 O O
postsurgical O O
maintenance O O
visits O O
. O O

Recurrent O O
infections O O
, O O
episodic O O
lymphopenia O O
and O O
impaired O O
cellular O O
immunity O O
. O O

After O O
3 O O
months O O
of O O
intervention O O
, O O
sustained O O
physical O O
training O O
was O O
associated O O
with O O
the O O
decrease O O
of O O
FVII B B_GENE/B_DISEASE
and O O
PAI B B_GENE
- I I_GENE
1 I I_GENE
levels O O
. O O

Thirty O O
- O O
three O O
percent O O
had O O
elevated O O
titers O O
( O O
above O O
1 O O
: O O
20 O O
dilution O O
) O O
. O O

Xa4 B B_GENE/B_DISEASE
is O O
a O O
dominantly O O
inherited O O
rice O O
gene O O
that O O
confers O O
resistance O O
to O O
Philippine O O
race O O
1 O O
of O O
the O O
bacterial O O
blight O O
pathogen O O
Xanthomonas O O
oryzae O O
pv O O
. O O
oryzae O O
in O O
rice O O
. O O

In O O
uraemic O O
patients O O
, O O
similar O O
maximum O O
serum O O
concentrations O O
were O O
found O O
after O O
a O O
single O O
7 O O
. O O
5 O O
mg O O
/ O O
kg O O
iv O O
dose O O
. O O

When O O
a O O
longer O O
- O O
714 O O
to O O
+ O O
78 O O
fragment O O
of O O
the O O
PBGD B B_GENE
promoter I I_GENE
is O O
used O O
, O O
the O O
- O O
70 O O
GATA O O
mutant O O
still O O
displays O O
erythroid O O
- O O
specific O O
activity O O
and O O
is O O
cis O O
- O O
activated O O
by O O
the O O
5 B B_GENE
' I I_GENE
HS I I_GENE
- I I_GENE
2 I I_GENE
enhancer I I_GENE
, O O
while O O
the O O
- O O
100 O O
CCACC O O
mutant O O
is O O
completely O O
inactive O O
in O O
the O O
absence O O
or O O
in O O
the O O
presence O O
of O O
the O O
5 B B_GENE
' I I_GENE
HS I I_GENE
- I I_GENE
2 I I_GENE
enhancer I I_GENE
. O O

Surprisingly O O
, O O
in O O
adult O O
animals O O
, O O
the O O
suprabasal O O
expression O O
of O O
dnRXR B B_GENE
alpha I I_GENE
significantly O O
reduced O O
the O O
ability O O
of O O
topically O O
applied O O
tRA O O
to O O
stimulate O O
proliferation O O
of O O
undifferentiated O O
keratinocytes O O
in O O
the O O
basal O O
layer O O
of O O
epidermis O O
. O O

In O O
many O O
other O O
contractile O O
protein O O
gene O O
families O O
, O O
genes O O
encoding O O
cardiac O O
isoforms O O
are O O
expressed O O
early O O
in O O
skeletal O O
muscle O O
development O O
and O O
are O O
later O O
repressed O O
. O O

1995 O O
. O O

For O O
il8ra B B_GENE
, O O
it O O
is O O
formed O O
from O O
two O O
exons O O
, O O
whereas O O
for O O
il8rb B B_GENE
, O O
seven O O
distinct O O
neutrophil O O
mRNAs O O
are O O
formed O O
by O O
alternative O O
splicing O O
of O O
11 O O
exons O O
. O O

Endocarditis O O
remains O O
a O O
life O O
- O O
threatening O O
disease O O
with O O
substantial O O
morbidity O O
and O O
mortality O O
. O O

From O O
this O O
comparison O O
of O O
aa O O
sequences O O
, O O
the O O
ATPK7 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
considered O O
to O O
be O O
a O O
member O O
of O O
a O O
novel O O
subfamily O O
of O O
Ser B B_GENE/B_BIO
/ I I_GENE/I_BIO
Thr I I_GENE/I_BIO
PKs I I_GENE/I_BIO
in O O
plants O O
. O O

Of O O
these O O
, O O
23 O O
( O O
13 O O
. O O
6 O O
% O O
) O O
were O O
due O O
to O O
GIB O O
( O O
Upper O O
GIB O O
= O O
19 O O
, O O
Lower O O
GIB O O
= O O
4 O O
) O O
. O O

The O O
E O O
. O O
multilocularis O O
/ O O
Mongolian O O
gerbil O O
system O O
can O O
replace O O
the O O
natural O O
canid O O
hosts O O
as O O
a O O
new O O
way O O
to O O
obtain O O
infective O O
eggs O O
and O O
to O O
analyze O O
host O O
- O O
parasite O O
interactions O O
. O O

E1 B B_GENE/B_NUMBER[MEASURE]
recognition O O
sequences O O
in O O
the O O
bovine O O
papillomavirus O O
type O O
1 O O
origin O O
of O O
DNA O O
replication O O
: O O
interaction O O
between O O
half O O
sites O O
of O O
the O O
inverted O O
repeats O O
. O O

Plasma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
prolactin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
concentrations O O
in O O
pinealectomized O O
ewes O O
receiving O O
melatonin O O
treatment O O
and O O
in O O
pineal O O
intact O O
ewes O O
maintained O O
under O O
a O O
non O O
- O O
24 O O
- O O
hour O O
photoperiod O O
. O O

It O O
is O O
targeted O O
to O O
peroxisomes O O
when O O
expressed O O
in O O
mammalian O O
cells O O
and O O
yeast O O
. O O

The O O
transcriptional O O
start O O
site O O
, O O
identified O O
by O O
primer O O
extension O O
and O O
S1 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclease I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O O
, O O
is O O
34 O O
nt O O
upstream O O
of O O
the O O
translation O O
initiation O O
codon O O
. O O

Nonlinearities O O
in O O
cochlear O O
hydrodynamics O O
. O O

Electronic O O
structure O O
and O O
optical O O
properties O O
of O O
the O O
B12O2 O O
crystal O O
. O O

Spongiosa O O
regeneration O O
in O O
the O O
millipore O O
chamber O O

Such O O
results O O
suggest O O
that O O
there O O
are O O
no O O
differences O O
in O O
the O O
BMR O O
of O O
age O O
- O O
and O O
weight O O
- O O
matched O O
Asian O O
Indian O O
males O O
, O O
other O O
tropical O O
populations O O
and O O
Americans O O
. O O

Similar O O
to O O
what O O
was O O
observed O O
for O O
P O O
. O O
putida O O
, O O
a O O
psrA B B_BACTERIUM[BIO]/B_GENE
null O O
mutant O O
of O O
P O O
. O O
aeruginosa O O
also O O
showed O O
a O O
90 O O
% O O
reduction O O
in O O
rpoS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
; O O
both O O
mutants O O
could O O
be O O
complemented O O
for O O
rpoS B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
promoter I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activity O O
when O O
the O O
psrA B B_GENE/B_BACTERIUM[BIO]
gene I I_GENE/I_BACTERIUM[BIO]
was O O
provided O O
in O O
trans O O
. O O

The O O
role O O
of O O
the O O
putative O O
C2 B B_MEASURE/B_PROTEIN[GENE]
domain O O
of O O
Nedd4 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
not O O
been O O
elucidated O O
. O O

ZF87 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O O
binds O O
the O O
ME1a1 O O
element O O
with O O
higher O O
affinity O O
than O O
the O O
ME1a2 O O
element O O
. O O

We O O
found O O
a O O
significant O O
increase O O
of O O
thromboxane O O
as O O
evidenced O O
by O O
the O O
major O O
urinary O O
metabolite O O
2 O O
, O O
3 O O
- O O
dinorthromboxane O O
B2 O O
in O O
the O O
oestrogen O O
group O O
as O O
compared O O
to O O
the O O
orchidectomy O O
group O O
. O O

However O O
the O O
precise O O
function O O
of O O
DNA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PK I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
DNA O O
double O O
- O O
strand O O
break O O
repair O O
is O O
not O O
known O O
. O O

In O O
this O O
report O O
, O O
we O O
have O O
examined O O
whether O O
PTP1B B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
effects O O
transformation O O
induced O O
by O O
p210 B B_GENE/B_LOCATION
bcr B I_GENE/I_LOCATION
- O O
abl B B_GENE/B_DISEASE
. O O

S1 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclease I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O O
of O O
the O O
RNA O O
from O O
a O O
number O O
of O O
QT6 O O
- O O
LD O O
clones O O
gave O O
similar O O
results O O
, O O
indicating O O
that O O
the O O
LD O O
population O O
was O O
composed O O
of O O
viruses O O
with O O
similar O O
but O O
not O O
identical O O
deletion O O
endpoints O O
. O O

Association O O
of O O
Smads B B_GENE
with O O
lymphoid B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
enhancer I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
binding I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
/ O O
T B B_MEASURE/B_GENE
cell I I_MEASURE/I_GENE
- I I_MEASURE/I_GENE
specific I I_MEASURE/I_GENE
factor I I_MEASURE/I_GENE
mediates O O
cooperative O O
signaling O O
by O O
the O O
transforming B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
wnt B B_GENE
pathways O O
. O O

The O O
three O O
OAS B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
flanked O O
by O O
markers B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
WI I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10614 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
cen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
and O O
D12S2293 B B_GENE/B_MEASURE
( O O
tel B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
and O O
are O O
contained O O
within O O
three O O
sets O O
of O O
overlapping O O
cosmid O O
clones O O
. O O

22 O O
. O O
6 O O
% O O
of O O
patients O O
were O O
found O O
to O O
be O O
positive O O
at O O
histology O O
in O O
the O O
corpus O O
mucosa O O
; O O
all O O
but O O
one O O
of O O
these O O
patients O O
had O O
elevated O O
circulating O O
IgG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
H O O
. O O
pylori O O
( O O
Group O O
C O O
) O O
. O O

Rottlerin O O
also O O
inhibited O O
the O O
activation O O
of O O
MAP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MEK B B_GENE/B_LOCATION
) O O
in O O
response O O
to O O
activated O O
Raf B B_GENE/B_DISEASE
, O O
but O O
had O O
no O O
effect O O
upon O O
c B B_GENE
- I I_GENE
Raf I I_GENE
activity O O
or O O
ERK B B_GENE/B_DISEASE
activation O O
by O O
activated O O
MEK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Quasidiatomic O O
study O O
of O O
Ly O O
- O O
alpha O O
- O O
producing O O
H2 O O
+ O O
- O O
Ne O O
collisions O O
at O O
keV O O
energies O O
. O O

The O O
NH O O
( O O
2 O O
) O O
- O O
terminus O O
of O O
all O O
three O O
proteins O O
contains O O
a O O
POZ O O
domain O O
, O O
a O O
conserved O O
120 O O
amino O O
acid O O
motif O O
involved O O
in O O
transcriptional O O
repression O O
and O O
protein O O
dimerization O O
. O O

The O O
isolation O O
of O O
crt5 B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
262 I I_GENE/I_MEASURE
, O O
an O O
additional O O
cdc B B_GENE/B_PERSON
allele I I_GENE/I_PERSON
of O O
POL1 B B_GENE/B_DISEASE
/ O O
CDC17 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
suggests O O
for O O
the O O
first O O
time O O
that O O
directly O O
blocking O O
DNA O O
replication O O
can O O
provide O O
a O O
signal O O
to O O
induce O O
the O O
DNA O O
damage O O
response O O
. O O

Greer O O
, O O
and O O
L O O
. O O
A O O
. O O

However O O
, O O
both O O
peptides O O
1 O O
- O O
49 O O
and O O
63 O O
- O O
87 O O
bound O O
to O O
PDE B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
solid O O
- O O
phase O O
binding O O
assay O O
. O O

The O O
mutation O O
also O O
preferentially O O
limits O O
( O O
compared O O
with O O
total O O
protein O O
synthesis O O
) O O
translation O O
of O O
an O O
induced O O
gene O O
that O O
depends O O
on O O
five O O
AGA O O
codons O O
, O O
i O O
. O O
e O O
. O O
, O O
the O O
lambda B B_GENE/B_PERSON
cI I I_GENE/I_PERSON
repressor I I_GENE/I_PERSON
gene I I_GENE/I_PERSON
. O O

Five O O
RNA O O
transcripts O O
of O O
about O O
1 O O
. O O
2 O O
to O O
1 O O
. O O
7 O O
kilobases O O
were O O
mapped O O
to O O
a O O
part O O
of O O
the O O
genome O O
of O O
insect O O
iridescent O O
virus O O
type O O
6 O O
( O O
Chilo O O
iridescent O O
virus O O
; O O
CIV O O
) O O
between O O
genome O O
coordinates O O
0 O O
. O O
832 O O
and O O
0 O O
. O O
856 O O
within O O
the O O
EcoRI B B_GENE/B_SPECIES[BIO]
DNA I B_GENE/I_SPECIES[BIO]
fragment I B_GENE/I_SPECIES[BIO]
F I B_GENE/I_SPECIES[BIO]
. O O

Other O O
similar O O
patients O O
must O O
be O O
found O O
before O O
it O O
is O O
established O O
that O O
the O O
colloid O O
cyst O O
is O O
part O O
of O O
the O O
nevoid O O
basal O O
cell O O
carcinoma O O
syndrome O O
. O O

Portions O O
of O O
the O O
3 O O
' O O
- O O
coding O O
and O O
3 O O
' O O
- O O
untranslated O O
regions O O
were O O
found O O
to O O
be O O
missing O O
from O O
the O O
7 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
topo I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
Northern O O
blot O O
analysis O O
. O O

A O O
GTP O O
/ O O
GDP O O
exchange O O
assay O O
was O O
used O O
to O O
assess O O
the O O
potential O O
role O O
of O O
Ras B B_GENE/B_DISEASE
in O O
the O O
pathway O O
leading O O
to O O
ERK B B_GENE
phosphorylation O O
; O O
DADLE O O
failed O O
to O O
stimulate O O
GTP O O
/ O O
GDP O O
exchange O O
in O O
comparison O O
to O O
PMA O O
. O O

Phenotypic O O
analysis O O
demonstrates O O
that O O
trio B B_GENE/B_ENT
and O O
Abl B B_GENE/B_PERSON
cooperate O O
in O O
regulating O O
axon O O
outgrowth O O
in O O
the O O
embryonic O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
. O O

Recombinant B B_PERSON/B_GENE
caspases I I_PERSON/I_GENE
are O O
typically O O
produced O O
in O O
Escherichia O O
coli O O
expression O O
systems O O
with O O
the O O
attendant O O
problems O O
of O O
solubilization O O
, O O
re O O
- O O
folding O O
and O O
activation O O
of O O
the O O
protease O O
. O O

This O O
bound O O
[ O O
3H O O
] O O
iloprost O O
with O O
high O O
affinity O O
and O O
stimulated O O
cAMP O O
production O O
when O O
exposed O O
to O O
agonist O O
. O O

Structure O O
of O O
the O O
connective O O
stroma O O
of O O
the O O
epididymis O O
in O O
the O O
zebu O O

In O O
a O O
series O O
of O O
papers O O
, O O
the O O
staging O O
system O O
for O O
melanoma O O
was O O
critically O O
analyzed O O
, O O
and O O
many O O
shortcomings O O
were O O
identified O O
. O O

Reproduction O O
and O O
maternal O O
response O O
of O O
the O O
rat O O
when O O
thiamine O O
intake O O
is O O
limited O O
. O O

Total O O
meso O O
- O O
pore O O
volume O O
and O O
surface O O
area O O
ranged O O
from O O
0 O O
. O O
004 O O
- O O
0 O O
. O O
08 O O
cm3 O O
g O O
( O O
- O O
1 O O
) O O
and O O
from O O
0 O O
. O O
33 O O
- O O
6 O O
. O O
9 O O
m2 O O
g O O
( O O
- O O
1 O O
) O O
respectively O O
, O O
accounting O O
for O O
up O O
33 O O
% O O
of O O
the O O
BET O O
surface O O
area O O
. O O

The O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
precursor O O
p100 B B_GENE
( O O
lyt B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
10 I I_GENE/I_DISEASE
, O O
p97 B B_MEASURE/B_GENE
, O O
p98 B B_MEASURE/B_GENE
) O O
generates O O
after O O
proteolytic O O
processing O O
a O O
52 O O
kDa O O
subunit O O
, O O
which O O
can O O
bind O O
to O O
kappa B B_GENE
B I I_GENE
- I I_GENE
motifs I I_GENE
. O O

Based O O
on O O
29 O O
determinations O O
of O O
the O O
glucose O O
from O O
sinigrin O O
, O O
analyzed O O
under O O
different O O
conditions O O
, O O
accuracy O O
of O O
the O O
total O O
glucosinolate O O
determination O O
was O O
94 O O
. O O
8 O O
+ O O
/ O O
- O O
7 O O
. O O
3 O O
% O O
. O O

Receptor B B_GENE/B_PERSON
- I I_GENE/I_PERSON
type I I_GENE/I_PERSON
serine I I_GENE/I_PERSON
/ I I_GENE/I_PERSON
threonine I I_GENE/I_PERSON
kinases I I_GENE/I_PERSON
( O O
RSKs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
have O O
been O O
organized O O
into O O
two O O
distinct O O
classes O O
known O O
as O O
types O O
I O O
and O O
II O O
on O O
the O O
basis O O
of O O
sequence O O
similarity O O
. O O

In O O
a O O
previous O O
study O O
of O O
transforming B B_GENE
growth I I_GENE
factor I I_GENE
- I I_GENE
beta1 I I_GENE
- O O
mediated O O
inhibition O O
of O O
the O O
cyclin B B_GENE
A I I_GENE
promoter I I_GENE
, O O
we O O
mapped O O
the O O
inhibitory O O
effect O O
to O O
the O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
in O O
the O O
present O O
study O O
of O O
IFN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
treatment O O
, O O
functional O O
analysis O O
by O O
transient O O
transfection O O
showed O O
that O O
inhibition O O
of O O
the O O
cyclin B B_GENE
A I I_GENE
promoter I I_GENE
persisted O O
despite O O
mutation O O
of O O
the O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
NF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
Y I I_GENE/I_LOCATION
, O O
or O O
CDE O O
elements O O
. O O

The O O
inactive O O
X O O
allele O O
, O O
however O O
, O O
is O O
hypermethylated O O
in O O
leukocytes O O
, O O
presumably O O
reflecting O O
early O O
X O O
inactivation O O
events O O
that O O
become O O
important O O
for O O
gene O O
dosage O O
in O O
expressing O O
lineages O O
. O O

Intensive O O
therapy O O
of O O
viral O O
hepatitis O O

Also O O
, O O
the O O
RVW O O
hypertrophy O O
, O O
the O O
IVS O O
hypertrophy O O
, O O
and O O
the O O
RV O O
high O O
pressure O O
load O O
to O O
the O O
LV O O
through O O
the O O
IVS O O
may O O
be O O
related O O
to O O
the O O
small O O
LV O O
, O O
high O O
EF O O
, O O
and O O
abnormal O O
two O O
chamber O O
inflow O O
in O O
the O O
PS O O
group O O
before O O
BV O O
. O O

Analysis O O
of O O
the O O
DNA O O
- O O
binding O O
and O O
transcriptional O O
activation O O
functions O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Fli I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
pattern O O
of O O
expression O O
and O O
differential O O
processing O O
suggests O O
a O O
role O O
for O O
inrpk1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
some O O
aspect O O
of O O
SD O O
photoperiodic O O
- O O
induced O O
flowering O O
in O O
morning O O
glory O O
. O O

Progressive O O
immunodeficiency O O
in O O
a O O
patient O O
with O O
IgA B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficiency O O

ESR O O
spectra O O
of O O
Er3 O O
+ O O
in O O
SmB6 O O
single O O
crystals O O
: O O
Dynamic O O
Jahn O O
- O O
Teller O O
effect O O
in O O
a O O
mixed O O
- O O
valence O O
compound O O
. O O

The O O
N O O
- O O
terminal O O
exon1 O O
had O O
no O O
homology O O
at O O
the O O
amino O O
acid O O
level O O
with O O
NGFI B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
mammalian O O
homologue O O
. O O

This O O
paper O O
describes O O
a O O
longitudinal O O
study O O
in O O
which O O
clinical O O
parameters O O
and O O
aspartate B B_ENZYME[GENE]
aminotransferase I I_ENZYME[GENE]
( O O
AST B B_GENE/B_ORGANIZATION
) O O
in O O
gingival O O
crevicular O O
fluid O O
( O O
GCF O O
) O O
were O O
monitored O O
bimonthly O O
over O O
a O O
6 O O
- O O
12 O O
months O O
period O O
in O O
970 O O
sites O O
from O O
7 O O
treated O O
periodontitis O O
patients O O
. O O

We O O
conclude O O
from O O
these O O
observations O O
that O O
the O O
cTnC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ile I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
composite O O
enhancer O O
that O O
functions O O
through O O
the O O
combined O O
interactions O O
of O O
at O O
least O O
five O O
regulatory O O
elements O O
and O O
their O O
cognate O O
binding O O
factors O O
: O O
three O O
or O O
four O O
E O O
- O O
boxes O O
, O O
a O O
MEF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
a O O
MEF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
identified O O
Tyr O O
( O O
112 O O
) O O
and O O
Leu O O
( O O
175 O O
) O O
within O O
the O O
RNA O O
- O O
binding O O
domain O O
of O O
the O O
U1 B B_GENE
70K I I_GENE
protein I I_GENE
to O O
be O O
cross O O
- O O
linked O O
to O O
G O O
( O O
28 O O
) O O
and O O
U O O
( O O
30 O O
) O O
in O O
stem O O
- O O
loop O O
I O O
, O O
respectively O O
. O O

Kudzu O O
extract O O
shows O O
potential O O
for O O
moderating O O
alcohol O O
abuse O O
. O O

BCV B B_PERSON/B_GENE
mRNAs I I_PERSON/I_GENE
5 I I_PERSON/I_GENE
and I I_PERSON/I_GENE
5 I I_PERSON/I_GENE
- I I_PERSON/I_GENE
1 I I_PERSON/I_GENE
appear O O
to O O
be O O
used O O
for O O
the O O
synthesis O O
of O O
the O O
12 O O
. O O
7 O O
- O O
and O O
9 O O
. O O
5 O O
- O O
kDa O O
proteins O O
, O O
respectively O O
, O O
which O O
demonstrates O O
a O O
pattern O O
of O O
expression O O
strikingly O O
different O O
from O O
that O O
utilized O O
by O O
MHV O O
. O O

Disaster O O
medicine O O

The O O
use O O
of O O
specific O O
somatic O O
cell O O
hybrids O O
have O O
allowed O O
us O O
to O O
locate O O
the O O
YAC O O
contig O O
telomeric O O
to O O
the O O
D3F15S2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
a O O
region O O
which O O
is O O
frequently O O
deleted O O
in O O
lung O O
carcinomas O O
. O O

Experiments O O
were O O
performed O O
without O O
polarization O O
or O O
with O O
cathodic O O
and O O
anodic O O
polarization O O
of O O
the O O
adsorbent O O
. O O

Chronic O O
active O O
hepatitis O O
and O O
cirrhosis O O
of O O
the O O
liver O O
. O O

This O O
regulation O O
is O O
mediated O O
by O O
several O O
kinases O O
that O O
phosphorylate O O
specific O O
residues O O
in O O
the O O
different O O
functional O O
domains O O
of O O
the O O
p53 B B_GENE
molecule I I_GENE
. O O

These O O
data O O
show O O
that O O
the O O
processing O O
of O O
specific O O
target O O
transcripts O O
, O O
such O O
as O O
the O O
P B B_GENE/B_BIO
- I I_GENE/I_BIO
element I I_GENE/I_BIO
mRNA I I_GENE/I_BIO
, O O
is O O
regulated O O
by O O
a O O
functional O O
PSI B B_GENE/B_DISEASE
- O O
U1 B B_GENE
snRNP O O
interaction O O
in O O
Drosophila O O
. O O

Effect O O
of O O
dimethyl O O
sulfoxide O O
on O O
cooling O O
rates O O
of O O
unrestrained O O
rats O O
. O O

In O O
four O O
calves O O
given O O
Haemonchus O O
contortus O O
larvae O O
, O O
the O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pepsinogen I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
concentration O O
rose O O
quickly O O
to O O
reach O O
a O O
mean O O
of O O
3 O O
. O O
5 O O
iu O O
tyrosine O O
on O O
day O O
14 O O
after O O
infection O O
. O O

These O O
results O O
strongly O O
suggest O O
that O O
HSV O O
- O O
1 O O
infection O O
inhibits O O
host O O
cell O O
splicing O O
through O O
the O O
action O O
of O O
ICP27 B B_GENE
. O O

Transformation O O
of O O
chicken O O
embryo O O
fibroblasts O O
( O O
CEF O O
) O O
with O O
the O O
Gag B B_GENE/B_LOCATION
- O O
Crk B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fusion O O
protein O O
results O O
in O O
the O O
elevation O O
of O O
tyrosine O O
phosphorylation O O
on O O
specific O O
cellular O O
proteins O O
with O O
molecular O O
weights O O
of O O
130 O O
, O O
000 O O
, O O
110 O O
, O O
000 O O
, O O
and O O
70 O O
, O O
000 O O
( O O
p130 B B_GENE/B_MEASURE
, O O
p110 B B_GENE/B_MEASURE
, O O
and O O
p70 B B_GENE/B_MEASURE
, O O
respectively O O
) O O
, O O
an O O
event O O
which O O
has O O
been O O
correlated O O
with O O
cell O O
transformation O O
. O O

Here O O
, O O
we O O
provide O O
direct O O
evidence O O
that O O
the O O
meiotic O O
defect O O
caused O O
by O O
either O O
unregulated O O
cAPK B B_GENE
activity O O
or O O
unregulated O O
ran1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
is O O
due O O
to O O
inability O O
to O O
induce O O
transcription O O
of O O
the O O
mei2 B B_GENE
+ I I_GENE
gene I I_GENE
, O O
which O O
is O O
required O O
for O O
meiotic O O
initiation O O
. O O

Ultrasonography O O
is O O
a O O
diagnostic O O
alternative O O
which O O
may O O
replace O O
arthrography O O
. O O

In O O
K562 O O
cells O O
, O O
using O O
the O O
bicistronic O O
vector O O
, O O
selection O O
with O O
colchicine O O
led O O
to O O
at O O
least O O
20 O O
- O O
fold O O
higher O O
expression O O
of O O
the O O
MDR1 B B_GENE
gene I I_GENE
product I I_GENE
than O O
did O O
selection O O
with O O
G418 O O
, O O
suggesting O O
that O O
the O O
stringent O O
MDR1 B B_GENE
selection O O
system O O
is O O
very O O
efficient O O
for O O
obtaining O O
overexpression O O
of O O
foreign O O
genes O O
. O O

In O O
this O O
report O O
, O O
several O O
health O O
behaviors O O
were O O
investigated O O
in O O
relation O O
to O O
maintaining O O
mobility O O
during O O
4 O O
years O O
of O O
follow O O
- O O
up O O
among O O
6 O O
, O O
981 O O
men O O
and O O
women O O
aged O O
65 O O
years O O
and O O
older O O
with O O
intact O O
mobility O O
at O O
baseline O O
between O O
1981 O O
and O O
1983 O O
who O O
lived O O
in O O
one O O
of O O
three O O
communities O O
: O O
East O O
Boston O O
, O O
Massachusetts O O
; O O
Iowa O O
and O O
Washington O O
counties O O
, O O
Iowa O O
; O O
and O O
New O O
Haven O O
, O O
Connecticut O O
. O O

Our O O
analysis O O
indicates O O
that O O
a O O
gene O O
correction O O
mechanism O O
has O O
been O O
operating O O
on O O
the O O
Hbbs B B_PROTEIN[GENE]/B_DISEASE
chromosome O O
to O O
keep O O
beta B B_PROTEIN[GENE]
s I I_PROTEIN[GENE]
and O O
beta B B_PROTEIN[GENE]
t I I_PROTEIN[GENE]
evolving O O
in O O
concert O O
, O O
whereas O O
on O O
the O O
Hbbd B B_GENE/B_PERSON
chromosome O O
, O O
beta B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dmin I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
diverged O O
considerably O O
from O O
beta B B_PERSON/B_GENE
dmaj I I_PERSON/I_GENE
. O O

kg O O
- O O
1 O O
respectively O O
. O O

We O O
identify O O
YY1 B B_GENE
recognition O O
sequences O O
within O O
the O O
vitamin O O
D O O
response O O
element O O
( O O
VDRE O O
) O O
of O O
the O O
osteocalcin B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
that O O
are O O
critical O O
for O O
YY1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O O
repression O O
of O O
vitamin O O
D O O
- O O
enhanced O O
promoter O O
activity O O
. O O

Back O O
- O O
ground O O
factors O O
which O O
affect O O
the O O
outcome O O
of O O
steroid O O
withdrawal O O
therapy O O
in O O
patients O O
with O O
chronic O O
type O O
B O O
hepatitis O O
- O O
- O O
statistical O O
evaluation O O
of O O
the O O
importance O O
of O O
the O O
mode O O
of O O
HBV O O
transmission O O

Point O O
mutations O O
of O O
Stat3 B B_GENE/B_LOCATION
within O O
the O O
interacting O O
domains O O
blocked O O
both O O
physical O O
interaction O O
of O O
Stat3 B B_GENE
with O O
c B B_GENE
- I I_GENE
Jun I I_GENE
and O O
their O O
cooperation O O
in O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
induced O O
transcription O O
directed O O
by O O
the O O
alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
macroglobulin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Three O O
patients O O
with O O
Mirizzi O O
type O O
II O O
syndrome O O
and O O
two O O
patients O O
with O O
Mirizzi O O
type O O
I O O
syndrome O O
were O O
treated O O
laparoscopically O O
. O O

Synchronous O O
multicentric O O
giant O O
cell O O
tumour O O
: O O
a O O
case O O
report O O
with O O
review O O
of O O
literature O O
. O O

From O O
the O O
comparison O O
of O O
the O O
nod B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
box I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
( O O
brady O O
) O O
rhizobia O O
with O O
a O O
more O O
divergent O O
nod B B_GENE/B_LOCATION
box I I_GENE/I_LOCATION
from O O
Azorhizobium O O
caulinodans O O
, O O
we O O
now O O
propose O O
a O O
modular O O
build O O
- O O
up O O
of O O
the O O
nod B B_GENE/B_LOCATION
box I I_GENE/I_LOCATION
with O O
the O O
sequence O O
A O O
- O O
T O O
- O O
C O O
- O O
N9 O O
- O O
G O O
- O O
A O O
- O O
T O O
as O O
the O O
binding O O
target O O
of O O
the O O
NodD B B_PROTEIN[GENE]/B_BIO
protein I I_PROTEIN[GENE]/I_BIO
( O O
the O O
NodD B B_GENE/B_MEASURE
box I I_GENE/I_MEASURE
) O O
. O O

The O O
prgX B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
is O O
adjacent O O
to O O
prgQ B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
provides O O
the O O
promoter O O
for O O
prgB B B_GENE/B_BACTERIUM[BIO]
expression O O
. O O

METHODS O O
: O O
A O O
discriminant O O
function O O
predicting O O
surgery O O
outcome O O
( O O
seizure O O
- O O
free O O
vs O O
. O O
non O O
- O O
seizure O O
- O O
free O O
) O O
was O O
computed O O
separately O O
for O O
samples O O
of O O
patients O O
with O O
left O O
( O O
n O O
= O O
79 O O
) O O
and O O
right O O
( O O
n O O
= O O
62 O O
) O O
temporal O O
lobectomy O O
( O O
LATL O O
, O O
RATL O O
) O O
. O O

It O O
is O O
likely O O
that O O
these O O
recordings O O
are O O
incomplete O O
; O O
the O O
actual O O
number O O
of O O
activated O O
neurons O O
is O O
estimated O O
to O O
be O O
about O O
300 O O
in O O
the O O
acutely O O
sensitized O O
preparation O O
. O O

The O O
possibility O O
to O O
use O O
this O O
method O O
for O O
common O O
diagnostic O O
problems O O
is O O
indicated O O
. O O

Genetic O O
analysis O O
of O O
the O O
role O O
of O O
herpes B B_GENE
simplex I I_GENE
virus I I_GENE
type I I_GENE
1 I I_GENE
glycoprotein I I_GENE
K I I_GENE
in O O
infectious O O
virus O O
production O O
and O O
egress O O
. O O

A O O
conventional O O
N O O
- O O
terminal O O
signal O O
sequence O O
was O O
not O O
detected O O
in O O
the O O
NodO B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Dynamic O O
expression O O
of O O
broad B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mediates O O
temporal O O
control O O
of O O
an O O
ecdysteroid O O
target O O
gene O O
at O O
the O O
onset O O
of O O
Drosophila O O
metamorphosis O O
. O O

The O O
study O O
was O O
carried O O
out O O
according O O
to O O
the O O
BSI O O
( O O
1980 O O
) O O
recommendations O O
for O O
testing O O
restorative O O
materials O O
in O O
vivo O O
. O O

Cellular O O
lysates O O
were O O
analyzed O O
for O O
luciferase B B_ENZYME[GENE]
and O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activities O O
. O O

Cytokines O O
and O O
steroid O O
hormones O O
use O O
different O O
sets O O
of O O
signal O O
transduction O O
pathways O O
, O O
which O O
seem O O
to O O
be O O
unrelated O O
. O O

This O O
mutant O O
also O O
functions O O
in O O
vivo O O
as O O
a O O
trans O O
- O O
acting O O
dominant O O
negative O O
regulator O O
: O O
the O O
transcriptional O O
inducibility O O
of O O
the O O
HIV B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
long I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
terminal I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
which O O
contains O O
two O O
potential O O
NF B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
by O O
phorbol O O
ester O O
( O O
PMA O O
) O O
is O O
inhibited O O
when O O
it O O
is O O
co O O
- O O
transfected O O
into O O
CD4 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
+ I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
T O O
cells O O
with O O
the O O
delta O O
SP O O
mutant O O
. O O

In O O
addition O O
, O O
measurements O O
of O O
shielded O O
and O O
unshielded O O
syringes O O
containing O O
99mTc O O
- O O
labelled O O
radiopharmaceuticals O O
were O O
carried O O
out O O
. O O

This O O
study O O
tests O O
the O O
hypothesis O O
that O O
O2 O O
is O O
a O O
critical O O
component O O
in O O
myocardial O O
protection O O
afforded O O
by O O
BCP O O
. O O

Biomass O O
growth O O
monitoring O O
using O O
pressure O O
drop O O
in O O
a O O
cocurrent O O
biofilter O O

This O O
alternative O O
splice O O
acceptor O O
site O O
is O O
also O O
used O O
by O O
a O O
biologically O O
active O O
provirus O O
with O O
an O O
efficiency O O
of O O
approximately O O
5 O O
% O O
compared O O
with O O
the O O
upstream O O
site O O
. O O

We O O
have O O
isolated O O
and O O
structurally O O
characterized O O
genomic O O
DNA O O
and O O
cDNA O O
sequences O O
encoding O O
ribulose B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bisphosphate I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboxylase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxygenase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Rbu I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
P2 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboxylase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
barley O O
( O O
Hordeum O O
vulgare O O
L O O
. O O
) O O
. O O

Expression O O
of O O
putative O O
constitutively O O
active O O
forms O O
of O O
DdMEK1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
ddmek1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
null O O
background O O
is O O
capable O O
, O O
at O O
least O O
partially O O
, O O
of O O
complementing O O
the O O
small O O
aggregate O O
size O O
defect O O
and O O
the O O
ability O O
to O O
activate O O
guanylyl B B_GENE
cyclase I I_GENE
. O O

Constant O O
slowing O O
of O O
median O O
MNCV O O
and O O
SNCV O O
and O O
ulnar O O
SNCV O O
without O O
changes O O
in O O
morphology O O
, O O
amplitude O O
and O O
duration O O
of O O
MAP O O
and O O
SAP O O
have O O
been O O
observed O O
in O O
92 O O
patients O O
, O O
with O O
persistent O O
abnormalities O O
in O O
64 O O
cases O O
after O O
six O O
months O O
. O O

Moreover O O
, O O
such O O
mutations O O
lead O O
to O O
a O O
dramatic O O
transition O O
in O O
chromatin O O
structure O O
: O O
the O O
DNase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hypersensitive I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
replaced O O
by O O
two O O
stable O O
, O O
sequence O O
- O O
positioned O O
nucleosomes O O
. O O

187 O O
- O O
200 O O
. O O

Experience O O
in O O
a O O
Kenya O O
district O O
hospital O O

The O O
2 B B_GENE
. I I_GENE
3 I I_GENE
x I I_GENE
10 I I_GENE
( I I_GENE
3 I I_GENE
) I I_GENE
base I I_GENE
SUF12 I I_GENE
+ I I_GENE
transcript I I_GENE
contains O O
an O O
open O O
reading O O
frame O O
sufficient O O
to O O
encode O O
a O O
88 O O
x O O
10 O O
( O O
3 O O
) O O
Mr O O
protein O O
. O O

A O O
new O O
family O O
of O O
rate O O
- O O
adaptive O O
pacemakers O O
accomplishes O O
this O O
circadian O O
rate O O
variation O O
by O O
modeling O O
the O O
patient O O
' O O
s O O
sleep O O
- O O
wake O O
cycle O O
using O O
a O O
time O O
- O O
of O O
- O O
day O O
clock O O
inside O O
the O O
device O O
. O O

Progestins O O
: O O
present O O
and O O
future O O
. O O

Bilirubin O O
and O O
red O O
cell O O
metabolism O O
in O O
relation O O
to O O
neonatal O O
jaundice O O
. O O

Each O O
of O O
these O O
materials O O
were O O
placed O O
by O O
means O O
of O O
three O O
different O O
placement O O
techniques O O
( O O
Bulk O O
pack O O
, O O
Horizontal O O
layering O O
and O O
Vertical O O
layering O O
) O O
into O O
class O O
II O O
cavities O O
in O O
extracted O O
human O O
molars O O
. O O

This O O
ligand O O
- O O
independent O O
pathway O O
can O O
function O O
through O O
another O O
androgen O O
- O O
regulated O O
promoter O O
as O O
shown O O
by O O
the O O
use O O
of O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mammary I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tumor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MMTV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CAT I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
sensitivity O O
for O O
ergometry O O
and O O
treadmill O O
testing O O
was O O
75 O O
and O O
62 O O
% O O
respectively O O
. O O

Morphologic O O
evidence O O
that O O
rhe O O
renal O O
calyx O O
and O O
pelvis O O
control O O
ureteric O O
activity O O
in O O
the O O
rabbit O O
. O O

Parelaphostrongylus O O
odocoilei O O
is O O
redescribed O O
from O O
worms O O
collected O O
from O O
the O O
type O O
host O O
( O O
Odocoileus O O
hemionus O O
columbianus O O
) O O
in O O
California O O
, O O
as O O
well O O
as O O
material O O
from O O
experimentally O O
infected O O
mule O O
deer O O
( O O
O O O
. O O
h O O
. O O
heminus O O
) O O
in O O
Alberta O O
. O O

Because O O
levels O O
of O O
Vo2DIR O O
and O O
Vo2INDIR O O
were O O
similar O O
in O O
both O O
groups O O
, O O
we O O
pooled O O
data O O
from O O
septic O O
and O O
control O O
animals O O
. O O

Further O O
interventions O O
were O O
: O O
nephrectomy O O
( O O
2x O O
) O O
, O O
resection O O
and O O
ligation O O
of O O
the O O
inferior O O
vena O O
cava O O
( O O
1x O O
) O O
, O O
resection O O
and O O
replacement O O
of O O
the O O
left O O
renal O O
vein O O
( O O
1x O O
) O O
. O O

OBJECTIVES O O
: O O
The O O
present O O
study O O
tested O O
the O O
hypothesis O O
that O O
stimulating O O
the O O
central O O
noradrenergic O O
system O O
using O O
the O O
new O O
noradrenaline O O
re O O
- O O
uptake O O
inhibitor O O
reboxetine O O
would O O
result O O
in O O
a O O
dose O O
- O O
dependent O O
enhancement O O
of O O
memory O O
for O O
emotional O O
material O O
in O O
man O O
. O O

We O O
examined O O
the O O
mechanisms O O
by O O
which O O
two O O
different O O
types O O
of O O
photonic O O
radiation O O
, O O
short O O
wavelength O O
UV O O
( O O
UV O O
- O O
C O O
) O O
and O O
gamma O O
radiation O O
, O O
activate O O
transcription O O
factor O O
NF B B_GENE
- I I_GENE
kappaB I I_GENE
. O O

However O O
, O O
coligation O O
of O O
Fc B B_GENE
gamma I I_GENE
RIIB1 I I_GENE
with O O
B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ag I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
BCR B B_GENE/B_LOCATION
) O O
inhibits O O
BCR B B_GENE/B_LOCATION
- O O
mediated O O
signaling O O
by O O
a O O
mechanism O O
that O O
may O O
involve O O
recruitment O O
of O O
phosphatases B B_GENE
SHP I I_GENE
- I I_GENE
1 I I_GENE
, O O
SHP B B_GENE
- I I_GENE
2 I I_GENE
, O O
and O O
the O O
SH2 B B_ENZYME[GENE]/B_LOCATION
containing I I_ENZYME[GENE]/I_LOCATION
inositol I I_ENZYME[GENE]/I_LOCATION
5 I I_ENZYME[GENE]/I_LOCATION
' I I_ENZYME[GENE]/I_LOCATION
phosphatase I I_ENZYME[GENE]/I_LOCATION
( O O
SHIP B B_LOCATION/B_GENE
) O O
to O O
the O O
phosphorylated O O
Fc B B_GENE/B_LOCATION
gamma I B_GENE/I_LOCATION
RIIB1 I B_GENE/I_LOCATION
immunoreceptor I B_GENE/I_LOCATION
tyrosine I B_GENE/I_LOCATION
- I B_GENE/I_LOCATION
based I B_GENE/I_LOCATION
inhibitory I B_GENE/I_LOCATION
motif I B_GENE/I_LOCATION
. O O

Using O O
the O O
standard O O
scoring O O
, O O
children O O
with O O
full O O
scale O O
IQ O O
< O O
or O O
= O O
84 O O
on O O
the O O
Wechsler O O
Preschool O O
and O O
Primary O O
Scale O O
of O O
Intelligence O O
at O O
age O O
4 O O
- O O
5 O O
years O O
were O O
poorly O O
identified O O
( O O
sensitivity O O
54 O O
% O O
) O O
from O O
the O O
composite O O
S O O
- O O
B O O
IV O O
score O O
at O O
age O O
3 O O
. O O

This O O
study O O
includes O O
200 O O
patients O O
treated O O
from O O
1964 O O
to O O
1978 O O
, O O
with O O
an O O
age O O
range O O
from O O
15 O O
to O O
102 O O
years O O
, O O
who O O
required O O
329 O O
generators O O
. O O

The O O
specificity O O
and O O
sensitivity O O
of O O
this O O
method O O
( O O
limit O O
of O O
detection O O
in O O
plasma O O
0 O O
. O O
025 O O
micrograms O O
/ O O
mL O O
and O O
< O O
or O O
= O O
0 O O
. O O
0125 O O
micrograms O O
/ O O
mL O O
for O O
febantel O O
and O O
its O O
metabolites O O
, O O
respectively O O
) O O
were O O
sufficiently O O
high O O
to O O
enable O O
us O O
to O O
characterize O O
the O O
time O O
course O O
of O O
the O O
drug O O
in O O
the O O
plasma O O
after O O
oral O O
administration O O
of O O
therapeutic O O
doses O O
to O O
sheep O O
. O O

We O O
have O O
identified O O
the O O
gene O O
encoding O O
sigma B B_GENE/B_LOCATION
E I I_GENE/I_LOCATION
using O O
a O O
genetic O O
screen O O
designed O O
to O O
isolate O O
trans O O
- O O
acting O O
mutations O O
that O O
abolish O O
expression O O
from O O
either O O
htrA B B_GENE/B_BACTERIUM[BIO]
or O O
rpoHP3 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
two O O
promoters O O
recognized O O
uniquely O O
by O O
sigma B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
containing O O
RNA B B_GENE/B_BIO
polymerase I I_GENE/I_BIO
. O O

Cytokinetics O O
of O O
the O O
Krebs O O
2 O O
carcinoma O O
. O O

Through O O
effective O O
use O O
of O O
laboratory O O
testing O O
database O O
, O O
it O O
will O O
be O O
possible O O
to O O
shift O O
away O O
our O O
vague O O
management O O
of O O
pre O O
- O O
analytic O O
phase O O
of O O
quality O O
control O O
so O O
far O O
to O O
its O O
established O O
system O O
based O O
on O O
objective O O
evaluation O O
. O O

One O O
promoter O O
, O O
p53P1 B B_GENE
, O O
is O O
located O O
100 O O
- O O
250 O O
bp O O
upstream O O
of O O
the O O
218 O O
- O O
bp O O
noncoding O O
first O O
exon O O
; O O
a O O
second O O
, O O
stronger O O
promoter O O
, O O
p53P2 B B_GENE
, O O
maps O O
within O O
the O O
first O O
intron O O
. O O

Both O O
PMP20 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
products I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contain O O
the O O
carboxyl O O
- O O
terminal O O
sequence O O
AKL O O
, O O
similar O O
to O O
the O O
putative O O
SKL O O
peroxisomal O O
sorting O O
sequence O O
( O O
Gould O O
, O O
S O O
. O O

The O O
likelihood O O
of O O
death O O
was O O
more O O
than O O
3 O O
times O O
higher O O
among O O
patients O O
in O O
the O O
ERA O O
- O O
II O O
group O O
( O O
mortality O O
risk O O
ratio O O
3 O O
. O O
82 O O
[ O O
95 O O
% O O
CI O O
1 O O
. O O
48 O O
% O O
to O O
9 O O
. O O
84 O O
] O O
, O O
p O O
= O O
0 O O
. O O
006 O O
) O O
. O O

Barium O O
mucosal O O
coating O O
was O O
judged O O
to O O
be O O
better O O
in O O
the O O
members O O
to O O
whom O O
magnesium O O
sulphate O O
was O O
administered O O
( O O
p O O
= O O
0 O O
. O O
0007 O O
) O O
. O O

In O O
both O O
immortalized O O
and O O
normal O O
diploid O O
human O O
cells O O
, O O
wt O O
AAV O O
targeted O O
integration O O
to O O
ch O O
- O O
19 O O
. O O

The O O
lipopolysaccharide O O
- O O
binding O O
protein O O
is O O
a O O
secretory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acute I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
whose O O
gene O O
is O O
transcriptionally O O
activated O O
by O O
APRF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
STAT B B_GENE
/ I I_GENE
3 I I_GENE
and O O
other O O
cytokine O O
- O O
inducible O O
nuclear O O
proteins O O
. O O

Tritium O O
concentrations O O
in O O
environmental O O
water O O
samples O O
were O O
found O O
to O O
be O O
determined O O
within O O
an O O
accuracy O O
of O O
10 O O
% O O
by O O
this O O
method O O
when O O
Vi O O
/ O O
Vf O O
was O O
14 O O
- O O
25 O O
. O O

This O O
region O O
does O O
not O O
contain O O
a O O
consensus O O
estrogen O O
response O O
element O O
, O O
and O O
ER B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O O
to O O
this O O
DNA O O
sequence O O
was O O
not O O
observed O O
. O O

The O O
strangulated O O
intestinal O O
pathologies O O
of O O
horses O O
are O O
accompanied O O
by O O
a O O
local O O
activation O O
of O O
the O O
neutrophils O O
, O O
that O O
can O O
be O O
revealed O O
by O O
measuring O O
the O O
tissular O O
enzymatic O O
activity O O
of O O
the O O
granulocytic O O
enzyme O O
myeloperoxidase B B_ENZYME[GENE]/B_MEASURE
( O O
MPO B B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

A O O
deletion O O
analysis O O
of O O
the O O
FAS1 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
lacking O O
the O O
previously O O
characterized O O
inositol O O
/ O O
choline O O
- O O
responsive O O
- O O
element O O
motif O O
defined O O
a O O
region O O
( O O
nucleotides O O
- O O
760 O O
to O O
- O O
850 O O
) O O
responsible O O
for O O
most O O
of O O
the O O
remaining O O
activation O O
potency O O
. O O

Here O O
we O O
report O O
the O O
fabrication O O
of O O
single O O
- O O
molecule O O
transistors O O
based O O
on O O
individual O O
C60 O O
molecules O O
connected O O
to O O
gold O O
electrodes O O
. O O

The O O
homeodomain B B_PROTEIN[GENE]/B_LOCATION
transcription I I_PROTEIN[GENE]/I_LOCATION
factor I I_PROTEIN[GENE]/I_LOCATION
CDP B I_PROTEIN[GENE]/I_LOCATION
/ O O
cut B B_PROTEIN[GENE]/B_LOCATION
interacts O O
with O O
the O O
cell O O
cycle O O
regulatory O O
element O O
of O O
histone B B_GENE
H4 I I_GENE
genes I I_GENE
packaged O O
into O O
nucleosomes O O
. O O

Furthermore O O
, O O
the O O
cognate O O
binding O O
protein O O
is O O
present O O
in O O
both O O
rat O O
and O O
human O O
( O O
HeLa O O
) O O
cell O O
nuclear O O
extracts O O
. O O

Transient O O
cotransfection O O
analyses O O
indicate O O
that O O
the O O
cooperative O O
association O O
of O O
NF B B_GENE
- I I_GENE
IL I I_GENE
- I I_GENE
6 I I_GENE
and O O
RelA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
IL B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
8 I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
results O O
in O O
synergistic O O
transcriptional O O
activation O O
. O O

Heart O O
rate O O
during O O
the O O
behavioral O O
avoidance O O
test O O
was O O
shown O O
to O O
be O O
as O O
susceptible O O
to O O
experimental O O
demand O O
as O O
other O O
studies O O
have O O
shown O O
approach O O
behaviors O O
to O O
be O O
influenced O O
. O O

Function O O
was O O
retained O O
when O O
one O O
copy O O
of O O
the O O
sequence O O
was O O
present O O
, O O
suggesting O O
that O O
this O O
sequence O O
represents O O
an O O
essential O O
element O O
. O O

Decreased O O
plasma O O
level O O
of O O
antithrombin B B_GENE
III I I_GENE
was O O
assumed O O
to O O
be O O
one O O
of O O
the O O
major O O
factors O O
underlying O O
hypercoagulable O O
state O O
in O O
nephrotic O O
syndrome O O
. O O

NO2 O O
pollution O O
on O O
major O O
trunk O O
roads O O
frequently O O
exceeded O O
British O O
and O O
European O O
Union O O
air O O
quality O O
standards O O
, O O
while O O
particle O O
pollution O O
was O O
lower O O
. O O

Cotransfection O O
of O O
pINV O O
- O O
2473 O O
, O O
a O O
construct O O
containing O O
2473 O O
base O O
pairs O O
of O O
hINV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
upstream I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
linked O O
to O O
luciferase B B_GENE
, O O
with O O
POU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homeodomain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Oct1 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
Oct2 B B_GENE/B_DISEASE
, O O
Brn4 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
SCIP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Skn1a B B_GENE/B_DISEASE
or O O
Skn1i B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
results O O
in O O
a O O
strong O O
suppression O O
of O O
basal O O
promoter O O
activity O O
. O O

87 O O
, O O
7270 O O
- O O
7274 O O
) O O
. O O

I O O
. O O

Genomic O O
DNA O O
blot O O
analysis O O
indicates O O
that O O
the O O
trout B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
L2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
a O O
cluster O O
- O O
like O O
organization O O
similar O O
to O O
the O O
trout B B_GENE
L1 I I_GENE
locus I I_GENE
and O O
the O O
IgL B B_GENE/B_MEASURE
locus I I_GENE/I_MEASURE
of O O
several O O
teleost O O
fish O O
. O O

Gore O O
& O O
Associates O O
, O O
Inc O O
. O O
) O O
standard O O
wall O O
graft O O
segments O O
varying O O
in O O
length O O
from O O
4 O O
to O O
12 O O
cm O O
. O O

The O O
region O O
immediately O O
following O O
the O O
promoter O O
and O O
5 O O
' O O
to O O
ORF1 O O
has O O
a O O
potential O O
transcription O O
terminator O O
sequence O O
. O O

Studies O O
on O O
recurrences O O
in O O
gingival O O
hyperplasia O O

Preface O O
and O O
acknowledgements O O
. O O

We O O
conclude O O
that O O
clonidine O O
3 O O
micrograms O O
/ O O
kg O O
produces O O
sedation O O
comparable O O
to O O
diazepam O O
0 O O
. O O
2 O O
mg O O
/ O O
kg O O
and O O
also O O
attenuates O O
the O O
intubation O O
response O O
without O O
increasing O O
the O O
incidence O O
of O O
complications O O
. O O

Pancreatic O O
expression O O
of O O
the O O
glucagon B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
gene I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
depends O O
on O O
multiple O O
transcription O O
factors O O
interacting O O
with O O
at O O
least O O
three O O
DNA O O
control O O
elements O O
: O O
G1 O O
, O O
the O O
upstream O O
promoter O O
element O O
, O O
and O O
G2 O O
and O O
G3 O O
, O O
two O O
enhancer O O
- O O
like O O
sequences O O
. O O

We O O
have O O
compared O O
the O O
ability O O
of O O
GST B B_GENE/B_BIO
- O O
Bem3 B B_MEASURE/B_GENE
to O O
serve O O
as O O
a O O
GAP B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
Cdc42Hs B B_GENE
relative O O
to O O
other O O
members O O
of O O
the O O
rho B B_GENE
- O O
GAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subfamily O O
and O O
found O O
the O O
following O O
order O O
of O O
potency O O
: O O
human B B_GENE
platelet I I_GENE
Cdc42Hs I I_GENE
GAP I I_GENE
> O O
p190 B B_GENE
> O O
Bem3 B B_GENE
> O O
break B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
point I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cluster I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
p85 B B_GENE
, O O
like O O
Bem2 B B_GENE
, O O
shows O O
no O O
GAP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activity O O
or O O
any O O
ability O O
to O O
bind O O
to O O
the O O
GTP O O
- O O
bound O O
form O O
of O O
Cdc42Hs B B_GENE
. O O

CONCLUSION O O
: O O
Men O O
presenting O O
with O O
urethritis O O
and O O
women O O
presenting O O
with O O
PID O O
both O O
have O O
significantly O O
greater O O
peripheral O O
blood O O
mononuclear O O
cell O O
proliferative O O
responses O O
to O O
the O O
DK20 O O
strain O O
of O O
C O O
trachomatis O O
than O O
controls O O
. O O

The O O
PDSS O O
identified O O
17 O O
( O O
94 O O
% O O
) O O
of O O
the O O
women O O
diagnosed O O
with O O
major O O
postpartum O O
depression O O
, O O
the O O
EPDS O O
identified O O
14 O O
of O O
these O O
women O O
( O O
78 O O
% O O
) O O
, O O
and O O
the O O
BDI O O
- O O
II O O
identified O O
10 O O
of O O
the O O
18 O O
women O O
( O O
56 O O
% O O
) O O
. O O

Men O O
and O O
women O O
entering O O
psychotherapy O O
more O O
often O O
had O O
negative O O
Wish O O
elements O O
than O O
others O O
. O O

Both O O
merR B B_GENE
genes I I_GENE
consist O O
of O O
a O O
408 O O
bp O O
ORF O O
coding O O
for O O
135 O O
amino O O
acids O O
. O O

The O O
same O O
slice O O
was O O
imaged O O
three O O
times O O
each O O
with O O
sequences O O
using O O
spatial O O
presaturation O O
or O O
not O O
. O O

Molecular O O
cloning O O
of O O
the O O
alpha B B_GENE
- I I_GENE
globin I I_GENE
transcription I I_GENE
factor I I_GENE
CP2 B I_GENE
. O O

The O O
most O O
distal O O
active O O
site O O
in O O
TIGA B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
created O O
by O O
excision O O
of O O
a O O
66 O O
- O O
bp O O
intron O O
. O O

Denaturing O O
gradient O O
gel O O
electrophoresis O O
( O O
DGGE O O
) O O
with O O
sequence O O
analysis O O
showed O O
that O O
PGCL4 B B_GENE
is O O
a O O
major O O
member O O
in O O
the O O
female O O
mammary O O
gland O O
, O O
and O O
in O O
the O O
submaxillary O O
and O O
lachrymal O O
glands O O
of O O
both O O
sexes O O
, O O
while O O
the O O
counterpart O O
in O O
male O O
liver O O
and O O
the O O
coagulate O O
glands O O
was O O
found O O
to O O
be O O
PGCL1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

Sesame O O
seed O O
should O O
also O O
be O O
considered O O
a O O
cause O O
of O O
allergic O O
reactions O O
to O O
drug O O
products O O
and O O
cosmetics O O
. O O

Ligand O O
binding O O
of O O
multi O O
- O O
chain O O
antigen O O
receptors O O
and O O
hematopoietin B B_GENE
/ O O
cytokine O O
receptors O O
results O O
in O O
rapid O O
activation O O
of O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PTK B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
- O O
dependent O O
signalling O O
molecules O O
such O O
as O O
phosphatidylinositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI B B_GENE/B_LOCATION
3 I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
kinase I I_GENE/I_LOCATION
) O O
. O O

The O O
UASB O O
reactors O O
treated O O
a O O
VFA O O
mixture O O
( O O
with O O
an O O
acetate O O
: O O
propionate O O
: O O
butyrate O O
ratio O O
of O O
5 O O
: O O
3 O O
: O O
2 O O
on O O
COD O O
basis O O
) O O
or O O
acetate O O
as O O
the O O
sole O O
substrate O O
at O O
different O O
COD O O
: O O
sulfate O O
ratios O O
. O O

The O O
authors O O
emphasize O O
absence O O
of O O
specific O O
signs O O
of O O
vagal O O
involvement O O
, O O
importance O O
for O O
diagnosis O O
of O O
surgical O O
extirpation O O
, O O
and O O
mildness O O
of O O
post O O
operative O O
course O O
. O O

Now O O
: O O
pleasure O O
in O O
work O O

This O O
article O O
reviews O O
current O O
concepts O O
of O O
pathophysiology O O
and O O
summarises O O
clinical O O
features O O
, O O
natural O O
history O O
and O O
available O O
treatments O O
. O O

Adequacy O O
of O O
the O O
Haldane O O
transformation O O
in O O
the O O
computation O O
of O O
exercise O O
V O O
O2 O O
in O O
man O O
. O O

Association O O
between O O
hyperhomocysteinemia O O
and O O
ischemic O O
heart O O
disease O O
in O O
Sri O O
Lankans O O
. O O

Radiological O O
imaging O O
such O O
as O O
UGI O O
series O O
and O O
CT O O
scan O O
was O O
useful O O
to O O
arrive O O
at O O
an O O
accurate O O
diagnosis O O
. O O

The O O
architecture O O
of O O
the O O
hRap1 B B_GENE/B_LOCATION
Myb B I_GENE/I_LOCATION
domain I I_GENE/I_LOCATION
is O O
very O O
close O O
to O O
that O O
of O O
each O O
of O O
the O O
Myb B B_GENE/B_BIO
domains I I_GENE/I_BIO
from O O
TRF1 B B_SPECIES[BIO]/B_GENE
, O O
scRap1p B B_GENE
and O O
c B B_GENE
- I I_GENE
Myb I I_GENE
. O O

We O O
have O O
raised O O
antibodies O O
against O O
a O O
peptide O O
specific O O
to O O
the O O
predicted O O
protein O O
product O O
of O O
this O O
second O O
mRNA O O
. O O

Because O O
controlled O O
- O O
release O O
niacin O O
seems O O
to O O
be O O
more O O
potent O O
than O O
crystalline O O
niacin O O
, O O
product O O
substitution O O
without O O
dose O O
adjustment O O
should O O
be O O
avoided O O
. O O

Interobserver O O
agreement O O
of O O
the O O
Nottingham O O
histologic O O
grading O O
scheme O O
for O O
infiltrating O O
duct O O
carcinoma O O
breast O O
. O O

This O O
dose O O
of O O
Na3 O O
citrate O O
produced O O
no O O
clinical O O
symptoms O O
suggestive O O
of O O
hypocalcaemia O O
in O O
these O O
subjects O O
, O O
even O O
though O O
the O O
use O O
of O O
acid O O
- O O
citrate O O
- O O
dextrose O O
, O O
NIH O O
formula O O
A O O
( O O
ACD O O
- O O
A O O
) O O
under O O
identical O O
conditions O O
has O O
been O O
reported O O
to O O
reduce O O
significantly O O
the O O
level O O
of O O
total O O
calcium O O
in O O
serum O O
, O O
and O O
concomitantly O O
increase O O
the O O
number O O
or O O
reactions O O
occurring O O
in O O
donors O O
. O O

The O O
phosphoprotein B B_GENE
pUL69 I I_GENE
of O O
human O O
cytomegalovirus O O
( O O
HCMV O O
) O O
, O O
which O O
is O O
a O O
herpesvirus O O
of O O
considerable O O
medical O O
importance O O
in O O
immunosuppressed O O
patients O O
and O O
newborns O O
, O O
has O O
previously O O
been O O
identified O O
as O O
an O O
early B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
late I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
viral I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
can O O
stimulate O O
several O O
viral O O
and O O
cellular O O
promoters O O
and O O
thus O O
exerts O O
a O O
rather O O
broad O O
activation O O
pattern O O
. O O

Southern O O
blot O O
analysis O O
performed O O
on O O
genomic O O
DNA O O
demonstrated O O
altered O O
CpG O O
methylation O O
within O O
intron O O
1 O O
in O O
DNA O O
from O O
all O O
BCC O O
compared O O
to O O
normal O O
, O O
mortal O O
human O O
mammary O O
epithelial O O
cells O O
( O O
HMEC O O
) O O
. O O

An O O
increased O O
incidence O O
of O O
ATN O O
has O O
been O O
reported O O
since O O
the O O
introduction O O
of O O
cyclosporin O O
A O O
. O O

Using O O
a O O
GTP O O
- O O
dependent O O
, O O
brefeldin O O
A O O
- O O
sensitive O O
in O O
vitro O O
AP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
assay O O
, O O
we O O
have O O
determined O O
here O O
the O O
parameters O O
of O O
the O O
AP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O O
reaction O O
. O O

Plasma B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
enteroglucagon I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
measured O O
before O O
and O O
during O O
three O O
hours O O
after O O
a O O
standard O O
meal O O
in O O
21 O O
untreated O O
adult O O
patients O O
with O O
suspected O O
coeliac O O
disease O O
who O O
all O O
had O O
villous O O
atrophy O O
of O O
the O O
small O O
intestinal O O
mucosa O O
and O O
malabsorption O O
, O O
and O O
in O O
nine O O
control O O
subjects O O
. O O

After O O
control O O
for O O
body O O
mass O O
index O O
, O O
trait O O
anxiety O O
and O O
anger O O
- O O
in O O
remained O O
independent O O
predictors O O
of O O
diastolic O O
blood O O
pressure O O
among O O
the O O
women O O
. O O

Regulation O O
of O O
the O O
human B B_GENE
stress I I_GENE
response I I_GENE
gene I I_GENE
GADD153 I I_GENE
expression O O
: O O
role O O
of O O
ETS1 B B_GENE
and O O
FLI B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
products I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

132 O O
varix O O
ligations O O
were O O
performed O O
during O O
44 O O
separate O O
EVL O O
sessions O O
. O O

Here O O
RFX B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
X2BP B B_PROTEIN[GENE]/B_LOCATION
/ O O
DNA O O
complexes O O
were O O
formed O O
on O O
all O O
class O O
II O O
isotypes O O
regardless O O
of O O
the O O
ability O O
of O O
the O O
X O O
box O O
region O O
to O O
bind O O
either O O
factor O O
individually O O
. O O

The O O
psi B B_GENE/B_DISEASE
zeta I I_GENE/I_DISEASE
gene I I_GENE/I_DISEASE
has O O
a O O
nonsense O O
mutation O O
in O O
exon O O
1 O O
but O O
has O O
identical O O
promoter O O
sequence O O
and O O
RNA O O
processing O O
sites O O
to O O
the O O
zeta B B_GENE/B_BIO
gene I I_GENE/I_BIO
, O O
raising O O
the O O
possibility O O
that O O
both O O
psi B B_PROTEIN[GENE]
zeta I I_PROTEIN[GENE]
and O O
zeta B B_GENE
are O O
transcriptionally O O
active O O
. O O

Prospects O O
of O O
chemosterilant O O
and O O
genetic O O
control O O
of O O
rodents O O
. O O

Serum O O
PRL B B_GENE
concentrations O O
significantly O O
increased O O
after O O
MCP O O
administration O O
in O O
normal O O
women O O
, O O
hyperprolactinemic O O
patients O O
with O O
normal O O
sella O O
and O O
patients O O
with O O
microadenoma O O
, O O
but O O
not O O
in O O
macroadenoma O O
patients O O
with O O
and O O
without O O
suprasellar O O
expansion O O
( O O
SSE O O
) O O
. O O

The O O
Id4 B B_GENE/B_BIO
protein I I_GENE/I_BIO
contains O O
a O O
HLH O O
domain O O
highly O O
conserved O O
among O O
the O O
dnHLH B B_GENE/B_BIO
proteins I I_GENE/I_BIO
from O O
mouse O O
and O O
drosophila O O
. O O

The O O
coding O O
region O O
of O O
nifA B B_GENE/B_BACTERIUM[BIO]
was O O
determined O O
using O O
a O O
translational O O
lacZ B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
by O O
site O O
- O O
directed O O
mutagenesis O O
to O O
identify O O
which O O
of O O
four O O
in O O
frame O O
AUG O O
codons O O
was O O
used O O
. O O

Like O O
troponin B B_GENE
Cs I I_GENE
and O O
calmodulins B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
PfCPK B B_GENE
also O O
contains O O
four O O
EF O O
hand O O
calcium O O
- O O
binding O O
motifs O O
. O O

A O O
third O O
group O O
( O O
n O O
= O O
10 O O
) O O
was O O
assigned O O
to O O
receive O O
the O O
canalith O O
repositioning O O
maneuver O O
without O O
mastoid O O
vibration O O
. O O

Upstream O O
of O O
the O O
afa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cluster I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
1 O O
. O O
2 O O
- O O
kb O O
region O O
was O O
found O O
to O O
be O O
96 O O
% O O
identical O O
to O O
the O O
RepFIB B B_LOCATION/B_GENE
sequence I I_LOCATION/I_GENE
of O O
one O O
of O O
the O O
enterotoxigenic O O
E O O
. O O
coli O O
plasmids O O
( O O
P307 O O
) O O
, O O
suggesting O O
a O O
common O O
ancestor O O
plasmid O O
. O O

We O O
hypothesize O O
that O O
the O O
ability O O
of O O
these O O
acidic O O
activators O O
to O O
specifically O O
interact O O
with O O
multiple O O
components O O
of O O
the O O
transcription O O
initiation O O
complex O O
likely O O
underlies O O
the O O
dramatic O O
functional O O
synergy O O
exhibited O O
by O O
this O O
class O O
of O O
activation O O
domains O O
in O O
vivo O O
. O O

Histological O O
and O O
immunophenotypic O O
studies O O
revealed O O
12 O O
large O O
cell O O
lymphomas O O
( O O
11 O O
B O O
cell O O
and O O
one O O
T O O
cell O O
) O O
, O O
two O O
small O O
noncleaved O O
cell O O
lymphomas O O
( O O
B O O
- O O
cell O O
phenotype O O
) O O
, O O
and O O
five O O
low O O
grade O O
B O O
- O O
cell O O
lymphomas O O
( O O
two O O
small O O
lymphocytic O O
and O O
three O O
follicular O O
mixed O O
lymphomas O O
) O O
. O O

The O O
determination O O
of O O
diacetyl O O
, O O
2 O O
, O O
3 O O
- O O
pentanedione O O
and O O
acetoin O O
was O O
performed O O
in O O
two O O
steps O O
. O O

There O O
also O O
may O O
be O O
osmotic O O
challenges O O
to O O
mucosal O O
cell O O
function O O
as O O
evidenced O O
by O O
the O O
different O O
reaction O O
rates O O
with O O
hyper O O
- O O
and O O
hypotonic O O
saline O O
. O O

In O O
F9 O O
, O O
which O O
is O O
a O O
prototype O O
of O O
embryonal O O
carcinoma O O
cells O O
expressing O O
hst B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
expression O O
of O O
hst B B_GENE
gene I I_GENE
is O O
positively O O
regulated O O
by O O
a O O
downstream O O
octamer O O
motif O O
that O O
functions O O
as O O
an O O
enhancer O O
. O O

The O O
reading O O
achievement O O
of O O
students O O
with O O
learning O O
disabilities O O
who O O
received O O
reading O O
instruction O O
through O O
the O O
DISTAR O O
program O O
was O O
compared O O
to O O
that O O
of O O
similar O O
students O O
using O O
basal O O
reader O O
materials O O
. O O

Two O O
putative O O
ATP O O
- O O
binding O O
domains O O
were O O
identified O O
, O O
one O O
in O O
the O O
amino O O
- O O
terminal O O
half O O
of O O
the O O
argA B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
encoded I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
other O O
in O O
the O O
carboxy O O
- O O
terminal O O
half O O
. O O

Chronic O O
granulocytic O O
leukemia O O
in O O
children O O
. O O

Purified O O
phosphorylated O O
PhoP B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
( O O
PhoPP B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O O
had O O
a O O
half O O
- O O
life O O
of O O
approximately O O
2 O O
. O O
5 O O
h O O
, O O
which O O
was O O
reduced O O
to O O
about O O
15 O O
min O O
by O O
addition O O
of O O
the O O
same O O
molar O O
amount O O
of O O
* B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PhoR I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
the O O
cytoplasmic O O
region O O
of O O
PhoR B B_GENE/B_DISEASE
) O O
. O O

This O O
transformation O O
suppression O O
by O O
Rb B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
further O O
shown O O
to O O
be O O
due O O
to O O
transcriptional O O
repression O O
of O O
neu B B_GENE
using O O
Rb B B_GENE
expressing O O
effector O O
plasmid O O
and O O
neu B B_GENE
promoter O O
- O O
chloramphenicol B B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
acetyltransferase I I_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
reporter O O
gene O O
. O O

Before O O
therapy O O
was O O
started O O
, O O
trabecular O O
bone O O
alterations O O
could O O
be O O
observed O O
which O O
were O O
typical O O
for O O
Paget O O
' O O
s O O
disease O O
of O O
bone O O
as O O
there O O
were O O
bulky O O
trabeculare O O
, O O
increased O O
remodelling O O
surfaces O O
and O O
giant O O
osteoclasts O O
. O O

Overexpression O O
of O O
N O O
- O O
terminal O O
mutations O O
disturbs O O
mitosis O O
and O O
produces O O
elongated O O
cells O O
, O O
Using O O
a O O
PCR O O
approach O O
, O O
we O O
isolated O O
a O O
putative O O
homologue O O
of O O
Prp4 B B_GENE
from O O
human O O
and O O
mouse O O
cells O O
. O O

1 O O
. O O

Biochemical O O
studies O O
and O O
studies O O
of O O
cells O O
expressing O O
mutant O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicate O O
that O O
IL B B_GENE
- I I_GENE
2 I I_GENE
- O O
induced O O
tyrosine B B_GENE
kinase I I_GENE
activation O O
initiates O O
a O O
complex O O
signaling O O
cascade O O
. O O

BACKGROUND O O
: O O
Peripheral O O
kappa B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonists O O
may O O
provide O O
a O O
new O O
therapeutic O O
approach O O
for O O
the O O
treatment O O
of O O
functional O O
dyspepsia O O
. O O

Fourteen O O
eyes O O
( O O
38 O O
. O O
9 O O
% O O
) O O
developed O O
DLK O O
after O O
an O O
epithelial O O
defect O O
, O O
representing O O
an O O
odds O O
ratio O O
of O O
13 O O
times O O
. O O

The O O
yeast O O
genome O O
contains O O
a O O
single O O
ORD1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
resides O O
on O O
chromosome O O
XI O O
. O O

The O O
system O O
consists O O
of O O
a O O
TV O O
unit O O
compatible O O
to O O
IBM O O
PC O O
/ O O
AT O O
and O O
software O O
. O O

Cloning O O
of O O
the O O
GATA B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
that O O
regulates O O
endothelin B B_GENE
- I I_GENE
1 I I_GENE
gene I I_GENE
expression O O
in O O
endothelial O O
cells O O
. O O

The O O
Synechococcus B B_GENE/B_BACTERIUM[BIO]
gene I I_GENE/I_BACTERIUM[BIO]
rps1 I I_GENE/I_BACTERIUM[BIO]
encoding O O
S1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
located O O
1 O O
. O O
1 O O
kb O O
downstream O O
from O O
psbB B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O O
which O O
encodes O O
the O O
photosystem B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
II I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
P680 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
chlorophyll I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
a I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
apoprotein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Two O O
- O O
dimensional O O
echocardiographic O O
parasternal O O
long O O
- O O
and O O
short O O
- O O
axis O O
views O O
were O O
obtained O O
during O O
graded O O
bleeding O O
by O O
rapid O O
withdrawal O O
of O O
blood O O
from O O
an O O
arterial O O
cannula O O
, O O
with O O
increments O O
of O O
5 O O
% O O
each O O
up O O
to O O
30 O O
% O O
of O O
calculated O O
blood O O
volume O O
. O O

A O O
comparison O O
of O O
the O O
rate O O
of O O
recovery O O
and O O
time O O
for O O
detection O O
of O O
mycobacteria O O
from O O
clinical O O
specimens O O
of O O
the O O
newly O O
developed O O
Mycobacteria O O
Growth O O
Indicator O O
Tube O O
( O O
MGIT O O
) O O
, O O
the O O
biphasic O O
Septi O O
- O O
Chek O O
, O O
and O O
the O O
egg O O
- O O
based O O
Ogawa O O
medium O O
was O O
made O O
. O O

As O O
in O O
IncP O O
alpha O O
plasmids O O
, O O
these O O
operons O O
are O O
transcribed O O
from O O
a O O
bidirectional O O
promoter O O
region O O
consisting O O
of O O
trfAp B B_GENE/B_BACTERIUM[BIO]
for O O
the O O
trfA B B_GENE
operon I I_GENE
and O O
trbAp B B_GENE
and O O
trbBp B B_GENE
for O O
the O O
trb B B_PERSON/B_GENE
operon I I_PERSON/I_GENE
. O O

CONCLUSIONS O O
: O O
These O O
principally O O
structural O O
studies O O
support O O
the O O
hypothesis O O
that O O
the O O
thrombus O O
is O O
a O O
self O O
- O O
sustaining O O
entity O O
that O O
may O O
have O O
significance O O
in O O
the O O
pathophysiologic O O
mechanism O O
of O O
abdominal O O
aortic O O
aneurysms O O
. O O

Electrophoretic O O
mobility O O
shift O O
analysis O O
of O O
protein O O
- O O
DNA O O
complexes O O
formed O O
with O O
nuclear O O
proteins O O
isolated O O
from O O
I3C O O
- O O
treated O O
and O O
- O O
untreated O O
cells O O
, O O
in O O
combination O O
with O O
supershift O O
assays O O
using O O
Sp1 B B_GENE
antibodies I I_GENE
, O O
demonstrated O O
that O O
the O O
Sp1 B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
in O O
the O O
CDK6 B B_GENE
promoter I I_GENE
forms O O
a O O
specific O O
I3C O O
- O O
responsive O O
DNA O O
- O O
protein O O
complex O O
that O O
contains O O
the O O
Sp1 B B_GENE/B_LOCATION
transcription I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
. O O

The O O
analysis O O
showed O O
that O O
the O O
morning O O
active O O
( O O
MA O O
) O O
individuals O O
rose O O
earlier O O
and O O
went O O
to O O
bed O O
earlier O O
than O O
the O O
evening O O
active O O
( O O
EA O O
) O O
individuals O O
, O O
and O O
the O O
former O O
had O O
a O O
longer O O
sleep O O
length O O
than O O
the O O
latter O O
during O O
days O O
with O O
a O O
morning O O
shift O O
, O O
while O O
the O O
opposite O O
was O O
true O O
for O O
afternoon O O
and O O
night O O
shifts O O
. O O

This O O
ERD O O
is O O
recorded O O
over O O
the O O
contralateral O O
central O O
region O O
. O O

Kluyveromyces O O
lactis O O
, O O
a O O
budding O O
yeast O O
related O O
to O O
Saccharomyces O O
cerevisiae O O
, O O
can O O
grow O O
on O O
a O O
wider O O
variety O O
of O O
substrates O O
and O O
shows O O
less O O
sensitivity O O
to O O
glucose O O
repression O O
than O O
does O O
Saccharomyces O O
cerevisiae O O
. O O

Low O O
- O O
affinity O O
E2 B B_GENE
- I I_GENE
binding I I_GENE
site I I_GENE
mediates O O
downmodulation O O
of O O
E2 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transactivation O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
papillomavirus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
late I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Untransformed O O
3T3 O O
cells O O
carry O O
abundant O O
1 O O
. O O
9 O O
kb O O
Hox B B_GENE/B_DISEASE
1 I I_GENE/I_DISEASE
. I I_GENE/I_DISEASE
3 I I_GENE/I_DISEASE
RNA O O
, O O
whereas O O
the O O
methylcholanthrene O O
- O O
transformed O O
MB66 O O
and O O
LTK O O
- O O
cells O O
or O O
3T3 O O
cells O O
transformed O O
by O O
the O O
oncogenes O O
src B B_GENE
, O O
fos B B_GENE
or O O
SV40 B B_GENE
T I I_GENE
antigen I I_GENE
express O O
only O O
low O O
levels O O
. O O

Although O O
analysis O O
of O O
the O O
similarity O O
between O O
the O O
44 O O
- O O
kDa O O
protein O O
and O O
the O O
E B B_PROTEIN[GENE]/B_BIO
. I I_PROTEIN[GENE]/I_BIO
coli I I_PROTEIN[GENE]/I_BIO
RecA I I_PROTEIN[GENE]/I_BIO
protein I I_PROTEIN[GENE]/I_BIO
did O O
not O O
show O O
any O O
significant O O
homology O O
between O O
them O O
, O O
it O O
revealed O O
their O O
identity O O
by O O
five O O
amino O O
- O O
acid O O
residues O O
involved O O
in O O
the O O
formation O O
of O O
the O O
epitope O O
that O O
recognized O O
the O O
paratope O O
of O O
the O O
RecA B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
subsequent O O
epitope O O
- O O
paratope O O
binding O O
of O O
these O O
proteins O O
. O O

Deoxyuridine O O
- O O
suppression O O
test O O
and O O
bone O O
marrow O O
culture O O
for O O
the O O
diagnosis O O
of O O
macrocytic O O
refractory O O
anaemias O O
. O O

Finally O O
, O O
synthetic O O
peptides O O
corresponding O O
to O O
the O O
mutant O O
proteins O O
were O O
assessed O O
for O O
the O O
ability O O
to O O
act O O
as O O
substrates O O
for O O
PR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
psoralens O O
are O O
being O O
used O O
in O O
research O O
projects O O
sponsored O O
by O O
the O O
National O O
Toxicology O O
Program O O
. O O

Root O O
surface O O
caries O O
incidence O O
in O O
the O O
groups O O
inoculated O O
with O O
A O O
. O O
viscosus O O
and O O
A O O
. O O
viscosus O O
plus O O
S O O
. O O
sobrinus O O
did O O
not O O
differ O O
. O O

These O O
results O O
demonstrate O O
that O O
the O O
entire O O
E3L B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
is O O
required O O
for O O
pathogenesis O O
in O O
the O O
mouse O O
model O O
. O O

The O O
development O O
of O O
various O O
pathological O O
lesions O O
in O O
thymus O O
, O O
spleen O O
, O O
lymph O O
nodes O O
and O O
bone O O
- O O
marrow O O
is O O
frequently O O
observed O O
. O O

Recently O O
, O O
we O O
have O O
demonstrated O O
that O O
mouse O O
microglial O O
cells O O
, O O
the O O
brain O O
macrophages O O
, O O
express O O
both O O
IL B B_GENE
- I I_GENE
15 I I_GENE
and O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
15 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
have O O
analyzed O O
the O O
role O O
of O O
the O O
HU B B_GENE
protein I I_GENE
in O O
invertasome O O
assembly O O
when O O
the O O
enhancer O O
is O O
located O O
at O O
variable O O
positions O O
close O O
to O O
one O O
of O O
the O O
recombination O O
sites O O
. O O

The O O
mode O O
of O O
action O O
is O O
often O O
suggested O O
as O O
an O O
explanation O O
for O O
the O O
different O O
slopes O O
of O O
concentration O O
- O O
effect O O
curves O O
. O O

This O O
may O O
be O O
another O O
example O O
of O O
the O O
principle O O
- O O
- O O
less O O
is O O
more O O
. O O

On O O
transfer O O
from O O
glucose O O
, O O
succinate O O
, O O
malate O O
, O O
or O O
glycerol O O
medium O O
to O O
citrate O O
medium O O
, O O
the O O
Cit O O
+ O O
Escherichia O O
coli O O
strains O O
showed O O
a O O
delay O O
of O O
36 O O
to O O
48 O O
h O O
before O O
growth O O
. O O

These O O
results O O
suggest O O
that O O
camptothecin O O
resistance O O
in O O
CEM O O
/ O O
DOX O O
cells O O
is O O
due O O
to O O
different O O
mechanism O O
( O O
s O O
) O O
than O O
topoisomerase B B_GENE/B_LOCATION
- O O
or O O
P B B_GENE
- I I_GENE
glycoprotein I I_GENE
- O O
associated O O
multidrug O O
resistance O O
. O O

Jornvall O O
, O O
B O O
. O O

Spontaneous O O
coronary O O
artery O O
spasm O O
during O O
coronary O O
angiography O O
in O O
a O O
patient O O
with O O
exercise O O
- O O
induced O O
ST O O
segment O O
elevation O O
. O O

Effectively O O
, O O
the O O
upstream O O
, O O
housekeeping O O
- O O
type O O
promoter O O
responds O O
to O O
FIXK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
positively O O
regulates O O
the O O
downstream O O
, O O
sigma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
54 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

K O O
. O O
, O O
Weiss O O
, O O
M O O
. O O

New O O
TB O O
respirator O O
standards O O
mean O O
more O O
choices O O
at O O
less O O
cost O O
. O O

Electrophoretic O O
mobility O O
- O O
shift O O
assays O O
using O O
oligonucleotides O O
derived O O
from O O
these O O
sites O O
demonstrated O O
formation O O
of O O
specific O O
DNA O O
- O O
protein O O
complexes O O
. O O

A O O
5789 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nucleotide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
long I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EcoRI I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragment I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
genome O O
of O O
Thermotoga O O
maritima O O
, O O
identified O O
by O O
cross O O
- O O
hybridization O O
to O O
L11 B B_PROTEIN[GENE]
, O O
L1 B B_PROTEIN[GENE]/B_MEASURE
, O O
L10 B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
L12 B B_PROTEIN[GENE]/B_MEASURE
ribosomal I I_PROTEIN[GENE]/I_MEASURE
protein I I_PROTEIN[GENE]/I_MEASURE
gene I I_PROTEIN[GENE]/I_MEASURE
sequences I I_PROTEIN[GENE]/I_MEASURE
from I I_PROTEIN[GENE]/I_MEASURE
Escherichia I I_PROTEIN[GENE]/I_MEASURE
coli I I_PROTEIN[GENE]/I_MEASURE
, O O
was O O
cloned O O
and O O
sequenced O O
. O O

Background O O
reduction O O
with O O
various O O
agents O O
had O O
a O O
prominent O O
effect O O
on O O
DTIn1 O O
as O O
well O O
as O O
99mTc O O
- O O
DTPA O O
biodistribution O O
. O O

These O O
data O O
suggest O O
that O O
reduction O O
in O O
PRA O O
may O O
have O O
contributed O O
to O O
the O O
hemodynamic O O
effects O O
of O O
this O O
peak B B_GENE
III I I_GENE
PDE I I_GENE
inhibitor O O
. O O

A O O
. O O

Prematurely O O
inactivating O O
p42 B B_GENE
MAPK I I_GENE
in O O
egg O O
extracts O O
resulted O O
in O O
a O O
corresponding O O
hastening O O
of O O
the O O
first O O
mitosis O O
. O O

The O O
use O O
of O O
ALAD B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
activity O O
and O O
EP O O
as O O
cumulative O O
lead O O
exposure O O
indicators O O
is O O
suggested O O
. O O

Binding O O
of O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBPs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
all O O
three O O
spi B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
UTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repressor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
although O O
rather O O
weak O O
, O O
was O O
confirmed O O
by O O
electrophoretic O O
mobility O O
shift O O
assays O O
that O O
otherwise O O
failed O O
to O O
reveal O O
specific O O
interactions O O
with O O
other O O
liver O O
nuclear O O
proteins O O
in O O
vitro O O
. O O

Cell O O
cycle O O
regulatory O O
components O O
have O O
been O O
largely O O
conserved O O
in O O
eukaryotes O O
; O O
however O O
, O O
orthologs O O
of O O
neither O O
CAK1 B B_GENE
nor O O
csk1 B B_GENE
have O O
been O O
identified O O
in O O
other O O
species O O
to O O
date O O
. O O

In O O
this O O
study O O
, O O
we O O
cloned O O
the O O
full O O
- O O
length O O
cDNA O O
of O O
mouse O O
PAX4 B B_GENE/B_DISEASE
by O O
RACE O O
( O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
) O O
using O O
RNA O O
from O O
MIN6 O O
cells O O
, O O
a O O
mouse O O
insulinoma O O
cell O O
line O O
. O O

Kohtz O O
, O O
J O O
. O O

Hence O O
the O O
GAP1 B B_GENE
gene I I_GENE
encodes O O
a O O
protein O O
with O O
characteristics O O
typical O O
of O O
integral O O
membrane O O
proteins O O
translocating O O
ligants O O
across O O
cellular O O
membranes O O
. O O

The O O
results O O
suggest O O
that O O
proenzyme O O
processing O O
is O O
not O O
essential O O
for O O
secretion O O
of O O
PC2 B B_GENE
, O O
but O O
peptides O O
containing O O
mutations O O
that O O
affect O O
the O O
ability O O
of O O
the O O
propeptide O O
( O O
and O O
cleavage O O
sites O O
) O O
to O O
fold O O
within O O
the O O
catalytic O O
pocket O O
are O O
not O O
transferred O O
beyond O O
the O O
early O O
stages O O
of O O
the O O
secretory O O
pathway O O
. O O

These O O
results O O
suggest O O
that O O
transcription O O
influences O O
aspects O O
of O O
gene O O
conversion O O
after O O
initiation O O
, O O
such O O
as O O
strand O O
invasion O O
and O O
/ O O
or O O
mismatch O O
repair O O
( O O
MMR O O
) O O
. O O

Important O O
prognostic O O
factors O O
for O O
the O O
results O O
of O O
physiotherapeutic O O
exercises O O
in O O
intermittent O O
claudication O O

Finally O O
, O O
in O O
samples O O
obtained O O
from O O
two O O
patients O O
with O O
drug O O
refractory O O
ALL O O
, O O
BAC O O
- O O
derived O O
probes O O
applied O O
to O O
archived O O
marrow O O
cells O O
demonstrated O O
that O O
a O O
breakpoint O O
occurred O O
between O O
MDR1 B B_GENE/B_DISEASE
and O O
sequences O O
500 O O
- O O
1000 O O
KB O O
telomeric O O
to O O
MDR1 B B_GENE
, O O
consistent O O
with O O
a O O
random O O
chromosomal O O
rearrangement O O
. O O

Application O O
of O O
the O O
method O O
using O O
an O O
11 O O
- O O
year O O
microseismicity O O
record O O
revealed O O
systematic O O
spatial O O
and O O
temporal O O
changes O O
in O O
the O O
slip O O
rate O O
that O O
were O O
synchronous O O
with O O
earthquake O O
activity O O
and O O
other O O
independent O O
measures O O
of O O
fault O O
- O O
zone O O
slip O O
. O O

One O O
of O O
these O O
clones O O
encodes O O
Xenopus B B_GENE
N I I_GENE
- I I_GENE
ras I I_GENE
. O O

The O O
Molteno O O
implant O O
is O O
an O O
effective O O
procedure O O
in O O
the O O
treatment O O
of O O
complicated O O
and O O
refractory O O
cases O O
of O O
glaucoma O O
in O O
high O O
- O O
risk O O
eyes O O
. O O

The O O
median O O
levels O O
of O O
t B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
PA I I_GENE/I_LOCATION
Ag I I_GENE/I_LOCATION
and O O
PAI B B_LOCATION/B_GENE
in O O
plasma O O
were O O
respectively O O
10 O O
. O O
7 O O
ng O O
/ O O
ml O O
( O O
interquartile O O
range O O
8 O O
. O O
6 O O
ng O O
/ O O
ml O O
) O O
and O O
15 O O
. O O
7 O O
IU O O
/ O O
ml O O
( O O
interquartile O O
range O O
12 O O
. O O
2 O O
IU O O
/ O O
ml O O
) O O
. O O

Stamps O O
in O O
cardiology O O
: O O
de O O
Musset O O
sign O O
. O O

A O O
factor O O
present O O
in O O
nuclear O O
extracts O O
of O O
wounded O O
potato O O
tubers O O
was O O
found O O
to O O
bind O O
specifically O O
to O O
nucleotides O O
located O O
between O O
- O O
135 O O
to O O
- O O
105 O O
, O O
suggesting O O
that O O
this O O
region O O
contains O O
important O O
cis O O
- O O
regulatory O O
elements O O
. O O

The O O
leucine O O
zipper O O
region O O
of O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
also O O
similar O O
to O O
that O O
of O O
the O O
AP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
/ O O
c B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
jun I I_GENE/I_MEASURE
family O O
of O O
transcription O O
factors O O
, O O
whose O O
DNA O O
- O O
binding O O
site O O
differs O O
from O O
the O O
ATF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
binding O O
site O O
at O O
a O O
single O O
position O O
. O O

The O O
R260A O O
mutant O O
, O O
as O O
expected O O
, O O
was O O
unable O O
to O O
support O O
mRNA O O
synthesis O O
in O O
vitro O O
in O O
a O O
transcription O O
reconstitution O O
reaction O O
as O O
well O O
as O O
transcription O O
in O O
vivo O O
of O O
a O O
minigenome O O
using O O
a O O
reverse O O
genetic O O
approach O O
. O O

PEAP O O
was O O
significantly O O
higher O O
in O O
IDC O O
patients O O
compared O O
to O O
controls O O
( O O
48 O O
. O O
7 O O
+ O O
/ O O
- O O
32 O O
. O O
6 O O
vs O O
. O O

Uterine O O
contractions O O
began O O
with O O
a O O
mean O O
latency O O
of O O
62 O O
min O O
in O O
the O O
PGF2 O O
alpha O O
infused O O
women O O
, O O
in O O
controls O O
uterine O O
activity O O
remained O O
unchanged O O
. O O

Were O O
this O O
hypothesis O O
correct O O
, O O
the O O
requirement O O
for O O
elF4A B B_GENE
should O O
correlate O O
with O O
the O O
degree O O
of O O
mRNA O O
secondary O O
structure O O
. O O

In O O
spite O O
of O O
the O O
presence O O
of O O
a O O
physician O O
, O O
the O O
real O O
pathology O O
of O O
an O O
indian O O
population O O
of O O
Colombie O O
is O O
not O O
very O O
well O O
known O O
. O O

A O O
retrospective O O
study O O
of O O
clozapine O O
and O O
electroencephalographic O O
abnormalities O O
in O O
schizophrenic O O
patients O O
. O O

The O O
concepts O O
were O O
developed O O
by O O
Mines O O
and O O
Garrey O O
during O O
the O O
next O O
10 O O
years O O
. O O

When O O
the O O
measured O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
in O O
the O O
pWP O O
- O O
transfected O O
cells O O
was O O
normalized O O
to O O
the O O
pCH110 O O
- O O
transfected O O
cells O O
( O O
an O O
appropriate O O
control O O
if O O
the O O
SV40 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
early I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
functions O O
constitutively O O
in O O
various O O
cell O O
lines O O
) O O
, O O
the O O
results O O
suggested O O
that O O
the O O
promoter O O
region O O
of O O
the O O
PLP B B_GENE
gene I I_GENE
contains O O
the O O
information O O
necessary O O
for O O
initiation O O
of O O
transcription O O
in O O
a O O
C6 O O
cell O O
- O O
specific O O
manner O O
. O O

PKK B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exists O O
in O O
three O O
discernible O O
forms O O
at O O
steady O O
state O O
: O O
an O O
underphosphorylated O O
form O O
of O O
100 O O
kDa O O
; O O
a O O
soluble O O
, O O
cytosolic O O
, O O
phosphorylated O O
form O O
of O O
110 O O
kDa O O
; O O
and O O
a O O
phosphorylated O O
, O O
detergent O O
- O O
insoluble O O
form O O
of O O
112 O O
kDa O O
. O O

The O O
P B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
ITIM I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
compelled I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
multi I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphoprotein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binds O O
to O O
and O O
activates O O
SHP B B_GENE
- I I_GENE
2 I I_GENE
, O O
which O O
in O O
turn O O
dephosphorylates O O
SHIP B B_GENE
and O O
Shc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
probably O O
other O O
substrates O O
. O O

When O O
PCR O O
was O O
used O O
to O O
amplify O O
agar O O
cultures O O
which O O
do O O
not O O
express O O
the O O
fimbriae O O
, O O
the O O
switch O O
region O O
was O O
OFF O O
only O O
. O O

Mechanisms O O
of O O
action O O
of O O
local O O
anaesthetics O O
. O O

Student O O
health O O

We O O
now O O
report O O
that O O
both O O
HSCR B B_GENE/B_MEASURE
mutations O O
impair O O
the O O
fixation O O
of O O
Shc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
RET B B_GENE
and O O
consequently O O
prevent O O
its O O
phosphorylation O O
. O O

The O O
only O O
quantities O O
which O O
were O O
significantly O O
different O O
between O O
appendicitis O O
and O O
a O O
normal O O
appendix O O
were O O
sex O O
, O O
duration O O
of O O
symptoms O O
, O O
anorexia O O
and O O
vomiting O O
. O O

We O O
propose O O
that O O
U73 B B_GENE
is O O
involved O O
in O O
methylation O O
of O O
the O O
G1739 O O
residue O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
28S I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Copyright O O
1999 O O
Academic O O
Press O O
. O O

Ganglia O O
are O O
cysts O O
which O O
frequently O O
occur O O
in O O
the O O
proximity O O
of O O
joints O O
. O O

Lysates O O
of O O
COS O O
cells O O
transfected O O
with O O
modified B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hGrzB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cDNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
able O O
to O O
hydrolyze O O
tert O O
- O O
butyloxycarbonyl O O
- O O
Ala O O
- O O
Ala O O
- O O
Asp O O
- O O
thiobenzyl O O
ester O O
( O O
Boc O O
- O O
Ala O O
- O O
Ala O O
- O O
Asp O O
- O O
SBzl O O
) O O
, O O
whereas O O
lysates O O
transfected O O
with O O
unmodified B B_GENE
hGrzB I I_GENE
cDNA I I_GENE
were O O
inactive O O
. O O

Proteins O O
PBP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
and O O
PBP B B_GENE
- I I_GENE
2 I I_GENE
bind O O
to O O
two O O
of O O
the O O
three O O
promoter O O
elements O O
in O O
the O O
trypanosomatid O O
Leptomonas O O
seymouri O O
. O O

Expression O O
of O O
medical O O
efficiency O O
by O O
integration O O
indicators O O
with O O
the O O
rational O O
utilization O O
of O O
budgeted O O
funds O O

The O O
present O O
study O O
tries O O
to O O
associate O O
some O O
of O O
the O O
causes O O
of O O
hot O O
ischaemia O O
during O O
the O O
agony O O
of O O
the O O
corpse O O
donor O O
and O O
to O O
evaluate O O
those O O
that O O
may O O
be O O
caused O O
by O O
sympathetic O O
efference O O
during O O
removal O O
. O O

The O O
enzyme O O
encoded O O
by O O
the O O
cloned O O
fragment O O
is O O
equally O O
active O O
on O O
pyruvate O O
and O O
hydroxypyruvate O O
, O O
indicating O O
that O O
the O O
enzyme O O
has O O
both O O
D B B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
lactate I B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
D I B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
glycerate I B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
dehydrogenase I B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
activities O O
. O O

Noise O O
in O O
STM O O
due O O
to O O
atoms O O
moving O O
in O O
the O O
tunneling O O
space O O
. O O

The O O
human O O
sequence O O
contains O O
the O O
element O O
TGACTCT O O
that O O
also O O
is O O
found O O
in O O
a O O
murine B B_GENE/B_SPECIES[BIO]
ras I B_GENE/I_SPECIES[BIO]
- I B_GENE/I_SPECIES[BIO]
responsive I B_GENE/I_SPECIES[BIO]
enhancer I B_GENE/I_SPECIES[BIO]
. O O

There O O
is O O
an O O
overall O O
functional O O
similarity O O
between O O
IL B B_GENE/B_SPECIES[BIO]
- I B_GENE/I_SPECIES[BIO]
6 I B_GENE/I_SPECIES[BIO]
and O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fos I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
since O O
transfection O O
of O O
excess O O
amounts O O
of O O
either O O
promoter O O
DNA O O
into O O
intact O O
HeLa O O
cells O O
modulates O O
the O O
function O O
of O O
the O O
heterologous O O
promoter O O
construct O O
. O O

Enhanced O O
phospholipid O O
hydrolysis O O
with O O
free O O
fatty O O
acid O O
and O O
thromboxane O O
accumulation O O
, O O
increased O O
release O O
of O O
excitatory O O
amino O O
acids O O
, O O
and O O
decreased O O
tissue O O
magnesium O O
levels O O
may O O
each O O
serve O O
to O O
worsen O O
secondary O O
tissue O O
damage O O
and O O
diminish O O
neurologic O O
recovery O O
after O O
spinal O O
cord O O
injury O O
associated O O
with O O
acute O O
alcohol O O
intoxication O O
. O O

To O O
determine O O
whether O O
the O O
transcript O O
encodes O O
an O O
active O O
enzyme O O
, O O
we O O
developed O O
a O O
novel O O
transient O O
embryonic O O
excision O O
assay O O
in O O
which O O
zebrafish O O
fertilized O O
eggs O O
were O O
co O O
- O O
injected O O
with O O
RNA O O
transcribed O O
in O O
vitro O O
using O O
the O O
Tol2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
template O O
and O O
a O O
plasmid O O
DNA O O
harboring O O
a O O
nonautonomous O O
Tol2 B B_LOCATION/B_GENE
element I B_LOCATION/I_GENE
, O O
which O O
has O O
a O O
deletion O O
in O O
the O O
transposase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
overall O O
objective O O
response O O
rate O O
( O O
RR O O
) O O
was O O
50 O O
% O O
[ O O
95 O O
% O O
confidence O O
interval O O
( O O
CI O O
) O O
= O O
29 O O
- O O
71 O O
% O O
] O O
including O O
four O O
complete O O
responses O O
and O O
eight O O
partial O O
responses O O
. O O

We O O
suggest O O
that O O
this O O
relatively O O
small O O
deletion O O
affects O O
a O O
segment O O
containing O O
3 B B_GENE/B_LOCATION
' I I_GENE/I_LOCATION
VH I I_GENE/I_LOCATION
genes I I_GENE/I_LOCATION
with O O
important O O
regulatory O O
functions O O
, O O
the O O
loss O O
of O O
which O O
leads O O
to O O
the O O
ali O O
phenotype O O
. O O

Two O O
SH2 B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
p120 B B_GENE
Ras B I_GENE
GTPase B I_GENE
- I I_GENE
activating I I_GENE
protein I I_GENE
bind O O
synergistically O O
to O O
tyrosine O O
phosphorylated O O
p190 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Rho O O
GTPase B B_GENE
- I I_GENE
activating I I_GENE
protein I I_GENE
. O O

p120 B B_GENE
GTPase B I_GENE
- I I_GENE
activating I I_GENE
protein I I_GENE
( O O
GAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
a O O
negative O O
regulator O O
of O O
Ras B B_GENE/B_DISEASE
that O O
functions O O
at O O
a O O
key O O
relay O O
point O O
in O O
signal O O
transduction O O
pathways O O
that O O
control O O
cell O O
proliferation O O
. O O

A O O
homologue O O
of O O
the O O
MAP B B_LOCATION/B_GENE
/ O O
ERK B B_GENE/B_DISEASE
family O O
of O O
protein O O
kinase O O
genes O O
is O O
expressed O O
in O O
vegetative O O
and O O
in O O
female O O
reproductive O O
organs O O
of O O
Petunia O O
hybrida O O
. O O

It O O
encodes O O
a O O
sequence O O
- O O
specific O O
transcription O O
factor O O
that O O
controls O O
, O O
in O O
concert O O
with O O
other O O
gene O O
products O O
, O O
differentiative O O
pathways O O
of O O
tissues O O
in O O
which O O
Scr B B_GENE/B_DISEASE
is O O
expressed O O
. O O

CONCLUSION O O
: O O
DMIPP O O
detects O O
regionally O O
hypoperfused O O
myocardium O O
, O O
in O O
which O O
agreement O O
between O O
MBF O O
and O O
fatty O O
acid O O
uptake O O
deteriorates O O
. O O

The O O
effect O O
of O O
guaiphenesin O O
on O O
absorption O O
and O O
bioavailability O O
of O O
paracetamol O O
from O O
composite O O
analgesic O O
preparations O O
. O O

Transcription O O
of O O
the O O
inserted O O
gene O O
into O O
the O O
predicted O O
subgenomic O O
polyadenylated O O
mRNA O O
was O O
demonstrated O O
by O O
Northern O O
( O O
RNA O O
) O O
blot O O
hybridization O O
analysis O O
, O O
and O O
the O O
encoded O O
protein O O
was O O
detected O O
by O O
enzyme O O
assay O O
and O O
by O O
radioimmunoprecipitation O O
. O O

These O O
results O O
suggest O O
that O O
panretinal O O
photocoagulation O O
offers O O
a O O
highly O O
effective O O
means O O
of O O
dealing O O
with O O
early O O
and O O
moderately O O
advanced O O
cases O O
of O O
angle O O
neovascularization O O
. O O

NBSII O O
is O O
essential O O
for O O
ribosome O O
- O O
stimulated O O
activity O O
. O O

Sixteen O O
patients O O
( O O
25 O O
. O O
4 O O
% O O
) O O
encountered O O
rejection O O
while O O
weaning O O
at O O
median O O
period O O
of O O
9 O O
. O O
5 O O
months O O
( O O
range O O
, O O
1 O O
- O O
63 O O
months O O
) O O
from O O
the O O
start O O
of O O
weaning O O
. O O

ALT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
alanine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
aminotransferase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
) O O
and O O
Hb B B_PROTEIN[GENE]/B_DISEASE
( O O
hemoglobin B B_DISEASE/B_PROTEIN[GENE]
) O O
appeared O O
to O O
be O O
predictive O O
for O O
efficacy O O
. O O

Theophylline O O
QID O O
, O O
TID O O
, O O
BID O O
and O O
now O O
QD O O
? O O

A O O
report O O
on O O
24 O O
- O O
hour O O
dosing O O
with O O
slow O O
- O O
release O O
theophylline O O
formulations O O
with O O
emphasis O O
on O O
analyses O O
of O O
data O O
used O O
to O O
obtain O O
Food O O
and O O
Drug O O
Administration O O
approval O O
for O O
Theo O O
- O O
24 O O
. O O

Signal O O
transduction O O
in O O
fibroblasts O O
stably O O
transformed O O
by O O
[ O O
Val12 O O
] O O
Ras O O
- O O
- O O
the O O
activities O O
of O O
extracellular B B_GENE
- I I_GENE
signal I I_GENE
- I I_GENE
regulated I I_GENE
kinase I I_GENE
and O O
Jun B B_GENE
N I I_GENE
- I I_GENE
terminal I I_GENE
kinase I I_GENE
are O O
only O O
moderately O O
increased O O
, O O
and O O
the O O
activity O O
of O O
the O O
delta O O
- O O
inhibitor O O
of O O
c B B_GENE
- I I_GENE
Jun I I_GENE
is O O
not O O
alleviated O O
. O O

Time O O
for O O
action O O
on O O
hepatitis O O
B O O
immunisation O O
. O O

By O O
24 O O
h O O
, O O
there O O
was O O
no O O
significant O O
difference O O
in O O
FFA O O
levels O O
from O O
shams O O
. O O

This O O
result O O
suggests O O
that O O
the O O
target O O
protein O O
specificity O O
of O O
E2s B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
altered O O
by O O
the O O
addition O O
of O O
appropriate O O
C O O
- O O
terminal O O
extensions O O
, O O
thus O O
providing O O
a O O
way O O
to O O
modify O O
the O O
selectivity O O
of O O
the O O
ubiquitin B B_PROTEIN[GENE]/B_BIO
system O O
. O O

Here O O
we O O
report O O
the O O
cloning O O
of O O
the O O
hemF B B_GENE
gene I I_GENE
, O O
encoding O O
the O O
aerobic O O
coproporphyrinogen B B_ENZYME[GENE]/B_MEASURE
III I I_ENZYME[GENE]/I_MEASURE
oxidase I I_ENZYME[GENE]/I_MEASURE
from I I_ENZYME[GENE]/I_MEASURE
Escherichia I I_ENZYME[GENE]/I_MEASURE
coli I I_ENZYME[GENE]/I_MEASURE
, O O
by O O
functional O O
complementation O O
of O O
a O O
Saccharomyces B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cerevisiae I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
HEM13 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutant I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

This O O
study O O
was O O
undertaken O O
to O O
evaluate O O
the O O
physical O O
and O O
biological O O
characteristics O O
of O O
nebulized O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
liposomes O O
. O O

Previous O O
studies O O
showed O O
that O O
a O O
palindromic O O
sequence O O
located O O
at O O
- O O
159 O O
base O O
pairs O O
is O O
essential O O
for O O
induction O O
of O O
cutinase B B_DISEASE/B_GENE
gene I I_DISEASE/I_GENE
in O O
Fusarium O O
solani O O
f O O
. O O

This O O
preliminary O O
study O O
reports O O
an O O
initial O O
evaluation O O
of O O
HMPAO O O
- O O
SPECT O O
imaging O O
for O O
assessing O O
regional O O
alterations O O
in O O
brain O O
function O O
during O O
opiate O O
dependence O O
and O O
withdrawal O O
. O O

Based O O
on O O
PCR O O
strategies O O
and O O
expression O O
studies O O
, O O
we O O
define O O
the O O
genomic O O
organization O O
of O O
the O O
FUT8b B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
present O O
study O O
demonstrates O O
that O O
the O O
proto B B_GENE
- I I_GENE
oncogene I I_GENE
c I I_GENE
- I I_GENE
jun I I_GENE
represses O O
transcription O O
of O O
the O O
human B B_GENE
CG I I_GENE
alpha I I_GENE
and O O
CG B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
promoters I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

c B B_GENE
- I I_GENE
Jun I I_GENE
repressed O O
the O O
CG B B_GENE
alpha I I_GENE
promoter I I_GENE
through O O
a O O
canonical O O
cAMP O O
response O O
element O O
( O O
CRE O O
) O O
that O O
is O O
known O O
to O O
bind O O
c B B_GENE
- I I_GENE
Jun I I_GENE
and O O
other O O
members O O
of O O
the O O
B B B_GENE/B_PERSON
- I I_GENE/I_PERSON
Zip I I_GENE/I_PERSON
transcription I I_GENE/I_PERSON
factor I I_GENE/I_PERSON
family I I_GENE/I_PERSON
. O O

Pulse O O
monitors O O
in O O
outpatient O O
dental O O
anaesthesia O O
. O O

The O O
sensitivity O O
of O O
99mTc O O
- O O
IgG B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scintigraphy O O
ranged O O
between O O
71 O O
% O O
and O O
100 O O
% O O
. O O

The O O
index O O
patient O O
, O O
a O O
10 O O
- O O
year O O
- O O
old O O
boy O O
, O O
presents O O
typical O O
symptoms O O
of O O
OPD O O
type O O
I O O
together O O
with O O
bowing O O
of O O
the O O
long O O
bones O O
and O O
abnormalities O O
of O O
the O O
thorax O O
and O O
spinal O O
column O O
. O O

The O O
cause O O
for O O
the O O
increase O O
in O O
plasma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ANP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
in O O
the O O
active O O
phase O O
remains O O
to O O
be O O
determined O O
. O O

A O O
genomic O O
clone O O
representing O O
the O O
5 O O
' O O
part O O
of O O
the O O
message O O
was O O
also O O
isolated O O
. O O

Antibiotics O O
and O O
CDCA O O
- O O
mediation O O
are O O
essential O O
for O O
symptomatic O O
therapy O O
. O O

The O O
main O O
side O O
- O O
effects O O
were O O
myelosuppression O O
, O O
mucositis O O
and O O
peripheral O O
neuropathy O O
, O O
which O O
were O O
all O O
common O O
and O O
often O O
severe O O
. O O

The O O
column O O
densities O O
of O O
frozen O O
molecular O O
hydrogen O O
and O O
methanol O O
are O O
inferred O O
to O O
be O O
about O O
2 O O
. O O
5 O O
x O O
10 O O
( O O
18 O O
) O O
and O O
3 O O
. O O
0 O O
x O O
10 O O
( O O
19 O O
) O O
, O O
respectively O O
. O O

Similarly O O
, O O
an O O
increase O O
in O O
CAT B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
expression O O
from O O
the O O
same O O
construct O O
( O O
pBLCAT O O
- O O
ENDOA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
was O O
also O O
observed O O
in O O
7AQS2 O O
. O O
1 O O
cells O O
. O O

We O O
recently O O
reported O O
the O O
cloning O O
and O O
sequencing O O
of O O
the O O
alpha B B_GENE
7 I I_GENE
integrin I I_GENE
chain I I_GENE
and O O
its O O
regulated O O
expression O O
during O O
the O O
development O O
of O O
skeletal O O
muscle O O
( O O
Song O O
et O O
al O O
. O O

These O O
mutations O O
prevent O O
FKBP12 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
rapamycin O O
binding O O
to O O
TOR2 B B_GENE
, O O
as O O
assayed O O
with O O
the O O
two O O
- O O
hybrid O O
system O O
. O O

Failure O O
to O O
demonstrate O O
a O O
major O O
anti O O
- O O
inflammatory O O
effect O O
with O O
alpha O O
tocopherol O O
supplementation O O
( O O
400 O O
IU O O
/ O O
day O O
) O O
in O O
normal O O
subjects O O
. O O

Results O O
on O O
the O O
use O O
of O O
amiodarone O O
in O O
the O O
prevention O O
of O O
paroxysmal O O
AF O O
have O O
been O O
equivocal O O
; O O
this O O
may O O
be O O
attributed O O
to O O
differences O O
in O O
defining O O
paroxysmal O O
AF O O
. O O

High O O
- O O
level O O
expression O O
of O O
sccypB B B_GENE/B_BACTERIUM[BIO]
as O O
well O O
as O O
of O O
sccypA B B_BIO/B_GENE
cloned O O
into O O
the O O
expression O O
vector O O
pIJ702 O O
did O O
not O O
produce O O
detectable O O
changes O O
in O O
growth O O
and O O
morphology O O
of O O
S O O
. O O
chrysomallus O O
and O O
S O O
. O O
lividans O O
. O O

Fas B B_GENE
( O O
APO B B_GENE
- I I_GENE
1 I I_GENE
/ O O
CD95 B B_GENE/B_MEASURE
) O O
, O O
which O O
is O O
a O O
member O O
of O O
the O O
tumor B B_GENE/B_LOCATION
necrosis I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
superfamily I I_GENE/I_LOCATION
, O O
is O O
a O O
cell O O
surface O O
receptor O O
that O O
induces O O
apoptosis O O
. O O

In O O
the O O
future O O
, O O
transoesophageal O O
echocardiography O O
may O O
be O O
used O O
to O O
measure O O
variations O O
in O O
wall O O
thickness O O
which O O
change O O
the O O
global O O
loading O O
conditions O O
in O O
the O O
basal O O
midwall O O
compartments O O
of O O
the O O
left O O
ventricle O O
. O O

We O O
studied O O
18 O O
dogs O O
, O O
anaesthetised O O
and O O
spontaneously O O
breathing O O
both O O
room O O
air O O
and O O
after O O
the O O
inhalation O O
of O O
a O O
gas O O
mixture O O
containing O O
10 O O
% O O
CO2 O O
, O O
20 O O
. O O
9 O O
% O O
O2 O O
, O O
and O O
69 O O
. O O
1 O O
% O O
N2 O O
, O O
to O O
determine O O
the O O
role O O
of O O
histamine O O
, O O
serotonin O O
, O O
and O O
acidaemia O O
in O O
pulmonary O O
hypertension O O
produced O O
by O O
hypercapnia O O
. O O

Sequencing O O
of O O
this O O
fragment O O
showed O O
that O O
the O O
MRP13 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coding O O
region O O
specifies O O
a O O
324 O O
- O O
amino O O
- O O
acid O O
basic O O
protein O O
with O O
a O O
calculated O O
Mr O O
of O O
37 O O
, O O
366 O O
. O O

Viral O O
complementary O O
15 B B_GENE
S I I_GENE
mRNA I I_GENE
that O O
directs O O
the O O
synthesis O O
of O O
N B B_GENE
protein I I_GENE
and O O
hybridizes O O
to O O
the O O
predicted O O
N B B_GENE/B_VIRUS[BIO]
gene I B_GENE/I_VIRUS[BIO]
DNA O O
has O O
been O O
identified O O
in O O
infected O O
cell O O
extracts O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
and O O
DNase B B_GENE
I I I_GENE
protection O O
analyses O O
revealed O O
that O O
FP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
bound O O
by O O
the O O
transcription O O
factor O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
Spi B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
1 I I_MEASURE/I_GENE
. O O

However O O
, O O
a O O
few O O
sites O O
in O O
the O O
genomes O O
of O O
EC O O
cells O O
permit O O
M B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
MuLVneo I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
delta I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Enh I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proviral O O
expression O O
. O O

Increasing O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sensitivity O O
in O O
type O O
I O O
diabetic O O
patients O O
should O O
alert O O
clinicians O O
to O O
the O O
possibility O O
of O O
glucocorticoid O O
deficiency O O
. O O

However O O
, O O
differential O O
utilization O O
of O O
these O O
determinants O O
mediate O O
RAR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
RXR B B_PROTEIN[GENE]/B_LOCATION
heterodimer O O
binding O O
to O O
DR O O
- O O
2 O O
and O O
DR O O
- O O
5 O O
RAREs O O
. O O

Galactorrhoea O O
is O O
a O O
rare O O
presentation O O
of O O
an O O
empty O O
sella O O
syndrome O O
. O O

Several O O
of O O
the O O
drugs O O
used O O
in O O
the O O
management O O
of O O
MAC O O
have O O
been O O
associated O O
with O O
significant O O
drug O O
interactions O O
involving O O
the O O
cytochrome B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
P450 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CYP B B_GENE/B_BIO
) O O
enzyme O O
system O O
. O O

Arterial O O
compliance O O
measurements O O
using O O
intraarterial O O
pulse O O
contour O O
analysis O O
and O O
a O O
modified O O
Windkessel O O
model O O
were O O
carried O O
out O O
in O O
19 O O
patients O O
with O O
isolated O O
systolic O O
hypertension O O
( O O
> O O
or O O
= O O
160 O O
/ O O
< O O
or O O
= O O
90 O O
mm O O
Hg O O
) O O
and O O
compared O O
to O O
measurements O O
in O O
29 O O
patients O O
with O O
essential O O
hypertension O O
( O O
diastolic O O
blood O O
pressure O O
[ O O
BP O O
] O O
> O O
or O O
= O O
95 O O
mm O O
Hg O O
) O O
and O O
47 O O
normotensive O O
control O O
subjects O O
. O O

Rather O O
than O O
seeking O O
a O O
blanket O O
characterization O O
of O O
an O O
essentially O O
heterogeneous O O
group O O
, O O
it O O
may O O
be O O
more O O
useful O O
to O O
consider O O
idiom O O
comprehension O O
a O O
secondary O O
manifestation O O
of O O
semantic O O
and O O
/ O O
or O O
pragmatic O O
difficulties O O
. O O

The O O
women O O
in O O
the O O
intermediate O O
calcium O O
group O O
had O O
approximately O O
the O O
same O O
mean O O
BMD O O
values O O
as O O
those O O
in O O
the O O
low O O
calcium O O
group O O
. O O

International O O
efforts O O
are O O
now O O
being O O
made O O
to O O
standardize O O
haemolytic O O
test O O
conditions O O
and O O
the O O
present O O
study O O
is O O
meant O O
as O O
a O O
contribution O O
to O O
this O O
. O O

The O O
transition O O
from O O
expression O O
of O O
early O O
meiotic O O
genes O O
to O O
expression O O
of O O
middle O O
sporulation O O
- O O
specific O O
genes O O
occurs O O
at O O
about O O
the O O
time O O
that O O
cells O O
exit O O
from O O
pachytene O O
and O O
form O O
the O O
meiosis O O
I O O
spindle O O
. O O

NF B B_GENE/B_PERSON
- I I_GENE/I_PERSON
kappaB I I_GENE/I_PERSON
DNA O O
- O O
protein O O
binding O O
and O O
ICAM B B_GENE
- I I_GENE
1 I I_GENE
promoter I I_GENE
activity O O
were O O
enhanced O O
by O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1beta I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
these O O
effects O O
were O O
inhibited O O
by O O
tyrphostin O O
23 O O
, O O
but O O
not O O
by O O
PD O O
98059 O O
or O O
SB O O
203580 O O
. O O

Peripheral O O
neuropathy O O
in O O
the O O
cherry O O
- O O
red O O
spot O O
- O O
myoclonus O O
syndrome O O
( O O
sialidosis O O
type O O
I O O
) O O
. O O

Using O O
the O O
two O O
- O O
hybrid O O
screening O O
method O O
, O O
we O O
have O O
identified O O
an O O
additional O O
component O O
of O O
the O O
CCAAT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
myb B B_GENE
proto I I_GENE
oncogene I I_GENE
product I I_GENE
( O O
c B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
Myb I I_GENE/I_DISEASE
) O O
is O O
a O O
transcriptional O O
regulator O O
and O O
its O O
expression O O
and O O
function O O
are O O
tightly O O
linked O O
to O O
the O O
cellular O O
entry O O
into O O
S O O
phase O O
and O O
DNA O O
synthesis O O
. O O

Both O O
the O O
p38 B B_GENE
kinase I I_GENE
inhibitor O O
SB205380 O O
( O O
SB O O
) O O
and O O
cotransfection O O
of O O
a O O
dominant O O
- O O
negative O O
mutant O O
of O O
p38 B B_GENE
kinase I I_GENE
reduced O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1beta I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O O
of O O
the O O
hBNP B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
promoter I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

CLINICAL O O
FEATURES O O
: O O
This O O
30 O O
- O O
yr O O
- O O
old O O
gravida O O
V O O
para O O
0 O O
woman O O
presented O O
to O O
the O O
anaesthesia O O
consultation O O
clinic O O
at O O
37 O O
- O O
wk O O
gestation O O
to O O
discuss O O
pain O O
relief O O
options O O
for O O
labour O O
and O O
delivery O O
. O O

In O O
addition O O
, O O
because O O
SB203580 O O
had O O
no O O
effect O O
of O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
or O O
ceramide O O
- O O
induced O O
apoptosis O O
, O O
our O O
results O O
strongly O O
argue O O
against O O
a O O
role O O
for O O
p38 B B_GENE
MAPK I I_GENE
in O O
the O O
induction O O
of O O
TNF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
or O O
ceramide O O
- O O
induced O O
apoptosis O O
. O O

Cognitive O O
measures O O
of O O
attention O O
included O O
the O O
Stroop O O
and O O
Controlled O O
Oral O O
Word O O
Association O O
Test O O
using O O
the O O
letters O O
" O O
C O O
, O O
" O O
" O O
F O O
, O O
" O O
and O O
" O O
L O O
" O O
( O O
COWAT O O
, O O
CFL O O
version O O
) O O
. O O

Effects O O
of O O
dietary O O
lipids O O
on O O
whole O O
- O O
body O O
retention O O
and O O
organ O O
distribution O O
of O O
organic O O
and O O
inorganic O O
mercury O O
in O O
mice O O
. O O

Sequential O O
immunoprecipitation O O
showed O O
all O O
detectable O O
p53 B B_GENE
to O O
be O O
of O O
the O O
PAb246 B B_GENE
+ I I_GENE
class O O
in O O
each O O
LPV O O
- O O
transformed O O
cell O O
line O O
, O O
suggesting O O
that O O
the O O
stable O O
p53 B B_GENE/B_MEASURE
was O O
indeed O O
wild O O
type O O
. O O

Tissue O O
- O O
specific O O
gene O O
regulation O O
of O O
eukaryotic O O
organisms O O
is O O
to O O
a O O
large O O
extent O O
mediated O O
by O O
transcription O O
factors O O
that O O
interact O O
with O O
genomic O O
DNA O O
sequences O O
in O O
a O O
sequence O O
- O O
specific O O
manner O O
. O O

Enhanced O O
quantum O O
correlations O O
in O O
bound O O
higher O O
- O O
order O O
solitons O O
Quantum O O
effects O O
in O O
N O O
- O O
bound O O
solitons O O
can O O
be O O
drastically O O
enhanced O O
compared O O
to O O
the O O
fundamental O O
soliton O O
. O O

The O O
data O O
suggest O O
that O O
compromised O O
fibrinolytic O O
capacity O O
may O O
be O O
a O O
contributing O O
factor O O
in O O
the O O
development O O
of O O
thrombosis O O
in O O
patients O O
with O O
the O O
lupus O O
anticoagulant O O
. O O

On O O
a O O
variety O O
of O O
fronts O O
, O O
chronic O O
bacterial O O
infection O O
is O O
being O O
found O O
to O O
be O O
significantly O O
associated O O
with O O
the O O
development O O
of O O
atherosclerosis O O
and O O
the O O
clinical O O
complications O O
of O O
unstable O O
angina O O
, O O
myocardial O O
infarction O O
, O O
and O O
stroke O O
. O O

Long O O
- O O
term O O
results O O
and O O
curative O O
mechanisms O O
of O O
vesicoureteral O O
reflux O O
by O O
endoscopic O O
injection O O
of O O
blood O O
. O O

Inspection O O
of O O
X B B_GENE/B_BIO
. I I_GENE/I_BIO
tropicalis I I_GENE/I_BIO
, I I_GENE/I_BIO
mouse I I_GENE/I_BIO
and I I_GENE/I_BIO
human I I_GENE/I_BIO
U6 I I_GENE/I_BIO
DNA I I_GENE/I_BIO
upstream I I_GENE/I_BIO
sequences I I_GENE/I_BIO
revealed O O
the O O
presence O O
of O O
a O O
TATA O O
box O O
as O O
well O O
as O O
of O O
the O O
proximal O O
and O O
enhancer O O
( O O
octamer O O
motif O O
) O O
elements O O
contained O O
in O O
snRNA O O
genes O O
transcribed O O
by O O
RNA B B_GENE/B_VIRUS[BIO]
polymerase I B_GENE/I_VIRUS[BIO]
II I B_GENE/I_VIRUS[BIO]
. O O

Characterization O O
of O O
an O O
unusual O O
tRNA O O
- O O
like O O
sequence O O
found O O
inserted O O
in O O
a O O
Neurospora O O
retroplasmid O O
. O O

Repeated O O
time O O
course O O
studies O O
in O O
the O O
same O O
patient O O
were O O
reproducible O O
although O O
the O O
absolute O O
concentrations O O
showed O O
some O O
variation O O
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PAX8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
generates O O
at O O
least O O
five O O
different O O
alternatively O O
spliced O O
transcripts O O
encoding O O
different O O
PAX8 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
data O O
show O O
that O O
both O O
Sp1 B B_GENE/B_LOCATION
and O O
Sp3 B B_GENE
transcription I I_GENE
factors I I_GENE
upregulate O O
HGF B B_GENE
promoter I I_GENE
activity O O
by O O
binding O O
to O O
the O O
Sp1 B B_GENE/B_TIME[MEASURE]
binding I I_GENE/I_TIME[MEASURE]
site I I_GENE/I_TIME[MEASURE]
at O O
position O O
- O O
318 O O
to O O
- O O
303 O O
bp O O
in O O
the O O
HGF B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
. O O

After O O
a O O
1 O O
- O O
h O O
rest O O
( O O
for O O
T2 O O
return O O
to O O
baseline O O
) O O
, O O
subjects O O
repeated O O
the O O
5 O O
- O O
min O O
protocol O O
, O O
followed O O
by O O
a O O
final O O
MRI O O
/ O O
MRS O O
. O O

The O O
cells O O
arrest O O
in O O
the O O
G1 O O
phase O O
of O O
the O O
cell O O
cycle O O
and O O
grow O O
a O O
projection O O
towards O O
one O O
another O O
forming O O
a O O
shmoo O O
projection O O
. O O

Mammalian O O
homologues O O
of O O
the O O
Polycomb B B_GENE
- I I_GENE
group I I_GENE
gene I I_GENE
Enhancer B I_GENE
of I I_GENE
zeste I I_GENE
mediate O O
gene O O
silencing O O
in O O
Drosophila O O
heterochromatin O O
and O O
at O O
S O O
. O O
cerevisiae O O
telomeres O O
. O O

With O O
six O O
reports O O
in O O
the O O
literature O O
that O O
show O O
there O O
is O O
an O O
order O O
to O O
melanoma O O
nodal O O
metastases O O
and O O
that O O
the O O
SLN O O
histology O O
is O O
reflective O O
of O O
the O O
histology O O
of O O
the O O
remainder O O
of O O
the O O
nodal O O
basin O O
, O O
the O O
more O O
conservative O O
SLN O O
biopsy O O
can O O
be O O
performed O O
to O O
adequately O O
stage O O
nodally O O
the O O
patient O O
with O O
melanoma O O
. O O

The O O
results O O
obtained O O
with O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
F304 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
R2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
indicate O O
that O O
structural O O
changes O O
in O O
E B B_LOCATION/B_PROTEIN[GENE]
. I B_LOCATION/I_PROTEIN[GENE]
coli I B_LOCATION/I_PROTEIN[GENE]
R2 I B_LOCATION/I_PROTEIN[GENE]
in O O
the O O
vicinity O O
of O O
this O O
helix O O
distortion O O
can O O
influence O O
the O O
catalytic O O
activity O O
of O O
the O O
holoenzyme O O
. O O

Cloning O O
and O O
characterization O O
of O O
the O O
5 O O
' O O
flanking O O
region O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ATP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
citrate I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lyase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Cryoglobulinaemia O O
among O O
maintenance O O
haemodialysis O O
patients O O
and O O
its O O
relation O O
to O O
hepatitis O O
C O O
infection O O
. O O

The O O
S3 B B_GENE
protein I I_GENE
also O O
contains O O
a O O
DNA O O
repair O O
activity O O
, O O
efficiently O O
processing O O
8 O O
- O O
oxoguanine O O
residues O O
in O O
DNA O O
via O O
an O O
N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
glycosylase I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
/ O O
apurinic B B_ENZYME[GENE]
- I I_ENZYME[GENE]
apyrimidinic I I_ENZYME[GENE]
( I I_ENZYME[GENE]
AP I I_ENZYME[GENE]
) I I_ENZYME[GENE]
lyase I I_ENZYME[GENE]
activity O O
. O O

We O O
present O O
here O O
a O O
statistical O O
technique O O
we O O
developed O O
to O O
identify O O
the O O
sequence O O
elements O O
that O O
may O O
be O O
responsible O O
for O O
this O O
cell O O
cycle O O
regulation O O
. O O

Computed O O
tomographic O O
( O O
CT O O
) O O
findings O O
of O O
pancreatic O O
ductal O O
adenocarcinoma O O
were O O
studied O O
with O O
the O O
combined O O
method O O
of O O
early O O
enhancement O O
CT O O
and O O
high O O
dose O O
enhancement O O
CT O O
in O O
72 O O
carcinomas O O
. O O

No O O
other O O
transcripts O O
of O O
different O O
length O O
could O O
be O O
detected O O
after O O
prolonged O O
exposure O O
. O O

We O O
conclude O O
, O O
therefore O O
, O O
that O O
in O O
the O O
absence O O
of O O
E1A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
E4orf4 B B_GENE
is O O
sufficient O O
by O O
itself O O
to O O
trigger O O
a O O
p53 B B_GENE
- O O
independent O O
apoptosis O O
pathway O O
that O O
may O O
operate O O
independently O O
of O O
the O O
known O O
zVAD O O
- O O
inhibitable O O
caspases B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
that O O
may O O
involve O O
an O O
as O O
yet O O
uncharacterized O O
mechanism O O
. O O

The O O
antiserum O O
used O O
for O O
immunoblotting O O
specifically O O
supershifts O O
uteroglobin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
gel O O
shift O O
experiments O O
. O O

The O O
nucleotide O O
sequence O O
of O O
the O O
estrogen B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Oreochromis I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aureus I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
OaER B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
indicates O O
that O O
the O O
hormone O O
- O O
binding O O
E O O
domain O O
is O O
composed O O
of O O
4 O O
exons O O
interspersed O O
by O O
short O O
introns O O
of O O
only O O
0 O O
. O O
18 O O
- O O
1 O O
. O O
3 O O
kb O O
each O O
. O O

The O O
nucleoporin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
98 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NUP98 B B_GENE/B_DISEASE
) O O
, O O
which O O
is O O
rearranged O O
in O O
several O O
acute O O
myeloid O O
leukemia O O
translocations O O
, O O
is O O
located O O
within O O
this O O
region O O
. O O

We O O
have O O
isolated O O
and O O
sequenced O O
cDNA O O
sequences O O
corresponding O O
to O O
two O O
novel O O
genes O O
that O O
map O O
to O O
Xq28 O O
. O O

A O O
new O O
direct O O
hemagglutination O O
test O O
( O O
HI O O
- O O
GONAVIS O O
) O O
for O O
urinary O O
LH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
compared O O
with O O
the O O
serum O O
radioimmuno O O
- O O
assay O O
of O O
LH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Diffusion O O
epidemic O O
models O O
with O O
incubation O O
and O O
crisscross O O
dynamics O O
. O O

The O O
encoded O O
Arabidopsis B B_GENE/B_LOCATION
U3 I I_GENE/I_LOCATION
snRNAs I I_GENE/I_LOCATION
can O O
be O O
folded O O
into O O
a O O
secondary O O
structure O O
which O O
is O O
more O O
similar O O
to O O
that O O
of O O
U3 B B_GENE/B_BIO
RNAs I I_GENE/I_BIO
from O O
lower O O
eukaryotes O O
rather O O
than O O
from O O
metazoa O O
. O O

Therapy O O
and O O
prevention O O
of O O
irreversible O O
shock O O
with O O
pharmacological O O
doses O O
of O O
some O O
corticosteroids O O

Fentanyl O O
citrate O O
( O O
0 O O
. O O
1 O O
mL O O
) O O
and O O
2H5 O O
- O O
fentanyl O O
( O O
internal O O
standard O O
, O O
0 O O
. O O
05 O O
mL O O
, O O
100 O O
mg O O
/ O O
L O O
) O O
were O O
extracted O O
with O O
Toxi O O
- O O
A O O
tubes O O
( O O
Toxi O O
- O O
Lab O O
, O O
Irvine O O
, O O
CA O O
) O O
and O O
analyzed O O
by O O
gas O O
chromatography O O
- O O
mass O O
spectrometry O O
. O O

Positive O O
effects O O
of O O
radioactive O O
therapy O O
in O O
Guarapari O O

The O O
LT B B_GENE
- I I_GENE
beta I I_GENE
gene I I_GENE
is O O
expressed O O
in O O
lymphoid O O
cells O O
and O O
organs O O
, O O
but O O
little O O
is O O
known O O
about O O
its O O
inducible O O
regulation O O
. O O

Ciprofloxacin O O
attained O O
a O O
peak O O
serum O O
concentration O O
of O O
1 O O
. O O
2 O O
mg O O
/ O O
l O O
and O O
a O O
serum O O
half O O
- O O
life O O
of O O
34 O O
min O O
. O O

Identification O O
of O O
an O O
osteocalcin B B_GENE
gene I I_GENE
promoter I I_GENE
sequence I I_GENE
that O O
binds O O
AP1 B B_GENE
. O O

Treatment O O
is O O
based O O
on O O
antifungal O O
drugs O O
, O O
most O O
frequently O O
nystatin O O
, O O
amphotericin O O
B O O
and O O
ketoconazole O O
. O O

Mutations O O
abolishing O O
MalK B B_GENE/B_BIO
function O O
not O O
only O O
result O O
in O O
inability O O
to O O
transport O O
maltose O O
but O O
also O O
cause O O
constitutive O O
expression O O
of O O
the O O
maltose B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
regulon I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Drosophila B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
melanogaster I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
casein I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DmCKII B B_GENE/B_TIME[MEASURE]
) O O
is O O
composed O O
of O O
catalytic O O
( O O
alpha O O
) O O
and O O
regulatory O O
( O O
beta O O
) O O
subunits O O
associated O O
as O O
an O O
alpha2beta2 O O
heterotetramer O O
. O O

The O O
aims O O
of O O
this O O
study O O
were O O
to O O
examine O O
whether O O
the O O
EORTC O O
( O O
European O O
Organisation O O
for O O
Research O O
and O O
Treatment O O
of O O
Cancer O O
) O O
QLQ O O
- O O
C30 O O
core O O
questionnaire O O
alone O O
could O O
distinguish O O
between O O
two O O
clinically O O
different O O
groups O O
of O O
patients O O
and O O
to O O
design O O
a O O
module O O
, O O
which O O
included O O
relevant O O
patient O O
- O O
defined O O
gastric O O
cancer O O
- O O
specific O O
variables O O
. O O

On O O
both O O
indocyanine O O
green O O
video O O
and O O
fluorescein O O
angiography O O
, O O
hypofluorescent O O
lesions O O
were O O
almost O O
the O O
same O O
size O O
as O O
the O O
light O O
yellow O O
area O O
and O O
the O O
dark O O
yellow O O
center O O
of O O
a O O
placoid O O
lesion O O
. O O

We O O
have O O
measured O O
percentage O O
O3 O O
uptake O O
in O O
30 O O
adult O O
Sprague O O
- O O
Dawley O O
rats O O
exposed O O
, O O
nose O O
only O O
, O O
for O O
1 O O
hr O O
to O O
0 O O
. O O
3 O O
, O O
0 O O
. O O
6 O O
, O O
or O O
1 O O
. O O
0 O O
ppm O O
O3 O O
. O O

The O O
signal O O
- O O
to O O
- O O
noise O O
ratio O O
( O O
SNR O O
) O O
was O O
calculated O O
in O O
the O O
T2 O O
- O O
weighted O O
sequence O O
. O O

Cell O O
rounding O O
was O O
abrogated O O
by O O
expression O O
of O O
either O O
kinase O O
- O O
dead O O
forms O O
of O O
US3 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PK I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
a O O
mutant O O
protein O O
lacking O O
the O O
acidic O O
cluster O O
in O O
the O O
kinase O O
regulatory O O
domain O O
. O O

Three O O
distinct O O
human B B_GENE/B_BIO
HDACs I I_GENE/I_BIO
are O O
homologous O O
to O O
RPD3 B B_GENE
, O O
a O O
yeast O O
transcriptional O O
regulator O O
. O O

The O O
4 O O
- O O
nt O O
sequence O O
of O O
the O O
rotavirus O O
3 O O
' O O
TE O O
represents O O
by O O
far O O
the O O
shortest O O
of O O
any O O
of O O
the O O
sequence O O
enhancers O O
known O O
to O O
stimulate O O
translation O O
. O O

OBJECTIVE O O
: O O
The O O
audiologic O O
presentation O O
of O O
vestibular O O
schwannoma O O
( O O
VS O O
) O O
associated O O
with O O
neurofibromatosis O O
type O O
2 O O
( O O
NF2 O O
) O O
has O O
not O O
been O O
well O O
characterized O O
. O O

Expression O O
of O O
these O O
chemokines O O
is O O
similar O O
in O O
that O O
both O O
require O O
the O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
element I I_GENE
and O O
additional O O
regions O O
such O O
as O O
the O O
CAAT B B_GENE
/ I I_GENE
enhancer I I_GENE
binding I I_GENE
protein I I_GENE
( O O
C B B_GENE/B_LOCATION
/ I I_GENE/I_LOCATION
EBP I I_GENE/I_LOCATION
) O O
element O O
of O O
the O O
IL B B_GENE
- I I_GENE
8 I I_GENE
promoter I I_GENE
. O O

The O O
meaning O O
of O O
hope O O
in O O
health O O
and O O
illness O O
. O O

Assessment O O
of O O
two O O
anion O O
- O O
exchange O O
resins O O
for O O
direct O O
use O O
in O O
the O O
screening O O
method O O
for O O
urinary O O
porphobilinogen O O
. O O

Aggravation O O
of O O
peripheral O O
- O O
blood O O
cytopenia O O
during O O
the O O
first O O
weeks O O
and O O
hypocellularity O O
of O O
bone O O
- O O
marrow O O
aspirates O O
at O O
the O O
end O O
of O O
therapy O O
suggest O O
that O O
low O O
- O O
dose O O
Ara O O
C O O
exerts O O
its O O
main O O
activity O O
by O O
suppression O O
of O O
leukaemic O O
growth O O
, O O
rather O O
than O O
by O O
induction O O
of O O
differentiation O O
in O O
malignant O O
cells O O
. O O

All O O
depressive O O
groups O O
showed O O
improved O O
error O O
measures O O
post O O
- O O
treatment O O
. O O

The O O
best O O
sequences O O
for O O
pelvic O O
study O O
are O O
, O O
in O O
our O O
experience O O
, O O
IR O O
or O O
short O O
TR O O
spin O O
- O O
echo O O
for O O
T1 O O
- O O
weighted O O
images O O
, O O
and O O
spin O O
- O O
echo O O
with O O
1200 O O
TR O O
for O O
T2 O O
images O O
. O O

Cells O O
were O O
co O O
- O O
infected O O
simultaneously O O
with O O
IBV O O
, O O
the O O
recombinant O O
FPV O O
( O O
rFPV O O
) O O
containing O O
the O O
D O O
- O O
RNA O O
sequence O O
and O O
a O O
second O O
rFPV O O
expressing O O
T7 B B_GENE
RNA I I_GENE
polymerase I I_GENE
for O O
the O O
initial O O
expression O O
of O O
the O O
D O O
- O O
RNA O O
transcript O O
, O O
subsequently O O
rescued O O
by O O
helper O O
IBV O O
. O O

Seasonal O O
variation O O
of O O
the O O
cadmium O O
content O O
of O O
Murex O O
trunculus O O
in O O
a O O
non O O
- O O
cadmium O O
polluted O O
environment O O
. O O

These O O
results O O
are O O
discussed O O
in O O
relation O O
to O O
predicted O O
isoform O O
L O O
diversity O O
across O O
human O O
tissues O O
and O O
cells O O
. O O

Doctors O O
given O O
intrathecal O O
methotrexate O O
had O O
headache O O
when O O
20 O O
gauge O O
standard O O
needle O O
was O O
used O O
. O O

The O O
AP B B_GENE
- I I_GENE
1 I I_GENE
recruited O O
by O O
ARF1 B B_GENE
. I I_GENE
GTP I I_GENE
is O O
released O O
from O O
the O O
Golgi O O
membrane O O
by O O
treatment O O
with O O
1 O O
M O O
Tris O O
- O O
HCl O O
( O O
pH O O
7 O O
) O O
or O O
upon O O
reincubation O O
at O O
37 O O
degreesC O O
, O O
whereas O O
AP B B_GENE
- I I_GENE
1 I I_GENE
recruited O O
with O O
GTPgammaS O O
or O O
by O O
a O O
constitutively O O
active O O
point O O
mutant O O
, O O
ARF1 B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
Q71L I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
, O O
remains O O
membrane O O
bound O O
after O O
either O O
treatment O O
. O O

The O O
formation O O
of O O
tumorlike O O
lesions O O
in O O
the O O
cockroach O O
leucophaea O O
maderae O O
after O O
anal O O
blockage O O
. O O

Fine O O
tangled O O
pili O O
expressed O O
by O O
Haemophilus O O
ducreyi O O
are O O
a O O
novel O O
class O O
of O O
pili O O
. O O

We O O
found O O
remarkable O O
differences O O
in O O
the O O
expression O O
patterns O O
of O O
MTB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Zf I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
two O O
other O O
hybridizable O O
mRNAs O O
of O O
5kb O O
and O O
8 O O
. O O
5 O O
kb O O
when O O
human O O
brain O O
and O O
primary O O
brain O O
tumors O O
were O O
compared O O
. O O

Carotid O O
body O O
chemoreceptor O O
activity O O
as O O
recorded O O
from O O
the O O
petrosal O O
ganglion O O
in O O
cats O O
. O O

To O O
explore O O
further O O
the O O
role O O
of O O
the O O
carboxyl O O
- O O
terminal O O
domain O O
in O O
determining O O
the O O
cell O O
cycle O O
function O O
of O O
CDC34 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
constructed O O
and O O
characterized O O
genes O O
encoding O O
chimeric B B_PROTEIN[GENE]/B_DISEASE
E2s I I_PROTEIN[GENE]/I_DISEASE
incorporating O O
sequences O O
from O O
CDC34 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
related O O
but O O
functionally O O
distinct O O
E2 B B_GENE/B_BIO
RAD6 B I_GENE/I_BIO
( O O
UBC2 B B_GENE
) O O
. O O

MAPKK B B_GENE
kinase I I_GENE
/ O O
MEKK B B_GENE
phosphorylates O O
and O O
activates O O
its O O
downstream O O
protein O O
kinase O O
, O O
MAPK B B_GENE
kinase I I_GENE
/ O O
MEK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
in O O
turn O O
activates O O
MAPK B B_GENE
. O O

Kondo O O
effect O O
in O O
Cu O O
( O O
Fe O O
) O O
films O O
. O O

However O O
, O O
ADAR1 B B_GENE
and O O
the O O
related O O
deaminase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ADAR2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
significant O O
expression O O
in O O
all O O
regions O O
of O O
the O O
brain O O
examined O O
, O O
including O O
cortex O O
, O O
hippocampus O O
, O O
olfactory O O
bulb O O
, O O
and O O
striatum O O
, O O
where O O
the O O
5 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HT2CR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pre I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
extensively O O
edited O O
. O O

To O O
investigate O O
its O O
transcription O O
, O O
1 O O
. O O
1 O O
kilobases O O
of O O
the O O
5 O O
' O O
- O O
flanking O O
sequence O O
were O O
fused O O
to O O
a O O
luciferase B B_GENE
reporter I I_GENE
gene I I_GENE
. O O

Influence O O
of O O
copper O O
addition O O
. O O

The O O
0 O O
. O O
018 O O
- O O
inch O O
FloWire O O
provides O O
a O O
high O O
- O O
fidelity O O
continuous O O
Doppler O O
signal O O
. O O

Monosulfates O O
of O O
16 O O
- O O
oxygenated O O
ketonic O O
C19 O O
steroids O O
in O O
adult O O
human O O
urine O O
. O O

Under O O
anaerobic O O
conditions O O
( O O
a O O
50 O O
- O O
day O O
experiment O O
) O O
these O O
organisms O O
degraded O O
15 O O
- O O
18 O O
% O O
of O O
the O O
TEM O O
, O O
20 O O
- O O
25 O O
% O O
of O O
some O O
alkanes O O
, O O
and O O
15 O O
- O O
18 O O
% O O
of O O
selected O O
polycyclic O O
aromatic O O
hydrocarbons O O
. O O

Further O O
, O O
we O O
will O O
review O O
our O O
evaluation O O
of O O
the O O
survival O O
rate O O
and O O
prognostic O O
factors O O
for O O
9 O O
, O O
262 O O
patients O O
from O O
1981 O O
to O O
1996 O O
. O O

MEASURES O O
: O O
SF O O
- O O
36 O O
questionnaires O O
were O O
completed O O
by O O
patients O O
at O O
both O O
initial O O
and O O
discharge O O
examinations O O
. O O

Temporal O O
recruitment O O
of O O
the O O
mSin3A B B_GENE
- O O
histone B B_GENE
deacetylase I I_GENE
corepressor O O
complex O O
to O O
the O O
ETS B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
domain I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
transcription I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
factor I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
Elk B I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
- I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
1 I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

The O O
cluster O O
was O O
mapped O O
to O O
nucleotides O O
- O O
464 O O
to O O
- O O
434 O O
( O O
relative O O
to O O
nucleotide O O
A O O
in O O
the O O
initiation O O
codon O O
) O O
in O O
genomic O O
DNA O O
. O O

In O O
addition O O
, O O
FOP B B_DISEASE/B_PROTEIN[GENE]
- O O
FGFR1 B B_PROTEIN[GENE]/B_MEASURE
- O O
expressing O O
cells O O
show O O
constitutive O O
phosphorylation O O
of O O
the O O
positive O O
regulator O O
of O O
translation O O
p70S6 B B_ENZYME[GENE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I B_ENZYME[GENE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
this O O
phosphorylation O O
is O O
inhibited O O
by O O
PI3 B B_GENE
- I I_GENE
kinase I I_GENE
and O O
mTOR B B_GENE
( O O
mammalian B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rapamycin I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
inhibitors O O
. O O

The O O
authors O O
report O O
two O O
cases O O
of O O
orbital O O
cavernous O O
hemangioma O O
diagnosed O O
by O O
Tc O O
- O O
99m O O
RBC O O
SPECT O O
. O O

Ciprofloxacin O O
levels O O
in O O
serum O O
and O O
blister O O
fluid O O
at O O
the O O
end O O
of O O
the O O
dosing O O
interval O O
( O O
8 O O
h O O
) O O
were O O
superior O O
or O O
almost O O
superior O O
to O O
MICs O O
for O O
sensitive O O
organisms O O
including O O
Pseudomonas O O
aeruginosa O O
. O O

Antibiotic O O
prophylaxis O O
in O O
a O O
surgical O O
setting O O

These O O
changes O O
persisted O O
during O O
the O O
first O O
week O O
. O O

Hyperlipemia O O
has O O
been O O
recently O O
described O O
in O O
children O O
with O O
migraine O O
, O O
being O O
suggested O O
that O O
this O O
alteration O O
is O O
in O O
the O O
base O O
of O O
the O O
disease O O
. O O

The O O
newly O O
identified O O
repressor O O
element O O
is O O
a O O
rare O O
example O O
of O O
a O O
naturally O O
occurring O O
perfect O O
palindromic O O
binding O O
motif O O
for O O
the O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
/ O O
Rel B B_GENE/B_DISEASE
family O O
of O O
transcription O O
factors O O
. O O

Tryptophan O O
induction O O
prevents O O
Rho B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O O
transcription O O
termination O O
in O O
the O O
leader O O
region O O
of O O
the O O
operon O O
. O O

There O O
remains O O
the O O
physiological O O
problem O O
- O O
- O O
one O O
which O O
has O O
always O O
been O O
foremost O O
in O O
Moruzzi O O
' O O
s O O
thinking O O
about O O
the O O
intrinsic O O
regulation O O
of O O
brain O O
activity O O
- O O
- O O
of O O
how O O
the O O
separate O O
actions O O
of O O
the O O
different O O
arousal O O
systems O O
are O O
brought O O
together O O
into O O
a O O
functional O O
whole O O
. O O

The O O
nramp2 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
is O O
comprised O O
of O O
17 O O
exons O O
and O O
spans O O
more O O
than O O
36 O O
kb O O
. O O

The O O
immune O O
response O O
seems O O
to O O
be O O
partially O O
responsible O O
for O O
both O O
protection O O
and O O
the O O
destructive O O
consequences O O
of O O
chlamydial O O
infection O O
. O O

Results O O
: O O
hepatic O O
hydatidosis O O
: O O
177 O O
patients O O
. O O

The O O
majority O O
of O O
putative O O
TSC2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O O
found O O
in O O
sporadic O O
rather O O
than O O
TSC2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
linked O O
families O O
. O O

Murine B B_GENE/B_LOCATION
ELAM I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
is O O
encoded O O
by O O
a O O
single O O
- O O
copy O O
gene O O
, O O
spanning O O
about O O
13 O O
kb O O
, O O
which O O
is O O
structurally O O
organized O O
into O O
14 O O
exons O O
and O O
13 O O
introns O O
; O O
very O O
similar O O
to O O
that O O
of O O
its O O
human O O
counterpart O O
. O O

A O O
biopsy O O
specimen O O
taken O O
from O O
the O O
frontal O O
branch O O
of O O
the O O
right O O
superficial O O
artery O O
revealed O O
segmental O O
intimal O O
thickening O O
consistent O O
with O O
intimal O O
fibroplasia O O
type O O
FMD O O
upon O O
histological O O
examination O O
. O O

Thus O O
in O O
this O O
study O O
we O O
used O O
in O O
vitro O O
methods O O
to O O
directly O O
evaluate O O
whether O O
isolated O O
human O O
saphenous O O
vein O O
segments O O
respond O O
to O O
vasoconstrictor O O
agents O O
at O O
arterial O O
pressure O O
levels O O
. O O

We O O
found O O
that O O
the O O
PRP20 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
is O O
identical O O
to O O
the O O
yeast B B_GENE/B_BIO
SRM1 I I_GENE/I_BIO
gene I I_GENE/I_BIO
( O O
Clark O O
and O O
Sprague O O
1989 O O
) O O
. O O

Basal O O
JNK B B_GENE
MAPK I I_GENE
kinase I I_GENE
activity O O
was O O
also O O
specifically O O
induced O O
by O O
deltaEGFR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
which O O
correlated O O
with O O
increased O O
phosphorylation O O
of O O
a O O
54 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kDa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
JNK2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
observed O O
in O O
deltaEGFR B B_GENE
- O O
containing O O
cells O O
. O O

PMA O O
produced O O
similar O O
results O O
, O O
but O O
the O O
induction O O
of O O
the O O
WT B B_GENE
AP1 I I_GENE
c B I_GENE
- I I_GENE
jun I I_GENE
promoter O O
- O O
CAT O O
plasmid O O
was O O
smaller O O
. O O

The O O
determination O O
of O O
antithrombin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AT B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
its O O
clinical O O
significance O O

One O O
ORF O O
extends O O
from O O
nucleotides O O
415 O O
to O O
1620 O O
, O O
encodes O O
402 O O
amino O O
acids O O
, O O
and O O
is O O
preceded O O
by O O
a O O
ribosome O O
- O O
binding O O
site O O
. O O

Glucose O O
consumption O O
of O O
the O O
human O O
brain O O
under O O
the O O
influence O O
of O O
intravenous O O
infusions O O
of O O
glucose O O
, O O
glucagon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
glucose O O
- O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE

D O O
. O O
, O O
Hughes O O
, O O
F O O
. O O

Deletion O O
of O O
CDC5 B B_GENE
was O O
lethal O O
and O O
resulted O O
in O O
a O O
dumbbell O O
- O O
shaped O O
terminal O O
morphology O O
, O O
with O O
the O O
nuclei O O
almost O O
divided O O
but O O
still O O
connected O O
. O O

These O O
cDNAs O O
were O O
found O O
to O O
be O O
derived O O
from O O
the O O
3 O O
" O O
- O O
untranslated O O
region O O
( O O
3 O O
" O O
- O O
UTR O O
) O O
of O O
the O O
methyl B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CpG I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MeCP2 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

A O O
) O O
During O O
O2 O O
- O O
ischemia O O
both O O
extracellular O O
[ O O
K O O
+ O O
] O O
and O O
change O O
of O O
pH O O
in O O
the O O
subepicardium O O
are O O
significantly O O
less O O
than O O
in O O
the O O
midmyocardium O O
. O O

The O O
generation O O
of O O
dorso O O
- O O
ventral O O
polarity O O
during O O
Drosophila O O
embryogenesis O O
is O O
regulated O O
by O O
the O O
action O O
of O O
12 O O
maternally O O
expressed O O
gene O O
products O O
, O O
the O O
dorsal B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
group I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Ultimobranchial O O
body O O
and O O
parathyroid O O
glands O O
of O O
the O O
freshwater O O
snake O O
Natrix O O
piscator O O
in O O
response O O
to O O
vitamin O O
D3 O O
administration O O
. O O

These O O
observations O O
suggest O O
that O O
the O O
AF O O
- O O
1 O O
region O O
of O O
PPARalpha B B_GENE
is O O
partially O O
silenced O O
by O O
corepressor O O
proteins O O
, O O
which O O
might O O
interact O O
in O O
a O O
phosphorylation O O
- O O
dependent O O
manner O O
. O O

Two O O
authors O O
, O O
two O O
journal O O
titles O O
, O O
two O O
drug O O
names O O
, O O
and O O
two O O
topics O O
of O O
a O O
general O O
medical O O
nature O O
were O O
retrieved O O
under O O
identical O O
circumstances O O
and O O
conditions O O
on O O
the O O
hosts O O
DATA O O
- O O
STAR O O
, O O
DIALOG O O
, O O
DIMDI O O
, O O
and O O
STN O O
. O O

However O O
, O O
in O O
a O O
variation O O
of O O
this O O
assay O O
in O O
which O O
the O O
protease O O
is O O
omitted O O
, O O
the O O
mutant O O
enzymes O O
exhibited O O
substantial O O
levels O O
of O O
prolyl B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
isomerase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
( O O
5 O O
- O O
20 O O
% O O
of O O
wild O O
- O O
type O O
) O O
, O O
revealing O O
that O O
these O O
mutations O O
confer O O
sensitivity O O
to O O
protease O O
digestion O O
and O O
that O O
the O O
classic O O
in O O
vitro O O
assay O O
for O O
prolyl B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
isomerase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
may O O
be O O
misleading O O
. O O

Nucleotide O O
sequence O O
of O O
the O O
gag B B_GENE
gene I I_GENE
and O O
gag B B_GENE/B_DISEASE
- O O
pol B B_GENE/B_DISEASE
junction O O
of O O
feline O O
leukemia O O
virus O O
. O O

Clinical O O
trial O O
endpoints O O
based O O
on O O
magnitude O O
of O O
reduction O O
in O O
HIV O O
- O O
1 O O
RNA O O
levels O O
provide O O
an O O
important O O
complement O O
to O O
endpoints O O
based O O
on O O
percentage O O
of O O
patients O O
achieving O O
complete O O
virologic O O
suppression O O
. O O

It O O
also O O
describes O O
the O O
preliminary O O
results O O
of O O
a O O
Phase O O
II O O
trial O O
going O O
on O O
at O O
the O O
Central O O
Institute O O
for O O
Tumors O O
in O O
Zagreb O O
, O O
using O O
a O O
combination O O
of O O
cis O O
- O O
DDP O O
, O O
5 O O
- O O
fluorouracil O O
and O O
vincristine O O
. O O

On O O
the O O
basis O O
of O O
the O O
physical O O
interactions O O
between O O
Sxl B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Snf B B_GENE/B_BACTERIUM[BIO]
, O O
we O O
present O O
a O O
model O O
for O O
Sxl B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
splicing O O
regulation O O
. O O

The O O
average O O
mean O O
difference O O
compared O O
with O O
the O O
low O O
and O O
the O O
intermediate O O
calcium O O
group O O
was O O
11 O O
% O O
for O O
the O O
femoral O O
neck O O
, O O
8 O O
- O O
11 O O
% O O
for O O
the O O
lumbar O O
spine O O
and O O
5 O O
- O O
6 O O
% O O
for O O
total O O
body O O
BMDs O O
. O O

We O O
cloned O O
the O O
BamHI B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
F I I_GENE/I_LOCATION
fragment I I_GENE/I_LOCATION
from O O
the O O
left O O
end O O
of O O
Ad4 O O
in O O
pUC13 O O
- O O
1 O O
between O O
the O O
SalI B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
BamHI B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
order O O
to O O
carry O O
out O O
the O O
structural O O
analysis O O
of O O
the O O
E1A B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
region I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Ad4 I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

We O O
reviewed O O
81 O O
patients O O
with O O
dementia O O
and O O
autopsy O O
findings O O
of O O
Alzheimer O O
' O O
s O O
disease O O
( O O
AD O O
) O O
to O O
identify O O
patients O O
with O O
seizures O O
or O O
myoclonus O O
after O O
onset O O
of O O
dementia O O
. O O

3 O O
. O O

In O O
both O O
RAW O O
cells O O
and O O
the O O
microglia O O
cell O O
line O O
EOC20 O O
, O O
two O O
IFN B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
activated O O
transcription O O
factors O O
, O O
STAT B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1alpha I I_GENE/I_DISEASE
and O O
IRF B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
, O O
bind O O
the O O
GAS B B_GENE/B_BACTERIUM[BIO]
and O O
IRF B B_GENE
elements I I_GENE
, O O
respectively O O
. O O

Thermal O O
changes O O
of O O
the O O
bovine O O
uterus O O
following O O
administration O O
of O O
estradiol O O
- O O
17beta O O
. O O

The O O
starting O O
dose O O
was O O
8 O O
mg O O
/ O O
m2 O O
administered O O
intravenously O O
( O O
IV O O
) O O
as O O
a O O
short O O
infusion O O
daily O O
for O O
5 O O
days O O
, O O
repeated O O
every O O
3 O O
weeks O O
with O O
dose O O
adjustments O O
depending O O
on O O
patient O O
tolerance O O
. O O

In O O
agreement O O
with O O
other O O
authors O O
, O O
we O O
recommend O O
the O O
procedure O O
as O O
a O O
safe O O
one O O
, O O
providing O O
satisfactory O O
results O O
. O O

After O O
inhibition O O
of O O
monoamine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
pargyline O O
( O O
10 O O
mg O O
/ O O
kg O O
. O O
i O O
. O O
v O O
. O O
) O O
, O O
the O O
effects O O
of O O
tyramine O O
( O O
1000 O O
micrograms O O
) O O
injected O O
into O O
the O O
hepatic O O
artery O O
were O O
potentiated O O
. O O

Helenalin O O
triggers O O
a O O
CD95 B B_GENE
death I I_GENE
receptor I I_GENE
- O O
independent O O
apoptosis O O
that O O
is O O
not O O
affected O O
by O O
overexpression O O
of O O
Bcl B B_GENE
- I I_GENE
x I I_GENE
( I I_GENE
L I I_GENE
) I I_GENE
or O O
Bcl B B_GENE
- I I_GENE
2 I I_GENE
. O O

Of O O
the O O
47 O O
women O O
with O O
AGCUS O O
, O O
16 O O
had O O
intraepithelial O O
or O O
invasive O O
neoplasms O O
( O O
34 O O
% O O
; O O
95 O O
% O O
confidence O O
interval O O
, O O
21 O O
- O O
49 O O
% O O
) O O
, O O
including O O
9 O O
low O O
or O O
high O O
grade O O
squamous O O
intraepithelial O O
lesions O O
, O O
1 O O
adenocarcinoma O O
in O O
situ O O
of O O
the O O
cervix O O
, O O
3 O O
adenocarcinomas O O
of O O
the O O
cervix O O
, O O
2 O O
adenocarcinomas O O
of O O
the O O
endometrium O O
and O O
1 O O
adenoid O O
basal O O
cell O O
carcinoma O O
of O O
the O O
cervix O O
. O O

The O O
DF3 B B_GENE/B_LOCATION
/ O O
MUC1 B B_GENE/B_MEASURE
gene O O
encodes O O
a O O
high B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecular I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
weight I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mucin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycoprotein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
is O O
overexpressed O O
at O O
the O O
transcriptional O O
level O O
in O O
the O O
majority O O
of O O
human O O
breast O O
cancers O O
. O O

The O O
organization O O
of O O
the O O
MBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
very O O
similar O O
to O O
the O O
arrangement O O
of O O
the O O
gene O O
encoding O O
the O O
highly O O
homologous B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pulmonary I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
surfactant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
apoprotein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
although O O
one O O
of O O
the O O
intron O O
positions O O
is O O
shifted O O
by O O
a O O
single O O
amino O O
acid O O
. O O

Hip O O
fracture O O
mortality O O
and O O
prospective O O
payment O O
system O O
. O O

Although O O
hSSTR5 B B_GENE/B_PERSON
displays O O
approximately O O
75 O O
% O O
sequence O O
identity O O
with O O
rat B B_GENE
SSTR5 I I_GENE
, O O
the O O
two O O
receptors O O
display O O
significantly O O
different O O
pharmacological O O
profiles O O
, O O
especially O O
with O O
respect O O
to O O
their O O
binding O O
affinities O O
for O O
the O O
SST B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analogue O O
SMS O O
201 O O
- O O
995 O O
. O O

A O O
significant O O
and O O
specific O O
reduction O O
in O O
binaural O O
peak O O
amplitude O O
and O O
area O O
of O O
the O O
echo O O
- O O
evoked O O
middle O O
- O O
latency O O
component O O
Pa O O
was O O
observed O O
. O O

EMBO O O
( O O
Eur O O
. O O

Arg O O
- O O
130 O O
, O O
Gly O O
- O O
132 O O
and O O
Lys O O
- O O
167 O O
are O O
conserved O O
in O O
all O O
members O O
of O O
the O O
type B B_GENE/B_BIO
IB I I_GENE/I_BIO
topoisomerase I I_GENE/I_BIO
family I I_GENE/I_BIO
. O O

2 O O
. O O

Prevalence O O
of O O
use O O
, O O
claims O O
volume O O
, O O
and O O
expenditures O O
were O O
compared O O
for O O
cisapride O O
, O O
proton O O
pump O O
inhibitors O O
, O O
histamine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonists O O
, O O
and O O
the O O
prokinetic O O
agent O O
metoclopramide O O
during O O
these O O
periods O O
. O O

Primer O O
extension O O
experiments O O
using O O
dbcAMP O O
- O O
differentiated O O
U937 O O
RNA O O
indicated O O
a O O
single O O
transcriptional O O
initiation O O
site O O
. O O

In O O
contrast O O
, O O
group O O
II O O
showed O O
a O O
significant O O
improvement O O
in O O
peak O O
VO2 O O
with O O
rate O O
adaptive O O
AV O O
delay O O
compared O O
to O O
fixed O O
AV O O
delay O O
programming O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

Effect O O
of O O
family O O
visits O O
on O O
the O O
blood O O
pressure O O
and O O
heart O O
rate O O
of O O
patients O O
in O O
the O O
coronary O O
- O O
care O O
unit O O
. O O

Wild O O
type O O
MEKK1 B B_GENE
enhances O O
promoter O O
activity O O
and O O
the O O
activity O O
can O O
be O O
inhibited O O
by O O
dominant O O
negative O O
MEKK1 B B_GENE
, O O
MEK1 B B_GENE
, O O
MEK7 B B_GENE
, O O
MEK3 B B_GENE
, O O
p38 B B_GENE/B_LOCATION
/ O O
RK B B_MEASURE/B_GENE
, O O
and O O
c B B_GENE
- I I_GENE
Jun I I_GENE
. O O

250 O O
, O O
302 O O
- O O
311 O O
] O O
. O O

The O O
studies O O
permit O O
considering O O
the O O
detected O O
shifts O O
in O O
the O O
immunity O O
system O O
an O O
important O O
component O O
of O O
the O O
pathogenesis O O
of O O
chronic O O
nontumorous O O
diseases O O
of O O
the O O
parotid O O
glands O O
. O O

Coexistence O O
of O O
Turner O O
' O O
s O O
syndrome O O
and O O
schizophrenia O O

An O O
scrR B B_GENE
promoter I I_GENE
fragment I I_GENE
, O O
which O O
dose O O
not O O
contain O O
a O O
sequence O O
resembling O O
OB B B_GENE/B_DISEASE
, O O
was O O
not O O
shifted O O
by O O
the O O
fusion O O
protein O O
. O O

Although O O
several O O
other O O
signal O O
transduction O O
molecules O O
also O O
contain O O
tandemly O O
occurring O O
SH3 B B_LOCATION/B_GENE
and O O
SH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
function O O
of O O
these O O
closely O O
spaced O O
domains O O
is O O
not O O
well O O
understood O O
. O O

CONCLUSIONS O O
: O O
In O O
the O O
majority O O
of O O
patients O O
with O O
severe O O
ulcerative O O
colitis O O
, O O
circulating O O
concentrations O O
of O O
NOX O O
are O O
increased O O
at O O
presentation O O
and O O
fall O O
promptly O O
during O O
parenteral O O
steroid O O
therapy O O
, O O
irrespective O O
of O O
clinical O O
outcome O O
. O O

The O O
duration O O
of O O
naloxone O O
appears O O
to O O
be O O
dose O O
- O O
related O O
, O O
statistically O O
significant O O
up O O
to O O
approximately O O
1 O O
. O O
5 O O
hr O O
. O O

But O O
if O O
one O O
equalizes O O
the O O
upper O O
limits O O
of O O
normal O O
for O O
both O O
markers O O
to O O
a O O
common O O
95 O O
% O O
specificity O O
, O O
the O O
tumour O O
- O O
indicating O O
sensitivity O O
of O O
CA B B_GENE/B_MEASURE
19 I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
9 I I_GENE/I_MEASURE
clearly O O
surpasses O O
that O O
of O O
CA B B_GENE/B_LOCATION
50 I I_GENE/I_LOCATION
. O O

Genomic O O
Southern O O
analysis O O
reveals O O
10 O O
to O O
15 O O
hybridising O O
fragments O O
, O O
suggesting O O
that O O
maize O O
contains O O
a O O
small O O
gene O O
family O O
. O O

Custom O O
- O O
made O O
orthoses O O
play O O
an O O
invaluable O O
role O O
in O O
achieving O O
a O O
wide O O
range O O
of O O
therapeutic O O
goals O O
: O O
improving O O
function O O
and O O
pinch O O
, O O
stabilizing O O
individual O O
joints O O
, O O
preventing O O
positional O O
contractures O O
, O O
protecting O O
joints O O
from O O
trauma O O
, O O
stretching O O
the O O
intrinsic O O
muscles O O
, O O
correcting O O
joint O O
- O O
and O O
soft O O
- O O
tissue O O
contractures O O
, O O
and O O
controlling O O
inflammation O O
. O O

Is O O
exposure O O
to O O
a O O
patient O O
with O O
Crohn O O
' O O
s O O
disease O O
an O O
environmental O O
factor O O
for O O
developing O O
the O O
disease O O
. O O

The O O
ZAG1 B B_GENE
protein I I_GENE
from O O
in O O
vitro O O
translations O O
binds O O
to O O
a O O
consensus O O
target O O
site O O
that O O
is O O
recognized O O
by O O
the O O
AG B B_GENE
protein I I_GENE
. O O

Pituitary O O
thyrotropic O O
adenoma O O
associated O O
with O O
congenital O O
hypothyroidism O O
. O O

This O O
region O O
was O O
unfavourable O O
, O O
due O O
to O O
malaria O O
in O O
the O O
past O O
. O O

Indeed O O
, O O
after O O
a O O
single O O
oral O O
dose O O
, O O
the O O
role O O
of O O
the O O
mu B B_GENE
- I I_GENE
receptor I I_GENE
agonist O O
component O O
of O O
the O O
antinociceptive O O
effect O O
of O O
tramadol O O
appears O O
to O O
be O O
minor O O
, O O
with O O
most O O
of O O
the O O
analgesic O O
effect O O
being O O
attributable O O
to O O
nonopioid O O
properties O O
of O O
the O O
parent O O
compound O O
. O O

Somatic O O
and O O
visceral O O
inputs O O
to O O
the O O
thoracic O O
spinal O O
cord O O
of O O
the O O
cat O O
: O O
effects O O
of O O
noxious O O
stimulation O O
of O O
the O O
biliary O O
system O O
. O O

We O O
have O O
produced O O
the O O
Ure2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
high O O
yield O O
in O O
Escherichia O O
coli O O
from O O
a O O
synthetic O O
gene O O
. O O

Transfection O O
of O O
both O O
Calu O O
- O O
6 O O
and O O
JEG O O
- O O
3 O O
cells O O
with O O
a O O
PKA B B_GENE
expression O O
vector O O
resulted O O
in O O
a O O
10 O O
- O O
fold O O
induction O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
renin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional O O
activity O O
in O O
constructs O O
containing O O
the O O
native O O
or O O
consensus O O
CRE O O
and O O
5 O O
- O O
fold O O
activation O O
in O O
a O O
construct O O
containing O O
a O O
nonfunctional O O
CRE O O
. O O

We O O
undertook O O
this O O
study O O
to O O
examine O O
the O O
relationship O O
between O O
systemic O O
oxygen O O
delivery O O
( O O
DO2 O O
) O O
and O O
tissue O O
oxygen O O
tension O O
( O O
TPO2 O O
) O O
in O O
hypovolemic O O
shock O O
. O O

White O O
female O O
cases O O
were O O
more O O
likely O O
to O O
have O O
worked O O
as O O
registered O O
nurses O O
than O O
were O O
the O O
controls O O
( O O
OR O O
= O O
1 O O
. O O
9 O O
, O O
95 O O
% O O
CI O O
= O O
1 O O
. O O
0 O O
- O O
3 O O
. O O
5 O O
) O O
. O O

Immunologic O O
tolerance O O
in O O
rats O O
during O O
13 O O
weeks O O
of O O
inhalation O O
exposure O O
to O O
trimellitic O O
anhydride O O
. O O

They O O
cause O O
temporary O O
disability O O
, O O
invalidity O O
and O O
mortality O O
of O O
a O O
great O O
part O O
of O O
the O O
productive O O
population O O
, O O
significantly O O
damaging O O
the O O
economic O O
status O O
of O O
the O O
country O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
The O O
QTd O O
and O O
JTd O O
intervals O O
in O O
39 O O
children O O
with O O
long O O
QT O O
syndrome O O
were O O
compared O O
to O O
those O O
of O O
50 O O
normal O O
age O O
- O O
matched O O
children O O
. O O

Both O O
parameters O O
were O O
determined O O
in O O
an O O
individual O O
eye O O
by O O
applying O O
the O O
dye O O
first O O
by O O
iontophoresis O O
and O O
then O O
by O O
intravitreal O O
injection O O
, O O
which O O
allows O O
the O O
influence O O
of O O
fluorescein O O
glucuronide O O
on O O
the O O
fluorophotometric O O
measurements O O
to O O
be O O
excluded O O
. O O

Organization O O
of O O
exons O O
suggests O O
that O O
, O O
similar O O
to O O
the O O
human B B_GENE/B_TIME[MEASURE]
VEGF I I_GENE/I_TIME[MEASURE]
gene I I_GENE/I_TIME[MEASURE]
, O O
alternative O O
splicing O O
generates O O
the O O
120 O O
- O O
, O O
164 O O
- O O
, O O
and O O
188 O O
- O O
amino O O
acid O O
isoforms O O
, O O
but O O
does O O
not O O
predict O O
a O O
fourth O O
VEGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isoform I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
corresponding O O
to O O
human B B_GENE/B_PERSON
VEGF206 I I_GENE/I_PERSON
. O O

Electron O O
microscopy O O
of O O
pH O O
7 O O
. O O
5 O O
- O O
treated O O
TMV O O
particles O O
incubated O O
in O O
SPN B B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
- O O
treated O O
wheatgerm O O
extract O O
or O O
rabbit O O
reticulocyte O O
lysate O O
, O O
showed O O
that O O
approximately O O
10 O O
% O O
of O O
virions O O
complexed O O
with O O
one O O
ribosome O O
and O O
approximately O O
10 O O
% O O
with O O
two O O
bound O O
ribosomes O O
, O O
confirming O O
that O O
omega O O
at O O
least O O
had O O
been O O
uncoated O O
. O O

Postheparin O O
lipoprotein B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lipase I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
measured O O
using O O
fat O O
emulsion O O
as O O
substrate O O
, O O
also O O
was O O
significantly O O
greater O O
in O O
female O O
rats O O
compared O O
with O O
males O O
. O O

The O O
authors O O
report O O
a O O
case O O
of O O
a O O
painful O O
wrist O O
related O O
to O O
a O O
" O O
Manieux O O
muscle O O
" O O
of O O
the O O
dorsal O O
aspect O O
of O O
the O O
hand O O
. O O

The O O
response O O
to O O
nitroglycerin O O
, O O
however O O
, O O
remained O O
intact O O
regardless O O
of O O
initial O O
reperfusion O O
pressure O O
. O O

Deletion O O
analysis O O
revealed O O
that O O
only O O
the O O
TM O O
domain O O
of O O
E2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
required O O
for O O
Golgi O O
targeting O O
. O O

In O O
addition O O
, O O
putative O O
binding O O
sites O O
for O O
SH3 B B_LOCATION/B_GENE
and O O
SH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
present O O
in O O
the O O
amino O O
- O O
terminal O O
half O O
of O O
the O O
molecule O O
. O O

All O O
rights O O
reserved O O
. O O

One O O
new O O
ORF O O
, O O
YBR0224 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
was O O
detected O O
, O O
coding O O
for O O
a O O
protein O O
with O O
918 O O
amino O O
acids O O
. O O

Bone O O
scintigraphy O O
is O O
an O O
excellent O O
screening O O
test O O
for O O
bone O O
lesions O O
and O O
Ga O O
- O O
67 O O
scintigraphy O O
is O O
a O O
useful O O
tool O O
for O O
detecting O O
inflammatory O O
lesions O O
. O O

Spontaneous O O
fracture O O
of O O
the O O
tarsal O O
bone O O
in O O
2 O O
cases O O
of O O
leprosy O O

They O O
are O O
transduced O O
through O O
TM O O
to O O
the O O
cytoplasmic O O
portion O O
( O O
cytoloops O O
and O O
the O O
C O O
- O O
terminal O O
tail O O
) O O
of O O
the O O
receptor O O
and O O
then O O
, O O
transferred O O
to O O
cytoplasmic O O
signaling O O
molecules O O
, O O
such O O
as O O
G B B_GENE
protein I I_GENE
. O O

Serum B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alkaline I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
creatine B B_ENZYME[GENE]
kinase I I_ENZYME[GENE]
activities O O
were O O
significantly O O
increased O O
in O O
the O O
A O O
praelongus O O
- O O
fed O O
pigs O O
and O O
significantly O O
decreased O O
in O O
Na2SeO4 O O
- O O
fed O O
pigs O O
. O O

This O O
group O O
showed O O
the O O
presence O O
of O O
bacteria O O
infiltrated O O
at O O
the O O
dentinal O O
tubules O O
coronally O O
and O O
into O O
the O O
root O O
canals O O
. O O

Seven O O
Zebu O O
cattle O O
were O O
also O O
exposed O O
to O O
challenge O O
at O O
the O O
same O O
time O O
. O O

The O O
effect O O
on O O
kidney O O
length O O
was O O
considerably O O
prolonged O O
compared O O
with O O
the O O
vascular O O
effect O O
. O O

Diabetic O O
osteopenia O O
, O O
a O O
known O O
chronic O O
complication O O
of O O
diabetes O O
, O O
has O O
been O O
demonstrated O O
with O O
alterations O O
in O O
the O O
calcium O O
- O O
vitamin O O
D O O
endocrine O O
system O O
. O O

An O O
in O O
vitro O O
Raf B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
assay O O
, O O
however O O
, O O
failed O O
to O O
detect O O
LPS O O
- O O
induced O O
Raf B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
in O O
RAW O O
264 O O
. O O
7 O O
cells O O
, O O
suggesting O O
that O O
in O O
RAW O O
264 O O
. O O
7 O O
cells O O
, O O
Raf B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
not O O
an O O
activating O O
component O O
of O O
the O O
LPS O O
signaling O O
pathway O O
regulating O O
MAPK B B_GENE
activity O O
or O O
sIL B B_GENE
- I I_GENE
1Ra I I_GENE
promoter I I_GENE
activity O O
. O O

Phosphorylation O O
of O O
the O O
ras B B_GENE/B_BIO
GTPase B I_GENE/I_BIO
- I I_GENE/I_BIO
activating I I_GENE/I_BIO
protein I I_GENE/I_BIO
( O O
GAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
by O O
the O O
p93c B B_ENZYME[GENE]
- I I_ENZYME[GENE]
fes I I_ENZYME[GENE]
protein B I_ENZYME[GENE]
- I I_ENZYME[GENE]
tyrosine I I_ENZYME[GENE]
kinase I I_ENZYME[GENE]
in O O
vitro O O
and O O
formation O O
of O O
GAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
fes B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
complexes O O
via O O
an O O
SH2 B B_GENE/B_DISEASE
domain O O
- O O
dependent O O
mechanism O O
. O O

Gingival O O
retraction O O
for O O
class O O
V O O
restorations O O
. O O

U O O
. O O
S O O
. O O
A O O
. O O

RET B B_GENE/B_LOCATION
/ O O
PTC B B_LOCATION/B_GENE
oncogenes O O
, O O
generated O O
by O O
chromosomal O O
rearrangements O O
in O O
papillary O O
thyroid O O
carcinomas O O
, O O
are O O
constitutively O O
activated O O
versions O O
of O O
proto B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
RET I I_GENE/I_LOCATION
, O O
a O O
gene O O
coding O O
for O O
a O O
receptor B B_GENE
- I I_GENE
type I I_GENE
tyrosine I I_GENE
kinase I I_GENE
( O O
TK B B_GENE/B_DISEASE
) O O
whose O O
ligand O O
is O O
still O O
unknown O O
. O O

PCC O O
6803 O O
mutant O O
impaired O O
in O O
cytochrome B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ENZYME[GENE]
c I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_ENZYME[GENE]
maturation O O
. O O

STUDY O O
OBJECTIVE O O
: O O
to O O
characterize O O
gas O O
exchange O O
and O O
cardiopulmonary O O
performance O O
during O O
maximal O O
progressive O O
arm O O
crank O O
exercise O O
. O O

The O O
goal O O
of O O
this O O
investigation O O
was O O
to O O
determine O O
whether O O
BMIPP O O
uptake O O
can O O
be O O
used O O
to O O
differentiate O O
viable O O
myocardium O O
from O O
scar O O
tissue O O
soon O O
after O O
coronary O O
thrombolysis O O
for O O
acute O O
myocardial O O
infarction O O
. O O

There O O
are O O
three O O
types O O
of O O
problems O O
: O O
problems O O
arising O O
before O O
the O O
drug O O
enters O O
the O O
body O O
( O O
solubilization O O
, O O
stabilization O O
and O O
improved O O
acceptability O O
) O O
; O O
problems O O
associated O O
with O O
the O O
penetration O O
and O O
fate O O
of O O
the O O
drug O O
in O O
the O O
body O O
( O O
absorption O O
, O O
barrier O O
crossing O O
, O O
duration O O
of O O
action O O
) O O
; O O
problems O O
relating O O
to O O
the O O
therapeutic O O
target O O
( O O
selective O O
local O O
delivery O O
) O O
. O O

The O O
cumulative O O
experience O O
in O O
liver O O
transplantation O O
since O O
the O O
introduction O O
of O O
cyclosporine O O
A O O
has O O
confirmed O O
its O O
efficacy O O
in O O
the O O
treatment O O
of O O
diverse O O
liver O O
diseases O O
in O O
children O O
and O O
adults O O
. O O

Northern O O
blot O O
analysis O O
of O O
liver O O
, O O
muscle O O
, O O
fat O O
, O O
and O O
pituitary O O
RNA O O
from O O
normal O O
( O O
DwDw O O
) O O
chickens O O
shows O O
a O O
major O O
transcript O O
of O O
4 O O
. O O
3 O O
kilobases O O
( O O
kb O O
) O O
and O O
three O O
minor O O
transcripts O O
( O O
0 O O
. O O
8 O O
, O O
1 O O
. O O
7 O O
, O O
and O O
3 O O
. O O
2 O O
kb O O
) O O
, O O
which O O
correspond O O
to O O
the O O
cGHR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Copyright O O
1999 O O
Academic O O
Press O O
. O O

Despite O O
a O O
lowering O O
of O O
her O O
plasma O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O O
during O O
therapy O O
with O O
valproic O O
acid O O
, O O
the O O
patient O O
' O O
s O O
tumour O O
showed O O
no O O
evidence O O
of O O
regression O O
while O O
she O O
was O O
taking O O
the O O
drug O O
. O O

The O O
Htf9 B B_GENE
- I I_GENE
a I I_GENE
gene I I_GENE
encodes O O
the O O
RanBP1 B B_GENE
protein I I_GENE
, O O
a O O
major O O
partner O O
of O O
the O O
Ran B B_ENZYME[GENE]/B_LOCATION
GTPase I I_ENZYME[GENE]/I_LOCATION
. O O

STUDY O O
DESIGN O O
: O O
Retrospective O O
review O O
. O O

Sequence O O
divergence O O
of O O
approximately O O
16 O O
% O O
reduced O O
transformation O O
frequencies O O
by O O
at O O
least O O
10 O O
- O O
fold O O
. O O

Our O O
studies O O
suggest O O
that O O
the O O
helicase B B_GENE/B_DISEASE
assembly O O
protein O O
is O O
responsible O O
for O O
loading O O
T4 B B_GENE
gene I I_GENE
41 I I_GENE
helicase I I_GENE
specifically O O
at O O
replication O O
forks O O
, O O
and O O
that O O
its O O
binding O O
sites O O
for O O
each O O
arm O O
must O O
hold O O
more O O
than O O
six O O
, O O
but O O
not O O
more O O
than O O
12 O O
nucleotides O O
. O O

During O O
the O O
1st O O
week O O
of O O
treatment O O
all O O
subjects O O
received O O
either O O
mianserin O O
30 O O
mg O O
or O O
clomipramine O O
75 O O
mg O O
once O O
daily O O
. O O

CBD O O
exploration O O
was O O
avoided O O
in O O
7 O O
patients O O
with O O
normal O O
POC O O
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
SHBG I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proximal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
analyzed O O
by O O
DNase B B_GENE
I I I_GENE
footprinting O O
, O O
and O O
the O O
functional O O
significance O O
of O O
6 O O
footprinted O O
regions O O
( O O
FP1 O O
- O O
FP6 O O
) O O
within O O
the O O
proximal O O
promoter O O
was O O
studied O O
in O O
human O O
HepG2 O O
hepatoblastoma O O
cells O O
. O O

We O O
exposed O O
Dorper O O
- O O
cross O O
ewes O O
at O O
approximately O O
120 O O
- O O
135 O O
days O O
of O O
gestation O O
to O O
a O O
hot O O
( O O
40 O O
degrees O O
C O O
, O O
60 O O
% O O
relative O O
humidity O O
) O O
and O O
a O O
cold O O
( O O
4 O O
degrees O O
C O O
, O O
90 O O
% O O
relative O O
humidity O O
) O O
environment O O
and O O
to O O
treadmill O O
exercise O O
( O O
2 O O
. O O
1 O O
km O O
/ O O
h O O
, O O
5 O O
degrees O O
gradient O O
) O O
and O O
measured O O
fetal O O
lamb O O
and O O
ewe O O
body O O
temperatures O O
using O O
previously O O
implanted O O
abdominal O O
radiotelemeters O O
. O O

Previously O O
identified O O
mutations O O
in O O
this O O
variant O O
have O O
been O O
within O O
or O O
close O O
to O O
the O O
coding O O
region O O
of O O
exon O O
1 O O
of O O
the O O
HMBS B B_GENE/B_DISEASE
gene I I_GENE/I_DISEASE
, O O
the O O
only O O
exon O O
that O O
is O O
expressed O O
solely O O
in O O
the O O
ubiquitous O O
isoform O O
. O O

As O O
an O O
approach O O
to O O
the O O
determination O O
of O O
structure O O
- O O
function O O
relationships O O
in O O
the O O
PRP4 B B_GENE/B_BIO
protein I I_GENE/I_BIO
, O O
we O O
have O O
isolated O O
more O O
than O O
fifty O O
new O O
alleles O O
of O O
the O O
PRP4 B B_GENE
gene I I_GENE
through O O
random O O
and O O
site O O
- O O
directed O O
mutagenesis O O
, O O
and O O
have O O
analyzed O O
the O O
phenotypes O O
of O O
many O O
of O O
them O O
. O O

Over O O
a O O
period O O
of O O
five O O
training O O
sessions O O
( O O
2 O O
. O O
5 O O
days O O
) O O
, O O
the O O
animals O O
learned O O
not O O
to O O
breathe O O
, O O
and O O
the O O
number O O
of O O
stimuli O O
received O O
in O O
the O O
fifth O O
session O O
was O O
significantly O O
lower O O
than O O
in O O
the O O
first O O
session O O
. O O

The O O
5 O O
' O O
- O O
flanking O O
region O O
of O O
the O O
gene O O
, O O
approximately O O
1 O O
. O O
1 O O
kbp O O
long O O
, O O
had O O
no O O
known O O
regulatory O O
elements O O
for O O
transcription O O
such O O
as O O
TATA O O
, O O
GC O O
, O O
and O O
CCAAT O O
boxes O O
. O O

We O O
find O O
that O O
Fus3p B B_GENE
and O O
Kss1p B B_GENE/B_DISEASE
both O O
control O O
G1 O O
arrest O O
through O O
multiple O O
functions O O
that O O
operate O O
in O O
parallel O O
with O O
Far1p B B_GENE
. O O

Tag B B_GENE
expression O O
induced O O
apoptosis O O
in O O
mammary O O
epithelial O O
cells O O
during O O
late O O
pregnancy O O
. O O

The O O
composition O O
of O O
renal O O
stones O O
analysed O O
by O O
infrared O O
spectroscopy O O
. O O

14 O O
. O O
9 O O
x O O
109 O O
L O O
- O O
1 O O
) O O
was O O
equal O O
for O O
both O O
groups O O
, O O
but O O
CCI O O
values O O
were O O
significantly O O
higher O O
for O O
the O O
bedside O O
filtered O O
PC O O
( O O
14 O O
. O O
1 O O
+ O O
/ O O
- O O
9 O O
. O O
5 O O
vs O O
. O O

In O O
this O O
study O O
, O O
the O O
case O O
of O O
a O O
patient O O
presenting O O
a O O
second O O
hepatocellular O O
carcinoma O O
13 O O
years O O
after O O
resection O O
of O O
a O O
first O O
tumor O O
of O O
the O O
same O O
type O O
is O O
reported O O
. O O

The O O
factors O O
defective O O
in O O
groups O O
A O O
( O O
CIITA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
C O O
( O O
RFX5 B B_LOCATION/B_GENE
) O O
and O O
D O O
( O O
RFXAP B B_GENE/B_LOCATION
) O O
have O O
been O O
identified O O
. O O

It O O
differed O O
significantly O O
by O O
country O O
( O O
from O O
2 O O
. O O
4 O O
% O O
in O O
the O O
United O O
Kingdom O O
to O O
24 O O
. O O
7 O O
% O O
in O O
Portugal O O
) O O
and O O
by O O
transmission O O
category O O
( O O
2 O O
. O O
7 O O
% O O
among O O
homo O O
/ O O
bisexuals O O
, O O
5 O O
. O O
8 O O
% O O
among O O
injecting O O
drug O O
users O O
, O O
13 O O
. O O
6 O O
% O O
among O O
heterosexual O O
subgroup O O
1 O O
) O O
. O O

On O O
a O O
national O O
level O O
, O O
undiscounted O O
costs O O
are O O
expected O O
to O O
increase O O
up O O
to O O
approximately O O
DF1 O O
42 O O
million O O
annually O O
during O O
the O O
first O O
40 O O
years O O
after O O
introduction O O
of O O
the O O
preventative O O
strategy O O
. O O

By O O
deletion O O
analysis O O
, O O
we O O
identified O O
the O O
regions O O
of O O
c B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
Jun I I_GENE/I_LOCATION
encoding O O
transformation O O
and O O
transactivation O O
functions O O
. O O

A O O
survey O O
of O O
274 O O
late O O
detected O O
cases O O
of O O
CDH O O
born O O
in O O
the O O
years O O
1970 O O
- O O
- O O
74 O O
is O O
presented O O
. O O

To O O
test O O
for O O
progesterone B B_PROTEIN[GENE]
receptor I I_PROTEIN[GENE]
- O O
mediated O O
activation O O
of O O
transcription O O
in O O
yeast O O
, O O
reporter O O
plasmids O O
were O O
constructed O O
to O O
transform O O
yeast O O
cells O O
expressing O O
PRB B B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
C1C2 B B_GENE/B_LOCATION
receptors I I_GENE/I_LOCATION
. O O

Fli B B_GENE
- I I_GENE
1 I I_GENE
is O O
a O O
proto O O
- O O
oncogene O O
which O O
is O O
rearranged O O
in O O
tumors O O
induced O O
by O O
three O O
different O O
retroviruses O O
, O O
Cas O O
- O O
Br O O
- O O
E O O
, O O
F O O
- O O
MuLV O O
, O O
and O O
10A1 O O
. O O

Ionic O O
composition O O
( O O
Na O O
+ O O
, O O
K O O
+ O O
, O O
Ca O O
+ O O
2 O O
, O O
and O O
Mg2 O O
+ O O
) O O
of O O
cerebrospinal O O
fluid O O
and O O
feeding O O
behavior O O
in O O
sheep O O
. O O

Materials O O
are O O
presented O O
of O O
a O O
comparative O O
study O O
of O O
morphological O O
and O O
cultural O O
properties O O
and O O
virulence O O
of O O
liophylized O O
cultures O O
of O O
Leishmania O O
tropica O O
major O O
after O O
their O O
rehydration O O
or O O
after O O
a O O
long O O
passage O O
on O O
the O O
NNN O O
medium O O
. O O

CONCLUSIONS O O
: O O
These O O
findings O O
imply O O
that O O
the O O
spinal O O
cord O O
is O O
not O O
a O O
simple O O
command O O
- O O
carrying O O
medium O O
from O O
the O O
brain O O
to O O
the O O
limbs O O
, O O
and O O
implies O O
that O O
some O O
computational O O
activities O O
take O O
place O O
at O O
the O O
spinal O O
cord O O
level O O
. O O

The O O
101st O O
annual O O
meeting O O
of O O
the O O
Japanese O O
Ophthalmological O O
Society O O
. O O

The O O
results O O
corroborate O O
the O O
proposed O O
physiological O O
function O O
of O O
CCoAOMT B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
elicited O O
plant O O
cells O O
and O O
may O O
shed O O
new O O
light O O
on O O
the O O
sequential O O
action O O
of O O
trans O O
- O O
active O O
factors O O
in O O
the O O
regulation O O
of O O
phenylpropanoid O O
genes O O
. O O

In O O
src B B_GENE/B_VIRUS[BIO]
- O O
transformed O O
cells O O
GAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forms O O
heteromeric O O
complexes O O
, O O
notably O O
with O O
a O O
highly O O
tyrosine O O
phosphorylated O O
62 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kDa I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
p62 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
study O O
of O O
characteristics O O
in O O
adult O O
asthmatics O O
who O O
are O O
sensitized O O
by O O
cats O O
and O O
dogs O O
allergens O O

PrRP B B_GENE/B_PERSON
rapidly O O
and O O
transiently O O
activated O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ERK B B_GENE/B_LOCATION
) O O
in O O
both O O
types O O
of O O
cells O O
. O O

Cell O O
- O O
free O O
extracts O O
of O O
E O O
. O O
coli O O
( O O
fpg B B_PROTEIN[GENE]/B_LOCATION
mutY B I_PROTEIN[GENE]/I_LOCATION
) O O
harboring O O
pYSB10 O O
possess O O
an O O
enzymatic O O
activity O O
that O O
cleaves O O
a O O
34 O O
- O O
mer O O
oligonucleotide O O
containing O O
a O O
single O O
8 O O
- O O
oxoG O O
opposite O O
a O O
cytosine O O
( O O
8 O O
- O O
OxoG O O
/ O O
C O O
) O O
. O O

Estrogen O O
pretreated O O
castrated O O
males O O
also O O
showed O O
no O O
change O O
in O O
myocardial O O
blood O O
flow O O
after O O
17 O O
beta O O
- O O
estradiol O O
, O O
but O O
coronary O O
flow O O
velocity O O
decreased O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
compared O O
with O O
baseline O O
1 O O
h O O
after O O
the O O
200 O O
ng O O
/ O O
kg O O
dose O O
( O O
from O O
1 O O
. O O
69 O O
+ O O
/ O O
- O O
0 O O
. O O
61 O O
to O O
1 O O
. O O
41 O O
+ O O
/ O O
- O O
0 O O
. O O
42 O O
kHz O O
) O O
and O O
diastolic O O
coronary O O
resistance O O
increased O O
significantly O O
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
compared O O
with O O
control O O
at O O
this O O
time O O
( O O
51 O O
+ O O
/ O O
- O O
15 O O
compared O O
with O O
39 O O
+ O O
/ O O
- O O
14 O O
mmHg O O
/ O O
mkHz O O
) O O
. O O

Acute O O
renal O O
vein O O
thrombosis O O
in O O
renal O O
allografts O O
: O O
detection O O
with O O
duplex O O
Doppler O O
US O O
. O O

Several O O
DNA O O
clones O O
were O O
obtained O O
by O O
this O O
procedure O O
, O O
one O O
of O O
which O O
, O O
clone O O
18 O O
, O O
is O O
reported O O
and O O
characterized O O
here O O
. O O

Long O O
- O O
range O O
mapping O O
by O O
pulse O O
- O O
field O O
gel O O
electrophoresis O O
indicated O O
that O O
the O O
three O O
mdr B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
closely O O
linked O O
on O O
a O O
genomic O O
DNA O O
segment O O
of O O
approximately O O
625 O O
kilobases O O
. O O

These O O
sequences O O
were O O
further O O
tested O O
for O O
the O O
presence O O
of O O
an O O
enhancer O O
element O O
, O O
by O O
their O O
ability O O
to O O
activate O O
a O O
fusion O O
reporter O O
gene O O
consisting O O
of O O
the O O
CAT B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
linked O O
to O O
the O O
gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
globin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
erythroid O O
( O O
K562 O O
) O O
and O O
non O O
- O O
erythroid O O
( O O
HeLa O O
) O O
cells O O
. O O

Two O O
sibs O O
with O O
identical O O
features O O
of O O
short O O
- O O
limbed O O
dwarfism O O
, O O
a O O
normal O O
skull O O
and O O
face O O
and O O
normal O O
intelligence O O
are O O
described O O
. O O

This O O
article O O
describes O O
a O O
program O O
that O O
resulted O O
in O O
a O O
75 O O
- O O
percent O O
reduction O O
of O O
inventory O O
over O O
a O O
five O O
- O O
year O O
interval O O
. O O

All O O
patients O O
received O O
marrow O O
from O O
HLA B B_GENE
- O O
identical O O
sibling O O
donors O O
, O O
underwent O O
similar O O
myeloablative O O
regimens O O
, O O
and O O
had O O
similar O O
pretreatment O O
characteristics O O
. O O

In O O
female O O
toads O O
, O O
Bufo O O
bufo O O
, O O
feeding O O
at O O
different O O
rates O O
, O O
the O O
uncorrected O O
value O O
of O O
n O O
was O O
0 O O
. O O
44 O O
, O O
when O O
metabolism O O
and O O
growth O O
were O O
expressed O O
as O O
kJ O O
kJ O O
- O O
1 O O
. O O

Subclones O O
stably O O
expressing O O
alpha1A B B_PROTEIN[GENE]/B_LOCATION
- O O
, O O
alpha1B B B_PROTEIN[GENE]/B_LOCATION
- O O
, O O
and O O
alpha1D B B_GENE
- O O
ARs O O
under O O
control O O
of O O
an O O
inducible O O
promoter O O
, O O
or O O
at O O
high O O
and O O
low O O
receptor O O
density O O
, O O
were O O
isolated O O
and O O
characterized O O
. O O

Analysis O O
of O O
WT1 B B_GENE
target I I_GENE
gene I I_GENE
expression O O
in O O
stably O O
transfected O O
cell O O
lines O O
. O O

Soluble O O
recombinant O O
RI B B_GENE
and O O
soluble O O
recombinant O O
C B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
associate O O
in O O
vitro O O
and O O
be O O
activated O O
by O O
cyclic O O
AMP O O
. O O

Simulation O O
results O O
based O O
on O O
the O O
presented O O
model O O
are O O
compared O O
with O O
the O O
experimental O O
data O O
for O O
two O O
types O O
of O O
cMUTs O O
reported O O
in O O
the O O
recent O O
literature O O
. O O

Electrophoretic O O
mobility O O
- O O
shift O O
assays O O
with O O
nuclear O O
extracts O O
from O O
COS O O
- O O
1 O O
cells O O
transfected O O
with O O
expression O O
vectors O O
for O O
SMADs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicate O O
that O O
SMAD3 B B_GENE/B_DISEASE
forms O O
a O O
complex O O
with O O
a O O
migration O O
similar O O
to O O
that O O
of O O
the O O
endogenous B B_GENE/B_MEASURE
TGF I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
beta I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
specific I I_GENE/I_MEASURE
complex I I_GENE/I_MEASURE
observed O O
in O O
fibroblast O O
extracts O O
. O O

The O O
newly O O
identified O O
NF B B_GENE/B_PERSON
kappa I I_GENE/I_PERSON
B I I_GENE/I_PERSON
enhancer I I_GENE/I_PERSON
( O O
TGGAAATTCC O O
) O O
is O O
bound O O
by O O
a O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
induced O O
nuclear O O
protein O O
and O O
appears O O
to O O
be O O
the O O
key O O
element O O
in O O
rapid O O
transcription O O
induction O O
by O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
and O O
TPA O O
) O O
, O O
while O O
transactivation O O
of O O
this O O
element O O
is O O
repressed O O
by O O
the O O
ligand O O
- O O
bound O O
glucocorticoid B B_GENE
receptor I I_GENE
. O O

In O O
the O O
second O O
group O O
, O O
which O O
consisted O O
of O O
babies O O
of O O
33 O O
to O O
36 O O
weeks O O
of O O
gestational O O
age O O
, O O
haptoglobin B B_DISEASE/B_GENE
was O O
detected O O
in O O
6 O O
infants O O
, O O
with O O
levels O O
less O O
than O O
25 O O
mg O O
/ O O
dl O O
in O O
3 O O
. O O

The O O
polypeptide O O
encoded O O
by O O
the O O
cDNA O O
contained O O
450 O O
amino O O
acids O O
with O O
a O O
calculated O O
M O O
( O O
r O O
) O O
of O O
52 O O
, O O
057 O O
, O O
and O O
showed O O
significant O O
homology O O
with O O
human O O
and O O
mouse B B_SPECIES[BIO]/B_GENE
CAD I I_SPECIES[BIO]/I_GENE
( O O
22 O O
% O O
identity O O
) O O
. O O

Correlation O O
of O O
alpha O O
activity O O
between O O
the O O
frontal O O
and O O
occipital O O
cortex O O
. O O

In O O
situ O O
localization O O
of O O
PCP B B_GENE/B_BIO
- I I_GENE/I_BIO
A1 I I_GENE/I_BIO
transcripts I I_GENE/I_BIO
revealed O O
that O O
they O O
accumulate O O
specifically O O
in O O
pollen O O
at O O
the O O
late O O
binucleate O O
/ O O
trinucleate O O
stage O O
of O O
development O O
rather O O
than O O
in O O
the O O
tapetum O O
, O O
which O O
previously O O
was O O
taken O O
to O O
be O O
the O O
principal O O
source O O
of O O
the O O
pollen O O
coat O O
. O O

Successful O O
resolution O O
of O O
progressive O O
multifocal O O
leukoencephalopathy O O
after O O
combination O O
therapy O O
with O O
cidofovir O O
and O O
cytosine O O
arabinoside O O
. O O

The O O
species O O
composition O O
and O O
abundance O O
upon O O
treatment O O
of O O
manure O O
with O O
polyethylene O O
, O O
polystyrene O O
and O O
glass O O
particles O O
was O O
similar O O
to O O
that O O
of O O
the O O
treatment O O
control O O
, O O
i O O
. O O
e O O
. O O
natural O O
and O O
inert O O
sand O O
. O O

However O O
, O O
H19 B B_GENE
and O O
IGF2 B B_GENE
lie O O
within O O
a O O
larger O O
imprinted O O
domain O O
, O O
and O O
the O O
gene O O
specificity O O
of O O
H19 B B_GENE/B_PERSON
epimutation O O
has O O
been O O
a O O
persistent O O
question O O
. O O

Here O O
we O O
report O O
the O O
cloning O O
, O O
by O O
either O O
peptide O O
sequencing O O
or O O
by O O
sequence O O
similarity O O
to O O
the O O
human O O
cDNAs O O
, O O
of O O
the O O
S O O
. O O
cerevisiae O O
genes O O
RFC1 B B_PROTEIN[GENE]/B_LOCATION
, O O
RFC2 B B_PROTEIN[GENE]/B_DISEASE
, O O
RFC3 B B_PROTEIN[GENE]/B_DISEASE
, O O
RFC4 B B_PROTEIN[GENE]/B_LOCATION
, O O
and O O
RFC5 B B_GENE/B_DISEASE
. O O

It O O
is O O
of O O
interest O O
that O O
, O O
aside O O
from O O
starvation O O
, O O
the O O
nutrition O O
catastrophes O O
of O O
the O O
past O O
, O O
including O O
scurvy O O
( O O
vitamin O O
C O O
deficiency O O
) O O
resulting O O
from O O
lack O O
of O O
fresh O O
vegetables O O
and O O
fruit O O
and O O
beriberi O O
( O O
vitamin O O
B1 O O
deficiency O O
) O O
from O O
consumption O O
of O O
polished O O
rice O O
, O O
are O O
forgotten O O
and O O
only O O
of O O
interest O O
as O O
history O O
. O O

This O O
sequence O O
can O O
interact O O
with O O
at O O
least O O
two O O
proteins O O
in O O
a O O
fibroblast O O
nuclear O O
extract O O
that O O
have O O
binding O O
characteristics O O
of O O
an O O
Ets B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
serum B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
molecular O O
event O O
( O O
s O O
) O O
underlying O O
the O O
functional O O
specificities O O
of O O
these O O
receptors O O
( O O
in O O
regulating O O
the O O
expression O O
of O O
their O O
native O O
target O O
genes O O
) O O
is O O
a O O
very O O
important O O
issue O O
that O O
remains O O
poorly O O
understood O O
. O O

MUS81 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encodes O O
a O O
novel O O
helix B B_ENZYME[GENE]/B_MEASURE
- I I_ENZYME[GENE]/I_MEASURE
hairpin I I_ENZYME[GENE]/I_MEASURE
- I I_ENZYME[GENE]/I_MEASURE
helix I I_ENZYME[GENE]/I_MEASURE
protein I I_ENZYME[GENE]/I_MEASURE
involved O O
in O O
the O O
response O O
to O O
UV O O
- O O
and O O
methylation O O
- O O
induced O O
DNA O O
damage O O
in O O
Saccharomyces O O
cerevisiae O O
. O O

Treatment O O
of O O
chronic O O
hepatitis O O
B O O
with O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
experience O O
in O O
western O O
countries O O
. O O

Several O O
positive O O
clones O O
were O O
isolated O O
, O O
one O O
of O O
which O O
encoded O O
the O O
C O O
- O O
terminal O O
253 O O
amino O O
acids O O
of O O
a O O
putative O O
RNA B B_GENE/B_BIO
helicase I I_GENE/I_BIO
, O O
a O O
DEAD B B_GENE/B_PERSON
box I I_GENE/I_PERSON
protein I I_GENE/I_PERSON
designated O O
DDX3 B B_PROTEIN[GENE]
. O O

Kerstin O O
takes O O
the O O
abbreviated O O
medical O O
education O O
. O O

In O O
this O O
case O O
myogenic O O
factors O O
are O O
not O O
initially O O
expressed O O
and O O
these O O
migratory O O
cells O O
are O O
characterized O O
by O O
the O O
expression O O
of O O
the O O
paired B B_MEASURE/B_PROTEIN[GENE]
- O O
box O O
gene O O
Pax3 B B_GENE/B_LOCATION
. O O

It O O
is O O
concluded O O
that O O
the O O
atherogenic O O
process O O
includes O O
stimulation O O
of O O
collagen B B_GENE/B_DISEASE
and O O
elastin B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synthesis O O
. O O

Phenotypic O O
responses O O
of O O
additional O O
mutants O O
, O O
including O O
exo1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
srs2 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
rad5 B B_GENE/B_LOCATION
, O O
and O O
rdh54 B B_NUMBER[MEASURE]/B_GENE
strains O O
, O O
suggest O O
roles O O
in O O
recombinational O O
repair O O
, O O
but O O
not O O
in O O
NHEJ O O
. O O

Furthermore O O
, O O
the O O
induction O O
of O O
cytochrome B B_GENE/B_DISEASE
P I I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
450 I I_GENE/I_DISEASE
1A1 I I_GENE/I_DISEASE
observed O O
in O O
the O O
cormorant O O
indicates O O
that O O
the O O
Ah B B_GENE
receptor I I_GENE
- O O
mediated O O
process O O
, O O
by O O
which O O
TCDD O O
and O O
related O O
chemicals O O
exert O O
many O O
of O O
their O O
toxicities O O
, O O
has O O
been O O
activated O O
. O O

RESULT O O
( O O
S O O
) O O
: O O
A O O
prospective O O
study O O
was O O
conducted O O
with O O
44 O O
cycles O O
for O O
34 O O
couples O O
with O O
nafarelin O O
acetate O O
( O O
group O O
1 O O
) O O
and O O
47 O O
cycles O O
for O O
40 O O
couples O O
with O O
buserelin O O
acetate O O
( O O
group O O
2 O O
) O O
with O O
a O O
long O O
IVF O O
protocol O O
; O O
68 O O
cycles O O
for O O
46 O O
couples O O
with O O
nafarelin O O
acetate O O
( O O
group O O
3 O O
) O O
and O O
56 O O
cycles O O
for O O
39 O O
couples O O
with O O
buserelin O O
acetate O O
( O O
group O O
4 O O
) O O
with O O
a O O
short O O
IVF O O
protocol O O
; O O
39 O O
cycles O O
for O O
32 O O
couples O O
with O O
nafarelin O O
acetate O O
( O O
group O O
5 O O
) O O
and O O
50 O O
cycles O O
for O O
30 O O
couples O O
with O O
buserelin O O
acetate O O
( O O
group O O
6 O O
) O O
with O O
a O O
long O O
ICSI O O
protocol O O
; O O
and O O
87 O O
cycles O O
for O O
60 O O
couples O O
with O O
nafarelin O O
acetate O O
( O O
group O O
7 O O
) O O
and O O
81 O O
cycles O O
for O O
61 O O
couples O O
with O O
buserelin O O
acetate O O
( O O
group O O
8 O O
) O O
with O O
a O O
short O O
ICSI O O
protocol O O
. O O

This O O
study O O
demonstrates O O
the O O
feasibility O O
and O O
potential O O
usefulness O O
of O O
syngeneic O O
BM O O
Txp O O
in O O
myeloma O O
. O O

In O O
this O O
work O O
, O O
we O O
determined O O
the O O
sequences O O
of O O
eight O O
VirF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
four O O
different O O
genes O O
, O O
by O O
DNase B B_GENE
I I I_GENE
or O O
hydroxyl O O
radical O O
footprinting O O
. O O

Although O O
they O O
are O O
similar O O
to O O
the O O
IL9R B B_GENE/B_TIME[MEASURE]
gene I I_GENE/I_TIME[MEASURE]
( O O
approximately O O
90 O O
% O O
identity O O
) O O
, O O
none O O
of O O
these O O
copies O O
encodes O O
a O O
functional O O
receptor O O
: O O
none O O
of O O
them O O
contains O O
sequences O O
homologous O O
to O O
the O O
5 O O
' O O
flanking O O
region O O
or O O
exon O O
1 O O
of O O
the O O
IL9R B B_GENE
gene I I_GENE
, O O
and O O
the O O
remaining O O
ORFs O O
have O O
been O O
inactivated O O
by O O
various O O
point O O
mutations O O
and O O
deletions O O
. O O

Type O O
II O O
neuroleptanalgesia O O
in O O
odonto O O
- O O
stomatology O O

While O O
reviewing O O
gastric O O
specimens O O
from O O
215 O O
baboons O O
, O O
we O O
found O O
diffuse O O
giant O O
mucosal O O
folds O O
in O O
2 O O
specimens O O
and O O
multiple O O
giant O O
mucosal O O
nodules O O
in O O
another O O
3 O O
. O O

To O O
investigate O O
whether O O
the O O
two O O
RPG B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
boxes I I_GENE/I_LOCATION
mediate O O
transcription O O
activation O O
of O O
both O O
the O O
L46 B B_PROTEIN[GENE]
and O O
S24 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
two O O
experimental O O
strategies O O
were O O
followed O O
: O O
cloning O O
of O O
the O O
respective O O
genes O O
on O O
multicopy O O
vectors O O
and O O
construction O O
of O O
fusion O O
genes O O
. O O

The O O
psychosocial O O
features O O
of O O
people O O
using O O
self O O
- O O
ignition O O
as O O
a O O
method O O
of O O
suicide O O
are O O
consistent O O
with O O
those O O
of O O
suicide O O
in O O
general O O
. O O

This O O
was O O
further O O
suggested O O
by O O
transactivation O O
assays O O
in O O
which O O
mouse O O
fibroblasts O O
were O O
transiently O O
transfected O O
with O O
a O O
human B B_GENE
beta I I_GENE
- I I_GENE
globin I I_GENE
reporter I I_GENE
gene I I_GENE
in O O
the O O
absence O O
and O O
presence O O
of O O
an O O
LKLF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
construct I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thus O O
, O O
in O O
addition O O
to O O
the O O
previously O O
characterized O O
FAS B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
interacting O O
with O O
the O O
inositol O O
/ O O
choline O O
- O O
responsive O O
- O O
element O O
motif O O
, O O
a O O
second O O
motif O O
common O O
to O O
the O O
promoter O O
regions O O
of O O
both O O
FAS B B_GENE/B_BIO
genes I I_GENE/I_BIO
could O O
be O O
identified O O
. O O

Reconstruction O O
time O O
for O O
a O O
64 O O
x O O
64 O O
matrix O O
is O O
approximately O O
45 O O
s O O
/ O O
transaxial O O
slice O O
. O O

One O O
hundred O O
cDNA O O
clones O O
were O O
sequenced O O
and O O
8 O O
RTKs B B_GENE/B_PERSON
were O O
identified O O
, O O
as O O
well O O
as O O
12 O O
non O O
- O O
RTKs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
2 O O
serine B B_GENE/B_BIO
/ I I_GENE/I_BIO
threonine I I_GENE/I_BIO
kinases I I_GENE/I_BIO
. O O

Roller O O
pumps O O
, O O
coronary O O
suction O O
and O O
an O O
open O O
cardiotomy O O
reservoir O O
were O O
used O O
. O O

Furthermore O O
, O O
it O O
was O O
found O O
that O O
the O O
Shb B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
overexpressing O O
cells O O
extended O O
neurites O O
in O O
response O O
to O O
epidermal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
growth I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Levels O O
of O O
p53 B B_GENE
were O O
substantially O O
increased O O
by O O
E1A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
during O O
adenovirus O O
infection O O
. O O

In O O
cases O O
of O O
intracapsular O O
prostatic O O
cancer O O
the O O
level O O
of O O
prostatic B B_GENE
acid I I_GENE
phosphatase I I_GENE
( O O
PAP B B_LOCATION/B_GENE
) O O
measured O O
by O O
radioimmunoassay O O
was O O
1 O O
. O O
4 O O
+ O O
/ O O
- O O
0 O O
. O O
8 O O
micrograms O O
/ O O
l O O
. O O

Healthy O O
subjects O O
received O O
the O O
following O O
regimens O O
, O O
dosed O O
to O O
steady O O
state O O
: O O
trovafloxacin O O
300 O O
mg O O
/ O O
24 O O
h O O
; O O
ciprofloxacin O O
400 O O
mg O O
/ O O
12 O O
h O O
; O O
trovafloxacin O O
300 O O
mg O O
/ O O
24 O O
h O O
plus O O
cefepime O O
2 O O
g O O
/ O O
12 O O
h O O
, O O
and O O
ciprofloxacin O O
400 O O
mg O O
/ O O
12 O O
h O O
plus O O
cefepime O O
2 O O
g O O
/ O O
12 O O
h O O
. O O

In O O
EGF B B_GENE
receptor I I_GENE
- O O
mediated O O
signaling O O
, O O
the O O
protein B B_GENE
kinase I I_GENE
PKB I I_GENE
/ O O
Akt B B_GENE
and O O
the O O
mitogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
N I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
function O O
downstream O O
of O O
phosphatidylinositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI B B_GENE/B_LOCATION
3 I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
kinase I I_GENE/I_LOCATION
) O O
. O O

Immunoprecipitation O O
of O O
cell O O
lysates O O
with O O
anti B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphotyrosine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
immunoblotting O O
showed O O
phosphorylated O O
forms O O
of O O
the O O
mitogenic O O
pathway O O
proteins O O
Shc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
MAPK B B_GENE
in O O
addition O O
to O O
p185 B B_GENE
( O O
neu B B_GENE/B_DISEASE
) O O
, O O
suggesting O O
that O O
the O O
Ras B B_GENE/B_DISEASE
to O O
MAPK B B_GENE/B_PERSON
mitogenic O O
pathway O O
is O O
activated O O
. O O

Acad O O
. O O

Bile O O
reflux O O
demonstrated O O
by O O
99m O O
Tc O O
disofenin O O
. O O

These O O
data O O
suggest O O
that O O
certain O O
of O O
the O O
nuclear O O
protein O O
import O O
functions O O
of O O
NTF2 B B_GENE/B_LOCATION
and O O
Ran B B_GENE/B_LOCATION
/ O O
TC4 B B_PROTEIN[GENE]/B_DISEASE
are O O
closely O O
linked O O
and O O
that O O
NTF2 B B_GENE/B_PERSON
may O O
serve O O
to O O
modulate O O
a O O
transport O O
step O O
involving O O
Ran B B_GENE/B_LOCATION
/ O O
TC4 B B_PROTEIN[GENE]/B_LOCATION
. O O

Almost O O
every O O
image O O
that O O
appears O O
during O O
a O O
therapy O O
session O O
reveals O O
a O O
symbolic O O
nature O O
, O O
but O O
the O O
very O O
concept O O
of O O
symbol O O
is O O
not O O
free O O
from O O
ambiguity O O
some O O
positions O O
originated O O
in O O
different O O
areas O O
of O O
investigation O O
are O O
mentioned O O
, O O
ending O O
with O O
a O O
description O O
of O O
the O O
traits O O
that O O
, O O
according O O
to O O
the O O
writer O O
, O O
bestow O O
a O O
symbolic O O
character O O
to O O
images O O
. O O

The O O
severity O O
of O O
the O O
psychomotor O O
retardation O O
varied O O
from O O
mild O O
to O O
severe O O
. O O

Both O O
oligonucleotide O O
cross O O
- O O
competition O O
and O O
antibody O O
supershift O O
experiments O O
established O O
that O O
the O O
double O O
- O O
strand O O
binding O O
protein O O
is O O
equivalent O O
to O O
Sp1 B B_GENE
. O O

The O O
wet O O
and O O
dry O O
methods O O
of O O
the O O
HA O O
synthesis O O
are O O
considered O O
. O O

All O O
these O O
abnormalities O O
returned O O
to O O
normal O O
after O O
removal O O
of O O
the O O
tumor O O
. O O

Molecular O O
analysis O O
indicated O O
that O O
inactivation O O
of O O
H B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2L I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
in O O
nearly O O
every O O
null O O
clone O O
resulted O O
from O O
an O O
apparent O O
deletion O O
or O O
rearrangement O O
of O O
5 B B_GENE
' I I_GENE
- I I_GENE
flanking I I_GENE
and I I_GENE
5 I I_GENE
' I I_GENE
- I I_GENE
coding I I_GENE
H I I_GENE
- I I_GENE
2L I I_GENE
sequences I I_GENE
, O O
with O O
breakpoints O O
consistently O O
mapping O O
to O O
within O O
a O O
550 O O
bp O O
GC O O
- O O
rich O O
region O O
between O O
exon O O
1 O O
and O O
the O O
middle O O
of O O
intron O O
2 O O
. O O

However O O
, O O
C B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
EBP I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulated O O
transcription O O
primarily O O
through O O
the O O
cAMP O O
- O O
responsive O O
element O O
( O O
CRE O O
) O O
, O O
which O O
maps O O
between O O
positions O O
- O O
77 O O
to O O
- O O
94 O O
, O O
but O O
not O O
at O O
the O O
more O O
5 O O
' O O
- O O
binding O O
sites O O
. O O

Heliox O O
improves O O
pulsus O O
paradoxus O O
and O O
peak O O
expiratory O O
flow O O
in O O
nonintubated O O
patients O O
with O O
severe O O
asthma O O
. O O

50 O O
- O O
fold O O
increase O O
in O O
foreign O O
protein O O
production O O
. O O

Ion O O
- O O
Bernstein O O
- O O
wave O O
heating O O
and O O
improved O O
confinement O O
in O O
the O O
Alcator O O
C O O
tokamak O O
. O O

However O O
, O O
the O O
molecular O O
mechanisms O O
by O O
which O O
specific O O
cis O O
- O O
and O O
trans O O
- O O
acting O O
factors O O
control O O
activity O O
of O O
the O O
prodynorphin B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
are O O
not O O
as O O
clearly O O
defined O O
. O O

Finally O O
, O O
antisense O O
mediated O O
reduction O O
of O O
Elk B B_GENE
- I I_GENE
1 I I_GENE
in O O
GH4 O O
cells O O
decreased O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
increased O O
prolactin B B_GENE
gene I I_GENE
expression O O
and O O
confirmed O O
the O O
requirement O O
for O O
Elk B B_GENE
- I I_GENE
1 I I_GENE
for O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
increased O O
prolactin B B_GENE
gene I I_GENE
expression O O
. O O

Substitutions O O
of O O
Asp11 O O
led O O
to O O
dominant O O
lethality O O
. O O

Three O O
modern O O
hematology O O
analyzers O O
( O O
Abbott O O
Cell O O
- O O
Dyn O O
3000 O O
, O O
Coulter O O
STKS O O
, O O
and O O
Sysmex O O
NE O O
- O O
8000 O O
) O O
with O O
high O O
throughput O O
and O O
5 O O
- O O
part O O
differential O O
capability O O
were O O
evaluated O O
using O O
a O O
protocol O O
designed O O
by O O
a O O
quality O O
team O O
. O O

Each O O
subject O O
was O O
injected O O
in O O
the O O
antecubital O O
vein O O
with O O
7 O O
mg O O
/ O O
kg O O
of O O
sodium O O
fluorescein O O
( O O
25 O O
% O O
solution O O
) O O
and O O
measurements O O
were O O
taken O O
1 O O
hr O O
postinjection O O
at O O
4 O O
. O O
5 O O
mm O O
and O O
7 O O
. O O
5 O O
mm O O
from O O
the O O
retina O O
. O O

The O O
cleft O O
walls O O
are O O
lined O O
with O O
highly O O
conserved O O
residues O O
and O O
NADP O O
is O O
bound O O
along O O
one O O
wall O O
. O O

cDNA O O
cloning O O
, O O
sequencing O O
and O O
chromosome O O
mapping O O
of O O
a O O
non B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
erythroid I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
spectrin I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fodrin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

( O O
1996 O O
) O O
J O O
. O O

To O O
define O O
the O O
molecular O O
mechanism O O
regulating O O
FGFR B B_GENE
- I I_GENE
1 I I_GENE
gene I I_GENE
expression O O
in O O
proliferating O O
myoblasts O O
and O O
post O O
- O O
mitotic O O
muscle O O
fibers O O
, O O
we O O
have O O
isolated O O
and O O
partially O O
characterized O O
the O O
avian O O
FGFR B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
1 I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
promoter O O
. O O

Moreover O O
, O O
FACT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O O
interacts O O
with O O
nucleosomes O O
and O O
histone O O
H2A B B_PROTEIN[GENE]
/ O O
H2B B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dimers O O
, O O
indicating O O
that O O
it O O
may O O
work O O
by O O
promoting O O
nucleosome O O
disassembly O O
upon O O
transcription O O
. O O

Measures O O
of O O
sedation O O
, O O
BIS O O
, O O
deltaBIS O O
( O O
absolute O O
change O O
of O O
BIS O O
after O O
a O O
painful O O
stimulus O O
) O O
, O O
memory O O
, O O
and O O
drug O O
concentration O O
were O O
obtained O O
at O O
each O O
target O O
drug O O
concentration O O
. O O

ER O O
and O O
DR O O
were O O
significantly O O
correlated O O
with O O
MIB B B_GENE
- I I_GENE
1 I I_GENE
LI O O
( O O
P O O
< O O
0 O O
. O O
01 O O
and O O
P O O
< O O
0 O O
. O O
05 O O
, O O
respectively O O
) O O
, O O
but O O
RI O O
and O O
Td O O
/ O O
Te O O
were O O
not O O
. O O

Psychophysical O O
evidence O O
is O O
given O O
for O O
the O O
existence O O
of O O
two O O
distinct O O
systems O O
in O O
human O O
vision O O
: O O
a O O
fast O O
, O O
sign O O
- O O
invariant O O
system O O
concerned O O
with O O
extracting O O
contours O O
and O O
a O O
slower O O
, O O
sign O O
- O O
sensitive O O
system O O
concerned O O
with O O
assigning O O
surface O O
color O O
. O O

Peripheral O O
visual O O
acuity O O
with O O
monovision O O
and O O
other O O
contact O O
lens O O
corrections O O
for O O
presbyopia O O
. O O

Fourteen O O
Centers O O
participated O O
in O O
this O O
trial O O
. O O

The O O
program O O
for O O
myogenic O O
differentiation O O
is O O
subject O O
to O O
negative O O
control O O
by O O
several O O
peptide O O
growth O O
factors O O
and O O
by O O
the O O
products O O
of O O
mutationally O O
activated O O
ras B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oncogenes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
persistently O O
activate O O
intracellular O O
cascades O O
normally O O
triggered O O
by O O
specific O O
growth O O
factors O O
. O O

Tetrazepam O O
: O O
a O O
benzodiazepine O O
which O O
dissociates O O
sedation O O
from O O
other O O
benzodiazepine O O
activities O O
. O O

The O O
difference O O
between O O
the O O
effects O O
of O O
the O O
two O O
dose O O
levels O O
of O O
Z O O
. O O

Plasmid O O
pNK21 O O
, O O
in O O
which O O
2 O O
. O O
05 O O
- O O
kb O O
sequence O O
covering O O
the O O
region O O
encoding O O
the O O
nitrilase B B_ENZYME[GENE]/B_BACTERIUM[BIO]
was O O
was O O
placed O O
under O O
the O O
control O O
of O O
the O O
lac B B_GENE/B_BIO
promoter I I_GENE/I_BIO
, O O
directed O O
overproduction O O
of O O
enzymatically B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
active I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
nitrilase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O O
response O O
to O O
addition O O
of O O
isopropyl O O
beta O O
- O O
D O O
- O O
thiogalactopyranoside O O
in O O
Escherichia O O
coli O O
. O O

A O O
method O O
for O O
determining O O
the O O
toxicity O O
of O O
neutralizers O O
for O O
antimicrobial O O
agents O O
to O O
A O O
. O O
castellanii O O
was O O
also O O
evaluated O O
. O O

Expression O O
in O O
all O O
lines O O
was O O
decreased O O
by O O
the O O
inclusion O O
of O O
regions O O
further O O
upstream O O
, O O
and O O
extinguished O O
by O O
the O O
inclusion O O
of O O
the O O
first O O
intron O O
. O O

Static O O
and O O
dynamic O O
MRI O O
of O O
the O O
normal O O
and O O
pathological O O
female O O
pelvic O O
floor O O

IENF O O
density O O
at O O
the O O
calf O O
was O O
lower O O
than O O
that O O
obtained O O
from O O
skin O O
at O O
more O O
proximal O O
sites O O
, O O
indicating O O
the O O
length O O
dependency O O
of O O
small O O
- O O
fiber O O
loss O O
in O O
these O O
neuropathies O O
. O O

Insertion O O
of O O
alternatively O O
spliced O O
exon O O
W O O
into O O
CREB B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
mRNA I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
during O O
spermatogenesis O O
results O O
in O O
a O O
polycistronic O O
RNA O O
that O O
encodes O O
two O O
novel O O
internally O O
translated O O
CREB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
repressor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
called O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CREBs I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
consisting O O
of O O
the O O
carboxy O O
- O O
terminal O O
DNA O O
- O O
binding O O
domain O O
devoid O O
of O O
the O O
transactivation O O
domains O O
. O O

A O O
continuous O O
- O O
flow O O
BIPAP O O
system O O
consists O O
of O O
a O O
high O O
- O O
flow O O
CPAP O O
system O O
, O O
a O O
reservoir O O
bag O O
, O O
and O O
a O O
pneumatically O O
controlled O O
membrane O O
valve O O
in O O
the O O
expiratory O O
limb O O
. O O

Older O O
females O O
had O O
lumbar O O
( O O
0 O O
. O O
6 O O
+ O O
/ O O
- O O
1 O O
. O O
3 O O
) O O
and O O
TB O O
( O O
1 O O
. O O
1 O O
+ O O
/ O O
- O O
1 O O
. O O
1 O O
) O O
BMD O O
Z O O
scores O O
greater O O
than O O
0 O O
( O O
both O O
, O O
p O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Smooth O O
pursuit O O
gain O O
and O O
the O O
percentage O O
of O O
total O O
eye O O
movement O O
due O O
to O O
various O O
saccadic O O
subtypes O O
were O O
computed O O
using O O
infrared O O
oculography O O
and O O
computerized O O
pattern O O
recognition O O
software O O
. O O

Upon O O
incubation O O
of O O
the O O
most O O
highly O O
purified O O
fractions O O
with O O
Mn O O
- O O
ATP O O
or O O
Mg O O
- O O
ATP O O
, O O
p40 B B_GENE
was O O
the O O
only O O
protein O O
phosphorylated O O
on O O
tyrosine O O
. O O

Consistent O O
with O O
this O O
hypothesis O O
, O O
alpha1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PDX I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevents O O
cleavage O O
of O O
BMP B B_GENE
- I I_GENE
4 I I_GENE
in O O
an O O
oocyte O O
translation O O
assay O O
. O O

A O O
p53 B B_GENE
cDNA I I_GENE
deletion O O
mutant O O
( O O
delta O O
pro O O
AE O O
) O O
, O O
which O O
lacks O O
this O O
entire O O
proline O O
- O O
rich O O
domain O O
( O O
deleted O O
for O O
amino O O
acids O O
62 O O
- O O
91 O O
) O O
, O O
was O O
created O O
and O O
characterized O O
for O O
a O O
variety O O
of O O
p53 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
functions O O
. O O

Our O O
results O O
suggest O O
that O O
Bry1 B B_GENE/B_LOCATION
/ O O
Skn7 B B_MEASURE/B_GENE
can O O
influence O O
the O O
expression O O
of O O
MCB O O
- O O
and O O
SCB O O
- O O
driven O O
gene O O
expression O O
in O O
budding O O
yeast O O
, O O
perhaps O O
including O O
genes O O
involved O O
in O O
cell O O
wall O O
metabolism O O
, O O
via O O
a O O
two O O
- O O
component O O
signal O O
transduction O O
pathway O O
which O O
activates O O
Bry1 B B_GENE
/ O O
Skn7 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
response O O
to O O
an O O
unidentified O O
signal O O
. O O

( O O
1992 O O
) O O
J O O
. O O

A O O
constructed O O
phylogenetic O O
tree O O
suggests O O
that O O
the O O
UbcP1 B B_BIO/B_GENE
protein I I_BIO/I_GENE
may O O
represent O O
a O O
member O O
of O O
a O O
distinct O O
subfamily O O
of O O
E2s B B_GENE/B_BIO
. O O

We O O
functionally O O
characterised O O
AtXPO1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
its O O
interaction O O
with O O
NESs O O
of O O
animal O O
and O O
plant O O
proteins O O
, O O
which O O
is O O
inhibited O O
by O O
the O O
cytotoxin O O
leptomycin O O
B O O
( O O
LMB O O
) O O
, O O
and O O
also O O
by O O
its O O
interaction O O
with O O
the O O
small B B_GENE
GTPase I I_GENE
Ran1 B I_GENE
in O O
the O O
yeast O O
two O O
- O O
hybrid O O
system O O
. O O

A O O
backward O O
look O O
at O O
urinary O O
tract O O
infections O O
. O O

The O O
expression O O
of O O
cor14b B B_GENE
was O O
strongly O O
impaired O O
in O O
the O O
barley O O
albino O O
mutant O O
an O O
, O O
suggesting O O
the O O
involvement O O
of O O
a O O
plastidial O O
factor O O
in O O
the O O
control O O
of O O
gene O O
expression O O
. O O

MRS O O
allowed O O
the O O
differentiation O O
of O O
the O O
following O O
metabolites O O
in O O
5 O O
patients O O
: O O
N O O
- O O
acetyl O O
- O O
aspartate O O
( O O
NAA O O
) O O
, O O
creatine O O
and O O
phosphocreatine O O
, O O
phosphorylcholine O O
and O O
glycerophosphorylcholine O O
, O O
beta O O
- O O
and O O
gamma O O
- O O
glutamate O O
( O O
GLU O O
) O O
. O O

Overall O O
, O O
free O O
- O O
chlorine O O
treatments O O
( O O
0 O O
. O O
3 O O
or O O
1 O O
. O O
0 O O
mg O O
/ O O
L O O
) O O
showed O O
significantly O O
lower O O
heterotrophic O O
plate O O
numbers O O
than O O
those O O
without O O
free O O
chlorine O O
. O O

S1 B B_GENE
nuclease I I_GENE
protection O O
mapping O O
and O O
primer O O
extension O O
analysis O O
allowed O O
us O O
to O O
propose O O
that O O
the O O
A O O
residue O O
located O O
19 O O
bp O O
upstream O O
from O O
the O O
translation O O
initiation O O
codon O O
is O O
the O O
site O O
of O O
transcription O O
initiation O O
. O O

Various O O
stimuli O O
inactivate O O
IkappaB B B_GENE
alpha I I_GENE
by O O
triggering O O
phosphorylation O O
of O O
the O O
N O O
- O O
terminal O O
residues O O
Ser32 O O
and O O
Ser36 O O
. O O

We O O
conclude O O
that O O
99mTc O O
- O O
HL91 O O
is O O
a O O
potent O O
marker O O
of O O
myocardial O O
viability O O
when O O
used O O
during O O
the O O
early O O
acute O O
phase O O
after O O
reperfusion O O
. O O

Three O O
patients O O
treated O O
with O O
amphotericin O O
B O O
, O O
single O O
course O O
as O O
well O O
as O O
multiple O O
courses O O
, O O
and O O
other O O
antifungal O O
agents O O
( O O
hydroxystilbamidine O O
and O O
miconazole O O
) O O
have O O
all O O
relapsed O O
. O O

An O O
infant O O
of O O
8 O O
months O O
with O O
congenital O O
glaucoma O O
and O O
hemophilia O O
A O O
lost O O
one O O
eye O O
due O O
to O O
haemorrhages O O
after O O
trabeculotomy O O
in O O
an O O
eye O O
hospital O O
. O O

Anderson O O
Hospital O O
and O O
Tumor O O
Institute O O
at O O
Houston O O
during O O
a O O
30 O O
- O O
year O O
interval O O
( O O
1944 O O
to O O
1974 O O
) O O
, O O
with O O
a O O
minimum O O
of O O
ten O O
years O O
of O O
follow O O
- O O
up O O
, O O
we O O
determined O O
that O O
the O O
major O O
prognostic O O
factor O O
of O O
survival O O
was O O
the O O
number O O
of O O
positive O O
nodes O O
. O O

We O O
have O O
now O O
isolated O O
cDNA O O
for O O
an O O
invertebrate B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Pax I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sea I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
urchin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
embryos I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
study O O
structural O O
diversity O O
of O O
the O O
three O O
homologous O O
loci O O
encoding O O
a O O
KN1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homeobox I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
hexaploid O O
wheat O O
genome O O
, O O
we O O
isolated O O
clones O O
from O O
a O O
cDNA O O
library O O
of O O
young O O
spikes O O
of O O
Japanese O O
common O O
wheat O O
cultivar O O
' O O
Norin O O
26 O O
' O O
. O O

Whether O O
or O O
not O O
these O O
novel O O
repeated O O
sequences O O
throughout O O
the O O
SMA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
involved O O
in O O
the O O
disease O O
remains O O
to O O
be O O
determined O O
. O O

Thus O O
, O O
Shp2 B B_GENE
regulates O O
phosphotyrosine O O
- O O
signalling O O
events O O
during O O
the O O
complex O O
ectodermal O O
- O O
mesenchymal O O
interactions O O
that O O
regulate O O
mammalian O O
budding O O
morphogenesis O O
. O O

Moyamoya O O
is O O
an O O
intriguing O O
and O O
controversial O O
syndrome O O
. O O

However O O
, O O
elimination O O
of O O
the O O
kinase O O
activity O O
of O O
DCAMKL1 B B_GENE
has O O
no O O
detectable O O
effect O O
on O O
its O O
microtubule O O
polymerization O O
activity O O
. O O

We O O
have O O
thus O O
cloned O O
two O O
yeast O O
homologs O O
of O O
mammalian B B_GENE
p220 I I_GENE
. O O

The O O
glucose O O
effect O O
on O O
the O O
pyruvate B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kinase I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gene I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
reversibly O O
antagonized O O
by O O
agents O O
increasing O O
intracellular O O
cAMP O O
. O O

An O O
identical O O
polypeptide O O
was O O
detected O O
by O O
Western O O
blot O O
analysis O O
of O O
K1F O O
virions O O
. O O

Patients O O
with O O
PLM O O
show O O
excessive O O
daytime O O
sleepiness O O
or O O
insomnia O O
. O O

Coexpression O O
of O O
CREB B B_GENE
- I I_GENE
binding I I_GENE
protein I I_GENE
( O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
/ O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
TReP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
132 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
an O O
additive O O
effect O O
on O O
promoter O O
activity O O
, O O
and O O
the O O
proteins O O
were O O
demonstrated O O
to O O
interact O O
physically O O
. O O

It O O
is O O
believed O O
that O O
the O O
operation O O
is O O
effective O O
because O O
it O O
cuts O O
the O O
spinothalamic O O
tract O O
( O O
STT O O
) O O
, O O
a O O
primary O O
pathway O O
carrying O O
nociceptive O O
information O O
from O O
the O O
spinal O O
cord O O
to O O
the O O
brain O O
in O O
humans O O
. O O

Catalase B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
plays O O
a O O
key O O
role O O
as O O
an O O
antioxidant O O
, O O
protecting O O
aerobic O O
organisms O O
from O O
the O O
toxic O O
effects O O
of O O
hydrogen O O
peroxide O O
, O O
and O O
in O O
some O O
cases O O
has O O
been O O
postulated O O
to O O
be O O
a O O
virulence O O
factor O O
. O O

Recovery O O
rates O O
of O O
energy O O
level O O
and O O
intracellular O O
pH O O
during O O
stimulation O O
at O O
100Hz O O
were O O
greater O O
than O O
those O O
observed O O
during O O
stimulation O O
at O O
30Hz O O
. O O

Recent O O
developments O O
in O O
the O O
study O O
of O O
growth O O
factors O O
: O O
GRF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
somatomedins B B_GENE/B_BACTERIUM[BIO]
. O O

New O O
concepts O O
of O O
condyloma O O
acuminata O O
in O O
children O O
. O O

This O O
is O O
the O O
first O O
clinical O O
case O O
report O O
of O O
NIHF O O
due O O
to O O
fetal O O
Kasabach O O
- O O
Merritt O O
syndrome O O
that O O
was O O
prenatally O O
diagnosed O O
by O O
sonography O O
, O O
computerized O O
tomography O O
, O O
and O O
percutaneous O O
umbilical O O
blood O O
sampling O O
. O O

Acetoacetate B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
decarboxylase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ADC B B_DISEASE/B_GENE
) O O
( O O
EC4 B B_PROTEIN[GENE]/B_DISEASE
. I I_PROTEIN[GENE]/I_DISEASE
1 I I_PROTEIN[GENE]/I_DISEASE
. I I_PROTEIN[GENE]/I_DISEASE
1 I I_PROTEIN[GENE]/I_DISEASE
. I I_PROTEIN[GENE]/I_DISEASE
4 I I_PROTEIN[GENE]/I_DISEASE
) O O
of O O
Clostridium O O
acetobutylicum O O
DSM O O
792 O O
was O O
purified O O
to O O
homogeneity O O
, O O
and O O
its O O
first O O
25 O O
N O O
- O O
terminal O O
amino O O
acids O O
were O O
determined O O
. O O

Transfer O O
of O O
health O O
care O O
to O O
natives O O
holds O O
much O O
promise O O
, O O
lecturers O O
say O O
. O O

The O O
sequence O O
of O O
the O O
127 B B_PROTEIN[GENE]/B_BIO
residue I I_PROTEIN[GENE]/I_BIO
NrfF I I_PROTEIN[GENE]/I_BIO
polypeptide I I_PROTEIN[GENE]/I_BIO
, I I_PROTEIN[GENE]/I_BIO
M I I_PROTEIN[GENE]/I_BIO
( I I_PROTEIN[GENE]/I_BIO
r I I_PROTEIN[GENE]/I_BIO
) I I_PROTEIN[GENE]/I_BIO
14 I I_PROTEIN[GENE]/I_BIO
, I I_PROTEIN[GENE]/I_BIO
522 I I_PROTEIN[GENE]/I_BIO
, O O
is O O
strikingly O O
similar O O
to O O
the O O
CcI2 B B_GENE/B_BIO
protein I I_GENE/I_BIO
of O O
R O O
. O O
capsulatus O O
, O O
especially O O
in O O
the O O
putative O O
haem O O
- O O
binding O O
motif O O
, O O
RCPQCQNQN O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O

For O O
rotating O O
stimuli O O
presented O O
to O O
the O O
dominant O O
eye O O
, O O
this O O
class O O
of O O
neurons O O
responded O O
best O O
to O O
rotation O O
of O O
the O O
visual O O
world O O
about O O
an O O
axis O O
oriented O O
near O O
the O O
horizontal O O
plane O O
and O O
approximately O O
45 O O
degrees O O
azimuth O O
. O O

None O O
of O O
these O O
patients O O
developed O O
clinical O O
events O O
before O O
disappearance O O
of O O
the O O
phospholipid O O
- O O
dependent O O
inhibitors O O
of O O
coagulation O O
. O O

In O O
spite O O
of O O
the O O
variability O O
of O O
DD95 O O
with O O
regard O O
to O O
body O O
weight O O
, O O
the O O
recovery O O
of O O
neuromuscular O O
transmission O O
in O O
the O O
patients O O
of O O
the O O
three O O
groups O O
is O O
comparable O O
. O O

We O O
have O O
studied O O
some O O
of O O
the O O
parameters O O
governing O O
the O O
expression O O
of O O
a O O
foreign O O
promoter O O
- O O
reporter O O
gene O O
construct O O
incorporated O O
into O O
herpes O O
simplex O O
virus O O
( O O
HSV O O
) O O
type O O
1 O O
. O O

Relation O O
between O O
clinical O O
and O O
roentgenological O O
scores O O
and O O
measures O O
of O O
lung O O
function O O
in O O
cystic O O
fibrosis O O
, O O
with O O
special O O
reference O O
to O O
pulmonary O O
Xenon133 O O
elimination O O
. O O

Each O O
fusion O O
leads O O
, O O
in O O
principle O O
, O O
to O O
the O O
same O O
effect O O
: O O
The O O
ret B B_GENE/B_LOCATION
tyrosine I I_GENE/I_LOCATION
kinase I I_GENE/I_LOCATION
is O O
uncoupled O O
from O O
its O O
stringent O O
physiological O O
regulation O O
by O O
replacement O O
of O O
its O O
5 O O
' O O
end O O
and O O
is O O
aberrantly O O
activated O O
by O O
the O O
5 O O
' O O
parts O O
of O O
fused O O
genes O O
in O O
thyrocytes O O
that O O
do O O
not O O
normally O O
express O O
ret B B_GENE
tyrosine I I_GENE
kinase I I_GENE
. O O

He O O
had O O
complained O O
of O O
fever O O
and O O
right O O
hypochondralgia O O
2 O O
months O O
after O O
being O O
operated O O
for O O
appendicitis O O
. O O

In O O
the O O
predicted O O
amino O O
acid O O
sequence O O
of O O
NPS1 B B_GENE
, O O
sequences O O
homologous O O
to O O
the O O
catalytic O O
domain O O
of O O
protein O O
kinases O O
were O O
found O O
. O O

Carcinoma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
production O O
may O O
have O O
played O O
a O O
role O O
in O O
the O O
development O O
of O O
the O O
observed O O
renal O O
lesions O O
. O O

These O O
results O O
provide O O
strong O O
evidence O O
that O O
conserved O O
interhelical O O
packing O O
interactions O O
in O O
the O O
gp41 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
core I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
important O O
determinants O O
of O O
HIV O O
- O O
1 O O
entry O O
and O O
its O O
inhibition O O
. O O

Lag O O
phases O O
were O O
14 O O
. O O
89 O O
hours O O
+ O O
/ O O
- O O
0 O O
. O O
77 O O
, O O
13 O O
. O O
33 O O
hours O O
+ O O
/ O O
- O O
0 O O
. O O
50 O O
, O O
20 O O
. O O
22 O O
hours O O
+ O O
/ O O
- O O
0 O O
. O O
76 O O
, O O
and O O
20 O O
. O O
00 O O
hours O O
+ O O
/ O O
- O O
0 O O
. O O
79 O O
, O O
respectively O O
, O O
for O O
endothelial O O
cell O O
- O O
induced O O
LDL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oxidation O O
. O O

Forty O O
- O O
eight O O
pregnant O O
adult O O
and O O
122 O O
fetal O O
guinea O O
pigs O O
were O O
sacrificed O O
at O O
intervals O O
throughout O O
gestation O O
and O O
the O O
carcasses O O
analyzed O O
for O O
a O O
variety O O
of O O
growth O O
parameters O O
. O O

Here O O
we O O
demonstrate O O
the O O
ability O O
of O O
oligonucleotides O O
containing O O
the O O
C4T O O
sequence O O
to O O
confer O O
heat O O
shock O O
inducibility O O
on O O
the O O
reporter O O
gene O O
and O O
show O O
that O O
the O O
presence O O
of O O
two O O
such O O
elements O O
produces O O
more O O
than O O
additive O O
effects O O
on O O
induction O O
. O O

The O O
HPV O O
E1 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
E2 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins O O
along O O
with O O
cellular O O
factors O O
, O O
are O O
required O O
for O O
replication O O
of O O
the O O
viral O O
genome O O
. O O

The O O
observed O O
alterations O O
in O O
lung O O
functions O O
in O O
these O O
subjects O O
indicate O O
that O O
individuals O O
performing O O
heavy O O
continuous O O
exercise O O
are O O
more O O
likely O O
to O O
be O O
affected O O
by O O
lower O O
O3 O O
levels O O
. O O

In O O
ten O O
other O O
endotoxin O O
- O O
albumin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
treated O O
pigs O O
PGE1 O O
infusion O O
( O O
0 O O
. O O
25 O O
micrograms O O
X O O
kg O O
- O O
1 O O
X O O
min O O
- O O
1 O O
) O O
was O O
begun O O
after O O
established O O
pulmonary O O
and O O
cardiovascular O O
dysfunction O O
, O O
for O O
closer O O
mimicking O O
of O O
clinical O O
use O O
. O O

The O O
main O O
new O O
features O O
of O O
this O O
version O O
are O O
that O O
end O O
- O O
tidal O O
PO2 O O
instead O O
of O O
inspiratory O O
PO2 O O
can O O
be O O
kept O O
constant O O
, O O
and O O
that O O
the O O
correcting O O
activity O O
of O O
both O O
controllers O O
( O O
capnostat O O
and O O
oxystat O O
) O O
is O O
proportional O O
to O O
the O O
magnitude O O
of O O
the O O
difference O O
between O O
the O O
actual O O
and O O
the O O
adjusted O O
end O O
- O O
tidal O O
PCO2 O O
or O O
PO2 O O
. O O

Like O O
the O O
human B B_GENE/B_PERSON
erythrocyte I I_GENE/I_PERSON
P4 I I_GENE/I_PERSON
. I I_GENE/I_PERSON
2 I I_GENE/I_PERSON
, O O
mouse B B_PROTEIN[GENE]/B_LOCATION
erythrocyte I I_PROTEIN[GENE]/I_LOCATION
P4 I I_PROTEIN[GENE]/I_LOCATION
. I I_PROTEIN[GENE]/I_LOCATION
2 I I_PROTEIN[GENE]/I_LOCATION
contains O O
regions O O
strikingly O O
homologous O O
with O O
the O O
transglutaminase O O
( O O
TGase O O
) O O
proteins O O
although O O
it O O
too O O
most O O
likely O O
lacks O O
TGase O O
crosslinking O O
activity O O
. O O

It O O
spans O O
20 O O
kilobases O O
, O O
consists O O
of O O
7 O O
exons O O
and O O
6 O O
introns O O
, O O
and O O
contains O O
a O O
TATA O O
motif O O
24 O O
nucleotides O O
upstream O O
of O O
the O O
transcriptional O O
start O O
site O O
. O O

Nine O O
months O O
after O O
the O O
end O O
of O O
the O O
vaccination O O
anti B B_DISEASE/B_GENE
- I B_DISEASE/I_GENE
HBsAg I B_DISEASE/I_GENE
levels O O
had O O
dropped O O
to O O
9 O O
+ O O
/ O O
- O O
4 O O
IU O O
/ O O
1 O O
( O O
M O O
+ O O
/ O O
- O O
SE O O
) O O
, O O
with O O
a O O
geometric O O
mean O O
of O O
5 O O
IU O O
/ O O
1 O O
, O O
in O O
the O O
nine O O
remaining O O
evaluable O O
patients O O
. O O

CONCLUSION O O
: O O
Ultrasound O O
biomicroscopy O O
is O O
a O O
useful O O
tool O O
for O O
the O O
evaluation O O
of O O
APVR O O
, O O
which O O
is O O
difficult O O
by O O
ordinary O O
methods O O
. O O

It O O
is O O
postulated O O
that O O
the O O
synthesis O O
of O O
the O O
peptidoglycan O O
layer O O
was O O
affected O O
by O O
the O O
antimetabolites O O
since O O
the O O
morphological O O
effects O O
were O O
strikingly O O
similar O O
to O O
those O O
caused O O
by O O
treatment O O
of O O
E O O
. O O
cloacae O O
with O O
disodium O O
edetate O O
plus O O
lysozyme B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O

Control O O
oligomers O O
of O O
scrambled O O
sequence O O
but O O
identical O O
base O O
composition O O
were O O
ineffective O O
, O O
and O O
no O O
TFO O O
- O O
induced O O
recombination O O
was O O
seen O O
in O O
a O O
control O O
LTK O O
( O O
- O O
) O O
cell O O
line O O
carrying O O
an O O
otherwise O O
identical O O
dual O O
TK B B_GENE
gene I I_GENE
construct I I_GENE
lacking O O
the O O
30 O O
- O O
bp O O
polypurine O O
target O O
site O O
. O O

( O O
i O O
) O O
Several O O
ribosomal O O
proteins O O
were O O
synthesized O O
in O O
substantial O O
excess O O
. O O

This O O
experience O O
would O O
recommend O O
consideration O O
of O O
home O O
nutritional O O
support O O
in O O
patients O O
with O O
systemic O O
scleroderma O O
when O O
the O O
disease O O
is O O
relatively O O
stable O O
and O O
no O O
major O O
organ O O
failure O O
is O O
present O O
. O O

In O O
the O O
present O O
study O O
we O O
prospectively O O
compared O O
side O O
effects O O
occurring O O
in O O
12 O O
patients O O
after O O
the O O
first O O
administration O O
of O O
low O O
- O O
dose O O
OKT3 O O
( O O
0 O O
. O O
5 O O
mg O O
twice O O
daily O O
) O O
induction O O
therapy O O
with O O
those O O
in O O
10 O O
patients O O
who O O
were O O
treated O O
with O O
a O O
conventional O O
dose O O
of O O
OKT3 O O
( O O
5 O O
mg O O
daily O O
) O O
for O O
acute O O
rejection O O
. O O

These O O
data O O
indicate O O
that O O
SB O O
203580 O O
sensitive O O
p38 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
MAP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
not O O
involved O O
in O O
okadaic O O
acid O O
mediated O O
increases O O
in O O
TRE O O
DNA O O
binding O O
and O O
transactivation O O
. O O

Together O O
, O O
these O O
results O O
indicate O O
that O O
YTS1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
bifunctional O O
protein O O
active O O
in O O
both O O
splicing O O
and O O
protein O O
synthesis O O
. O O

Oscillatory O O
flow O O
is O O
reestablished O O
in O O
the O O
model O O
at O O
the O O
capillary O O
- O O
cerebrospinal O O
fluid O O
and O O
capillary O O
- O O
venous O O
interfaces O O
. O O

Sgs B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
one O O
of O O
the O O
eight O O
known O O
genes O O
coding O O
for O O
larval O O
secretion O O
proteins O O
in O O
Drosophila O O
melanogaster O O
. O O

Human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
myotonic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dystrophy I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DMPK B B_GENE/B_LOCATION
) O O
is O O
a O O
member O O
of O O
a O O
novel O O
class O O
of O O
multidomain O O
protein O O
kinases O O
that O O
regulate O O
cell O O
size O O
and O O
shape O O
in O O
a O O
variety O O
of O O
organisms O O
. O O

The O O
human B B_GENE/B_LOCATION
BRCA1 I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
also O O
contains O O
a O O
conserved O O
E2F B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
is O O
similarly O O
regulated O O
by O O
E2F1 B B_GENE
and O O
Rb B B_GENE
. O O

The O O
translated O O
sequence O O
of O O
the O O
FLI B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LRR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
FLAP B B_DISEASE/B_GENE
) O O
encodes O O
a O O
novel O O
protein O O
not O O
represented O O
in O O
the O O
data O O
base O O
. O O

Corticosteroid O O
treatment O O
before O O
, O O
during O O
, O O
or O O
after O O
fludarabine O O
treatment O O
in O O
patients O O
with O O
alkylator O O
- O O
resistant O O
, O O
low O O
- O O
grade O O
lymphoid O O
malignancies O O
who O O
have O O
not O O
received O O
PCP O O
prophylaxis O O
is O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
opportunistic O O
pulmonary O O
infections O O
. O O

In O O
this O O
respect O O
, O O
the O O
promoter O O
structure O O
of O O
COX B B_BIO/B_GENE
genes I I_BIO/I_GENE
resemble O O
those O O
of O O
many O O
house O O
- O O
keeping O O
genes O O
. O O

In O O
vitro O O
, O O
cytokine O O
- O O
or O O
hypoxia O O
- O O
induced O O
up O O
- O O
regulation O O
of O O
Fas B B_GENE
expression O O
is O O
associated O O
with O O
RTC O O
apoptosis O O
. O O

The O O
site O O
of O O
acetylation O O
of O O
Tat B B_GENE
was O O
mapped O O
to O O
the O O
double O O
- O O
lysine O O
motif O O
in O O
a O O
highly O O
conserved O O
region O O
, O O
( O O
49 O O
) O O
RKKRRQ O O
( O O
54 O O
) O O
, O O
of O O
the O O
basic O O
RNA O O
- O O
binding O O
motif O O
of O O
Tat B B_GENE/B_DISEASE
. O O

These O O
results O O
suggest O O
that O O
the O O
PVB O O
therapy O O
is O O
not O O
sufficient O O
to O O
cure O O
the O O
cases O O
with O O
choriocarcinoma O O
element O O
or O O
bulky O O
metastasis O O
. O O

The O O
KEMAR O O
measurements O O
show O O
that O O
the O O
two O O
models O O
give O O
an O O
improvement O O
of O O
the O O
signal O O
- O O
to O O
- O O
noise O O
ratio O O
of O O
approximately O O
7 O O
. O O
5 O O
dB O O
in O O
a O O
diffuse O O
sound O O
field O O
. O O

Indirect O O
determination O O
of O O
maximal O O
O2 O O
consumption O O
in O O
man O O
. O O

Using O O
unidirectional O O
PCR O O
we O O
isolated O O
a O O
361 O O
- O O
bp O O
5 O O
' O O
promoter O O
region O O
and O O
delineated O O
the O O
intronic O O
/ O O
exonic O O
boundaries O O
which O O
include O O
a O O
non O O
- O O
coding O O
exon O O
1 O O
, O O
a O O
single O O
intron O O
, O O
and O O
a O O
coding O O
exon O O
2 O O
, O O
a O O
structure O O
that O O
is O O
typical O O
of O O
genes O O
of O O
the O O
RNase B B_SPECIES[BIO]/B_GENE
A I I_SPECIES[BIO]/I_GENE
superfamily I I_SPECIES[BIO]/I_GENE
. O O

D O O
. O O

When O O
lipid O O
X O O
was O O
combined O O
with O O
ticarcillin O O
, O O
survival O O
differences O O
were O O
both O O
significant O O
and O O
prolonged O O
. O O

Central O O
treatment O O
unit O O
saves O O
nurses O O
, O O
adds O O
income O O
, O O
improves O O
care O O
. O O

Gold O O
flaxseed O O
( O O
whole O O
or O O
ground O O
) O O
fed O O
at O O
levels O O
of O O
5 O O
or O O
15 O O
% O O
were O O
compared O O
to O O
a O O
1 O O
. O O
5 O O
% O O
menhaden O O
oil O O
or O O
a O O
typical O O
control O O
layer O O
ration O O
. O O

An O O
enhancement O O
of O O
benign O O
liver O O
tumors O O
( O O
tumorigenic O O
effect O O
) O O
was O O
observed O O
only O O
in O O
CF1 O O
male O O
mice O O
( O O
17 O O
/ O O
56 O O
at O O
the O O
only O O
tested O O
dose O O
: O O
400 O O
ppm O O
vs O O
. O O

This O O
C O O
- O O
terminal O O
domain O O
contains O O
several O O
YxxI O O
/ O O
L O O
motifs O O
reminiscent O O
of O O
LMP2A B B_GENE/B_DISEASE
and O O
a O O
putative O O
TRAF B B_GENE/B_LOCATION
binding I B_GENE/I_LOCATION
site I B_GENE/I_LOCATION
as O O
in O O
LMP1 B B_SPECIES[BIO]/B_GENE
. O O

Omitting O O
part O O
of O O
the O O
experimental O O
NOE O O
- O O
derived O O
distances O O
results O O
in O O
reduced O O
restraint O O
violations O O
and O O
lower O O
R O O
factors O O
but O O
impairs O O
structural O O
convergence O O
in O O
the O O
rMD O O
refinement O O
. O O

Cardiac O O
lesion O O
in O O
exotoxic O O
shock O O

Risk O O
factors O O
for O O
atherosclerosis O O
related O O
to O O
nutrition O O
are O O
hypercholesterolemia O O
, O O
hyperglycemia O O
- O O
diabetes O O
, O O
and O O
for O O
hypertension O O
, O O
obesity O O
, O O
high O O
salt O O
intake O O
, O O
and O O
excessive O O
use O O
of O O
alcohol O O
. O O

This O O
mutation O O
was O O
associated O O
with O O
reduced O O
or O O
absent O O
expression O O
of O O
TGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RI I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
p53 B B_GENE
protein I I_GENE
in O O
tumor O O
tissues O O
. O O

However O O
, O O
they O O
had O O
no O O
cross O O
- O O
resistance O O
to O O
quinolone O O
, O O
josamycin O O
and O O
tylosin O O
. O O

Seventy O O
- O O
nine O O
percent O O
of O O
the O O
children O O
screened O O
and O O
91 O O
. O O
0 O O
% O O
of O O
the O O
children O O
with O O
PbB O O
at O O
least O O
10 O O
micrograms O O
/ O O
dL O O
were O O
Hispanic O O
. O O

Normal O O
dogs O O
were O O
exposed O O
to O O
either O O
10 O O
, O O
15 O O
, O O
or O O
30 O O
Gy O O
of O O
X O O
rays O O
to O O
a O O
single O O
hemisphere O O
and O O
the O O
gross O O
and O O
histopathologic O O
changes O O
were O O
evaluated O O
qualitatively O O
. O O

YACs O O
selected O O
from O O
our O O
contig O O
will O O
be O O
the O O
starting O O
point O O
for O O
the O O
cloning O O
of O O
the O O
LGMD2B B B_GENE/B_BIO
gene I I_GENE/I_BIO
and O O
thereby O O
establish O O
the O O
biological O O
basis O O
for O O
this O O
form O O
of O O
muscular O O
dystrophy O O
and O O
its O O
relationship O O
with O O
the O O
other O O
limb O O
- O O
girdle O O
muscular O O
dystrophies O O
. O O

The O O
amount O O
of O O
ERCC1 B B_GENE
detectable O O
by O O
immunoblotting O O
is O O
reduced O O
in O O
group O O
1 O O
, O O
group O O
4 O O
and O O
XP O O
- O O
F O O
extracts O O
. O O

Optimized O O
USF B B_LOCATION/B_GENE
and O O
MYC B B_GENE/B_MEASURE
DNA O O
- O O
binding O O
sites O O
, O O
which O O
differ O O
in O O
the O O
nucleotides O O
bordering O O
the O O
hexanucleotide O O
box O O
displace O O
the O O
E B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
C4 I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
in O O
competition O O
assays O O
but O O
with O O
lesser O O
efficiency O O
than O O
the O O
E B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
C4 I I_GENE/I_MEASURE
site I I_GENE/I_MEASURE
itself O O
. O O

Screening O O
of O O
human O O
cDNA O O
libraries O O
has O O
identified O O
two O O
different O O
5 O O
' O O
- O O
termini O O
and O O
alternatively O O
spliced O O
forms O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Fli I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Fli B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1b I I_GENE/I_LOCATION
) O O
, O O
suggesting O O
the O O
possible O O
existence O O
of O O
two O O
independent O O
promoters O O
. O O

A O O
surge O O
in O O
the O O
rate O O
of O O
ascorbyl O O
radical O O
production O O
, O O
directly O O
correlated O O
with O O
oxyradical O O
stress O O
and O O
an O O
abrupt O O
fall O O
in O O
superoxide B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dismutase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
in O O
the O O
granuloma O O
, O O
indicates O O
' O O
switching O O
on O O
' O O
of O O
a O O
free O O
radical O O
- O O
dependent O O
machinery O O
for O O
the O O
formation O O
of O O
granuloma O O
after O O
vasectomy O O
. O O

After O O
5 O O
- O O
h O O
thermal O O
induction O O
of O O
cells O O
carrying O O
the O O
runaway O O
recombinant O O
pBS1 O O
, O O
protein B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B2 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constituted O O
40 O O
% O O
of O O
the O O
soluble O O
protein O O
fraction O O
of O O
the O O
cells O O
. O O

Peak O O
reactive O O
hyperemia O O
( O O
mL O O
. O O
min O O
- O O
1 O O
. O O
100 O O
mL O O
- O O
1 O O
) O O
was O O
determined O O
in O O
the O O
calf O O
and O O
forearm O O
immediately O O
before O O
and O O
after O O
12 O O
weeks O O
of O O
training O O
. O O

These O O
characteristics O O
add O O
to O O
the O O
suitability O O
of O O
NM441 O O
as O O
an O O
effective O O
prodrug O O
of O O
NM394 O O
. O O

Vorozole O O
( O O
Rivizor O O
) O O
is O O
a O O
potent O O
and O O
stereospecific O O
inhibitor O O
of O O
aromatase B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O O
shown O O
promising O O
endocrine O O
effects O O
in O O
phase O O
I O O
studies O O
. O O

In O O
5 O O
cases O O
, O O
combined O O
sensitization O O
to O O
mercury O O
and O O
other O O
metal O O
salts O O
, O O
particularly O O
gold O O
sodium O O
thiosulfate O O
( O O
GST O O
) O O
and O O
palladium O O
chloride O O
( O O
PDC O O
) O O
, O O
was O O
observed O O
. O O

Gene O O
structure O O
and O O
precursor O O
processing O O
. O O

The O O
content O O
of O O
monoamine O O
metabolites O O
, O O
5 O O
- O O
hydroxyindoleacetic O O
acid O O
, O O
5 O O
- O O
HIAA O O
, O O
and O O
homovanillic O O
acid O O
( O O
HVA O O
) O O
, O O
and O O
- O O
- O O
for O O
17 O O
patients O O
- O O
- O O
tryptophan O O
, O O
in O O
the O O
cerebrospinal O O
fluid O O
was O O
determined O O
. O O

One O O
month O O
after O O
administration O O
of O O
131I O O
, O O
the O O
29 O O
cats O O
evaluated O O
were O O
clinically O O
improved O O
, O O
and O O
24 O O
( O O
83 O O
% O O
) O O
of O O
the O O
29 O O
cats O O
evaluated O O
had O O
normal O O
serum O O
T4 O O
concentrations O O
, O O
3 O O
cats O O
( O O
10 O O
% O O
) O O
remained O O
hyperthyroxinemic O O
, O O
and O O
2 O O
cats O O
( O O
7 O O
% O O
) O O
were O O
hypothyroxinemic O O
. O O

These O O
findings O O
suggest O O
that O O
T3R B B_GENE
can O O
repress O O
or O O
activate O O
transcription O O
while O O
tethered O O
to O O
the O O
LBD O O
of O O
GAL4 B B_PROTEIN[GENE]/B_SPECIES[BIO]
- O O
RXR B B_GENE
and O O
that O O
heterodimerization O O
can O O
occur O O
in O O
vivo O O
without O O
stabilization O O
by O O
hormone O O
response O O
elements O O
. O O

Most O O
interestingly O O
, O O
although O O
the O O
effector O O
plasmid O O
containing O O
the O O
ICP27 B B_GENE
gene I I_GENE
had O O
little O O
effect O O
on O O
its O O
own O O
, O O
two O O
different O O
and O O
marked O O
effects O O
depending O O
on O O
the O O
target O O
were O O
observed O O
when O O
ICP27 B B_GENE
was O O
combined O O
with O O
ICP4 B B_GENE
or O O
ICP0 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
both O O
. O O

In O O
renal O O
vein O O
thrombosis O O
, O O
similar O O
pattern O O
to O O
acute O O
tubular O O
necrosis O O
was O O
found O O
but O O
RI O O
venography O O
was O O
helpful O O
. O O

TOM1 B B_GENE/B_PERSON
encodes O O
a O O
member O O
of O O
the O O
hect B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
domain O O
- O O
containing O O
E3 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
ubiquitin B I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
ligase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
family O O
that O O
is O O
required O O
for O O
growth O O
at O O
elevated O O
temperatures O O
. O O

Genomic O O
clones O O
containing O O
the O O
C O O
. O O
briggsae O O
gene O O
are O O
able O O
to O O
completely O O
rescue O O
the O O
unc B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
119 I I_DISEASE/I_GENE
phenotype I I_DISEASE/I_GENE
in O O
transgenic O O
C O O
. O O
elegans O O
mutants O O
. O O

The O O
rapid O O
decrease O O
of O O
plasma O O
potassium O O
during O O
the O O
first O O
two O O
hours O O
of O O
standard O O
HD O O
causes O O
a O O
membrane O O
hyperpolarization O O
. O O

Region O O
- O O
specific O O
enhancers O O
near O O
two O O
mammalian B B_GENE/B_LOCATION
homeo I I_GENE/I_LOCATION
box I I_GENE/I_LOCATION
genes I I_GENE/I_LOCATION
define O O
adjacent O O
rostrocaudal O O
domains O O
in O O
the O O
central O O
nervous O O
system O O
. O O

In O O
this O O
study O O
, O O
we O O
report O O
the O O
cloning O O
and O O
sequencing O O
of O O
several O O
overlapping O O
cDNAs O O
encoding O O
approximately O O
4 O O
. O O
1 O O
kb O O
of O O
the O O
human B B_GENE
homologue I I_GENE
of I I_GENE
Wnt I I_GENE
- I I_GENE
5A I I_GENE
. O O

Subtype O O
- O O
and O O
response O O
element O O
- O O
dependent O O
differences O O
in O O
transactivation O O
by O O
peroxisome B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

MRI O O
visualization O O
of O O
proteoglycan O O
depletion O O
in O O
articular O O
cartilage O O
via O O
intravenous O O
administration O O
of O O
Gd O O
- O O
DTPA O O
. O O

We O O
then O O
developed O O
a O O
yeast O O
artificial O O
chromosome O O
( O O
YAC O O
) O O
contig O O
for O O
this O O
region O O
. O O

We O O
suggest O O
that O O
the O O
induction O O
of O O
IFNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
requires O O
cooperation O O
between O O
alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
F1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
IRF B B_GENE
- I I_GENE
1 I I_GENE
. O O

Heterologous O O
hybridization O O
with O O
a O O
rps12 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
gene I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
specific O O
probe O O
from O O
Euglena O O
has O O
revealed O O
the O O
presence O O
of O O
rps12 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
homologous I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequences I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
within O O
the O O
inverted O O
repeat O O
of O O
Spirodela O O
chloroplast O O
DNA O O
on O O
the O O
fragment B B_GENE
BamHI I I_GENE
- I I_GENE
V I I_GENE
. O O

However O O
, O O
to O O
date O O
, O O
no O O
viable O O
in O O
vitro O O
- O O
generated O O
deletion O O
mutant O O
of O O
PSTVd O O
has O O
been O O
reported O O
. O O

In O O
HMEC O O
stably O O
transfected O O
with O O
an O O
ER B B_GENE
mutant I I_GENE
containing O O
a O O
deletion O O
in O O
the O O
second O O
zinc O O
finger O O
of O O
the O O
DNA O O
- O O
binding O O
domain O O
, O O
E O O
and O O
HT O O
had O O
different O O
effects O O
on O O
EBBP B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
expression O O
; O O
EBBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulation O O
by O O
E O O
was O O
dramatically O O
reduced O O
while O O
the O O
effects O O
of O O
HT O O
were O O
augmented O O
. O O

The O O
gag B B_GENE/B_LOCATION
- O O
myc B B_BACTERIUM[BIO]/B_GENE
proteins O O
encoded O O
by O O
these O O
variants O O
efficiently O O
localized O O
to O O
the O O
cell O O
nucleus O O
. O O

UPR O O
elements O O
present O O
in O O
other O O
ER O O
chaperone O O
genes O O
, O O
such O O
as O O
yeast B B_GENE
KAR2 I I_GENE
( O O
BiP B B_GENE/B_LOCATION
) O O
, O O
mammalian B B_GENE/B_DISEASE
GRP78 I I_GENE/I_DISEASE
( O O
BiP B B_GENE/B_DISEASE
) O O
, O O
and O O
GRP94 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
function O O
in O O
an O O
analogous O O
manner O O
to O O
that O O
in O O
FKB2 B B_GENE/B_BIO
. O O

The O O
objective O O
of O O
this O O
research O O
was O O
to O O
determine O O
if O O
ergotamine O O
, O O
an O O
ergopeptine O O
alkaloid O O
isolated O O
from O O
Neotyphodium O O
- O O
infected O O
grasses O O
and O O
associated O O
with O O
toxicoses O O
in O O
livestock O O
, O O
altered O O
plasma O O
concentrations O O
of O O
reproductive O O
hormones O O
in O O
follicular O O
phase O O
heifers O O
and O O
in O O
cows O O
given O O
a O O
progestin O O
implant O O
. O O

Acute O O
spontaneous O O
subdural O O
haematoma O O
. O O

Strains O O
carrying O O
a O O
snf1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O O
unable O O
to O O
grow O O
on O O
sucrose O O
, O O
galactose O O
, O O
maltose O O
, O O
melibiose O O
, O O
or O O
nonfermentable O O
carbon O O
sources O O
; O O
utilization O O
of O O
these O O
carbon O O
sources O O
is O O
regulated O O
by O O
glucose O O
repression O O
. O O

2 O O
) O O
Depending O O
on O O
the O O
structure O O
, O O
certain O O
compounds O O
are O O
sequestered O O
in O O
the O O
cornea O O
( O O
presumably O O
the O O
stroma O O
) O O
and O O
form O O
a O O
release O O
system O O
into O O
the O O
anterior O O
aqueous O O
. O O

The O O
results O O
of O O
the O O
neural O O
network O O
were O O
compared O O
with O O
those O O
of O O
a O O
density O O
mask O O
( O O
thresholds O O
, O O
- O O
750 O O
/ O O
- O O
300 O O
H O O
) O O
, O O
with O O
a O O
radiologist O O
serving O O
as O O
the O O
gold O O
standard O O
. O O

These O O
data O O
also O O
suggest O O
the O O
existence O O
of O O
a O O
mechanism O O
by O O
which O O
regulatory O O
subunits O O
modulate O O
the O O
PI B B_GENE
3 I I_GENE
- I I_GENE
kinase I I_GENE
- O O
mediated O O
signals O O
, O O
independent O O
of O O
the O O
kinase O O
activity O O
, O O
possibly O O
through O O
subcellular O O
localization O O
of O O
the O O
catalytic O O
subunit O O
or O O
interaction O O
with O O
additional O O
signaling O O
molecules O O
. O O

These O O
results O O
suggest O O
that O O
the O O
PVB O O
therapy O O
is O O
not O O
sufficient O O
to O O
cure O O
the O O
cases O O
with O O
choriocarcinoma O O
element O O
or O O
bulky O O
metastasis O O
. O O

Right O O
- O O
sided O O
hemiplegia O O
of O O
5 O O
years O O
duration O O
occurred O O
in O O
the O O
remaining O O
case O O
. O O

Plasmid O O
subclones O O
of O O
the O O
hr1a B B_GENE/B_SPECIES[BIO]
- O O
containing O O
AcMNPV O O
HindIII B B_MEASURE/B_PROTEIN[GENE]
- O O
N O O
fragment O O
were O O
examined O O
for O O
their O O
ability O O
to O O
replicate O O
in O O
virus O O
- O O
infected O O
( O O
Spodoptera O O
frugiperda O O
) O O
Sf9 O O
cells O O
, O O
and O O
to O O
stimulate O O
transcription O O
when O O
linked O O
in O O
cis O O
with O O
a O O
39K B B_GENE
gene I I_GENE
promoter I I_GENE
- I I_GENE
beta I I_GENE
- I I_GENE
glucuronidase I I_GENE
fusion I I_GENE
and O O
cotransfected O O
into O O
cells O O
along O O
with O O
a O O
plasmid O O
( O O
ple O O
- O O
1 O O
) O O
containing O O
the O O
gene O O
encoding O O
the O O
trans O O
- O O
acting O O
factor O O
IE B B_GENE
- I I_GENE
1 I I_GENE
. O O

Divergent O O
regions O O
of O O
the O O
posterior O O
left O O
hemisphere O O
used O O
for O O
decoding O O
and O O
storage O O
of O O
information O O
emerged O O
in O O
each O O
working O O
memory O O
versus O O
control O O
task O O
comparison O O
. O O

In O O
normal O O
B O O
cells O O
stimulated O O
by O O
LPS O O
or O O
IL B B_LOCATION/B_GENE
- I I_LOCATION/I_GENE
4 I I_LOCATION/I_GENE
, O O
new O O
complexes O O
appear O O
that O O
bind O O
to O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
NF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
respectively O O
, O O
located O O
within O O
the O O
- O O
125 O O
/ O O
- O O
101 O O
region O O
. O O

Here O O
, O O
we O O
describe O O
the O O
crystal O O
structure O O
at O O
2 O O
. O O
5 O O
A O O
resolution O O
of O O
a O O
fragment O O
of O O
the O O
integrase B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
of I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Rous I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sarcoma I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
residues I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
49 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
286 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
both O O
the O O
conserved O O
catalytic O O
domain O O
and O O
a O O
modulatory O O
DNA O O
- O O
binding O O
domain O O
( O O
C O O
domain O O
) O O
. O O

Vectorcardiography O O
in O O
coronary O O
patients O O
with O O
the O O
electrocardiographic O O
RS O O
segment O O
in O O
the O O
V1 O O
lead O O

The O O
B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
aphidicola I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
argS I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
rrn I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragments I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
endosymbionts O O
from O O
seven O O
species O O
of O O
aphids O O
had O O
promoter O O
activities O O
in O O
E O O
. O O
coli O O
which O O
ranged O O
from O O
6 O O
to O O
135 O O
% O O
of O O
that O O
observed O O
with O O
a O O
comparable O O
DNA O O
fragment O O
of O O
E B B_BIO/B_GENE
. I I_BIO/I_GENE
coli I I_BIO/I_GENE
rrnB I I_BIO/I_GENE
. O O

The O O
adeno O O
- O O
associated O O
virus O O
type O O
2 O O
( O O
AAV O O
- O O
2 O O
) O O
Rep78 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Rep68 B B_MEASURE/B_GENE
regulatory O O
proteins O O
are O O
pleiotropic O O
effectors O O
of O O
viral O O
and O O
cellular O O
DNA O O
replication O O
, O O
of O O
cellular O O
transformation O O
by O O
viral O O
and O O
cellular O O
oncogenes O O
, O O
and O O
of O O
homologous O O
and O O
heterologous O O
gene O O
expression O O
. O O

Role O O
of O O
the O O
CCAAT B B_GENE
/ I I_GENE
enhancer I I_GENE
binding I I_GENE
protein I I_GENE
- I I_GENE
alpha I I_GENE
transcription I I_GENE
factor I I_GENE
in O O
the O O
glucocorticoid O O
stimulation O O
of O O
p21waf1 B B_GENE
/ O O
cip1 B B_GENE/B_DISEASE
gene O O
promoter O O
activity O O
in O O
growth O O
- O O
arrested O O
rat O O
hepatoma O O
cells O O
. O O

Long O O
- O O
term O O
ambulatory O O
measurement O O
of O O
transcutaneous O O
arterial O O
CO2 O O
pressure O O
( O O
PCO2 O O
) O O
offers O O
an O O
opportunity O O
to O O
test O O
directly O O
the O O
co O O
- O O
occurrence O O
of O O
panic O O
and O O
hyperventilation O O
under O O
natural O O
conditions O O
. O O

The O O
highly O O
conserved O O
region O O
of O O
U6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
snRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
a O O
structural O O
similarity O O
with O O
the O O
catalytic O O
domain O O
of O O
the O O
negative O O
strand O O
of O O
the O O
satellite O O
RNA O O
of O O
tobacco O O
ring O O
spot O O
virus O O
[ O O
( O O
- O O
) O O
sTRSV O O
] O O
, O O
suggesting O O
that O O
the O O
highly O O
conserved O O
region O O
of O O
U6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
snRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
forms O O
the O O
catalytic O O
center O O
. O O

This O O
report O O
describes O O
the O O
isolation O O
and O O
recombinant O O
expression O O
of O O
a O O
cDNA O O
clone O O
encoding O O
HER4 B B_GENE
, O O
the O O
fourth O O
member O O
of O O
the O O
human B B_GENE
epidermal I I_GENE
growth I I_GENE
factor I I_GENE
receptor I I_GENE
( O O
EGFR B B_GENE/B_LOCATION
) O O
family O O
. O O

In O O
conclusion O O
, O O
when O O
pulmonary O O
abnormalities O O
are O O
found O O
in O O
HTLV O O
- O O
1 O O
carriers O O
, O O
we O O
should O O
be O O
careful O O
in O O
determining O O
whether O O
such O O
pulmonary O O
involvements O O
are O O
etiologically O O
related O O
to O O
HTLV O O
- O O
1 O O
infection O O
. O O

A O O
clinical O O
trial O O
of O O
a O O
new O O
mitomycin O O
C O O
derivative O O
, O O
KW O O
- O O
2083 O O
( O O
7 O O
- O O
N O O
- O O
( O O
p O O
- O O
hydroxyphenyl O O
) O O
- O O
mitomycin O O
C O O
) O O

Excess O O
recombinant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PTB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
squelches O O
the O O
splicing O O
switch O O
and O O
reestablishes O O
exon O O
skipping O O
as O O
the O O
predominant O O
splicing O O
pathway O O
. O O

A O O
child O O
presumed O O
to O O
have O O
the O O
21 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydroxylase I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficiency O O
form O O
of O O
congenital O O
adrenal O O
hyperplasia O O
was O O
studied O O
extensively O O
as O O
an O O
infant O O
. O O

Inability O O
of O O
niacin O O
to O O
protect O O
from O O
in O O
vivo O O
hyperoxia O O
or O O
in O O
vitro O O
microsomal O O
lipid O O
peroxidation O O
. O O

MDA O O
- O O
MB O O
- O O
468 O O
cells O O
were O O
stably O O
transfected O O
with O O
either O O
a O O
plasmid O O
having O O
a O O
CMV B B_GENE
promoter I I_GENE
- O O
driven O O
rabbit B B_GENE
beta I I_GENE
- I I_GENE
globin I I_GENE
gene I I_GENE
or O O
plasmids O O
having O O
a O O
CMV B B_GENE
promoter I I_GENE
- O O
driven O O
chimeric O O
gadd45 B B_GENE/B_SPECIES[BIO]
5 O O
" O O
- O O
UTR O O
- O O
rabbit B B_GENE
beta I I_GENE
- I I_GENE
globin I I_GENE
gene O O
, O O
where O O
the O O
entire B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gadd45 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
" I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
UTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
298 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
a O O
45 O O
bp O O
subfragment O O
of O O
the O O
gadd45 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
" I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
UTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
10 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
55 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
positioned O O
at O O
the O O
5 O O
" O O
- O O
end O O
of O O
the O O
rabbit B B_GENE
beta I I_GENE
- I I_GENE
globin I I_GENE
gene I I_GENE
. O O

The O O
University O O
of O O
North O O
Carolina O O
caries O O
risk O O
assessment O O
was O O
conducted O O
between O O
1986 O O
and O O
1989 O O
with O O
5000 O O
children O O
initially O O
in O O
grades O O
1 O O
and O O
5 O O
from O O
low O O
fluoride O O
sites O O
in O O
South O O
Carolina O O
and O O
Maine O O
. O O

Following O O
EGF B B_GENE
or O O
NGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O O
of O O
the O O
v O O
- O O
CrkPC12 O O
cells O O
, O O
the O O
v B B_GENE
- I I_GENE
Crk I I_GENE
protein O O
itself O O
became O O
tyrosine O O
phosphorylated O O
within O O
1 O O
min O O
. O O

BCR B B_GENE/B_LOCATION
- O O
ABL B B_PROTEIN[GENE]/B_LOCATION
expression O O
confers O O
cross O O
- O O
resistance O O
to O O
multiple O O
genotoxic O O
anticancer O O
drugs O O
by O O
inhibition O O
of O O
the O O
apoptotic O O
response O O
to O O
DNA O O
damage O O
in O O
association O O
with O O
cell O O
cycle O O
arrest O O
at O O
the O O
G2 O O
- O O
M O O
restriction O O
point O O
. O O

RESULTS O O
: O O
After O O
lavage O O
, O O
a O O
rapid O O
decrease O O
in O O
arterial O O
pH O O
and O O
PaO2 O O
, O O
and O O
an O O
increase O O
in O O
PaCO2 O O
and O O
PIP O O
were O O
observed O O
in O O
all O O
animals O O
. O O

CONCLUSIONS O O
: O O
Elevation O O
of O O
TBARS O O
and O O
decrease O O
of O O
GSH O O
show O O
the O O
presence O O
of O O
oxidative O O
stress O O
during O O
the O O
PFD O O
treatment O O
with O O
hemodiafilter O O
SG3 O O
. O O

Ozone O O
uptake O O
was O O
assessed O O
in O O
awake O O
, O O
spontaneously O O
breathing O O
Fischer O O
- O O
344 O O
Sprague O O
- O O
Dawley O O
, O O
and O O
Long O O
- O O
Evans O O
rats O O
and O O
Hartley O O
guinea O O
pigs O O
to O O
provide O O
data O O
on O O
the O O
dosimetry O O
of O O
O3 O O
in O O
small O O
laboratory O O
animals O O
. O O

E O O
. O O
R O O
. O O
C O O
. O O
P O O
. O O

is O O
an O O
important O O
advance O O
in O O
diagnosis O O
. O O

Deletion O O
analysis O O
of O O
the O O
3 O O
. O O
5kb O O
DNA O O
fragment O O
revealed O O
that O O
the O O
region O O
between O O
- O O
125 O O
to O O
+ O O
1 O O
, O O
containing O O
a O O
single O O
Sp1 B B_GENE
binding I I_GENE
site I I_GENE
, O O
is O O
essential O O
for O O
transcription O O
of O O
the O O
embigin B B_GENE
gene I I_GENE
. O O

Resistance O O
to O O
Mup O O
was O O
classified O O
as O O
low O O
( O O
minimal O O
inhibitory O O
concentration O O
[ O O
MIC O O
] O O
> O O
or O O
= O O
8 O O
microg O O
/ O O
mL O O
) O O
or O O
high O O
( O O
MIC O O
> O O
or O O
= O O
512 O O
microg O O
/ O O
mL O O
) O O
degree O O
. O O

Extragonadal O O
endodermal O O
sinus O O
tumors O O
in O O
the O O
head O O
and O O
neck O O
are O O
very O O
rare O O
. O O

Lesions O O
of O O
this O O
kind O O
resemble O O
those O O
in O O
vitamin O O
A O O
- O O
deficient O O
chickens O O
and O O
are O O
the O O
first O O
to O O
be O O
induced O O
by O O
excess O O
vitamin O O
E O O
. O O

Essential O O
fatty O O
acid O O
deficiency O O
in O O
childhood O O

The O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
GF O O
- O O
109203X O O
abolished O O
the O O
activation O O
by O O
phorbol O O
ester O O
and O O
inhibited O O
the O O
effect O O
of O O
CCK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
by O O
78 O O
% O O
but O O
had O O
no O O
effect O O
on O O
EGF B B_GENE
- O O
activated O O
MAPK B B_GENE
activity O O
. O O

Activated O O
FGFR3 B B_GENE/B_LOCATION
predominantly O O
interacts O O
with O O
GRB2 B B_GENE
. I I_GENE
Sos I I_GENE
in O O
complex O O
with O O
a O O
previously O O
identified O O
90 O O
- O O
kDa O O
protein O O
and O O
designated O O
protein B B_GENE
80K I I_GENE
- I I_GENE
H I I_GENE
. O O

Evidence O O
for O O
a O O
role O O
of O O
Smad6 B B_GENE
in O O
chick O O
cardiac O O
development O O
. O O

Excellent O O
results O O
were O O
recorded O O
in O O
390 O O
( O O
83 O O
. O O
69 O O
% O O
) O O
of O O
the O O
patients O O
, O O
improvement O O
in O O
46 O O
( O O
9 O O
. O O
87 O O
% O O
) O O
where O O
in O O
the O O
majority O O
a O O
varicose O O
complex O O
was O O
involved O O
. O O

Mutational O O
analysis O O
of O O
yeast B B_GENE/B_BIO
CEG1 I I_GENE/I_BIO
demonstrated O O
that O O
four O O
of O O
the O O
five O O
conserved O O
motifs O O
are O O
essential O O
for O O
capping B B_GENE/B_LOCATION
enzyme I I_GENE/I_LOCATION
function O O
in O O
vivo O O
. O O

We O O
report O O
on O O
a O O
case O O
discovered O O
in O O
a O O
13 O O
year O O
- O O
old O O
girl O O
presenting O O
with O O
anaemia O O
. O O

STUDY O O
SELECTION O O
: O O
Not O O
applicable O O
. O O

Co O O
- O O
expression O O
of O O
PLD1 B B_GENE
in O O
COS O O
- O O
7 O O
cells O O
with O O
the O O
two O O
recombinant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CK2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunits I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
alpha O O
or O O
beta O O
, O O
suggests O O
that O O
the O O
association O O
of O O
PLD1 B B_GENE
with O O
the O O
kinase O O
is O O
through O O
the O O
beta O O
subunit O O
. O O

For O O
capsules O O
containing O O
only O O
the O O
drug O O
, O O
the O O
value O O
of O O
T50 O O
increased O O
as O O
the O O
particle O O
size O O
of O O
the O O
drug O O
decreased O O
. O O

The O O
LAB O O
in O O
the O O
cecum O O
( O O
mean O O
9 O O
. O O
4 O O
log O O
CFU O O
/ O O
g O O
) O O
increased O O
slightly O O
with O O
increasing O O
abattoir O O
holding O O
time O O
. O O

Our O O
objective O O
was O O
to O O
find O O
possible O O
predictors O O
for O O
the O O
expression O O
and O O
progression O O
of O O
LJM O O
and O O
to O O
evaluate O O
the O O
relationship O O
between O O
LJM O O
and O O
other O O
long O O
- O O
term O O
complications O O
of O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O O
diabetes O O
mellitus O O
. O O

Human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
recombinant I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
erythropoietin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
r B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
HuEPO I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
EprexR B B_MEASURE/B_PROTEIN[GENE]
) O O
was O O
administered O O
to O O
8 O O
children O O
with O O
chronic O O
renal O O
failure O O
and O O
high O O
transfusion O O
requirement O O
. O O

CONCLUSIONS O O
: O O
LHB O O
is O O
simple O O
, O O
easy O O
and O O
safe O O
to O O
implement O O
, O O
and O O
is O O
the O O
only O O
technique O O
capable O O
of O O
maintaining O O
independent O O
upper O O
and O O
lower O O
body O O
perfusion O O
pressure O O
. O O

Northern O O
analyses O O
further O O
confirm O O
that O O
the O O
expression O O
of O O
endogenous O O
alpha B B_GENE
- I I_GENE
ENaC I I_GENE
gene I I_GENE
in O O
salivary O O
Pa O O
- O O
4 O O
cells O O
is O O
suppressed O O
by O O
an O O
ectopic O O
HMGI B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overexpression O O
. O O

Removal O O
of O O
cyclin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
cdks B B_LOCATION/B_GENE
) O O
or O O
cdk2 B B_GENE
from O O
these O O
extracts O O
using O O
affinity O O
matrices O O
severely O O
inhibits O O
initiation O O
of O O
S O O
phase O O
. O O

Gel O O
mobility O O
shift O O
analyses O O
reveal O O
that O O
FRTL O O
- O O
5 O O
thyroid O O
cell O O
nuclear O O
extracts O O
form O O
a O O
specific O O
protein O O
/ O O
DNA O O
complex O O
with O O
this O O
region O O
, O O
which O O
is O O
prevented O O
by O O
the O O
TTF B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
1 I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
binding I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
element I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
the O O
TG B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
; O O
FRT O O
and O O
BRL O O
cell O O
nuclear O O
extracts O O
do O O
not O O
have O O
TTF B B_GENE
- I I_GENE
1 I I_GENE
and O O
do O O
not O O
form O O
this O O
complex O O
. O O

The O O
Sty1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
stimulated O O
by O O
a O O
variety O O
of O O
different O O
stress O O
conditions O O
including O O
osmotic O O
and O O
oxidative O O
stress O O
and O O
heat O O
shock O O
. O O

No O O
viral O O
RNA O O
replication O O
could O O
be O O
detected O O
in O O
cells O O
transfected O O
with O O
mutant O O
RNAs O O
. O O

Acad O O
. O O

Comparison O O
of O O
the O O
genes O O
coding O O
for O O
mouse O O
and O O
human O O
p36 B B_GENE
( O O
annexin B B_GENE
II I I_GENE
) O O
and O O
mouse O O
, O O
rat O O
and O O
human O O
p35 B B_GENE
( O O
annexin B B_GENE
I I I_GENE
) O O
and O O
pigeon O O
cp35 B B_PROTEIN[GENE]
( O O
an O O
annexin B B_ENZYME[GENE]/B_NUMBER[MEASURE]
I I I_ENZYME[GENE]/I_NUMBER[MEASURE]
- I I_ENZYME[GENE]/I_NUMBER[MEASURE]
related I I_ENZYME[GENE]/I_NUMBER[MEASURE]
protein I I_ENZYME[GENE]/I_NUMBER[MEASURE]
) O O
shows O O
strong O O
genomic O O
structural O O
conservation O O
supporting O O
the O O
hypothesis O O
that O O
these O O
genes O O
had O O
a O O
common O O
ancestor O O
. O O

When O O
incubated O O
with O O
infective O O
larvae O O
which O O
had O O
penetrated O O
mouse O O
skin O O
, O O
both O O
normal O O
and O O
immune O O
cells O O
attached O O
to O O
larvae O O
in O O
the O O
absence O O
of O O
serum O O
. O O

A O O
31 O O
- O O
year O O
- O O
old O O
man O O
with O O
primary O O
myelofibrosis O O
initially O O
received O O
low O O
dose O O
Ara O O
C O O
. O O

FEurea O O
was O O
also O O
measured O O
during O O
stable O O
graft O O
function O O
, O O
7 O O
- O O
14 O O
days O O
prior O O
to O O
allograft O O
dysfunction O O
. O O

Nonsuicidal O O
mortality O O
in O O
late O O
- O O
life O O
depression O O
. O O

Few O O
triers O O
or O O
users O O
had O O
received O O
SLT O O
counseling O O
from O O
their O O
dentist O O
despite O O
high O O
dental O O
utilization O O
rates O O
. O O

However O O
, O O
UV O O
resistance O O
is O O
only O O
minimally O O
restored O O
, O O
and O O
mutant O O
cells O O
remain O O
sensitive O O
to O O
gamma O O
radiation O O
. O O

In O O
addition O O
, O O
we O O
show O O
that O O
expression O O
of O O
antisense O O
mRNA O O
for O O
p130CAS B B_GENE
resulted O O
in O O
reversion O O
of O O
the O O
transformed O O
phenotype O O
of O O
all O O
these O O
cell O O
lines O O
. O O

Starches O O
had O O
no O O
effect O O
. O O

Maximal O O
Expiratory O O
Flow O O
Rates O O
such O O
as O O
Peak O O
Expiratory O O
Flow O O
Rate O O
( O O
PEFR O O
) O O
, O O
rates O O
at O O
25 O O
% O O
, O O
50 O O
% O O
and O O
75 O O
% O O
of O O
forced O O
vital O O
capacity O O
( O O
V O O
max O O
25 O O
% O O
, O O
V O O
max O O
50 O O
% O O
and O O
V O O
max O O
75 O O
% O O
) O O
and O O
forced O O
expiratory O O
flow O O
during O O
the O O
middle O O
half O O
of O O
forced O O
vital O O
capacity O O
( O O
FEF O O
25 O O
- O O
75 O O
% O O
) O O
were O O
measured O O
in O O
273 O O
healthy O O
non O O
- O O
smoking O O
adults O O
( O O
144 O O
males O O
, O O
129 O O
females O O
) O O
aged O O
15 O O
- O O
63 O O
years O O
living O O
in O O
Madras O O
. O O

The O O
amino O O
acid O O
sequence O O
of O O
the O O
protein O O
encoded O O
by O O
MSK1 B B_GENE/B_LOCATION
is O O
homologous O O
to O O
yeast B B_GENE
cytoplasmic I I_GENE
lysyl I I_GENE
- I I_GENE
tRNA I I_GENE
synthetase I I_GENE
and O O
to O O
the O O
product O O
of O O
the O O
herC B B_GENE
gene I I_GENE
, O O
which O O
has O O
recently O O
been O O
suggested O O
to O O
code O O
for O O
the O O
Escherichia O O
coli O O
enzyme O O
. O O

Similar O O
to O O
the O O
D B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
B B B_PROTEIN[GENE]/B_DISEASE
/ O O
B B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
E B B_PROTEIN[GENE]/B_LOCATION
proteins I I_PROTEIN[GENE]/I_LOCATION
, O O
the O O
F B B_PROTEIN[GENE]/B_DISEASE
and O O
G B B_PROTEIN[GENE]/B_LOCATION
proteins I I_PROTEIN[GENE]/I_LOCATION
do O O
not O O
possess O O
any O O
of O O
the O O
known O O
RNA O O
binding O O
motifs O O
, O O
suggesting O O
that O O
other O O
types O O
of O O
RNA O O
- O O
protein O O
interactions O O
occur O O
in O O
the O O
snRNP O O
core O O
. O O

These O O
observations O O
suggest O O
that O O
clr4 B B_GENE
+ I I_GENE
and O O
rik1 B B_GENE
+ I I_GENE
must O O
play O O
a O O
role O O
in O O
the O O
assembly O O
of O O
Swi6p B B_GENE/B_BACTERIUM[BIO]
into O O
a O O
transcriptionally O O
silent O O
, O O
inaccessible O O
chromatin O O
structure O O
at O O
fission O O
yeast O O
centromeres O O
which O O
is O O
required O O
to O O
facilitate O O
interactions O O
with O O
spindle O O
microtubules O O
and O O
to O O
ensure O O
normal O O
chromosome O O
segregation O O
. O O

Characterization O O
of O O
a O O
DEAD B B_GENE
box I I_GENE
ATPase I I_GENE
/ O O
RNA B B_ENZYME[GENE]
helicase I I_ENZYME[GENE]
protein O O
of O O
Arabidopsis O O
thaliana O O
. O O

Oligo O O
- O O
[ O O
alpha O O
] O O
- O O
deoxynucleotides O O
can O O
be O O
derived O O
by O O
stabilizing O O
( O O
intercalating O O
) O O
agents O O
or O O
reactive O O
groups O O
( O O
cleaving O O
reagents O O
, O O
cross O O
- O O
linkers O O
. O O
. O O
. O O
) O O
. O O

This O O
vector O O
should O O
be O O
applicable O O
for O O
high O O
- O O
throughput O O
characterization O O
of O O
new O O
open O O
reading O O
frames O O
found O O
in O O
genome O O
sequencing O O
. O O

The O O
subjects O O
were O O
17 O O
patients O O
with O O
android O O
obesity O O
( O O
four O O
men O O
and O O
13 O O
women O O
) O O
aged O O
21 O O
to O O
58 O O
years O O
with O O
a O O
body O O
mass O O
index O O
( O O
BMI O O
) O O
ranging O O
from O O
32 O O
. O O
0 O O
to O O
52 O O
. O O
2 O O
kg O O
/ O O
m2 O O
and O O
an O O
abdominal O O
- O O
gluteal O O
ratio O O
greater O O
than O O
1 O O
. O O
0 O O
. O O

No O O
universally O O
accepted O O
standardized O O
classification O O
system O O
for O O
acne O O
vulgaris O O
exists O O
, O O
although O O
there O O
is O O
a O O
strong O O
need O O
for O O
it O O
. O O

Neither O O
symptoms O O
, O O
virions O O
, O O
nor O O
viral O O
RNA O O
was O O
detectable O O
in O O
plants O O
inoculated O O
with O O
this O O
mutant O O
or O O
a O O
mutant O O
with O O
a O O
frameshift O O
mutation O O
in O O
the O O
coat B B_GENE
gene I I_GENE
. O O

The O O
cumulative O O
length O O
of O O
the O O
RGSV O O
genome O O
, O O
including O O
RNAs O O
5 O O
and O O
6 O O
, O O
was O O
25142 O O
nt O O
. O O

Risk O O
ratios O O
decreased O O
with O O
increasing O O
age O O
and O O
increased O O
with O O
number O O
of O O
breast O O
biopsies O O
, O O
family O O
history O O
of O O
breast O O
cancer O O
, O O
estrogen O O
use O O
, O O
time O O
between O O
screenings O O
, O O
no O O
comparison O O
with O O
previous O O
mammograms O O
, O O
and O O
the O O
radiologist O O
' O O
s O O
tendency O O
to O O
call O O
mammograms O O
abnormal O O
. O O

The O O
AtNMT1 B B_GENE
expression O O
profile O O
indicated O O
ubiquity O O
in O O
roots O O
, O O
stem O O
, O O
leaves O O
, O O
flowers O O
, O O
and O O
siliques O O
( O O
approximately O O
1 O O
. O O
7 O O
kb O O
transcript O O
and O O
approximately O O
50 O O
kDa O O
immunoreactive O O
polypeptide O O
) O O
but O O
a O O
greater O O
level O O
in O O
the O O
younger O O
tissue O O
, O O
which O O
are O O
developmentally O O
very O O
active O O
. O O

At O O
a O O
cutoff O O
point O O
for O O
KISA O O
% O O
of O O
100 O O
, O O
280 O O
of O O
281 O O
participants O O
( O O
99 O O
. O O
6 O O
% O O
) O O
were O O
correctly O O
classified O O
. O O

Following O O
replicate O O
control O O
measurements O O
, O O
test O O
ramps O O
were O O
repeated O O
in O O
the O O
presence O O
of O O
sodium O O
nitroprusside O O
( O O
1 O O
microM O O
) O O
and O O
phentolamine O O
( O O
1 O O
microM O O
) O O
to O O
eliminate O O
potential O O
smooth O O
muscle O O
and O O
alpha B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
1 I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
adrenoceptor I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
effects O O
, O O
respectively O O
. O O

Behavioral O O
effects O O
of O O
benzodiazepine O O
ligands O O
in O O
non O O
- O O
dependent O O
, O O
diazepam O O
- O O
dependent O O
and O O
diazepam O O
- O O
withdrawn O O
baboons O O
. O O

This O O
paper O O
reports O O
estimates O O
of O O
the O O
prevalence O O
of O O
mental O O
retardation O O
and O O
associated O O
factors O O
based O O
on O O
a O O
population O O
survey O O
of O O
2 O O
- O O
to O O
9 O O
- O O
year O O
- O O
old O O
children O O
in O O
Greater O O
Karachi O O
, O O
Pakistan O O
. O O

Thus O O
, O O
an O O
increase O O
in O O
lactate O O
concentration O O
of O O
the O O
magnitude O O
observed O O
during O O
alkali O O
therapy O O
need O O
not O O
indicate O O
a O O
worsening O O
of O O
the O O
metabolic O O
picture O O
in O O
lactic O O
acidosis O O
. O O

Adjusting O O
a O O
steady O O
- O O
state O O
warfarin O O
dose O O
depends O O
on O O
the O O
measured O O
INR O O
values O O
and O O
clinical O O
factors O O
: O O
the O O
dose O O
does O O
not O O
need O O
to O O
be O O
adjusted O O
for O O
a O O
single O O
INR O O
that O O
is O O
slightly O O
out O O
of O O
range O O
, O O
and O O
most O O
changes O O
should O O
alter O O
the O O
total O O
weekly O O
dose O O
by O O
5 O O
% O O
to O O
20 O O
% O O
. O O

All O O
of O O
this O O
region O O
is O O
part O O
of O O
a O O
prominent O O
CpG O O
island O O
that O O
may O O
be O O
acting O O
as O O
an O O
extended O O
, O O
enhancer O O
- O O
independent O O
promoter O O
. O O

Comparison O O
of O O
Healon O O
and O O
Amvisc O O
. O O

Large O O
volumes O O
of O O
bone O O
marrow O O
may O O
be O O
required O O
for O O
certain O O
types O O
of O O
autologous O O
bone O O
marrow O O
transplants O O
. O O

Further O O
analysis O O
of O O
the O O
CAP59 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Cryptococcus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
neoformans I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
structure O O
defined O O
by O O
forced O O
expression O O
and O O
description O O
of O O
a O O
new O O
ribosomal B B_GENE
protein I I_GENE
- I I_GENE
encoding I I_GENE
gene I I_GENE
. O O

We O O
speculate O O
that O O
the O O
enhancing O O
effect O O
of O O
glucose O O
and O O
galactose O O
on O O
fructose O O
absorption O O
may O O
be O O
due O O
to O O
activation O O
of O O
the O O
fructose B B_ENZYME[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
carrier I I_ENZYME[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Virol O O
. O O

The O O
data O O
from O O
animal O O
experiments O O
indicate O O
that O O
the O O
incidence O O
of O O
solid O O
tumors O O
in O O
marrow O O
transplant O O
patients O O
may O O
still O O
rise O O
in O O
the O O
coming O O
decades O O
. O O

Patients O O
adopt O O
new O O
sets O O
based O O
partly O O
on O O
the O O
original O O
topic O O
and O O
partly O O
on O O
their O O
own O O
personal O O
idiosyncratic O O
concerns O O
. O O

The O O
NS B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
resolved O O
at O O
a O O
pI O O
value O O
close O O
to O O
5 O O
. O O
5 O O
as O O
three O O
groups O O
of O O
unevenly O O
phosphorylated O O
polypeptides O O
, O O
each O O
composed O O
of O O
at O O
least O O
two O O
protein O O
species O O
. O O

Prevalence O O
of O O
rheumatic O O
diseases O O
in O O
a O O
rural O O
population O O
in O O
western O O
India O O
: O O
a O O
WHO O O
- O O
ILAR O O
COPCORD O O
Study O O
. O O

This O O
interaction O O
is O O
functional O O
as O O
it O O
leads O O
to O O
retargeting O O
of O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
p50 B I_GENE
from O O
the O O
nucleus O O
to O O
the O O
cytoplasm O O
. O O

The O O
orf2 O O
gene O O
product O O
is O O
a O O
protein O O
of O O
79 O O
amino O O
acids O O
with O O
characteristics O O
similar O O
to O O
those O O
of O O
the O O
Tat B B_PROTEIN[GENE]/B_LOCATION
( O O
transactivator B B_PROTEIN[GENE]/B_LOCATION
) O O
proteins O O
of O O
the O O
ungulate O O
lentiviruses O O
. O O

The O O
use O O
of O O
medication O O
is O O
of O O
minor O O
importance O O
in O O
the O O
treatment O O
of O O
flight O O
phobia O O
. O O

Elevated O O
total O O
serum O O
calcium O O
to O O
a O O
level O O
of O O
11 O O
. O O
9 O O
+ O O
/ O O
- O O
0 O O
. O O
2 O O
mg O O
/ O O
dl O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
compared O O
to O O
control O O
group O O
) O O
developed O O
in O O
the O O
gentamicin O O
/ O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2 O O
vitamin O O
D3 O O
group O O
on O O
day O O
4 O O
, O O
2 O O
days O O
prior O O
to O O
pronounced O O
structural O O
damage O O
, O O
and O O
continued O O
to O O
be O O
elevated O O
through O O
day O O
7 O O
. O O

Rac2 B B_GENE
, O O
a O O
member O O
of O O
the O O
Rho B B_GENE/B_PERSON
family I I_GENE/I_PERSON
of O O
GTPases B B_GENE/B_BIO
, O O
is O O
highly O O
expressed O O
in O O
myeloid O O
cells O O
and O O
is O O
a O O
regulator O O
of O O
the O O
NADPH B B_GENE
- I I_GENE
oxidase I I_GENE
complex I I_GENE
. O O

In O O
vitro O O
kinase O O
assays O O
on O O
isolated O O
microvilli O O
and O O
microvillar O O
fractions O O
enriched O O
in O O
the O O
putative O O
signal O O
transduction O O
particle O O
showed O O
a O O
high O O
specific O O
activity O O
of O O
tyrosine B B_GENE/B_DISEASE
kinase I I_GENE/I_DISEASE
activity O O
compared O O
to O O
that O O
of O O
membranes O O
from O O
EGF B B_GENE
receptor I I_GENE
- O O
overexpressing O O
A431 O O
cells O O
maximally O O
activated O O
by O O
EGF B B_GENE
. O O

Effect O O
of O O
infantile O O
undernutrition O O
on O O
adult O O
sucrose O O
solution O O
consumption O O
in O O
the O O
rat O O
. O O

In O O
the O O
studies O O
described O O
in O O
this O O
report O O
, O O
we O O
have O O
identified O O
two O O
potential O O
Ets B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
binding O O
sites O O
, O O
EBS1 B B_GENE/B_DISEASE
and O O
EBS2 B B_GENE
, O O
which O O
are O O
conserved O O
in O O
both O O
the O O
human O O
and O O
murine O O
interleukin B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
2 I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
enhancers O O
. O O

Although O O
the O O
Gly252Arg O O
substitution O O
observed O O
in O O
UM O O
: O O
JG5 O O
is O O
non O O
- O O
conservative O O
, O O
it O O
was O O
not O O
possible O O
to O O
distinguish O O
whether O O
it O O
is O O
a O O
mutation O O
or O O
a O O
polymorphism O O
. O O

This O O
region O O
shows O O
46 O O
% O O
identity O O
with O O
the O O
calmodulin B B_LOCATION/B_GENE
- I I_LOCATION/I_GENE
binding I I_LOCATION/I_GENE
region I I_LOCATION/I_GENE
of O O
rat B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
brain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ca2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
calmodulin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
32 O O
% O O
identity O O
with O O
the O O
equivalent O O
region O O
of O O
chicken B B_GENE
smooth I I_GENE
muscle I I_GENE
myosin I I_GENE
light I I_GENE
chain I I_GENE
kinase I I_GENE
. O O

The O O
perforated O O
splint O O
gives O O
superior O O
results O O
by O O
virtue O O
of O O
the O O
fact O O
that O O
it O O
does O O
not O O
require O O
to O O
be O O
removed O O
for O O
purposes O O
of O O
hygiene O O
and O O
can O O
thus O O
produce O O
a O O
satisfactory O O
result O O
even O O
in O O
those O O
patients O O
who O O
fail O O
to O O
grasp O O
the O O
technique O O
of O O
removal O O
and O O
replacement O O
of O O
the O O
splint O O
. O O

It O O
contains O O
31 O O
exons O O
and O O
a O O
high O O
proportion O O
of O O
class O O
0 O O
introns O O
, O O
alternative O O
splicing O O
of O O
which O O
results O O
in O O
significant O O
levels O O
of O O
variant O O
transcripts O O
that O O
maintain O O
the O O
original O O
open O O
reading O O
frame O O
of O O
MRP B B_GENE
mRNA I I_GENE
. O O

Issues O O
discussed O O
include O O
the O O
validity O O
of O O
the O O
MMPI O O
Mf O O
scale O O
, O O
questions O O
of O O
sample O O
representativeness O O
, O O
whether O O
" O O
straights O O
" O O
can O O
do O O
adequate O O
research O O
on O O
homosexuality O O
, O O
differences O O
in O O
heterosexual O O
and O O
homosexual O O
sexuality O O
, O O
the O O
role O O
of O O
subculture O O
acculturation O O
in O O
homosexual O O
psychological O O
adjustment O O
, O O
and O O
the O O
use O O
of O O
cluster O O
- O O
analysis O O
to O O
generate O O
typologies O O
of O O
homosexualities O O
. O O

A O O
brief O O
discussion O O
for O O
the O O
relationship O O
among O O
these O O
formulas O O
is O O
given O O
. O O

Lamivudine O O
therapy O O
for O O
acute O O
hepatitis O O
B O O
infection O O
following O O
peripheral O O
blood O O
stem O O
cell O O
transplantation O O
. O O

These O O
findings O O
suggest O O
that O O
NMDA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
blockade O O
may O O
ameliorate O O
the O O
dyskinetic O O
complications O O
of O O
long O O
- O O
term O O
levodopa O O
therapy O O
, O O
without O O
diminishing O O
the O O
beneficial O O
effects O O
on O O
parkinsonian O O
signs O O
. O O

Furthermore O O
, O O
the O O
secondary O O
stress O O
responses O O
were O O
more O O
pronounced O O
and O O
the O O
ability O O
to O O
recover O O
from O O
them O O
seemed O O
to O O
be O O
impaired O O
in O O
exposed O O
fish O O
as O O
compared O O
to O O
unexposed O O
fish O O
. O O

The O O
distinct O O
spatial O O
pattern O O
of O O
expression O O
, O O
and O O
unusual O O
amino O O
acid O O
sequence O O
in O O
its O O
DNA O O
binding O O
domain O O
, O O
may O O
indicate O O
a O O
particular O O
role O O
for O O
DTEF B B_GENE
- I I_GENE
1 I I_GENE
in O O
cell O O
- O O
specific O O
gene O O
regulation O O
. O O

Usher O O
syndrome O O
1C O O
( O O
USH1C O O
) O O
is O O
a O O
congenital O O
condition O O
manifesting O O
profound O O
hearing O O
loss O O
, O O
the O O
absence O O
of O O
vestibular O O
function O O
, O O
and O O
eventual O O
retinal O O
degeneration O O
. O O

Implantation O O
is O O
contraindicated O O
for O O
severe O O
dysplasia O O
of O O
the O O
cochlea O O
and O O
for O O
the O O
recently O O
described O O
variety O O
of O O
x O O
- O O
linked O O
deafness O O
with O O
deficient O O
bone O O
at O O
the O O
fundus O O
of O O
the O O
internal O O
auditory O O
meatus O O
. O O

Scleraxis B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
overexpression O O
enhanced O O
expression O O
of O O
the O O
aggrecan B B_GENE
gene I I_GENE
, O O
which O O
is O O
not O O
normally O O
expressed O O
at O O
high O O
levels O O
in O O
these O O
osteoblastic O O
cells O O
. O O

This O O
study O O
demonstrates O O
that O O
the O O
exposure O O
to O O
sulphur O O
mustard O O
results O O
in O O
very O O
low O O
androgen O O
levels O O
and O O
hypo O O
- O O
responsiveness O O
to O O
GnRH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
the O O
first O O
five O O
weeks O O
and O O
normalization O O
by O O
the O O
twelfth O O
week O O
after O O
injury O O
. O O

New O O
results O O
of O O
importance O O
for O O
optimization O O
of O O
the O O
postoperative O O
course O O
] O O
Complications O O
after O O
major O O
surgery O O
may O O
be O O
related O O
to O O
factors O O
in O O
the O O
surgical O O
stress O O
response O O
with O O
endocrine O O
- O O
metabolic O O
and O O
inflammatory O O
changes O O
. O O

Four O O
multicannulated O O
Holstein O O
steers O O
( O O
initial O O
BW O O
424 O O
+ O O
/ O O
- O O
16 O O
kg O O
) O O
were O O
used O O
in O O
a O O
4 O O
x O O
4 O O
Latin O O
square O O
to O O
determine O O
the O O
influence O O
of O O
protein O O
supplementation O O
on O O
forage O O
intake O O
, O O
site O O
and O O
extent O O
of O O
digestion O O
, O O
and O O
nutrient O O
flow O O
in O O
steers O O
consuming O O
dormant O O
bluestem O O
- O O
range O O
forage O O
( O O
2 O O
. O O
3 O O
% O O
CP O O
) O O
. O O

Patients O O
with O O
risk O O
factors O O
were O O
compared O O
with O O
those O O
without O O
risk O O
factors O O
. O O

The O O
dermatoglyphic O O
pattern O O
demostrates O O
a O O
distal O O
triradius O O
and O O
small O O
whorl O O
abnormalities O O
. O O

The O O
term O O
Kartagener O O
syndrome O O
applies O O
to O O
this O O
syndrome O O
when O O
accompanied O O
by O O
infertility O O
and O O
dextrocardia O O
or O O
situs O O
inversus O O
. O O

Finally O O
, O O
we O O
tested O O
whether O O
activation O O
by O O
either O O
of O O
these O O
factors O O
is O O
dependent O O
on O O
components O O
of O O
the O O
SAGA B B_GENE/B_LOCATION
complex I B_GENE/I_LOCATION
. O O

The O O
antimicrobial O O
of O O
choice O O
for O O
initial O O
prophylactic O O
therapy O O
among O O
asymptomatic O O
pregnant O O
women O O
exposed O O
to O O
Bacillus O O
anthracis O O
is O O
ciprofloxacin O O
, O O
500 O O
mg O O
twice O O
a O O
day O O
for O O
60 O O
days O O
. O O

Overexpression O O
of O O
eIF4E B B_GENE
transforms O O
cells O O
, O O
and O O
mutations O O
in O O
eIF4E B B_GENE
arrest O O
cells O O
in O O
G O O
, O O
in O O
cdc33 B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O O

Benzyl O O
alcohol O O
administration O O
in O O
neonates O O
. O O

Repression O O
of O O
the O O
herpes B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
simplex I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
its O O
gene O O
product O O
( O O
ICP4 B B_GENE/B_DISEASE
) O O
within O O
the O O
context O O
of O O
the O O
viral O O
genome O O
is O O
conditioned O O
by O O
the O O
distance O O
and O O
stereoaxial O O
alignment O O
of O O
the O O
ICP4 B B_GENE/B_LOCATION
DNA I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
relative O O
to O O
the O O
TATA O O
box O O
. O O

As O O
anticipated O O
, O O
both O O
intracellular O O
p54 B B_GENE
- O O
SAPKbeta B B_GENE
activation O O
and O O
Bcl B B_GENE
- I I_GENE
2 I I_GENE
phosphorylation O O
are O O
blocked O O
by O O
co O O
- O O
transfection O O
with O O
the O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific O O
phosphatase O O
MKP3 B B_GENE
/ O O
PYST1 B B_GENE/B_MEASURE
. O O

PATIENT O O
( O O
S O O
) O O
: O O
Two O O
hundred O O
thirty O O
- O O
eight O O
patients O O
with O O
RPLs O O
, O O
48 O O
patients O O
with O O
recurrent O O
IVF O O
- O O
ET O O
failure O O
and O O
179 O O
nonpregnant O O
and O O
120 O O
pregnant O O
control O O
group O O
women O O
. O O

Many O O
of O O
the O O
metabolic O O
effects O O
induced O O
by O O
thiazide O O
diuretics O O
, O O
however O O
, O O
can O O
be O O
limited O O
by O O
the O O
use O O
of O O
low O O
doses O O
. O O

Teboroxime O O
is O O
a O O
new O O
boronic O O
acid O O
adduct O O
of O O
technetium O O
dioxime O O
( O O
BATO O O
) O O
compound O O
that O O
demonstrates O O
favorable O O
characteristics O O
in O O
preliminary O O
studies O O
. O O

The O O
total O O
area O O
under O O
the O O
blood O O
glucose O O
curve O O
over O O
the O O
initial O O
value O O
was O O
not O O
altered O O
2 O O
h O O
after O O
treatment O O
with O O
SH O O
B O O
209 O O
AB O O
or O O
Neogynon O O
. O O

In O O
all O O
cases O O
, O O
a O O
large O O
fraction O O
of O O
soluble O O
Al O O
became O O
insoluble O O
in O O
the O O
stomach O O
after O O
ingestion O O
. O O

To O O
assess O O
the O O
safety O O
of O O
the O O
angiotensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
converting I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
enalapril O O
a O O
multicenter O O
, O O
open O O
, O O
randomized O O
, O O
prazosin O O
- O O
controlled O O
trial O O
was O O
designed O O
comparing O O
the O O
incidence O O
and O O
severity O O
of O O
symptomatic O O
hypotension O O
on O O
the O O
first O O
day O O
of O O
treatment O O
. O O

Glucose O O
may O O
reduce O O
slightly O O
the O O
pool O O
of O O
amino O O
nitrogen O O
available O O
for O O
albumin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
urea O O
synthesis O O
by O O
diverting O O
some O O
of O O
the O O
infused O O
amino O O
acids O O
from O O
protein O O
synthesis O O
by O O
the O O
liver O O
to O O
muscle O O
. O O

BACKGROUND O O
. O O

Results O O
demonstrated O O
that O O
for O O
both O O
S O O
. O O
europaea O O
and O O
A O O
. O O
prostrata O O
, O O
the O O
total O O
number O O
of O O
seeds O O
that O O
germinated O O
decreased O O
throughout O O
the O O
growing O O
season O O
. O O

A O O
nationwide O O
record O O
linkage O O
of O O
the O O
Finnish O O
Twin O O
Cohort O O
Study O O
( O O
FTCS O O
) O O
with O O
the O O
Hospital O O
Discharge O O
Registry O O
and O O
the O O
Registry O O
of O O
Rights O O
for O O
Free O O
medication O O
is O O
presented O O
. O O

Considering O O
these O O
two O O
facts O O
together O O
, O O
we O O
propose O O
that O O
vasectomy O O
may O O
lead O O
to O O
decrease O O
in O O
the O O
incidence O O
of O O
prostatic O O
tumors O O
- O O
a O O
disease O O
that O O
claims O O
nearly O O
22 O O
, O O
000 O O
lives O O
each O O
year O O
in O O
the O O
United O O
States O O
alone O O
. O O

Antibodies O O
specific O O
to O O
the O O
different O O
members O O
of O O
the O O
Jun B B_PERSON/B_GENE
and O O
Fos B B_GENE
family I I_GENE
of I I_GENE
transcription I I_GENE
factors I I_GENE
show O O
that O O
, O O
in O O
gel O O
retardation O O
assays O O
, O O
a O O
Jun B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
like I I_PROTEIN[GENE]/I_MEASURE
factor I I_PROTEIN[GENE]/I_MEASURE
is O O
a O O
component O O
of O O
the O O
H3 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

She O O
had O O
been O O
diagnosed O O
with O O
severe O O
aplastic O O
anemia O O
1 O O
year O O
previously O O
and O O
, O O
while O O
hospitalized O O
, O O
had O O
received O O
methyl O O
prednisolone O O
pulse O O
therapy O O
, O O
which O O
was O O
not O O
successful O O
. O O

The O O
recombinant B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
L I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
F I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transferase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
as O O
active O O
as O O
the O O
previously O O
purified O O
wild O O
type O O
enzyme O O
and O O
contains O O
no O O
detectable O O
RNA O O
component O O
. O O

Cord O O
formation O O
in O O
BACTEC O O
7H12 O O
medium O O
for O O
rapid O O
, O O
presumptive O O
identification O O
of O O
Mycobacterium O O
tuberculosis O O
complex O O
. O O

Moreover O O
, O O
site O O
- O O
specific O O
integration O O
of O O
the O O
ITR O O
- O O
flanked O O
DNA O O
was O O
also O O
detected O O
by O O
PCR O O
amplification O O
of O O
the O O
ITR B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
aavs1 I I_GENE/I_LOCATION
junction I I_GENE/I_LOCATION
in O O
transduced O O
human O O
fibroblasts O O
. O O

Oct B B_GENE
- I I_GENE
1 I I_GENE
is O O
a O O
ubiquitously O O
expressed O O
regulatory O O
gene O O
of O O
the O O
POU B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
domain I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
family I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O O

( O O
3 O O
) O O
With O O
the O O
exception O O
of O O
the O O
anteroposterior O O
direction O O
of O O
layers O O
II O O
- O O
- O O
III O O
and O O
the O O
mediolateral O O
direction O O
of O O
layer O O
IV O O
, O O
the O O
vertical O O
conductivity O O
of O O
the O O
cortex O O
was O O
always O O
greater O O
than O O
either O O
of O O
the O O
horizontal O O
conductivities O O
. O O

The O O
relationship O O
between O O
polymorphonuclear O O
granulocytes O O
and O O
cartilage O O
destruction O O
in O O
rheumatoid O O
arthritis O O
. O O

RESULTS O O
: O O
Twenty O O
- O O
two O O
patients O O
( O O
30 O O
% O O
) O O
showed O O
ST O O
- O O
segment O O
depression O O
during O O
AEM O O
and O O
34 O O
( O O
49 O O
% O O
) O O
on O O
ExT O O
. O O

The O O
virus O O
must O O
progress O O
past O O
the O O
immediate O O
- O O
early O O
phase O O
and O O
express O O
an O O
early B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
product I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
s I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
activation O O
of O O
cyclin B B_GENE/B_DISEASE
E I I_GENE/I_DISEASE
expression O O
. O O

In O O
group O O
I O O
during O O
the O O
pain O O
free O O
period O O
26 O O
of O O
81 O O
patients O O
had O O
positive O O
thallium O O
- O O
201 O O
scans O O
, O O
whereas O O
20 O O
patients O O
had O O
an O O
abnormal O O
ECG O O
at O O
that O O
time O O
; O O
during O O
angina O O
18 O O
patients O O
had O O
transient O O
ECG O O
changes O O
. O O

The O O
prototype O O
now O O
structures O O
oncology O O
- O O
related O O
information O O
available O O
on O O
the O O
Internet O O
and O O
also O O
places O O
resources O O
maintained O O
locally O O
at O O
users O O
' O O
disposal O O
. O O

Binding O O
of O O
the O O
TorR B B_GENE/B_BIO
regulator I I_GENE/I_BIO
to O O
cis O O
- O O
acting O O
direct O O
repeats O O
activates O O
tor B B_GENE/B_BACTERIUM[BIO]
operon I I_GENE/I_BACTERIUM[BIO]
expression O O
. O O

For O O
the O O
most O O
part O O
, O O
only O O
aerobic O O
microbial O O
degradation O O
systems O O
have O O
been O O
reported O O
so O O
far O O
. O O

Asymptomatic O O
ischaemia O O
during O O
daily O O
life O O
in O O
stable O O
coronary O O
artery O O
disease O O
: O O
relevant O O
or O O
redundant O O
? O O

In O O
contrast O O
to O O
Phase O O
III O O
, O O
which O O
has O O
a O O
single O O
study O O
design O O
- O O
- O O
the O O
controlled O O
, O O
randomized O O
, O O
double O O
- O O
blind O O
study O O
- O O
- O O
Phase O O
IV O O
requires O O
different O O
designs O O
for O O
each O O
of O O
the O O
many O O
different O O
questions O O
. O O

Treatment O O
with O O
polyinosinic O O
- O O
polycytidylic O O
acid O O
to O O
induce O O
expression O O
of O O
Cre B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
complete O O
disruption O O
of O O
the O O
Arnt B B_GENE
gene I I_GENE
and O O
loss O O
of O O
ARNT B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
messenger I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
mRNA O O
) O O
expression O O
in O O
liver O O
. O O

Physical O O
map O O
of O O
the O O
genome O O
of O O
sonchus O O
yellow O O
net O O
virus O O
, O O
a O O
plant O O
rhabdovirus O O
with O O
six O O
genes O O
and O O
conserved O O
gene O O
junction O O
sequences O O
. O O

Tubular O O
dysfunction O O
in O O
renal O O
lithiasis O O
: O O
cause O O
or O O
consequence O O
? O O
] O O
To O O
investigate O O
whether O O
overall O O
tubular O O
dysfunction O O
is O O
encountered O O
in O O
a O O
particular O O
subgroup O O
of O O
patients O O
with O O
urolithiasis O O
, O O
the O O
following O O
parameters O O
of O O
renal O O
tubular O O
function O O
have O O
been O O
measured O O
in O O
fasting O O
morning O O
urine O O
in O O
124 O O
male O O
stone O O
formers O O
: O O
excretion O O
of O O
lysozyme B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glutamyl I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transpeptidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
gamma B B_LOCATION/B_PROTEIN[GENE]
- I I_LOCATION/I_PROTEIN[GENE]
GT I I_LOCATION/I_PROTEIN[GENE]
) O O
, O O
fractional O O
excretion O O
( O O
FE O O
) O O
or O O
glucose O O
, O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
bicarbonate O O
after O O
an O O
alkali O O
load O O
, O O
and O O
theoretical O O
phosphate O O
threshold O O
( O O
TmP O O
/ O O
GFR O O
) O O
. O O

As O O
expected O O
, O O
the O O
QOLS O O
- O O
N O O
had O O
a O O
lower O O
correlation O O
with O O
physical O O
health O O
( O O
r O O
= O O
0 O O
. O O
24 O O
, O O
p O O
< O O
0 O O
. O O
000 O O
) O O
and O O
self O O
- O O
reported O O
symptoms O O
( O O
r O O
= O O
- O O
0 O O
. O O
20 O O
, O O
p O O
< O O
0 O O
. O O
001 O O
) O O
, O O
and O O
a O O
higher O O
correlation O O
with O O
mental O O
health O O
( O O
r O O
= O O
0 O O
. O O
52 O O
, O O
p O O
< O O
0 O O
. O O
000 O O
) O O
. O O

In O O
the O O
case O O
of O O
the O O
pT181 O O
plasmid O O
, O O
inactivation O O
of O O
the O O
initiator B B_ENZYME[GENE]
RepC I I_ENZYME[GENE]
protein I I_ENZYME[GENE]
occurs O O
by O O
the O O
attachment O O
of O O
an O O
oligonucleotide O O
to O O
its O O
active O O
tyrosine O O
residue O O
. O O

Xanthoepocin O O
, O O
a O O
new O O
antibiotic O O
from O O
Penicillium O O
simplicissimum O O
IFO5762 O O
. O O

Extracellular B B_GENE
regulated I I_GENE
kinases I I_GENE
( I I_GENE
ERK I I_GENE
) I I_GENE
1 I I_GENE
and O O
ERK2 B B_GENE/B_MEASURE
are O O
authentic O O
substrates O O
for O O
the O O
dual B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
specificity I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
VHR I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Leukocytoclasic O O
vasculitis O O
during O O
treatment O O
with O O
low O O
- O O
dose O O
captopril O O

H O O
. O O

Truncations O O
from O O
Hip B B_GENE/B_DISEASE
' O O
s O O
N O O
terminus O O
resulted O O
in O O
an O O
apparent O O
loss O O
of O O
Hip B B_GENE/B_DISEASE
homo O O
- O O
oligomerization O O
, O O
but O O
these O O
mutants O O
retained O O
association O O
with O O
hsp70 B B_GENE
and O O
were O O
recovered O O
in O O
receptor O O
complexes O O
. O O

The O O
biological O O
basis O O
for O O
the O O
changes O O
in O O
CNAPs O O
produced O O
by O O
CS2 O O
is O O
under O O
investigation O O
. O O

A O O
very O O
large O O
PC O O
LAN O O
as O O
the O O
basis O O
for O O
a O O
hospital O O
information O O
system O O
. O O

This O O
was O O
tragically O O
highlighted O O
by O O
the O O
death O O
of O O
a O O
17 O O
year O O
old O O
dental O O
nurse O O
after O O
taking O O
a O O
single O O
1 O O
g O O
tablet O O
of O O
sodium O O
nitrite O O
. O O

The O O
human O O
protein O O
is O O
encoded O O
by O O
a O O
900 O O
- O O
base O O
pair O O
- O O
long O O
mRNA O O
that O O
is O O
expressed O O
in O O
the O O
glandular O O
epithelial O O
cells O O
of O O
the O O
endometrium O O
in O O
a O O
cyclic O O
manner O O
; O O
in O O
addition O O
, O O
it O O
is O O
found O O
in O O
the O O
mucosal O O
epithelial O O
cells O O
of O O
the O O
fallopian O O
tubes O O
. O O

In O O
this O O
report O O
, O O
we O O
describe O O
a O O
patient O O
with O O
renal O O
cell O O
carcinoma O O
who O O
experienced O O
ventricular O O
tachycardia O O
while O O
undergoing O O
treatment O O
with O O
high O O
- O O
dose O O
bolus O O
IL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Four O O
antifungal O O
agents O O
were O O
compared O O
: O O
amphotericin O O
B O O
, O O
flucytosine O O
, O O
miconazole O O
, O O
and O O
ketoconazole O O
. O O

Conversion O O
of O O
an O O
NF B B_GENE
- I I_GENE
kappaB I I_GENE
into O O
a O O
GABP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O O
site O O
is O O
likely O O
to O O
have O O
occurred O O
also O O
during O O
the O O
worldwide O O
spread O O
of O O
HIV O O
- O O
1 O O
, O O
as O O
we O O
noticed O O
the O O
same O O
LTR O O
modification O O
in O O
subtype O O
E O O
isolates O O
from O O
Thailand O O
. O O

Protein O O
binding O O
to O O
UAS1MLS1 B B_GENE
was O O
observed O O
with O O
extracts O O
from O O
derepressed O O
but O O
not O O
from O O
repressed O O
cells O O
, O O
and O O
could O O
be O O
competed O O
for O O
by O O
an O O
excess O O
of O O
the O O
unlabelled O O
CSRE O O
( O O
ICL1 B B_PROTEIN[GENE]/B_LOCATION
) O O
sequence O O
. O O

We O O
then O O
isolated O O
the O O
full O O
- O O
length O O
coding O O
region O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
BACH1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O O
expressed O O
sequence O O
tags O O
, O O
reverse O O
transcription O O
- O O
polymerase O O
chain O O
reaction O O
and O O
rapid O O
amplification O O
of O O
cDNA O O
ends O O
. O O

Authors O O
present O O
the O O
anatomical O O
variations O O
of O O
the O O
course O O
of O O
the O O
inferior O O
mesenteric O O
artery O O
and O O
its O O
branches O O
in O O
62 O O
human O O
fetus O O
. O O

The O O
7 B B_GENE
. I I_GENE
2 I I_GENE
kb I I_GENE
EcoRI I I_GENE
fragment I I_GENE
of I I_GENE
AfMNPV I I_GENE
was O O
cloned O O
and O O
the O O
nucleotide O O
sequences O O
of O O
the O O
polyhedrin B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
coding O O
region O O
and O O
its O O
flanking O O
regions O O
were O O
determined O O
. O O

1 O O
. O O

The O O
resulting O O
threshold O O
elevation O O
curves O O
fell O O
into O O
a O O
small O O
number O O
of O O
distinct O O
groups O O
, O O
suggesting O O
the O O
existence O O
of O O
discrete O O
spatial O O
frequency O O
mechanisms O O
in O O
human O O
central O O
vision O O
. O O

Because O O
c B B_GENE
- I I_GENE
myb I I_GENE
encodes O O
a O O
transcriptional O O
activator O O
that O O
functions O O
via O O
DNA O O
binding O O
, O O
it O O
is O O
likely O O
that O O
c B B_GENE
- I I_GENE
myb I I_GENE
exerts O O
its O O
biological O O
activity O O
by O O
regulating O O
the O O
transcription O O
of O O
genes O O
required O O
for O O
DNA O O
synthesis O O
and O O
cell O O
cycle O O
progression O O
. O O

The O O
rest O O
of O O
the O O
3 O O
' O O
untranslated O O
sequences O O
were O O
common O O
to O O
both O O
cDNA O O
clones O O
. O O

Coexpression O O
of O O
c B B_GENE
- I I_GENE
Rel I I_GENE
in O O
combination O O
with O O
ATF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
CREB2 B B_GENE
, O O
or O O
ATF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
CREB2 B B_GENE/B_MEASURE
leads O O
to O O
synergistic O O
transactivation O O
of O O
a O O
CD28RE B B_GENE
- I I_GENE
TRE I I_GENE
reporter I I_GENE
plasmid O O
in O O
quiescent O O
Jurkat O O
T O O
- O O
cells O O
. O O

Conventional O O
toxicological O O
considerations O O
suggest O O
that O O
the O O
adverse O O
health O O
effects O O
of O O
any O O
necessary O O
increase O O
in O O
coal O O
combustion O O
effluents O O
would O O
be O O
greatest O O
per O O
unit O O
of O O
coal O O
in O O
those O O
areas O O
which O O
are O O
most O O
heavily O O
populated O O
and O O
have O O
the O O
highest O O
preexisting O O
levels O O
of O O
the O O
gas O O
- O O
aerosol O O
complex O O
. O O

The O O
genes O O
on O O
each O O
chromosome O O
involved O O
in O O
this O O
translocation O O
have O O
been O O
identified O O
as O O
the O O
transcription O O
factor O O
- O O
encoding O O
genes O O
PAX3 B B_GENE/B_DISEASE
and O O
FKHR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Anesthesia O O
was O O
induced O O
by O O
droperidol O O
0 O O
. O O
2 O O
mg O O
. O O
kg O O
- O O
1 O O
, O O
fentanyl O O
50 O O
micrograms O O
, O O
thiamylal O O
150 O O
- O O
250 O O
mg O O
, O O
and O O
succinylcholine O O
1 O O
mg O O
. O O
kg O O
- O O
1 O O
, O O
and O O
maintained O O
with O O
nitrous O O
oxide O O
and O O
O2 O O
( O O
67 O O
: O O
33 O O
) O O
supplemented O O
with O O
repeated O O
i O O
. O O
v O O
. O O
doses O O
of O O
fentanyl O O
( O O
within O O
15 O O
micrograms O O
. O O
kg O O
- O O
1 O O
) O O
. O O

Complexities O O
in O O
the O O
host O O
- O O
pathogen O O
interactions O O
during O O
actual O O
infection O O
with O O
Gram O O
- O O
negative O O
bacteria O O
may O O
account O O
for O O
the O O
difficulties O O
in O O
demonstrating O O
this O O
phenomena O O
in O O
vivo O O
. O O

This O O
novel O O
TRPC7 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
could O O
be O O
a O O
candidate O O
gene O O
for O O
genetic O O
disorders O O
such O O
as O O
bipolar O O
affective O O
disorder O O
, O O
nonsyndromic O O
hereditary O O
deafness O O
, O O
Knobloch O O
syndrome O O
, O O
and O O
holoprosencephaly O O
, O O
which O O
were O O
mapped O O
to O O
this O O
region O O
. O O

We O O
present O O
the O O
case O O
of O O
a O O
patient O O
who O O
presented O O
an O O
unusually O O
large O O
mucoid O O
cyst O O
measuring O O
38 O O
x O O
25 O O
mm O O
in O O
an O O
uncommon O O
localization O O
, O O
the O O
right O O
maxillary O O
. O O

Acoustic O O
- O O
property O O
measurements O O
of O O
the O O
oxide O O
superconductor O O
BaPb1 O O
- O O
xBixO3 O O
by O O
the O O
sphere O O
- O O
resonance O O
method O O
. O O

In O O
7 O O
men O O
and O O
1 O O
woman O O
who O O
died O O
suddenly O O
the O O
functionally O O
important O O
areas O O
of O O
myocardium O O
in O O
the O O
sino O O
- O O
auricular O O
area O O
and O O
the O O
subendocardial O O
layers O O
of O O
left O O
ventricle O O
were O O
obtained O O
by O O
necropsy O O
no O O
more O O
than O O
3 O O
h O O
after O O
death O O
, O O
and O O
then O O
prepared O O
for O O
study O O
by O O
electron O O
microscopy O O
. O O

IGF B B_PERSON/B_GENE
- I I_PERSON/I_GENE
I I I_PERSON/I_GENE
levels O O
were O O
measured O O
in O O
the O O
CSF O O
of O O
11 O O
children O O
with O O
autism O O
( O O
4 O O
females O O
, O O
7 O O
males O O
; O O
mean O O
age O O
3 O O
. O O
8 O O
years O O
, O O
SD O O
1 O O
. O O
1 O O
) O O
using O O
a O O
sensitive O O
radioimmunoassay O O
method O O
and O O
compared O O
with O O
levels O O
in O O
11 O O
control O O
participants O O
( O O
6 O O
females O O
, O O
5 O O
males O O
; O O
mean O O
age O O
3 O O
. O O
8 O O
years O O
) O O
. O O

In O O
a O O
subsequent O O
phase O O
- O O
II O O
clinical O O
trial O O
safety O O
and O O
efficacy O O
of O O
transrectal O O
HIFU O O
as O O
a O O
novel O O
minimally O O
invasive O O
treatment O O
modality O O
for O O
patients O O
with O O
symptomatic O O
benign O O
prostatic O O
hyperplasia O O
( O O
BPH O O
; O O
n O O
= O O
102 O O
) O O
was O O
determined O O
. O O

Slowly O O
adapting O O
type O O
I O O
mechanoreceptor O O
discharge O O
as O O
a O O
function O O
of O O
dynamic O O
force O O
versus O O
dynamic O O
displacement O O
of O O
glabrous O O
skin O O
of O O
raccoon O O
and O O
squirrel O O
monkey O O
hand O O
. O O

FACS O O
analysis O O
demonstrated O O
that O O
MCs O O
had O O
reached O O
middle O O
to O O
late O O
G1 O O
phase O O
of O O
cell O O
cycle O O
progression O O
at O O
this O O
timepoint O O
. O O

Analysis O O
of O O
tobacco O O
mRNA O O
using O O
the O O
ACBF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cDNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
probe O O
showed O O
that O O
while O O
ACBF B B_GENE
mRNA I I_GENE
was O O
present O O
in O O
all O O
tissues O O
examined O O
, O O
the O O
highest O O
transcript O O
accumulation O O
occurred O O
in O O
stem O O
tissues O O
. O O

Cotransfection O O
experiments O O
revealed O O
that O O
both O O
hGATA B B_GENE
- I I_GENE
4 I I_GENE
and O O
PMA O O
/ O O
A23187 O O
stimulation O O
are O O
necessary O O
for O O
the O O
IL B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
5 I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
activation O O
. O O

Here O O
we O O
show O O
that O O
expression O O
of O O
KRAB B B_GENE/B_DISEASE
domain I I_GENE/I_DISEASE
suppresses O O
in O O
vivo O O
the O O
activating O O
function O O
of O O
various O O
defined O O
activating B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
we O O
demonstrate O O
that O O
the O O
KRAB B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
specifically O O
silences O O
the O O
activity O O
of O O
promoters O O
whose O O
initiation O O
is O O
dependent O O
on O O
the O O
presence O O
of O O
a O O
TATA O O
box O O
. O O

Adult O O
- O O
onset O O
parkinsonism O O
has O O
appeared O O
in O O
several O O
previously O O
unaffected O O
members O O
in O O
families O O
with O O
DRD O O
suggesting O O
that O O
this O O
may O O
be O O
an O O
additional O O
phenotypical O O
expression O O
of O O
the O O
disease O O
. O O

We O O
tested O O
the O O
effects O O
of O O
antifungal O O
drugs O O
on O O
adherence O O
of O O
Candida O O
albicans O O
in O O
vitro O O
. O O

The O O
signs O O
of O O
enterocolitis O O
, O O
pathological O O
microbial O O
flora O O
in O O
the O O
stool O O
and O O
changes O O
in O O
the O O
colon O O
mucosa O O
were O O
absent O O
. O O

These O O
results O O
support O O
an O O
in O O
vivo O O
interaction O O
between O O
Nck B B_GENE
and O O
CKI B B_GENE
- I I_GENE
gamma2 I I_GENE
and O O
suggest O O
that O O
CKI B B_GENE/B_PERSON
- I I_GENE/I_PERSON
gamma2 I I_GENE/I_PERSON
could O O
be O O
involved O O
in O O
signaling O O
pathways O O
downstream O O
of O O
RTKs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Correlation O O
of O O
nitrogen O O
, O O
carbohydrate O O
and O O
lipid O O
metabolic O O
indices O O
in O O
rats O O
cooled O O
under O O
conditions O O
of O O
an O O
altered O O
gaseous O O
environment O O

Reactivation O O
of O O
hepatitis O O
B O O
virus O O
replication O O
is O O
a O O
rare O O
event O O
during O O
the O O
natural O O
history O O
of O O
chronic O O
hepatitis O O
B O O
. O O

A O O
minimal O O
region O O
which O O
stimulates O O
origin O O
function O O
mapped O O
to O O
50 O O
amino O O
acids O O
within O O
the O O
C O O
- O O
terminus O O
of O O
Abf1p B B_GENE
. O O

Cutaneous O O
melanoma O O
and O O
bilateral O O
retinoblastoma O O
. O O

Treatment O O
of O O
JEA2 O O
cells O O
with O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IL I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
7 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
induces O O
CBLB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphorylation O O
as O O
well O O
. O O

Phosphorylation O O
by O O
Cdc28 B B_GENE
activates O O
the O O
Cdc20 B B_GENE
- O O
dependent O O
activity O O
of O O
the O O
anaphase O O
- O O
promoting O O
complex O O
. O O

The O O
amount O O
of O O
overlap O O
in O O
VFI O O
, O O
EF O O
, O O
and O O
RVF O O
values O O
among O O
the O O
clinical O O
groups O O
was O O
considerable O O
. O O

After O O
5 O O
, O O
850 O O
C14 O O
BP O O
, O O
the O O
decrease O O
in O O
Acer O O
stands O O
could O O
be O O
attributed O O
to O O
fire O O
as O O
suggested O O
by O O
the O O
strong O O
increase O O
in O O
Betula O O
and O O
by O O
the O O
delayed O O
expansion O O
of O O
Pinus O O
cembra O O
. O O

Assays O O
of O O
APRE O O
- O O
luciferase B B_GENE
reporter O O
plasmids O O
transfected O O
into O O
HepG2 O O
cells O O
show O O
that O O
a O O
mutated O O
APRE O O
that O O
binds O O
only O O
BPi B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions O O
as O O
an O O
IL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inducible O O
enhancer O O
, O O
whereas O O
a O O
mutated O O
APRE O O
that O O
binds O O
only O O
BPc B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O O
not O O
. O O

Several O O
sequences O O
resembling O O
binding O O
sites O O
for O O
liver O O
- O O
and O O
fat O O
body O O
- O O
specific O O
transcription O O
factors O O
were O O
identified O O
within O O
1 O O
kb O O
upstream O O
and O O
downstream O O
of O O
the O O
gene O O
. O O

Northern O O
blot O O
analysis O O
linked O O
Plk B B_GENE
expression O O
to O O
the O O
proliferative O O
activity O O
of O O
cells O O
and O O
tissues O O
. O O

It O O
also O O
showed O O
which O O
amino O O
acid O O
residues O O
would O O
contact O O
an O O
extended O O
TATA O O
box O O
with O O
a O O
B B B_GENE
recognition I I_GENE
element I I_GENE
, O O
and O O
evolutionary O O
conservation O O
of O O
the O O
TBP B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
TFB B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
DNA O O
complex O O
orientation O O
between O O
two O O
archaeal O O
organisms O O
with O O
widely O O
different O O
optimal O O
temperature O O
for O O
growth O O
( O O
37 O O
and O O
100 O O
degrees O O
C O O
) O O
. O O

Studies O O
with O O
and O O
without O O
attenuating O O
media O O
were O O
performed O O
, O O
and O O
myocardium O O
- O O
to O O
- O O
defect O O
count O O
ratios O O
and O O
defect O O
sizes O O
from O O
dual O O
- O O
isotope O O
SPECT O O
images O O
were O O
compared O O
to O O
myocardium O O
- O O
to O O
- O O
defect O O
count O O
ratios O O
and O O
defect O O
sizes O O
from O O
single O O
- O O
isotope O O
( O O
201Tl O O
and O O
99mTc O O
) O O
SPECT O O
images O O
. O O

Comparison O O
of O O
this O O
gene O O
with O O
the O O
available O O
databases O O
reveals O O
very O O
significant O O
homology O O
to O O
the O O
ETS B B_MEASURE/B_GENE
factor I I_MEASURE/I_GENE
PE B I_MEASURE/I_GENE
- I I_MEASURE/I_GENE
1 I I_MEASURE/I_GENE
and O O
probable O O
near O O
- O O
identity O O
with O O
the O O
recently O O
cloned O O
factor O O
ERF B B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Patients O O
with O O
Eales O O
' O O
disease O O
, O O
chorioretinitis O O
, O O
central O O
serous O O
retinopathy O O
, O O
or O O
malignant O O
choroidal O O
melanoma O O
were O O
tested O O
for O O
HLA B B_GENE/B_VIRUS[BIO]
antigen O O
deviation O O
. O O

Copyright O O
1999 O O
Academic O O
Press O O
. O O

The O O
1 O O
. O O
5 O O
- O O
Mb O O
region O O
was O O
covered O O
by O O
137 O O
cosmids O O
with O O
a O O
minimum O O
overlap O O
set O O
of O O
52 O O
cosmids O O
assigned O O
to O O
17 O O
bins O O
and O O
9 O O
contigs O O
. O O

Estrogen O O
has O O
positive O O
effects O O
on O O
mood O O
, O O
sexual O O
function O O
, O O
target O O
end O O
organs O O
and O O
cognitive O O
function O O
, O O
and O O
may O O
play O O
an O O
important O O
role O O
in O O
the O O
etiology O O
of O O
Alzheimer O O
' O O
s O O
Disease O O
by O O
acting O O
to O O
prevent O O
amyloid O O
plaque O O
formation O O
, O O
oxidative O O
stress O O
, O O
or O O
deterioration O O
of O O
the O O
cholinergic O O
neurotransmitter O O
system O O
. O O

These O O
data O O
also O O
demonstrate O O
that O O
insulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
TPA O O
activate O O
MBP B B_GENE
/ O O
MAP2 B B_GENE
kinase O O
activity O O
by O O
de O O
novo O O
phosphorylation O O
of O O
threonine O O
and O O
tyrosine O O
residues O O
via O O
a O O
very O O
similar O O
pathway O O
. O O

Effect O O
of O O
capsaicin O O
on O O
hexobarbital O O
- O O
anesthetized O O
rats O O

Triethylene O O
glycol O O
. O O

Such O O
tetranucleotides O O
are O O
common O O
in O O
promoter O O
regions O O
, O O
particularly O O
in O O
activating B B_GENE
transcription I I_GENE
factor I I_GENE
/ O O
cyclic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AMP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ATF B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
CREB B B_GENE
) O O
and O O
E O O
- O O
box O O
motifs O O
, O O
suggesting O O
that O O
PIF B B_PERSON/B_GENE
may O O
modulate O O
the O O
transcription O O
of O O
many O O
genes O O
. O O

Red O O
blood O O
cell O O
binding O O
of O O
99mTc O O
- O O
EC O O
and O O
131I O O
- O O
OIH O O
was O O
6 O O
. O O
1 O O
% O O
and O O
20 O O
% O O
, O O
respectively O O
. O O

The O O
dominant O O
inhibitory O O
biological O O
activity O O
of O O
the O O
N O O
terminus O O
correlated O O
with O O
its O O
ability O O
to O O
impair O O
EGF B B_GENE
- O O
dependent O O
activation O O
of O O
GTP B B_GENE
- I I_GENE
Ras I I_GENE
and O O
of O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
well O O
with O O
the O O
ability O O
of O O
endogenous O O
Sos B B_GENE/B_DISEASE
to O O
form O O
a O O
stable O O
complex O O
with O O
activated O O
EGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
characterization O O
of O O
fly O O
receptors O O
with O O
features O O
similar O O
to O O
mammalian B B_GENE/B_SPECIES[BIO]
glycoprotein I B_GENE/I_SPECIES[BIO]
hormone I B_GENE/I_SPECIES[BIO]
receptors I B_GENE/I_SPECIES[BIO]
allows O O
a O O
better O O
understanding O O
of O O
the O O
evolution O O
of O O
this O O
unique O O
group O O
of O O
GPCRs B B_GENE/B_BIO
and O O
future O O
elucidation O O
of O O
their O O
ligand O O
signaling O O
mechanisms O O
. O O

Here O O
we O O
show O O
that O O
these O O
sequences O O
are O O
essential O O
for O O
processing O O
of O O
U18 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
snR38 B B_GENE
snoRNAs I I_GENE
and O O
that O O
they O O
compensate O O
for O O
the O O
lack O O
of O O
a O O
canonical O O
terminal O O
stem O O
. O O

The O O
use O O
of O O
aluminum O O
hydroxide O O
was O O
associated O O
with O O
an O O
increase O O
in O O
fecal O O
fluoride O O
excretion O O
and O O
a O O
decrease O O
in O O
net O O
absorption O O
of O O
fluoride O O
regardless O O
of O O
the O O
intake O O
fluoride O O
, O O
calcium O O
, O O
phosphorus O O
, O O
or O O
magnesium O O
. O O

In O O
humans O O
, O O
there O O
was O O
a O O
statistically O O
significant O O
decrease O O
of O O
TEWL O O
on O O
both O O
forearm O O
and O O
thigh O O
in O O
CS O O
- O O
treated O O
patients O O
compared O O
to O O
non O O
- O O
CS O O
- O O
treated O O
patients O O
and O O
controls O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

Kramer O O
Hamburg O O
1988 O O
, O O
ISBN O O
: O O
3 O O
926952 O O
07 O O
5 O O
) O O
, O O
the O O
syndromatic O O
day O O
- O O
to O O
- O O
day O O
shifting O O
of O O
the O O
psychopathological O O
features O O
with O O
manic O O
, O O
depressive O O
and O O
several O O
mixed O O
states O O
has O O
a O O
well O O
- O O
defined O O
time O O
structure O O
, O O
as O O
in O O
25 O O
patients O O
studied O O
and O O
reported O O
on O O
in O O
this O O
paper O O
. O O

Analysis O O
of O O
exon O O
2 O O
of O O
the O O
factor B B_GENE/B_BIO
IX I I_GENE/I_BIO
gene I I_GENE/I_BIO
revealed O O
a O O
C O O
- O O
- O O
> O O
T O O
mutation O O
in O O
codon O O
10 O O
of O O
the O O
propeptide O O
region O O
, O O
resulting O O
in O O
the O O
substitution O O
of O O
alanine O O
by O O
valine O O
. O O

There O O
was O O
a O O
direct O O
proportional O O
relationship O O
between O O
the O O
spiral O O
artery O O
flow O O
and O O
the O O
pressure O O
difference O O
between O O
the O O
spiral O O
artery O O
and O O
the O O
amniotic O O
fluid O O
; O O
the O O
pressure O O
difference O O
per O O
flow O O
( O O
the O O
resistance O O
of O O
the O O
cotyledonary O O
unit O O
) O O
was O O
found O O
to O O
be O O
1 O O
- O O
- O O
3 O O
mm O O
Hg O O
. O O

ml O O
- O O
1 O O
. O O
min O O
( O O
8 O O
- O O
- O O
24kPa O O
. O O
ml O O
- O O
1 O O
. O O
s O O
) O O
. O O

The O O
cells O O
were O O
densely O O
ciliated O O
, O O
each O O
cilium O O
showing O O
a O O
typical O O
9 O O
+ O O
2 O O
fibrilar O O
pattern O O
. O O

Immunofluorescence O O
obtained O O
using O O
antibodies O O
against O O
alphaI B B_GENE
SigmaI I I_GENE
/ I I_GENE
+ I I_GENE
+ I I_GENE
betaI I I_GENE
SigmaI I I_GENE
spectrin I I_GENE
and O O
Abl B B_GENE
tyrosine I I_GENE
kinase I I_GENE
but O O
not O O
against O O
alphaII B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
betaII I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
spectrin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
colocalized O O
with O O
the O O
overexpressed O O
green B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fluorescent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
SH3 B B_GENE
- I I_GENE
binding I I_GENE
protein I I_GENE
. O O

Extracellular B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
cancer O O
biomarker O O
: O O
its O O
expression O O
by O O
tumor O O
cells O O
and O O
reversal O O
by O O
a O O
myristate O O
- O O
lacking O O
Calpha O O
and O O
RIIbeta O O
subunit O O
overexpression O O
. O O

Detection O O
of O O
sinusoidal O O
gratings O O
by O O
pattern O O
- O O
specific O O
detectors O O
: O O
further O O
evidence O O
for O O
the O O
correlation O O
principle O O
in O O
human O O
vision O O
. O O

This O O
B O O
- O O
box O O
is O O
not O O
present O O
in O O
ETS1 B B_GENE/B_DISEASE
, O O
ETS2 B B_GENE/B_DISEASE
, O O
PEA3 B B_GENE/B_DISEASE
or O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
these O O
proteins O O
were O O
unable O O
to O O
form O O
ternary O O
complexes O O
with O O
SRF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
Egrl B B_PROTEIN[GENE]/B_BIO
- O O
SREs O O
or O O
c B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
fos I I_GENE/I_LOCATION
SRE O O
. O O

MADS B B_GENE
- I I_GENE
box I I_GENE
genes I I_GENE
in O O
plants O O
are O O
a O O
diverse O O
class O O
of O O
transcription O O
factors O O
that O O
are O O
involved O O
in O O
regulating O O
developmental O O
processes O O
, O O
particularly O O
meristem O O
and O O
organ O O
identity O O
during O O
floral O O
development O O
. O O

Thirty O O
- O O
five O O
pts O O
were O O
transplanted O O
for O O
constitutional O O
disease O O
: O O
Fanconi O O
anemia O O
( O O
FA O O
) O O
( O O
26 O O
pts O O
) O O
, O O
Dyskeratosis O O
congenita O O
( O O
2 O O
pts O O
) O O
, O O
Blackfan O O
- O O
Diamond O O
erythroblastopenia O O
( O O
2 O O
pts O O
) O O
, O O
Glanzmann O O
thrombasthenia O O
( O O
1 O O
pt O O
) O O
, O O
osteopetrosis O O
( O O
1 O O
pt O O
) O O
and O O
Gaucher O O
' O O
s O O
disease O O
( O O
1 O O
pt O O
) O O
. O O

Viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
U I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Vpu B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O O
is O O
a O O
protein O O
encoded O O
by O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV O O
- O O
1 O O
) O O
that O O
promotes O O
the O O
degradation O O
of O O
the O O
virus O O
receptor O O
, O O
CD4 B B_GENE
, O O
and O O
enhances O O
the O O
release O O
of O O
virus O O
particles O O
from O O
cells O O
. O O

Because O O
the O O
variation O O
in O O
the O O
carbohydrate O O
content O O
of O O
human O O
milk O O
is O O
very O O
small O O
, O O
a O O
more O O
simple O O
alternative O O
approach O O
would O O
be O O
to O O
include O O
only O O
an O O
average O O
carbohydrate O O
value O O
for O O
an O O
estimate O O
of O O
energy O O
content O O
. O O

Level O O
II O O
mosaicism O O
occurred O O
in O O
0 O O
. O O
9 O O
per O O
cent O O
of O O
CVS O O
mesenchyme O O
and O O
1 O O
. O O
5 O O
per O O
cent O O
of O O
amniotic O O
fluid O O
cultures O O
and O O
in O O
general O O
was O O
not O O
perceived O O
to O O
be O O
of O O
sufficient O O
concern O O
to O O
warrant O O
cytogenetic O O
follow O O
- O O
up O O
studies O O
. O O

Biol O O
. O O

IV O O
. O O

Sleeping O O
position O O
and O O
sudden O O
infant O O
death O O
syndrome O O
( O O
SIDS O O
) O O
: O O
effect O O
of O O
an O O
intervention O O
programme O O
to O O
avoid O O
prone O O
sleeping O O
. O O

CSEn B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulated O O
transcription O O
of O O
a O O
variety O O
of O O
promoters O O
, O O
including O O
the O O
hCS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
human B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
thymidine B B_GENE
kinase I I_GENE
, O O
and O O
Rous B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sarcoma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
human O O
choriocarcinoma O O
cell O O
lines O O
( O O
BeWo O O
and O O
JEG O O
- O O
3 O O
) O O
but O O
not O O
HeLa O O
cells O O
or O O
rat O O
somatolactotrophes O O
( O O
GC O O
) O O
. O O

Pretreatment O O
of O O
human O O
skin O O
with O O
tRA O O
inhibited O O
UV O O
induction O O
of O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
, O O
consequently O O
, O O
AP B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
. O O

c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibition O O
occurred O O
via O O
a O O
posttranscriptional O O
mechanism O O
, O O
since O O
tRA O O
did O O
not O O
inhibit O O
UV O O
induction O O
of O O
c B B_GENE
- I I_GENE
Jun I I_GENE
mRNA I I_GENE
. O O

Thus O O
, O O
apoptosis O O
in O O
hematopoietic O O
cells O O
is O O
the O O
end O O
result O O
of O O
a O O
conflict O O
between O O
death O O
and O O
survival O O
signals O O
, O O
rather O O
than O O
a O O
simple O O
death O O
by O O
default O O
. O O

CONCLUSIONS O O
: O O
Results O O
of O O
this O O
study O O
suggest O O
that O O
both O O
male O O
and O O
female O O
soldiers O O
who O O
are O O
diagnosed O O
with O O
chlamydia O O
infections O O
have O O
relatively O O
high O O
risks O O
of O O
reinfection O O
through O O
their O O
20s O O
. O O

During O O
seed O O
maturation O O
, O O
the O O
transcriptional O O
activity O O
of O O
napin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
regulated O O
by O O
developmental O O
signals O O
involving O O
the O O
transcriptional B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activator I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ABI3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
abscisic O O
acid O O
( O O
ABA O O
) O O
. O O

DESIGN O O
: O O
Intradermally O O
injected O O
human O O
squamous O O
cell O O
carcinoma O O
cells O O
were O O
grown O O
to O O
40 O O
to O O
80 O O
mm3 O O
in O O
athymic O O
nude O O
mice O O
and O O
irradiated O O
with O O
675 O O
- O O
nm O O
light O O
( O O
75 O O
J O O
/ O O
cm2 O O
, O O
75 O O
mW O O
/ O O
cm2 O O
) O O
24 O O
hours O O
after O O
the O O
intraperitoneal O O
injection O O
of O O
SiPc O O
IV O O
( O O
1 O O
. O O
0 O O
mg O O
/ O O
kg O O
) O O
. O O

This O O
results O O
in O O
a O O
decreased O O
secretion O O
of O O
immunoglobulin B B_GENE
A I I_GENE
, O O
and O O
, O O
consequently O O
, O O
a O O
decreased O O
resistance O O
against O O
infections O O
. O O

The O O
absolute O O
CD4 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
count O O
of O O
patients O O
with O O
de O O
novo O O
IBD O O
was O O
210 O O
- O O
700 O O
cells O O
/ O O
ml O O
at O O
the O O
time O O
of O O
IBD O O
. O O

Categorisation O O
of O O
the O O
different O O
substructures O O
within O O
the O O
sections O O
allows O O
them O O
to O O
be O O
analysed O O
and O O
displayed O O
separately O O
. O O

To O O
study O O
the O O
mechanisms O O
and O O
the O O
signaling O O
pathways O O
involved O O
, O O
IGF B B_PERSON/B_GENE
- I I_PERSON/I_GENE
1R I I_PERSON/I_GENE
promoter I I_PERSON/I_GENE
reporter I I_PERSON/I_GENE
constructs I I_PERSON/I_GENE
were O O
transiently O O
transfected O O
in O O
CHO O O
- O O
AT1 O O
cells O O
that O O
overexpress O O
angiotensin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AT1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Natl O O
. O O

Coexpression O O
of O O
a O O
dominant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
negative I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antagonized O O
the O O
ras B B_GENE/B_DISEASE
- O O
dependent O O
stimulation O O
of O O
the O O
92 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kDa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gelatinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter O O
- O O
driven O O
CAT B B_GENE
reporter I I_GENE
. O O

In O O
two O O
patients O O
, O O
a O O
male O O
homosexual O O
and O O
an O O
hemophiliac O O
, O O
thrombocytopenia O O
was O O
associated O O
with O O
AIDS O O
- O O
related O O
complex O O
. O O

However O O
, O O
LXRalpha B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibited O O
binding O O
of O O
PPARalpha B B_GENE
/ O O
RXRalpha B B_GENE
heterodimers O O
to O O
PPREs O O
, O O
and O O
coexpression O O
of O O
LXRalpha B B_GENE/B_PERSON
in O O
mammalian O O
cells O O
antagonized O O
peroxisome O O
proliferator O O
signaling O O
mediated O O
by O O
PPARalpha B B_GENE
/ O O
RXRalpha B B_GENE
in O O
vivo O O
. O O

The O O
results O O
can O O
be O O
summarized O O
as O O
follows O O
. O O

These O O
findings O O
suggest O O
that O O
the O O
mechanism O O
of O O
ribosomal O O
frameshifting O O
at O O
the O O
PVM O O
signal O O
is O O
different O O
from O O
the O O
one O O
described O O
by O O
the O O
' O O
simultaneous O O
slippage O O
' O O
model O O
in O O
that O O
only O O
the O O
string O O
of O O
four O O
adenosine O O
nucleotides O O
represents O O
the O O
slippery O O
sequence O O
involved O O
in O O
a O O
- O O
1 O O
P O O
- O O
site O O
slippage O O
. O O

CTDK1 B B_GENE/B_LOCATION
and O O
CTDK2 B B_GENE
also O O
differ O O
in O O
their O O
protein O O
substrate O O
specificity O O
. O O

A O O
Laboratory O O
Manual O O
, O O
2nd O O
ed O O
. O O

A O O
mean O O
value O O
for O O
HbA1 B B_PROTEIN[GENE]/B_DISEASE
greater O O
than O O
10 O O
% O O
was O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
progression O O
of O O
retinopathy O O
and O O
a O O
mean O O
value O O
less O O
than O O
8 O O
. O O
7 O O
% O O
was O O
associated O O
with O O
a O O
diminished O O
risk O O
. O O

Allergic O O
field O O
: O O
how O O
to O O
detect O O
it O O
? O O

The O O
preparative O O
regimen O O
consisted O O
of O O
fractionated O O
total O O
body O O
irradiation O O
( O O
TBI O O
) O O
and O O
cyclophosphamide O O
( O O
CY O O
) O O
. O O

NGF B B_PERSON/B_GENE
also O O
induced O O
a O O
synthetic O O
promoter O O
with O O
repeated O O
Sp1 B B_GENE/B_LOCATION
sites I I_GENE/I_LOCATION
linked O O
to O O
a O O
core O O
promoter O O
, O O
and O O
a O O
plasmid O O
regulated O O
by O O
a O O
chimeric O O
transactivator O O
in O O
which O O
the O O
Gal4 B B_GENE/B_MEASURE
DNA I I_GENE/I_MEASURE
binding I I_GENE/I_MEASURE
domain I I_GENE/I_MEASURE
is O O
fused O O
to O O
the O O
Sp1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transactivation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
indicating O O
that O O
this O O
transactivation O O
domain O O
is O O
regulated O O
by O O
NGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
toxicity O O
of O O
copper O O
to O O
the O O
collembolan O O
Folsomia O O
fimetaria O O
L O O
. O O
was O O
studied O O
in O O
soil O O
incubated O O
with O O
copper O O
sulfate O O
for O O
different O O
periods O O
before O O
the O O
introduction O O
of O O
collembolans O O
, O O
to O O
assess O O
the O O
effect O O
of O O
aging O O
of O O
contamination O O
on O O
the O O
toxicity O O
of O O
copper O O
. O O

The O O
frequency O O
of O O
severe O O
congestive O O
heart O O
failure O O
( O O
Killip O O
class O O
III O O
or O O
IV O O
) O O
at O O
admission O O
was O O
significantly O O
higher O O
in O O
patients O O
with O O
early O O
presentation O O
, O O
than O O
with O O
late O O
presentation O O
( O O
30 O O
. O O
7 O O
% O O
vs O O
7 O O
. O O
6 O O
% O O
, O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

The O O
Giessener O O
Tumordokumentationssystem O O
( O O
GTDS O O
) O O
is O O
such O O
a O O
disease O O
specific O O
system O O
. O O

Measurement O O
of O O
protein O O
in O O
natural O O
rubber O O
latex O O
. O O

In O O
cotransfection O O
assays O O
, O O
a O O
small O O
fragment O O
of O O
Sin B B_GENE/B_DISEASE
retaining O O
the O O
Src B B_GENE
- O O
SH3 B B_GENE/B_LOCATION
- O O
binding O O
site O O
and O O
one O O
tyrosine O O
- O O
containing O O
motif O O
induced O O
c B B_GENE
- I I_GENE
Src I I_GENE
activation O O
as O O
measured O O
by O O
a O O
transcriptional O O
reporter O O
. O O

The O O
related O O
tumor O O
suppressor O O
, O O
p130 B B_GENE
, O O
also O O
effects O O
this O O
function O O
. O O

p107 B B_GENE/B_MEASURE
levels O O
increase O O
substantially O O
as O O
cells O O
progress O O
through O O
S O O
phase O O
. O O

Transcriptional O O
regulation O O
of O O
the O O
murine B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
k I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
fgf I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Further O O
, O O
cells O O
cotransfected O O
with O O
a O O
UF B B_GENE
promoter I I_GENE
- O O
luciferase B B_GENE/B_DISEASE
( O O
- O O
1935UF B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Luc B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
reporter O O
gene O O
and O O
the O O
BTEB B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
expression O O
vector O O
had O O
2 O O
- O O
fold O O
higher O O
Luc B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
than O O
those O O
cotransfected O O
with O O
reporter O O
gene O O
and O O
pcDNA O O
- O O
3 O O
. O O

Evasion O O
of O O
host O O
immunity O O
by O O
Toxocara O O
canis O O
infective O O
larvae O O
is O O
mediated O O
by O O
the O O
nematode O O
surface O O
coat O O
, O O
which O O
is O O
shed O O
in O O
response O O
to O O
binding O O
by O O
host O O
antibody O O
molecules O O
or O O
effector O O
cells O O
. O O

A O O
Frank O O
vectorcardiogram O O
was O O
recorded O O
before O O
and O O
every O O
15 O O
- O O
30 O O
minutes O O
for O O
10 O O
hours O O
after O O
the O O
occlusion O O
. O O

In O O
agreement O O
with O O
this O O
, O O
archaea O O
appear O O
to O O
lack O O
eIF5 B B_GENE
, O O
eIF2B B B_GENE
and O O
the O O
lysine O O
- O O
rich O O
binding O O
domain O O
for O O
these O O
factors O O
in O O
their O O
eIF2beta B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
homolog I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Derepression O O
of O O
RAR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
by O O
expressing O O
a O O
dominant O O
- O O
negative O O
corepressor O O
resulted O O
in O O
embryos O O
that O O
exhibited O O
phenotypes O O
similar O O
to O O
those O O
treated O O
by O O
RA O O
. O O

Chemiluminescence O O
induced O O
by O O
opsonized O O
zymosan O O
increased O O
significantly O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
after O O
treatment O O
with O O
bacterial O O
extracts O O
, O O
whereas O O
no O O
significant O O
changes O O
were O O
observed O O
in O O
the O O
fMLP O O
- O O
stimulated O O
PMNs O O
. O O

Lastly O O
, O O
several O O
restriction O O
length O O
polymorphisms O O
were O O
identified O O
and O O
mapped O O
within O O
a O O
1 O O
kb O O
region O O
located O O
immediately O O
upstream O O
from O O
the O O
JH B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cluster I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Radiographic O O
spatial O O
frequencies O O
essential O O
to O O
the O O
diagnosis O O
of O O
incipient O O
interproximal O O
lesions O O
. O O

Promoter O O
region O O
of O O
the O O
human B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
2A I I_GENE/I_LOCATION
adrenergic I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
. O O

( O O
1982 O O
) O O
. O O

( O O
99m O O
) O O
Tc O O
Ethyl O O
Cysteinate O O
Dimer O O
stable O O
during O O
6h O O
has O O
contributed O O
to O O
develop O O
ictal O O
studies O O
to O O
evaluate O O
the O O
location O O
of O O
partial O O
seizure O O
. O O

LiF O O
thermoluminescence O O
dosimeters O O
( O O
TLD O O
) O O
in O O
chip O O
form O O
were O O
placed O O
onto O O
1 O O
eyelid O O
, O O
the O O
skin O O
over O O
the O O
thyroid O O
, O O
and O O
the O O
patient O O
' O O
s O O
clothes O O
covering O O
the O O
region O O
of O O
breasts O O
and O O
ovaries O O
of O O
female O O
patients O O
and O O
the O O
testicles O O
of O O
male O O
patients O O
. O O

Thus O O
, O O
the O O
in O O
vivo O O
function O O
of O O
Gle2p B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
strictly O O
coupled O O
to O O
the O O
short O O
GLEBS B B_GENE/B_LOCATION
within O O
Nup116p B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
links O O
this O O
putative O O
mRNA O O
transport O O
factor O O
to O O
the O O
nuclear O O
pores O O
. O O

The O O
structure O O
of O O
the O O
murine B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Dtk I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
determined O O
. O O

In O O
previous O O
studies O O
, O O
we O O
showed O O
that O O
the O O
nuclear O O
import O O
of O O
SREBP B B_GENE
- I I_GENE
2 I I_GENE
occurs O O
via O O
the O O
direct O O
interaction O O
of O O
importin B B_GENE
beta I I_GENE
with O O
the O O
HLH O O
- O O
Zip O O
domain O O
. O O

In O O
the O O
normal O O
controls O O
the O O
plasma B B_GENE
FPA I I_GENE
level O O
( O O
mean O O
+ O O
/ O O
- O O
SD O O
) O O
was O O
1 O O
. O O
43 O O
+ O O
/ O O
- O O
0 O O
. O O
46 O O
ng O O
/ O O
ml O O
. O O

In O O
this O O
study O O
we O O
cloned O O
the O O
cDNA O O
of O O
AD1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ag I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
a O O
rat O O
basophilic O O
leukemia O O
2H3 O O
cDNA O O
library O O
. O O

The O O
procedure O O
was O O
technically O O
successful O O
in O O
12 O O
of O O
14 O O
( O O
86 O O
% O O
) O O
stenoses O O
in O O
the O O
fibromuscular O O
dysplasia O O
subgroup O O
but O O
in O O
only O O
one O O
of O O
five O O
( O O
20 O O
% O O
) O O
lesions O O
in O O
the O O
neurofibromatosis O O
subgroup O O
. O O

Conventional O O
and O O
digital O O
radiography O O
of O O
the O O
heart O O
, O O
aorta O O
, O O
and O O
pulmonary O O
vascularity O O
. O O

Regulation O O
of O O
the O O
p21 B B_GENE
- I I_GENE
activated I I_GENE
kinase I I_GENE
( O O
PAK B B_GENE/B_PERSON
) O O
by O O
a O O
human B B_SPECIES[BIO]/B_GENE
Gbeta I I_SPECIES[BIO]/I_GENE
- I I_SPECIES[BIO]/I_GENE
like I I_SPECIES[BIO]/I_GENE
WD O O
- O O
repeat O O
protein O O
, O O
hPIP1 B B_GENE/B_LOCATION
. O O

Other O O
clinicopathological O O
features O O
have O O
no O O
definite O O
influence O O
in O O
survival O O
expectancy O O
. O O

These O O
studies O O
suggest O O
that O O
tandem O O
alpha O O
- O O
helices O O
located O O
near O O
the O O
C O O
- O O
terminus O O
of O O
PC B B_GENE
- I I_GENE
TP I I_GENE
facilitate O O
membrane O O
binding O O
and O O
extraction O O
of O O
phosphatidylcholines O O
. O O

The O O
striking O O
similarity O O
in O O
preference O O
for O O
mismatched O O
and O O
weakly O O
paired O O
nucleotides O O
for O O
binding O O
and O O
for O O
excision O O
suggests O O
a O O
functional O O
relationship O O
between O O
binding O O
and O O
cleavage O O
reactions O O
. O O

Interestingly O O
, O O
these O O
" O O
activation O O
- O O
defective O O
" O O
mutants O O
segregated O O
into O O
two O O
classes O O
: O O
1 O O
) O O
those O O
that O O
were O O
unable O O
to O O
form O O
dimers O O
but O O
that O O
could O O
still O O
form O O
higher O O
order O O
oligomers O O
and O O
transform O O
cells O O
, O O
and O O
2 O O
) O O
those O O
that O O
were O O
defective O O
for O O
PDGF B B_GENE
- I I_GENE
R I I_GENE
binding O O
and O O
were O O
transformation O O
- O O
incompetent O O
. O O

APL O O
patients O O
showed O O
a O O
low O O
, O O
yet O O
variable O O
, O O
level O O
of O O
JEM B B_GENE
- I I_GENE
1 I I_GENE
mRNA I I_GENE
in O O
bone O O
marrow O O
. O O

CONCLUSIONS O O
: O O
The O O
results O O
show O O
that O O
intranasal O O
challenge O O
with O O
FLU O O
induces O O
changes O O
in O O
leukocyte O O
histamine O O
release O O
, O O
but O O
not O O
other O O
systemic O O
immune O O
and O O
inflammatory O O
responses O O
. O O

We O O
have O O
shown O O
previously O O
that O O
EGF B B_GENE
receptor I I_GENE
activation O O
stimulates O O
gastrin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O O
expression O O
through O O
a O O
GC O O
- O O
rich O O
element O O
called O O
gERE O O
. O O

The O O
secondary O O
end O O
points O O
included O O
creatine B B_ENZYME[GENE]/B_DISEASE
kinase I B_ENZYME[GENE]/I_DISEASE
peak O O
, O O
ventricular O O
fibrillation O O
/ O O
tachycardia O O
within O O
the O O
first O O
24 O O
hours O O
, O O
death O O
and O O
congestive O O
heart O O
failure O O
within O O
the O O
30 O O
- O O
day O O
follow O O
- O O
up O O
, O O
and O O
30 O O
- O O
day O O
left O O
ventricular O O
ejection O O
fraction O O
. O O

Prevention O O
of O O
gravid O O
Rhesus O O
isoimmunization O O

All O O
relapses O O
occurred O O
within O O
the O O
first O O
year O O
and O O
were O O
confined O O
to O O
patients O O
with O O
PS O O
II O O
disease O O
and O O
four O O
or O O
more O O
sites O O
of O O
involvement O O
. O O

This O O
demonstrates O O
the O O
presence O O
of O O
a O O
PKC B B_GENE
- O O
dependent O O
pathway O O
which O O
functions O O
independently O O
from O O
Lck B B_GENE/B_LOCATION
in O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O O
. O O

This O O
interesting O O
exon O O
junction O O
resulted O O
in O O
novel O O
deduced O O
amino O O
terminal O O
open O O
reading O O
frames O O
, O O
which O O
are O O
completely O O
in O O
- O O
frame O O
with O O
sequences O O
located O O
further O O
downstream O O
. O O

Cell O O
lines O O
expressing O O
single O O
amino O O
acid O O
substitutions O O
of O O
the O O
carboxyl O O
- O O
terminal O O
asparagine O O
of O O
CD2 B B_GENE
are O O
incapable O O
of O O
avidity O O
regulation O O
by O O
TCR B B_GENE
signaling O O
, O O
PMA O O
treatment O O
, O O
or O O
elevation O O
of O O
intracellular O O
cAMP O O
levels O O
, O O
demonstrating O O
that O O
each O O
of O O
these O O
stimuli O O
utilizes O O
a O O
common O O
structural O O
element O O
for O O
regulating O O
CD2 B B_GENE
avidity O O
. O O

12 O O
per O O
cent O O
was O O
observed O O
with O O
the O O
use O O
of O O
tetracycline O O
and O O
4 O O
- O O
epianhydrotetracycline O O
in O O
doses O O
of O O
1000 O O
and O O
100gamma O O
per O O
embryo O O
respectively O O
. O O

Present O O
investigation O O
was O O
undertaken O O
to O O
elucidate O O
what O O
pharmacokinetic O O
parameters O O
in O O
animal O O
experiment O O
could O O
be O O
of O O
more O O
predictable O O
for O O
human O O
clinical O O
trial O O
of O O
beta O O
- O O
blocking O O
agents O O
. O O

When O O
transfected O O
into O O
HepG2 O O
cells O O
, O O
which O O
lack O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
mouse B B_GENE
ob I I_GENE
promoter I I_GENE
was O O
only O O
weakly O O
active O O
. O O

Between O O
1988 O O
and O O
1995 O O
, O O
341 O O
children O O
with O O
acute O O
myeloid O O
leukaemia O O
( O O
AML O O
) O O
were O O
treated O O
on O O
the O O
Medical O O
Research O O
Council O O
Acute O O
Myeloid O O
Leukaemia O O
Trial O O
( O O
MRC O O
AML10 O O
) O O
. O O

A O O
heterologous O O
promoter O O
construct O O
containing O O
three O O
repeats O O
of O O
a O O
consensus O O
Sp1 B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
, O O
cloned O O
upstream O O
of O O
a O O
single O O
copy O O
of O O
the O O
ZII B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CREB B B_GENE/B_LOCATION
/ O O
AP1 B B_GENE/B_LOCATION
) O O
element O O
from O O
the O O
BZLF1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
linked O O
to O O
the O O
beta B B_GENE/B_SPECIES[BIO]
- I B_GENE/I_SPECIES[BIO]
globin I B_GENE/I_SPECIES[BIO]
TATA O O
box O O
, O O
exhibited O O
phorbol O O
ester O O
inducibility O O
. O O

Appl O O
. O O

Thus O O
, O O
the O O
predicted O O
M3 O O
ORF O O
is O O
a O O
functional O O
gene O O
that O O
encodes O O
an O O
abundant O O
secreted O O
protein O O
which O O
is O O
a O O
candidate O O
for O O
interacting O O
with O O
host O O
cellular O O
receptors O O
or O O
cytokines O O
. O O

Protein O O
metabolism O O
disorders O O
in O O
burns O O

The O O
cumulative O O
dose O O
to O O
nursing O O
staff O O
for O O
the O O
week O O
after O O
treatment O O
was O O
dependent O O
on O O
patient O O
mobility O O
and O O
was O O
estimated O O
at O O
0 O O
. O O
08 O O
mSv O O
for O O
a O O
self O O
- O O
caring O O
patient O O
to O O
6 O O
. O O
3 O O
mSv O O
for O O
a O O
totally O O
helpless O O
patient O O
( O O
1840 O O
MBq O O
/ O O
group O O
A O O
) O O
. O O

JCAHO O O
to O O
use O O
ORYX O O
data O O
to O O
detect O O
sentinel O O
events O O
. O O

We O O
also O O
show O O
that O O
psbH B B_GENE/B_LOCATION
and O O
psbT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
transcribed O O
from O O
the O O
upstream O O
psbB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
that O O
the O O
psbH B B_GENE/B_MEASURE
mRNA I I_GENE/I_MEASURE
has O O
its O O
own O O
target O O
sequence O O
for O O
Mbb1 B B_GENE/B_PERSON
function O O
. O O

To O O
test O O
whether O O
Cd O O
exposure O O
would O O
increase O O
Ca O O
release O O
from O O
bone O O
during O O
pregnancy O O
and O O
lactation O O
in O O
relation O O
to O O
the O O
etiological O O
mechanism O O
of O O
Itai O O
- O O
Itai O O
disease O O
, O O
virgin O O
female O O
mice O O
with O O
45Ca O O
prelabeled O O
skeletons O O
( O O
15 O O
microCi O O
/ O O
mouse O O
) O O
were O O
subjected O O
to O O
one O O
round O O
of O O
pregnancy O O
/ O O
lactation O O
and O O
were O O
exposed O O
to O O
a O O
Ca O O
- O O
deficient O O
diet O O
containing O O
0 O O
, O O
5 O O
, O O
or O O
25 O O
ppm O O
Cd O O
or O O
25 O O
ppm O O
Pb O O
for O O
32 O O
days O O
, O O
from O O
conception O O
until O O
Lactation O O
Day O O
14 O O
. O O

O5257 B B_PERSON/B_GENE
shows O O
homology O O
with O O
the O O
SAS2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
another O O
hypothetical O O
protein O O
from O O
yeast O O
. O O

Principles O O
of O O
thyroid O O
hormone O O
treatment O O

Significance O O
of O O
esophagocardiac O O
reflexes O O
for O O
inducing O O
thoracic O O
pain O O

The O O
fate O O
of O O
ochratoxin O O
A O O
during O O
malting O O
and O O
brewing O O
. O O

METHODS O O
: O O
Precision O O
and O O
accuracy O O
were O O
measured O O
using O O
controls O O
and O O
method O O
comparison O O
studies O O
. O O

Messenger O O
RNA O O
for O O
the O O
Ad2 B B_GENE/B_BIO
DNA I I_GENE/I_BIO
binding I I_GENE/I_BIO
protein I I_GENE/I_BIO
: O O
DNA O O
sequences O O
encoding O O
the O O
first O O
leader O O
and O O
heterogenity O O
at O O
the O O
mRNA O O
5 O O
' O O
end O O
. O O

Consistent O O
with O O
this O O
hypothesis O O
, O O
stimulation O O
of O O
A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2A I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
R I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
PKA B B_GENE
enhanced O O
nuclear B B_GENE
aPKC I I_GENE
activity O O
. O O

Atrial O O
dissociation O O
. O O

However O O
, O O
depending O O
upon O O
the O O
promoter O O
context O O
, O O
we O O
observed O O
cooperative O O
interactions O O
between O O
the O O
two O O
domains O O
to O O
confer O O
high O O
DNA O O
- O O
binding O O
affinity O O
and O O
specificity O O
. O O

As O O
a O O
result O O
, O O
relative O O
biological O O
effects O O
( O O
RBE O O
) O O
of O O
2 O O
. O O
3 O O
- O O
2 O O
. O O
7 O O
was O O
obtained O O
from O O
the O O
straight O O
line O O
that O O
was O O
given O O
by O O
modifying O O
by O O
the O O
method O O
of O O
least O O
squares O O
the O O
curves O O
of O O
the O O
frequency O O
of O O
anomalous O O
fetuses O O
in O O
total O O
implants O O
and O O
survived O O
embryos O O
irradiated O O
from O O
20 O O
to O O
120 O O
rad O O
by O O
Cf O O
- O O
252 O O
and O O
from O O
80 O O
to O O
220 O O
rad O O
by O O
Co O O
- O O
60 O O
on O O
day O O
8 O O
of O O
pregnancy O O
. O O

To O O
our O O
knowledge O O
108 O O
cases O O
of O O
EAT O O
treated O O
by O O
catheter O O
ablation O O
of O O
the O O
ectopic O O
focus O O
are O O
reported O O
in O O
the O O
literature O O
with O O
a O O
success O O
rate O O
superior O O
to O O
90 O O
% O O
. O O

Following O O
immunization O O
of O O
transgenic O O
mice O O
, O O
hybrid O O
molecules O O
were O O
isolated O O
from O O
B O O
cell O O
DNA O O
which O O
contained O O
the O O
transgene O O
recombined O O
with O O
the O O
endogenous B B_GENE
IgH I I_GENE
locus I I_GENE
. O O

It O O
produced O O
extrapyramidal O O
disturbances O O
in O O
nearly O O
every O O
subject O O
, O O
the O O
most O O
common O O
being O O
akathisia O O
and O O
the O O
most O O
severe O O
, O O
in O O
the O O
case O O
of O O
one O O
individual O O
, O O
being O O
acute O O
dystonia O O
. O O

Northern O O
blot O O
analysis O O
indicated O O
that O O
both O O
human O O
and O O
murine O O
genes O O
encode O O
approximately O O
6 O O
- O O
kb O O
transcripts O O
. O O

Transforming B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates O O
the O O
promoter O O
of O O
cyclin B B_GENE
- I I_GENE
dependent I I_GENE
kinase I I_GENE
inhibitor O O
p15INK4B B B_GENE
through O O
an O O
Sp1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
consensus I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Cox O O
proportional O O
hazard O O
analysis O O
identified O O
dialysis O O
modality O O
and O O
pre O O
- O O
dialysis O O
UV O O
of O O
less O O
than O O
1 O O
, O O
000 O O
ml O O
/ O O
m2 O O
per O O
24 O O
h O O
as O O
the O O
only O O
significant O O
risk O O
factors O O
for O O
UV O O
survival O O
. O O

The O O
hyperpigmentation O O
is O O
linked O O
to O O
the O O
presence O O
of O O
numerous O O
single O O
melanosomes O O
and O O
polymelanosomes O O
in O O
keratinocytes O O
at O O
all O O
levels O O
of O O
the O O
epidermis O O
, O O
and O O
in O O
dermal O O
Factor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
XIIIa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
positive O O
dendrocytes O O
. O O

The O O
mouse B B_GENE
alpha I I_GENE
A I I_GENE
- I I_GENE
CRYBP1 I I_GENE
gene I I_GENE
specifies O O
a O O
2 O O
, O O
688 O O
- O O
amino O O
acid O O
protein O O
with O O
72 O O
% O O
amino O O
acid O O
identity O O
to O O
its O O
human O O
homologue O O
, O O
PRDII B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BF1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Methylation O O
interference O O
analysis O O
established O O
at O O
single O O
nucleotide O O
resolution O O
that O O
purified O O
recombinant O O
Fos B B_GENE/B_LOCATION
and O O
Jun B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bind O O
in O O
a O O
sequence O O
- O O
specific O O
manner O O
to O O
the O O
AP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
within O O
the O O
VDRE O O
and O O
OC B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
box I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
include O O
urinalysis O O
, O O
chest O O
X O O
- O O
P O O
, O O
ECG O O
, O O
hematological O O
examinations O O
( O O
RBC O O
, O O
WBC O O
, O O
Ht O O
, O O
Hb B B_LOCATION/B_PROTEIN[GENE]
, O O
PLT O O
and O O
ESR O O
) O O
and O O
biochemical O O
tests O O
( O O
AST B B_PROTEIN[GENE]/B_LOCATION
, O O
ALT B B_PROTEIN[GENE]/B_PERSON
, O O
ALP B B_PROTEIN[GENE]/B_LOCATION
, O O
gamma B B_LOCATION/B_GENE
GTP I I_LOCATION/I_GENE
, O O
LDH B B_PROTEIN[GENE]
, O O
CPK B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
Chol O O
, O O
T O O
- O O
Bil O O
, O O
TP O O
, O O
Alb B B_PROTEIN[GENE]/B_LOCATION
, O O
TG O O
, O O
BUN O O
, O O
Cr O O
, O O
Glu O O
, O O
Na O O
, O O
K O O
, O O
Ca O O
, O O
P O O
and O O
CRP B B_LOCATION/B_GENE
) O O
. O O

All O O
patients O O
studied O O
were O O
pregnant O O
women O O
and O O
their O O
delivered O O
children O O
. O O

Current O O
body O O
size O O
( O O
wt O O
/ O O
ht2 O O
) O O
was O O
significantly O O
associated O O
with O O
life O O
- O O
time O O
weight O O
dissatisfaction O O
in O O
both O O
sexes O O
( O O
P O O
less O O
than O O
0 O O
. O O
0005 O O
) O O
. O O

Mad3 B B_GENE
and O O
Mad4 B B_GENE/B_LOCATION
: O O
novel O O
Max B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
interacting O O
transcriptional O O
repressors O O
that O O
suppress O O
c B B_GENE
- I I_GENE
myc I I_GENE
dependent O O
transformation O O
and O O
are O O
expressed O O
during O O
neural O O
and O O
epidermal O O
differentiation O O
. O O

CONCLUSIONS O O
: O O
Patients O O
' O O
attainment O O
of O O
TGB O O
monotherapy O O
was O O
associated O O
with O O
their O O
achievement O O
of O O
positive O O
changes O O
of O O
varying O O
degree O O
on O O
psychological O O
tests O O
. O O

The O O
pcaR B B_GENE/B_LOCATION
regulatory I I_GENE/I_LOCATION
locus I I_GENE/I_LOCATION
has O O
been O O
found O O
to O O
be O O
required O O
for O O
both O O
induction O O
of O O
all O O
of O O
the O O
genes O O
within O O
the O O
pca B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulon I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
pcaBDC B B_LOCATION/B_GENE
, O O
pcaIJ B B_LOCATION/B_GENE
, O O
and O O
pcaF B B_GENE/B_LOCATION
) O O
and O O
the O O
chemotactic O O
response O O
of O O
the O O
bacteria O O
to O O
aromatic O O
compounds O O
. O O

Furthermore O O
, O O
we O O
have O O
identified O O
the O O
major O O
open O O
reading O O
frame O O
( O O
RF4 O O
; O O
2 O O
. O O
3 O O
kb O O
) O O
as O O
being O O
essential O O
for O O
activation O O
, O O
and O O
we O O
have O O
shown O O
that O O
the O O
NF B B_GENE/B_LOCATION
kappa I I_GENE/I_LOCATION
B I I_GENE/I_LOCATION
, O O
SP1 B B_GENE/B_DISEASE
, O O
and O O
TATA O O
box O O
motifs O O
in O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
all O O
required O O
for O O
full O O
induction O O
of O O
the O O
promoter O O
by O O
the O O
HHV B B_GENE
- I I_GENE
6 I I_GENE
- I I_GENE
encoded I I_GENE
transactivator I I_GENE
. O O

However O O
, O O
mutations O O
of O O
the O O
C O O
- O O
rich O O
element O O
that O O
disrupted O O
a O O
GC O O
box O O
located O O
on O O
the O O
inverse O O
strand O O
eliminated O O
PMA O O
responsiveness O O
and O O
, O O
in O O
gel O O
mobility O O
shift O O
assays O O
, O O
eliminated O O
binding O O
of O O
Sp1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

TFIIB B B_GENE/B_LOCATION
and O O
VDR B B_GENE
can O O
also O O
interact O O
directly O O
, O O
and O O
these O O
factors O O
synergize O O
to O O
mediate O O
transactivation O O
. O O

Both O O
algorithms O O
have O O
been O O
implemented O O
and O O
applied O O
to O O
data O O
simulated O O
for O O
a O O
scanner O O
with O O
a O O
large O O
axial O O
aperture O O
( O O
30 O O
degrees O O
) O O
, O O
and O O
also O O
to O O
data O O
acquired O O
with O O
the O O
ECAT O O
HR O O
and O O
the O O
ECAT O O
HR O O
+ O O
scanners O O
. O O

The O O
well O O
- O O
trained O O
group O O
was O O
measured O O
once O O
in O O
the O O
respiration O O
chamber O O
for O O
36 O O
h O O
according O O
to O O
the O O
same O O
protocol O O
. O O

Samarium O O
- O O
153 O O
for O O
intravascular O O
irradiation O O
therapy O O
with O O
liquid O O
- O O
filled O O
balloons O O
to O O
prevent O O
restenosis O O
: O O
acute O O
and O O
long O O
- O O
term O O
results O O
in O O
a O O
hypercholesterolemic O O
rabbit O O
restenosis O O
model O O
. O O

Only O O
viable O O
bacteria O O
at O O
a O O
high O O
concentration O O
induced O O
purulent O O
otitis O O
media O O
, O O
which O O
was O O
culture O O
positive O O
in O O
58 O O
% O O
of O O
the O O
cases O O
on O O
day O O
4 O O
. O O

Polyoma O O
virus O O
in O O
urine O O
during O O
pregnancy O O
. O O

Transfer O O
of O O
F O O
- O O
like O O
plasmids O O
is O O
regulated O O
by O O
the O O
FinOP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
system O O
, O O
which O O
controls O O
the O O
expression O O
of O O
traJ B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
positive O O
regulator O O
of O O
the O O
transfer O O
operon O O
. O O

Conversion O O
of O O
glucose O O
phosphate O O
- O O
14C O O
to O O
glucose O O
- O O
14C O O
in O O
passage O O
through O O
human O O
brain O O
in O O
vivo O O
. O O

A O O
simple O O
technique O O
for O O
obtaining O O
ultra O O
- O O
thin O O
sections O O
of O O
coccidian O O
oocysts O O
is O O
reported O O
. O O

Dual O O
signal O O
peptides O O
mediate O O
the O O
signal B B_GENE/B_LOCATION
recognition I I_GENE/I_LOCATION
particle I I_GENE/I_LOCATION
/ O O
Sec B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
independent O O
insertion O O
of O O
a O O
thylakoid O O
membrane O O
polyprotein O O
, O O
PsbY B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
resulting O O
score O O
, O O
which O O
allowed O O
the O O
disease O O
to O O
be O O
expressed O O
as O O
a O O
continuous O O
variable O O
, O O
was O O
effectively O O
utilized O O
to O O
see O O
the O O
correlations O O
between O O
the O O
severity O O
of O O
coronary O O
arterial O O
disease O O
( O O
CAD O O
) O O
and O O
individual O O
risk O O
factors O O
/ O O
risk O O
markers O O
. O O

On O O
guanidine O O
and O O
the O O
treatment O O
of O O
botulism O O
. O O

In O O
our O O
case O O
the O O
development O O
of O O
the O O
tumor O O
at O O
the O O
posterior O O
side O O
of O O
the O O
prostate O O
, O O
the O O
lack O O
of O O
PSA B B_GENE
immunoreactivity O O
and O O
the O O
presence O O
of O O
mucinous O O
glands O O
, O O
sometimes O O
" O O
endocervical O O
- O O
like O O
" O O
, O O
could O O
suggest O O
an O O
origin O O
from O O
embryonic O O
mullerian O O
remnants O O
in O O
the O O
prostatic O O
utricle O O
rather O O
than O O
urogenital O O
sinus O O
. O O

Upon O O
increasing O O
the O O
Marangoni O O
number O O
beyond O O
this O O
threshold O O
, O O
the O O
initially O O
stationary O O
flow O O
becomes O O
quickly O O
time O O
dependent O O
. O O

The O O
results O O
showed O O
differential O O
activation O O
of O O
each O O
parahippocampal O O
region O O
during O O
verbal O O
memory O O
tasks O O
in O O
which O O
the O O
side O O
activated O O
shifted O O
depending O O
on O O
the O O
nature O O
of O O
the O O
task O O
employed O O
; O O
an O O
increase O O
in O O
rCBF O O
in O O
the O O
left O O
parahippocampal O O
gyrus O O
was O O
associated O O
with O O
retrieval O O
strategy O O
of O O
non O O
- O O
matching O O
, O O
and O O
an O O
increase O O
in O O
rCBF O O
in O O
the O O
right O O
parahippocampal O O
gyrus O O
was O O
associated O O
with O O
retrieval O O
strategy O O
of O O
matching O O
. O O

Evolution O O
of O O
cytomegalovirus O O
antibodies O O
of O O
maternal O O
origin O O
and O O
acquired O O
, O O
throughout O O
the O O
first O O
year O O
of O O
life O O

Demonstration O O
of O O
changes O O
in O O
fetal O O
liver O O
erythropoiesis O O
using O O
echo O O
- O O
planar O O
magnetic O O
resonance O O
imaging O O
. O O

The O O
actual O O
placement O O
of O O
the O O
lesions O O
was O O
determined O O
after O O
mapping O O
of O O
the O O
GPi O O
by O O
microrecording O O
, O O
using O O
stimulation O O
to O O
identify O O
the O O
sensorimotor O O
region O O
and O O
its O O
somatotopic O O
organization O O
. O O

Effect O O
of O O
prostaglandin O O
E2 O O
on O O
experimental O O
atherosclerosis O O
. O O

Both O O
the O O
arterial O O
and O O
venous O O
thrombi O O
were O O
clearly O O
discernible O O
at O O
2 O O
to O O
8 O O
h O O
after O O
injection O O
of O O
99Tcm O O
- O O
SZ O O
- O O
51 O O
. O O

The O O
effect O O
of O O
lung O O
edema O O
on O O
pulmonary O O
vasoactivity O O
of O O
furosemide O O
. O O

However O O
, O O
the O O
malaria O O
vectors O O
Anopheles O O
funestus O O
and O O
An O O
. O O
gambiae O O
have O O
both O O
become O O
more O O
abundant O O
during O O
the O O
1970s O O
and O O
1980s O O
and O O
sporozoite O O
- O O
positive O O
specimens O O
of O O
both O O
have O O
been O O
found O O
. O O

Soluble O O
extracts O O
from O O
FGF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
treated O O
as O O
compared O O
with O O
quiescent O O
fibroblasts O O
exhibited O O
up O O
to O O
3 O O
- O O
fold O O
higher O O
kinase O O
activity O O
towards O O
S6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
exogenously O O
added O O
rat B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
liver I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
40S I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ribosomes I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
a O O
synthetic O O
peptide O O
, O O
RRLSSLRA O O
. O O

In O O
bell O O
pepper O O
, O O
a O O
gene O O
encoding O O
a O O
major O O
plastid O O
- O O
lipid O O
associated O O
protein O O
is O O
expressed O O
as O O
both O O
partially O O
and O O
totally O O
spliced O O
transcripts O O
( O O
respectively O O
PAP2 B B_GENE/B_DISEASE
and O O
PAP1 B B_GENE/B_DISEASE
) O O
. O O

We O O
conclude O O
that O O
LGCS O O
is O O
successful O O
in O O
treating O O
esophageal O O
varices O O
in O O
the O O
setting O O
of O O
hyperdynamic O O
portal O O
circulation O O
with O O
acceptable O O
liver O O
function O O
. O O

Candidate O O
factors O O
have O O
been O O
identified O O
by O O
the O O
observation O O
that O O
changes O O
in O O
glucocorticoid O O
induction O O
parameters O O
in O O
CV O O
- O O
1 O O
cells O O
could O O
be O O
reproduced O O
by O O
varying O O
the O O
cellular O O
levels O O
of O O
coactivators O O
[ O O
transcriptional B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
intermediary I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TIF2 B B_GENE
) O O
, O O
steroid B B_GENE/B_PERSON
receptor I I_GENE/I_PERSON
coactivator I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
( O O
SRC B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
) O O
, O O
and O O
amplified B B_PROTEIN[GENE]/B_DISEASE
in I I_PROTEIN[GENE]/I_DISEASE
breast I I_PROTEIN[GENE]/I_DISEASE
cancer I I_PROTEIN[GENE]/I_DISEASE
1 I I_PROTEIN[GENE]/I_DISEASE
( O O
AIB1 B B_GENE/B_SPECIES[BIO]
) O O
] O O
, O O
comodulator O O
[ O O
CREB B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
] O O
, O O
or O O
corepressor O O
[ O O
silencing B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mediator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
retinoid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
thyroid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hormone I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SMRT B B_GENE/B_LOCATION
) O O
] O O
without O O
concomitant O O
increases O O
in O O
GR B B_GENE/B_DISEASE
. O O

Immunoblot O O
analyses O O
revealed O O
that O O
the O O
loss O O
of O O
activator O O
function O O
coincides O O
with O O
selective O O
removal O O
of O O
the O O
C B B_ENZYME[GENE]
- I I_ENZYME[GENE]
terminal I I_ENZYME[GENE]
domain I I_ENZYME[GENE]
( I I_ENZYME[GENE]
CTD I I_ENZYME[GENE]
) I I_ENZYME[GENE]
- I I_ENZYME[GENE]
hyperphosphorylated I I_ENZYME[GENE]
RNAP I I_ENZYME[GENE]
IIO I I_ENZYME[GENE]
along O O
with O O
NC2 B B_GENE
. O O

At O O
9 O O
months O O
postpartum O O
, O O
serum O O
fT4 O O
and O O
fT3 O O
levels O O
were O O
low O O
normal O O
( O O
8 O O
. O O
0 O O
and O O
1 O O
. O O
7 O O
pmol O O
/ O O
L O O
, O O
respectively O O
) O O
, O O
but O O
TSH B B_GENE
was O O
not O O
raised O O
( O O
0 O O
. O O
4 O O
mU O O
/ O O
L O O
) O O
. O O

RESULTS O O
: O O
Three O O
patients O O
did O O
not O O
tolerate O O
PPI O O
medication O O
and O O
were O O
managed O O
by O O
treatment O O
with O O
type O O
2 O O
histamine O O
( O O
H2 O O
) O O
blockers O O
. O O

It O O
is O O
considered O O
important O O
, O O
therefore O O
, O O
when O O
treating O O
diabetic O O
patients O O
with O O
peripheral O O
neuropathy O O
not O O
to O O
assume O O
that O O
the O O
diabetes O O
itself O O
is O O
the O O
cause O O
in O O
all O O
cases O O
. O O

TFIIIB B B_GENE/B_DISEASE
assembles O O
autonomously O O
on O O
the O O
upstream O O
promoter O O
of O O
the O O
yeast B B_GENE
U6 I I_GENE
snRNA I I_GENE
( O O
SNR6 B B_PROTEIN[GENE]/B_LOCATION
) O O
gene O O
in O O
vitro O O
, O O
through O O
the O O
interaction O O
of O O
its O O
TBP B B_GENE/B_LOCATION
subunit I I_GENE/I_LOCATION
with O O
a O O
consensus O O
TATA O O
box O O
located O O
at O O
base O O
pair O O
- O O
30 O O
. O O

Mutational O O
analysis O O
of O O
the O O
IME2 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
UAS I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reveals O O
two O O
critical O O
sequence O O
elements O O
: O O
a O O
G O O
+ O O
C O O
- O O
rich O O
sequence O O
( O O
called O O
URS1 O O
) O O
, O O
previously O O
identified O O
at O O
many O O
meiotic O O
genes O O
, O O
and O O
a O O
newly O O
described O O
element O O
, O O
the O O
T4C O O
site O O
, O O
that O O
we O O
found O O
at O O
a O O
subset O O
of O O
meiotic O O
genes O O
. O O

Our O O
results O O
show O O
that O O
a O O
combination O O
of O O
Pfu B B_GENE/B_BACTERIUM[BIO]
exo I I_GENE/I_BACTERIUM[BIO]
( I I_GENE/I_BACTERIUM[BIO]
- I I_GENE/I_BACTERIUM[BIO]
) I I_GENE/I_BACTERIUM[BIO]
at O O
the O O
primer O O
extension O O
step O O
and O O
Taq B B_LOCATION/B_GENE
at O O
the O O
PCR O O
amplification O O
step O O
is O O
ideal O O
for O O
in O O
vivo O O
DNA O O
analysis O O
and O O
DNA O O
damage O O
mapping O O
using O O
LMPCR O O
. O O

Effect O O
of O O
TNF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IL B B_GENE
- I I_GENE
1 I I_GENE
, O O
and O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
proliferation O O
of O O
human O O
Tenon O O
' O O
s O O
capsule O O
fibroblasts O O
in O O
tissue O O
culture O O
. O O

Estimating O O
the O O
health O O
care O O
costs O O
of O O
smokers O O
. O O

Using O O
lacZ B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
inducible O O
T O O
cells O O
as O O
a O O
probe O O
, O O
we O O
screened O O
a O O
splenic O O
cDNA O O
library O O
in O O
transiently O O
transfected O O
antigen O O
- O O
presenting O O
cells O O
( O O
APCs O O
) O O
and O O
isolated O O
a O O
cDNA O O
clone O O
that O O
allowed O O
expression O O
of O O
the O O
appropriate O O
peptide B B_GENE
/ I I_GENE
Kb I I_GENE
MHC I I_GENE
complex I I_GENE
in O O
APC O O
. O O

Endotoxemia O O
and O O
bacteremia O O
in O O
patients O O
with O O
sepsis O O
syndrome O O
in O O
the O O
intensive O O
care O O
unit O O
. O O

Early O O
attempts O O
for O O
modifying O O
growth O O
functions O O
to O O
annual O O
variations O O
dating O O
back O O
up O O
to O O
2 O O
decades O O
are O O
recalled O O
together O O
with O O
examples O O
for O O
their O O
application O O
showing O O
rather O O
different O O
degrees O O
of O O
approximation O O
. O O

A O O
significant O O
reduction O O
in O O
total O O
cellular O O
p27 B B_GENE
protein I I_GENE
levels O O
and O O
a O O
moderate O O
reduction O O
in O O
p27 B B_GENE
mRNA I I_GENE
are O O
observed O O
, O O
but O O
no O O
changes O O
in O O
Cdk B B_GENE/B_PERSON
regulatory O O
kinases O O
and O O
phosphatases O O
occur O O
. O O

Genetic O O
linkage O O
mapping O O
of O O
the O O
CYP11A1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O O
the O O
cholesterol O O
side O O
- O O
chain O O
cleavage O O
P450scc B B_GENE/B_LOCATION
close O O
to O O
the O O
CYP1A1 B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
gene I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
D15S204 B B_GENE/B_LOCATION
in O O
the O O
chromosome O O
15q22 O O
. O O
33 O O
- O O
q23 O O
region O O
. O O

Genetic O O
and O O
physiological O O
experiments O O
suggest O O
a O O
close O O
relationship O O
between O O
cdc27 B B_GENE
+ I I_GENE
and O O
the O O
cdc2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
key O O
regulator O O
of O O
mitosis O O
in O O
yeast O O
and O O
also O O
in O O
higher O O
eukaryotic O O
cells O O
. O O

The O O
study O O
was O O
performed O O
in O O
a O O
class O O
100 O O
laminar O O
flow O O
clean O O
bench O O
in O O
order O O
to O O
minimize O O
particulate O O
contamination O O
from O O
extraneous O O
sources O O
. O O

The O O
cloned O O
rRNA O O
operon O O
was O O
transcribed O O
in O O
vitro O O
by O O
using O O
purified B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polymerase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Escherichia I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coli I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Of O O
the O O
CSF O O
tested O O
, O O
24 O O
stimulated O O
oxygen O O
consumption O O
above O O
our O O
cut O O
off O O
, O O
and O O
8 O O
did O O
not O O
( O O
0 O O
. O O
84 O O
+ O O
/ O O
- O O
0 O O
. O O
34 O O
, O O
n O O
= O O
24 O O
compared O O
with O O
the O O
rate O O
of O O
0 O O
. O O
27 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
mumol O O
/ O O
min O O
/ O O
g O O
dry O O
wt O O
, O O
respectively O O
; O O
SD O O
n O O
= O O
8 O O
) O O
at O O
180 O O
minutes O O
. O O

The O O
kinetics O O
of O O
[ O O
14C O O
] O O
NG O O
in O O
the O O
blood O O
of O O
the O O
dosed O O
animals O O
was O O
followed O O
. O O

These O O
clones O O
contain O O
most O O
of O O
the O O
exon O O
of O O
cyclin B B_GENE/B_LOCATION
D2 I I_GENE/I_LOCATION
except O O
exon O O
5 O O
. O O

One O O
had O O
a O O
48 O O
- O O
hour O O
cycle O O
and O O
the O O
other O O
a O O
24 O O
- O O
hour O O
cycle O O
. O O

This O O
action O O
could O O
be O O
antagonized O O
by O O
aminophylline O O
, O O
a O O
competitive O O
antagonist O O
on O O
P1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
purinoceptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Evidence O O
for O O
Gcr1p B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
Gcr2p B B_GENE
interaction O O
has O O
been O O
presented O O
earlier O O
and O O
is O O
now O O
supported O O
by O O
the O O
isolation O O
of O O
mutations O O
in O O
Gcr1p B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
suppressing O O
gcr2 B B_GENE
, O O
as O O
assessed O O
by O O
growth O O
and O O
enzyme O O
assay O O
. O O

Keys O O
can O O
be O O
used O O
for O O
identifying O O
species O O
from O O
the O O
European O O
part O O
of O O
the O O
USSR O O
and O O
north O O
- O O
eastern O O
Kazakhstan O O
. O O

Plasma O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
patients O O
with O O
colorectal O O
cancer O O
. O O

The O O
extent O O
of O O
myocardial O O
ischemia O O
in O O
the O O
coronary O O
sinus O O
study O O
was O O
significantly O O
correlated O O
to O O
the O O
coronary O O
diameters O O
of O O
the O O
proximal O O
and O O
middle O O
segments O O
of O O
the O O
Ramus O O
interventricularis O O
anterior O O
and O O
the O O
middle O O
segment O O
of O O
the O O
Ramus O O
circumflexus O O
( O O
r O O
= O O
0 O O
. O O
87 O O
, O O
p O O
< O O
0 O O
. O O
02 O O
) O O
. O O

The O O
in O O
- O O
plane O O
orientational O O
anisotropy O O
of O O
the O O
8CB O O
films O O
grown O O
on O O
unidirectionally O O
photopolymerized O O
PVCN O O
substrates O O
is O O
considerably O O
lower O O
than O O
the O O
intrinsic O O
surface O O
orientational O O
anisotropy O O
of O O
these O O
substrates O O
, O O
which O O
can O O
explain O O
the O O
generally O O
found O O
weak O O
surface O O
anchoring O O
of O O
liquid O O
crystals O O
on O O
PVCN O O
alignment O O
layers O O
. O O

The O O
rifampicin O O
resistance O O
of O O
uvsW B B_DISEASE/B_GENE
- O O
repressed O O
replication O O
suggests O O
that O O
it O O
involves O O
either O O
tertiary O O
initiation O O
or O O
some O O
novel O O
mode O O
of O O
initiation O O
. O O

Pharmacokinetics O O
of O O
skin O O
penetration O O
. O O

Furthermore O O
, O O
the O O
regulation O O
conferred O O
on O O
a O O
reporter O O
gene O O
in O O
Drosophila O O
by O O
three O O
closely O O
related O O
sequences O O
demonstrates O O
that O O
even O O
subtle O O
sequence O O
changes O O
within O O
an O O
E O O
box O O
or O O
flanking O O
bases O O
have O O
dramatic O O
consequences O O
on O O
the O O
overall O O
repertoire O O
of O O
proteins O O
that O O
can O O
bind O O
in O O
vivo O O
. O O

Buspirone O O
therapy O O
for O O
Type O O
A O O
behavior O O
, O O
hostility O O
, O O
and O O
perceived O O
stress O O
in O O
cardiac O O
patients O O
. O O

Recently O O
we O O
have O O
performed O O
a O O
detailed O O
analysis O O
of O O
specific O O
neuronal O O
populations O O
affected O O
by O O
the O O
mutation O O
which O O
shed O O
new O O
light O O
on O O
the O O
role O O
of O O
Krox B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
20 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
segmentation O O
and O O
on O O
the O O
physiological O O
consequences O O
of O O
its O O
inactivation O O
. O O

A O O
species O O
comparison O O
of O O
cDNA O O
sequences O O
and O O
isolation O O
of O O
a O O
genomic O O
clone O O
. O O

The O O
inhibition O O
of O O
monoamine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAO B B_GENE/B_PERSON
) O O
by O O
tranylcypromine O O
was O O
studied O O
in O O
6 O O
healthy O O
volunteers O O
given O O
increasing O O
doses O O
of O O
10 O O
, O O
15 O O
, O O
20 O O
and O O
25 O O
mg O O
/ O O
day O O
over O O
a O O
4 O O
- O O
week O O
period O O
. O O

Deletion O O
mutagenesis O O
of O O
the O O
promoter O O
indicated O O
that O O
a O O
positive O O
regulatory O O
element O O
( O O
PRE O O
) O O
was O O
likely O O
to O O
exist O O
downstream O O
of O O
the O O
UL94 B B_GENE/B_PERSON
mRNA I I_GENE/I_PERSON
start I I_GENE/I_PERSON
site I I_GENE/I_PERSON
, O O
while O O
a O O
negative O O
regulatory O O
element O O
( O O
NRE O O
) O O
was O O
present O O
upstream O O
of O O
the O O
TATA O O
box O O
. O O

Expression O O
of O O
Helios B B_GENE/B_BIO
was O O
detected O O
in O O
the O O
earliest O O
hematopoietic O O
sites O O
of O O
the O O
embryo O O
, O O
in O O
hematopoietic O O
stem O O
cells O O
in O O
the O O
adult O O
and O O
was O O
subsequently O O
restricted O O
to O O
a O O
subset O O
of O O
cells O O
in O O
the O O
T O O
cell O O
lineage O O
. O O

Metapsychiatry O O
is O O
a O O
term O O
born O O
of O O
necessity O O
to O O
designate O O
the O O
important O O
but O O
hitherto O O
unclassified O O
interface O O
between O O
psychiatry O O
and O O
mysticism O O
. O O

Effects O O
of O O
negative O O
pi O O
mesons O O
on O O
mouse O O
bone O O
marrow O O
cells O O
. O O

Using O O
probes O O
containing O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
iNOS B B_GENE
gene I I_GENE
revealed O O
further O O
binding O O
of O O
different O O
complexes O O
, O O
all O O
of O O
which O O
were O O
strongly O O
inducible O O
by O O
cAMP O O
and O O
to O O
a O O
lower O O
extent O O
also O O
by O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1beta I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
Pi O O
signals O O
are O O
conveyed O O
to O O
PHO8 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
binding O O
of O O
PHO4 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
positive O O
regulatory O O
factor O O
, O O
to O O
a O O
promoter O O
region O O
of O O
PHO8 B B_GENE/B_BIO
( O O
PHO8p B B_PROTEIN[GENE]/B_LOCATION
) O O
under O O
the O O
influence O O
of O O
the O O
PHO B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
regulatory O O
circuit O O
. O O

Thus O O
, O O
the O O
end O O
of O O
a O O
linearized O O
DNA O O
fragment O O
can O O
initiate O O
new O O
DNA O O
synthesis O O
by O O
BIR O O
in O O
which O O
the O O
newly O O
synthesized O O
DNA O O
is O O
displaced O O
and O O
subsequently O O
forms O O
circles O O
by O O
NHEJ O O
. O O

It O O
would O O
seem O O
that O O
caution O O
should O O
be O O
exercised O O
in O O
using O O
HPL B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
values O O
as O O
an O O
index O O
of O O
placental O O
function O O
in O O
anaemic O O
women O O
. O O

A O O
case O O
of O O
acquired O O
immune O O
deficiency O O
syndrome O O
before O O
1980 O O
. O O

These O O
data O O
suggest O O
that O O
multiple O O
genetic O O
recombination O O
among O O
bacteriophages O O
with O O
different O O
immunities O O
took O O
place O O
to O O
generate O O
the O O
prophage O O
VT1 O O
- O O
Sakai O O
. O O

The O O
adenovirus B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E1B I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
19 I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
000 I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
19K I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
potent O O
inhibitor O O
of O O
apoptosis O O
and O O
cooperates O O
with O O
E1A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
transform O O
primary O O
rodent O O
cells O O
. O O

Desensitization O O
of O O
the O O
growth B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
induced O O
Janus B B_GENE/B_LOCATION
kinase I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
( O O
Jak B B_GENE
2 I I_GENE
) O O
/ O O
signal B B_GENE/B_MEASURE
transducer I I_GENE/I_MEASURE
and I I_GENE/I_MEASURE
activator I I_GENE/I_MEASURE
of I I_GENE/I_MEASURE
transcription I I_GENE/I_MEASURE
5 I I_GENE/I_MEASURE
( O O
Stat5 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
- O O
signaling O O
pathway O O
requires O O
protein O O
synthesis O O
and O O
phospholipase B B_GENE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
C I B_GENE/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O O

In O O
two O O
separate O O
studies O O
, O O
specimens O O
of O O
saliva O O
from O O
57 O O
individuals O O
over O O
the O O
age O O
of O O
65 O O
years O O
( O O
mean O O
age O O
, O O
76 O O
. O O
7 O O
years O O
) O O
and O O
37 O O
persons O O
under O O
the O O
age O O
of O O
40 O O
years O O
( O O
mean O O
age O O
, O O
28 O O
. O O
8 O O
years O O
) O O
were O O
examined O O
for O O
concentrations O O
of O O
IgA B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
functions O O
of O O
volume O O
, O O
total O O
protein O O
, O O
and O O
electrolyte O O
conductivity O O
; O O
some O O
were O O
also O O
tested O O
for O O
IgG B B_GENE
and O O
IgM B B_GENE
content O O
. O O

E2A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
HLF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
mediated O O
cell O O
transformation O O
requires O O
both O O
the O O
trans O O
- O O
activation O O
domains O O
of O O
E2A B B_GENE/B_LOCATION
and O O
the O O
leucine O O
zipper O O
dimerization O O
domain O O
of O O
HLF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
Seldinger O O
technique O O
for O O
difficult O O
transurethral O O
catheterization O O
: O O
a O O
gentle O O
alternative O O
to O O
suprapubic O O
puncture O O
( O O
Br O O
J O O
Surg O O
2000 O O
; O O
87 O O
: O O
1729 O O
- O O
30 O O
) O O
. O O

We O O
screened O O
an O O
A O O
. O O
thaliana O O
cDNA O O
library O O
, O O
whose O O
inserts O O
are O O
under O O
the O O
control O O
of O O
the O O
galactose O O
- O O
inducible O O
GAL10 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
, O O
for O O
cDNAs O O
which O O
enabled O O
YDH8 O O
cells O O
to O O
grow O O
at O O
the O O
restrictive O O
temperature O O
. O O

We O O
generated O O
" O O
signature O O
" O O
oligonucleotides O O
from O O
these O O
CDR3s B B_GENE
and O O
probed O O
PCR O O
amplified O O
V B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
products I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
synovium O O
and O O
PBLs O O
of O O
the O O
same O O
patient O O
, O O
and O O
from O O
PBLs O O
and O O
spleen O O
of O O
individuals O O
without O O
rheumatic O O
disease O O
. O O

One O O
of O O
the O O
major O O
transcripts O O
encodes O O
MEQ B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
339 O O
- O O
amino O O
- O O
acid O O
bZIP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
is O O
homologous O O
to O O
the O O
Jun B B_PERSON/B_GENE
/ O O
Fos B B_GENE/B_LOCATION
family O O
of O O
transcription O O
factors O O
. O O

An O O
emended O O
diagnosis O O
of O O
Tylocephalum O O
is O O
proposed O O
excluding O O
this O O
feature O O
, O O
along O O
with O O
distribution O O
of O O
the O O
testes O O
in O O
the O O
preovarian O O
field O O
and O O
circummedullary O O
distribution O O
of O O
vitelline O O
follicles O O
. O O

Induction O O
of O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
IFNalpha B B_PROTEIN[GENE]/B_LOCATION
) O O
gene O O
expression O O
in O O
virus O O
- O O
infected O O
cells O O
requires O O
phosphorylation O O
- O O
induced O O
activation O O
of O O
the O O
transcription O O
factors O O
IRF3 B B_GENE
and O O
IRF7 B B_GENE
. O O

Moreover O O
, O O
since O O
the O O
integrated O O
transforming O O
DNA O O
was O O
not O O
altered O O
or O O
lost O O
expression O O
of O O
the O O
RbcS2 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
: O O
aadA B B_GENE/B_BACTERIUM[BIO]
: O O
: O O
RbcS2 B B_GENE
gene I I_GENE
( I I_GENE
s I I_GENE
) I I_GENE
appears O O
to O O
be O O
repressed O O
. O O

Donehower O O
and O O
H O O
. O O

A O O
characteristic O O
feature O O
is O O
their O O
tendency O O
to O O
form O O
homo O O
- O O
and O O
/ O O
or O O
heterodimeric O O
complexes O O
. O O

Further O O
, O O
more O O
recent O O
communications O O
suggest O O
that O O
liver O O
disease O O
led O O
to O O
a O O
differential O O
alteration O O
of O O
the O O
cytochrome B B_BODY_PART_OR_ORGAN_COMPONENT/B_ENZYME[GENE]
P I I_BODY_PART_OR_ORGAN_COMPONENT/I_ENZYME[GENE]
- I I_BODY_PART_OR_ORGAN_COMPONENT/I_ENZYME[GENE]
450s I I_BODY_PART_OR_ORGAN_COMPONENT/I_ENZYME[GENE]
with O O
regard O O
to O O
protein O O
content O O
and O O
activity O O
. O O

Apparent O O
Buschke O O
- O O
Loewenstein O O
tumour O O
of O O
the O O
penis O O
. O O

This O O
effect O O
was O O
stronger O O
after O O
multiple O O
predoses O O
of O O
sertraline O O
, O O
when O O
imipramine O O
Cmax O O
and O O
AUC O O
( O O
0 O O
- O O
infinity O O
) O O
were O O
increased O O
by O O
39 O O
% O O
and O O
68 O O
% O O
, O O
respectively O O
. O O

Mutations O O
in O O
nifR1 B B_GENE
( O O
ntrC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
and O O
nifR4 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
rpoN B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
encoding O O
sigma54 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
had O O
no O O
influence O O
on O O
xdh B B_GENE
gene I I_GENE
expression O O
. O O

We O O
therefore O O
propose O O
that O O
PRR2 B B_GENE/B_LOCATION
, O O
and O O
not O O
PVR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
is O O
the O O
true O O
human O O
homolog O O
of O O
MPH B B_DISEASE/B_GENE
. O O

Swarming O O
of O O
Moraxella O O

Biochem O O
. O O

In O O
contrast O O
, O O
vRel B B_GENE/B_PERSON
lacks O O
a O O
strong O O
C O O
- O O
terminal O O
gene O O
activation O O
function O O
, O O
since O O
a O O
LexA B B_GENE/B_LOCATION
fusion I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
containing O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
vRel I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alone O O
only O O
weakly O O
activated O O
transcription O O
. O O

Bovine O O
anaplasmosis O O
: O O
susceptibility O O
of O O
seronegative O O
cows O O
from O O
an O O
infected O O
herd O O
to O O
experimental O O
infection O O
with O O
Anaplasma O O
marginale O O
. O O

Because O O
of O O
gut O O
fermentation O O
, O O
a O O
substantial O O
portion O O
( O O
16 O O
- O O
80 O O
% O O
) O O
of O O
N O O
is O O
absorbed O O
as O O
ammonia O O
N O O
( O O
NH3N O O
) O O
. O O

The O O
densities O O
ranged O O
between O O
2 O O
and O O
3976 O O
neurites O O
/ O O
mm2 O O
skin O O
surface O O
, O O
but O O
the O O
overlap O O
between O O
subjects O O
and O O
without O O
PHN O O
was O O
small O O
. O O

Zoonotic O O
areas O O
in O O
which O O
HIV O O
co O O
- O O
infection O O
is O O
common O O
could O O
also O O
be O O
at O O
risk O O
as O O
sandflies O O
can O O
become O O
infected O O
from O O
co O O
- O O
infected O O
individuals O O
. O O

The O O
determination O O
of O O
antithrombin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AT B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
its O O
clinical O O
significance O O

The O O
kinetics O O
of O O
erythromycin O O
( O O
E O O
. O O
) O O
was O O
studied O O
in O O
16 O O
patients O O
with O O
different O O
degrees O O
of O O
impairment O O
of O O
renal O O
function O O
after O O
a O O
single O O
intravenous O O
dose O O
. O O

The O O
MALDI O O
- O O
TOF O O
experiment O O
, O O
however O O
, O O
proved O O
to O O
be O O
superior O O
to O O
the O O
GC O O
experiment O O
, O O
particularly O O
with O O
regard O O
to O O
baseline O O
resolution O O
of O O
unsaturated O O
acids O O
. O O

Modern O O
aspects O O
of O O
shock O O
- O O
treatment O O
in O O
extensive O O
burns O O
( O O
author O O
' O O
s O O
transl O O
) O O

Of O O
the O O
private O O
practices O O
accredited O O
in O O
August O O
1995 O O
, O O
40 O O
. O O
6 O O
per O O
cent O O
( O O
122 O O
) O O
participated O O
. O O

A O O
Drosophila O O
subobscura O O
genomic O O
fragment O O
containing O O
all O O
the O O
exons O O
and O O
the O O
late O O
and O O
early O O
promotors O O
in O O
the O O
Sxl B B_GENE
gene I I_GENE
of I I_GENE
D I I_GENE
. I I_GENE
melanogaster I I_GENE
was O O
isolated O O
. O O

Collectively O O
, O O
a O O
unique O O
mechanism O O
involving O O
NF B B_GENE
- I I_GENE
ATp I I_GENE
appears O O
to O O
regulate O O
the O O
cell O O
type O O
- O O
specific O O
and O O
activation O O
- O O
dependent O O
expression O O
of O O
the O O
SCM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
results O O
admit O O
that O O
a O O
ribosome O O
scanning O O
mechanism O O
of O O
the O O
MP B B_GENE
gene I I_GENE
expression O O
from O O
I O O
( O O
2 O O
) O O
sgRNA O O
operates O O
concurrently O O
. O O

The O O
three O O
- O O
dimensional O O
structure O O
of O O
the O O
E O O
. O O
coli O O
CR O O
domain O O
indicates O O
that O O
this O O
sequence O O
conservation O O
is O O
likely O O
to O O
result O O
in O O
a O O
conserved O O
structural O O
motif O O
. O O

Otosclerosis O O
in O O
monozygotic O O
twins O O
: O O
clinical O O
and O O
genetical O O
analysis O O

The O O
critical O O
obstacle O O
in O O
modeling O O
psychiatric O O
disorders O O
has O O
been O O
limited O O
information O O
about O O
their O O
origin O O
and O O
underlying O O
neural O O
mechanisms O O
. O O

BACKGROUND O O
: O O
Allergic O O
rhinoconjunctivitis O O
is O O
a O O
common O O
disorder O O
, O O
affecting O O
> O O
20 O O
% O O
of O O
people O O
of O O
all O O
socioeconomic O O
strata O O
. O O

The O O
results O O
of O O
these O O
studies O O
indicate O O
that O O
EHV B B_GENE
- I I_GENE
1 I I_GENE
gp13 I I_GENE
is O O
the O O
structural O O
homolog O O
of O O
herpes B B_GENE/B_VIRUS[BIO]
simplex I B_GENE/I_VIRUS[BIO]
virus I B_GENE/I_VIRUS[BIO]
glycoprotein I B_GENE/I_VIRUS[BIO]
C I B_GENE/I_VIRUS[BIO]
and O O
further O O
suggest O O
that O O
the O O
epitope O O
- O O
containing O O
N O O
- O O
terminal O O
amino O O
acid O O
sequences O O
of O O
the O O
herpesvirus B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
gC I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
like I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
glycoproteins I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
have O O
undergone O O
more O O
extensive O O
evolutionary O O
divergence O O
than O O
the O O
C O O
- O O
terminal O O
sequences O O
. O O

Within O O
the O O
final O O
11 O O
amino O O
acids O O
there O O
are O O
5 O O
aromatic O O
, O O
2 O O
basic O O
, O O
and O O
no O O
acidic O O
residues O O
and O O
it O O
has O O
been O O
proposed O O
that O O
these O O
residues O O
stack O O
with O O
and O O
electrostatically O O
interact O O
with O O
the O O
kinked O O
DNA O O
at O O
the O O
site O O
of O O
a O O
pyrimidine O O
dimer O O
. O O

By O O
contrast O O
, O O
footprint O O
II O O
at O O
position O O
- O O
125 O O
is O O
common O O
to O O
both O O
HeLa O O
and O O
GH3 O O
cell O O
extracts O O
and O O
overlies O O
a O O
15 O O
- O O
base O O
- O O
pair O O
sequence O O
found O O
in O O
all O O
members O O
of O O
the O O
growth B B_BIO/B_GENE
hormone I I_BIO/I_GENE
gene I I_BIO/I_GENE
family I I_BIO/I_GENE
. O O

Significance O O
of O O
the O O
determination O O
of O O
vascular O O
tonus O O
in O O
the O O
differential O O
diagnosis O O
of O O
rheumatic O O
and O O
arteriosclerotic O O
lesions O O
of O O
the O O
heart O O
and O O
vessels O O
in O O
middle O O
- O O
aged O O
and O O
elderly O O
persons O O
with O O
fibrillation O O
arrhythmia O O

The O O
gene O O
responsible O O
for O O
multiple O O
endocrine O O
neoplasia O O
type O O
1 O O
( O O
MEN1 B B_GENE/B_DISEASE
) O O
, O O
a O O
heritable O O
predisposition O O
to O O
endocrine O O
tumours O O
in O O
man O O
, O O
has O O
recently O O
been O O
identified O O
. O O

Toxicological O O
effects O O
of O O
dietary O O
Maillard O O
reaction O O
products O O
in O O
the O O
rat O O
. O O

AST B B_GENE
activity O O
in O O
PMNs O O
was O O
significantly O O
low O O
, O O
approximately O O
2 O O
% O O
of O O
that O O
observed O O
in O O
HPLFs O O
. O O

Specifically O O
, O O
we O O
engineered O O
two O O
chimeras O O
in O O
which O O
the O O
N O O
- O O
terminal O O
lobe O O
of O O
the O O
SH1 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
domain I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
c B B_GENE
- I I_GENE
Abl I I_GENE
was O O
swapped O O
with O O
that O O
of O O
v B B_GENE
- I I_GENE
Src I I_GENE
. O O

Biochemical O O
analyses O O
revealed O O
that O O
the O O
concentration O O
of O O
norepinephrine O O
was O O
reduced O O
significantly O O
in O O
cortex O O
- O O
hippocampus O O
and O O
olfactory O O
bulb O O
but O O
not O O
in O O
other O O
regions O O
, O O
while O O
dopamine O O
and O O
serotonin O O
levels O O
were O O
not O O
altered O O
in O O
any O O
brain O O
region O O
examined O O
. O O

The O O
cDNA O O
contains O O
a O O
reading O O
frame O O
for O O
a O O
145 O O
- O O
amino O O
- O O
acid O O
protein O O
and O O
it O O
lacks O O
the O O
UGA O O
codons O O
, O O
which O O
have O O
been O O
found O O
in O O
the O O
reading O O
frame O O
of O O
the O O
mouse B B_GENE
MCS I I_GENE
cDNA I I_GENE
and O O
have O O
been O O
presumed O O
to O O
encode O O
the O O
selenocysteine O O
in O O
the O O
amino O O
terminal O O
of O O
the O O
deduced O O
mouse O O
amino O O
acid O O
sequence O O
. O O

These O O
results O O
suggest O O
that O O
repetitive O O
GAA O O
sequences O O
enhance O O
splicing O O
by O O
binding O O
a O O
protein O O
complex O O
containing O O
a O O
sequence O O
- O O
specific O O
RNA O O
binding O O
protein O O
and O O
a O O
general O O
splicing O O
activator O O
that O O
, O O
in O O
turn O O
, O O
recruit O O
additional O O
SR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Letter O O
: O O
Dehydrated O O
test O O
strip O O
for O O
the O O
detection O O
of O O
yeasts O O
. O O

Cell O O
sloughing O O
with O O
proparacaine O O
. O O

Cytomegalovirus O O
infection O O
- O O
- O O
modern O O
diagnosis O O

Highly O O
conserved O O
regions O O
called O O
src B B_PROTEIN[GENE]
homology I I_PROTEIN[GENE]
2 I I_PROTEIN[GENE]
and O O
3 O O
( O O
SH2 B B_GENE
and O O
SH3 B B_PROTEIN[GENE]
) O O
, O O
comprising O O
amino O O
acid O O
residues O O
88 O O
to O O
250 O O
, O O
are O O
believed O O
to O O
modulate O O
the O O
protein B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
present O O
in O O
the O O
carboxy O O
- O O
terminal O O
halves O O
of O O
the O O
src B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
propose O O
2 O O
separate O O
PAI B B_GENE
- I I_GENE
1 I I_GENE
inductory O O
pathways O O
for O O
PMA O O
and O O
IL B B_GENE/B_NUMBER[MEASURE]
- I I_GENE/I_NUMBER[MEASURE]
1alpha I I_GENE/I_NUMBER[MEASURE]
in O O
HepG2 O O
, O O
both O O
involving O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation O O
; O O
the O O
serum O O
- O O
induced O O
signaling O O
pathway O O
may O O
( O O
partially O O
) O O
overlap O O
with O O
the O O
PMA O O
- O O
activated O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
mitogen B B_GENE
- I I_GENE
activated I I_GENE
protein I I_GENE
kinase I I_GENE
kinase I I_GENE
pathway O O
, O O
leading O O
to O O
c B B_GENE
- I I_GENE
Jun I I_GENE
homodimer I I_GENE
binding O O
to O O
the O O
PAI B B_GENE
- I I_GENE
1 I I_GENE
TRE O O
. O O

We O O
show O O
that O O
sae1 B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
and O O
sae3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutations I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
each O O
confer O O
a O O
distinct O O
defect O O
in O O
meiotic O O
recombination O O
. O O

G6620 B B_PROTEIN[GENE]
is O O
the O O
3 O O
' O O
end O O
of O O
the O O
MOL1 B B_GENE
gene I I_GENE
coding O O
for O O
a O O
polypeptide O O
similar O O
to O O
stress O O
- O O
inducible O O
proteins O O
from O O
Fusarium O O
; O O
G6630 B B_PROTEIN[GENE]
is O O
the O O
NAT2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
encodes O O
a O O
methionine B B_ENZYME[GENE]
N I I_ENZYME[GENE]
- I I_ENZYME[GENE]
acetyltransferase I I_ENZYME[GENE]
; O O
G6635 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
the O O
RPL30B B B_GENE
gene I I_GENE
coding O O
for O O
the O O
ribosomal B B_GENE
protein I I_GENE
L30 I I_GENE
; O O
G6658 B B_PROTEIN[GENE]/B_LOCATION
is O O
RSR1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
encoding O O
a O O
ras B B_ENZYME[GENE]
- I I_ENZYME[GENE]
related I I_ENZYME[GENE]
protein I I_ENZYME[GENE]
; O O
G6667 B B_PROTEIN[GENE]/B_LOCATION
is O O
CYS4 B B_GENE/B_LOCATION
, O O
the O O
gene O O
for O O
cystathionine B B_GENE
beta I I_GENE
- I I_GENE
synthase I I_GENE
; O O
G6670 B B_PROTEIN[GENE]/B_LOCATION
is O O
identical O O
to O O
ORF2 O O
located O O
close O O
to O O
CYS4 B B_GENE
; O O
G6673 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
PEM1 B B_PROTEIN[GENE]/B_LOCATION
/ O O
CHO2 B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
encoding O O
a O O
phosphatidylethanolamine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
; O O
G7001 B B_PROTEIN[GENE]/B_PERSON
is O O
the O O
NSR1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coding O O
for O O
a O O
nuclear O O
signal O O
recognition O O
protein O O
. O O

Transcriptional O O
analysis O O
of O O
this O O
gene O O
cluster O O
was O O
performed O O
by O O
detecting O O
the O O
presence O O
of O O
mRNAs O O
spanning O O
adjacent O O
genes O O
as O O
well O O
as O O
by O O
using O O
a O O
promoterless O O
lacZ B B_GENE
reporter I I_GENE
gene I I_GENE
fused O O
to O O
each O O
of O O
the O O
seven O O
genes O O
contained O O
in O O
the O O
tol B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
oprL B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
locus O O
. O O

Serum O O
IgG B B_GENE
and O O
IgA B B_GENE
level O O
were O O
decreased O O
. O O

Histopathologically O O
, O O
( O O
mice O O
killed O O
with O O
high O O
doses O O
of O O
GMC O O
- O O
II O O
, O O
given O O
orally O O
) O O
there O O
were O O
diffuse O O
hyperemia O O
of O O
the O O
liver O O
, O O
parenchymal O O
degeneration O O
of O O
the O O
kidney O O
tubuli O O
epithelium O O
, O O
and O O
edema O O
and O O
emphysema O O
of O O
the O O
lungs O O
. O O

The O O
contribution O O
of O O
reviewers O O
and O O
editors O O
to O O
the O O
scientific O O
work O O
of O O
the O O
authors O O

The O O
effects O O
of O O
space O O
radiation O O
are O O
partially O O
known O O
on O O
astronauts O O
, O O
but O O
much O O
remains O O
to O O
be O O
discovered O O
. O O

Wingless B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
Wnt B B_GENE/B_DISEASE
signaling O O
directs O O
cell O O
- O O
fate O O
choices O O
during O O
embryonic O O
development O O
. O O

RNase B B_GENE
protection O O
analysis O O
reveals O O
a O O
10 O O
- O O
fold O O
increase O O
in O O
the O O
expression O O
of O O
SCD2 B B_GENE
mRNA I I_GENE
during O O
3T3 O O
- O O
L1 O O
preadipocyte O O
differentiation O O
. O O

To O O
determine O O
whether O O
transcription O O
of O O
orfX O O
and O O
vfr B B_LOCATION/B_PROTEIN[GENE]
are O O
controlled O O
by O O
the O O
same O O
mechanisms O O
that O O
control O O
transcription O O
of O O
the O O
region O O
of O O
the O O
divergent O O
ORF O O
( O O
dorf O O
) O O
and O O
of O O
crp B B_GENE
, O O
we O O
compared O O
the O O
vfr B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
orfX O O
and O O
crp B B_GENE/B_DISEASE
- O O
dorf O O
intergenic O O
regions O O
. O O

As O O
a O O
member O O
of O O
the O O
uncoupling B B_GENE/B_PERSON
protein I I_GENE/I_PERSON
family I I_GENE/I_PERSON
, O O
UCP2 B B_GENE
is O O
ubiquitously O O
expressed O O
in O O
rodents O O
and O O
humans O O
, O O
implicating O O
a O O
major O O
role O O
in O O
thermogenesis O O
. O O

Copyright O O
1998 O O
Academic O O
Press O O
. O O

Parental O O
and O O
vector O O
- O O
transfected O O
MCF7 O O
cells O O
, O O
which O O
were O O
sensitive O O
to O O
the O O
growth O O
- O O
inhibitory O O
effects O O
of O O
atRA O O
, O O
exhibited O O
atRA O O
- O O
dependent O O
retinoic B B_GENE
acid I I_GENE
receptor I I_GENE
( O O
RAR B B_PROTEIN[GENE]/B_LOCATION
) O O
transactivation O O
and O O
transrepression O O
of O O
12 O O
- O O
O O O
- O O
tetradecanoylphorbol O O
- O O
13 O O
- O O
acetate O O
- O O
induced O O
AP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
activity O O
. O O

The O O
majority O O
of O O
the O O
respondents O O
( O O
83 O O
. O O
4 O O
% O O
) O O
considered O O
that O O
coitus O O
should O O
not O O
be O O
stopped O O
during O O
pregnancy O O
. O O

Based O O
on O O
the O O
ratios O O
of O O
the O O
areas O O
under O O
the O O
concentration O O
- O O
time O O
curves O O
in O O
CSF O O
and O O
serum O O
, O O
the O O
overall O O
penetration O O
of O O
rifampicin O O
into O O
CSF O O
was O O
0 O O
. O O
13 O O
- O O
0 O O
. O O
42 O O
( O O
median O O
= O O
0 O O
. O O
22 O O
) O O
. O O

The O O
differential O O
diagnosis O O
of O O
mineral O O
oil O O
lipidosis O O
in O O
lymph O O
nodes O O
with O O
reaction O O
to O O
radiopaque O O
oils O O
and O O
Whipple O O
' O O
s O O
disease O O
is O O
discussed O O
. O O

With O O
rats O O
fed O O
on O O
the O O
Zn O O
- O O
sufficient O O
diet O O
, O O
NaFe3 O O
+ O O
EDTA O O
and O O
Na2EDTA O O
similarly O O
increased O O
the O O
absorption O O
, O O
urinary O O
excretion O O
and O O
retention O O
of O O
Zn O O
but O O
to O O
a O O
lesser O O
extent O O
. O O

99Tcm O O
- O O
labelled O O
albumin B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
colloid O O
, O O
albures O O
( O O
radius O O
250 O O
nm O O
) O O
or O O
nanocoll O O
( O O
radius O O
25 O O
nm O O
) O O
, O O
or O O
both O O
were O O
used O O
as O O
test O O
substances O O
to O O
study O O
the O O
kinetics O O
of O O
vascular O O
clearance O O
after O O
RES O O
stimulation O O
. O O

These O O
findings O O
indicated O O
that O O
p35 B B_GENE
is O O
a O O
trans O O
- O O
dominant O O
factor O O
that O O
facilitates O O
AcMNPV O O
growth O O
in O O
a O O
cell O O
line O O
- O O
specific O O
manner O O
. O O

Pseudotumor O O
form O O
of O O
pulmonary O O
nocardia O O
infection O O
( O O
Nocardia O O
nova O O
) O O
in O O
a O O
renal O O
transplant O O
patient O O

Hematological O O
parameters O O
( O O
leukocyte O O
, O O
neutrophil O O
and O O
platelet O O
counts O O
) O O
and O O
liver O O
function O O
tests O O
were O O
determined O O
by O O
standard O O
procedures O O
. O O

Karyo O O
- O O
and O O
cytometric O O
investigations O O
of O O
cortical O O
layer O O
V O O
pyramidal O O
neurons O O
of O O
albino O O
rat O O
after O O
three O O
various O O
fixations O O

Clinical O O
experience O O
gained O O
from O O
a O O
combined O O
study O O
of O O
252Cf O O
brachytherapy O O
by O O
the O O
staff O O
- O O
members O O
of O O
the O O
Research O O
Institute O O
of O O
Medical O O
Radiology O O
, O O
USSR O O
AMS O O
, O O
was O O
generalized O O
. O O

The O O
team O O
physician O O
and O O
conditioning O O
of O O
athletes O O
for O O
sports O O
: O O
a O O
consensus O O
statement O O
. O O

To O O
probe O O
the O O
inter O O
- O O
relationship O O
between O O
the O O
virion O O
- O O
anchoring O O
function O O
and O O
the O O
oligomerization O O
function O O
, O O
we O O
constructed O O
two O O
serotype O O
3 O O
( O O
T3 O O
) O O
sigma B B_LOCATION/B_GENE
1 I B_LOCATION/I_GENE
deletion O O
mutants O O
in O O
SV40 O O
expression O O
vectors O O
, O O
one O O
lacking O O
the O O
hydrophobic O O
tail O O
and O O
the O O
hinge O O
, O O
and O O
the O O
other O O
lacking O O
an O O
adjacent O O
region O O
which O O
constituted O O
part O O
of O O
the O O
coiled O O
- O O
coil O O
. O O

AIMS O O
: O O
The O O
aim O O
of O O
this O O
study O O
was O O
to O O
assess O O
static O O
and O O
dynamic O O
bone O O
changes O O
in O O
patients O O
suffering O O
from O O
rickets O O
. O O

The O O
law O O
and O O
the O O
chiropractor O O
. O O

In O O
contrast O O
, O O
overexpression O O
of O O
the O O
DREB2A B B_GENE
cDNA I I_GENE
induced O O
weak O O
expression O O
of O O
the O O
target O O
genes O O
under O O
unstressed O O
conditions O O
and O O
caused O O
growth O O
retardation O O
of O O
the O O
transgenic O O
plants O O
. O O

Our O O
findings O O
suggest O O
that O O
AIF O O
may O O
be O O
a O O
morphologic O O
correlate O O
of O O
tumor O O
regression O O
following O O
preoperative O O
cytotoxic O O
chemotherapy O O
. O O

Efficacy O O
of O O
probiotic O O
feed O O
additives O O
: O O
guidelines O O
for O O
the O O
evaluation O O
of O O
the O O
efficiency O O
of O O
microorganisms O O
in O O
dogs O O
, O O
cats O O
, O O
and O O
horses O O
] O O
Probiotic O O
microorganisms O O
are O O
frequently O O
in O O
use O O
as O O
feed O O
additives O O
for O O
farm O O
and O O
pet O O
animals O O
. O O

Lung O O
transplantation O O
is O O
warranted O O
for O O
stable O O
, O O
ventilator O O
- O O
dependent O O
recipients O O
. O O

Site O O
- O O
directed O O
mutagenesis O O
shows O O
that O O
sites O O
throughout O O
the O O
IRE B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alter O O
negative O O
control O O
and O O
IRE B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
BP I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O O
reflecting O O
the O O
fact O O
that O O
the O O
footprint O O
of O O
the O O
IRE B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BP I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
over O O
the O O
entire O O
IRE B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

An O O
alternative O O
approach O O
to O O
random O O
integration O O
of O O
large O O
DNA O O
fragments O O
into O O
plants O O
is O O
to O O
utilize O O
one O O
of O O
several O O
site O O
- O O
specific O O
recombination O O
( O O
SSR O O
) O O
systems O O
, O O
such O O
as O O
Cre B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
lox B B_GENE/B_BIO
. O O

Neonatal O O
masculinization O O
affects O O
maternal O O
behavior O O
sensitivity O O
in O O
female O O
rats O O
. O O

Recombinant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mouse I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GSTT1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
catalytically O O
active O O
towards O O
1 O O
, O O
2 O O
- O O
epoxy O O
- O O
3 O O
- O O
( O O
p O O
- O O
nitrophenoxy O O
) O O
propane O O
, O O
4 O O
- O O
nitrobenzyl O O
chloride O O
and O O
dichloromethane O O
. O O

In O O
addition O O
, O O
six O O
other O O
landmarks O O
favored O O
the O O
xeroradiograph O O
but O O
not O O
to O O
the O O
degree O O
of O O
statistical O O
significance O O
. O O

Sequence O O
and O O
deletion O O
analysis O O
of O O
the O O
recombination B B_GENE/B_BIO
enhancement I I_GENE/I_BIO
gene I I_GENE/I_BIO
( O O
ref B B_PROTEIN[GENE]/B_DISEASE
) O O
of O O
bacteriophage O O
P1 O O
: O O
evidence O O
for O O
promoter O O
- O O
operator O O
and O O
attenuator O O
- O O
antiterminator O O
control O O
. O O

A O O
high O O
titer O O
of O O
anti B B_DISEASE/B_GENE
- I B_DISEASE/I_GENE
HBc I B_DISEASE/I_GENE
, O O
thus O O
suggested O O
to O O
be O O
an O O
indicator O O
of O O
persistent O O
hepatitis O O
B O O
virus O O
infection O O
, O O
was O O
found O O
rarely O O
in O O
seronegative O O
patients O O
with O O
chronic O O
hepatitis O O
, O O
non O O
- O O
alcoholic O O
cirrhosis O O
, O O
or O O
alcoholic O O
liver O O
diseases O O
. O O

Adaptability O O
of O O
Nippostrongylus O O
brasiliensis O O
( O O
Travassos O O
, O O
1914 O O
) O O
to O O
lead O O
contamination O O

Eph B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
their O O
membrane O O
- O O
associated O O
ephrin B B_PERSON/B_GENE
ligands I I_PERSON/I_GENE
regulate O O
cell O O
- O O
cell O O
interactions O O
during O O
development O O
. O O

We O O
discuss O O
the O O
possibility O O
that O O
DNA O O
- O O
protein O O
interactions O O
at O O
homologous O O
nucleotide O O
sequences O O
like O O
those O O
identified O O
in O O
PII O O
are O O
part O O
of O O
a O O
regulatory O O
gene O O
cascade O O
that O O
participates O O
in O O
timing O O
fla B B_GENE
gene I I_GENE
expression O O
in O O
the O O
C O O
. O O
crescentus O O
cell O O
cycle O O
. O O

Postcontrast O O
images O O
were O O
also O O
acquired O O
in O O
the O O
sagittal O O
( O O
six O O
patients O O
) O O
and O O
coronal O O
( O O
three O O
patients O O
) O O
planes O O
. O O

Nature O O
of O O
the O O
thermopower O O
in O O
bipolar O O
semiconductors O O
. O O

To O O
increase O O
the O O
number O O
of O O
circulating O O
polymorphonuclear O O
neutrophils O O
, O O
the O O
patient O O
was O O
treated O O
with O O
recombinant O O
granulocyte B B_GENE
- I I_GENE
macrophage I I_GENE
colony I I_GENE
- I I_GENE
stimulating I I_GENE
factor I I_GENE
( O O
GM B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CSF I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
at O O
a O O
dose O O
of O O
2 O O
micrograms O O
protein O O
/ O O
kg O O
bodyweight O O
s O O
. O O
c O O
. O O
/ O O
12 O O
h O O
. O O

By O O
using O O
methanol O O
- O O
0 O O
. O O
15 O O
M O O
borate O O
buffer O O
of O O
pH O O
8 O O
. O O
0 O O
, O O
cate B B_ENZYME[GENE]
- I I_ENZYME[GENE]
chol I I_ENZYME[GENE]
- I I_ENZYME[GENE]
O I I_ENZYME[GENE]
- I I_ENZYME[GENE]
methyltransferase I I_ENZYME[GENE]
activity O O
might O O
be O O
assayed O O
. O O

All O O
patients O O
were O O
peritonitis O O
- O O
free O O
at O O
least O O
6 O O
weeks O O
before O O
each O O
PET O O
. O O

The O O
amino O O
acid O O
residues O O
and O O
subdomains O O
important O O
for O O
DNA O O
binding O O
, O O
hormone O O
binding O O
, O O
dimerization O O
, O O
and O O
transactivation O O
are O O
mostly O O
conserved O O
among O O
all O O
VDR B B_GENE/B_SPECIES[BIO]
species O O
. O O

Transcripts O O
appear O O
to O O
be O O
initiated O O
from O O
an O O
upstream O O
promoter O O
, O O
P1 O O
, O O
located O O
in O O
front O O
of O O
the O O
tRNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
met1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
from O O
three O O
internal O O
promoters O O
: O O
P2 O O
is O O
located O O
immediately O O
in O O
front O O
of O O
the O O
tRNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
met2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
PL10 O O
is O O
near O O
the O O
beginning O O
of O O
the O O
L1 B B_PROTEIN[GENE]
- O O
L10 B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intergenic O O
space O O
, O O
and O O
PL12 O O
is O O
at O O
the O O
end O O
of O O
the O O
L10 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Based O O
on O O
the O O
deduced O O
amino O O
acid O O
sequence O O
identity O O
we O O
designated O O
GAPC1 B B_GENE
and O O
GAPC2 B B_PROTEIN[GENE]
as O O
group O O
I O O
( O O
97 O O
% O O
identical O O
) O O
and O O
GAPC3 B B_GENE
and O O
GAPC4 B B_PROTEIN[GENE]
as O O
group O O
II O O
( O O
99 O O
. O O
4 O O
% O O
identical O O
) O O
. O O

A O O
case O O
of O O
functioning O O
parathyroid O O
carcinoma O O
with O O
hypereninemic O O
hypertension O O
. O O

Finally O O
, O O
gel O O
shift O O
assays O O
showed O O
that O O
ORF2 O O
was O O
able O O
to O O
bind O O
to O O
promoter O O
fragment O O
566 O O
- O O
888 O O
. O O

Critical O O
review O O
of O O
general O O
results O O

Saturated O O
fatty O O
acids O O
induce O O
a O O
1 O O
. O O
6 O O
- O O
fold O O
increase O O
in O O
transcription O O
activity O O
, O O
whereas O O
a O O
large O O
family O O
of O O
unsaturated O O
fatty O O
acids O O
repress O O
OLE1 B B_GENE/B_BIO
transcription O O
as O O
much O O
as O O
60 O O
- O O
fold O O
. O O

This O O
polypeptide O O
includes O O
the O O
first O O
three O O
zinc O O
fingers O O
of O O
the O O
TFIIIA B B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
DNA I I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
binding I I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
domain I I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

An O O
exception O O
is O O
the O O
Bcl B B_GENE
- I I_GENE
6 I I_GENE
gene I I_GENE
, O O
encoding O O
a O O
transcription O O
factor O O
, O O
which O O
was O O
found O O
to O O
be O O
mutated O O
in O O
normal O O
human O O
memory O O
B O O
cells O O
. O O

3 O O
. O O

A O O
chest O O
- O O
X O O
ray O O
film O O
showed O O
infiltrative O O
shadows O O
in O O
the O O
right O O
middle O O
and O O
lower O O
lung O O
fields O O
, O O
but O O
a O O
chest O O
CT O O
scan O O
showed O O
an O O
abnormal O O
lung O O
density O O
in O O
the O O
right O O
lower O O
lobe O O
. O O

In O O
both O O
liver O O
and O O
pancreatic O O
islet O O
, O O
glucokinase B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
subject O O
to O O
inhibition O O
by O O
a O O
regulatory O O
protein O O
( O O
GCKR B B_GENE
) O O
. O O

MRI O O
measurements O O
of O O
the O O
brain O O
. O O

Of O O
concern O O
is O O
the O O
high O O
, O O
unexplained O O
prevalence O O
of O O
BV O O
among O O
African O O
- O O
American O O
women O O
, O O
who O O
are O O
also O O
at O O
extremely O O
high O O
risk O O
for O O
preterm O O
birth O O
. O O

The O O
use O O
of O O
bentonite O O
in O O
the O O
compounding O O
of O O
hydrogels O O

Cotransfection O O
of O O
expression O O
plasmids O O
encoding O O
the O O
protein B B_GENE
kinase I I_GENE
A I I_GENE
inhibitor O O
, O O
or O O
an O O
inactive O O
protein B B_ENZYME[GENE]
kinase I I_ENZYME[GENE]
A I I_ENZYME[GENE]
( O O
PKA B B_GENE/B_LOCATION
) O O
catalytic O O
beta O O
subunit O O
, O O
inhibited O O
both O O
forskolin O O
and O O
PACAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activation O O
of O O
chromogranin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O O
, O O
revealing O O
that O O
PACAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
trans O O
- O O
activation O O
is O O
highly O O
dependent O O
on O O
PKA B B_GENE
. O O

GH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
rapid O O
tyrosine O O
phosphorylation O O
of O O
a O O
protein O O
at O O
approximately O O
93 O O
kDa O O
in O O
normal O O
fibroblasts O O
, O O
and O O
Western O O
blotting O O
with O O
STAT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
specific I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O O
STAT5 B B_GENE
activation O O
( O O
phosphorylation O O
) O O
by O O
GH O O
. O O

The O O
most O O
valid O O
method O O
was O O
the O O
AXB O O
bearing O O
with O O
the O O
cephalometric O O
clinical O O
diagnosis O O
a O O
90 O O
. O O
91 O O
% O O
concordance O O
. O O

The O O
cyanobacterial B B_BIO/B_PROTEIN[GENE]
phycobilisome I B_BIO/I_PROTEIN[GENE]
is O O
a O O
large O O
protein O O
complex O O
located O O
on O O
the O O
photosynthetic O O
membrane O O
. O O

One O O
day O O
after O O
injection O O
48 O O
% O O
of O O
the O O
injected O O
activity O O
was O O
in O O
the O O
skeleton O O
, O O
9 O O
. O O
3 O O
% O O
in O O
the O O
liver O O
, O O
3 O O
% O O
in O O
the O O
kidneys O O
and O O
4 O O
. O O
4 O O
% O O
in O O
the O O
rest O O
of O O
the O O
organs O O
. O O

OBJECTIVE O O
: O O
To O O
assess O O
laboratory O O
practice O O
in O O
the O O
examination O O
of O O
blood O O
films O O
for O O
malarial O O
parasites O O
. O O

BACKGROUND O O
: O O
A O O
thorough O O
understanding O O
of O O
malignant O O
fibrous O O
histiocytoma O O
( O O
MFH O O
) O O
, O O
the O O
most O O
common O O
subtype O O
of O O
soft O O
tissue O O
sarcoma O O
, O O
will O O
lead O O
to O O
improved O O
histologic O O
- O O
specific O O
protocols O O
. O O

Furthermore O O
, O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O O
both O O
TGF B B_GENE
- I I_GENE
beta I I_GENE
- O O
and O O
Smad B B_GENE
- O O
induced O O
transcription O O
in O O
a O O
Smad4 B B_GENE
/ O O
DPC4 B B_MEASURE/B_PROTEIN[GENE]
- O O
dependent O O
fashion O O
. O O

Sequences O O
within O O
and O O
flanking O O
hypersensitive O O
sites O O
3 O O
and O O
2 O O
of O O
the O O
beta B B_PROTEIN[GENE]/B_DISEASE
- I I_PROTEIN[GENE]/I_DISEASE
globin I I_PROTEIN[GENE]/I_DISEASE
locus O O
control O O
region O O
required O O
for O O
synergistic O O
versus O O
additive O O
interaction O O
with O O
the O O
epsilon B B_GENE/B_BIO
- I I_GENE/I_BIO
globin I I_GENE/I_BIO
gene I I_GENE/I_BIO
promoter I I_GENE/I_BIO
. O O

Functional O O
importance O O
of O O
a O O
properly O O
folded O O
surface O O
loop O O
covering O O
the O O
catalytic O O
center O O
. O O

The O O
most O O
frequent O O
abnormality O O
was O O
GH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deficiency O O
( O O
six O O
cases O O
) O O
, O O
followed O O
by O O
gonadotropin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
four O O
cases O O
) O O
, O O
cortisol O O
( O O
four O O
cases O O
) O O
, O O
and O O
TSH B B_GENE
( O O
one O O
case O O
) O O
, O O
whereas O O
four O O
patients O O
showed O O
high O O
serum B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PRL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
values O O
. O O

Recombinant O O
vaccinia O O
viruses O O
that O O
express O O
the O O
bacteriophage B B_GENE
T3 I I_GENE
RNA I I_GENE
polymerase I I_GENE
( O O
VV B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T3pol I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
or O O
the O O
Escherichia B B_ENZYME[GENE]
coli I I_ENZYME[GENE]
lac I I_ENZYME[GENE]
repressor I I_ENZYME[GENE]
( O O
VV B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lacI I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
under O O
control O O
of O O
the O O
early B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
late I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
vaccinia I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P7 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
constructed O O
. O O

Shields O O
needed O O
for O O
pacemakers O O
. O O

Confocal O O
fluorescent O O
microscopy O O
analysis O O
demonstrated O O
that O O
WT O O
, O O
VaI O O
, O O
and O O
VaII O O
all O O
distribute O O
equally O O
to O O
the O O
cell O O
surface O O
while O O
, O O
as O O
expected O O
, O O
a O O
WT O O
mutant O O
lacking O O
the O O
two O O
C O O
- O O
terminal O O
valine O O
residues O O
does O O
not O O
. O O

However O O
, O O
it O O
is O O
not O O
easy O O
to O O
establish O O
the O O
diagnosis O O
of O O
thoracic O O
MFH O O
. O O

In O O
both O O
cell O O
types O O
, O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
led O O
to O O
a O O
dose O O
- O O
dependent O O
increase O O
in O O
the O O
association O O
of O O
tyrosine B B_GENE
phosphorylated I I_GENE
IRS I I_GENE
- I I_GENE
1 I I_GENE
with O O
the O O
SH2 B B_PROTEIN[GENE]
domain I I_PROTEIN[GENE]
of O O
the O O
p85 B B_ENZYME[GENE]/B_PERSON
regulatory I I_ENZYME[GENE]/I_PERSON
subunit I I_ENZYME[GENE]/I_PERSON
of O O
PI B B_GENE
- I I_GENE
3 I I_GENE
kinase I I_GENE
, O O
and O O
also O O
increased O O
the O O
amount O O
of O O
PI B B_ENZYME[GENE]
kinase I I_ENZYME[GENE]
activity O O
detected O O
in O O
anti B B_GENE/B_PERSON
- I I_GENE/I_PERSON
IRS I I_GENE/I_PERSON
- I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
immunoprecipitates O O
. O O

The O O
" O O
Ulm O O
Zucker O O
Uhr O O
System O O
" O O
comprises O O
a O O
microdialysis O O
probe O O
, O O
a O O
biosensor O O
( O O
Glucosensor O O
Unitec O O
Ulm O O
s O O
. O O
c O O
. O O
) O O
, O O
a O O
sender O O
transferring O O
telemetrically O O
the O O
glucose O O
concentrations O O
, O O
and O O
a O O
receiving O O
indicator O O
. O O

The O O
Xenopus B B_GENE
annexin I I_GENE
II I I_GENE
heavy I I_GENE
chain I I_GENE
lacks O O
the O O
highly O O
conserved O O
tyrosine O O
at O O
position O O
23 O O
which O O
is O O
the O O
site O O
of O O
src B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oncogene I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tyrosine B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kinase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphorylation O O
in O O
the O O
murine O O
protein O O
. O O

No O O
bafilomycin O O
- O O
sensitive O O
ATPase B B_ENZYME[GENE]
is O O
detected O O
in O O
a O O
vacuolar O O
fraction O O
. O O

Plasmids O O
bearing O O
the O O
P B B_PROTEIN[GENE]/B_DISEASE
. I I_PROTEIN[GENE]/I_DISEASE
stipitis I I_PROTEIN[GENE]/I_DISEASE
URA3 I I_PROTEIN[GENE]/I_DISEASE
gene I I_PROTEIN[GENE]/I_DISEASE
and O O
ARS2 O O
element O O
produced O O
more O O
than O O
30 O O
, O O
000 O O
transformants O O
per O O
micrograms O O
of O O
plasmid O O
DNA O O
. O O

Unfractionated O O
heparin O O
( O O
UFH O O
) O O
given O O
at O O
a O O
dose O O
of O O
0 O O
. O O
3 O O
mg O O
x O O
kg O O
- O O
1 O O
bolus O O
+ O O
0 O O
. O O
3 O O
mg O O
x O O
kg O O
- O O
1 O O
x O O
h O O
- O O
1 O O
infusion O O
did O O
not O O
improve O O
the O O
incidence O O
of O O
reperfusion O O
or O O
lower O O
the O O
incidence O O
of O O
reocclusion O O
. O O

The O O
scores O O
for O O
these O O
three O O
factors O O
, O O
which O O
corresponded O O
to O O
recognizable O O
dimensions O O
of O O
depressive O O
illness O O
, O O
were O O
then O O
correlated O O
with O O
rCBF O O
. O O

Cloning O O
, O O
sequence O O
analysis O O
, O O
and O O
expression O O
of O O
the O O
gene B B_GENE
encoding I I_GENE
formaldehyde I I_GENE
dismutase I I_GENE
from I I_GENE
Pseudomonas I I_GENE
putida I I_GENE
F61 I I_GENE
. O O

However O O
, O O
at O O
the O O
time O O
of O O
salvage O O
treatment O O
, O O
the O O
mean O O
serum B B_GENE
PSA I I_GENE
levels O O
were O O
9 O O
. O O
1 O O
and O O
1 O O
. O O
1 O O
ng O O
/ O O
mL O O
for O O
the O O
salvage O O
RP O O
and O O
salvage O O
RT O O
groups O O
, O O
respectively O O
( O O
P O O
= O O
0 O O
. O O
0001 O O
) O O
. O O

Protease O O
digestion O O
and O O
alkaline O O
extraction O O
of O O
microsomes O O
containing O O
labeled O O
mutant O O
proteins O O
further O O
showed O O
that O O
segment O O
3 O O
was O O
sufficient O O
for O O
stable O O
membrane O O
anchoring O O
of O O
the O O
glycoproteins O O
, O O
indicating O O
that O O
this O O
segment O O
may O O
specify O O
the O O
transmembrane O O
domain O O
of O O
the O O
gB B B_GENE
glycoprotein I I_GENE
. O O

The O O
mean O O
times O O
to O O
LNR O O
in O O
these O O
groups O O
were O O
42 O O
. O O
0 O O
months O O
( O O
range O O
, O O
3 O O
. O O
0 O O
- O O
194 O O
. O O
5 O O
months O O
) O O
and O O
49 O O
. O O
0 O O
months O O
( O O
range O O
, O O
3 O O
. O O
6 O O
- O O
209 O O
. O O
0 O O
months O O
) O O
respectively O O
. O O

A O O
gene O O
( O O
FMR B B_GENE
- I I_GENE
1 I I_GENE
) O O
was O O
identified O O
within O O
a O O
four O O
cosmid O O
contig O O
of O O
YAC O O
DNA O O
that O O
expresses O O
a O O
4 O O
. O O
8 O O
kb O O
message O O
in O O
human O O
brain O O
. O O

Exogenous O O
heart O O
stress O O
raised O O
log O O
circulating O O
NE O O
concentration O O
in O O
proportion O O
to O O
the O O
rise O O
in O O
heart O O
rate O O
at O O
a O O
given O O
work O O
load O O
so O O
that O O
the O O
usual O O
relationship O O
between O O
these O O
variables O O
, O O
previously O O
observed O O
during O O
other O O
stresses O O
, O O
was O O
preserved O O
. O O

The O O
implication O O
of O O
Rac B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Cdc42 B B_GENE
was O O
analyzed O O
in O O
transient O O
transfection O O
experiments O O
using O O
either O O
constitutively O O
active O O
( O O
V12 O O
) O O
or O O
dominant O O
- O O
interfering O O
( O O
N17 O O
) O O
mutants O O
. O O

The O O
bioconversion O O
of O O
penicillin O O
G O O
, O O
an O O
inexpensive O O
substrate O O
, O O
to O O
the O O
valuable O O
intermediate O O
for O O
semisynthetic O O
cephalosporin O O
production O O
, O O
deacetoxycephalosporin O O
G O O
( O O
DAOG O O
) O O
, O O
had O O
been O O
recently O O
shown O O
to O O
be O O
increased O O
by O O
eliminating O O
agitation O O
and O O
adding O O
decane O O
. O O

Elevated O O
potassium O O
stimulation O O
of O O
GAL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
completely O O
blocked O O
, O O
but O O
pituitary O O
adenylyl B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cyclase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activating I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polypeptide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
histamine O O
stimulations O O
were O O
only O O
partially O O
blocked O O
, O O
by O O
cycloheximide O O
. O O

GBF1 B B_GENE/B_DISEASE
and O O
GBF2 B B_PROTEIN[GENE]
mRNA I I_PROTEIN[GENE]
is O O
present O O
in O O
light O O
and O O
dark O O
grown O O
leaves O O
as O O
well O O
as O O
in O O
roots O O
. O O

We O O
now O O
report O O
identification O O
and O O
analysis O O
of O O
transcriptional O O
activities O O
mediated O O
by O O
three O O
cis O O
- O O
acting O O
sites O O
within O O
a O O
90 O O
- O O
bp O O
portion O O
of O O
the O O
rDNA O O
enhancer O O
designated O O
the O O
modulator O O
region O O
. O O

A O O
porcine O O
model O O
of O O
diffuse O O
axonal O O
injury O O
, O O
developed O O
with O O
information O O
from O O
these O O
physical O O
models O O
and O O
earlier O O
in O O
vitro O O
tissue O O
modeling O O
studies O O
, O O
is O O
used O O
to O O
correlate O O
histologic O O
and O O
radiologic O O
evidence O O
of O O
axonal O O
injury O O
to O O
predicted O O
regions O O
of O O
injury O O
from O O
the O O
experimental O O
and O O
theoretical O O
analysis O O
. O O

Sample O O
size O O
requirement O O
for O O
repeated O O
measurements O O
in O O
continuous O O
data O O
. O O

A O O
transient O O
induction O O
of O O
both O O
c B B_GENE
- I I_GENE
fos I I_GENE
and O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
TPA O O
was O O
observed O O
in O O
both O O
cell O O
populations O O
, O O
together O O
with O O
an O O
associated O O
suppression O O
of O O
BSP B B_GENE
mRNA I I_GENE
in O O
the O O
fetal O O
rat O O
calvarial O O
cells O O
. O O

Videoanalysis O O
confirms O O
the O O
ballistic O O
character O O
of O O
the O O
initial O O
phase O O
of O O
the O O
reaching O O
movement O O
. O O

HPV O O
- O O
16 O O
MARs O O
are O O
context O O
dependent O O
transcriptional O O
enhancers O O
, O O
and O O
activated O O
expression O O
of O O
HPV O O
- O O
16 O O
oncogenes O O
dependent O O
on O O
chromosomal O O
integration O O
may O O
positively O O
select O O
tumorigenic O O
cells O O
during O O
the O O
multistep O O
etiology O O
of O O
cervical O O
cancer O O
. O O

Sociological O O
analysis O O
of O O
the O O
family O O
. O O

This O O
enhancer O O
element O O
functioned O O
in O O
a O O
position O O
- O O
and O O
orientation O O
- O O
independent O O
manner O O
both O O
on O O
the O O
Pax B B_SPECIES[BIO]/B_GENE
- I I_SPECIES[BIO]/I_GENE
QNR I I_SPECIES[BIO]/I_GENE
P0 I I_SPECIES[BIO]/I_GENE
promoter I I_SPECIES[BIO]/I_GENE
and O O
the O O
heterologous B B_GENE/B_BIO
thymidine I I_GENE/I_BIO
kinase I I_GENE/I_BIO
promoter I I_GENE/I_BIO
. O O

These O O
data O O
suggest O O
that O O
overexpression O O
of O O
MT B B_GENE/B_DISEASE
potentiates O O
the O O
growth O O
of O O
MCF7 O O
cells O O
, O O
whereas O O
downregulation O O
of O O
MT B B_GENE/B_DISEASE
elicits O O
antiproliferative O O
effects O O
. O O

A O O
multivariant O O
study O O
of O O
pituitary O O
adenoma O O
, O O
obtainment O O
of O O
two O O
logistic O O
regression O O
equations O O
as O O
an O O
auxiliary O O
support O O
in O O
the O O
diagnosis O O
of O O
these O O
tumors O O
. O O

Bile O O
salts O O
, O O
hormonal O O
control O O
, O O
and O O
the O O
male O O
disadvantage O O
. O O

Number O O
of O O
warm O O
- O O
units O O
with O O
higher O O
rates O O
of O O
firing O O
and O O
greater O O
thermal O O
coefficients O O
, O O
comparable O O
to O O
those O O
of O O
warm O O
- O O
units O O
in O O
the O O
adult O O
, O O
gradually O O
increased O O
with O O
growth O O
. O O

Such O O
unique O O
recognition O O
capabilities O O
are O O
generated O O
with O O
minimal O O
alterations O O
in O O
the O O
CDR3 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
loops O O
of O O
the O O
TCR B B_GENE
. O O

To O O
this O O
effect O O
, O O
the O O
present O O
survey O O
puts O O
in O O
evidence O O
that O O
the O O
maximum O O
delay O O
of O O
stream O O
that O O
guarantees O O
the O O
good O O
dimensional O O
stability O O
of O O
these O O
class O O
A O O
alginates O O
is O O
of O O
45 O O
minutes O O
in O O
the O O
hot O O
and O O
humid O O
climatic O O
tropical O O
country O O
conditions O O
. O O

Gene B B_GENE/B_LOCATION
1 I B_GENE/I_LOCATION
of I B_GENE/I_LOCATION
the I B_GENE/I_LOCATION
murine I B_GENE/I_LOCATION
coronavirus I B_GENE/I_LOCATION
, I B_GENE/I_LOCATION
MHV I B_GENE/I_LOCATION
- I B_GENE/I_LOCATION
A59 I B_GENE/I_LOCATION
, O O
encodes O O
approximately O O
800 O O
kDa O O
of O O
protein O O
products O O
within O O
two O O
overlapping O O
open O O
reading O O
frames O O
( O O
ORFs O O
1a O O
and O O
1b O O
) O O
. O O

For O O
this O O
interaction O O
, O O
the O O
C O O
- O O
terminal O O
part O O
of O O
Sp1 B B_GENE
and O O
the O O
N O O
terminus O O
of O O
E2F1 B B_GENE
, O O
a O O
domain O O
also O O
present O O
in O O
E2F2 B B_GENE
and O O
E2F3 B B_GENE
but O O
absent O O
in O O
E2F4 B B_GENE
and O O
E2F5 B B_GENE
, O O
were O O
essential O O
. O O

Our O O
results O O
suggest O O
a O O
biological O O
role O O
for O O
Elf B B_GENE
- I I_GENE
1 I I_GENE
in O O
the O O
regulation O O
of O O
IgH B B_GENE
gene I I_GENE
expression O O
, O O
attribute O O
a O O
functional O O
role O O
for O O
receptor O O
- O O
induced O O
AP B B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
B O O
lymphocytes O O
and O O
provide O O
evidence O O
for O O
a O O
direct O O
link O O
between O O
IgM B B_GENE
receptor I I_GENE
- O O
mediated O O
signalling O O
and O O
3 O O
' O O
enhancer O O
activation O O
. O O

Oncogenic O O
activation O O
of O O
RET B B_GENE
is O O
detected O O
in O O
human O O
papillary O O
thyroid O O
tumours O O
and O O
in O O
multiple O O
endocrine O O
neoplasia O O
type O O
2 O O
syndromes O O
. O O

CD4 B B_GENE
degradation O O
mediated O O
by O O
Vpu B B_GENE/B_BACTERIUM[BIO]
does O O
not O O
require O O
the O O
ER O O
chaperone O O
calnexin B B_GENE/B_LOCATION
and O O
is O O
dependent O O
on O O
an O O
intact O O
ubiquitin B B_GENE
- O O
conjugating O O
system O O
. O O

These O O
effects O O
were O O
antagonized O O
by O O
prior O O
administration O O
of O O
1 O O
- O O
( O O
2 O O
- O O
methoxyphenyl O O
) O O
- O O
4 O O
- O O
[ O O
- O O
( O O
2 O O
- O O
phthalimido O O
) O O
butyl O O
] O O
piperazine O O
) O O
( O O
0 O O
. O O
5 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
. O O

PURPOSE O O
: O O
To O O
evaluate O O
the O O
effect O O
of O O
adding O O
a O O
pulsating O O
bristle O O
action O O
to O O
the O O
established O O
oscillating O O
/ O O
rotating O O
action O O
of O O
the O O
Braun O O
Oral O O
- O O
B O O
Ultra O O
Plaque O O
Remover O O
( O O
D9 O O
) O O
on O O
plaque O O
removal O O
. O O

Sub O O
- O O
inhibitory O O
and O O
post O O
- O O
antibiotic O O
effects O O
of O O
spiramycin O O
and O O
erythromycin O O
on O O
Staphylococcus O O
aureus O O
. O O

The O O
CydDC B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
system I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
appears O O
to O O
be O O
the O O
first O O
prokaryotic O O
example O O
of O O
a O O
heterodimeric B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
ABC I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transport I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
system I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
which O O
each O O
polypeptide O O
contains O O
both O O
hydrophobic O O
and O O
ATP O O
- O O
binding O O
domains O O
. O O

The O O
single O O
- O O
copy O O
U20 B B_GENE
sequence I I_GENE
is O O
located O O
on O O
the O O
same O O
DNA O O
strand O O
as O O
the O O
nucleolin B B_GENE/B_BIO
mRNA I I_GENE/I_BIO
. O O

The O O
coding O O
sequence O O
of O O
rat B B_GENE
MEK I I_GENE
kinase I I_GENE
1 I I_GENE
( O O
MEKK1 B B_GENE/B_DISEASE
) O O
has O O
been O O
determined O O
from O O
multiple O O
, O O
independent O O
cDNA O O
clones O O
. O O

In O O
response O O
to O O
the O O
need O O
for O O
better O O
quantitative O O
estimates O O
of O O
the O O
regional O O
distribution O O
of O O
the O O
active O O
bone O O
marrow O O
organ O O
in O O
infants O O
and O O
children O O
, O O
a O O
method O O
using O O
various O O
anatomical O O
data O O
has O O
been O O
developed O O
. O O

We O O
compared O O
these O O
responses O O
for O O
six O O
hatchling O O
and O O
eight O O
adult O O
Chrysemys O O
picta O O
from O O
an O O
Ohio O O
population O O
. O O

On O O
the O O
basis O O
of O O
experiments O O
with O O
mutant O O
virus O O
and O O
transfection O O
with O O
isolated O O
genes O O
, O O
the O O
herpes B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
simplex I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
virus I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
immediate I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
early I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gene I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
product O O
ICP4 B B_GENE/B_MEASURE
is O O
known O O
to O O
positively O O
regulate O O
the O O
transcription O O
of O O
viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
early I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
late I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
negatively O O
regulate O O
expression O O
from O O
its O O
own O O
promoter O O
. O O

A O O
female O O
infant O O
with O O
isolated O O
noncompaction O O
of O O
ventricular O O
myocardium O O
who O O
developed O O
ventricular O O
tachyarrhythmia O O
is O O
described O O
. O O

Recent O O
, O O
highly O O
visible O O
reviews O O
on O O
the O O
subject O O
have O O
clearly O O
pointed O O
out O O
that O O
little O O
is O O
known O O
about O O
the O O
cellular O O
mechanisms O O
through O O
which O O
inhaled O O
asbestos O O
fibers O O
cause O O
the O O
well O O
known O O
, O O
debilitating O O
lung O O
disease O O
- O O
asbestosis O O
( O O
i O O
. O O
e O O
. O O
interstitial O O
pulmonary O O
fibrosis O O
) O O
. O O

The O O
POU B B_GENE/B_DISEASE
- O O
specific O O
domain O O
of O O
Pit B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
is O O
essential O O
for O O
sequence O O
- O O
specific O O
, O O
high O O
affinity O O
DNA O O
binding O O
and O O
DNA O O
- O O
dependent O O
Pit B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
- O O
Pit B B_GENE
- I I_GENE
1 I I_GENE
interactions O O
. O O

Also O O
, O O
the O O
placebo O O
nondepressed O O
patients O O
had O O
significantly O O
better O O
treatment O O
outcome O O
compared O O
with O O
the O O
placebo O O
depressed O O
patients O O
. O O

Obtaining O O
kidney O O
cells O O
from O O
a O O
beagle O O
puppy O O
( O O
RPB O O
- O O
1 O O
) O O
and O O
the O O
establishment O O
of O O
a O O
cryopreservation O O
bank O O

These O O
results O O
suggest O O
an O O
essential O O
role O O
of O O
the O O
binding O O
of O O
HNF B B_GENE
- I I_GENE
4 I I_GENE
and O O
/ O O
or O O
HNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
6 O O
beta O O
A O O
- O O
A O O
site O O
on O O
the O O
basal O O
transcriptional O O
activation O O
of O O
the O O
CYP3A2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
liver O O
cells O O
. O O

It O O
is O O
envisaged O O
that O O
the O O
WHOQOL O O
- O O
BREF O O
will O O
be O O
most O O
useful O O
in O O
studies O O
that O O
require O O
a O O
brief O O
assessment O O
of O O
quality O O
of O O
life O O
, O O
for O O
example O O
, O O
in O O
large O O
epidemiological O O
studies O O
and O O
clinical O O
trials O O
where O O
quality O O
of O O
life O O
is O O
of O O
interest O O
. O O

Usefulness O O
of O O
glucocorticoids O O
in O O
the O O
treatment O O
of O O
congestive O O
heart O O
failure O O

The O O
chromosomal O O
location O O
of O O
these O O
YACs O O
was O O
verified O O
using O O
FISH O O
, O O
which O O
also O O
demonstrated O O
their O O
nonchimeric O O
nature O O
. O O

For O O
evaluation O O
of O O
the O O
model O O
, O O
simulations O O
of O O
physiological O O
excitation O O
and O O
of O O
pathologies O O
( O O
Wolff O O
- O O
Parkinson O O
- O O
White O O
syndrome O O
, O O
complete O O
AV O O
- O O
block O O
, O O
inferior O O
wall O O
ischaemia O O
) O O
were O O
examined O O
. O O

The O O
authors O O
report O O
about O O
the O O
exeresis O O
of O O
a O O
pyelonephrictic O O
left O O
small O O
kidney O O
with O O
laparoscopic O O
surgery O O
. O O

New O O
protein O O
- O O
free O O
products O O
for O O
diet O O
therapy O O
in O O
chronic O O
renal O O
insufficiency O O

Unestablished O O
quail O O
myoblasts O O
were O O
infected O O
with O O
a O O
retroviral O O
vector O O
encoding O O
the O O
oncogenic O O
form O O
of O O
H B B_GENE
- I I_GENE
Ras I I_GENE
in O O
order O O
to O O
investigate O O
the O O
mechanism O O
by O O
which O O
this O O
oncoprotein O O
interferes O O
with O O
terminal O O
differentiation O O
. O O

Early O O
detection O O
and O O
signs O O
of O O
hepatoangiosarcoma O O
among O O
vinyl O O
chloride O O
workers O O
. O O

VP4 B B_GENE/B_SPECIES[BIO]
differentially O O
regulates O O
TRAF2 B B_GENE
signaling O O
, O O
disengaging O O
JNK B B_GENE
activation O O
while O O
directing O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
to O O
effect O O
rotavirus O O
- O O
specific O O
cellular O O
responses O O
. O O

On O O
the O O
3rd O O
day O O
after O O
ischemia O O
of O O
the O O
remained O O
kidney O O
for O O
30 O O
min O O
, O O
structural O O
components O O
of O O
the O O
walls O O
of O O
the O O
glomerular O O
arterioles O O
and O O
those O O
of O O
the O O
filtration O O
- O O
reabsorption O O
barrier O O
undergo O O
certain O O
ultrastructural O O
changes O O
, O O
that O O
with O O
time O O
elapsed O O
( O O
7 O O
, O O
14 O O
days O O
) O O
gradually O O
pass O O
away O O
, O O
and O O
amount O O
of O O
cells O O
with O O
hypertrophic O O
processes O O
increases O O
. O O

The O O
purified O O
RAG1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
overexpressed O O
in O O
E O O
. O O
coli O O
exhibited O O
the O O
expected O O
cleavage O O
activity O O
when O O
combined O O
with O O
RAG2 B B_GENE
purified O O
from O O
transfected O O
293T O O
cells O O
. O O

19 O O
, O O
4967 O O
- O O
4973 O O
) O O
. O O

Preventing O O
the O O
heterosexual O O
spread O O
of O O
HIV O O
into O O
this O O
vulnerable O O
population O O
is O O
a O O
formidable O O
public O O
health O O
challenge O O
. O O

Moreover O O
, O O
we O O
show O O
that O O
GATA B B_GENE
- I I_GENE
1 I I_GENE
and O O
Sp1 B B_GENE
synergize O O
from O O
a O O
distance O O
in O O
constructs O O
designed O O
to O O
mimic O O
the O O
architecture O O
of O O
globin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
control I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
downstream O O
globin B B_GENE/B_LOCATION
promoters I B_GENE/I_LOCATION
. O O

Superovulation O O
with O O
intrauterine O O
insemination O O
( O O
SO O O
- O O
IUI O O
) O O
has O O
been O O
suggested O O
as O O
an O O
alternative O O
to O O
gamete O O
intrafallopian O O
transfer O O
( O O
GIFT O O
) O O
, O O
despite O O
the O O
absence O O
of O O
controlled O O
or O O
comparative O O
trials O O
. O O

Mammalian O O
chromosome O O
ends O O
contain O O
long O O
arrays O O
of O O
TTAGGG O O
repeats O O
that O O
are O O
complexed O O
to O O
a O O
telomere O O
specific O O
protein O O
, O O
the O O
TTAGGG B B_GENE
repeat I I_GENE
binding I I_GENE
factor I I_GENE
, O O
TRF1 B B_GENE/B_DISEASE
. O O

Genotype O O
- O O
phenotype O O
correlations O O
in O O
male O O
patients O O
with O O
a O O
partial O O
nullisomy O O
of O O
the O O
X O O
chromosome O O
have O O
suggested O O
that O O
at O O
least O O
one O O
locus O O
involved O O
in O O
MRX O O
is O O
on O O
Xp22 O O
. O O
3 O O
. O O

The O O
gene O O
, O O
from O O
the O O
initiator O O
methionine O O
to O O
the O O
polyadenylation O O
site O O
, O O
is O O
contained O O
within O O
13 O O
244 O O
basepairs O O
and O O
contains O O
19 O O
exons O O
. O O

In O O
the O O
unit O O
housing O O
of O O
a O O
compact O O
cyclotron O O
and O O
positron O O
emission O O
CT O O
( O O
PET O O
) O O
, O O
positron O O
emitting O O
gas O O
such O O
as O O
15O O O
, O O
11C O O
, O O
C15O2 O O
, O O
C15O O O
etc O O
. O O

is O O
supplied O O
from O O
a O O
cyclotron O O
to O O
a O O
PET O O
room O O
through O O
a O O
transportation O O
pipe O O
with O O
an O O
appropriate O O
shield O O
to O O
reduce O O
positron O O
annihilation O O
radiation O O
. O O

Adhesion O O
was O O
inhibited O O
by O O
mAbs O O
against O O
the O O
COOH O O
- O O
terminus O O
and O O
central O O
cell O O
binding O O
domains O O
of O O
fibronectin B B_GENE
, O O
as O O
well O O
as O O
by O O
the O O
corresponding O O
CS1 B B_GENE/B_LOCATION
and O O
RGD B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptides I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
results O O
were O O
not O O
obtained O O
using O O
either O O
preimmune O O
sera O O
or O O
antiserum O O
specific O O
for O O
the O O
luminal O O
portion O O
of O O
the O O
glycoprotein O O
precursor O O
. O O

Cerebral O O
blood O O
flow O O
was O O
measured O O
using O O
the O O
iv O O
method O O
of O O
133 O O
- O O
Xe O O
CBF O O
determination O O
and O O
AVDO2 O O
was O O
measured O O
using O O
systemic O O
arterial O O
- O O
jugular O O
venous O O
oxygen O O
content O O
differences O O
. O O

Activation O O
of O O
the O O
mitogen B B_GENE
- I I_GENE
activated I I_GENE
protein I I_GENE
kinase I I_GENE
( O O
MAPK B B_GENE/B_LOCATION
) O O
pathway O O
enhances O O
long O O
- O O
range O O
transactivation O O
by O O
the O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
globin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
control I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
LCR O O
) O O
( O O
W O O
. O O

In O O
situ O O
hybridization O O
of O O
whole O O
- O O
mount O O
mouse O O
embryos O O
with O O
Mex5 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antisense I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
provide O O
no O O
evidence O O
for O O
the O O
exclusion O O
of O O
Mex5 B B_GENE
during O O
embryonic O O
development O O
. O O

In O O
three O O
other O O
patients O O
the O O
electrophysiologic O O
characteristics O O
of O O
atrioventricular O O
conduction O O
prevented O O
a O O
demonstration O O
of O O
these O O
differences O O
. O O

Human O O
psychophysical O O
analysis O O
of O O
receptive O O
field O O
- O O
like O O
properties O O
- O O
- O O
II O O
. O O

3 O O
. O O

New O O
strategies O O
are O O
needed O O
to O O
prevent O O
coronary O O
rethrombosis O O
in O O
patients O O
with O O
minimal O O
atherosclerosis O O
after O O
thrombolytic O O
therapy O O
for O O
acute O O
myocardial O O
infarction O O
. O O

The O O
Ick B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
not O O
involved O O
in O O
antibody O O
- O O
mediated O O
CD4 B B_GENE
( O O
CDR3 B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
loop I I_GENE/I_DISEASE
) O O
signal O O
transduction O O
that O O
inhibits O O
HIV O O
- O O
1 O O
transcription O O
. O O

Programmed O O
peritoneal O O
lavage O O
in O O
suppurative O O
complications O O
of O O
perforated O O
ulcer O O
of O O
the O O
stomach O O

Deletion O O
analysis O O
of O O
the O O
7 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GATA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
revealed O O
that O O
a O O
1 O O
. O O
1 O O
- O O
kb O O
DNA O O
sequence O O
is O O
critical O O
for O O
expression O O
of O O
GATA B B_GENE
- I I_GENE
2 I I_GENE
in O O
neurons O O
. O O

The O O
fusion O O
gene O O
cassette O O
was O O
placed O O
under O O
the O O
control O O
of O O
a O O
vaccinia B B_GENE/B_PERSON
virus I I_GENE/I_PERSON
early I I_GENE/I_PERSON
promoter I I_GENE/I_PERSON
and O O
cloned O O
in O O
a O O
host O O
- O O
restricted O O
fowlpox O O
viral O O
vector O O
. O O

Psoriasis O O
on O O
tumor O O
. O O

These O O
data O O
suggest O O
that O O
the O O
secreted O O
, O O
truncated O O
receptor O O
encoded O O
by O O
the O O
2 B B_GENE
. I I_GENE
6 I I_GENE
- I I_GENE
kb I I_GENE
c I I_GENE
- I I_GENE
erbB I I_GENE
transcript I I_GENE
can O O
bind O O
to O O
TGF B B_GENE
alpha I I_GENE
and O O
may O O
play O O
an O O
important O O
growth O O
- O O
regulatory O O
function O O
in O O
vitro O O
. O O

A O O
close O O
homologue O O
of O O
the O O
APK2a B B_GENE/B_BIO
gene I I_GENE/I_BIO
, O O
named O O
APK2b B B_PROTEIN[GENE]/B_BIO
, O O
was O O
also O O
isolated O O
from O O
the O O
Arabidopsis O O
cDNA O O
library O O
. O O

Thus O O
, O O
the O O
rates O O
of O O
a B B_GENE
- I I_GENE
factor I I_GENE
receptor I I_GENE
endocytosis O O
and O O
consequent O O
vacuolar O O
turnover O O
depend O O
on O O
the O O
available O O
level O O
of O O
ubiquitin B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
in O O
the O O
cell O O
. O O

Using O O
the O O
same O O
approach O O
we O O
have O O
shown O O
that O O
hFIRE B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binds O O
the O O
stimulatory O O
proteins O O
Sp1 B B_GENE/B_LOCATION
and O O
Sp3 B B_GENE
in O O
addition O O
to O O
CBF B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Non O O
- O O
specific O O
immunological O O
abnormalities O O
were O O
detected O O
in O O
8 O O
of O O
the O O
13 O O
patients O O
in O O
whom O O
they O O
were O O
looked O O
for O O
. O O

Using O O
a O O
combined O O
pharmacokinetic O O
- O O
pharmacodynamic O O
model O O
, O O
the O O
impact O O
of O O
various O O
factors O O
on O O
the O O
effective O O
bioavailability O O
and O O
on O O
its O O
estimation O O
, O O
using O O
the O O
intravenous O O
- O O
to O O
- O O
oral O O
dose O O
ratio O O
required O O
to O O
produce O O
the O O
same O O
area O O
under O O
the O O
response O O
time O O
curve O O
after O O
acute O O
administration O O
, O O
are O O
explored O O
. O O

CONCLUSIONS O O
: O O
The O O
RRM O O
is O O
one O O
of O O
the O O
most O O
common O O
and O O
best O O
characterized O O
RNA O O
- O O
binding O O
motifs O O
. O O

The O O
cyclin B B_GENE/B_BIO
- I I_GENE/I_BIO
dependent I I_GENE/I_BIO
kinase I I_GENE/I_BIO
Cdk2 B I_GENE/I_BIO
associates O O
with O O
cyclins B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
D I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
has O O
been O O
implicated O O
in O O
the O O
control O O
of O O
the O O
G1 O O
to O O
S O O
phase O O
transition O O
in O O
mammals O O
. O O

Mol O O
. O O

The O O
amino B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
terminal I I_GENE/I_LOCATION
gag I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
encoded I I_GENE/I_LOCATION
region I I_GENE/I_LOCATION
of O O
P140gag B B_GENE/B_MEASURE
- O O
fps B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
contains O O
a O O
phosphotyrosine O O
residue O O
in O O
addition O O
to O O
normal O O
gag B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphorylation O O
sites O O
. O O

Rad18 B B_GENE/B_SPECIES[BIO]
is O O
required O O
for O O
DNA O O
repair O O
and O O
checkpoint O O
responses O O
in O O
fission O O
yeast O O
. O O

A O O
less O O
common O O
and O O
much O O
more O O
perplexing O O
circumstance O O
occurs O O
when O O
evaluating O O
patients O O
with O O
sarcoidosis O O
established O O
for O O
several O O
years O O
present O O
with O O
evidence O O
of O O
progressive O O
or O O
chronic O O
pulmonary O O
involvement O O
and O O
dyspnea O O
. O O

2 O O
, O O
4 O O
- O O
and O O
2 O O
, O O
6 O O
- O O
toluenediamine O O
in O O
hydrolysed O O
plasma O O
and O O
urine O O
after O O
test O O
- O O
chamber O O
exposure O O
of O O
humans O O
to O O
2 O O
, O O
4 O O
- O O
and O O
2 O O
, O O
6 O O
- O O
toluene O O
diisocyanate O O
. O O

Further O O
studies O O
are O O
warranted O O
to O O
determine O O
whether O O
these O O
findings O O
are O O
idiosyncratic O O
, O O
coincidental O O
, O O
or O O
a O O
more O O
general O O
phenomenon O O
. O O

After O O
1 O O
day O O
, O O
none O O
of O O
the O O
labeled O O
erythrocytes O O
were O O
detected O O
. O O

This O O
substrate O O
was O O
cleaved O O
efficiently O O
in O O
trans O O
by O O
protease B B_ENZYME[GENE]
3C I I_ENZYME[GENE]
derived O O
from O O
another O O
recombinant O O
vaccinia O O
virus O O
expressing O O
a O O
3C B B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
precursor I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
activity O O
of O O
gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glutamyl I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transpeptidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
serum O O
of O O
problem O O
drinkers O O
. O O

Patients O O
with O O
endocarditis O O
or O O
vascular O O
infection O O
were O O
more O O
frequently O O
immunocompromised O O
and O O
older O O
than O O
those O O
with O O
acute O O
Q O O
fever O O
. O O

The O O
effects O O
of O O
oxalate O O
- O O
containing O O
products O O
on O O
the O O
exposed O O
dentine O O
surface O O
: O O
an O O
SEM O O
investigation O O
. O O

The O O
technique O O
used O O
by O O
this O O
system O O
involves O O
a O O
transient O O
, O O
externally O O
applied O O
increase O O
in O O
resistance O O
to O O
breathing O O
. O O

We O O
evaluated O O
99mTc O O
- O O
ECD O O
SPECT O O
comparing O O
with O O
rCBF O O
images O O
obtained O O
by O O
PET O O
in O O
12 O O
patients O O
with O O
spinocerebellar O O
degeneration O O
( O O
SCD O O
) O O
. O O

In O O
particular O O
, O O
lacZ B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthesised O O
this O O
way O O
are O O
highly O O
unstable O O
and O O
yield O O
little O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
thalamic O O
SD O O
was O O
regularly O O
triggered O O
by O O
short O O
( O O
0 O O
. O O
02 O O
- O O
0 O O
. O O
05 O O
s O O
) O O
high O O
- O O
frequency O O
( O O
200 O O
- O O
500 O O
Hz O O
) O O
ES O O
of O O
the O O
parietal O O
cortical O O
surface O O
. O O

All O O
three O O
SSV O O
- O O
transformed O O
cells O O
secreted O O
v B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sis I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
product I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p44 B B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

p44 B B_GENE
was O O
secreted O O
but O O
remained O O
tightly O O
associated O O
with O O
the O O
cell O O
surface O O
. O O

It O O
is O O
suggested O O
that O O
the O O
mechanism O O
of O O
intestinal O O
absorption O O
of O O
vitamin O O
D O O
and O O
25 O O
- O O
hydroxy O O
- O O
vitamin O O
D O O
may O O
differ O O
in O O
man O O
, O O
the O O
absorption O O
of O O
25 O O
- O O
hydroxy O O
- O O
vitamin O O
D O O
possibly O O
being O O
less O O
dependent O O
on O O
bile O O
acids O O
. O O

It O O
tends O O
to O O
be O O
higher O O
between O O
frazioni O O
of O O
the O O
same O O
community O O
than O O
between O O
communities O O
. O O

The O O
BRSV B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
6573 O O
nt O O
in O O
length O O
and O O
the O O
derived O O
polypeptide O O
has O O
2162 O O
aa O O
. O O

Availability O O
of O O
a O O
less O O
palatable O O
diet O O
( O O
chow O O
) O O
following O O
presentation O O
of O O
palatable O O
diets O O
will O O
not O O
result O O
in O O
diminished O O
caloric O O
intake O O
, O O
body O O
weight O O
, O O
obesity O O
and O O
hyperinsulinemia O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
With O O
an O O
array O O
of O O
112 O O
unipole O O
, O O
epicardial O O
maps O O
of O O
electrically O O
induced O O
AF O O
in O O
6 O O
dogs O O
( O O
acute O O
group O O
) O O
, O O
self O O
- O O
sustained O O
AF O O
in O O
6 O O
dogs O O
( O O
chronic O O
group O O
) O O
, O O
and O O
sinus O O
rhythm O O
and O O
atrial O O
pacing O O
in O O
3 O O
dogs O O
( O O
control O O
group O O
) O O
were O O
analyzed O O
before O O
and O O
after O O
creating O O
linear O O
radiofrequency O O
ablation O O
lesions O O
in O O
both O O
atria O O
that O O
eliminated O O
the O O
AF O O
. O O

The O O
effects O O
of O O
inoculum O O
size O O
, O O
medium O O
, O O
temperature O O
, O O
and O O
duration O O
of O O
growth O O
on O O
the O O
in O O
vitro O O
susceptibility O O
testing O O
of O O
Aspergillus O O
fumigatus O O
were O O
investigated O O
using O O
broth O O
micro O O
- O O
and O O
macro O O
- O O
dilution O O
techniques O O
. O O

We O O
have O O
analyzed O O
the O O
function O O
of O O
these O O
putative O O
SL O O
structures O O
in O O
RNA O O
translation O O
by O O
constructing O O
chimeric B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
chloramphenicol I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
acetyltransferase I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( B B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
CAT I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
RNAs I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
flanked O O
either O O
by O O
both O O
5 O O
' O O
- O O
and O O
3 O O
' O O
- O O
terminal O O
sequence O O
domains O O
from O O
the O O
RV O O
genome O O
or O O
several O O
deletion O O
derivatives O O
of O O
the O O
same O O
sequences O O
. O O

Periarteritis O O
nodosa O O
with O O
ruptures O O
of O O
the O O
renal O O
vessels O O
and O O
the O O
persistence O O
of O O
the O O
hepatitis O O
B O O
and O O
C O O
viruses O O
in O O
the O O
blood O O

Despite O O
the O O
fact O O
that O O
biochemical O O
estimates O O
of O O
bone O O
turnover O O
indicate O O
that O O
( O O
short O O
- O O
term O O
) O O
administration O O
of O O
rhGH B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
IGF B B_GENE
- I I_GENE
I I I_GENE
stimulates O O
bone O O
metabolism O O
in O O
non O O
- O O
osteoporotic O O
older O O
people O O
, O O
no O O
significant O O
changes O O
have O O
been O O
observed O O
in O O
bone O O
mineral O O
density O O
at O O
the O O
proximal O O
femur O O
. O O

Compression O O
of O O
pulmonary O O
artery O O
and O O
right O O
ventricular O O
outflow O O
tract O O
by O O
aneurysm O O
of O O
ascending O O
aorta O O
. O O

However O O
, O O
patients O O
with O O
DPX O O
should O O
be O O
observed O O
for O O
the O O
potential O O
occurrence O O
of O O
an O O
associated O O
condition O O
. O O

However O O
, O O
FosB B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
FosB B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O O
not O O
differ O O
in O O
all O O
trans O O
- O O
regulatory O O
properties O O
: O O
Trans O O
- O O
activation O O
of O O
a O O
5x O O
TRE B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CAT I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reporter O O
construct O O
in O O
HeLa O O
and O O
NIH O O
- O O
3T3 O O
cells O O
was O O
found O O
with O O
both O O
FosB B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forms O O
. O O

Mutations O O
in O O
glnB B B_GENE/B_BACTERIUM[BIO]
, O O
nifR1 B B_GENE
( O O
ntrC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
, O O
and O O
NifR4 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ntrA B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encoding O O
sigma B B_GENE/B_LOCATION
54 I I_GENE/I_LOCATION
) O O
had O O
no O O
influence O O
on O O
put B B_GENE
gene I I_GENE
expression O O
. O O

Impact O O
of O O
cytokine O O
gene O O
polymorphisms O O
on O O
outcomes O O
of O O
coronary O O
artery O O
bypass O O
graft O O
surgery O O
. O O

Blood O O
and O O
whole O O
- O O
brain O O
mercury O O
concentrations O O
were O O
determined O O
in O O
pups O O
on O O
PN O O
0 O O
( O O
birth O O
) O O
and O O
PN O O
21 O O
( O O
weaning O O
) O O
. O O

By O O
subtractive O O
and O O
differential O O
screening O O
, O O
we O O
have O O
cloned O O
12 O O
of O O
these O O
sequences O O
, O O
2 O O
of O O
which O O
were O O
c B B_GENE
- I I_GENE
fos I I_GENE
and O O
krox B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
24 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

When O O
stratifying O O
FLM O O
values O O
< O O
34 O O
and O O
> O O
34 O O
wks O O
' O O
gestation O O
, O O
again O O
no O O
difference O O
was O O
found O O
in O O
mean O O
difference O O
of O O
L O O
/ O O
S O O
and O O
LB O O
before O O
and O O
after O O
34 O O
wks O O
. O O

Cotransfection O O
of O O
a O O
junB B B_GENE/B_BACTERIUM[BIO]
stimulated O O
the O O
basal O O
activity O O
of O O
the O O
alpha B B_GENE
2 I I_GENE
( I I_GENE
I I I_GENE
) I I_GENE
collagen I I_GENE
promoter I I_GENE
93 O O
- O O
fold O O
, O O
respectively O O
. O O

Glutathione B B_GENE/B_PERSON
reductase I I_GENE/I_PERSON
( O O
GR B B_LOCATION/B_PROTEIN[GENE]
) O O
was O O
purified O O
from O O
the O O
cyanobacterium O O
Anabaena O O
PCC O O
7120 O O
. O O

Additional O O
simulations O O
account O O
for O O
interactions O O
of O O
spatial O O
frequency O O
with O O
stimulus O O
duration O O
, O O
effects O O
of O O
adaptation O O
, O O
and O O
properties O O
of O O
residual O O
traces O O
, O O
as O O
opposed O O
to O O
visual O O
persistence O O
. O O

Fractional O O
Ca O O
retention O O
was O O
measured O O
from O O
the O O
72 O O
- O O
h O O
postdose O O
WBR O O
divided O O
by O O
WBR O O
at O O
time O O
0 O O
. O O

METHODS O O
: O O
The O O
study O O
population O O
included O O
70 O O
patients O O
with O O
acute O O
coronary O O
syndromes O O
( O O
14 O O
with O O
recent O O
acute O O
myocardial O O
infarction O O
and O O
56 O O
with O O
unstable O O
angina O O
pectoris O O
) O O
, O O
105 O O
patients O O
with O O
stable O O
angina O O
pectoris O O
, O O
and O O
75 O O
control O O
subjects O O
. O O

5 O O
' O O
- O O
Deletion O O
of O O
the O O
Stat B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
abolished O O
all O O
promoter O O
- O O
reporter O O
activity O O
in O O
response O O
to O O
PRL B B_GENE
. O O

Plasma B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
beta I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
thromboglobulin I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
( O O
beta B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
TG I I_PROTEIN[GENE]/I_LOCATION
) O O
, O O
a O O
platelet O O
- O O
specific O O
protein O O
, O O
is O O
a O O
marker O O
of O O
intravascular O O
platelet O O
degranulation O O
. O O

John O O
' O O
s O O
wort O O

DESIGN O O
, O O
SETTING O O
AND O O
SUBJECTS O O
: O O
The O O
analysis O O
is O O
based O O
on O O
data O O
collected O O
in O O
the O O
first O O
two O O
rounds O O
of O O
the O O
nationally O O
representative O O
Ghana O O
Living O O
Standards O O
Survey O O
, O O
held O O
in O O
1987 O O
/ O O
88 O O
( O O
GLSS O O
- O O
I O O
) O O
and O O
1988 O O
/ O O
89 O O
( O O
GLSS O O
- O O
II O O
) O O
, O O
with O O
both O O
surveys O O
covering O O
approximately O O
3000 O O
households O O
. O O

The O O
DNA O O
- O O
binding O O
proteins O O
are O O
without O O
effect O O
on O O
the O O
transcription O O
of O O
plasmids O O
lacking O O
binding O O
sites O O
or O O
when O O
the O O
binding O O
sites O O
are O O
located O O
further O O
upstream O O
. O O

The O O
RTI40 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
spans O O
35 O O
kilobase O O
pairs O O
; O O
it O O
contains O O
6 O O
exons O O
and O O
at O O
least O O
6 O O
rat O O
Identifier O O
repetitive O O
elements O O
. O O

DP B B_PROTEIN[GENE]
- I I_PROTEIN[GENE]
1 I I_PROTEIN[GENE]
and O O
DP B B_GENE
- I I_GENE
2 I I_GENE
encode O O
maternally O O
stored O O
transcripts O O
that O O
are O O
expressed O O
during O O
early O O
development O O
. O O

However O O
, O O
an O O
analogous O O
myristoylated O O
peptide O O
derived O O
from O O
c B B_GENE
- I I_GENE
Yes I I_GENE
also O O
has O O
no O O
inhibitory O O
activity O O
. O O

The O O
oral O O
movements O O
which O O
did O O
occur O O
in O O
the O O
HAL O O
- O O
treated O O
rats O O
were O O
slower O O
than O O
normal O O
. O O

These O O
sequence O O
differences O O
are O O
reflected O O
in O O
differences O O
in O O
gene O O
expression O O
in O O
three O O
cell O O
lines O O
. O O

This O O
pathway O O
has O O
been O O
reported O O
to O O
mediate O O
heterodimer O O
interactions O O
with O O
the O O
proapoptotic O O
regulator O O
, O O
Bad B B_GENE
. O O

Mutating O O
bases O O
- O O
142 O O
to O O
- O O
151 O O
abolishes O O
formation O O
of O O
complex O O
VII O O
and O O
partially O O
inhibits O O
complex O O
IV O O
, O O
suggesting O O
that O O
the O O
proteins O O
forming O O
these O O
complexes O O
bind O O
neighboring O O
segments O O
of O O
DNA O O
. O O

The O O
DFA O O
slide O O
prepared O O
from O O
the O O
ThinPrep O O
Test O O
and O O
the O O
conventional O O
DFA O O
sample O O
prepared O O
from O O
the O O
endocervical O O
swab O O
were O O
evaluated O O
independently O O
. O O

Moclobemide O O
is O O
a O O
well O O
- O O
tolerated O O
alternative O O
antidepressant O O
, O O
but O O
there O O
is O O
a O O
need O O
for O O
prospective O O
controlled O O
trials O O
to O O
evaluate O O
its O O
long O O
- O O
term O O
efficacy O O
. O O

Hormonal O O
replacement O O
therapy O O
for O O
women O O
with O O
a O O
personal O O
history O O
of O O
breast O O
cancer O O
? O O

Recently O O
, O O
we O O
reported O O
that O O
SMRT B B_GENE
also O O
directly O O
associates O O
with O O
LAZ3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
BCL B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
6 I I_GENE/I_DISEASE
) O O
, O O
a O O
POZ O O
/ O O
Zn O O
finger O O
transcriptional O O
repressor O O
involvedin O O
the O O
pathogenesis O O
of O O
non O O
- O O
Hodgkin O O
lymphomas O O
. O O

Using O O
reporter O O
gene O O
constructs O O
driven O O
by O O
the O O
CD4 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
, O O
we O O
report O O
that O O
HHV O O
- O O
6 O O
can O O
efficiently O O
transactivate O O
such O O
genetic O O
elements O O
. O O

Characterization O O
of O O
a O O
cDNA B B_GENE/B_LOCATION
encoding I I_GENE/I_LOCATION
CNN I I_GENE/I_LOCATION
predicts O O
a O O
novel O O
structural O O
protein O O
with O O
three O O
leucine O O
zipper O O
motifs O O
and O O
several O O
coiled O O
- O O
coil O O
domains O O
exhibiting O O
limited O O
homology O O
to O O
the O O
rod O O
portion O O
of O O
myosin B B_GENE
. O O

A O O
preformed O O
SREBP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1a I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
32P I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bound O O
specifically O O
to O O
membrane O O
- O O
immobilized O O
GST B B_GENE/B_BIO
- O O
CBP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
fusion O O
proteins O O
that O O
contained O O
amino O O
- O O
terminal O O
portions O O
of O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Previous O O
work O O
established O O
that O O
the O O
TAL1 B B_GENE
proteins I I_GENE
are O O
phosphorylated O O
exclusively O O
on O O
serine O O
and O O
identified O O
Ser122 O O
as O O
a O O
substrate O O
for O O
the O O
mitogen B B_ENZYME[GENE]
- I I_ENZYME[GENE]
activated I I_ENZYME[GENE]
protein I I_ENZYME[GENE]
kinase I I_ENZYME[GENE]
ERK B I_ENZYME[GENE]
- I I_ENZYME[GENE]
1 I I_ENZYME[GENE]
. O O

Rapid O O
, O O
sensitive O O
gas O O
chromatographic O O
analysis O O
of O O
8 O O
- O O
methoxypsoralen O O
in O O
human O O
plasma O O
. O O

If O O
the O O
size O O
of O O
the O O
cystic O O
liver O O
- O O
lesions O O
excludes O O
a O O
curative O O
operative O O
treatment O O
or O O
if O O
the O O
patient O O
refuses O O
surgery O O
, O O
the O O
indication O O
for O O
chemotherapy O O
with O O
mebendazole O O
is O O
given O O
. O O

When O O
cotransfected O O
with O O
the O O
HIV B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LTR I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CAT B I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O O
CV O O
- O O
1 O O
cells O O
, O O
both O O
the O O
pCD41 B B_GENE/B_MEASURE
and O O
pGD41 B B_GENE
clones O O
trans O O
- O O
activated O O
the O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Exit O O
from O O
mitosis O O
in O O
Drosophila O O
syncytial O O
embryos O O
requires O O
proteolysis O O
and O O
cyclin B B_GENE
degradation O O
, O O
and O O
is O O
associated O O
with O O
localized O O
dephosphorylation O O
. O O

Cough O O
- O O
CPR O O
, O O
a O O
deep O O
rhythmic O O
forceful O O
cough O O
repeated O O
30 O O
- O O
60 O O
times O O
per O O
minute O O
, O O
can O O
be O O
an O O
effective O O
resuscitative O O
technique O O
during O O
emergencies O O
occurring O O
in O O
the O O
cardiac O O
catheterization O O
laboratory O O
. O O

Probiotics O O
, O O
prebiotics O O
, O O
vaccination O O
, O O
and O O
acidification O O
of O O
drinking O O
water O O
were O O
assessed O O
as O O
means O O
of O O
reducing O O
Salmonella O O
. O O

Gas O O
exchange O O
was O O
measured O O
breath O O
by O O
breath O O
. O O

Analysis O O
of O O
nt O O
sequence O O
was O O
carried O O
out O O
on O O
three O O
out O O
of O O
the O O
more O O
than O O
15 O O
of O O
these O O
regions O O
present O O
in O O
the O O
mouse O O
genome O O
. O O

However O O
, O O
both O O
RAR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
and O O
RXR B B_PROTEIN[GENE]/B_LOCATION
- O O
specific O O
ligands O O
increase O O
CaSki O O
number O O
by O O
> O O
or O O
= O O
20 O O
% O O
. O O

Also O O
, O O
in O O
patients O O
with O O
MYD O O
, O O
there O O
was O O
a O O
significant O O
decrease O O
in O O
arterial O O
PO2 O O
from O O
the O O
seated O O
posture O O
to O O
the O O
supine O O
posture O O
, O O
without O O
a O O
significant O O
change O O
in O O
the O O
arterial O O
PCO2 O O
. O O

The O O
primary O O
structures O O
of O O
the O O
human B B_SPECIES[BIO]/B_PROTEIN[GENE]
KB I I_SPECIES[BIO]/I_PROTEIN[GENE]
cell I I_SPECIES[BIO]/I_PROTEIN[GENE]
( I I_SPECIES[BIO]/I_PROTEIN[GENE]
FR I I_SPECIES[BIO]/I_PROTEIN[GENE]
- I I_SPECIES[BIO]/I_PROTEIN[GENE]
KB1 I I_SPECIES[BIO]/I_PROTEIN[GENE]
) I I_SPECIES[BIO]/I_PROTEIN[GENE]
folate I I_SPECIES[BIO]/I_PROTEIN[GENE]
receptor I I_SPECIES[BIO]/I_PROTEIN[GENE]
( O O
FR B B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
and O O
of O O
a O O
human B B_GENE/B_BIO
placental I I_GENE/I_BIO
( I I_GENE/I_BIO
FR I I_GENE/I_BIO
- I I_GENE/I_BIO
P2 I I_GENE/I_BIO
) I I_GENE/I_BIO
FR I I_GENE/I_BIO
, O O
proteins O O
important O O
in O O
cellular O O
accumulation O O
of O O
folates O O
, O O
have O O
been O O
deduced O O
from O O
cDNA O O
sequences O O
. O O

The O O
general O O
concept O O
of O O
RARE B B_DISEASE/B_GENE
- O O
cleavage O O
mapping O O
as O O
well O O
as O O
its O O
applications O O
and O O
limitations O O
are O O
discussed O O
. O O

To O O
further O O
investigate O O
the O O
role O O
of O O
PKR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
transcriptional O O
signaling O O
, O O
we O O
expressed O O
the O O
wild B B_GENE
type I I_GENE
human I I_GENE
PKR I I_GENE
and O O
a O O
catalytically O O
inactive O O
dominant O O
negative O O
PKR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
murine O O
pre O O
- O O
B O O
lymphoma O O
70Z O O
/ O O
3 O O
cells O O
. O O

Reasons O O
are O O
presented O O
to O O
support O O
the O O
contention O O
that O O
this O O
increase O O
is O O
in O O
part O O
real O O
. O O

Patients O O
received O O
either O O
sodium O O
cephalothin O O
or O O
placebo O O
intravenously O O
before O O
the O O
procedure O O
and O O
for O O
up O O
to O O
8 O O
additional O O
doses O O
. O O

In O O
- O O
111 O O
- O O
BLMC O O
uptake O O
was O O
directly O O
proportional O O
to O O
Ki B B_GENE
- I I_GENE
67 I I_GENE
/ O O
MIB B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
1 I I_MEASURE/I_GENE
activity O O
and O O
number O O
of O O
mitoses O O
in O O
tumor O O
tissue O O
. O O

Heating O O
had O O
no O O
effect O O
upon O O
either O O
force O O
decline O O
or O O
slowing O O
of O O
relaxation O O
during O O
fatiguing O O
contractions O O
. O O

Binding O O
of O O
transformed O O
Ah B B_GENE
receptor I I_GENE
complex I I_GENE
to O O
a O O
dioxin O O
responsive O O
transcriptional O O
enhancer O O
: O O
evidence O O
for O O
two O O
distinct O O
heteromeric O O
DNA O O
- O O
binding O O
forms O O
. O O

Interestingly O O
, O O
VDR B B_GENE
was O O
able O O
to O O
bind O O
to O O
VDREs O O
with O O
high O O
affinity O O
and O O
to O O
fully O O
activate O O
transcription O O
in O O
intact O O
yeast O O
cells O O
in O O
the O O
presence O O
of O O
the O O
retinoid B B_GENE
X I I_GENE
receptor I I_GENE
( O O
RXR B B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

Thus O O
, O O
it O O
appears O O
that O O
moxalactam O O
is O O
a O O
reliable O O
and O O
useful O O
antibiotic O O
for O O
the O O
treatment O O
of O O
complicated O O
urinary O O
tract O O
infections O O
. O O

A O O
fine O O
- O O
structure O O
radiation O O
hybrid O O
map O O
for O O
the O O
region O O
that O O
extends O O
from O O
D8S520 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
distal O O
) O O
to O O
D8S1759 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
proximal O O
) O O
was O O
prepared O O
, O O
followed O O
by O O
construction O O
of O O
a O O
single O O
, O O
integrated O O
YAC O O
/ O O
BAC O O
contig O O
for O O
the O O
interval O O
. O O

The O O
protein O O
contains O O
a O O
SHAQKYF O O
amino O O
acid O O
signature O O
motif O O
in O O
the O O
second O O
myb B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
is O O
highly O O
conserved O O
in O O
a O O
number O O
of O O
recently O O
identified O O
plant B B_GENE/B_BIO
myb I I_GENE/I_BIO
- I I_GENE/I_BIO
related I I_GENE/I_BIO
genes I I_GENE/I_BIO
, O O
thus O O
defining O O
a O O
new O O
class O O
of O O
plant O O
DNA O O
- O O
binding O O
proteins O O
. O O

IV O O
. O O

It O O
has O O
been O O
shown O O
that O O
renin B B_GENE
secretion O O
is O O
stimulated O O
by O O
endothelin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
recently O O
discovered O O
peptide O O
with O O
strong O O
vasoconstrictive O O
properties O O
and O O
stimulating O O
effects O O
on O O
renin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
secretion O O
. O O

The O O
encoded O O
260 B B_MEASURE/B_PROTEIN[GENE]
- I I_MEASURE/I_PROTEIN[GENE]
amino I I_MEASURE/I_PROTEIN[GENE]
- I I_MEASURE/I_PROTEIN[GENE]
acid I I_MEASURE/I_PROTEIN[GENE]
( I I_MEASURE/I_PROTEIN[GENE]
aa I I_MEASURE/I_PROTEIN[GENE]
) I I_MEASURE/I_PROTEIN[GENE]
( I I_MEASURE/I_PROTEIN[GENE]
H1 I I_MEASURE/I_PROTEIN[GENE]
- I I_MEASURE/I_PROTEIN[GENE]
I I I_MEASURE/I_PROTEIN[GENE]
) I I_MEASURE/I_PROTEIN[GENE]
and O O
240 B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
aa I I_PROTEIN[GENE]/I_LOCATION
( I I_PROTEIN[GENE]/I_LOCATION
H1 I I_PROTEIN[GENE]/I_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
II I I_PROTEIN[GENE]/I_LOCATION
) I I_PROTEIN[GENE]/I_LOCATION
polypeptides I I_PROTEIN[GENE]/I_LOCATION
possess O O
the O O
typical O O
tripartite O O
organization O O
of O O
animal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
H1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
histones I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
variable O O
N O O
- O O
and O O
C O O
- O O
terminal O O
domains O O
flanking O O
a O O
conserved O O
' O O
globular O O
' O O
DNA O O
- O O
binding O O
domain O O
. O O

Instead O O
, O O
the O O
large O O
difference O O
in O O
ssDNA O O
- O O
binding O O
affinities O O
reflects O O
the O O
loss O O
of O O
hexamerization O O
ability O O
by O O
uvsY B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
suggesting O O
that O O
a O O
form O O
of O O
intrahexamer O O
synergism O O
or O O
cooperativity O O
between O O
binding O O
sites O O
within O O
the O O
uvsY B B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hexamer I I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leads O O
to O O
its O O
high O O
observed O O
affinity O O
for O O
ssDNA O O
. O O

No O O
significant O O
difference O O
was O O
seen O O
found O O
between O O
the O O
two O O
groups O O
in O O
the O O
degree O O
of O O
postoperative O O
deterioration O O
in O O
cardiopulmonary O O
function O O
or O O
in O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
. O O

The O O
PK O O
domain O O
showed O O
pairwise O O
in O O
vitro O O
binding O O
interactions O O
with O O
the O O
pseudokinase O O
, O O
HisRS B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
C O O
- O O
term O O
domains O O
; O O
additionally O O
, O O
the O O
HisRS B B_ENZYME[GENE]/B_LOCATION
domain I I_ENZYME[GENE]/I_LOCATION
interacted O O
with O O
the O O
C O O
- O O
term O O
region O O
. O O

To O O
initiate O O
our O O
analysis O O
of O O
factors O O
required O O
for O O
eIF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
2 I I_GENE/I_DISEASE
alpha I I_GENE/I_DISEASE
expression O O
, O O
selected O O
a O O
CAP O O
- O O
proximal O O
element O O
shown O O
by O O
in O O
vivo O O
methylation O O
protection O O
analysis O O
to O O
bind O O
a O O
potential O O
regulatory O O
factor O O
. O O

Furthermore O O
, O O
addition O O
of O O
the O O
recombinant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
YA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunit I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
restores O O
NF B B_GENE
- I I_GENE
Y I I_GENE
binding O O
. O O

Reversible O O
pressure O O
- O O
induced O O
amorphization O O
in O O
solid O O
C70 O O
: O O
Raman O O
and O O
photoluminescence O O
study O O
. O O

Alternative O O
roles O O
of O O
these O O
DNA O O
motifs O O
as O O
activators O O
of O O
early O O
mRNA O O
transcription O O
and O O
as O O
an O O
initiator O O
element O O
for O O
late O O
mRNA O O
transcription O O
help O O
explain O O
how O O
polyomavirus O O
gene O O
expression O O
is O O
regulated O O
during O O
lytic O O
growth O O
and O O
provides O O
a O O
model O O
for O O
cellular O O
transcription O O
during O O
development O O
. O O

Our O O
results O O
suggest O O
that O O
Sp1 B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
can O O
function O O
as O O
a O O
distinct O O
TGF B B_GENE/B_PERSON
- I I_GENE/I_PERSON
beta I I_GENE/I_PERSON
responsive I I_GENE/I_PERSON
element I I_GENE/I_PERSON
for O O
TGF B B_GENE
- I I_GENE
beta I I_GENE
mediated O O
promoter O O
expression O O
and O O
Sp1 B B_GENE/B_LOCATION
per O O
se O O
can O O
mediate O O
this O O
response O O
. O O

Phase O O
I O O
study O O
of O O
5 O O
- O O
fluorouracil O O
and O O
leucovorin O O
by O O
a O O
14 O O
- O O
day O O
circadian O O
infusion O O
in O O
metastatic O O
adenocarcinoma O O
patients O O
. O O

The O O
results O O
of O O
this O O
study O O
demonstrate O O
that O O
release O O
of O O
a O O
single O O
pulley O O
after O O
repair O O
of O O
the O O
tendons O O
in O O
this O O
area O O
improved O O
gliding O O
excursions O O
of O O
the O O
tendons O O
and O O
reduced O O
resistance O O
to O O
motion O O
of O O
the O O
repaired O O
tendons O O
, O O
and O O
provide O O
support O O
for O O
partial O O
A2 O O
pulley O O
incision O O
after O O
repair O O
of O O
the O O
tendons O O
in O O
the O O
area O O
of O O
the O O
pulley O O
. O O

Heart O O
rate O O
and O O
oxygen O O
consumption O O
increased O O
75 O O
+ O O
/ O O
- O O
4 O O
bpm O O
and O O
26 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
4 O O
ml O O
O2 O O
/ O O
kg O O
x O O
min O O
( O O
- O O
1 O O
) O O
from O O
supine O O
resting O O
values O O
, O O
respectively O O
. O O

Prolongation O O
of O O
prothrombin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time O O
was O O
not O O
due O O
to O O
depletion O O
of O O
vitamin O O
K O O
- O O
dependent O O
coagulation O O
factors O O
or O O
manifest O O
fibrinolysis O O
, O O
but O O
due O O
to O O
the O O
presence O O
of O O
circulating O O
fibrinogen B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibrinmonomer I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
FDP O O
complexes O O
. O O

Effect O O
of O O
tetracycline O O
on O O
the O O
glycogen O O
- O O
producing O O
function O O
of O O
the O O
liver O O
and O O
intestinal O O
microflora O O
in O O
white O O
mice O O

A O O
case O O
report O O
. O O

Mutation O O
of O O
K14 O O
in O O
H3 B B_GENE
, O O
which O O
serves O O
as O O
the O O
major O O
target O O
of O O
recombinant B B_GENE
Gcn5p I I_GENE
acetylation O O
in O O
vitro O O
, O O
confers O O
a O O
strong O O
, O O
synthetic O O
growth O O
defect O O
in O O
gcn5 B B_GENE/B_DISEASE
cells O O
. O O

On O O
the O O
other O O
hand O O
, O O
V3 O O
" O O
values O O
were O O
not O O
significantly O O
correlated O O
with O O
the O O
degree O O
of O O
tremor O O
, O O
seborrhea O O
, O O
and O O
duration O O
of O O
the O O
illness O O
. O O

All O O
patients O O
whose O O
PSA B B_GENE
levels O O
reached O O
0 O O
. O O
1 O O
ng O O
. O O
/ O O
ml O O
. O O

In O O
addition O O
, O O
we O O
found O O
that O O
the O O
transactivation O O
mediated O O
by O O
the O O
p68c B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
ets I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
pr I I_GENE/I_LOCATION
p55erg B I_GENE/I_LOCATION
through O O
the O O
Polyomavirus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
specifically O O
inhibited O O
by O O
the O O
p46kDaPax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
QNR I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
transient O O
transfection O O
assay O O
. O O

Treatment O O
with O O
ACE B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibitors O O
after O O
acute O O
myocardial O O
infarction O O

Conversely O O
, O O
as O O
a O O
GAL B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
4 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
chimera I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
the O O
isolated O O
LAZ3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
BCL6 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
BTB B I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
POZ O O
domain O O
appears O O
nearly O O
as O O
efficient O O
as O O
the O O
entire O O
protein O O
at O O
inducing O O
transcriptional O O
repression O O
. O O

A O O
new O O
myocyte B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancer I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
recognizes O O
a O O
conserved O O
element O O
associated O O
with O O
multiple O O
muscle O O
- O O
specific O O
genes O O
. O O

Diclofenac O O
sodium O O
: O O
blood O O
concentration O O
of O O
the O O
slow O O
- O O
release O O
form O O
and O O
influence O O
on O O
the O O
metabolism O O
of O O
kallikrein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O O

The O O
LS B B_GENE/B_BIO
gene I I_GENE/I_BIO
promoter I I_GENE/I_BIO
sequence I I_GENE/I_BIO
has O O
homology O O
with O O
Escherichia O O
coli O O
promoter O O
sequences O O
; O O
its O O
terminator O O
sequence O O
is O O
capable O O
of O O
forming O O
a O O
stem O O
- O O
and O O
- O O
loop O O
structure O O
. O O

We O O
demonstrate O O
that O O
the O O
recently O O
proposed O O
synthetic O O
imaging O O
technique O O
[ O O
J O O
. O O

Overexpression O O
of O O
either O O
Sp1 B B_GENE
or O O
phosphorylated B B_GENE
CREB I I_GENE
transactivated O O
the O O
mCgA B B_GENE
promoter I I_GENE
dose O O
dependently O O
, O O
while O O
coexpression O O
of O O
both O O
transcription O O
factors O O
resulted O O
in O O
an O O
additive O O
mCgA B B_GENE
promoter I I_GENE
response O O
. O O

The O O
data O O
obtained O O
with O O
cellular O O
RNA O O
from O O
HepG2 O O
cells O O
demonstrated O O
that O O
transcription O O
is O O
initiated O O
891 O O
bases O O
upstream O O
of O O
the O O
translation O O
- O O
start O O
site O O
and O O
that O O
the O O
polyadenylation O O
site O O
is O O
located O O
550 O O
bases O O
downstream O O
of O O
the O O
stop O O
codon O O
. O O

Finally O O
, O O
there O O
is O O
now O O
appropriate O O
recognition O O
of O O
the O O
pivotal O O
role O O
of O O
BP O O
reduction O O
in O O
forestalling O O
pressure O O
- O O
related O O
cardiovascular O O
complications O O
, O O
even O O
among O O
high O O
- O O
risk O O
persons O O
with O O
diabetes O O
mellitus O O
and O O
renal O O
insufficiency O O
. O O

It O O
is O O
hypothesized O O
this O O
occurs O O
through O O
antagonism O O
of O O
PML B B_GENE/B_DISEASE
/ O O
RAR B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
actions O O
in O O
these O O
leukemic O O
cells O O
. O O

13 O O
: O O
961 O O
- O O
969 O O
, O O
1993 O O
) O O
suggested O O
that O O
T B B_GENE
antigen I I_GENE
could O O
mediate O O
transcriptional O O
activation O O
through O O
interaction O O
with O O
the O O
TATA B B_GENE/B_BIO
- I I_GENE/I_BIO
binding I I_GENE/I_BIO
protein I I_GENE/I_BIO
, O O
as O O
well O O
as O O
upstream O O
bound O O
transcription O O
factors O O
. O O

Activation O O
of O O
the O O
cytotactin B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
promoter I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
by O O
the O O
homeobox B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Evx I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CONCLUSION O O
/ O O
INTERPRETATION O O
: O O
We O O
found O O
an O O
increased O O
risk O O
of O O
hip O O
fracture O O
in O O
women O O
younger O O
than O O
75 O O
years O O
with O O
Type O O
I O O
diabetes O O
or O O
with O O
Type O O
II O O
diabetes O O
of O O
long O O
duration O O
. O O

Maternal O O
behavior O O
was O O
assessed O O
using O O
observational O O
techniques O O
. O O

Rat B B_GENE/B_DISEASE
p8 I I_GENE/I_DISEASE
mRNA I I_GENE/I_DISEASE
was O O
discovered O O
because O O
of O O
its O O
strong O O
activation O O
in O O
pancreas O O
during O O
the O O
acute O O
phase O O
of O O
pancreatitis O O
. O O

LV O O
compliance O O
was O O
determined O O
from O O
the O O
slope O O
of O O
the O O
LV O O
end O O
- O O
diastolic O O
pressure O O
( O O
LVEDP O O
) O O
vs O O
. O O

The O O
practice O O
of O O
measuring O O
of O O
AChE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
in O O
acute O O
poisoning O O
is O O
limited O O
. O O

Vasodilation O O
in O O
congestive O O
heart O O
failure O O
is O O
an O O
established O O
therapeutic O O
principal O O
. O O

The O O
effects O O
of O O
cefazolin O O
, O O
given O O
into O O
the O O
III O O
cerebral O O
ventricle O O
at O O
different O O
doses O O
were O O
studied O O
on O O
GABA O O
content O O
, O O
GAD O O
and O O
GABA O O
- O O
T O O
in O O
the O O
brain O O
- O O
stem O O
of O O
young O O
chickens O O
( O O
Gallus O O
domesticus O O
) O O
. O O

Subclones O O
of O O
R15 O O
which O O
reverted O O
to O O
kappa B B_GENE/B_DISEASE
light I I_GENE/I_DISEASE
chain I I_GENE/I_DISEASE
production O O
contained O O
genomic O O
deletions O O
of O O
R15ns O O
and O O
/ O O
or O O
the O O
surrounding O O
intron O O
. O O

The O O
disorders O O
are O O
accompanied O O
by O O
consistent O O
, O O
but O O
similarly O O
reversible O O
, O O
electroencephalographic O O
changes O O
. O O

The O O
delayed O O
activation O O
of O O
the O O
prostaglandin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
H I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoter O O
in O O
bovine O O
granulosa O O
cells O O
is O O
associated O O
with O O
down O O
- O O
regulation O O
of O O
truncated O O
upstream B B_GENE
stimulatory I I_GENE
factor I I_GENE
- I I_GENE
2 I I_GENE
. O O

Mean O O
latency O O
periods O O
were O O
29 O O
. O O
6 O O
among O O
insulators O O
, O O
35 O O
. O O
4 O O
among O O
dock O O
workers O O
, O O
43 O O
. O O
7 O O
in O O
a O O
heterogeneous O O
group O O
defined O O
as O O
various O O
, O O
46 O O
. O O
4 O O
in O O
non O O
- O O
shipbuilding O O
industry O O
workers O O
, O O
49 O O
. O O
4 O O
in O O
shipyard O O
workers O O
, O O
51 O O
. O O
7 O O
among O O
women O O
with O O
a O O
history O O
of O O
domestic O O
exposure O O
to O O
asbestos O O
, O O
and O O
56 O O
. O O
2 O O
in O O
people O O
employed O O
in O O
maritime O O
trades O O
. O O

The O O
strategy O O
uses O O
RNA B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligase I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
add O O
DNA O O
oligonucleotide O O
priming O O
sites O O
to O O
the O O
RNA O O
for O O
subsequent O O
reverse O O
transcription O O
and O O
PCR O O
( O O
RNA B B_PROTEIN[GENE]/B_LOCATION
ligase I I_PROTEIN[GENE]/I_LOCATION
, O O
reverse O O
transcription O O
- O O
PCR O O
, O O
or O O
RL O O
/ O O
RT O O
/ O O
PCR O O
) O O
. O O

We O O
analyzed O O
the O O
effects O O
of O O
light O O
on O O
tubulin B B_GENE
mRNA I I_GENE
abundance O O
in O O
Arabidopsis O O
seedlings O O
using O O
RNA O O
gel O O
blot O O
hybridizations O O
and O O
gene O O
- O O
specific O O
probes O O
. O O

More O O
important O O
, O O
ligand O O
- O O
activated O O
insulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphorylate O O
SHC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O O
, O O
indicating O O
that O O
SHC B B_GENE/B_PERSON
proteins I I_GENE/I_PERSON
could O O
be O O
direct O O
substrates O O
for O O
insulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
chimera O O
transduced O O
IL B B_GENE
- I I_GENE
4 I I_GENE
- O O
specific O O
signals O O
in O O
response O O
to O O
IL B B_GENE
- I I_GENE
2 I I_GENE
binding O O
and O O
dramatically O O
enhanced O O
type O O
2 O O
responses O O
( O O
IL B B_GENE
- I I_GENE
4 I I_GENE
, O O
IL B B_GENE
- I I_GENE
5 I I_GENE
, O O
and O O
immunoglobulin B B_GENE
E I I_GENE
production O O
) O O
upon O O
in O O
vitro O O
TCR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O O
or O O
in O O
vivo O O
antigen O O
challenge O O
. O O

A O O
distinct O O
5 O O
' O O
- O O
sequence O O
in O O
clone O O
hMIWC2 O O
suggested O O
an O O
alternative O O
upstream O O
transcription O O
initiation O O
site O O
. O O

Two O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
N I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acetylglucosaminyltransferases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
forming O O
the O O
core O O
2 O O
O O O
- O O
glycan O O
branch O O
, O O
C2GnT O O
and O O
the O O
I B B_MEASURE/B_GENE
antigen I I_MEASURE/I_GENE
, O O
IGnT B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
are O O
homologous O O
to O O
each O O
other O O
in O O
three O O
regions O O
of O O
the O O
catalytic O O
domain O O
( O O
A O O
, O O
B O O
, O O
C O O
) O O
and O O
their O O
genes O O
reside O O
at O O
the O O
same O O
locus O O
, O O
chromosome O O
9 O O
, O O
band O O
q21 O O
( O O
Bierhuizen O O
, O O
M O O
. O O
F O O
. O O
A O O
. O O
, O O
Mattei O O
, O O
M O O
. O O
- O O
G O O
. O O
and O O
Fukuda O O
, O O
M O O
. O O
, O O
Genes O O
Dev O O
. O O
, O O
7 O O
, O O
468 O O
- O O
478 O O
, O O
1993 O O
) O O
. O O

Significantly O O
higher O O
levels O O
of O O
vitamin O O
C O O
and O O
catalase B B_ENZYME[GENE]
activity O O
were O O
found O O
in O O
vegetarians O O
( O O
C O O
- O O
63 O O
. O O
6 O O
and O O
86 O O
. O O
5 O O
mumol O O
/ O O
l O O
; O O
CAT O O
- O O
1497 O O
and O O
1313 O O
U O O
/ O O
ml O O
for O O
males O O
and O O
females O O
, O O
respectively O O
) O O
when O O
compared O O
to O O
nonvegetarians O O
( O O
C O O
- O O
41 O O
. O O
3 O O
and O O
54 O O
. O O
4 O O
mumol O O
/ O O
l O O
; O O
CAT O O
- O O
1192 O O
and O O
1086 O O
U O O
/ O O
ml O O
) O O
. O O

Cutting O O
the O O
intraorbital O O
nerves O O
produced O O
a O O
temporary O O
retrieval O O
impairment O O
that O O
was O O
indistinguishable O O
from O O
that O O
produced O O
by O O
intramystacial O O
lidocaine O O
injection O O
. O O

Developmental O O
regulation O O
of O O
expression O O
of O O
the O O
malate B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
transgenic O O
plants O O
. O O

In O O
contrast O O
, O O
no O O
change O O
in O O
the O O
level O O
of O O
either O O
p53 B B_GENE
or O O
activation O O
of O O
mdm2 B B_GENE
protein I I_GENE
by O O
p53 B B_GENE
was O O
observed O O
in O O
hamster O O
UV61 O O
cells O O
after O O
UV O O
exposure O O
. O O

The O O
mouse O O
lactoferrin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O O
promoter O O
was O O
active O O
in O O
human O O
endometrium O O
carcinoma O O
RL O O
95 O O
- O O
2 O O
cells O O
and O O
in O O
rat O O
glioma O O
C6 O O
cells O O
. O O

The O O
1 O O
- O O
year O O
and O O
2 O O
- O O
year O O
survival O O
rates O O
for O O
the O O
patients O O
with O O
N0 O O
- O O
3 O O
significantly O O
exceeded O O
those O O
of O O
N4 O O
patients O O
. O O

The O O
subjects O O
' O O
lungs O O
were O O
ventilated O O
with O O
N2O O O
in O O
O2 O O
( O O
FIO2 O O
0 O O
. O O
3 O O
) O O
to O O
the O O
end O O
- O O
tidal O O
CO2 O O
present O O
before O O
anesthesia O O
, O O
and O O
then O O
CBF O O
was O O
measured O O
using O O
intravenous O O
133Xe O O
and O O
ten O O
scintillation O O
counters O O
, O O
five O O
over O O
each O O
cerebral O O
hemisphere O O
. O O

This O O
indicates O O
changes O O
in O O
postvaccination O O
allergy O O
to O O
BCG O O
. O O

In O O
contrast O O
, O O
inhibition O O
of O O
MAPK B B_GENE
activity O O
by O O
MAPK B B_GENE
kinase I I_GENE
inhibitor O O
( O O
PD O O
98059 O O
) O O
or O O
by O O
overexpression O O
of O O
kinase O O
- O O
deficient O O
MAPKs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activated O O
basal O O
and O O
GnRH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stimulated O O
GnRHR B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Luc B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
. O O

The O O
influence O O
of O O
gas O O
composition O O
in O O
the O O
air O O
cell O O
on O O
pipping O O
and O O
liver O O
metabolism O O
in O O
embryonic O O
chicks O O
. O O

New O O
, O O
selective O O
catechol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
O I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O O
as O O
therapeutic O O
agents O O
in O O
Parkinson O O
' O O
s O O
disease O O
. O O

Furthermore O O
, O O
the O O
social O O
learning O O
theory O O
of O O
depression O O
, O O
developed O O
by O O
Lewinsohn O O
, O O
is O O
described O O
. O O

Laser O O
soldering O O
with O O
exogenous O O
fibrinogen B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
feasible O O
without O O
topical O O
administration O O
of O O
additional O O
clotting O O
agents O O
, O O
significantly O O
improves O O
the O O
bursting O O
strength O O
of O O
primary O O
laser O O
welded O O
anastomoses O O
, O O
and O O
appears O O
to O O
result O O
from O O
urokinase B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- O O
resistant O O
fibrinogen B B_GENE
cross O O
- O O
linking O O
. O O

Intensity O O
variations O O
from O O
the O O
variable O O
TR O O
were O O
removed O O
, O O
and O O
the O O
data O O
were O O
evaluated O O
for O O
correlation O O
with O O
the O O
lateralized O O
stimulus O O
. O O

Routine O O
imaging O O
modalities O O
revealed O O
a O O
total O O
of O O
79 O O
metastases O O
. O O

We O O
have O O
previously O O
reported O O
that O O
analgesic O O
doses O O
of O O
morphine O O
accelerate O O
mortality O O
of O O
rats O O
exposed O O
to O O
hemorrhage O O
( O O
Feuerstein O O
and O O
Siren O O
: O O
Circ O O
Shock O O
19 O O
: O O
293 O O
- O O
300 O O
, O O
1986 O O
) O O
. O O

We O O
describe O O
a O O
novel O O
stat B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
related I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
p93 B B_GENE
, O O
that O O
is O O
found O O
in O O
EGF B B_GENE
- O O
treated O O
A431 O O
cell O O
extracts O O
but O O
appears O O
to O O
be O O
absent O O
in O O
bovine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fibroblast I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
bFGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
IFN B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
tumor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
necrosis I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
TNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
and O O
untreated O O
cells O O
. O O

p185c B B_GENE
- O O
neu B B_GENE
+ O O
, O O
EGFr B B_GENE
+ I I_GENE
( O O
M1 B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
and O O
p185c B B_GENE
- O O
neu B B_GENE
- O O
kinase O O
inactive O O
, O O
EGFr B B_GENE
+ I I_GENE
( O O
NEN757 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
expressing O O
cells O O
undergo O O
different O O
mitotic O O
responses O O
to O O
EGF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

In O O
addition O O
, O O
Fc B B_GENE
epsilon I I_GENE
R1 I I_GENE
cross O O
- O O
linking O O
activates O O
PI B B_GENE
3 I I_GENE
- I I_GENE
kinase I I_GENE
. O O

Ribosome O O
association O O
of O O
GCN2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
translational O O
activator O O
of O O
the O O
GCN4 B B_GENE
gene I I_GENE
of O O
Saccharomyces O O
cerevisiae O O
. O O

Treatment O O
with O O
H7 O O
did O O
not O O
affect O O
IL B B_GENE
- I I_GENE
4R I I_GENE
- O O
mediated O O
immediate O O
signaling O O
events O O
such O O
as O O
tyrosine O O
phosphorylation O O
of O O
Jak1 B B_GENE
, O O
Jak3 B B_GENE
, O O
insulin B B_GENE
receptor I I_GENE
substrate I I_GENE
( I I_GENE
IRS I I_GENE
) I I_GENE
- I I_GENE
1 I I_GENE
and O O
IRS B B_GENE
- I I_GENE
2 I I_GENE
, O O
or O O
tyrosine O O
phosphorylation O O
and O O
DNA O O
binding O O
of O O
Stat6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

When O O
the O O
VBP B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
was O O
solely O O
expressed O O
, O O
it O O
located O O
to O O
the O O
cytoplasm O O
and O O
did O O
not O O
localize O O
to O O
the O O
nucleus O O
. O O

Consistent O O
with O O
other O O
experiments O O
with O O
these O O
compounds O O
, O O
cocaine O O
was O O
the O O
most O O
potent O O
of O O
the O O
group O O
. O O

The O O
significance O O
of O O
these O O
changes O O
in O O
relation O O
to O O
the O O
control O O
of O O
phosphorus O O
balance O O
in O O
ruminants O O
is O O
discussed O O
. O O

Transfection O O
assays O O
using O O
the O O
first O O
600 O O
bp O O
of O O
the O O
upstream O O
nucleotide O O
sequences O O
indicated O O
that O O
a O O
region O O
from O O
- O O
75 O O
to O O
- O O
120 O O
was O O
necessary O O
for O O
the O O
ALDH2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gene I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
expression O O
, O O
and O O
especially O O
NF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
Y I I_GENE/I_LOCATION
/ O O
CP1 B B_GENE
binding O O
site O O
from O O
- O O
92 O O
to O O
- O O
96 O O
( O O
CCAAT O O
box O O
) O O
is O O
important O O
in O O
the O O
expression O O
of O O
the O O
gene O O
. O O

This O O
distinct O O
biochemical O O
difference O O
between O O
STAT5A B B_GENE
and O O
STAT5B B B_GENE
was O O
confirmed O O
with O O
purified O O
activated O O
STAT5 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
recombinant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
results O O
show O O
that O O
in O O
uninfected O O
NIH O O
- O O
3T3 O O
cells O O
Avarol O O
( O O
i O O
) O O
causes O O
a O O
50 O O
% O O
reduction O O
of O O
the O O
growth O O
rate O O
only O O
at O O
the O O
high O O
concentration O O
of O O
29 O O
. O O
6 O O
microM O O
and O O
( O O
ii O O
) O O
is O O
accumulated O O
in O O
the O O
cytoplasm O O
close O O
to O O
the O O
nucleus O O
. O O

Blood B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coagulation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
X I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
activated O O
form O O
Factor B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Xa I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
play O O
an O O
essential O O
role O O
in O O
the O O
midphase O O
of O O
the O O
clotting O O
cascade O O
. O O

The O O
exon O O
sequences O O
determined O O
from O O
genomic O O
DNA O O
sequencing O O
showed O O
some O O
differences O O
when O O
compared O O
to O O
the O O
published O O
rat B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
GLUT2 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cDNA I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
three O O
more O O
slower O O
migrating O O
Stat5B B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bands O O
observed O O
in O O
response O O
to O O
GH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
contain O O
phosphorylated O O
tyrosyl O O
residues O O
. O O

The O O
maximum O O
levels O O
of O O
reporter O O
proteins O O
attained O O
in O O
transformed O O
cells O O
after O O
prolonged O O
induction O O
represented O O
from O O
1 O O
% O O
to O O
7 O O
% O O
of O O
total O O
cellular O O
protein O O
. O O

Specifically O O
, O O
we O O
demonstrate O O
that O O
this O O
25 O O
- O O
base O O
pair O O
region O O
mediates O O
the O O
up O O
- O O
regulatory O O
effect O O
of O O
TGF B B_GENE
- I I_GENE
beta I I_GENE
on O O
COL1A2 B B_GENE
promoter I I_GENE
activity O O
and O O
allows O O
antagonistic O O
activity O O
of O O
TNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
TGF B B_GENE
- I I_GENE
beta I I_GENE
effect O O
. O O

Sin4 B B_GENE
and O O
Srb10 B B_GENE/B_DISEASE
, O O
components O O
of O O
specific O O
RNA B B_GENE/B_BIO
polymerase I I_GENE/I_BIO
II I I_GENE/I_BIO
sub I I_GENE/I_BIO
- I I_GENE/I_BIO
complexes I I_GENE/I_BIO
that O O
are O O
required O O
for O O
Ssn6 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Tup1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
repression O O
activity O O
, O O
are O O
found O O
to O O
be O O
required O O
for O O
Sfl1 B B_GENE/B_BIO
repression O O
function O O
. O O

Translation O O
of O O
mok B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
tightly O O
regulated O O
by O O
Sok B B_GENE/B_BIO
RNA I I_GENE/I_BIO
, O O
and O O
Sok B B_GENE/B_BIO
RNA I I_GENE/I_BIO
thus O O
regulates O O
hok B B_SPECIES[BIO]/B_GENE
translation O O
indirectly O O
through O O
mok B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Depending O O
on O O
the O O
patient O O
' O O
s O O
body O O
position O O
telemetrically O O
measured O O
CSF O O
- O O
pressures O O
varied O O
between O O
- O O
20 O O
cmH2O O O
in O O
erect O O
and O O
15 O O
cmH2O O O
in O O
supine O O
position O O
. O O

One O O
- O O
hour O O
O3 O O
, O O
NO2 O O
, O O
and O O
SO2 O O
personal O O
exposures O O
were O O
measured O O
using O O
samplers O O
developed O O
in O O
our O O
laboratory O O
, O O
while O O
short O O
- O O
term O O
PM2 O O
. O O
5 O O
, O O
CO O O
, O O
and O O
VOCs O O
exposures O O
were O O
measured O O
using O O
currently O O
available O O
monitors O O
. O O

We O O
hypothesized O O
that O O
subjects O O
would O O
demonstrate O O
PKAR O O
during O O
both O O
hopping O O
and O O
stepping O O
, O O
adding O O
support O O
to O O
the O O
hypothesis O O
that O O
PKAR O O
is O O
a O O
centrally O O
mediated O O
adaptation O O
of O O
general O O
locomotor O O
trajectory O O
that O O
is O O
not O O
specific O O
to O O
the O O
form O O
of O O
locomotion O O
used O O
while O O
on O O
the O O
rotating O O
disk O O
. O O

In O O
this O O
study O O
, O O
transcriptional O O
fusions O O
were O O
constructed O O
between O O
the O O
xcpP B B_GENE/B_BACTERIUM[BIO]
and O O
xcpR B B_GENE
genes I I_GENE
and O O
the O O
lacZ B B_GENE/B_PERSON
reporter I I_GENE/I_PERSON
. O O

To O O
explore O O
the O O
mechanism O O
of O O
insulin B B_GENE
receptor I I_GENE
phosphorylation O O
we O O
have O O
used O O
NIH3T3 O O
cells O O
transfected O O
with O O
two O O
receptor O O
constructs O O
: O O
one O O
encoding O O
a O O
chimeric O O
receptor O O
composed O O
of O O
the O O
extracellular O O
domain O O
of O O
the O O
human B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
EGF I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
the O O
cytosolic O O
domain O O
of O O
the O O
human B B_GENE
insulin I I_GENE
receptor I I_GENE
beta I I_GENE
- I I_GENE
subunit I I_GENE
, O O
and O O
a O O
second O O
construct O O
encoding O O
a O O
kinase O O
- O O
defiecient O O
human B B_PROTEIN[GENE]
insulin I I_PROTEIN[GENE]
receptor I I_PROTEIN[GENE]
. O O

It O O
is O O
pathogenetically O O
proved O O
to O O
use O O
antithrombin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
III I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
concentrate O O
preparations O O
with O O
anti O O
- O O
and O O
dysaggregatory O O
properties O O
, O O
fibronectin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
preparations O O
, O O
trasylol O O
or O O
its O O
analogs O O
during O O
complex O O
preoperative O O
preparation O O
of O O
patients O O
. O O

Stimulation O O
of O O
the O O
endosteal O O
bone O O
formation O O
rate O O
was O O
mainly O O
impaired O O
in O O
D O O
- O O
depleted O O
rats O O
, O O
resulting O O
in O O
trabecular O O
bone O O
loss O O
, O O
which O O
, O O
in O O
- O O
D O O
mother O O
rats O O
, O O
was O O
associated O O
with O O
decreased O O
bone O O
ash O O
and O O
total O O
bone O O
calcium O O
. O O

Hematopoietic B B_GENE
progenitor I I_GENE
kinase I I_GENE
1 I I_GENE
( O O
HPK1 B B_GENE/B_LOCATION
) O O
is O O
a O O
member O O
of O O
the O O
mitogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MAP4K B B_GENE/B_LOCATION
) O O
family O O
and O O
an O O
upstream O O
activator O O
of O O
the O O
c B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
Jun I I_GENE/I_DISEASE
N I I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
terminal I I_GENE/I_DISEASE
kinase I I_GENE/I_DISEASE
( O O
JNK B B_GENE/B_ORGANIZATION
) O O
signaling O O
cascade O O
. O O

To O O
investigate O O
this O O
possibility O O
, O O
we O O
conducted O O
split O O
- O O
visual O O
- O O
field O O
studies O O
in O O
which O O
we O O
manipulated O O
stimulus O O
sets O O
, O O
recognition O O
task O O
, O O
and O O
exposure O O
duration O O
. O O

In O O
conclusion O O
, O O
ANH O O
had O O
no O O
negative O O
effects O O
on O O
the O O
endocrine O O
stress O O
response O O
during O O
orthopedic O O
surgery O O
under O O
epidural O O
anesthesia O O
. O O

Finally O O
, O O
the O O
conservation O O
of O O
the O O
two O O
residues O O
most O O
sensitive O O
to O O
mutations O O
( O O
Y949 O O
and O O
Y953 O O
) O O
in O O
TM11 O O
, O O
and O O
in O O
the O O
homologous O O
TM5 O O
, O O
of O O
all O O
mammalian B B_BIO/B_GENE
P I I_BIO/I_GENE
- I I_BIO/I_GENE
gps I I_BIO/I_GENE
and O O
also O O
in O O
other O O
ABC B B_BIO/B_GENE
transporters I I_BIO/I_GENE
, O O
suggests O O
that O O
these O O
residues O O
and O O
domains O O
may O O
play O O
an O O
important O O
role O O
in O O
structural O O
as O O
well O O
as O O
mechanistic O O
aspects O O
common O O
to O O
this O O
family O O
of O O
proteins O O
. O O

The O O
enigma O O
of O O
aging O O
bone O O
loss O O
. O O

Furthermore O O
, O O
we O O
show O O
that O O
Nck B B_GENE
- I I_GENE
2 I I_GENE
is O O
capable O O
of O O
recognizing O O
several O O
key O O
components O O
of O O
growth B B_GENE
factor I I_GENE
receptor I I_GENE
kinase I I_GENE
- O O
signaling O O
pathways O O
including O O
EGF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
PDGF B B_GENE
receptor I I_GENE
- I I_GENE
beta I I_GENE
, O O
and O O
IRS B B_GENE
- I I_GENE
1 I I_GENE
. O O

These O O
two O O
enhancer O O
elements O O
also O O
enhanced O O
transcription O O
when O O
fused O O
separately O O
to O O
the O O
basal O O
promoter O O
region O O
of O O
the O O
chicken B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
vimentin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

When O O
they O O
were O O
exposed O O
to O O
intermittent O O
schedules O O
of O O
punishment O O
( O O
fixed O O
- O O
interval O O
[ O O
FI O O
] O O
120 O O
s O O
or O O
FI O O
300 O O
s O O
) O O
, O O
SIB O O
for O O
all O O
but O O
1 O O
of O O
the O O
participants O O
increased O O
to O O
levels O O
similar O O
to O O
those O O
observed O O
during O O
baseline O O
. O O

Deep O O
bite O O
CL O O
II O O
Div O O
. O O

Patients O O
with O O
binocular O O
pregeniculate O O
visual O O
loss O O
, O O
patients O O
with O O
balanced O O
binocular O O
pregeniculate O O
loss O O
without O O
RAPD O O
, O O
and O O
patients O O
with O O
monocular O O
pregeniculate O O
visual O O
loss O O
had O O
significantly O O
larger O O
pupils O O
than O O
age O O
- O O
matched O O
controls O O
. O O

Protein O O
sequencing O O
, O O
electrophoretic O O
mobility O O
shift O O
assay O O
, O O
and O O
immunoblot O O
analyses O O
identify O O
p54 B B_GENE
and O O
p47 B B_GENE
/ I I_GENE
48 I I_GENE
as O O
members O O
of O O
the O O
hepatocyte B B_GENE/B_DISEASE
nuclear I I_GENE/I_DISEASE
factor I I_GENE/I_DISEASE
3 I I_GENE/I_DISEASE
( O O
HNF3 B B_GENE/B_LOCATION
[ O O
forkhead B B_PROTEIN[GENE]/B_BIO
] O O
) O O
family O O
of O O
transcription O O
factors O O
. O O

p54 B B_GENE/B_DISEASE
belongs O O
to O O
the O O
subfamily O O
of O O
HNF3 B B_GENE/B_BIO
beta I I_GENE/I_BIO
proteins I I_GENE/I_BIO
, O O
while O O
p47 B B_GENE/B_TIME[MEASURE]
/ I I_GENE/I_TIME[MEASURE]
48 I I_GENE/I_TIME[MEASURE]
binding O O
activity O O
includes O O
HNF3 B B_GENE/B_PERSON
gamma I I_GENE/I_PERSON
. O O

In O O
this O O
cross O O
- O O
over O O
controlled O O
study O O
, O O
five O O
male O O
volunteers O O
donated O O
one O O
unit O O
of O O
red O O
cells O O
by O O
MCS O O
and O O
one O O
unit O O
of O O
whole O O
blood O O
by O O
the O O
conventional O O
manual O O
method O O
, O O
3 O O
months O O
apart O O
. O O

Promoter O O
activity O O
was O O
assayed O O
by O O
transient O O
transfection O O
of O O
luciferase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
nested O O
deletions O O
of O O
the O O
upstream O O
sequence O O
in O O
the O O
human O O
RPE O O
cell O O
lines O O
ARPE19 O O
and O O
D407 O O
, O O
as O O
well O O
as O O
in O O
the O O
SK O O
- O O
Mel O O
- O O
28 O O
and O O
HeLa O O
cell O O
lines O O
. O O

This O O
model O O
system O O
exploits O O
the O O
polyomavirus O O
late O O
transcription O O
termination O O
and O O
polyadenylation O O
signals O O
, O O
which O O
are O O
sufficiently O O
weak O O
to O O
allow O O
the O O
production O O
of O O
many O O
multigenome O O
- O O
length O O
primary O O
transcripts O O
with O O
repeating O O
introns O O
, O O
exons O O
, O O
and O O
poly O O
( O O
A O O
) O O
sites O O
. O O

Magnification O O
- O O
corrected O O
planimetry O O
of O O
the O O
parapapillary O O
region O O
was O O
performed O O
according O O
to O O
Littmann O O
' O O
s O O
method O O
in O O
312 O O
unselected O O
eyes O O
with O O
chronic O O
primary O O
open O O
- O O
angle O O
glaucoma O O
and O O
in O O
125 O O
normal O O
eyes O O
of O O
an O O
age O O
- O O
and O O
refraction O O
- O O
matched O O
control O O
group O O
using O O
optic O O
disk O O
photographs O O
. O O

Although O O
the O O
elevated O O
signalling O O
is O O
eliminated O O
by O O
deletion O O
of O O
Ste20p B B_GENE/B_BIO
( O O
or O O
components O O
downstream O O
of O O
Ste20p B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
the O O
growth O O
and O O
morphological O O
abnormalities O O
of O O
cells O O
lacking O O
Akr1p B B_GENE/B_SPECIES[BIO]
are O O
not O O
rescued O O
by O O
deletion O O
of O O
any O O
of O O
the O O
known O O
pheromone O O
response O O
pathway O O
components O O
. O O

Southern O O
hybridization O O
of O O
genomic O O
DNA O O
from O O
WT O O
and O O
Lp B B_PROTEIN[GENE]/B_LOCATION
/ O O
Lp B B_PROTEIN[GENE]/B_LOCATION
embryos O O
failed O O
to O O
identify O O
specific O O
rearrangements O O
at O O
or O O
near O O
the O O
Nhlh1 B B_GENE/B_LOCATION
locus I I_GENE/I_LOCATION
, O O
and O O
Northern O O
RNA O O
blotting O O
and O O
RT O O
- O O
PCR O O
evaluation O O
of O O
Nhlh1 B B_GENE
mRNA I I_GENE
expression O O
indicated O O
that O O
both O O
the O O
levels O O
and O O
types O O
of O O
Nhlh1 B B_GENE
mRNAs I I_GENE
produced O O
in O O
WT O O
and O O
Lp B B_LOCATION/B_PROTEIN[GENE]
/ O O
Lp B B_PROTEIN[GENE]/B_LOCATION
embryos O O
were O O
indistinguishable O O
. O O

In O O
addition O O
, O O
mrp17 B B_GENE/B_PERSON
- I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
, O O
in O O
combination O O
with O O
some O O
mutations O O
affecting O O
another O O
mitochondrial O O
ribosomal O O
protein O O
, O O
caused O O
a O O
synthetic O O
defective O O
phenotype O O
. O O

Expression O O
, O O
characterization O O
, O O
and O O
genomic O O
structure O O
of O O
carp B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
JAK1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Significantly O O
, O O
the O O
murine B B_GENE/B_BIO
P I I_GENE/I_BIO
- I I_GENE/I_BIO
selectin I I_GENE/I_BIO
gene I I_GENE/I_BIO
had O O
several O O
features O O
not O O
found O O
in O O
the O O
human O O
gene O O
. O O

Fluorescent O O
in O O
situ O O
hybridization O O
( O O
FISH O O
) O O
analysis O O
showed O O
that O O
the O O
novel O O
regions O O
involved O O
in O O
the O O
NFKB2 B B_GENE
rearrangement O O
originated O O
from O O
chromosome O O
7q34 O O
, O O
thus O O
implying O O
the O O
occurrence O O
of O O
a O O
t O O
( O O
7 O O
; O O
10 O O
) O O
( O O
q34 O O
; O O
q24 O O
) O O
reciprocal O O
chromosomal O O
translocation O O
. O O

Transient O O
- O O
expression O O
assay O O
analysis O O
of O O
subclones O O
of O O
pPstI O O
- O O
G O O
localized O O
the O O
trans O O
- O O
active O O
factor O O
to O O
a O O
3 B B_GENE
. I I_GENE
0 I I_GENE
- I I_GENE
kilobase I I_GENE
XbaI I I_GENE
fragment I I_GENE
. O O

This O O
is O O
the O O
first O O
report O O
that O O
the O O
PH B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
an O O
IRS B B_GENE/B_DISEASE
protein I I_GENE/I_DISEASE
can O O
function O O
in O O
a O O
dominant O O
negative O O
manner O O
to O O
inhibit O O
insulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
. O O

A O O
29 O O
. O O
425 O O
kb O O
segment O O
on O O
the O O
left O O
arm O O
of O O
yeast O O
chromosome O O
XV O O
contains O O
more O O
than O O
twice O O
as O O
many O O
unknown O O
as O O
known O O
open O O
reading O O
frames O O
. O O

The O O
first O O
270 O O
bp O O
of O O
the O O
promoter O O
region O O
were O O
sequenced O O
and O O
found O O
to O O
contain O O
a O O
CATAA O O
box O O
rather O O
than O O
a O O
TATAA O O
box O O
and O O
several O O
DNA O O
motifs O O
found O O
in O O
activation O O
genes O O
. O O

C O O
. O O
glabrata O O
cells O O
containing O O
the O O
CBF1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
under O O
the O O
influence O O
of O O
a O O
shutdown O O
promoter O O
( O O
tetO O O
- O O
ScHOP O O
) O O
arrested O O
their O O
growth O O
after O O
5 O O
h O O
of O O
cultivation O O
in O O
the O O
presence O O
of O O
the O O
reactive O O
drug O O
doxycycline O O
. O O

SF1 B B_GENE/B_LOCATION
/ O O
mBBP B B_MEASURE/B_PROTEIN[GENE]
utilizes O O
a O O
" B B_GENE/B_MEASURE
maxi I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
K I I_GENE/I_MEASURE
homology I I_GENE/I_MEASURE
" I I_GENE/I_MEASURE
( O O
maxi B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
KH I I_PROTEIN[GENE]/I_LOCATION
) O O
domain O O
for O O
recognition O O
of O O
the O O
single O O
- O O
stranded O O
BPS O O
and O O
requires O O
a O O
cooperative O O
interaction O O
with O O
splicing O O
factor O O
U2AF65 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bound O O
to O O
an O O
adjacent O O
polypyrimidine O O
tract O O
( O O
PPT O O
) O O
for O O
high O O
- O O
affinity O O
binding O O
. O O

Validity O O
of O O
the O O
short O O
- O O
form O O
QIF O O
was O O
assessed O O
by O O
correlation O O
with O O
motor O O
scores O O
and O O
using O O
analysis O O
of O O
variance O O
by O O
motor O O
levels O O
and O O
motor O O
score O O
groupings O O
. O O

Juvenile O O
angiofibromas O O
. O O

Comment O O
on O O
" O O
Critical O O
behavior O O
of O O
a O O
binary O O
mixture O O
of O O
protein O O
and O O
salt O O
water O O
" O O

In O O
addition O O
, O O
there O O
was O O
an O O
increase O O
in O O
the O O
amount O O
of O O
p120 B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
Ras I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
specific O O
GTPase B B_GENE
- I I_GENE
activating I I_GENE
protein I I_GENE
( O O
GAP B B_LOCATION/B_GENE
) O O
and O O
GAP B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- O O
associated O O
p190 O O
. O O

Pregnancy O O
was O O
ensued O O
in O O
4 O O
cases O O
in O O
group O O
I O O
. O O

The O O
1 O O
. O O
3 O O
- O O
kb O O
DNA O O
, O O
when O O
placed O O
upstream O O
of O O
the O O
chloramphenicol B B_GENE/B_BIO
acetyltransferase I I_GENE/I_BIO
gene I I_GENE/I_BIO
, O O
was O O
shown O O
to O O
be O O
functionally O O
active O O
. O O

Controversy O O
exists O O
regarding O O
both O O
the O O
natural O O
life O O
cycle O O
for O O
this O O
parasite O O
as O O
well O O
as O O
the O O
species O O
identity O O
of O O
opossum O O
Sarcocystis O O
. O O

The O O
mean O O
was O O
66 O O
cells O O
/ O O
mm2 O O
in O O
the O O
laser O O
group O O
and O O
63 O O
. O O
7 O O
cells O O
/ O O
mm2 O O
in O O
the O O
control O O
group O O
. O O

Prazosin O O
in O O
the O O
treatment O O
of O O
high O O
blood O O
pressure O O

The O O
5 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
HT3 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
antagonist O O
ondansetron O O
reduced O O
alcohol O O
intake O O
in O O
both O O
the O O
medium O O
and O O
high O O
alcohol O O
preferring O O
rats O O
at O O
doses O O
between O O
0 O O
. O O
01 O O
and O O
0 O O
. O O
16 O O
mg O O
/ O O
kg O O
. O O

Oral O O
hypoglycemic O O
agents O O

1 O O
. O O

In O O
this O O
system O O
, O O
enhancers O O
act O O
primarily O O
to O O
increase O O
the O O
probability O O
of O O
rapid O O
and O O
efficient O O
transcription O O
complex O O
formation O O
and O O
initiation O O
. O O

The O O
pepI B B_GENE
gene I I_GENE
was O O
overexpressed O O
in O O
Escherichia O O
coli O O
. O O

The O O
level O O
of O O
transcription O O
generated O O
by O O
all O O
of O O
these O O
activators O O
is O O
greater O O
than O O
the O O
sum O O
of O O
the O O
levels O O
generated O O
by O O
individual O O
factors O O
, O O
a O O
phenomenon O O
designated O O
transcriptional O O
synergy O O
. O O

Conservation O O
of O O
this O O
zinc O O
finger O O
motif O O
from O O
yeast O O
to O O
mouse O O
and O O
human O O
implies O O
functional O O
importance O O
. O O

This O O
nuclear O O
/ O O
organellar O O
gene O O
transfer O O
event O O
is O O
strikingly O O
similar O O
to O O
the O O
experimentally O O
accessible O O
process O O
of O O
nuclear O O
integration O O
of O O
introduced O O
heterologous O O
DNA O O
. O O

RESULTS O O
: O O
In O O
the O O
test O O
data O O
set O O
, O O
the O O
single O O
- O O
sample O O
model O O
was O O
confirmed O O
to O O
give O O
excellent O O
estimation O O
of O O
the O O
AUC O O
: O O
AUC O O
( O O
mg O O
/ O O
ml O O
x O O
min O O
) O O
= O O
0 O O
. O O
93 O O
x O O
C3h O O
+ O O
0 O O
. O O
47 O O
( O O
MPE O O
% O O
= O O
4 O O
. O O
4 O O
% O O
, O O
RMSE O O
% O O
= O O
8 O O
. O O
9 O O
% O O
) O O
. O O

Comparison O O
between O O
the O O
Ricketts O O
and O O
Bimler O O
therapeutic O O
technics O O
in O O
the O O
treatment O O
of O O
cases O O
of O O
class O O
II O O
, O O
division O O
I O O
mmalocclusion O O

We O O
conclude O O
that O O
exercise O O
- O O
induced O O
ST O O
- O O
segment O O
elevation O O
in O O
patients O O
without O O
a O O
history O O
of O O
myocardial O O
infarction O O
or O O
left O O
ventricular O O
aneurysm O O
is O O
caused O O
by O O
coronary O O
spasm O O
of O O
a O O
major O O
coronary O O
vessel O O
. O O

Xnr3 B B_GENE
is O O
transcriptionally O O
activated O O
by O O
wnt B B_GENE
signaling O O
during O O
gastrulation O O
in O O
the O O
Xenopus O O
embryo O O
. O O

For O O
economical O O
reasons O O
, O O
we O O
could O O
not O O
send O O
a O O
questionnaire O O
to O O
all O O
the O O
35 O O
, O O
779 O O
individuals O O
, O O
but O O
based O O
the O O
investigation O O
on O O
a O O
SRS O O
of O O
4 O O
, O O
000 O O
men O O
, O O
post O O
- O O
stratified O O
in O O
a O O
high O O
- O O
risk O O
and O O
a O O
low O O
- O O
risk O O
group O O
. O O

Effect O O
of O O
choline O O
magnesium O O
trisalicylate O O
on O O
prostacyclin O O
production O O
by O O
isolated O O
vascular O O
tissue O O
of O O
the O O
rat O O
. O O

The O O
sequences O O
of O O
two O O
previously O O
known O O
tail B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
R B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
S B B_PROTEIN[GENE]/B_DISEASE
, O O
of O O
the O O
temperate O O
bacteriophage O O
P2 O O
and O O
the O O
sequence O O
of O O
an O O
additional O O
open O O
reading O O
frame O O
( O O
orf O O
- O O
30 O O
) O O
located O O
between O O
S B B_OTHER/B_PROTEIN[GENE]
and O O
V B B_PROTEIN[GENE]/B_LOCATION
, O O
were O O
determined O O
. O O

The O O
high O O
prevalence O O
of O O
atrial O O
septal O O
defect O O
in O O
tetralogy O O
of O O
Fallot O O
is O O
cited O O
as O O
a O O
possible O O
analogy O O
because O O
right O O
ventricular O O
pressure O O
is O O
high O O
and O O
right O O
ventricular O O
compliance O O
is O O
low O O
from O O
birth O O
. O O

The O O
stress O O
/ O O
BHV O O
- O O
1 O O
model O O
resulted O O
in O O
a O O
mild O O
respiratory O O
infection O O
in O O
all O O
calves O O
with O O
no O O
difference O O
observed O O
between O O
treatment O O
groups O O
. O O

Solution O O
of O O
the O O
Boltzmann O O
equation O O
in O O
a O O
random O O
magnetic O O
field O O
. O O

RESULTS O O
: O O
At O O
short O O
dwell O O
times O O
, O O
uncorrected O O
( O O
whole O O
plasma O O
) O O
D O O
/ O O
P O O
and O O
Cp O O
of O O
urea O O
values O O
were O O
higher O O
than O O
the O O
corrected O O
( O O
plasma O O
water O O
) O O
values O O
by O O
5 O O
. O O
7 O O
% O O
- O O
5 O O
. O O
9 O O
% O O
. O O

The O O
recovery O O
of O O
xanthomegnin O O
added O O
to O O
corn O O
samples O O
at O O
levels O O
of O O
0 O O
. O O
75 O O
- O O
- O O
9 O O
. O O
6 O O
mg O O
/ O O
kg O O
averaged O O
41 O O
% O O
with O O
a O O
coefficient O O
of O O
variation O O
of O O
25 O O
% O O
. O O

The O O
extraordinary O O
high O O
substrate O O
specificity O O
of O O
rPulA B B_PROTEIN[GENE]/B_SPECIES[BIO]
together O O
with O O
its O O
thermal O O
stability O O
makes O O
this O O
enzyme O O
a O O
good O O
candidate O O
for O O
biotechnological O O
applications O O
in O O
the O O
starch O O
- O O
processing O O
industry O O
. O O

A O O
relationship O O
between O O
the O O
immunological O O
changes O O
and O O
the O O
disease O O
stage O O
was O O
discovered O O
: O O
the O O
index O O
of O O
the O O
3H O O
- O O
thymidine O O
incorporation O O
was O O
found O O
to O O
be O O
67 O O
. O O
9 O O
at O O
the O O
stage O O
of O O
disease O O
exacerbation O O
, O O
and O O
208 O O
. O O
8 O O
at O O
the O O
stage O O
of O O
remission O O
; O O
the O O
complement O O
titre O O
reached O O
, O O
respectively O O
, O O
46 O O
. O O
64 O O
+ O O
/ O O
- O O
5 O O
. O O
28 O O
and O O
112 O O
. O O
0 O O
+ O O
/ O O
- O O
6 O O
. O O
0 O O
units O O
per O O
ml O O
. O O

Sodium O O
dodecylsulfate O O
polyacrylamide O O
gel O O
electrophoresis O O
( O O
SDS O O
- O O
PAGE O O
) O O
showed O O
two O O
bands O O
of O O
about O O
the O O
same O O
intensity O O
with O O
apparent O O
molecular O O
masses O O
of O O
24 O O
. O O
5 O O
and O O
22 O O
. O O
5 O O
kDa O O
. O O

Consistent O O
with O O
an O O
effect O O
on O O
transcription O O
, O O
p21 B B_GENE
was O O
localized O O
in O O
nuclei O O
of O O
transfected O O
cells O O
. O O

Analysis O O
of O O
pseudo B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
VH I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gene I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
segment I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
recombination I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
products I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
reveals O O
no O O
bias O O
in O O
D B B_MEASURE/B_GENE
gene I I_MEASURE/I_GENE
segment I I_MEASURE/I_GENE
reading O O
frame O O
utilization O O
. O O

Plasma B B_GENE/B_MEASURE
prolactin I B_GENE/I_MEASURE
concentrations O O
during O O
incubation O O
, O O
25 O O
. O O
8 O O
+ O O
/ O O
- O O
2 O O
. O O
3 O O
ng O O
/ O O
ml O O
, O O
decreased O O
to O O
baseline O O
levels O O
, O O
10 O O
. O O
8 O O
+ O O
/ O O
- O O
1 O O
. O O
9 O O
ng O O
/ O O
ml O O
, O O
within O O
24 O O
hr O O
after O O
nestbox O O
removal O O
. O O

After O O
30 O O
weeks O O
of O O
amifostine O O
therapy O O
, O O
the O O
morphology O O
of O O
the O O
MDS O O
switched O O
to O O
a O O
chronic O O
myelomonocytic O O
leukemia O O
( O O
CMML O O
) O O
- O O
like O O
appearance O O
, O O
with O O
continuously O O
increasing O O
leukocytes O O
, O O
so O O
that O O
we O O
discontinued O O
amifostine O O
therapy O O
for O O
1 O O
month O O
to O O
exclude O O
a O O
possible O O
side O O
effect O O
of O O
amifostine O O
. O O

Heart O O
disease O O
. O O

A O O
new O O
B O O
- O O
cell O O
- O O
specific O O
enhancer O O
element O O
has O O
been O O
identified O O
3 O O
' O O
of O O
E4 B B_GENE/B_MEASURE
and O O
the O O
octamerlike O O
motifs O O
in O O
the O O
human B B_GENE/B_BIO
immunoglobulin I I_GENE/I_BIO
heavy I I_GENE/I_BIO
- I I_GENE/I_BIO
chain I I_GENE/I_BIO
gene I I_GENE/I_BIO
enhancer I I_GENE/I_BIO
. O O

CONCLUSIONS O O
: O O
This O O
initial O O
experience O O
indicates O O
that O O
there O O
is O O
short O O
- O O
to O O
middle O O
- O O
term O O
efficiency O O
and O O
safety O O
when O O
using O O
GKS O O
to O O
treat O O
MTLE O O
. O O

Two O O
cases O O
of O O
Paraquat O O
poisoning O O
of O O
anticonservative O O
origin O O
are O O
described O O
. O O

Genetic O O
mutation O O
or O O
loss O O
of O O
activin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
transforming B B_GENE/B_LOCATION
growth I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
beta I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
TGFbeta I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
function O O
has O O
been O O
shown O O
in O O
human O O
lymphoid O O
, O O
breast O O
, O O
and O O
colorectal O O
tumors O O
as O O
well O O
as O O
Hep2B O O
and O O
Mv1Lu O O
cell O O
lines O O
. O O

A O O
poly O O
( O O
ortho O O
ester O O
) O O
designed O O
for O O
combined O O
ocular O O
delivery O O
of O O
dexamethasone O O
sodium O O
phosphate O O
and O O
5 O O
- O O
fluorouracil O O
: O O
subconjunctival O O
tolerance O O
and O O
in O O
vitro O O
release O O
. O O

We O O
now O O
describe O O
a O O
HepG2 B B_GENE/B_LOCATION
cell I I_GENE/I_LOCATION
casein I I_GENE/I_LOCATION
kinase I I_GENE/I_LOCATION
II I I_GENE/I_LOCATION
beta I I_GENE/I_LOCATION
subunit I I_GENE/I_LOCATION
cDNA I I_GENE/I_LOCATION
of O O
2 O O
. O O
57 O O
kb O O
containing O O
96 O O
bases O O
of O O
5 O O
' O O
untranslated O O
sequence O O
, O O
645 O O
bases O O
of O O
open O O
reading O O
frame O O
, O O
and O O
1832 O O
bases O O
of O O
3 O O
' O O
untranslated O O
sequence O O
with O O
two O O
polyadenylation O O
consensus O O
signal O O
sequences O O
and O O
two O O
poly O O
( O O
A O O
) O O
stretches O O
. O O

Diagnostic O O
importance O O
of O O
determining O O
leucine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
aminotransferase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
in O O
acute O O
pancreatitis O O

Therapeutic O O
iodine O O
125 O O
for O O
hyperthyroidism O O
: O O
evidence O O
for O O
a O O
special O O
radiobiological O O
effect O O
on O O
the O O
follicular O O
cell O O
. O O

Maintenance O O
metabolizable O O
- O O
energy O O
( O O
ME O O
) O O
requirement O O
averaged O O
31 O O
. O O
0 O O
kcal O O
/ O O
kg O O
body O O
wt O O
. O O

This O O
finding O O
is O O
of O O
importance O O
because O O
it O O
completes O O
an O O
explanation O O
for O O
central O O
near O O
- O O
location O O
errors O O
in O O
the O O
partial O O
- O O
report O O
bar O O
- O O
probe O O
task O O
. O O

Nedocromil O O
sodium O O
shifted O O
the O O
severity O O
of O O
the O O
early O O
allergic O O
reaction O O
( O O
EAR O O
) O O
from O O
mean O O
- O O
34 O O
. O O
8 O O
% O O
to O O
- O O
6 O O
. O O
9 O O
% O O
and O O
inhibited O O
the O O
later O O
allergic O O
reaction O O
( O O
LAR O O
) O O
from O O
- O O
30 O O
. O O
5 O O
% O O
to O O
+ O O
0 O O
. O O
4 O O
% O O
( O O
p O O
less O O
than O O
0 O O
. O O
005 O O
) O O
. O O

The O O
Mer1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
the O O
KH O O
motif O O
found O O
in O O
some O O
RNA O O
- O O
binding O O
proteins O O
, O O
and O O
RNA O O
gel O O
mobility O O
shift O O
assays O O
demonstrate O O
that O O
Mer1 B B_GENE/B_BIO
binds O O
specifically O O
to O O
MER2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Results O O
obtained O O
from O O
the O O
tritium O O
test O O
and O O
direct O O
chemical O O
analysis O O
were O O
compared O O
. O O

We O O
found O O
that O O
in O O
anesthetized O O
, O O
paralyzed O O
cats O O
, O O
the O O
visual O O
evoked O O
potential O O
( O O
VEP O O
) O O
was O O
dependent O O
only O O
on O O
magnitude O O
of O O
delta O O
C O O
at O O
each O O
pattern O O
transition O O
, O O
and O O
was O O
independent O O
of O O
the O O
starting O O
or O O
ending O O
contrast O O
level O O
. O O

Experiment O O
B O O
: O O
Clinical O O
, O O
biochemical O O
, O O
and O O
histological O O
variables O O
were O O
measured O O
over O O
a O O
12 O O
- O O
day O O
period O O
after O O
the O O
zymosan O O
had O O
been O O
given O O
. O O

Direct O O
saturation O O
analysis O O

From O O
this O O
asymmetry O O
, O O
we O O
suggested O O
previously O O
that O O
GCN4 B B_GENE
interacts O O
with O O
nonequivalent O O
and O O
possibly O O
overlapping O O
half O O
- O O
sites O O
( O O
ATGAC O O
and O O
ATGAG O O
) O O
that O O
have O O
different O O
affinities O O
. O O

Furthermore O O
the O O
aldosterone O O
stimulating O O
effect O O
of O O
low O O
sodium O O
diet O O
( O O
17 O O
children O O
) O O
, O O
severe O O
and O O
prolonged O O
vomiting O O
( O O
19 O O
children O O
) O O
and O O
synthetic O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
10 O O
children O O
) O O
has O O
been O O
studied O O
by O O
our O O
modified O O
method O O
. O O

A O O
case O O
control O O
study O O
( O O
1 O O
: O O
2 O O
) O O
of O O
182 O O
pairs O O
of O O
Hepatitis O O
A O O
was O O
carried O O
out O O
in O O
Weng O O
- O O
ling O O
Zhe O O
- O O
jiang O O
during O O
April O O
1988 O O
. O O

Although O O
cDNA O O
encoding O O
a O O
human B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
phagocyte I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
formyl I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
peptide I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
reported O O
recently O O
( O O
Boulay O O
, O O
F O O
. O O
, O O
Tardif O O
, O O
M O O
. O O
, O O
Brouchon O O
, O O
L O O
. O O
, O O
and O O
Vignais O O
, O O
P O O
. O O

In O O
NIH O O
3T3 O O
fibroblasts O O
the O O
high O O
affinity O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2R I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bearing O O
a O O
deletion O O
of O O
a O O
region O O
rich O O
in O O
acidic O O
amino O O
acids O O
( O O
the O O
" O O
acidic O O
" O O
region O O
) O O
in O O
the O O
IL B B_GENE
- I I_GENE
2R I I_GENE
beta I I_GENE
- I I_GENE
chain I I_GENE
failed O O
to O O
induce O O
the O O
tyrosine O O
phosphorylation O O
of O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
well O O
as O O
the O O
expression O O
of O O
the O O
all O O
three O O
nuclear O O
proto O O
- O O
oncogenes O O
. O O

A O O
small O O
molecule O O
ILK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
suppresses O O
the O O
phosphorylation O O
of O O
PKB B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
Ser O O
- O O
473 O O
but O O
not O O
the O O
Thr O O
- O O
308 O O
site O O
in O O
the O O
PTEN B B_GENE/B_DISEASE
mutant O O
cells O O
. O O

The O O
avian O O
carcinoma O O
virus O O
MH2 O O
contains O O
a O O
hybrid O O
gene O O
delta B B_PROTEIN[GENE]/B_VIRUS[BIO]
gag I I_PROTEIN[GENE]/I_VIRUS[BIO]
- O O
mht B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
a O O
contiguous O O
open O O
reading O O
frame O O
of O O
2682 O O
base O O
pairs O O
as O O
well O O
as O O
v B B_SPECIES[BIO]/B_GENE
- I I_SPECIES[BIO]/I_GENE
myc I I_SPECIES[BIO]/I_GENE
and O O
avian O O
helper O O
virus O O
- O O
related O O
sequences O O
. O O
delta B B_GENE/B_VIRUS[BIO]
gag I I_GENE/I_VIRUS[BIO]
is O O
a O O
partial O O
retroviral B B_GENE
core I I_GENE
protein I I_GENE
gene I I_GENE
while O O
v B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mht I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
v B B_GENE
- I I_GENE
myc I I_GENE
are O O
cell O O
- O O
drived O O
sequences O O
. O O

The O O
results O O
in O O
the O O
untreated O O
patients O O
demonstrate O O
the O O
primary O O
importance O O
of O O
bulk O O
reduction O O
at O O
initial O O
laparotomy O O
. O O

These O O
findings O O
also O O
demonstrate O O
that O O
unless O O
excluded O O
by O O
other O O
factors O O
, O O
the O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
likely O O
to O O
be O O
located O O
along O O
the O O
length O O
of O O
nascent O O
transcripts O O
. O O

We O O
have O O
now O O
completed O O
the O O
primary O O
structure O O
of O O
fibrillin B B_GENE
, O O
elucidated O O
the O O
exon O O
/ O O
intron O O
organization O O
of O O
the O O
gene O O
and O O
derived O O
a O O
physical O O
map O O
of O O
the O O
genetic O O
locus O O
. O O

The O O
BCL B B_GENE/B_SPECIES[BIO]
- I B_GENE/I_SPECIES[BIO]
6 I B_GENE/I_SPECIES[BIO]
POZ O O
domain O O
and O O
other O O
POZ O O
domains O O
interact O O
with O O
the O O
co O O
- O O
repressors O O
N B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CoR I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
SMRT B B_GENE/B_LOCATION
. O O

Cytokine O O
inducibility O O
of O O
VCAM1 B B_GENE/B_DISEASE
in O O
endothelial O O
cells O O
utilizes O O
the O O
interaction O O
of O O
heterodimeric O O
p50 B B_GENE
/ O O
p65 B B_GENE/B_MEASURE
proteins O O
with O O
IRF B B_GENE
- I I_GENE
1 I I_GENE
. O O

In O O
particular O O
, O O
MF O O
males O O
receiving O O
either O O
a O O
5 O O
. O O
0 O O
- O O
mg O O
/ O O
kg O O
CDP O O
dose O O
or O O
a O O
3 O O
. O O
0 O O
- O O
mg O O
/ O O
kg O O
RO O O
dose O O
explored O O
the O O
object O O
more O O
often O O
than O O
MM O O
males O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

To O O
gain O O
additional O O
insights O O
into O O
this O O
novel O O
apoptotic O O
checkpoint O O
, O O
we O O
have O O
now O O
characterized O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
survivin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Both O O
proteins O O
share O O
sequence O O
similarity O O
with O O
the O O
myelin B B_GENE
- I I_GENE
associated I I_GENE
glycoprotein I I_GENE
, O O
an O O
adhesion O O
molecule O O
of O O
oligodendrocytes O O
and O O
Schwann O O
cells O O
that O O
has O O
been O O
implicated O O
in O O
the O O
process O O
of O O
myelination O O
, O O
raising O O
the O O
important O O
question O O
of O O
whether O O
myelin B B_GENE/B_BIO
- I I_GENE/I_BIO
associated I I_GENE/I_BIO
glycoprotein I I_GENE/I_BIO
is O O
also O O
a O O
sialic B B_PROTEIN[GENE]/B_PERSON
acid I I_PROTEIN[GENE]/I_PERSON
- I I_PROTEIN[GENE]/I_PERSON
binding I I_PROTEIN[GENE]/I_PERSON
protein I I_PROTEIN[GENE]/I_PERSON
. O O

Localized O O
Bicaudal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O O
a O O
protein O O
containing O O
a O O
KH O O
domain O O
, O O
the O O
RNA O O
binding O O
motif O O
of O O
FMR1 B B_GENE
. O O

Indigenous O O
microbial O O
flora O O
and O O
the O O
large O O
intestine O O
in O O
tadpoles O O
. O O

Copyright O O
1998 O O
The O O
Association O O
for O O
the O O
Study O O
of O O
Animal O O
Behaviour O O
. O O

In O O
contrast O O
to O O
the O O
restricted O O
tissue O O
expression O O
of O O
gonadotropin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
TSH B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
gonads O O
and O O
thyroid O O
, O O
respectively O O
, O O
LGR4 B B_GENE
is O O
expressed O O
in O O
diverse O O
tissues O O
including O O
ovary O O
, O O
testis O O
, O O
adrenal O O
, O O
placenta O O
, O O
thymus O O
, O O
spinal O O
cord O O
, O O
and O O
thyroid O O
, O O
whereas O O
LGR5 B B_GENE/B_MEASURE
is O O
found O O
in O O
muscle O O
, O O
placenta O O
, O O
spinal O O
cord O O
, O O
and O O
brain O O
. O O

Not O O
only O O
will O O
it O O
substantially O O
reduce O O
incident O O
cases O O
of O O
hepatitis O O
B O O
for O O
the O O
next O O
decade O O
, O O
it O O
will O O
also O O
provide O O
a O O
framework O O
for O O
the O O
successful O O
introduction O O
of O O
future O O
adolescent O O
vaccine O O
initiatives O O
in O O
Australia O O
. O O

A O O
new O O
technique O O
for O O
the O O
identification O O
of O O
phases O O
contained O O
within O O
a O O
polymer O O
blend O O
is O O
described O O
in O O
this O O
paper O O
. O O

Their O O
central O O
projections O O
were O O
indistinguishable O O
from O O
those O O
of O O
control O O
axons O O
in O O
all O O
four O O
trigeminal O O
subnuclei O O
. O O

The O O
JNK B B_GENE/B_DISEASE
/ O O
SAPK B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator O O
mixed B B_GENE/B_LOCATION
lineage I I_GENE/I_LOCATION
kinase I I_GENE/I_LOCATION
3 I I_GENE/I_LOCATION
( O O
MLK3 B B_GENE
) O O
transforms O O
NIH O O
3T3 O O
cells O O
in O O
a O O
MEK B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O O
fashion O O
. O O

The O O
decision O O
support O O
system O O
uses O O
the O O
network O O
at O O
its O O
core O O
and O O
helps O O
not O O
only O O
in O O
reaching O O
a O O
diagnosis O O
but O O
also O O
in O O
finding O O
the O O
optimal O O
way O O
to O O
reach O O
that O O
diagnosis O O
. O O

In O O
contrast O O
to O O
the O O
effect O O
on O O
DNA O O
replication O O
, O O
the O O
L13V O O
substitution O O
in O O
large B B_GENE/B_BIO
T I I_GENE/I_BIO
antigen I I_GENE/I_BIO
did O O
not O O
prevent O O
complex O O
formation O O
with O O
Hsc70 B B_GENE
and O O
the O O
Rb B B_GENE/B_BIO
protein I I_GENE/I_BIO
. O O

To O O
explore O O
the O O
effect O O
of O O
persistent O O
cardiomegaly O O
on O O
cardiovascular O O
function O O
, O O
groups O O
of O O
newborn O O
rats O O
inhaled O O
up O O
to O O
500 O O
ppm O O
CO O O
for O O
33 O O
days O O
, O O
after O O
which O O
development O O
continued O O
in O O
ambient O O
air O O
. O O

Bandwidth O O
of O O
auditory O O
units O O
in O O
the O O
chick O O
forebrain O O
( O O
field O O
L O O
/ O O
Hv O O
complex O O
) O O
was O O
measured O O
with O O
isointensity O O
tone O O
stimuli O O
. O O

Members O O
of O O
the O O
steroid B B_GENE/B_BIO
/ I I_GENE/I_BIO
hormone I I_GENE/I_BIO
nuclear I I_GENE/I_BIO
receptor I I_GENE/I_BIO
superfamily I I_GENE/I_BIO
regulate O O
target O O
gene O O
transcription O O
via O O
recognition O O
and O O
association O O
with O O
specific O O
cis O O
- O O
acting O O
sequences O O
of O O
DNA O O
, O O
called O O
hormone O O
response O O
elements O O
( O O
HREs O O
) O O
. O O

Indeed O O
, O O
DEX O O
also O O
enhanced O O
the O O
RA O O
- O O
dependent O O
increase O O
in O O
RARbeta B B_GENE
mRNA I I_GENE
in O O
a O O
cycloheximide O O
- O O
sensitive O O
manner O O
. O O

The O O
highest O O
concentration O O
of O O
respirable O O
mineral O O
fibres O O
was O O
found O O
during O O
the O O
overhaul O O
of O O
a O O
truck O O
with O O
asbestos O O
insulation O O
; O O
respirable O O
fibre O O
concentration O O
reached O O
the O O
value O O
of O O
5 O O
f O O
/ O O
cm3 O O
, O O
and O O
total O O
dust O O
concentration O O
- O O
the O O
value O O
of O O
about O O
80 O O
mg O O
/ O O
m3 O O
. O O

Avian B B_GENE/B_BIO
EMILIN I I_GENE/I_BIO
was O O
extracted O O
from O O
19 O O
- O O
day O O
- O O
old O O
embryonic O O
chick O O
aortas O O
and O O
associated O O
blood O O
vessels O O
and O O
purified O O
by O O
ion O O
- O O
exchange O O
chromatography O O
and O O
gel O O
filtration O O
. O O

We O O
report O O
here O O
that O O
AChE B B_GENE/B_BIO
activity O O
tends O O
to O O
decrease O O
in O O
individuals O O
sampled O O
in O O
tanks O O
at O O
a O O
salinity O O
of O O
30 O O
per O O
thousand O O
as O O
temperature O O
increases O O
. O O

Mating O O
response O O
, O O
ovulation O O
rate O O
, O O
follicle O O
and O O
corpus O O
luteum O O
size O O
, O O
gestation O O
length O O
, O O
pregnancy O O
rate O O
, O O
lambing O O
rate O O
, O O
and O O
lamb O O
birth O O
weight O O
were O O
recorded O O
. O O

Membrane O O
extraction O O
has O O
been O O
interfaced O O
with O O
gas O O
chromatography O O
and O O
mass O O
spectroscopy O O
for O O
the O O
analysis O O
of O O
volatile O O
organics O O
in O O
water O O
. O O

A O O
significant O O
difference O O
in O O
the O O
distribution O O
of O O
antibodies O O
to O O
thyroglobulin B B_GENE
and O O
thyroid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
peroxidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
found O O
in O O
subgroup O O
2 O O
. O O

Here O O
, O O
we O O
characterize O O
TCR B B_GENE
/ O O
CD48 B B_GENE
and O O
TCR B B_GENE
/ O O
CD28 B B_GENE/B_LOCATION
costimulation O O
in O O
T O O
cells O O
expressing O O
Lck B B_GENE
Src B I_GENE
homology I I_GENE
3 I I_GENE
( O O
SH3 B B_GENE
) O O
mutants O O
. O O

High O O
expression O O
of O O
p51A B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
TAp63gamma B B_GENE/B_LOCATION
) O O
in O O
the O O
skeletal O O
muscle O O
tissue O O
drove O O
us O O
to O O
investigate O O
a O O
differentiation O O
- O O
inducible O O
myoblastic O O
cell O O
line O O
which O O
showed O O
increased O O
p51A B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
after O O
differentiation O O
induction O O
. O O

The O O
rate O O
for O O
Arm O O
III O O
( O O
CAF O O
therapy O O
) O O
was O O
61 O O
. O O
5 O O
% O O
( O O
32 O O
/ O O
52 O O
) O O
, O O
a O O
little O O
higher O O
than O O
that O O
for O O
the O O
other O O
two O O
. O O

These O O
results O O
induce O O
that O O
the O O
putative O O
TATA O O
box O O
and O O
initiator O O
are O O
not O O
involved O O
in O O
the O O
promoter O O
activity O O
, O O
and O O
that O O
the O O
vitronectin B B_GENE
promoter I I_GENE
lacks O O
the O O
TATA O O
box O O
, O O
initiator O O
and O O
GC O O
box O O
. O O

The O O
related O O
adhesion B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
focal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
tyrosine O O
- O O
phosphorylated O O
after O O
beta1 B B_GENE
- I I_GENE
integrin I I_GENE
stimulation O O
in O O
B O O
cells O O
and O O
binds O O
to O O
p130cas B B_GENE
. O O

Earlier O O
reports O O
have O O
localized O O
mutations O O
which O O
affect O O
the O O
processing O O
and O O
transport O O
of O O
herpes O O
simplex O O
virus O O
1 O O
glycoproteins O O
to O O
a O O
region O O
located O O
between O O
the O O
genes O O
specifying O O
glycoprotein B B_GENE/B_ORGANISM_FUNCTION
B I I_GENE/I_ORGANISM_FUNCTION
and O O
the O O
major O O
viral O O
DNA O O
- O O
binding O O
protein O O
( O O
beta B B_GENE/B_DISEASE
8 I I_GENE/I_DISEASE
) O O
. O O

These O O
results O O
indicate O O
that O O
the O O
2127 O O
- O O
bp O O
cDNA O O
encodes O O
a O O
functional O O
feline O O
L B B_ENZYME[GENE]/B_MEASURE
/ I I_ENZYME[GENE]/I_MEASURE
B I I_ENZYME[GENE]/I_MEASURE
/ I I_ENZYME[GENE]/I_MEASURE
K I I_ENZYME[GENE]/I_MEASURE
- I I_ENZYME[GENE]/I_MEASURE
type I I_ENZYME[GENE]/I_MEASURE
ALP I I_ENZYME[GENE]/I_MEASURE
expressed O O
on O O
cell O O
surfaces O O
via O O
phosphatidylinositol O O
- O O
glycan O O
linkage O O
. O O

Our O O
experience O O
suggests O O
that O O
T2 O O
weighting O O
is O O
adequate O O
and O O
is O O
the O O
method O O
of O O
choice O O
for O O
the O O
early O O
recognition O O
of O O
necrosis O O
of O O
the O O
lunate O O
. O O

Analysis O O
of O O
a O O
Het B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
mutation O O
in O O
Anabaena O O
sp O O
. O O
strain O O
PCC O O
7120 O O
implicates O O
a O O
secondary O O
metabolite O O
in O O
the O O
regulation O O
of O O
heterocyst O O
spacing O O
. O O

p56 B B_GENE/B_DISEASE
( O O
lck B B_GENE/B_BACTERIUM[BIO]
) O O
utilizes O O
Shc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Grb2 B B_GENE/B_LOCATION
adaptors I I_GENE/I_LOCATION
to O O
mediate O O
activation O O
of O O
p21 B B_GENE/B_DISEASE
( O O
ras B B_GENE/B_DISEASE
) O O
in O O
the O O
thymoblast O O
lines O O
by O O
promoting O O
tyrosine O O
phosphorylation O O
of O O
the O O
Shc B B_GENE/B_BIO
protein I I_GENE/I_BIO
and O O
constitutive O O
interaction O O
between O O
Shc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Grb2 B B_GENE
. O O

The O O
rec8 B B_GENE/B_DISEASE
( I I_GENE/I_DISEASE
+ I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
, O O
rec10 B B_MEASURE/B_GENE
( I I_MEASURE/I_GENE
+ I I_MEASURE/I_GENE
) I I_MEASURE/I_GENE
, O O
and O O
rec11 B B_GENE/B_BIO
( I I_GENE/I_BIO
+ I I_GENE/I_BIO
) I I_GENE/I_BIO
genes I I_GENE/I_BIO
of I I_GENE/I_BIO
the I I_GENE/I_BIO
fission I I_GENE/I_BIO
yeast I I_GENE/I_BIO
Schizosaccharomyces I I_GENE/I_BIO
pombe I I_GENE/I_BIO
exhibit O O
similar O O
specificities O O
for O O
meiotic O O
recombination O O
and O O
rec8 B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
+ I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
is O O
required O O
for O O
sister O O
chromatid O O
cohesion O O
and O O
homolog O O
pairing O O
. O O

Based O O
on O O
the O O
results O O
of O O
this O O
analysis O O
, O O
we O O
also O O
predict O O
that O O
the O O
budding B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
yeast I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
arsenate I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resistance I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Acr2 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
ORF B B_GENE/B_PERSON
Ygr203w I I_GENE/I_PERSON
encode O O
protein O O
phosphatases O O
with O O
catalytic O O
properties O O
similar O O
to O O
that O O
of O O
the O O
Cdc25 B B_SPECIES[BIO]/B_GENE
family I I_SPECIES[BIO]/I_GENE
. O O

At O O
onset O O
of O O
first O O
post O O
- O O
weaning O O
estrus O O
, O O
sows O O
received O O
either O O
an O O
intravulval O O
injection O O
of O O
3 O O
. O O
75 O O
mg O O
of O O
prostaglandin O O
analogue O O
( O O
PGF O O
) O O
or O O
, O O
served O O
as O O
a O O
non O O
- O O
injected O O
control O O
( O O
CON O O
) O O
. O O

We O O
concluded O O
that O O
HFV O O
can O O
achieve O O
values O O
of O O
CO2 O O
elimination O O
close O O
to O O
the O O
estimated O O
metabolic O O
CO2 O O
production O O
in O O
normal O O
unintubated O O
subjects O O
over O O
short O O
periods O O
of O O
time O O
. O O

The O O
PHO5 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
is O O
activated O O
by O O
the O O
Pho4p B B_GENE
transcription I I_GENE
factor I I_GENE
, O O
which O O
itself O O
is O O
negatively O O
regulated O O
through O O
phosphorylation O O
by O O
the O O
products O O
of O O
PHO80 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
PHO85 B B_GENE
. O O

Although O O
the O O
only O O
authoritative O O
way O O
to O O
determine O O
the O O
effect O O
of O O
diet O O
on O O
urinary O O
pH O O
is O O
a O O
feeding O O
trial O O
, O O
there O O
is O O
no O O
universally O O
accepted O O
protocol O O
for O O
measuring O O
urinary O O
pH O O
. O O

Endothelial O O
purine O O
content O O
. O O

Possibilities O O
and O O
limints O O
of O O
immunofluorescence O O
in O O
the O O
laboratory O O
diagnosis O O
of O O
rabies O O

The O O
5 O O
' O O
half O O
of O O
the O O
EWS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
recently O O
been O O
described O O
to O O
be O O
fused O O
to O O
the O O
3 O O
' O O
regions O O
of O O
genes O O
encoding O O
the O O
DNA O O
- O O
binding O O
domain O O
of O O
several O O
transcriptional O O
regulators O O
, O O
including O O
ATF1 B B_GENE/B_LOCATION
, O O
FLI B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
, O O
and O O
ERG B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
several O O
human O O
tumors O O
. O O

PDGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O O
CDK2 B B_GENE
activity O O
in O O
mesangial O O
cells O O
and O O
decreased O O
the O O
level O O
of O O
p27 B B_GENE
( O O
kip1 B B_PROTEIN[GENE]/B_LOCATION
) O O
cyclin O O
kinase O O
inhibitor O O
protein O O
. O O

Recombinant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
apoA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
recovered O O
from O O
the O O
soluble O O
fraction O O
of O O
the O O
bacterial O O
cell O O
pellet O O
was O O
purified O O
to O O
greater O O
than O O
95 O O
% O O
homogeneity O O
by O O
reversed O O
- O O
phase O O
high O O
- O O
performance O O
liquid O O
chromatography O O
. O O

On O O
average O O
, O O
rCMRglc O O
values O O
were O O
23 O O
% O O
below O O
control O O
values O O
for O O
all O O
regions O O
studied O O
, O O
with O O
the O O
greatest O O
differences O O
in O O
posterior O O
brain O O
regions O O
( O O
visual O O
association O O
cortex O O
, O O
primary O O
visual O O
cortex O O
, O O
and O O
parietal O O
cortex O O
) O O
and O O
thalamus O O
. O O

Thus O O
, O O
Tax1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activates O O
CArG O O
- O O
mediated O O
transcription O O
without O O
mitogenic O O
signals O O
through O O
interaction O O
with O O
a O O
CArG B B_GENE/B_PERSON
- I I_GENE/I_PERSON
binding I I_GENE/I_PERSON
factor I I_GENE/I_PERSON
, O O
p67SRF B B_GENE
. O O

In O O
experiment O O
1 O O
, O O
subjects O O
were O O
required O O
to O O
discriminate O O
male O O
from O O
female O O
faces O O
and O O
no O O
hemispheric O O
asymmetries O O
were O O
found O O
. O O

Membrane O O
depolarization O O
is O O
a O O
critical O O
element O O
of O O
neuronal O O
signaling O O
. O O

The O O
transcription O O
start O O
site O O
was O O
localized O O
224 O O
bp O O
upstream O O
the O O
ATG O O
codon O O
by O O
RNase B B_ENZYME[GENE]
protection O O
and O O
primer O O
extension O O
mapping O O
. O O

All O O
the O O
cognate O O
gene O O
clones O O
were O O
constructed O O
, O O
using O O
either O O
PCR O O
products O O
amplified O O
from O O
genomic O O
DNA O O
, O O
or O O
gap O O
- O O
repair O O
. O O

Rising O O
antibody O O
titres O O
to O O
the O O
astrovirus O O
particles O O
were O O
demonstrated O O
in O O
one O O
child O O
, O O
and O O
IgM B B_GENE/B_DISEASE
was O O
also O O
demonstrated O O
in O O
this O O
patient O O
' O O
s O O
serum O O
. O O

Effect O O
of O O
isobarin O O
on O O
electrocardiographic O O
indices O O
in O O
hypertensive O O
disease O O

Although O O
RAD17 B B_GENE/B_DISEASE
, O O
RAD24 B B_GENE/B_DISEASE
and O O
MEC3 B B_GENE/B_MEASURE
are O O
not O O
required O O
for O O
cell O O
cycle O O
arrest O O
when O O
S O O
phase O O
is O O
inhibited O O
by O O
hydroxyurea O O
( O O
HU O O
) O O
, O O
they O O
do O O
contribute O O
to O O
the O O
viability O O
of O O
yeast O O
cells O O
grown O O
in O O
the O O
presence O O
of O O
HU O O
, O O
possibly O O
because O O
they O O
are O O
required O O
for O O
the O O
repair O O
of O O
HU O O
- O O
induced O O
DNA O O
damage O O
. O O

Long O O
chain O O
acyl O O
- O O
CoA O O
esters O O
are O O
important O O
intermediates O O
in O O
degradation O O
and O O
synthesis O O
of O O
fatty O O
acids O O
, O O
as O O
well O O
as O O
having O O
important O O
functions O O
in O O
regulation O O
of O O
intermediary O O
metabolism O O
and O O
gene O O
expression O O
. O O

PTP1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
lacZ B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O O
indicate O O
that O O
PTP1 B B_GENE
is O O
spatially O O
localized O O
to O O
prestalk O O
and O O
anterior O O
- O O
like O O
cell O O
types O O
. O O

When O O
translated O O
in O O
- O O
frame O O
with O O
PKC B B_GENE
zeta I I_GENE
, O O
a O O
stop O O
codon O O
is O O
located O O
28 O O
amino O O
acids O O
towards O O
the O O
N O O
- O O
terminus O O
of O O
the O O
divergence O O
point O O
and O O
the O O
intervening O O
sequence O O
lacks O O
an O O
expected O O
initiating O O
methionine O O
. O O
psi B B_GENE
PKC I I_GENE
zeta I I_GENE
is O O
non O O
- O O
functional O O
in O O
terms O O
of O O
protein O O
synthesis O O
since O O
Western O O
blotting O O
with O O
an O O
antibody O O
directed O O
against O O
the O O
C O O
- O O
terminus O O
of O O
PKC B B_GENE
zeta I I_GENE
failed O O
to O O
reveal O O
a O O
protein O O
smaller O O
than O O
PKC B B_GENE/B_MEASURE
zeta I B_GENE/I_MEASURE
, O O
and O O
synthetic O O
psi B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
PKC I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
zeta I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
failed O O
to O O
support O O
protein O O
synthesis O O
in O O
a O O
translation O O
system O O
in O O
vitro O O
. O O

W O O
. O O
, O O
and O O
Touster O O
, O O
O O O
. O O

Electrically O O
induced O O
undulations O O
and O O
their O O
competition O O
with O O
electrically O O
induced O O
convection O O
in O O
cholesteric O O
liquid O O
crystals O O
. O O

These O O
conditions O O
may O O
determine O O
an O O
increase O O
in O O
the O O
level O O
of O O
indoor O O
pollutants O O
( O O
tobacco O O
smoke O O
, O O
gases O O
produced O O
by O O
cooling O O
processes O O
etc O O
. O O
) O O
and O O
of O O
allergens O O
derived O O
from O O
mites O O
, O O
domestic O O
animals O O
and O O
cockroaches O O
. O O

Nevertheless O O
, O O
lower O O
doses O O
which O O
alone O O
were O O
lacking O O
in O O
activity O O
( O O
100 O O
- O O
250 O O
mg O O
/ O O
kg O O
B1 O O
and O O
B6 O O
, O O
1 O O
- O O
2 O O
. O O
5 O O
mg O O
/ O O
kg O O
B12 O O
p O O
. O O
o O O
. O O
) O O
dose O O
- O O
dependently O O
potentiated O O
the O O
antinociceptive O O
of O O
diclofenac O O
. O O

Changes O O
in O O
water O O
and O O
electrolyte O O
content O O
of O O
the O O
brain O O
and O O
edema O O
formation O O
after O O
acute O O
, O O
drug O O
- O O
induced O O
hypertension O O
were O O
studied O O
in O O
albino O O
rabbits O O
. O O

Like O O
Rev B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
Erb B B_PROTEIN[GENE]/B_MEASURE
, O O
BD73 B B_GENE/B_LOCATION
binds O O
as O O
a O O
monomer O O
to O O
a O O
DNA O O
sequence O O
which O O
consists O O
of O O
a O O
specific O O
A O O
/ O O
T O O
- O O
rich O O
sequence O O
upstream O O
of O O
the O O
consensus O O
hexameric O O
half O O
- O O
site O O
specified O O
by O O
the O O
P O O
box O O
of O O
the O O
DNA O O
- O O
binding O O
domain O O
. O O

In O O
contrast O O
, O O
the O O
holo B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
dTFIIA I I_GENE/I_MEASURE
( O O
L O O
/ O O
S O O
) O O
binds O O
TBP B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
high O O
affinity O O
. O O

Overexpression O O
of O O
wild O O
type O O
and O O
SeCys O O
/ O O
Cys O O
mutant O O
of O O
human B B_GENE/B_LOCATION
thioredoxin I I_GENE/I_LOCATION
reductase I I_GENE/I_LOCATION
in O O
E O O
. O O
coli O O
: O O
the O O
role O O
of O O
selenocysteine O O
in O O
the O O
catalytic O O
activity O O
. O O

Biopsy O O
of O O
the O O
lesion O O
revealed O O
granulomatous O O
inflammation O O
and O O
numerous O O
septate O O
hyphae O O
. O O

Western O O
and O O
immunocytochemical O O
analysis O O
implied O O
that O O
PREB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
accumulates O O
specifically O O
in O O
GH3 O O
cell O O
nuclei O O
. O O

Two O O
genes O O
from O O
the O O
family O O
encoding O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ribosomal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
S16 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
cloned O O
, O O
sequenced O O
, O O
and O O
analyzed O O
. O O

A O O
novel O O
serine B B_ENZYME[GENE]/B_LOCATION
kinase I I_ENZYME[GENE]/I_LOCATION
activated O O
by O O
rac1 B B_GENE/B_DISEASE
/ O O
CDC42Hs B B_GENE/B_BIO
- O O
dependent O O
autophosphorylation O O
is O O
related O O
to O O
PAK65 B B_GENE
and O O
STE20 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
deduced O O
gene O O
product O O
was O O
found O O
to O O
have O O
significant O O
sequence O O
similarity O O
to O O
the O O
yeast B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
prokaryotic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polymerase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunits I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
involved O O
with O O
subunit O O
assembly O O
. O O

Maximum O O
overexpression O O
of O O
holoenzyme O O
activity O O
was O O
achieved O O
by O O
the O O
inclusion O O
in O O
such O O
plasmids O O
of O O
Salmonella O O
typhimurium O O
cysG O O
, O O
which O O
encodes O O
a O O
uroporphyrinogen B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
III I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
required O O
for O O
the O O
synthesis O O
of O O
siroheme O O
, O O
a O O
cofactor O O
for O O
the O O
hemoprotein O O
. O O

Overexpression O O
of O O
SNURF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cultured O O
mammalian O O
cells O O
enhanced O O
not O O
only O O
androgen O O
, O O
glucocorticoid O O
, O O
and O O
progesterone B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dependent O O
transactivation O O
but O O
also O O
basal O O
transcription O O
from O O
steroid O O
- O O
regulated O O
promoters O O
. O O

The O O
human O O
protein O O
binds O O
most O O
strongly O O
to O O
the O O
SH3 B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
from O O
the O O
abl B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
proto I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
oncogene I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Suprapubic O O
and O O
intravesical O O
methods O O

These O O
data O O
show O O
that O O
tyrosine O O
phosphorylation O O
by O O
FES B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
affects O O
the O O
interaction O O
of O O
BCR B B_GENE
with O O
multiple O O
signaling O O
partners O O
and O O
suggest O O
a O O
general O O
role O O
for O O
BCR B B_GENE/B_DISEASE
in O O
non O O
- O O
receptor O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulation O O
and O O
signal O O
transduction O O
. O O

From O O
1977 O O
to O O
1985 O O
, O O
42 O O
patients O O
with O O
squamous O O
cell O O
carcinoma O O
of O O
the O O
anal O O
canal O O
were O O
treated O O
with O O
mitomycin O O
C O O
( O O
15 O O
mg O O
/ O O
m2 O O
) O O
and O O
5 O O
- O O
fluorouracil O O
( O O
750 O O
mg O O
/ O O
m2 O O
) O O
on O O
day O O
1 O O
, O O
5 O O
- O O
FU O O
( O O
750 O O
mg O O
/ O O
m2 O O
/ O O
d O O
) O O
alone O O
on O O
days O O
2 O O
to O O
5 O O
, O O
and O O
radiation O O
therapy O O
( O O
3000 O O
cGy O O
) O O
on O O
days O O
7 O O
to O O
28 O O
. O O

For O O
any O O
given O O
age O O
, O O
high O O
- O O
stressed O O
plantaris O O
tendons O O
were O O
of O O
a O O
higher O O
fatigue O O
quality O O
than O O
low O O
- O O
stressed O O
extensor O O
tendons O O
. O O

In O O
addition O O
to O O
TAK1 B B_GENE
, O O
TGF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
also O O
stimulated O O
JNK B B_GENE
activity O O
. O O

Foamy O O
viruses O O
( O O
FVs O O
) O O
express O O
the O O
Gag B B_GENE
protein I I_GENE
as O O
a O O
precursor O O
with O O
a O O
molecular O O
mass O O
of O O
74 O O
kDa O O
( O O
pr74 B B_PROTEIN[GENE]/B_MEASURE
) O O
from O O
which O O
a O O
70 O O
- O O
kDa O O
protein O O
( O O
p70 B B_PROTEIN[GENE]/B_DISEASE
) O O
is O O
cleaved O O
by O O
the O O
viral O O
protease O O
. O O

Our O O
results O O
suggest O O
that O O
at O O
least O O
some O O
chloroplast B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
wheat O O
mtDNA O O
are O O
transcribed O O
, O O
with O O
transcripts O O
undergoing O O
processing O O
, O O
post O O
- O O
transcriptional O O
modification O O
and O O
3 O O
' O O
- O O
CCA O O
addition O O
, O O
to O O
produce O O
mature O O
tRNAs O O
that O O
may O O
participate O O
in O O
mitochondrial O O
protein O O
synthesis O O
. O O

If O O
, O O
however O O
, O O
myocardial O O
stunning O O
is O O
severe O O
, O O
and O O
it O O
involves O O
large O O
parts O O
of O O
the O O
LV O O
and O O
thus O O
impairs O O
global O O
LV O O
function O O
, O O
it O O
can O O
be O O
reversed O O
with O O
inotropic O O
agents O O
and O O
procedures O O
. O O

268 O O
, O O
6858 O O
- O O
6861 O O
) O O
. O O

The O O
occurrence O O
of O O
the O O
different O O
types O O
of O O
TCRB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
rearrangement O O
patterns O O
has O O
implications O O
for O O
PCR O O
- O O
based O O
clonality O O
assessment O O
and O O
for O O
PCR O O
- O O
based O O
detection O O
of O O
minimal O O
residual O O
disease O O
via O O
TCRB B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis O O
. O O

Six O O
patients O O
underwent O O
an O O
electrophysiologic O O
study O O
. O O

Rats O O
on O O
the O O
multiple O O
oral O O
dosage O O
regimen O O
were O O
given O O
unlabelled O O
HMCF O O
in O O
their O O
drinking O O
water O O
for O O
13 O O
days O O
before O O
the O O
administration O O
of O O
a O O
bolus O O
dose O O
of O O
[ O O
14C O O
] O O
HMCF O O
on O O
day O O
14 O O
. O O

After O O
multivariate O O
analysis O O
, O O
TWA O O
correlated O O
with O O
age O O
( O O
P O O
= O O
0 O O
. O O
02 O O
) O O
and O O
LV O O
function O O
( O O
P O O
= O O
0 O O
. O O
002 O O
) O O
and O O
occurred O O
more O O
often O O
in O O
patients O O
after O O
nonanterior O O
MI O O
( O O
P O O
= O O
0 O O
. O O
03 O O
) O O
. O O

No O O
patient O O
demonstrated O O
a O O
decrease O O
in O O
bone O O
marrow O O
fibrosis O O
as O O
determined O O
by O O
serial O O
procollagen B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
PC B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
III I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
serum O O
level O O
analysis O O
. O O

Asthma O O
diagnoses O O
were O O
made O O
according O O
to O O
recommended O O
National O O
Asthma O O
Expert O O
Panel O O
Guidelines O O
. O O

Charcot O O
joints O O
. O O

Idealized O O
versus O O
realized O O
overall O O
treatment O O
times O O
. O O

Non O O
- O O
suppressed O O
thyroidal O O
radioactive O O
iodine O O
uptake O O
( O O
RAIU O O
) O O
in O O
thyrotoxic O O
phase O O
in O O
a O O
case O O
of O O
subacute O O
thyroiditis O O
with O O
thyroid O O
- O O
stimulating O O
antibodies O O
( O O
TSAb O O
) O O
. O O

Bilateral O O
renal O O
oncocytoma O O
in O O
a O O
Greyhound O O
dog O O
. O O

Uncoupling O O
gene O O
activity O O
from O O
chromatin O O
structure O O
: O O
promoter O O
mutations O O
can O O
inactivate O O
transcription O O
of O O
the O O
yeast B B_GENE/B_BIO
HSP82 I I_GENE/I_BIO
gene I I_GENE/I_BIO
without O O
eliminating O O
nucleosome O O
- O O
free O O
regions O O
. O O

Ectopic O O
expression O O
of O O
cyclin B B_GENE
D1 I I_GENE
in O O
progestin O O
- O O
inhibited O O
cells O O
led O O
to O O
the O O
reappearance O O
of O O
the O O
120 O O
- O O
kDa O O
active O O
form O O
of O O
cyclin B B_GENE
E I I_GENE
- O O
Cdk2 B B_PROTEIN[GENE]/B_MEASURE
preceding O O
the O O
resumption O O
of O O
cell O O
cycle O O
progression O O
. O O

Because O O
the O O
wa B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
2 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
was O O
mapped O O
previously O O
to O O
the O O
vicinity O O
of O O
the O O
EGF B B_GENE/B_DISEASE
/ I I_GENE/I_DISEASE
TGF I I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
alpha I I_GENE/I_DISEASE
receptor I I_GENE/I_DISEASE
( O O
EGFR B B_GENE/B_LOCATION
) O O
gene O O
on O O
mouse O O
chromosome O O
11 O O
, O O
we O O
hypothesized O O
that O O
the O O
wa B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
2 I I_DISEASE/I_GENE
phenotype I I_DISEASE/I_GENE
might O O
result O O
from O O
a O O
defect O O
in O O
either O O
the O O
expression O O
or O O
activity O O
of O O
EGFR B B_GENE/B_BIO
, O O
or O O
both O O
. O O

Region O O
I O O
includes O O
the O O
two O O
cysteine O O
- O O
cysteine O O
zinc O O
fingers O O
that O O
comprise O O
a O O
DNA O O
- O O
binding O O
domain O O
which O O
typifies O O
all O O
members O O
of O O
the O O
superfamily O O
. O O

Southern O O
zoo O O
blot O O
analysis O O
indicated O O
that O O
ZNF236 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
conserved O O
in O O
the O O
genomes O O
of O O
all O O
mammalian O O
species O O
tested O O
, O O
but O O
not O O
in O O
yeast O O
. O O

RNA O O
determinants O O
required O O
for O O
L4 B B_GENE/B_DISEASE
- O O
mediated O O
attenuation O O
control O O
of O O
the O O
S10 B B_GENE/B_BIO
r I I_GENE/I_BIO
- I I_GENE/I_BIO
protein I I_GENE/I_BIO
operon I I_GENE/I_BIO
of I I_GENE/I_BIO
Escherichia I I_GENE/I_BIO
coli I I_GENE/I_BIO
. O O

Spodoptera O O
frugiperda O O
( O O
Sf9 O O
) O O
cells O O
have O O
proved O O
a O O
suitable O O
cell O O
system O O
in O O
which O O
to O O
study O O
this O O
association O O
and O O
to O O
produce O O
recombinant B B_GENE
CR3 I I_GENE
, O O
and O O
we O O
show O O
here O O
that O O
another O O
lepidopteran O O
cell O O
line O O
, O O
Trichoplusia O O
niTN O O
- O O
5B1 O O
- O O
4 O O
( O O
High O O
- O O
Five O O
) O O
cells O O
, O O
allows O O
the O O
recovery O O
of O O
large O O
amounts O O
of O O
functional B B_GENE
recombinant I I_GENE
CR3 I I_GENE
. O O

INTERVENTIONS O O
: O O
Postoperative O O
follow O O
- O O
up O O
consisted O O
of O O
serial O O
determination O O
of O O
different O O
biochemical O O
markers O O
( O O
CK B B_GENE/B_LOCATION
, O O
CK B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
MB I I_GENE/I_LOCATION
, O O
cTnI B B_LOCATION/B_GENE
) O O
, O O
ECGs O O
, O O
and O O
echocardiography O O
. O O

At O O
the O O
first O O
phase O O
( O O
1 O O
- O O
43 O O
ms O O
for O O
the O O
VMN O O
and O O
1 O O
- O O
10 O O
ms O O
for O O
the O O
LN O O
) O O
the O O
hypothalamic O O
- O O
cortical O O
responses O O
completely O O
inhibited O O
the O O
formation O O
of O O
the O O
VC O O
response O O
to O O
the O O
light O O
stimulus O O
. O O

6 O O
, O O
320 O O
cells O O
/ O O
mm3 O O
, O O
respectively O O
; O O
P O O
less O O
than O O
. O O
005 O O
) O O
; O O
twelve O O
( O O
86 O O
% O O
) O O
of O O
the O O
14 O O
inmates O O
who O O
developed O O
AIDS O O
had O O
counts O O
of O O
less O O
than O O
5 O O
, O O
000 O O
cells O O
/ O O
mm3 O O
, O O
compared O O
with O O
only O O
six O O
( O O
14 O O
% O O
) O O
of O O
the O O
42 O O
controls O O
( O O
P O O
less O O
than O O
. O O
00001 O O
) O O
. O O

There O O
is O O
, O O
however O O
, O O
uncertainty O O
as O O
to O O
how O O
results O O
obtained O O
in O O
recent O O
experiments O O
scale O O
up O O
to O O
landscape O O
and O O
regional O O
levels O O
and O O
generalize O O
across O O
ecosystem O O
types O O
and O O
processes O O
. O O

The O O
facilitation O O
started O O
preceding O O
the O O
onset O O
of O O
electromyographic O O
activity O O
of O O
the O O
masseter O O
muscle O O
. O O

The O O
recruitment O O
of O O
constitutively O O
phosphorylated O O
p185 B B_GENE/B_DISEASE
( O O
neu B B_GENE/B_DISEASE
) O O
and O O
the O O
activated O O
mitogenic O O
pathway O O
proteins O O
to O O
this O O
membrane O O
- O O
microfilament O O
interaction O O
site O O
provides O O
a O O
physical O O
model O O
for O O
integrating O O
the O O
assembly O O
of O O
the O O
mitogenic O O
pathway O O
with O O
the O O
transmission O O
of O O
growth O O
factor O O
signal O O
to O O
the O O
cytoskeleton O O
. O O

Deletion O O
of O O
the O O
region O O
from O O
amino O O
acid O O
residues O O
2 O O
- O O
67 O O
in O O
E1A B B_GENE/B_MEASURE
, O O
which O O
has O O
been O O
postulated O O
to O O
interact O O
with O O
p300 B B_GENE/B_LOCATION
/ O O
CBP B B_MEASURE/B_GENE
, O O
also O O
abolished O O
the O O
inhibitory O O
effect O O
of O O
E1A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
deletion O O
of O O
the O O
region O O
from O O
residues O O
120 O O
to O O
140 O O
had O O
no O O
effect O O
. O O

Quantitative O O
Tl O O
- O O
201 O O
analysis O O
after O O
stress O O
has O O
also O O
shown O O
viable O O
myocardium O O
in O O
most O O
mild O O
to O O
moderate O O
( O O
51 O O
% O O
to O O
85 O O
% O O
of O O
normal O O
uptake O O
) O O
irreversible O O
Tl O O
- O O
201 O O
defects O O
. O O

The O O
point O O
mutation O O
Asp O O
- O O
316 O O
- O O
- O O
> O O
Asn O O
in O O
the O O
C O O
- O O
terminus O O
of O O
p38 B B_GENE
, O O
analogous O O
to O O
the O O
ERK2 B B_GENE
( O O
extracellular B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
signal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
sevenmaker B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation O O
, O O
dramatically O O
decreases O O
its O O
binding O O
to O O
MKP B B_GENE
- I I_GENE
1 I I_GENE
and O O
substantially O O
compromises O O
its O O
stimulatory O O
effect O O
on O O
the O O
catalytic O O
activity O O
of O O
this O O
phosphatase O O
. O O

J O O
. O O

Causal O O
modeling O O
combines O O
theory O O
and O O
research O O
, O O
and O O
because O O
the O O
interpretation O O
of O O
data O O
is O O
possible O O
only O O
within O O
the O O
context O O
of O O
the O O
proposed O O
theory O O
, O O
it O O
offers O O
an O O
important O O
method O O
for O O
advancing O O
the O O
science O O
while O O
maintaining O O
the O O
specificity O O
of O O
the O O
practice O O
. O O

BCR B B_PROTEIN[GENE]/B_LOCATION
- O O
ABL B B_MEASURE/B_GENE
elicits O O
transformation O O
of O O
both O O
fibroblast O O
and O O
hematopoietic O O
cells O O
and O O
blocks O O
apoptosis O O
following O O
cytokine O O
deprivation O O
in O O
various O O
factor O O
- O O
dependent O O
cells O O
. O O

Aggregation O O
in O O
washed O O
platelets O O
from O O
rats O O
with O O
diabetes O O
was O O
enhanced O O
. O O

Mutations O O
in O O
Saccharomyces O O
cerevisiae O O
that O O
block O O
meiotic O O
prophase O O
chromosome O O
metabolism O O
and O O
confer O O
cell O O
cycle O O
arrest O O
at O O
pachytene O O
identify O O
two O O
new O O
meiosis B B_GENE/B_BIO
- I I_GENE/I_BIO
specific I I_GENE/I_BIO
genes I I_GENE/I_BIO
SAE1 I I_GENE/I_BIO
and O O
SAE3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Isolation O O
and O O
characterization O O
of O O
human O O
orthologs O O
of O O
yeast O O
CCR4 B B_GENE
- O O
NOT B B_GENE/B_LOCATION
complex O O
subunits O O
. O O

Thus O O
, O O
the O O
i B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
leader I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
is O O
a O O
viral O O
gene O O
product O O
of O O
unknown O O
function O O
and O O
high O O
stability O O
that O O
is O O
made O O
in O O
large O O
quantities O O
at O O
intermediate O O
times O O
of O O
productive O O
infection O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O

CONCLUSIONS O O
: O O
Latanoprost O O
administered O O
once O O
daily O O
was O O
significantly O O
more O O
effective O O
in O O
reducing O O
IOP O O
compared O O
with O O
unoprostone O O
administered O O
twice O O
daily O O
in O O
patients O O
with O O
POAG O O
and O O
OH O O
. O O

The O O
molecular O O
dynamics O O
simulations O O
provide O O
insight O O
into O O
the O O
conformational O O
flexibility O O
of O O
these O O
analogs O O
. O O

In O O
alfalfa O O
, O O
the O O
insecticides O O
caused O O
significant O O
mortality O O
to O O
most O O
of O O
the O O
insects O O
evaluated O O
. O O

Injections O O
of O O
PD O O
solutions O O
with O O
13 O O
. O O
6 O O
, O O
22 O O
. O O
7 O O
, O O
and O O
38 O O
. O O
6 O O
g O O
/ O O
liter O O
of O O
glucose O O
reduced O O
the O O
ingestion O O
of O O
sucrose O O
by O O
12 O O
. O O
4 O O
% O O
, O O
23 O O
. O O
6 O O
% O O
and O O
36 O O
. O O
1 O O
% O O
, O O
respectively O O
, O O
but O O
did O O
not O O
affect O O
the O O
ingestion O O
of O O
protein O O
. O O

It O O
is O O
recommended O O
that O O
area O O
correction O O
be O O
attempted O O
in O O
bioequivalence O O
studies O O
of O O
drugs O O
where O O
high O O
intrasubject O O
variability O O
in O O
clearance O O
is O O
known O O
or O O
suspected O O
. O O

Expression O O
of O O
the O O
E2 B B_GENE
protein I I_GENE
resulted O O
in O O
rapid O O
repression O O
of O O
HPV B B_GENE/B_VIRUS[BIO]
E6 I I_GENE/I_VIRUS[BIO]
and O O
E7 B B_PROTEIN[GENE]
expression O O
, O O
followed O O
approximately O O
12 O O
h O O
later O O
by O O
profound O O
inhibition O O
of O O
cellular O O
DNA O O
synthesis O O
. O O

Immunoblotting O O
with O O
antiphosphotyrosine O O
antibody O O
showed O O
that O O
many O O
yeast O O
proteins O O
, O O
including O O
the O O
p34CDC28 B B_ENZYME[GENE]
kinase I I_ENZYME[GENE]
, O O
became O O
phosphorylated O O
at O O
tyrosine O O
in O O
cells O O
expressing O O
v B B_GENE
- I I_GENE
src I I_GENE
. O O

Renal O O
cell O O
carcinoma O O
induced O O
Coombs O O
negative O O
autoimmune O O
hemolytic O O
anemia O O
and O O
severe O O
thrombocytopenia O O
responsive O O
to O O
nephrectomy O O
. O O

Pretreatment O O
of O O
rats O O
with O O
different O O
dose O O
levels O O
of O O
CCl4 O O
resulted O O
in O O
a O O
prolongation O O
of O O
TMO O O
half O O
- O O
life O O
, O O
and O O
increase O O
of O O
the O O
area O O
under O O
the O O
curve O O
( O O
AUC O O
) O O
, O O
and O O
a O O
decrease O O
of O O
clearance O O
, O O
but O O
the O O
apparent O O
volume O O
of O O
distribution O O
( O O
Vd O O
) O O
was O O
not O O
significantly O O
decreased O O
. O O

In O O
cells O O
co O O
- O O
expressing O O
high O O
levels O O
of O O
the O O
p38 B B_GENE
( O O
MAPK B B_GENE
) O O
kinase O O
( O O
MKK3 B B_GENE
) O O
together O O
with O O
the O O
p38 B B_GENE
( O O
MAPK B B_GENE/B_DISEASE
) O O
, O O
a O O
significant O O
inhibition O O
of O O
mitogen O O
- O O
induced O O
cyclin B B_GENE
D1 I I_GENE
expression O O
was O O
observed O O
. O O

In O O
patients O O
autografted O O
in O O
CR1 O O
, O O
the O O
transplant O O
- O O
related O O
mortality O O
( O O
TRM O O
) O O
was O O
15 O O
+ O O
/ O O
- O O
4 O O
% O O
, O O
the O O
relapse O O
incidence O O
( O O
RI O O
) O O
was O O
58 O O
+ O O
/ O O
- O O
5 O O
% O O
, O O
the O O
leukaemia O O
- O O
free O O
survival O O
( O O
LFS O O
) O O
was O O
36 O O
+ O O
/ O O
- O O
5 O O
% O O
and O O
the O O
overall O O
survival O O
was O O
47 O O
+ O O
/ O O
- O O
5 O O
% O O
at O O
3 O O
years O O
. O O

Administration O O
of O O
FR O O
34235 O O
reduced O O
aortic O O
blood O O
pressure O O
and O O
increased O O
cardiac O O
output O O
in O O
anesthetized O O
dogs O O
with O O
an O O
ameroid O O
- O O
induced O O
coronary O O
artery O O
occlusion O O
. O O

The O O
primary O O
conditions O O
for O O
acceptable O O
hospital O O
use O O
were O O
that O O
exhaled O O
- O O
volume O O
monitoring O O
be O O
performed O O
for O O
all O O
patients O O
and O O
that O O
O2 O O
monitoring O O
be O O
performed O O
both O O
when O O
setting O O
FIO2 O O
and O O
continuously O O
when O O
FIO2 O O
levels O O
are O O
critical O O
. O O

The O O
RHO1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O O
a O O
homolog O O
of O O
the O O
mammalian O O
RhoA B B_GENE/B_BIO
small I I_GENE/I_BIO
GTP I I_GENE/I_BIO
- I I_GENE/I_BIO
binding I I_GENE/I_BIO
protein I I_GENE/I_BIO
in O O
the O O
yeast O O
Saccharomyces O O
cerevisiae O O
. O O

As O O
regards O O
the O O
short O O
stature O O
, O O
they O O
have O O
proved O O
that O O
the O O
syndrome O O
is O O
related O O
to O O
low O O
levels O O
of O O
somatomedin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
C I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
SmC B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

2 O O
. O O

Menstrual O O
and O O
lunar O O
cycles O O
. O O

HBO O O
had O O
marked O O
effects O O
on O O
these O O
enzymes O O
: O O
lung B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
SOD I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
increased O O
( O O
guinea O O
pigs O O
47 O O
% O O
, O O
rats O O
88 O O
% O O
) O O
and O O
CAT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
GSHPx B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities O O
decreased O O
( O O
33 O O
% O O
) O O
in O O
brain O O
and O O
lung O O
. O O

Phylogenetic O O
analysis O O
of O O
yeast O O
, O O
invertebrate O O
, O O
and O O
multiple O O
mammalian O O
isoforms O O
of O O
SNF4 B B_GENE
shows O O
that O O
the O O
gene O O
duplication O O
likely O O
occurred O O
early O O
in O O
the O O
metazoan O O
lineage O O
, O O
as O O
the O O
protein O O
products O O
of O O
the O O
different O O
loci O O
are O O
relatively O O
divergent O O
. O O

Hard O O
methacrylic O O
polymers O O
. O O

Thus O O
the O O
Hi O O
- O O
RARE O O
represents O O
a O O
new O O
type O O
of O O
RA O O
response O O
element O O
with O O
a O O
role O O
in O O
the O O
modulation O O
of O O
the O O
expression O O
of O O
MHC B B_GENE
class I I_GENE
1 I I_GENE
family O O
genes O O
. O O

We O O
found O O
multiple O O
transcription O O
start O O
sites O O
located O O
within O O
a O O
15 O O
- O O
base O O
pair O O
region O O
, O O
205 O O
base O O
pairs O O
upstream O O
of O O
the O O
translation O O
start O O
codon O O
. O O

The O O
structural O O
intestinal O O
defects O O
are O O
presumed O O
to O O
be O O
the O O
result O O
of O O
defective O O
collagen B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O O
in O O
these O O
hereditary O O
connective O O
tissue O O
disorders O O
. O O

Rev O O
. O O

Incidence O O
of O O
beta O O
- O O
thalassemia O O
carriers O O
and O O
those O O
deficient O O
in O O
erythrocyte B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydrogenase I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
greater O O
Buenos O O
Aires O O
area O O

Both O O
v B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Myb I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
c B B_GENE
- I I_GENE
Myb I I_GENE
bind O O
specifically O O
to O O
delta B B_GENE
E3 I I_GENE
. O O

Anatomical O O
considerations O O
in O O
transsphenoidal O O
hypophysectomy O O
. O O

An O O
hcr1 B B_GENE
null O O
mutant O O
was O O
viable O O
, O O
but O O
showed O O
slight O O
reduction O O
of O O
growth O O
when O O
compared O O
with O O
the O O
wild O O
- O O
type O O
strain O O
. O O

Further O O
, O O
we O O
find O O
that O O
the O O
BMI1 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
can O O
also O O
interact O O
with O O
itself O O
. O O

Indeed O O
, O O
ectopic O O
expression O O
of O O
MOX4 B B_GENE
in O O
aerobic O O
cells O O
resulted O O
in O O
partially O O
constitutive O O
expression O O
of O O
DAN1 B B_GENE
. O O

We O O
measured O O
electromyograms O O
( O O
EMG O O
) O O
of O O
the O O
alae O O
nasi O O
to O O
determine O O
the O O
relationship O O
between O O
their O O
activity O O
and O O
timing O O
to O O
contraction O O
of O O
the O O
rib O O
cage O O
muscles O O
and O O
diaphragm O O
during O O
obstructive O O
apnea O O
in O O
nine O O
patients O O
. O O

Hybridization O O
was O O
detected O O
between O O
polyadenylated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
H I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
isolated O O
from O O
the O O
majority O O
of O O
the O O
hybridomas O O
, O O
and O O
the O O
VH B B_DISEASE/B_GENE
probe O O
. O O

The O O
standardized O O
incidence O O
in O O
Europeans O O
has O O
risen O O
significantly O O
to O O
4 O O
. O O
7 O O
/ O O
10 O O
( O O
5 O O
) O O
/ O O
year O O
from O O
3 O O
. O O
4 O O
/ O O
10 O O
( O O
5 O O
) O O
/ O O
year O O
in O O
the O O
1970s O O
( O O
chi O O
2 O O
= O O
8 O O
. O O
1 O O
, O O
p O O
less O O
than O O
0 O O
. O O
005 O O
) O O
. O O

Loss O O
of O O
pRb B B_GENE
or O O
p107 B B_GENE
binding O O
results O O
in O O
the O O
loss O O
of O O
transforming O O
activity O O
. O O

The O O
analysis O O
of O O
results O O
suggests O O
that O O
seroprevalence O O
of O O
Lyme O O
borreliosis O O
in O O
dogs O O
of O O
the O O
Kosice O O
region O O
is O O
not O O
negligible O O
. O O

Peak O O
insulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O O
to O O
glucose O O
infusion O O
declined O O
from O O
Groups O O
1 O O
to O O
3 O O
( O O
51 O O
+ O O
/ O O
- O O
14 O O
, O O
42 O O
. O O
4 O O
+ O O
/ O O
- O O
31 O O
, O O
20 O O
. O O
4 O O
+ O O
/ O O
- O O
6 O O
. O O
8 O O
microU O O
/ O O
ml O O
, O O
respectively O O
) O O
with O O
Group O O
3 O O
exhibiting O O
a O O
significantly O O
decreased O O
mean O O
peak O O
level O O
compared O O
to O O
the O O
other O O
groups O O
. O O

Iris O O
binding O O
and O O
bioavailability O O
. O O

The O O
proliferative O O
potential O O
of O O
the O O
pilocytic O O
astrocytoma O O
: O O
the O O
relation O O
between O O
MIB B B_GENE
- I I_GENE
1 I I_GENE
labeling O O
and O O
clinical O O
and O O
neuro O O
- O O
radiological O O
follow O O
- O O
up O O
. O O

RESULTS O O
: O O
Here O O
, O O
we O O
report O O
the O O
identification O O
of O O
two O O
major O O
and O O
novel O O
Shc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tyrosine O O
phosphorylation O O
sites O O
, O O
Y239 O O
and O O
Y240 O O
. O O

Dominant O O
- O O
negative O O
upf1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O O
were O O
isolated O O
following O O
in O O
vitro O O
mutagenesis O O
of O O
a O O
plasmid O O
containing O O
the O O
UPF1 B B_GENE
gene I I_GENE
. O O

The O O
tensile O O
strengths O O
of O O
an O O
adhesive O O
luting O O
resin O O
' O O
Panavia O O
EX O O
' O O
to O O
the O O
bovine O O
dentin O O
decreased O O
significantly O O
by O O
the O O
zinc O O
iontophoresis O O
. O O

We O O
previously O O
identified O O
a O O
highly O O
conserved O O
L O O
- O O
X O O
- O O
X O O
- O O
L O O
- O O
F O O
sequence O O
near O O
the O O
C O O
terminus O O
of O O
the O O
p6 B B_GENE/B_LOCATION
domain I I_GENE/I_LOCATION
of O O
the O O
Gag B B_GENE
precursor I I_GENE
as O O
the O O
major O O
virion O O
association O O
motif O O
for O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Vpr I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Papillomavirus O O
type O O
16 O O
oncogenes O O
downregulate O O
expression O O
of O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
responsive O O
genes O O
and O O
upregulate O O
proliferation O O
- O O
associated O O
and O O
NF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
kappaB I I_GENE/I_DISEASE
- O O
responsive O O
genes O O
in O O
cervical O O
keratinocytes O O
. O O

The O O
A3B3 O O
domain O O
had O O
a O O
mass O O
of O O
34 O O
, O O
462 O O
, O O
with O O
a O O
glycosylation O O
mass O O
of O O
14 O O
, O O
900 O O
, O O
in O O
good O O
agreement O O
with O O
seven O O
N O O
- O O
linked O O
glycosylation O O
sites O O
of O O
average O O
mass O O
2100 O O
. O O

We O O
found O O
that O O
the O O
frequency O O
spectrum O O
of O O
physiologic O O
chest O O
sounds O O
is O O
contained O O
entirely O O
within O O
that O O
of O O
jet O O
rotocraft O O
noise O O
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CA11 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
appears O O
to O O
be O O
located O O
between O O
the O O
secretor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fucosyltransferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cluster I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
FUT1 B B_PROTEIN[GENE]
- O O
FUT2 B B_PROTEIN[GENE]/B_MEASURE
- O O
FUT2P B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
the O O
D B B_GENE
- I I_GENE
site I I_GENE
binding I I_GENE
protein I I_GENE
gene I I_GENE
( O O
DBP B B_GENE/B_DISEASE
) O O
on O O
chromosome O O
19q13 O O
. O O
3 O O
. O O

These O O
segments O O
may O O
represent O O
pseudogenes O O
. O O

The O O
fusion O O
of O O
AML1 B B_GENE/B_DISEASE
to O O
MDS1 B B_GENE/B_DISEASE
is O O
in O O
frame O O
, O O
and O O
adds O O
127 O O
codons O O
to O O
the O O
interrupted O O
AML1 B B_GENE/B_LOCATION
. O O

In O O
this O O
study O O
, O O
the O O
effect O O
of O O
the O O
antibiotic O O
lasalocid O O
on O O
the O O
rumen O O
anaerobic O O
fungus O O
Neocallimastix O O
frontalis O O
RK O O
21 O O
was O O
examined O O
. O O

WBC O O
differential O O
( O O
SEG O O
, O O
BAND O O
, O O
LYMPH O O
, O O
MONO O O
, O O
EOSINO O O
, O O
BASO O O
) O O
usually O O
showed O O
log O O
- O O
normal O O
distribution O O
. O O

A O O
model O O
for O O
oligomerization O O
- O O
dependent O O
subunit O O
folding O O
. O O

Chromosome O O
- O O
specific O O
STSs O O
for O O
27 O O
telomeres O O
were O O
identified O O
from O O
the O O
196 O O
TYACs O O
. O O

Second O O
, O O
overexpression O O
of O O
RIM11 B B_GENE
can O O
suppress O O
an O O
ime1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
missense O O
mutation O O
( O O
ime1 B B_PROTEIN[GENE]/B_DISEASE
- I I_PROTEIN[GENE]/I_DISEASE
L321F I I_PROTEIN[GENE]/I_DISEASE
) O O
but O O
not O O
an O O
ime1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deletion O O
. O O

Calculation O O
of O O
energy O O
levels O O
, O O
E1 O O
transition O O
amplitudes O O
, O O
and O O
parity O O
violation O O
in O O
francium O O
. O O

All O O
except O O
the O O
last O O
two O O
interventions O O
are O O
physical O O
treatments O O
that O O
create O O
a O O
wound O O
- O O
tissue O O
environment O O
conducive O O
to O O
healing O O
. O O

This O O
50 O O
- O O
kDa O O
protein O O
contains O O
two O O
SH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
an O O
inter B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
SH2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
p85alpha B B_GENE
, O O
but O O
the O O
SH3 B B_GENE
and O O
bcr B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
homology I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
domains I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
p85alpha B B_GENE/B_PERSON
were O O
replaced O O
by O O
a O O
unique O O
6 O O
- O O
amino O O
acid O O
sequence O O
. O O

A O O
clinical O O
double O O
- O O
blind O O
trial O O
of O O
topical O O
miconazole O O
and O O
clotrimazole O O
against O O
superficial O O
fungal O O
infections O O
and O O
erythrasma O O
. O O

Studies O O
on O O
low O O
- O O
dose O O
oral O O
contraceptives O O
: O O
cervical O O
mucus O O
and O O
plasma O O
hormone O O
changes O O
in O O
relation O O
to O O
circulating O O
D O O
- O O
norgestrel O O
and O O
17alpha O O
ethynyl O O
- O O
estradiol O O
concentrations O O
. O O

Herewith O O
C O O
. O O
psittaci O O
could O O
be O O
diagnosed O O
in O O
all O O
positive O O
samples O O
. O O

The O O
more O O
sustained O O
effect O O
of O O
cyclofenil O O
on O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
secretion O O
with O O
a O O
reduced O O
frequency O O
of O O
relapse O O
, O O
and O O
the O O
lower O O
oestradiol O O
level O O
, O O
which O O
might O O
indicate O O
a O O
reduced O O
risk O O
of O O
thromboembolism O O
, O O
suggest O O
that O O
this O O
drug O O
has O O
some O O
advantage O O
over O O
bromocriptine O O
in O O
the O O
inhibition O O
of O O
postpartum O O
lactation O O
. O O

Simulations O O
of O O
velocities O O
, O O
vorticity O O
, O O
pressure O O
and O O
certain O O
stress O O
values O O
were O O
developed O O
by O O
a O O
computer O O
and O O
displayed O O
for O O
man O O
- O O
machine O O
interaction O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
report O O
the O O
entire O O
genomic O O
structure O O
of O O
KCNQ1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
consists O O
of O O
19 O O
exons O O
spanning O O
400 O O
kb O O
on O O
chromosome O O
11p15 O O
. O O
5 O O
. O O

Northern O O
( O O
RNA O O
) O O
blot O O
hybridization O O
analysis O O
with O O
the O O
p68c B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
ets I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
1 I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- O O
specific O O
sequence O O
and O O
RNase B B_ENZYME[GENE]
protection O O
experiments O O
showed O O
that O O
the O O
corresponding O O
mRNA O O
was O O
expressed O O
in O O
normal O O
chicken O O
spleen O O
and O O
not O O
in O O
normal O O
chicken O O
thymus O O
or O O
in O O
various O O
T O O
lymphoid O O
cell O O
lines O O
. O O

To O O
investigate O O
this O O
issue O O
, O O
we O O
used O O
a O O
recognition O O
task O O
in O O
which O O
two O O
strings O O
of O O
letters O O
are O O
presented O O
sequentially O O
. O O

Kettin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
large O O
modular O O
protein O O
associated O O
with O O
thin O O
filaments O O
in O O
the O O
Z O O
- O O
disc O O
region O O
of O O
insect O O
muscles O O
. O O

This O O
review O O
chronicles O O
the O O
characteristics O O
of O O
deliberate O O
and O O
accidental O O
mass O O
poisonings O O
that O O
occurred O O
in O O
World O O
Wars O O
I O O
and O O
II O O
, O O
in O O
Bhopal O O
, O O
and O O
in O O
other O O
historical O O
cases O O
up O O
to O O
and O O
including O O
modern O O
wars O O
. O O

By O O
incorporating O O
a O O
stent O O
with O O
posts O O
that O O
pivot O O
about O O
their O O
base O O
, O O
such O O
that O O
a O O
10 O O
% O O
expansion O O
at O O
the O O
commissures O O
is O O
realized O O
, O O
we O O
were O O
able O O
to O O
reduce O O
the O O
compressive O O
commissural O O
stressing O O
from O O
250 O O
to O O
150 O O
kPa O O
. O O

The O O
cooperation O O
between O O
health O O
and O O
hospital O O
services O O

The O O
free O O
fraction O O
of O O
amitriptyline O O
( O O
AT O O
) O O
, O O
measured O O
by O O
equilibrium O O
dialysis O O
in O O
plasma O O
from O O
29 O O
AT O O
- O O
treated O O
depressed O O
patients O O
, O O
was O O
5 O O
. O O
4 O O
- O O
9 O O
. O O
8 O O
% O O
( O O
mean O O
7 O O
. O O
7 O O
% O O
) O O
, O O
which O O
was O O
the O O
same O O
as O O
the O O
values O O
in O O
26 O O
healthy O O
controls O O
( O O
4 O O
. O O
9 O O
- O O
9 O O
. O O
6 O O
% O O
, O O
mean O O
7 O O
. O O
6 O O
% O O
) O O
. O O

Different O O
effects O O
of O O
reoxygenation O O
on O O
the O O
electrical O O
activity O O
of O O
ventricular O O
muscle O O
. O O

Metastatic O O
tumours O O
of O O
bone O O
in O O
Nigerians O O
. O O

However O O
, O O
microinjection O O
of O O
reconstituted O O
mRNPs O O
into O O
Xenopus O O
oocytes O O
demonstrates O O
that O O
although O O
translational O O
repression O O
occurs O O
in O O
the O O
absence O O
of O O
consensus O O
RNA O O
binding O O
sequences O O
for O O
FRGY2 B B_GENE
, O O
the O O
presence O O
of O O
FRGY2 B B_GENE
recognition I I_GENE
elements I I_GENE
within O O
mRNA O O
potentiates O O
translational O O
repression O O
. O O

Any O O
respectative O O
material O O
( O O
class O O
0 O O
) O O
was O O
not O O
obtained O O
from O O
334 O O
patients O O
( O O
4 O O
. O O
2 O O
% O O
) O O
, O O
class O O
I O O
- O O
II O O
findings O O
belonged O O
to O O
6m141 O O
patients O O
( O O
76 O O
. O O
7 O O
% O O
) O O
, O O
950 O O
patients O O
( O O
11 O O
. O O
9 O O
% O O
) O O
were O O
classified O O
as O O
class O O
HII O O
and O O
IV O O
, O O
578 O O
patients O O
( O O
7 O O
. O O
2 O O
% O O
) O O
as O O
class O O
V O O
. O O

However O O
, O O
whether O O
this O O
was O O
associated O O
with O O
spleen O O
removal O O
after O O
adjustment O O
for O O
risk O O
factors O O
was O O
not O O
determined O O
. O O

Virgin O O
, O O
P O O
. O O

IL B B_GENE/B_BACTERIUM[BIO]
- I B_GENE/I_BACTERIUM[BIO]
6 I B_GENE/I_BACTERIUM[BIO]
was O O
detected O O
in O O
the O O
urine O O
of O O
52 O O
% O O
of O O
children O O
with O O
pyelonephritis O O
compared O O
with O O
15 O O
% O O
of O O
other O O
children O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

We O O
have O O
determined O O
the O O
complete O O
cDNA O O
sequence O O
of O O
rat B B_GENE
plectin I I_GENE
from O O
a O O
number O O
of O O
well O O
- O O
characterized O O
overlapping O O
lambda O O
gt11 O O
clones O O
. O O

SETTING O O
- O O
- O O
Hospital O O
laboratories O O
in O O
the O O
United O O
States O O
submitting O O
pneumococcal O O
isolates O O
to O O
the O O
CDC O O
between O O
October O O
1 O O
, O O
1991 O O
, O O
and O O
September O O
30 O O
, O O
1992 O O
. O O

The O O
terminal O O
a O O
sequence O O
of O O
the O O
herpes O O
simplex O O
virus O O
genome O O
contains O O
the O O
promoter O O
of O O
a O O
gene O O
located O O
in O O
the O O
repeat O O
sequences O O
of O O
the O O
L O O
component O O
. O O

In O O
contrast O O
to O O
p62 B B_GENE
( O O
dok B B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
, O O
DOKL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lacks O O
YxxP O O
motifs O O
in O O
the O O
C O O
terminus O O
and O O
does O O
not O O
bind O O
to O O
Ras B B_GENE
GTPase I I_GENE
- I I_GENE
activating I I_GENE
protein I I_GENE
( O O
RasGAP B B_GENE/B_DISEASE
) O O
upon O O
phosphorylation O O
. O O

These O O
observations O O
demonstrate O O
that O O
KSR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
capable O O
of O O
uncoupling O O
the O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O O
from O O
its O O
target O O
phosphorylation O O
, O O
and O O
thus O O
provide O O
a O O
novel O O
mechanism O O
for O O
modulating O O
the O O
Ras B B_GENE/B_DISEASE
- O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
pathway O O
. O O

G B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CSF I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
10 O O
microg O O
/ O O
kg O O
) O O
was O O
started O O
on O O
day O O
+ O O
1 O O
and O O
all O O
patients O O
engrafted O O
within O O
a O O
median O O
day O O
number O O
of O O
12 O O
( O O
range O O
, O O
10 O O
- O O
22 O O
) O O
until O O
leukocytes O O
> O O
1 O O
. O O
0 O O
x O O
10 O O
( O O
9 O O
) O O
/ O O
l O O
and O O
a O O
median O O
day O O
number O O
of O O
56 O O
( O O
range O O
, O O
10 O O
- O O
180 O O
) O O
until O O
platelets O O
> O O
20 O O
. O O
0 O O
x O O
10 O O
( O O
9 O O
) O O
/ O O
l O O
( O O
ie O O
platelet O O
transfusion O O
independence O O
) O O
. O O

A O O
higher O O
percentage O O
of O O
children O O
with O O
cerebral O O
malaria O O
( O O
40 O O
per O O
cent O O
) O O
than O O
with O O
non O O
- O O
cerebral O O
malaria O O
( O O
29 O O
per O O
cent O O
) O O
or O O
controls O O
( O O
20 O O
per O O
cent O O
) O O
also O O
had O O
either O O
serum B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ferritin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
< O O
100 O O
micrograms O O
/ O O
l O O
and O O
inflammation O O
or O O
sTfR B B_GENE
> O O
7 O O
. O O
3 O O
mg O O
/ O O
l O O
or O O
both O O
. O O

During O O
the O O
burst O O
period O O
( O O
approximately O O
5 O O
- O O
10 O O
min O O
) O O
, O O
local O O
blood O O
H2O2 O O
concentrations O O
and O O
xanthine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activities O O
were O O
highly O O
correlated O O
( O O
r O O
= O O
0 O O
. O O
999 O O
) O O
. O O

Previous O O
studies O O
have O O
demonstrated O O
that O O
the O O
21 O O
- O O
or O O
the O O
72 O O
- O O
bp O O
repeat O O
transcriptional O O
control O O
elements O O
enhance O O
the O O
efficiency O O
of O O
SV40 O O
DNA O O
replication O O
in O O
vivo O O
, O O
provided O O
either O O
of O O
these O O
repeats O O
is O O
located O O
near O O
the O O
end O O
of O O
the O O
core O O
replication O O
origin O O
containing O O
the O O
17 O O
- O O
bp O O
A O O
+ O O
T O O
- O O
containing O O
sequence O O
. O O

UV O O
cross O O
- O O
linking O O
and O O
Southwestern O O
analysis O O
suggested O O
that O O
KTP1 B B_GENE
is O O
a O O
DNA O O
- O O
binding O O
protein O O
clearly O O
distinct O O
from O O
AP2 B B_GENE
, O O
and O O
this O O
protein O O
may O O
be O O
responsible O O
for O O
the O O
basal O O
keratinocyte O O
- O O
specific O O
expression O O
of O O
the O O
BPAG1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Here O O
we O O
demonstrate O O
that O O
a O O
region O O
of O O
high O O
homology O O
between O O
the O O
members O O
of O O
this O O
class O O
of O O
proteins O O
contains O O
a O O
type O O
A O O
nucleotide O O
binding O O
site O O
consensus O O
sequence O O
which O O
has O O
ATPase B B_ENZYME[GENE]
activity O O
and O O
is O O
sufficient O O
to O O
bind O O
DNA O O
containing O O
specific O O
mismatched O O
residues O O
. O O

Copyright O O
1999 O O
Academic O O
Press O O
. O O

Nickel O O
release O O
from O O
tools O O
on O O
the O O
Swedish O O
market O O
. O O

NF B B_GENE
- I I_GENE
kappaB I I_GENE
only O O
partially O O
mediates O O
Epstein B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Barr I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
virus I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
latent I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
membrane I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activation O O
of O O
B O O
cells O O
. O O

Purified O O
fER B B_GENE
exhibited O O
a O O
distribution O O
constant O O
( O O
KD O O
) O O
for O O
17 O O
beta O O
- O O
estradiol O O
of O O
0 O O
. O O
45 O O
nM O O
. O O

The O O
long O O
terminal O O
repeat O O
is O O
590 O O
bp O O
in O O
length O O
, O O
with O O
the O O
U3 O O
region O O
containing O O
consensus O O
sequences O O
likely O O
to O O
be O O
involved O O
in O O
viral O O
gene O O
expression O O
. O O

The O O
peptides O O
are O O
generated O O
in O O
the O O
cytosol O O
, O O
then O O
translocated O O
across O O
the O O
membrane O O
of O O
the O O
endoplasmic O O
reticulum O O
by O O
the O O
transporter B B_ENZYME[GENE]
associated I I_ENZYME[GENE]
with I I_ENZYME[GENE]
antigen I I_ENZYME[GENE]
processing I I_ENZYME[GENE]
( O O
TAP B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

It O O
competes O O
with O O
the O O
calcium O O
ion O O
which O O
brings O O
about O O
inhibition O O
of O O
myosine B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
therefore O O
a O O
drop O O
in O O
phosphorylated O O
myosine O O
. O O

Comparison O O
with O O
the O O
data O O
of O O
clinical O O
development O O
and O O
hemodynamic O O
results O O

Sera O O
collected O O
in O O
1973 O O
- O O
1975 O O
from O O
3053 O O
residents O O
of O O
12 O O
selected O O
Alaskan O O
Eskimo O O
villages O O
were O O
tested O O
for O O
evidence O O
of O O
hepatitis O O
B O O
virus O O
infection O O
. O O

Injection O O
of O O
horseradish B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
peroxidase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
HRP B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
into O O
the O O
cerebellar O O
flocculus O O
of O O
the O O
rat O O
was O O
employed O O
to O O
identify O O
neurons O O
in O O
the O O
abducens O O
nucleus O O
that O O
project O O
to O O
the O O
flocculus O O
. O O

To O O
assay O O
for O O
sequences O O
that O O
could O O
potentially O O
regulate O O
Xenopus B B_GENE
proenkephalin I I_GENE
expression O O
, O O
we O O
transfected O O
constructs O O
that O O
contained O O
upstream O O
genomic O O
sequences O O
linked O O
to O O
the O O
CAT B B_GENE
reporter I I_GENE
gene I I_GENE
into O O
various O O
eukaryotic O O
cell O O
lines O O
. O O

This O O
suggests O O
that O O
the O O
ratio O O
of O O
IL B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
6 I I_GENE/I_LOCATION
to O O
IL B B_GENE
- I I_GENE
10 I I_GENE
may O O
be O O
used O O
to O O
predict O O
the O O
injury O O
severity O O
after O O
trauma O O
. O O

UVB O O
- O O
induced O O
association O O
of O O
tumor B B_GENE
necrosis I I_GENE
factor I I_GENE
( I I_GENE
TNF I I_GENE
) I I_GENE
receptor I I_GENE
1 I I_GENE
/ O O
TNF B B_GENE/B_MEASURE
receptor I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
associated I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
2 I I_GENE/I_MEASURE
mediates O O
activation O O
of O O
Rel B B_GENE
proteins I I_GENE
. O O

In O O
the O O
cervical O O
enlargement O O
they O O
were O O
located O O
in O O
the O O
middle O O
part O O
of O O
lamina O O
VII O O
and O O
in O O
lamina O O
VIII O O
, O O
accounting O O
for O O
about O O
25 O O
% O O
of O O
the O O
total O O
labeled O O
neurons O O
. O O

Nature O O
and O O
incidence O O
of O O
conditioned O O
responses O O
in O O
a O O
methadone O O
population O O
: O O
a O O
comparison O O
of O O
laboratory O O
, O O
clinic O O
, O O
and O O
naturalistic O O
settings O O
. O O

While O O
some O O
still O O
automatically O O
refuse O O
all O O
patients O O
with O O
positive O O
mediastinoscopy O O
, O O
most O O
authors O O
still O O
remain O O
very O O
interventionistic O O
for O O
N2 O O
patients O O
selected O O
on O O
very O O
accurate O O
criteria O O
that O O
are O O
analyzed O O
above O O
. O O

Our O O
previous O O
studies O O
demonstrated O O
that O O
the O O
promyelocytic O O
leukemia O O
gene O O
, O O
PML B B_GENE/B_DISEASE
which O O
involved O O
in O O
the O O
15 O O
; O O
17 O O
translocation O O
in O O
acute O O
promyelocytic O O
leukemia O O
( O O
APL O O
) O O
is O O
a O O
growth O O
and O O
transformation O O
suppressor O O
. O O

A O O
sharp O O
transition O O
from O O
a O O
random O O
chaotic O O
state O O
to O O
a O O
correlated O O
turbulent O O
state O O
of O O
finite O O
coherence O O
time O O
is O O
found O O
when O O
the O O
Rayleigh O O
number O O
becomes O O
larger O O
than O O
a O O
critical O O
value O O
Ra O O
( O O
c O O
) O O
approximately O O
equal O O
to O O
5 O O
x O O
10 O O
( O O
7 O O
) O O
. O O

Our O O
data O O
define O O
Ile O O
( O O
16 O O
) O O
, O O
Val O O
( O O
18 O O
) O O
, O O
Val O O
( O O
31 O O
) O O
, O O
and O O
Ile O O
( O O
33 O O
) O O
as O O
crucial O O
for O O
protein B B_GENE/B_BIO
S I I_GENE/I_BIO
binding O O
, O O
with O O
secondary O O
effects O O
from O O
Leu O O
( O O
38 O O
) O O
and O O
Val O O
( O O
39 O O
) O O
. O O

In O O
the O O
yeast O O
two O O
- O O
hybrid O O
assays O O
, O O
PNRC B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interacted O O
with O O
the O O
orphan O O
receptors O O
SF1 B B_GENE/B_LOCATION
and O O
ERRalpha1 B B_GENE
in O O
a O O
ligand O O
- O O
independent O O
manner O O
. O O

Nuclear O O
export O O
of O O
proteins O O
in O O
plants O O
: O O
AtXPO1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
export O O
receptor O O
for O O
leucine O O
- O O
rich O O
nuclear O O
export O O
signals O O
in O O
Arabidopsis O O
thaliana O O
. O O

Thus O O
, O O
CR2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possesses O O
an O O
essential O O
function O O
besides O O
pRb B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
binding O O
. O O

From O O
the O O
autopsy O O
findings O O
, O O
in O O
5 O O
out O O
of O O
the O O
remaining O O
23 O O
expired O O
patients O O
, O O
Legionella O O
pneumonia O O
seemed O O
to O O
be O O
successfully O O
treated O O
, O O
but O O
other O O
disease O O
or O O
other O O
bacterial O O
pneumonia O O
put O O
an O O
end O O
to O O
the O O
patients O O
. O O

Nitroglycerin O O
( O O
glyceryl O O
trinitrate O O
) O O
as O O
a O O
monoamine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
. O O

This O O
high O O
dose O O
5 O O
- O O
FU O O
+ O O
Act O O
- O O
D O O
protocol O O
was O O
effective O O
for O O
drug O O
resistant O O
cases O O
with O O
MEA O O
protocol O O
. O O

CONCLUSIONS O O
: O O
Transpulmonary O O
stable O O
air O O
microbubbles O O
bound O O
to O O
a O O
galactose O O
carrier O O
represent O O
a O O
useful O O
and O O
safe O O
contrast O O
agent O O
in O O
case O O
of O O
an O O
insufficient O O
native O O
signal O O
in O O
transcranial O O
Doppler O O
investigation O O
. O O

K562 O O
erythroleukemia O O
cells O O
stably O O
transfected O O
with O O
constructs O O
containing O O
the O O
human B B_GENE/B_LOCATION
Agamma I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
globin I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
linked O O
to O O
an O O
enhanced B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
green I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fluorescent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EGFP B B_GENE/B_DISEASE
) O O
reporter O O
, O O
with O O
or O O
without O O
HS2 O O
, O O
were O O
analyzed O O
for O O
EGFP B B_GENE
expression O O
by O O
flow O O
cytometry O O
. O O

Gastrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulates O O
transcription O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histidine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
decarboxylase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HDC B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
gene O O
through O O
binding O O
to O O
the O O
G B B_GENE
- I I_GENE
protein I I_GENE
- O O
coupled O O
cholecystokinin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
gastrin B B_PROTEIN[GENE]
receptor I I_PROTEIN[GENE]
. O O

mph1 B B_GENE/B_DISEASE
functions O O
upstream O O
of O O
mad2 B B_GENE/B_BIO
, O O
a O O
previously O O
characterized O O
component O O
of O O
the O O
spindle O O
checkpoint O O
. O O

Hepatocyte B B_GENE/B_MEASURE
growth I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
( O O
HGF B B_GENE
) O O
is O O
an O O
inducible O O
cytokine O O
that O O
is O O
essential O O
for O O
the O O
normal O O
growth O O
and O O
development O O
of O O
various O O
tissues O O
, O O
such O O
as O O
the O O
liver O O
. O O

However O O
, O O
all O O
pathophysiologic O O
assessments O O
reported O O
to O O
date O O
have O O
been O O
carried O O
out O O
during O O
or O O
immediately O O
after O O
IVOX O O
utilization O O
. O O

The O O
first O O
decision O O
in O O
management O O
is O O
to O O
consider O O
cardioversion O O
which O O
can O O
be O O
achieved O O
in O O
suitable O O
cases O O
electrically O O
, O O
or O O
pharmacologically O O
with O O
a O O
class O O
Ic O O
antiarrhythmic O O
drug O O
like O O
flecainide O O
or O O
propafenone O O
. O O

Structure O O
and O O
chromosomal O O
localization O O
of O O
the O O
human O O
gene O O
of O O
the O O
phosphotyrosyl B B_GENE/B_MEASURE
phosphatase I I_GENE/I_MEASURE
activator I I_GENE/I_MEASURE
( O O
PTPA B B_GENE/B_DISEASE
) O O
of O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Since O O
1988 O O
Modulit O O
- O O
SZ O O
- O O
20 O O
has O O
been O O
tested O O
for O O
localization O O
of O O
nephroliths O O
and O O
ureteroliths O O
. O O

JCAHO O O
moves O O
to O O
rewrite O O
many O O
rules O O
to O O
lessen O O
hospitals O O
' O O
regulatory O O
burden O O
. O O

These O O
transcripts O O
directed O O
the O O
synthesis O O
of O O
three O O
proteins O O
: O O
the O O
virus B B_GENE
trans I I_GENE
- I I_GENE
activator I I_GENE
protein I I_GENE
( O O
EIAV B B_GENE/B_DISEASE
Tat I I_GENE/I_DISEASE
) O O
encoded O O
by O O
ORF O O
S1 O O
, O O
a O O
protein O O
of O O
unknown O O
function O O
encoded O O
by O O
ORF O O
S2 O O
, O O
and O O
the O O
virus O O
envelope B B_GENE
glycoprotein I I_GENE
. O O

However O O
, O O
no O O
significant O O
difference O O
in O O
either O O
the O O
Valsalva O O
ratio O O
or O O
delta O O
SBP O O
was O O
found O O
between O O
diabetic O O
patients O O
and O O
controls O O
. O O

Transmural O O
metabolic O O
heterogeneity O O
at O O
high O O
cardiac O O
work O O
states O O
. O O

We O O
therefore O O
investigated O O
whether O O
the O O
promoter O O
activity O O
of O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
TRH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
directly O O
regulated O O
by O O
RA O O
using O O
a O O
transient O O
transfection O O
assay O O
into O O
CV O O
- O O
1 O O
cells O O
. O O

Spinal O O
injuries O O
in O O
a O O
multiple O O
trauma O O
patient O O
. O O

Statistical O O
aspects O O
of O O
the O O
relation O O
of O O
the O O
radioprotective O O
action O O
of O O
mercaptoethylamine O O
derivatives O O
and O O
analogs O O
to O O
their O O
electron O O
parameters O O

Cerebellar O O
functional O O
compensation O O
after O O
its O O
complete O O
destruction O O
by O O
a O O
neoplasm O O

The O O
RNA O O
, O O
whether O O
antisense O O
, O O
ribozyme O O
, O O
or O O
RNA O O
aptamer O O
, O O
must O O
be O O
efficiently O O
transcribed O O
, O O
stabilized O O
against O O
rapid O O
degradation O O
, O O
folded O O
correctly O O
, O O
and O O
directed O O
to O O
the O O
part O O
of O O
the O O
cell O O
where O O
it O O
can O O
be O O
most O O
effective O O
. O O

The O O
enzyme B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
ACC I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
catalyses O O
the O O
last O O
step O O
of O O
ethylene O O
biosynthesis O O
in O O
plants O O
, O O
converting O O
1 O O
- O O
aminocyclopropane O O
- O O
1 O O
- O O
carboxylic O O
acid O O
( O O
ACC O O
) O O
to O O
ethylene O O
. O O

A O O
99m O O
Tc O O
bone O O
scan O O
showed O O
a O O
focal O O
area O O
of O O
an O O
increased O O
uptake O O
at O O
the O O
site O O
of O O
the O O
mass O O
below O O
the O O
calcaneus O O
. O O

Renal O O
function O O
was O O
evaluated O O
in O O
a O O
group O O
of O O
24 O O
patients O O
( O O
21 O O
men O O
and O O
3 O O
women O O
, O O
mean O O
age O O
47 O O
years O O
) O O
who O O
had O O
survived O O
the O O
malignant O O
phase O O
of O O
hypertension O O
during O O
the O O
period O O
of O O
1969 O O
- O O
1979 O O
. O O

The O O
need O O
for O O
such O O
guidelines O O
is O O
clear O O
on O O
both O O
clinical O O
and O O
scientific O O
grounds O O
. O O

When O O
expressed O O
in O O
thymidine B B_GENE
kinase I I_GENE
- O O
deficient O O
L O O
cells O O
or O O
3T3 O O
cells O O
, O O
C B B_GENE
/ I I_GENE
EBPalpha I I_GENE
is O O
detected O O
in O O
a O O
protein O O
complex O O
which O O
binds O O
to O O
the O O
E2F B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
found O O
in O O
the O O
promoters O O
of O O
the O O
genes O O
for O O
E2F B B_GENE
- I I_GENE
1 I I_GENE
and O O
dihydrofolate B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reductase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DHFR B B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

Members O O
of O O
the O O
CRE B B_GENE
- I I_GENE
binding I I_GENE
protein I I_GENE
( O O
CREB B B_GENE/B_DISEASE
) O O
/ O O
activating B B_GENE
transcription I I_GENE
factor I I_GENE
transcription O O
family O O
as O O
well O O
as O O
members O O
of O O
the O O
Jun B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Fos B B_GENE/B_LOCATION
family O O
have O O
been O O
shown O O
to O O
bind O O
to O O
this O O
sequence O O
. O O

Csk B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
C B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
terminal I I_GENE/I_LOCATION
Src I I_GENE/I_LOCATION
kinase I I_GENE/I_LOCATION
) O O
is O O
a O O
protein B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
phosphorylates O O
Src B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
member I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tails I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
resulting O O
in O O
downregulation O O
of O O
Src B B_GENE/B_NUMBER[MEASURE]
family O O
members O O
. O O

In O O
clinical O O
stroke O O
cardiovascular O O
abnormalities O O
are O O
frequently O O
neglected O O
although O O
they O O
occur O O
more O O
often O O
than O O
it O O
is O O
generally O O
assumed O O
. O O

In O O
the O O
presence O O
of O O
high O O
concentrations O O
( O O
propofol O O
100 O O
microg O O
mL O O
- O O
1 O O
, O O
thiopental O O
50 O O
microg O O
mL O O
- O O
1 O O
) O O
marked O O
relaxation O O
was O O
observed O O
( O O
propofol O O
- O O
32 O O
% O O
up O O
to O O
- O O
49 O O
% O O
, O O
P O O
< O O
0 O O
, O O
05 O O
; O O
thiopental O O
- O O
23 O O
% O O
up O O
to O O
- O O
67 O O
% O O
, O O
P O O
< O O
0 O O
. O O
05 O O
) O O
. O O

Mutations O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PTEN I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Guanylyl B B_GENE/B_LOCATION
cyclase I I_GENE/I_LOCATION
C I I_GENE/I_LOCATION
, O O
the O O
apparent O O
guanylin B B_GENE/B_PERSON
receptor I I_GENE/I_PERSON
, O O
was O O
found O O
in O O
abundant O O
amounts O O
in O O
the O O
intestine O O
by O O
Northern O O
analysis O O
, O O
and O O
by O O
the O O
polymerase O O
chain O O
reaction O O
or O O
cDNA O O
cloning O O
it O O
was O O
also O O
found O O
in O O
adrenal O O
gland O O
, O O
airway O O
epithelial O O
cells O O
, O O
brain O O
, O O
and O O
olfactory O O
and O O
tracheal O O
mucosa O O
. O O

In O O
the O O
present O O
study O O
we O O
have O O
used O O
Southern O O
blot O O
analysis O O
to O O
demonstrate O O
that O O
TSG6 B B_GENE
is O O
a O O
single O O
- O O
copy O O
gene O O
in O O
the O O
human O O
and O O
murine O O
species O O
. O O

As O O
well O O
, O O
variation O O
in O O
capillary O O
size O O
and O O
density O O
was O O
apparent O O
between O O
ventricles O O
in O O
the O O
fetal O O
and O O
neonatal O O
periods O O
. O O

The O O
Polycomb B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
group I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
involved O O
in O O
maintenance O O
of O O
the O O
silenced O O
state O O
of O O
several O O
developmentally O O
regulated O O
genes O O
. O O

Uncertainty O O
exists O O
about O O
the O O
function O O
of O O
these O O
potential O O
isoforms O O
of O O
the O O
Cbfa1 B B_GENE
gene I I_GENE
. O O

When O O
using O O
the O O
high O O
- O O
impedance O O
testing O O
device O O
, O O
the O O
post O O
shock O O
rhythm O O
was O O
initially O O
displayed O O
as O O
' O O
no O O
signal O O
' O O
( O O
Hewlett O O
Packard O O
XL O O
) O O
or O O
' O O
asystole O O
' O O
( O O
Physio O O
- O O
Control O O
LIFEPAK O O
9 O O
) O O
. O O

Human B B_GENE
CD38 I I_GENE
, O O
a O O
leukocyte O O
receptor O O
and O O
ectoenzyme O O
, O O
is O O
a O O
member O O
of O O
a O O
novel O O
eukaryotic O O
gene O O
family O O
of O O
nicotinamide B B_GENE/B_NUMBER[MEASURE]
adenine I I_GENE/I_NUMBER[MEASURE]
dinucleotide I I_GENE/I_NUMBER[MEASURE]
+ I I_GENE/I_NUMBER[MEASURE]
- I I_GENE/I_NUMBER[MEASURE]
converting I I_GENE/I_NUMBER[MEASURE]
enzymes I I_GENE/I_NUMBER[MEASURE]
: O O
extensive O O
structural O O
homology O O
with O O
the O O
genes O O
for O O
murine B B_SPECIES[BIO]/B_GENE
bone I I_SPECIES[BIO]/I_GENE
marrow I I_SPECIES[BIO]/I_GENE
stromal I I_SPECIES[BIO]/I_GENE
cell I I_SPECIES[BIO]/I_GENE
antigen I I_SPECIES[BIO]/I_GENE
1 I I_SPECIES[BIO]/I_GENE
and O O
aplysian B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ADP I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ribosyl I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyclase I I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

From O O
the O O
deduced O O
amino O O
acid O O
sequence O O
, O O
a O O
molecular O O
weight O O
of O O
38 O O
, O O
549 O O
was O O
calculated O O
for O O
the O O
ADH B B_GENE
subunit I I_GENE
. O O

The O O
higher O O
level O O
of O O
calories O O
was O O
attained O O
by O O
an O O
increased O O
intake O O
of O O
carbohydrates O O
. O O

A O O
simple O O
algorithm O O
fitting O O
the O O
data O O
for O O
the O O
moving O O
192Ir O O
source O O
is O O
proposed O O
. O O

TAF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates O O
transcription O O
constitutively O O
and O O
was O O
mapped O O
to O O
the O O
first O O
32 O O
amino O O
acids O O
of O O
the O O
A O O
- O O
region O O
. O O

For O O
the O O
first O O
, O O
short O O
- O O
term O O
( O O
concurrent O O
) O O
TAL O O
, O O
two O O
different O O
- O O
flavored O O
stimuli O O
were O O
presented O O
at O O
the O O
same O O
time O O
, O O
one O O
associated O O
with O O
simultaneous O O
intragastric O O
administration O O
of O O
an O O
aversive O O
product O O
, O O
hypertonic O O
NaCl O O
, O O
and O O
the O O
other O O
with O O
saline O O
. O O

The O O
great O O
cardiac O O
vein O O
flow O O
became O O
zero O O
due O O
to O O
the O O
cardiac O O
arrest O O
and O O
remained O O
at O O
zero O O
for O O
a O O
moment O O
( O O
dead O O
time O O
) O O
after O O
the O O
initiation O O
of O O
reperfusion O O
. O O

INTERNET O O
is O O
literally O O
a O O
world O O
of O O
data O O
, O O
dialogue O O
, O O
and O O
discourse O O
on O O
any O O
topic O O
imaginable O O
, O O
right O O
at O O
your O O
fingertips O O
. O O

Attention O O
is O O
devoted O O
in O O
particular O O
to O O
the O O
action O O
of O O
thermoregulating O O
nervous O O
and O O
hormonal O O
mechanisms O O
. O O

The O O
formation O O
of O O
a O O
D O O
- O O
loop O O
is O O
an O O
essential O O
step O O
in O O
DNA O O
double O O
- O O
strand O O
break O O
repair O O
through O O
recombination O O
. O O

The O O
cDNA O O
is O O
predicted O O
to O O
encode O O
a O O
polypeptide O O
of O O
298 O O
amino O O
acids O O
that O O
is O O
homologous O O
to O O
the O O
Y B B_GENE
- I I_GENE
box I I_GENE
( I I_GENE
inverted I I_GENE
CCAAT I I_GENE
) I I_GENE
family I I_GENE
of I I_GENE
DNA I I_GENE
- I I_GENE
binding I I_GENE
transcription I I_GENE
factors I I_GENE
. O O

Toward O O
this O O
end O O
, O O
we O O
used O O
two O O
cultured O O
colon O O
cancer O O
cell O O
lines O O
; O O
one O O
( O O
RKO O O
) O O
has O O
a O O
transcriptionally O O
activated O O
u B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
PAR I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
, O O
and O O
the O O
other O O
( O O
GEO O O
) O O
overexpresses O O
the O O
receptor O O
only O O
after O O
phorbol O O
ester O O
treatment O O
. O O

The O O
two O O
yeast B B_PROTEIN[GENE]/B_BIO
pheromone I I_PROTEIN[GENE]/I_BIO
receptors I I_PROTEIN[GENE]/I_BIO
, O O
the O O
a B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
alpha I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
factor I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
receptors I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
share O O
many O O
functional O O
similarities O O
: O O
both O O
G B B_GENE/B_LOCATION
protein I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
coupled I I_GENE/I_LOCATION
receptors I I_GENE/I_LOCATION
couple O O
to O O
the O O
same O O
downstream O O
signal O O
transduction O O
pathway O O
, O O
and O O
both O O
receptors O O
undergo O O
feedback O O
regulation O O
involving O O
increased O O
phosphorylation O O
on O O
their O O
C O O
- O O
terminal O O
domains O O
in O O
response O O
to O O
ligand O O
challenge O O
. O O

Moreover O O
, O O
the O O
formation O O
of O O
the O O
complex O O
between O O
IclR B B_GENE
and O O
the O O
operator O O
/ O O
promoter O O
region O O
has O O
been O O
found O O
to O O
be O O
impaired O O
by O O
phosphoenol O O
pyruvate O O
but O O
insensitive O O
to O O
acetate O O
, O O
acetyl O O
- O O
CoA O O
, O O
pyruvate O O
, O O
and O O
oxaloacetate O O
. O O

After O O
enzymatic O O
hydrolysis O O
of O O
the O O
water O O
soluble O O
fraction O O
, O O
it O O
is O O
shown O O
that O O
28 O O
% O O
is O O
again O O
extractable O O
by O O
DCM O O
of O O
which O O
57 O O
% O O
consists O O
of O O
unchanged O O
SC4453 O O
which O O
is O O
therefore O O
the O O
main O O
partner O O
of O O
conjugated O O
products O O
. O O

The O O
expression O O
pattern O O
of O O
the O O
reporter O O
gene O O
was O O
compared O O
to O O
that O O
of O O
the O O
endogenous B B_GENE/B_PERSON
PDGFbeta I I_GENE/I_PERSON
r I I_GENE/I_PERSON
gene I I_GENE/I_PERSON
. O O

This O O
complex O O
was O O
eliminated O O
by O O
mutation O O
of O O
either O O
half O O
- O O
site O O
, O O
and O O
it O O
was O O
supershifted O O
by O O
antibodies O O
against O O
chicken B B_GENE
ovalbumin I I_GENE
upstream I I_GENE
promoter I I_GENE
- I I_GENE
transcription I I_GENE
factor I I_GENE
( O O
COUP B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
TF I I_PROTEIN[GENE]/I_LOCATION
) O O
. O O

The O O
fz B B_GENE
- I I_GENE
1 I I_GENE
and O O
fz B B_GENE
- I I_GENE
2 I I_GENE
genes I I_GENE
are O O
widely O O
expressed O O
in O O
rat O O
tissues O O
with O O
the O O
highest O O
steady O O
- O O
state O O
levels O O
of O O
mRNA O O
in O O
kidney O O
, O O
liver O O
, O O
heart O O
, O O
uterus O O
, O O
and O O
ovary O O
. O O

fz B B_GENE/B_PERSON
- I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
and I I_GENE/I_PERSON
- I I_GENE/I_PERSON
2 I I_GENE/I_PERSON
mRNA I I_GENE/I_PERSON
levels O O
were O O
greater O O
in O O
neonatal O O
than O O
in O O
corresponding O O
adult O O
tissues O O
. O O

These O O
results O O
indicate O O
that O O
the O O
changes O O
in O O
the O O
patient O O
' O O
s O O
thyroid O O
scan O O
and O O
RAIU O O
were O O
attributable O O
to O O
the O O
presence O O
of O O
TSAb O O
. O O

The O O
methods O O
used O O
were O O
the O O
AOAC O O
method O O
of O O
dilution O O
and O O
heating O O
; O O
the O O
addition O O
of O O
mercuric O O
chloride O O
, O O
charcoal O O
, O O
and O O
Carrez O O
reagents O O
at O O
2 O O
different O O
pH O O
values O O
; O O
and O O
direct O O
analysis O O
of O O
sample O O
supernatants O O
with O O
no O O
treatment O O
( O O
control O O
) O O
. O O

Cytochemical O O
and O O
ultrastructural O O
observations O O
on O O
the O O
tegument O O
of O O
the O O
trematode O O
Megalodiscus O O
temperatus O O
. O O

A O O
40 O O
- O O
fold O O
stimulation O O
of O O
chloramphenicol B B_GENE
acetyltransferase I I_GENE
activity O O
mediated O O
by O O
four O O
tandem O O
repeats O O
of O O
the O O
SNE B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
induced O O
within O O
2 O O
h O O
( O O
and O O
up O O
to O O
250 O O
- O O
fold O O
within O O
6 O O
h O O
) O O
after O O
addition O O
of O O
TPA O O
in O O
DNA O O
- O O
transfected O O
U O O
- O O
937 O O
cells O O
, O O
indicating O O
that O O
the O O
stimulation O O
appeared O O
likely O O
to O O
be O O
a O O
true O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
mediated O O
signal O O
transduction O O
event O O
rather O O
than O O
a O O
differentiation O O
response O O
. O O

This O O
increased O O
frequency O O
of O O
infection O O
has O O
been O O
accompanied O O
by O O
significant O O
excess O O
mortality O O
. O O

Deletion O O
mutants O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CHOP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
identify O O
a O O
region O O
comprising O O
nucleotides O O
- O O
75 O O
to O O
- O O
104 O O
required O O
for O O
both O O
constitutive O O
and O O
ER O O
- O O
stress O O
- O O
inducible O O
expression O O
. O O

The O O
duration O O
of O O
PGE2 O O
and O O
PGF2 O O
alpha O O
elevations O O
as O O
well O O
as O O
the O O
peak O O
values O O
were O O
influenced O O
by O O
day O O
of O O
the O O
cycle O O
. O O

We O O
propose O O
that O O
the O O
cDNA O O
encodes O O
an O O
apical O O
plasma O O
membrane O O
protein O O
that O O
plays O O
a O O
role O O
in O O
the O O
functional O O
expression O O
of O O
the O O
amiloride O O
- O O
sensitive O O
epithelial O O
sodium O O
channel O O
. O O

Electrophysiology O O
and O O
pharmacology O O
of O O
epicardial O O
, O O
endocardial O O
, O O
and O O
M O O
cells O O
. O O

In O O
contrast O O
, O O
an O O
N B B_GENE/B_BIO
- I I_GENE/I_BIO
terminal I I_GENE/I_BIO
RNAP I I_GENE/I_BIO
mutant I I_GENE/I_BIO
that O O
has O O
a O O
decreased O O
capacity O O
to O O
bind O O
single O O
- O O
stranded O O
RNA O O
forms O O
halted O O
complexes O O
with O O
much O O
lower O O
levels O O
of O O
stability O O
than O O
the O O
WT O O
enzyme O O
, O O
and O O
these O O
complexes O O
are O O
not O O
stabilized O O
by O O
the O O
presence O O
of O O
the O O
NT O O
strand O O
. O O

A O O
cephalothoracophagus O O
disymmetros O O
buffalo O O
calf O O
. O O

A O O
mouse O O
brain O O
cDNA O O
library O O
in O O
lambdagt11 O O
was O O
screened O O
for O O
this O O
association O O
, O O
and O O
two O O
positive O O
clones O O
encoding O O
tyrosine B B_GENE
phosphatase I I_GENE
SH B I_GENE
- I I_GENE
PTP2 I I_GENE
were O O
isolated O O
. O O

Disorganization O O
scores O O
of O O
the O O
hypertrophy O O
zone O O
and O O
trabecular O O
bone O O
were O O
low O O
, O O
approaching O O
normal O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
, O O
for O O
turkey O O
poults O O
fed O O
on O O
diets O O
with O O
phytase B B_LOCATION/B_PROTEIN[GENE]
supplementation O O
, O O
and O O
tibial O O
abnormality O O
scores O O
were O O
linearly O O
decreased O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
as O O
nP O O
levels O O
increased O O
( O O
zero O O
score O O
is O O
considered O O
normal O O
) O O
. O O

Repression O O
was O O
strictly O O
dependent O O
on O O
the O O
presence O O
of O O
upstream O O
Oshox1 B B_GENE/B_LOCATION
binding O O
sites O O
in O O
the O O
reporter O O
gene O O
constructs O O
and O O
a O O
function O O
of O O
the O O
N O O
- O O
terminal O O
region O O
of O O
Oshox1 B B_GENE
, O O
preceding O O
the O O
homeodomain B B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Ondansetron O O
is O O
thus O O
an O O
effective O O
first O O
- O O
line O O
antiemetic O O
in O O
children O O
undergoing O O
chemotherapy O O
, O O
radiotherapy O O
and O O
surgery O O
. O O

To O O
elucidate O O
the O O
molecular O O
mechanism O O
by O O
which O O
the O O
Ras B B_GENE/B_DISEASE
signaling O O
pathway O O
activates O O
a O O
cell O O
- O O
type O O
- O O
specific O O
gene O O
, O O
we O O
have O O
used O O
the O O
pituitary B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rat I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolactin I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
rPRL B B_PROTEIN[GENE]/B_DISEASE
) O O
promoter O O
as O O
a O O
target O O
of O O
oncogenic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ras I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Raf B B_GENE/B_DISEASE
in O O
GH4 O O
rat O O
pituitary O O
cells O O
. O O

The O O
human O O
RFC B B_GENE/B_BIO
- I I_GENE/I_BIO
1 I I_GENE/I_BIO
gene I I_GENE/I_BIO
differs O O
from O O
the O O
mouse O O
and O O
hamster O O
genes O O
both O O
in O O
terms O O
of O O
the O O
total O O
number O O
of O O
exons O O
and O O
in O O
regard O O
to O O
alternatives O O
of O O
exon O O
1 O O
which O O
encode O O
5 O O
' O O
end O O
heterogeneity O O
. O O

Type O O
C O O
units O O
summate O O
the O O
responses O O
to O O
the O O
two O O
- O O
tone O O
stimulus O O
, O O
and O O
show O O
little O O
or O O
no O O
inhibitory O O
influences O O
. O O

HGF B B_MEASURE/B_GENE
treatment O O
increased O O
cyclin B B_GENE
A I I_GENE
, O O
cyclin B B_GENE
G1 I I_GENE
and O O
nuclear O O
transcriptional O O
factor O O
( O O
NFkappaB B B_GENE/B_DISEASE
) O O
protein O O
expression O O
. O O

Since O O
blood O O
serotonin O O
is O O
primarily O O
produced O O
peripherally O O
, O O
these O O
results O O
suggest O O
that O O
some O O
aspect O O
of O O
peripheral O O
serotonin O O
metabolism O O
is O O
abnormal O O
in O O
major O O
depression O O
. O O

Although O O
several O O
large O O
waterborne O O
outbreaks O O
occurred O O
during O O
the O O
past O O
decade O O
, O O
most O O
were O O
in O O
small O O
communities O O
. O O

Cytogenetic O O
structures O O
showed O O
a O O
mixte O O
karyotype O O
: O O
mosaicim O O
46 O O
XX O O
/ O O
46 O O
XY O O
with O O
a O O
ratio O O
of O O
a O O
80 O O
/ O O
20 O O
. O O

The O O
1 O O
. O O
6 O O
- O O
kb O O
cDNA O O
( O O
CBF B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
A I I_PROTEIN[GENE]/I_MEASURE
) O O
encoding O O
285 O O
amino O O
acids O O
( O O
aa O O
) O O
was O O
obtained O O
, O O
and O O
a O O
beta B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
galactosidase I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
fusion I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
bacterially O O
produced O O
from O O
the O O
cDNA O O
, O O
bound O O
to O O
DNA O O
fragments O O
containing O O
several O O
CArG O O
boxes O O
. O O

In O O
this O O
paper O O
we O O
review O O
evidence O O
on O O
smoking O O
and O O
lung O O
cancer O O
among O O
Latinos O O
, O O
including O O
findings O O
from O O
several O O
unpublished O O
studies O O
and O O
technical O O
reports O O
. O O

Despite O O
these O O
high O O
initial O O
rates O O
of O O
transcription O O
, O O
of O O
all O O
the O O
promoter O O
constructs O O
only O O
LAT B B_DISEASE/B_PROTEIN[GENE]
- O O
LTR O O
was O O
able O O
to O O
remain O O
transcriptionally O O
active O O
after O O
the O O
establishment O O
of O O
a O O
latent O O
state O O
. O O

We O O
concluded O O
that O O
these O O
results O O
support O O
the O O
feasibility O O
and O O
usefulness O O
of O O
N O O
- O O
of O O
- O O
1 O O
RCT O O
in O O
rheumatology O O
practice O O
. O O

Sci O O
. O O

These O O
extrachromosomal O O
copies O O
can O O
be O O
isolated O O
as O O
covalently O O
closed O O
molecules O O
with O O
lengths O O
around O O
3mu O O
. O O

Comparison O O
of O O
the O O
footprint O O
patterns O O
of O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
human I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HPRT I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
demonstrated O O
that O O
the O O
in O O
vivo O O
binding O O
of O O
regulatory O O
proteins O O
between O O
these O O
species O O
is O O
generally O O
conserved O O
but O O
not O O
identical O O
. O O

Our O O
Northern O O
and O O
Southern O O
blot O O
analyses O O
of O O
meningiomas O O
clearly O O
suggest O O
the O O
CLH B B_GENE
- I I_GENE
22 I I_GENE
gene I I_GENE
may O O
be O O
involved O O
in O O
the O O
tumor O O
development O O
and O O
can O O
be O O
considered O O
as O O
a O O
candidate O O
for O O
a O O
tumor O O
suppressor O O
. O O

Plasmodium O O
vivax O O
malaria O O
. O O

This O O
set O O
of O O
genetic O O
and O O
physical O O
interactions O O
suggests O O
a O O
role O O
for O O
yeast O O
RNA O O
- O O
binding O O
proteins O O
in O O
transcriptional O O
regulation O O
. O O

POPULATION O O
AND O O
METHODS O O
: O O
105 O O
patients O O
were O O
followed O O
prospectively O O
( O O
male O O
: O O
87 O O
% O O
; O O
age O O
: O O
56 O O
+ O O
/ O O
- O O
10 O O
) O O
; O O
clinical O O
evaluation O O
was O O
performed O O
in O O
the O O
1st O O
, O O
3rd O O
and O O
6th O O
month O O
, O O
SEKG O O
in O O
the O O
4th O O
month O O
and O O
recatheterization O O
for O O
angiographic O O
control O O
in O O
the O O
6th O O
month O O
. O O

All O O
other O O
cysts O O
showed O O
a O O
unilocular O O
, O O
purely O O
cystic O O
pattern O O
, O O
with O O
homogeneous O O
fluids O O
, O O
although O O
the O O
T2 O O
relaxation O O
times O O
of O O
four O O
lesions O O
overlapped O O
those O O
of O O
odontogenic O O
keratocysts O O
. O O

Genetic O O
diagnosis O O
of O O
respiratory O O
diseases O O

The O O
c B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Jun I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
delta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
domain I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibits O O
neuroendocrine O O
promoter O O
activity O O
in O O
a O O
DNA O O
sequence O O
- O O
and O O
pituitary O O
- O O
specific O O
manner O O
. O O

Cross O O
- O O
sectional O O
studies O O
continue O O
to O O
dominate O O
. O O

The O O
role O O
of O O
the O O
medical O O
facilities O O
in O O
the O O
prognosis O O
of O O
the O O
patient O O
with O O
tetanus O O
specially O O
the O O
importance O O
of O O
considering O O
at O O
the O O
same O O
time O O
the O O
severity O O
of O O
the O O
disease O O
and O O
the O O
characteristics O O
of O O
the O O
therapy O O
deserve O O
further O O
study O O
in O O
order O O
to O O
contribute O O
to O O
the O O
development O O
of O O
the O O
medical O O
assistance O O
to O O
the O O
patients O O
with O O
tetanus O O
. O O

Differences O O
were O O
not O O
found O O
in O O
colons O O
by O O
SEM O O
. O O

Increasing O O
the O O
height O O
of O O
the O O
agar O O
column O O
overlying O O
the O O
SN O O
fabric O O
diminished O O
the O O
inhibitory O O
effect O O
of O O
SN O O
on O O
microbial O O
growth O O
. O O

Neither O O
raw O O
nor O O
retrograded O O
resistant O O
starch O O
lowers O O
fasting O O
serum O O
cholesterol O O
concentrations O O
in O O
healthy O O
normolipidemic O O
subjects O O
. O O

( O O
5 O O
) O O
. O O

Hepatitis O O
B O O
markers O O
in O O
Lancashire O O
police O O
officers O O
. O O

In O O
the O O
other O O
two O O
groups O O
( O O
NAAR O O
and O O
PLA O O
) O O
, O O
no O O
variation O O
in O O
this O O
serum O O
protease O O
was O O
observed O O
. O O

Maximum O O
likelihood O O
estimation O O
in O O
covariance O O
structure O O
analysis O O
with O O
truncated O O
data O O
. O O

A O O
single O O
dose O O
of O O
Cef O O
was O O
administered O O
intravenously O O
to O O
11 O O
patients O O
with O O
autoimmune O O
diseases O O
and O O
varying O O
degrees O O
of O O
renal O O
impairment O O
( O O
Group O O
I O O
CLCR O O
less O O
than O O
50 O O
ml O O
/ O O
min O O
, O O
Group O O
II O O
CLCR O O
greater O O
than O O
50 O O
ml O O
/ O O
min O O
) O O
. O O

The O O
liver O O
- O O
specific O O
sequence O O
contains O O
unique O O
consensus O O
sites O O
for O O
phosphorylation O O
by O O
cyclic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AMP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
by O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Effect O O
of O O
gentamycin O O
on O O
the O O
kidney O O
functional O O
state O O
in O O
experimental O O
pyelonephritis O O

They O O
represent O O
a O O
physiologically O O
more O O
meaningful O O
pattern O O
than O O
the O O
arithmetic O O
mean O O
with O O
standard O O
deviation O O
. O O

The O O
Valpha B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
Vbeta B B_GENE
domains I I_GENE
have O O
the O O
canonical O O
features O O
of O O
known O O
teleost B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
mammalian I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
TCR I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
V I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
domains I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
conserved O O
residues O O
in O O
the O O
beginning O O
of O O
FR2 B B_PROTEIN[GENE]/B_LOCATION
and O O
at O O
the O O
end O O
of O O
FR3 B B_GENE
. O O

Whether O O
this O O
lack O O
of O O
preferential O O
repair O O
has O O
to O O
be O O
explained O O
by O O
a O O
defect O O
in O O
repair O O
or O O
in O O
general O O
transcription O O
is O O
unclear O O
at O O
present O O
. O O

This O O
study O O
examines O O
LEIBNIZ O O
' O O
idea O O
of O O
Veterinary O O
medicine O O
in O O
a O O
biographical O O
context O O
. O O

Dipetalonema O O
( O O
Acanthocheilonema O O
) O O
didelphis O O
sp O O
. O O

n O O
. O O

While O O
there O O
is O O
growing O O
evidence O O
that O O
perception O O
and O O
imagery O O
share O O
common O O
neural O O
substrates O O
, O O
the O O
fact O O
that O O
D O O
. O O
F O O
. O O
shows O O
intact O O
visual O O
imagery O O
in O O
the O O
face O O
of O O
a O O
massive O O
perceptual O O
deficit O O
in O O
form O O
vision O O
challenges O O
recent O O
suggestions O O
that O O
these O O
two O O
psychological O O
processes O O
share O O
common O O
input O O
pathways O O
in O O
early O O
vision O O
. O O

An O O
ethnic O O
analysis O O
was O O
made O O
of O O
8947 O O
cases O O
of O O
primary O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
tumors O O
seen O O
at O O
the O O
Armed O O
Forces O O
Institute O O
of O O
Pathology O O
( O O
AFIP O O
) O O
, O O
Washington O O
, O O
DC O O
, O O
from O O
1971 O O
to O O
1985 O O
. O O

In O O
this O O
report O O
, O O
we O O
demonstrate O O
that O O
FRS2 B B_GENE
forms O O
a O O
complex O O
with O O
the O O
N B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
terminal I I_GENE/I_MEASURE
SH2 I I_GENE/I_MEASURE
domain I I_GENE/I_MEASURE
of O O
the O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Shp2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
response O O
to O O
FGF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O O
. O O

It O O
is O O
concluded O O
that O O
the O O
drinking O O
ampules O O
of O O
VP O O
- O O
16 O O
- O O
213 O O
can O O
be O O
replaced O O
with O O
the O O
new O O
oral O O
capsules O O
with O O
a O O
recommended O O
initial O O
dose O O
of O O
100 O O
- O O
130 O O
mg O O
/ O O
m2 O O
given O O
in O O
5 O O
- O O
day O O
courses O O
every O O
21 O O
- O O
28 O O
days O O
. O O

Although O O
the O O
number O O
of O O
kits O O
has O O
increased O O
, O O
the O O
precision O O
has O O
improved O O
, O O
showing O O
that O O
more O O
robust O O
methods O O
are O O
now O O
employed O O
. O O

These O O
results O O
establish O O
that O O
the O O
DNA O O
fragment O O
we O O
have O O
isolated O O
contains O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gp130 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
that O O
interleukin B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
6 I I_GENE/I_DISEASE
type I I_GENE/I_DISEASE
cytokines I I_GENE/I_DISEASE
may O O
influence O O
the O O
activity O O
of O O
this O O
promoter O O
via O O
activated O O
STATs B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
unexpected O O
prevalence O O
of O O
c B B_GENE
- I I_GENE
myc I I_GENE
and O O
alpha B B_GENE
- I I_GENE
tubulin I I_GENE
in O O
the O O
S O O
- O O
phase O O
library O O
is O O
supported O O
by O O
Northern O O
analysis O O
of O O
RNA O O
from O O
phase O O
- O O
synchronous O O
cells O O
. O O

Growth O O
factors O O
promote O O
cell O O
survival O O
through O O
phosphorylation O O
of O O
Bad B B_GENE
, O O
resulting O O
in O O
its O O
dissociation O O
from O O
Bcl B B_GENE
- I I_GENE
2 I I_GENE
and O O
Bcl B B_GENE
- I I_GENE
x I I_GENE
( I I_GENE
L I I_GENE
) I I_GENE
and O O
its O O
association O O
with O O
14 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3tau I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
representative O O
group O O
of O O
patients O O
undergoing O O
open O O
radical O O
nephrectomy O O
for O O
clinical O O
T1 O O
, O O
T2 O O
lesions O O
was O O
also O O
identified O O
. O O

By O O
applying O O
a O O
sufficiently O O
strong O O
crusher O O
gradient O O
in O O
the O O
EPI O O
pulse O O
sequence O O
, O O
the O O
temporal O O
variation O O
induced O O
by O O
SSFP O O
disturbance O O
can O O
be O O
suppressed O O
due O O
to O O
diffusion O O
. O O

However O O
, O O
in O O
each O O
case O O
in O O
which O O
either O O
the O O
DQ B B_GENE/B_MEASURE
alpha I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
or I I_GENE/I_MEASURE
DQ I I_GENE/I_MEASURE
beta I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
chain I I_GENE/I_MEASURE
was O O
exchanged O O
, O O
major O O
alterations O O
or O O
reversals O O
of O O
this O O
pattern O O
of O O
interaction O O
were O O
observed O O
. O O

From O O
1998 O O
to O O
1999 O O
, O O
a O O
large O O
number O O
of O O
community O O
- O O
acquired O O
respiratory O O
tract O O
isolates O O
of O O
Streptococcus O O
pneumoniae O O
( O O
n O O
= O O
566 O O
) O O
, O O
Haemophilus O O
influenzae O O
( O O
n O O
= O O
513 O O
) O O
and O O
Moraxella O O
catarrhalis O O
( O O
n O O
= O O
228 O O
) O O
were O O
collected O O
from O O
15 O O
centres O O
in O O
Australia O O
, O O
Hong O O
Kong O O
, O O
Japan O O
, O O
China O O
, O O
the O O
Philippines O O
, O O
Singapore O O
, O O
South O O
Africa O O
and O O
Taiwan O O
through O O
the O O
SENTRY O O
Antimicrobial O O
Surveillance O O
Program O O
. O O

Diethyldithiocarbamate O O
and O O
amphetamine O O
stereotype O O
behavior O O
. O O

We O O
used O O
an O O
immobilized O O
template O O
- O O
based O O
assay O O
to O O
examine O O
transcription O O
termination O O
by O O
VA1 B B_PROTEIN[GENE]/B_DISEASE
, O O
7SL B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
Alu B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
III I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
templates O O
and O O
the O O
role O O
of O O
transcript O O
release O O
in O O
the O O
pol B B_LOCATION/B_GENE
III I B_LOCATION/I_GENE
terminator O O
- O O
dependent O O
inhibition O O
of O O
processing O O
of O O
B1 B B_PROTEIN[GENE]/B_DISEASE
- O O
Alu B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transcripts O O
. O O

A O O
novel O O
zinc O O
finger O O
- O O
containing O O
RNA O O
- O O
binding O O
protein O O
conserved O O
from O O
fruitflies O O
to O O
humans O O
. O O

Although O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
activate O O
ERK B B_GENE
- I I_GENE
1 I I_GENE
in O O
HepG2 O O
cells O O
, O O
STAT3 B B_GENE
transactivation O O
and O O
Ser O O
( O O
727 O O
) O O
phosphorylation O O
were O O
not O O
reduced O O
by O O
using O O
the O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
ERK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MEK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
inhibitor O O
PD98059 O O
or O O
by O O
overexpression O O
of O O
dominant O O
- O O
negative O O
Raf B B_GENE/B_DISEASE
. O O

Tritiated O O
1 O O
, O O
24 O O
, O O
25 O O
- O O
trihydroxyvitamin O O
D3 O O
was O O
synthesized O O
biologically O O
and O O
used O O
as O O
tracer O O
to O O
monitor O O
the O O
recovery O O
of O O
endogenous O O
metabolite O O
during O O
isolation O O
from O O
serum O O
. O O

Nuclear O O
runoff O O
assays O O
show O O
that O O
complementation O O
by O O
HPV16 B B_DISEASE/B_GENE
E7 I B_DISEASE/I_GENE
restores O O
the O O
ability O O
of O O
the O O
E1A B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O O
stimulate O O
early B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
at O O
the O O
level O O
of O O
transcription O O
. O O

Yet O O
IL B B_GENE
- I I_GENE
2 I I_GENE
and O O
IFN B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
are O O
independently O O
regulated O O
, O O
as O O
demonstrated O O
by O O
their O O
differential O O
expression O O
in O O
certain O O
T O O
cell O O
subsets O O
, O O
suggesting O O
that O O
the O O
regulatory O O
elements O O
in O O
these O O
two O O
genes O O
must O O
differ O O
. O O

We O O
conclude O O
that O O
a O O
0 O O
. O O
25 O O
mg O O
dose O O
of O O
triazolam O O
does O O
not O O
effectively O O
counteract O O
a O O
posture O O
- O O
induced O O
sleep O O
disturbance O O
, O O
but O O
induces O O
changes O O
in O O
the O O
EEG O O
spectra O O
which O O
are O O
typical O O
for O O
benzodiazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
agonists O O
. O O

Anisotropy O O
of O O
Hc2 O O
and O O
the O O
breadth O O
of O O
the O O
resistive O O
transition O O
of O O
polycrystalline O O
YBa2Cu O O

Microscopic O O
examination O O
of O O
these O O
colonies O O
showed O O
a O O
high O O
percentage O O
of O O
histiocytes O O
identical O O
to O O
those O O
seen O O
in O O
the O O
patient O O
' O O
s O O
bone O O
marrow O O
. O O

Functional O O
uncoupling O O
of O O
the O O
Janus B B_GENE
kinase I I_GENE
3 I I_GENE
- O O
Stat5 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathway O O
in O O
malignant O O
growth O O
of O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
1 O O
- O O
transformed O O
human O O
T O O
cells O O
. O O

The O O
combination O O
of O O
ICP47 B B_GENE
and O O
US11 B B_MEASURE/B_GENE
rendered O O
fibroblasts O O
negative O O
for O O
surface B B_GENE
class I I_GENE
I I I_GENE
MHC I I_GENE
and O O
allowed O O
a O O
class B B_GENE/B_DISEASE
I I I_GENE/I_DISEASE
MHC I I_GENE/I_DISEASE
- O O
low O O
population O O
of O O
T O O
cells O O
to O O
be O O
sorted O O
by O O
flow O O
cytometry O O
. O O

Although O O
IRS B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
, I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
2 I I_GENE/I_MEASURE
, I I_GENE/I_MEASURE
and I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
4 I I_GENE/I_MEASURE
are O O
similar O O
in O O
overall O O
structure O O
, O O
IRS B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
3 I I_GENE/I_MEASURE
is O O
approximately O O
50 O O
% O O
shorter O O
and O O
differs O O
with O O
respect O O
to O O
sites O O
of O O
tyrosine O O
phosphorylation O O
. O O

The O O
interaction O O
of O O
different O O
protein O O
systems O O
with O O
microtubules O O
is O O
a O O
critical O O
step O O
in O O
the O O
cellular O O
function O O
of O O
these O O
organelles O O
. O O

Sailer O O
, O O
K O O
. O O

Copyright O O
2000 O O
Academic O O
Press O O
. O O

This O O
element O O
was O O
required O O
for O O
both O O
basal O O
and O O
activated O O
expression O O
and O O
almost O O
certainly O O
functions O O
as O O
a O O
TATA B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
binding I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
interaction O O
site O O
. O O

In O O
HepG2 O O
cells O O
, O O
SREBP B B_GENE
- I I_GENE
1c I I_GENE
mRNA I I_GENE
and O O
precursor O O
protein O O
levels O O
were O O
induced O O
by O O
treatment O O
with O O
22 O O
( O O
R O O
) O O
- O O
hydroxycholesterol O O
and O O
9 O O
- O O
cis O O
- O O
retinoic O O
acid O O
, O O
confirming O O
that O O
endogenous O O
LXR B B_PROTEIN[GENE]/B_MEASURE
- O O
RXR B B_PROTEIN[GENE]/B_DISEASE
activation O O
can O O
induce O O
endogenous B B_GENE
SREBP I I_GENE
- I I_GENE
1c I I_GENE
expression O O
. O O

Univariate O O
and O O
multivariate O O
analysis O O
was O O
used O O
to O O
calculate O O
the O O
5 O O
- O O
year O O
survival O O
probabilities O O
with O O
respect O O
to O O
the O O
following O O
variables O O
: O O
age O O
( O O
< O O
or O O
= O O
65 O O
, O O
> O O
65 O O
) O O
, O O
sex O O
, O O
depth O O
of O O
invasion O O
( O O
mucosal O O
, O O
submucosal O O
) O O
tumor O O
location O O
( O O
upper O O
, O O
middle O O
and O O
lower O O
third O O
) O O
, O O
gross O O
appearance O O
( O O
type O O
I O O
, O O
type O O
II O O
and O O
type O O
III O O
) O O
, O O
size O O
( O O
< O O
or O O
= O O
1 O O
. O O
5 O O
cm O O
, O O
> O O
1 O O
. O O
5 O O
cm O O
) O O
, O O
presence O O
or O O
absence O O
of O O
lymph O O
node O O
metastasis O O
, O O
histological O O
type O O
( O O
intestinal O O
, O O
diffuse O O
) O O
, O O
extent O O
of O O
lymphadenectomy O O
( O O
limited O O
or O O
extended O O
) O O
, O O
and O O
type O O
of O O
gastrectomy O O
( O O
total O O
or O O
distal O O
subtotal O O
) O O
. O O

This O O
integration O O
results O O
in O O
the O O
production O O
of O O
MMTV B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
/ I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mdr3 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
fusion I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
transcripts I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O O
originate O O
from O O
the O O
antisense O O
5 B B_GENE/B_LOCATION
' I B_GENE/I_LOCATION
LTR I B_GENE/I_LOCATION
of O O
the O O
provirus O O
. O O

In O O
32 O O
of O O
them O O
the O O
results O O
of O O
an O O
exercise O O
performance O O
test O O
based O O
on O O
heart O O
rate O O
response O O
to O O
submaximal O O
exercise O O
( O O
VO2 O O
, O O
170 O O
[ O O
bpm O O
] O O
) O O
was O O
compared O O
with O O
another O O
index O O
of O O
physical O O
performance O O
capacity O O
, O O
which O O
is O O
independent O O
from O O
heart O O
rate O O
: O O
the O O
ventilatory O O
threshold O O
. O O

Four O O
of O O
15 O O
patients O O
with O O
R2 B B_DISEASE/B_GENE
had O O
rheumatoid O O
arthritis O O
and O O
in O O
two O O
of O O
these O O
four O O
cases O O
the O O
antibody O O
was O O
of O O
the O O
IgA B B_PROTEIN[GENE]/B_DISEASE
class O O
. O O

Phosphate O O
compounds O O
in O O
isolated O O
, O O
perfused O O
hearts O O
during O O
pH O O
variation O O
due O O
to O O
changes O O
in O O
extracellular O O
PCO2 O O
and O O
bicarbonate O O

Vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
Dbl B B_GENE
are O O
members O O
of O O
a O O
novel O O
class O O
of O O
oncogene O O
proteins O O
that O O
share O O
significant O O
sequence O O
identity O O
in O O
a O O
approximately O O
250 O O
- O O
amino O O
- O O
acid O O
domain O O
, O O
designated O O
the O O
Dbl B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
homology I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
domain I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Serum O O
AFP B B_GENE
is O O
a O O
useful O O
tumor O O
marker O O
for O O
monitoring O O
the O O
results O O
of O O
therapy O O
. O O

The O O
data O O
show O O
that O O
processing O O
time O O
as O O
a O O
function O O
of O O
intensity O O
is O O
modified O O
not O O
only O O
at O O
the O O
retina O O
but O O
also O O
at O O
later O O
processing O O
sites O O
. O O

Identification O O
of O O
masked O O
toxins O O
in O O
the O O
exotoxin O O
complex O O
of O O
Staphylococcus O O
pyogenes O O
und O O
Cl O O
. O O
perfringens O O
; O O
significance O O
of O O
their O O
existence O O
for O O
clarifying O O
of O O
the O O
masking O O
mechanism O O

Unlike O O
LANA1 B B_GENE
, O O
LANA2 B B_GENE/B_LOCATION
does O O
not O O
elicit O O
a O O
serologic O O
response O O
from O O
patients O O
with O O
KS O O
, O O
PEL O O
, O O
or O O
CD O O
as O O
measured O O
by O O
Western O O
blot O O
hybridization O O
. O O

However O O
, O O
this O O
posttranslational O O
modification O O
of O O
the O O
gar2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
does O O
not O O
appear O O
to O O
be O O
essential O O
for O O
normal O O
production O O
of O O
18S B B_GENE
rRNA I I_GENE
. O O

Here O O
, O O
we O O
analyzed O O
the O O
interaction O O
of O O
CYT B B_GENE
- I I_GENE
18 I I_GENE
with O O
a O O
small O O
RNA O O
( O O
P4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
corresponding O O
to O O
the O O
isolated O O
P4 B B_GENE/B_LOCATION
- I B_GENE/I_LOCATION
P6 I B_GENE/I_LOCATION
domain I B_GENE/I_LOCATION
of O O
the O O
N B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
crassa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mitochondrial I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
large I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunit I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ribosomal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
intron I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
deduced O O
amino O O
acid O O
sequence O O
of O O
PutR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
154 O O
amino O O
acid O O
residues O O
) O O
showed O O
homology O O
to O O
the O O
small O O
regulatory O O
proteins O O
Lrp B B_GENE
, O O
BkdR B B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
and O O
AsnC B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

When O O
yeast O O
cells O O
reach O O
a O O
critical O O
size O O
in O O
late O O
G1 O O
they O O
simultaneously O O
start O O
budding O O
, O O
initiate O O
DNA O O
synthesis O O
, O O
and O O
activate O O
transcription O O
of O O
a O O
set O O
of O O
genes O O
that O O
includes O O
G1 B B_GENE/B_DISEASE
cyclins I I_GENE/I_DISEASE
CLN1 B I_GENE/I_DISEASE
, O O
CLN2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
many O O
DNA O O
synthesis O O
genes O O
. O O

Functional O O
PET O O
scanning O O
in O O
the O O
preoperative O O
assessment O O
of O O
cerebral O O
arteriovenous O O
malformations O O
. O O

Accordingly O O
, O O
superpeptide O O
antigenic O O
material O O
was O O
readily O O
detected O O
by O O
immunoblotting O O
cell O O
extracts O O
and O O
enriched O O
in O O
vacuolar O O
preparations O O
of O O
PrA B B_GENE
deficient O O
mutant O O
cells O O
. O O

Blockade O O
of O O
T O O
cell O O
activation O O
using O O
a O O
surface O O
- O O
linked O O
single O O
- O O
chain O O
antibody O O
to O O
CTLA B B_GENE
- I I_GENE
4 I I_GENE
( O O
CD152 B B_GENE
) O O
. O O

Water O O
pair O O
and O O
three O O
- O O
body O O
potential O O
of O O
spectroscopic O O
quality O O
from O O
Ab O O
initio O O
calculations O O

4 O O
) O O
Mutation O O
of O O
the O O
three O O
extracellular O O
cysteine O O
residues O O
of O O
GFKAR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O O
that O O
the O O
two O O
conserved O O
cysteine O O
residues O O
( O O
C305 O O
and O O
C385 O O
) O O
, O O
located O O
between O O
two O O
transmembrane O O
segments O O
, O O
form O O
a O O
solvent O O
- O O
accessible O O
disulfide O O
bond O O
. O O

In O O
this O O
work O O
, O O
we O O
have O O
used O O
Xenopus O O
oocyte O O
maturation O O
as O O
a O O
read O O
- O O
out O O
for O O
examining O O
the O O
ability O O
of O O
the O O
neu B B_GENE/B_BIO
tyrosine B I_GENE/I_BIO
kinase I I_GENE/I_BIO
( O O
p185neu B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
to O O
participate O O
with O O
the O O
epidermal B B_GENE/B_BIO
growth I I_GENE/I_BIO
factor I I_GENE/I_BIO
( I I_GENE/I_BIO
EGF I I_GENE/I_BIO
) I I_GENE/I_BIO
receptor I I_GENE/I_BIO
in O O
a O O
common O O
signal O O
transduction O O
pathway O O
. O O

The O O
best O O
- O O
studied O O
neurotrophin O O
, O O
nerve B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
NGF B B_GENE/B_LOCATION
) O O
, O O
is O O
a O O
major O O
survival O O
factor O O
in O O
sympathetic O O
and O O
sensory O O
neurons O O
and O O
promotes O O
differentiation O O
in O O
a O O
well O O
- O O
studied O O
model O O
system O O
, O O
PC12 O O
cells O O
. O O

In O O
contrast O O
, O O
MAPK B B_GENE/B_LOCATION
activation O O
stimulated O O
by O O
the O O
Gq B B_GENE
- O O
coupled O O
alpha O O
1B O O
AR O O
or O O
M1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
muscarinic B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cholinergic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
unaffected O O
by O O
expression O O
of O O
beta B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ARKct I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
RasN17 B B_GENE
expression O O
or O O
by O O
PTK B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibitors O O
, O O
but O O
is O O
blocked O O
by O O
expression O O
of O O
N B B_GENE
delta I I_GENE
Raf I I_GENE
or O O
by O O
PKC B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depletion O O
. O O

Transcriptional O O
analysis O O
indicates O O
that O O
human B B_GENE/B_SPECIES[BIO]
TBP I I_GENE/I_SPECIES[BIO]
functions O O
poorly O O
at O O
promoters O O
recognized O O
by O O
RNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
III I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
at O O
RNA B B_GENE/B_LOCATION
Pol I I_GENE/I_LOCATION
II I I_GENE/I_LOCATION
promoters I I_GENE/I_LOCATION
lacking O O
a O O
conventional O O
TATA O O
element O O
. O O

The O O
steady O O
- O O
state O O
levels O O
of O O
Cdk2 B B_GENE
, O O
Cdk4 B B_GENE
and O O
Cyclin B B_GENE
A I I_GENE
proteins I I_GENE
were O O
unaffected O O
by O O
HPR O O
, O O
while O O
those O O
of O O
Cyclin B B_GENE
D1 I I_GENE
were O O
significantly O O
reduced O O
in O O
all O O
three O O
cell O O
lines O O
. O O

Mapping O O
the O O
5 O O
' O O
and O O
3 O O
' O O
termini O O
of O O
TED B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicated O O
that O O
the O O
LTRs O O
have O O
a O O
retroviral O O
U3 O O
- O O
R O O
- O O
U5 O O
structural O O
organization O O
that O O
is O O
capable O O
of O O
directing O O
the O O
synthesis O O
of O O
transcripts O O
that O O
represent O O
potential O O
substrates O O
for O O
reverse O O
transcription O O
and O O
intermediates O O
in O O
transposition O O
. O O

Human O O
forearm O O
was O O
used O O
as O O
a O O
dummy O O
ear O O
and O O
the O O
electrode O O
HN O O
- O O
5 O O
was O O
fixed O O
thereon O O
, O O
and O O
a O O
sound O O
stimulus O O
of O O
90dBnHL O O
was O O
delivered O O
by O O
the O O
earphone O O
( O O
NC O O
- O O
3 O O
) O O
. O O

These O O
proteins O O
were O O
detected O O
by O O
an O O
antibody O O
which O O
recognizes O O
the O O
N O O
- O O
terminus O O
of O O
SRK3 B B_GENE
and O O
, O O
in O O
an O O
F2 O O
progeny O O
segregating O O
for O O
the O O
S3 B B_GENE/B_MEASURE
haplotype I I_GENE/I_MEASURE
, O O
were O O
only O O
expressed O O
in O O
plants O O
possessing O O
the O O
S3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
haplotype I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
blood O O
pressures O O
in O O
43 O O
subjects O O
were O O
compared O O
during O O
rapid O O
weight O O
loss O O
and O O
at O O
identical O O
weights O O
during O O
post O O
- O O
fast O O
weight O O
gain O O
( O O
Study O O
A O O
) O O
. O O

Total O O
body O O
water O O
and O O
distribution O O
space O O
of O O
Na24 O O
in O O
women O O
with O O
various O O
body O O
weight O O

Three O O
experiments O O
using O O
20 O O
microM O O
2 O O
- O O
( O O
hydroxyamino O O
) O O
- O O
1 O O
- O O
methyl O O
- O O
6 O O
- O O
phenylimidazo O O
[ O O
4 O O
, O O
5 O O
- O O
b O O
] O O
pyridine O O
( O O
N O O
- O O
OH O O
- O O
PhIP O O
) O O
were O O
performed O O
to O O
induce O O
mutations O O
in O O
the O O
dihydrofolate B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
reductase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DHFR B B_PROTEIN[GENE]/B_LOCATION
) O O
gene O O
of O O
a O O
hemizygous O O
Chinese O O
hamster O O
ovary O O
( O O
CHO O O
) O O
cell O O
line O O
( O O
UA21 O O
) O O
. O O

This O O
is O O
mediated O O
by O O
vascular O O
remodeling O O
, O O
an O O
active O O
process O O
that O O
results O O
in O O
a O O
change O O
in O O
the O O
geometry O O
of O O
the O O
blood O O
vessel O O
. O O

Our O O
results O O
separate O O
these O O
factors O O
into O O
four O O
regulatory O O
classes O O
: O O
( O O
i O O
) O O
constitutive O O
factors O O
, O O
such O O
as O O
Oct B B_GENE
- I I_GENE
1 I I_GENE
and O O
probably O O
Sp1 B B_GENE
, O O
that O O
are O O
expressed O O
in O O
thymocytes O O
at O O
all O O
stages O O
; O O
( O O
ii O O
) O O
inducible O O
factors O O
, O O
such O O
as O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
and O O
complexes O O
binding O O
to O O
the O O
region O O
of O O
a O O
CD28 B B_GENE
response I I_GENE
element I I_GENE
, O O
that O O
can O O
be O O
activated O O
in O O
all O O
thymocytes O O
, O O
including O O
those O O
cells O O
( O O
CD4 B B_GENE
+ I I_GENE
CD8 B I_GENE
+ I I_GENE
TcRlow B I_GENE
) O O
that O O
can O O
undergo O O
selection O O
; O O
( O O
iii O O
) O O
inducible O O
factors O O
, O O
such O O
as O O
NF B B_GENE
- I I_GENE
AT I I_GENE
and O O
AP B B_GENE
- I I_GENE
1 I I_GENE
, O O
that O O
can O O
be O O
activated O O
in O O
mature O O
( O O
CD4 B B_GENE/B_PERSON
+ I I_GENE/I_PERSON
CD8 B I_GENE/I_PERSON
- I I_GENE/I_PERSON
TcRhigh B I_GENE/I_PERSON
) O O
and O O
immature O O
( O O
CD4 B B_GENE/B_PERSON
- I I_GENE/I_PERSON
CD8 B I_GENE/I_PERSON
- I I_GENE/I_PERSON
TcR B I_GENE/I_PERSON
- I I_GENE/I_PERSON
) O O
thymocytes O O
alike O O
but O O
not O O
in O O
the O O
transitional O O
stages O O
when O O
the O O
cells O O
( O O
CD4 B B_GENE/B_MEASURE
+ I I_GENE/I_MEASURE
CD8 B I_GENE/I_MEASURE
+ I I_GENE/I_MEASURE
TcRlow B I_GENE/I_MEASURE
) O O
are O O
subject O O
to O O
selection O O
; O O
and O O
( O O
iv O O
) O O
a O O
factor O O
containing O O
CREB B B_GENE/B_MEASURE
, O O
which O O
can O O
be O O
activated O O
in O O
thymocytes O O
of O O
all O O
developmental O O
stages O O
by O O
culture O O
but O O
does O O
not O O
require O O
specific O O
induction O O
. O O

Thus O O
, O O
22 O O
% O O
of O O
MDS O O
responded O O
to O O
oral O O
PLAC O O
. O O

Posterior O O
osteophytes O O
around O O
the O O
posterior O O
edges O O
of O O
vertebral O O
body O O
resulted O O
in O O
intervertebral O O
insufficiency O O
, O O
and O O
corresponded O O
to O O
hypertrophic O O
spur O O
in O O
osteochondrosis O O
. O O

They O O
showed O O
moderate O O
in O O
vitro O O
antifungal O O
activity O O
against O O
a O O
wide O O
variety O O
of O O
fungi O O
and O O
yeasts O O
including O O
clinically O O
important O O
pathogens O O
, O O
and O O
were O O
highly O O
effective O O
in O O
systemic O O
infection O O
with O O
Candida O O
albicans O O
in O O
mice O O
after O O
iv O O
and O O
im O O
administrations O O
. O O

We O O
also O O
show O O
that O O
in O O
fusions O O
with O O
the O O
DNA O O
binding O O
domain O O
of O O
GAL4 B B_GENE/B_SPECIES[BIO]
, O O
full O O
activity O O
requires O O
the O O
entire O O
BHV B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
alpha I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
TIF I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
although O O
both O O
amino O O
and O O
carboxyl O O
termini O O
display O O
some O O
activity O O
on O O
their O O
own O O
. O O

The O O
induction O O
by O O
dexamethasone O O
of O O
rat B B_GENE
liver I I_GENE
CYP3A1 I I_GENE
differs O O
from O O
classical O O
glucocorticoid O O
gene O O
regulation O O
in O O
part O O
because O O
both O O
glucocorticoids O O
and O O
antiglucocorticoids O O
such O O
as O O
pregnenolone O O
16 O O
alpha O O
- O O
carbonitrile O O
( O O
PCN O O
) O O
induce O O
CYP3A1 B B_GENE
through O O
transcriptional O O
gene O O
activation O O
. O O

This O O
surface O O
in O O
specimens O O
from O O
unfertilized O O
eggs O O
is O O
almost O O
flat O O
. O O

Fetal O O
transplants O O
rescue O O
axial O O
muscle O O
representations O O
in O O
M1 O O
cortex O O
of O O
neonatally O O
transected O O
rats O O
that O O
develop O O
weight O O
support O O
. O O

We O O
examined O O
the O O
contribution O O
of O O
the O O
M B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MuLV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
transcriptional O O
activity O O
and O O
pathogenesis O O
of O O
M O O
- O O
MuLV O O
by O O
constructing O O
LTRs O O
containing O O
heterologous O O
enhancer O O
elements O O
. O O

There O O
were O O
no O O
major O O
postoperative O O
complications O O
and O O
at O O
follow O O
- O O
up O O
of O O
the O O
13 O O
patients O O
at O O
10 O O
to O O
26 O O
months O O
after O O
operation O O
the O O
results O O
were O O
satisfactory O O
. O O

The O O
immunoreactive O O
antithrombin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
III I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
increased O O
significantly O O
while O O
the O O
increase O O
in O O
antithrombin B B_GENE
III I I_GENE
activity O O
was O O
insignificant O O
in O O
20 O O
male O O
Caucasian O O
Danes O O
upon O O
3 O O
weeks O O
supplementation O O
of O O
the O O
diet O O
with O O
10 O O
ml O O
daily O O
of O O
a O O
cod O O
liver O O
oil O O
concentrate O O
. O O

Northern O O
blot O O
analysis O O
confirmed O O
that O O
ADAMTS B B_GENE
- I I_GENE
1 I I_GENE
was O O
up O O
- O O
regulated O O
in O O
both O O
metaphyseal O O
( O O
14 O O
- O O
to O O
35 O O
- O O
fold O O
) O O
and O O
diaphyseal O O
( O O
4 O O
. O O
2 O O
- O O
fold O O
) O O
bone O O
1 O O
h O O
after O O
PTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
38 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
injection O O
and O O
returned O O
to O O
control O O
levels O O
by O O
24 O O
h O O
. O O

The O O
transcriptional B B_GENE/B_DISEASE
transactivator I I_GENE/I_DISEASE
( O O
Tas B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
of O O
simian O O
foamy O O
virus O O
type O O
1 O O
strongly O O
augments O O
gene O O
expression O O
directed O O
by O O
both O O
the O O
promoter O O
in O O
the O O
viral O O
long O O
terminal O O
repeat O O
and O O
the O O
newly O O
discovered O O
internal O O
promoter O O
located O O
within O O
the O O
env B B_GENE
gene I I_GENE
. O O

In O O
the O O
other O O
two O O
cases O O
, O O
fluoxetine O O
adjunct O O
produced O O
benefits O O
with O O
no O O
additional O O
side O O
effects O O
. O O

Deletion O O
of O O
this O O
consensus O O
element O O
from O O
the O O
spo6 B B_GENE/B_BIO
promoter I I_GENE/I_BIO
abolished O O
the O O
transcription O O
of O O
spo6 B B_GENE
+ I I_GENE
and O O
resulted O O
in O O
a O O
sporulation O O
deficiency O O
. O O

Chem O O
. O O

Mutations O O
in O O
the O O
beta B B_GENE
- I I_GENE
galactosidase I I_GENE
gene I I_GENE
result O O
in O O
the O O
lysosomal O O
storage O O
disorders O O
GM1 O O
- O O
gangliosidosis O O
and O O
Morquio O O
B O O
syndrome O O
. O O

Results O O
indicated O O
that O O
hobbies O O
/ O O
leisure O O
activities O O
, O O
mobility O O
, O O
transport O O
, O O
social O O
relationships O O
, O O
working O O
capacity O O
, O O
energy O O
and O O
doing O O
things O O
slower O O
were O O
aspects O O
relevant O O
to O O
IPF O O
patients O O
' O O
QOL O O
. O O

We O O
have O O
generated O O
transgenic O O
fly O O
strains O O
with O O
mutations O O
affecting O O
specific O O
TRA B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
isoforms I I_GENE/I_LOCATION
to O O
investigate O O
their O O
individual O O
roles O O
in O O
regulating O O
the O O
alternative O O
processing O O
of O O
doublesex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
exuperantia B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
tra B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
studies O O
define O O
a O O
class O O
of O O
DNA O O
elements O O
with O O
a O O
mode O O
of O O
action O O
that O O
has O O
not O O
been O O
heretofore O O
described O O
. O O

We O O
were O O
able O O
to O O
demonstrate O O
a O O
significant O O
statistical O O
interaction O O
effect O O
between O O
gender O O
and O O
globulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
protein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
concentration O O
on O O
Vu O O
( O O
p O O
= O O
0 O O
. O O
022 O O
) O O
. O O

Chest O O
X O O
- O O
P O O
revealed O O
an O O
abnormal O O
shadow O O
in O O
the O O
left O O
upper O O
lobe O O
. O O

From O O
the O O
frozen O O
specimen O O
, O O
a O O
large O O
number O O
of O O
sections O O
with O O
good O O
morphologic O O
characteristics O O
may O O
be O O
produced O O
. O O

CrkII B B_GENE
and O O
CrkL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
constitutively O O
formed O O
complex O O
with O O
the O O
guanine B B_GENE
nucleotide I I_GENE
exchange I I_GENE
factor I I_GENE
C3G B I_GENE
, O O
in O O
unstimulated O O
as O O
well O O
as O O
PDGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stimulated O O
cells O O
. O O

In O O
further O O
support O O
of O O
the O O
biological O O
significance O O
of O O
these O O
DNA O O
- O O
protein O O
interactions O O
, O O
the O O
IL2RA B B_GENE/B_MEASURE
oligonucleotide O O
from O O
- O O
291 O O
to O O
- O O
245 O O
proved O O
to O O
be O O
sufficient O O
in O O
either O O
orientation O O
to O O
confer O O
PMA O O
inducibility O O
to O O
the O O
mitogen O O
- O O
insensitive O O
thymidine B B_GENE/B_LOCATION
kinase I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
in O O
Jurkat O O
cells O O
. O O

The O O
plasma O O
steroid O O
levels O O
in O O
the O O
CAPD O O
patients O O
after O O
each O O
infusion O O
rate O O
were O O
equal O O
to O O
or O O
greater O O
than O O
the O O
levels O O
in O O
normal O O
subjects O O
. O O

With O O
BCPP O O
protocol O O
, O O
12 O O
achieved O O
a O O
complete O O
response O O
, O O
11 O O
evidenced O O
a O O
75 O O
% O O
response O O
, O O
and O O
7 O O
displayed O O
a O O
50 O O
% O O
response O O
. O O

The O O
RPC31 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O O
the O O
C31 B B_ENZYME[GENE]
subunit I I_ENZYME[GENE]
of I I_ENZYME[GENE]
Saccharomyces I I_ENZYME[GENE]
cerevisiae I I_ENZYME[GENE]
RNA I I_ENZYME[GENE]
polymerase I I_ENZYME[GENE]
C I I_ENZYME[GENE]
( I I_ENZYME[GENE]
III I I_ENZYME[GENE]
) I I_ENZYME[GENE]
has O O
been O O
isolated O O
, O O
starting O O
from O O
a O O
C O O
- O O
terminal O O
fragment O O
cloned O O
on O O
a O O
lambda O O
gt11 O O
library O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
demonstrated O O
that O O
sequences O O
within O O
this O O
region O O
bind O O
members O O
of O O
the O O
Sp1 B B_GENE/B_BIO
family I I_GENE/I_BIO
of I I_GENE/I_BIO
transcription I I_GENE/I_BIO
factors I I_GENE/I_BIO
. O O

The O O
phosphatase O O
active O O
site O O
is O O
located O O
within O O
residues O O
367 O O
- O O
374 O O
. O O

After O O
at O O
least O O
one O O
year O O
follow O O
- O O
up O O
, O O
argon O O
laser O O
showed O O
a O O
statistically O O
significant O O
effect O O
( O O
p O O
less O O
of O O
0 O O
, O O
01 O O
; O O
Kolmogorow O O
- O O
Smirnov O O
test O O
) O O
on O O
the O O
stabilization O O
or O O
the O O
amelioration O O
of O O
visual O O
acuity O O
compared O O
with O O
the O O
non O O
treated O O
group O O
. O O

Further O O
studies O O
aim O O
at O O
characterizing O O
the O O
trans O O
- O O
acting O O
factors O O
that O O
mediate O O
the O O
spatial O O
and O O
temporal O O
expression O O
of O O
Hox B B_GENE
genes I I_GENE
in O O
the O O
developing O O
embryo O O
. O O

Contraindications O O
to O O
adenosine O O
and O O
drug O O
interactions O O
are O O
noted O O
in O O
this O O
article O O
. O O

As O O
to O O
the O O
side O O
effects O O
of O O
SISO O O
, O O
cylindruria O O
with O O
aggravation O O
of O O
microscopic O O
hematuria O O
and O O
elevations O O
of O O
GOT B B_GENE/B_DISEASE
, O O
GPT B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
A1 B B_LOCATION/B_GENE
- I I_LOCATION/I_GENE
P I I_LOCATION/I_GENE
were O O
observed O O
each O O
one O O
of O O
them O O
, O O
respectively O O
. O O

Serum B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
C3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
measured O O
in O O
1 O O
, O O
282 O O
school O O
children O O
with O O
abnormal O O
urinary O O
findings O O
between O O
1980 O O
and O O
1997 O O
. O O

Computer O O
analysis O O
revealed O O
that O O
the O O
human B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
P1 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
corresponding O O
to O O
amino O O
acid O O
residues O O
within O O
the O O
N O O
- O O
terminal O O
RNA O O
binding O O
domain O O
displays O O
high O O
homology O O
( O O
greater O O
than O O
54 O O
% O O
identity O O
; O O
61 O O
to O O
94 O O
% O O
similarity O O
) O O
with O O
two O O
animal O O
virus O O
proteins O O
which O O
possess O O
RNA O O
binding O O
activity O O
( O O
vaccinia B B_PROTEIN[GENE]/B_SPECIES[BIO]
virus I I_PROTEIN[GENE]/I_SPECIES[BIO]
E3L I I_PROTEIN[GENE]/I_SPECIES[BIO]
; O O
rotavirus B B_VIRUS[BIO]/B_PROTEIN[GENE]
VP2 I B_VIRUS[BIO]/I_PROTEIN[GENE]
) O O
and O O
two O O
proteins O O
of O O
unknown O O
function O O
( O O
murine B B_GENE
TIK I I_GENE
; O O
rotavirus B B_VIRUS[BIO]/B_GENE
NS34 I I_VIRUS[BIO]/I_GENE
) O O
, O O
but O O
which O O
are O O
likely O O
RNA O O
binding O O
proteins O O
. O O

Determinants O O
of O O
recurrent O O
ischaemia O O
and O O
revascularisation O O
procedures O O
after O O
thrombolysis O O
with O O
recombinant O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plasminogen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
primary O O
coronary O O
occlusion O O
. O O

Experimental O O
exposure O O
of O O
poults O O
with O O
each O O
of O O
two O O
strains O O
representing O O
the O O
rarely O O
reported O O
capsular O O
group O O
B O O
indicated O O
that O O
both O O
were O O
virulent O O
. O O

Computer O O
system O O
trains O O
employees O O
to O O
meet O O
JCAHO O O
safety O O
ED O O
requirements O O
. O O

Finally O O
, O O
transfection O O
of O O
Grb10 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
specific O O
mutations O O
in O O
their O O
SH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O O
apoptosis O O
in O O
HTC O O
- O O
IR O O
and O O
COS O O
- O O
7 O O
cells O O
. O O

Comparison O O
of O O
dose O O
volume O O
histograms O O
revealed O O
that O O
the O O
6 O O
- O O
field O O
plan O O
spared O O
relatively O O
more O O
heart O O
whereas O O
the O O
8 O O
- O O
field O O
plan O O
spared O O
relatively O O
more O O
lung O O
. O O

We O O
have O O
demonstrated O O
that O O
a O O
putative O O
HOX B B_GENE/B_MEASURE
cofactor I I_GENE/I_MEASURE
, O O
PBX1A B B_GENE
, O O
participates O O
in O O
cooperative O O
DNA O O
binding O O
with O O
HOXA B B_GENE
- I I_GENE
1 I I_GENE
and O O
the O O
Deformed B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
group O O
protein O O
HOXD B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
4 I I_GENE/I_LOCATION
. O O

The O O
CHL B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
CTF B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
gene O O
product O O
of O O
Saccharomyces O O
cerevisiae O O
is O O
important O O
for O O
chromosome O O
transmission O O
and O O
normal O O
cell O O
cycle O O
progression O O
in O O
G2 O O
/ O O
M O O
. O O

Heterotrimeric O O
guanine B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
G B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
function O O
as O O
signal O O
transducers O O
for O O
a O O
variety O O
of O O
hormone O O
- O O
coupled O O
enzyme O O
and O O
ion O O
transport O O
systems O O
in O O
eukaryotic O O
cells O O
. O O

In O O
contrast O O
, O O
polypropylene O O
glycol O O
, O O
PG O O
- O O
C O O
, O O
and O O
corn O O
oil O O
all O O
removed O O
68 O O
- O O
86 O O
% O O
of O O
the O O
MDI O O
in O O
the O O
first O O
h O O
, O O
74 O O
- O O
79 O O
% O O
at O O
4 O O
h O O
, O O
and O O
72 O O
- O O
86 O O
% O O
at O O
8 O O
h O O
. O O

DDD O O
( O O
R O O
) O O
pacing O O
with O O
automatic O O
mode O O
switch O O
in O O
patients O O
with O O
paroxysmal O O
atrial O O
fibrillation O O
following O O
AV O O
nodal O O
ablation O O
. O O

There O O
was O O
a O O
highly O O
significant O O
decrease O O
in O O
serum B B_DISEASE/B_GENE
eosinophil I I_DISEASE/I_GENE
cationic I I_DISEASE/I_GENE
protein I I_DISEASE/I_GENE
in O O
patients O O
with O O
elevated O O
AGA B B_GENE/B_DISEASE
. O O

It O O
is O O
required O O
for O O
correct O O
expression O O
of O O
both O O
genes O O
. O O

A O O
comparison O O
between O O
attenuation O O
- O O
corrected O O
and O O
- O O
uncorrected O O
transmission O O
- O O
emission O O
SPECT O O
images O O
obtained O O
with O O
Tl O O
- O O
201 O O
in O O
CAD O O
patients O O

Accumulation O O
of O O
amines O O
in O O
the O O
isolated O O
perfused O O
rabbit O O
lung O O
. O O

Since O O
it O O
is O O
often O O
necessary O O
to O O
resort O O
to O O
thoracotomy O O
as O O
a O O
final O O
step O O
in O O
making O O
such O O
a O O
diagnosis O O
, O O
we O O
have O O
sought O O
a O O
procedure O O
that O O
is O O
simpler O O
while O O
capable O O
of O O
providing O O
the O O
same O O
information O O
. O O

Both O O
control O O
and O O
Mn O O
- O O
exposed O O
quail O O
accumulated O O
5 O O
to O O
10 O O
times O O
more O O
Mn O O
in O O
their O O
livers O O
than O O
similarly O O
treated O O
rodents O O
. O O

A O O
retrospective O O
analysis O O
of O O
data O O
accumulated O O
over O O
a O O
21 O O
- O O
month O O
period O O
, O O
from O O
December O O
1989 O O
to O O
September O O
1991 O O
, O O
regarding O O
investigational O O
use O O
of O O
a O O
308 O O
nanometer O O
Xenon O O
Chloride O O
Excimer O O
Laser O O
Coronary O O
Angioplasty O O
( O O
ELCA O O
) O O
system O O
( O O
Advanced O O
Interventional O O
Systems O O
, O O
Inc O O
. O O
, O O
Irvine O O
, O O
CA O O
) O O
was O O
performed O O
. O O

Presently O O
, O O
we O O
made O O
chain O O
pair O O
switch O O
, O O
chimeric O O
, O O
and O O
site O O
mutant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gamma I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
delta I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TCRs I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
transfected O O
them O O
into O O
TCR O O
- O O
mutant O O
Jurkat O O
T O O
cells O O
to O O
examine O O
the O O
effects O O
of O O
changing O O
the O O
TCR B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gamma I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
junctional I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequences I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
on O O
reactivity O O
to O O
prenyl B B_GENE
pyrophosphate I I_GENE
Ags I I_GENE
. O O

Fos B B_GENE/B_LOCATION
/ O O
Jun B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bound O O
to O O
an O O
unacetylated O O
nucleosome O O
with O O
only O O
a O O
4 O O
- O O
to O O
5 O O
- O O
fold O O
reduction O O
in O O
DNA O O
binding O O
affinity O O
compared O O
with O O
naked O O
DNA O O
. O O

Activated B B_GENE
Ki I I_GENE
- I I_GENE
Ras I I_GENE
suppresses O O
12 O O
- O O
O O O
- O O
tetradecanoylphorbol O O
- O O
13 O O
- O O
acetate O O
- O O
induced O O
activation O O
of O O
the O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Jun I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NH2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
colon O O
cancer O O
cells O O
. O O

Electromobility O O
shift O O
analysis O O
using O O
oligonucleotides O O
encompassing O O
the O O
proximal O O
, O O
distal O O
, O O
and O O
BED O O
/ O O
AP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
- O O
binding O O
regions O O
failed O O
to O O
demonstrate O O
selective O O
transactivation O O
after O O
CD2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O O
of O O
LPMC O O
. O O

The O O
present O O
report O O
shows O O
that O O
a O O
cis O O
- O O
acting O O
element O O
between O O
- O O
189 O O
and O O
- O O
175 O O
bp O O
, O O
which O O
binds O O
thyroid B B_GENE
transcription I I_GENE
factor I I_GENE
- I I_GENE
1 I I_GENE
( O O
TTF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
) O O
, O O
is O O
involved O O
in O O
both O O
activities O O
. O O

Despite O O
their O O
high O O
degree O O
of O O
sequence O O
similarity O O
, O O
all O O
five O O
RFC B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
essential O O
for O O
cell O O
proliferation O O
in O O
S O O
. O O
cerevisiae O O
. O O

Moreover O O
, O O
we O O
show O O
that O O
ectopic O O
expression O O
of O O
the O O
E2A B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E12 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
this O O
macrophage O O
line O O
results O O
in O O
the O O
induction O O
of O O
many O O
B O O
lineage O O
genes O O
, O O
including O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IL7Ralpha B B_GENE
, O O
lambda5 B B_GENE
, O O
and O O
Rag B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
ability O O
to O O
induce O O
kappa B B_GENE/B_DISEASE
light I I_GENE/I_DISEASE
chain I I_GENE/I_DISEASE
in O O
response O O
to O O
mitogen O O
. O O

Also O O
, O O
anti B B_GENE
- I I_GENE
HIV I I_GENE
gp120 I I_GENE
and O O
anti B B_GENE
- I I_GENE
CD4 I I_GENE
crosslinking O O
induced O O
a O O
10 O O
- O O
15 O O
- O O
fold O O
increase O O
in O O
levels O O
of O O
both O O
PI B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
PI I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
in O O
anti B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
CD4 I I_DISEASE/I_GENE
precipitates O O
. O O

More O O
than O O
80 O O
% O O
appropriate O O
lever O O
responding O O
was O O
established O O
after O O
27 O O
, O O
38 O O
and O O
44 O O
daily O O
training O O
sessions O O
with O O
DN O O
- O O
2327 O O
, O O
diazepam O O
and O O
PTZ O O
, O O
respectively O O
, O O
as O O
the O O
training O O
drug O O
. O O

We O O
have O O
used O O
nuclear O O
magnetic O O
resonance O O
( O O
NMR O O
) O O
to O O
obtain O O
the O O
structure O O
of O O
an O O
RNA O O
" O O
kissing O O
" O O
hairpin O O
complex O O
formed O O
between O O
the O O
HIV O O
- O O
2 O O
TAR O O
hairpin O O
loop O O
and O O
a O O
hairpin O O
with O O
a O O
complementary O O
loop O O
sequence O O
. O O

RESULTS O O
: O O
In O O
men O O
, O O
weight O O
/ O O
height2 O O
met O O
the O O
criteria O O
for O O
a O O
satisfactory O O
index O O
in O O
that O O
there O O
was O O
a O O
very O O
strong O O
correlation O O
with O O
triceps O O
skinfold O O
, O O
and O O
a O O
negligible O O
correlation O O
with O O
height O O
. O O

PRP20 B B_GENE/B_PERSON
is O O
related O O
, O O
both O O
in O O
structure O O
and O O
function O O
, O O
to O O
the O O
RCC1 B B_GENE/B_BIO
gene I I_GENE/I_BIO
of O O
mammals O O
and O O
the O O
PIM1 B B_GENE/B_BIO
gene I I_GENE/I_BIO
of O O
Schizosaccharomyces O O
pombe O O
, O O
both O O
of O O
which O O
appear O O
to O O
regulate O O
entry O O
into O O
mitosis O O
and O O
chromosome O O
condensation O O
. O O

No O O
consensus O O
binding O O
sequence O O
could O O
be O O
discerned O O
in O O
these O O
fragments O O
and O O
bound O O
factor O O
is O O
in O O
rapid O O
equilibrium O O
with O O
unbound O O
. O O

A O O
selective O O
transcriptional O O
induction O O
system O O
for O O
mammalian O O
cells O O
based O O
on O O
Gal4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
estrogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fusion O O
proteins O O
. O O

Kinase O O
renaturation O O
tests O O
designed O O
to O O
detect O O
reactivated O O
protein O O
kinases O O
after O O
electrophoresis O O
in O O
sodium O O
dodecyl O O
sulfate O O
- O O
polyacrylamide O O
gels O O
revealed O O
the O O
presence O O
of O O
a O O
60 O O
- O O
kDa O O
kinase O O
in O O
the O O
washed O O
immunoprecipitate O O
obtained O O
from O O
liver O O
cytosol O O
using O O
anti B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
AHR I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
IgG B B_GENE/B_LOCATION
) O O
and O O
protein O O
A O O
/ O O
G O O
/ O O
agarose O O
beads O O
but O O
not O O
when O O
a O O
nonspecific O O
IgG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
used O O
instead O O
of O O
anti B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
AHR I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Immunoblotting O O
using O O
a O O
phosphospecific B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Src I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
416Y I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
a O O
ceramide O O
- O O
induced O O
increase O O
in O O
pp60 B B_GENE/B_DISEASE
( O O
src B B_GENE/B_MEASURE
) O O
tyrosine O O
phosphorylation O O
. O O

In O O
contrast O O
, O O
dominant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
negative I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Rac I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
N17Rac1 B B_PROTEIN[GENE]/B_LOCATION
) O O
inhibited O O
JNK B B_GENE
activation O O
by O O
Galpha12 B B_GENE
in O O
HEK293 O O
cells O O
as O O
well O O
as O O
three O O
other O O
cell O O
lines O O
. O O

Metabolic O O
studies O O
of O O
tetrabenazine O O
, O O
a O O
psychotropic O O
drug O O
in O O
animals O O
and O O
man O O
. O O

Reading O O
disability O O
in O O
twins O O
. O O

These O O
results O O
suggest O O
that O O
1a B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
also O O
interacts O O
independently O O
with O O
the O O
ER O O
and O O
viral O O
RNA O O
, O O
is O O
a O O
key O O
organizer O O
of O O
RNA O O
replication O O
complex O O
assembly O O
. O O

Effect O O
of O O
a O O
high O O
sugar O O
intake O O
on O O
some O O
metabolic O O
and O O
regulatory O O
indicators O O
in O O
young O O
men O O
. O O

Production O O
of O O
a O O
chicken O O
meat O O
infusion O O
broth O O
suitable O O
for O O
the O O
mass O O
production O O
of O O
a O O
Haemophilus O O
gallinarum O O
bacterin O O
. O O

The O O
results O O
indicate O O
that O O
expression O O
of O O
proU B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
E O O
. O O
coli O O
is O O
directed O O
from O O
two O O
promoters O O
, O O
one O O
( O O
P2 O O
) O O
characterized O O
earlier O O
by O O
other O O
workers O O
with O O
the O O
start O O
site O O
of O O
transcription O O
60 O O
nucleotides O O
upstream O O
of O O
the O O
initiation O O
codon O O
of O O
the O O
first O O
structural O O
gene O O
( O O
proV B B_LOCATION/B_PROTEIN[GENE]
) O O
, O O
and O O
the O O
other O O
( O O
P1 O O
) O O
situated O O
250 O O
nucleotides O O
upstream O O
of O O
proV B B_GENE
. O O

The O O
maximal O O
rise O O
in O O
plasma O O
adrenaline O O
was O O
of O O
similar O O
magnitude O O
in O O
all O O
three O O
groups O O
but O O
a O O
lower O O
plasma O O
glucose O O
was O O
required O O
to O O
stimulate O O
this O O
hormonal O O
response O O
in O O
the O O
' O O
unaware O O
' O O
patients O O
, O O
in O O
whom O O
the O O
plasma O O
adrenaline O O
concentration O O
was O O
lower O O
at O O
the O O
time O O
of O O
the O O
reaction O O
. O O

Through O O
interactions O O
with O O
the O O
pre O O
- O O
mRNA O O
and O O
the O O
CTD O O
domain O O
of O O
the O O
Polymerase B B_GENE/B_LOCATION
II I I_GENE/I_LOCATION
, O O
SR B B_GENE/B_BIO
proteins I I_GENE/I_BIO
have O O
been O O
shown O O
to O O
regulate O O
alternative O O
splicing O O
. O O

One O O
child O O
, O O
recently O O
fed O O
, O O
vomited O O
a O O
small O O
amount O O
of O O
breast O O
milk O O
after O O
a O O
short O O
period O O
of O O
crying O O
and O O
apparently O O
had O O
a O O
laryngospasm O O
, O O
shown O O
by O O
a O O
sudden O O
drop O O
in O O
the O O
PtcO2 O O
level O O
without O O
any O O
other O O
signs O O
of O O
discomfort O O
. O O

Changes O O
in O O
the O O
size O O
and O O
organisation O O
of O O
the O O
brain O O
in O O
man O O
and O O
his O O
ancestors O O
. O O

Only O O
Staphylococcus O O
xylosus O O
SX63 O O
was O O
detected O O
as O O
a O O
strain O O
with O O
high O O
adherence O O
activity O O
. O O

It O O
also O O
produces O O
an O O
NH2 O O
terminus O O
that O O
corresponds O O
to O O
an O O
equivalent O O
NH2 O O
terminus O O
on O O
the O O
processed O O
matrix O O
form O O
of O O
the O O
similar O O
alpha1 B B_PROTEIN[GENE]
( I I_PROTEIN[GENE]
XI I I_PROTEIN[GENE]
) I I_PROTEIN[GENE]
chain I I_PROTEIN[GENE]
, O O
thus O O
suggesting O O
physiological O O
significance O O
. O O

Transmission O O
of O O
mutans O O
streptococci O O
to O O
infants O O
following O O
short O O
term O O
application O O
of O O
an O O
iodine O O
- O O
NaF O O
solution O O
to O O
mothers O O
' O O
dentition O O
. O O

Expression O O
of O O
Msx B B_GENE
- I I_GENE
1 I I_GENE
and O O
Msx B B_GENE
- I I_GENE
2 I I_GENE
has O O
been O O
studied O O
during O O
development O O
of O O
the O O
osteoblast O O
phenotype O O
, O O
but O O
the O O
role O O
of O O
Dlx B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
this O O
context O O
and O O
in O O
the O O
regulation O O
of O O
bone O O
- O O
expressed O O
genes O O
is O O
unknown O O
. O O

Scalp O O
blood O O
flow O O
was O O
recorded O O
by O O
a O O
laser O O
Doppler O O
flow O O
sensor O O
that O O
was O O
incorporated O O
in O O
the O O
transcutaneous O O
PO2 O O
electrode O O
. O O

Mycobacterium O O
tuberculosis O O
inhibits O O
IFN B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptional O O
responses O O
without O O
inhibiting O O
activation O O
of O O
STAT1 B B_GENE
. O O

Rabbit B B_SPECIES[BIO]/B_GENE
KCC1 I I_SPECIES[BIO]/I_GENE
( O O
rbKCC1 B B_GENE
) O O
and O O
rat B B_GENE
KCC1 I I_GENE
( O O
rtKCC1 B B_GENE/B_SPECIES[BIO]
) O O
were O O
cloned O O
by O O
screening O O
rabbit O O
kidney O O
and O O
rat O O
brain O O
cDNA O O
libraries O O
using O O
homologous O O
cDNA O O
probes O O
. O O

However O O
, O O
using O O
wet O O
weight O O
/ O O
dry O O
weight O O
methodology O O
, O O
we O O
found O O
that O O
administration O O
of O O
U74006F O O
significantly O O
reduced O O
water O O
content O O
in O O
the O O
right O O
hippocampus O O
( O O
contralateral O O
to O O
the O O
site O O
of O O
injury O O
) O O
compared O O
to O O
saline O O
- O O
treated O O
animals O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

GH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulated O O
the O O
activity O O
of O O
promoter O O
fragments O O
with O O
5 O O
' O O
- O O
ends O O
between O O
nucleotide O O
( O O
nt O O
) O O
- O O
2001 O O
and O O
nt O O
- O O
653 O O
by O O
1 O O
. O O
9 O O
- O O
to O O
2 O O
. O O
7 O O
- O O
fold O O
. O O

We O O
have O O
recently O O
shown O O
that O O
induced O O
expression O O
of O O
a O O
CDK B B_GENE/B_DISEASE
target O O
site O O
- O O
deficient O O
mutant O O
, O O
Op18 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
S25A O O
, O O
S38A O O
, O O
blocks O O
human O O
cell O O
lines O O
during O O
G2 O O
/ O O
M O O
transition O O
. O O

The O O
brains O O
were O O
processed O O
according O O
to O O
the O O
tetramethylbenzidine O O
( O O
TMB O O
) O O
protocol O O
of O O
Mesulam O O
( O O
' O O
78 O O
) O O
and O O
studied O O
with O O
darkfield O O
microscopy O O
. O O

Seizure O O
recurrence O O
( O O
HR O O
1 O O
. O O
30 O O
; O O
95 O O
% O O
CI O O
= O O
0 O O
. O O
84 O O
, O O
2 O O
. O O
01 O O
) O O
and O O
antiepileptic O O
drug O O
treatment O O
( O O
HR O O
0 O O
. O O
97 O O
; O O
95 O O
% O O
CI O O
= O O
0 O O
. O O
67 O O
, O O
1 O O
. O O
38 O O
) O O
did O O
not O O
influence O O
mortality O O
rate O O
. O O

One O O
day O O
postoperatively O O
, O O
the O O
mononuclear O O
leukocyte O O
beta B B_GENE/B_MEASURE
2 I B_GENE/I_MEASURE
- I B_GENE/I_MEASURE
receptor I B_GENE/I_MEASURE
density O O
decreased O O
maximally O O
by O O
45 O O
+ O O
/ O O
- O O
11 O O
% O O
in O O
the O O
enflurane O O
patients O O
, O O
and O O
by O O
53 O O
+ O O
/ O O
- O O
6 O O
% O O
in O O
the O O
neurolept O O
patients O O
. O O

The O O
serum O O
levels O O
of O O
cortisol O O
and O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
after O O
nasal O O
instillation O O
of O O
a O O
suspension O O
of O O
vaginal O O
exudate O O
showed O O
lower O O
values O O
than O O
in O O
control O O
conditions O O
( O O
nasal O O
instillation O O
of O O
saline O O
) O O
. O O

Innervation O O
of O O
reticular O O
papillae O O
in O O
sheep O O
and O O
goats O O
. O O

Biochemical O O
status O O
was O O
examined O O
using O O
erythrocyte O O
enzyme O O
function O O
and O O
blood O O
vitamin O O
levels O O
. O O

Sexual O O
adventurism O O
, O O
high O O
- O O
risk O O
behavior O O
, O O
and O O
human O O
immunodeficiency O O
virus O O
- O O
1 O O
seroconversion O O
among O O
the O O
Chicago O O
MACS O O
- O O
CCS O O
cohort O O
, O O
1984 O O
to O O
1992 O O
. O O

Pendulin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
Drosophila O O
protein O O
with O O
cell O O
cycle O O
- O O
dependent O O
nuclear O O
localization O O
, O O
is O O
required O O
for O O
normal O O
cell O O
proliferation O O
. O O

Paradoxically O O
there O O
is O O
a O O
decrease O O
in O O
the O O
level O O
of O O
soluble B B_GENE
A I I_GENE
beta I I_GENE
secreted O O
from O O
the O O
cells O O
. O O

Signaling O O
through O O
mitogen B B_GENE
- I I_GENE
activated I I_GENE
protein I I_GENE
kinase I I_GENE
and O O
Rac B B_GENE/B_PERSON
/ O O
Rho B B_GENE
does O O
not O O
duplicate O O
the O O
effects O O
of O O
activated O O
Ras B B_GENE/B_DISEASE
on O O
skeletal O O
myogenesis O O
. O O

Internalization O O
of O O
prolactin B B_GENE
receptor I I_GENE
and O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
transfected O O
cells O O
does O O
not O O
involve O O
nuclear O O
translocation O O
. O O

Using O O
mammalian O O
expression O O
vectors O O
( O O
pRSV O O
- O O
neo O O
and O O
pSV2 O O
- O O
neo O O
) O O
, O O
antisense O O
constructs O O
for O O
perforin B B_GENE/B_BACTERIUM[BIO]
and O O
granzyme B B_GENE
B I I_GENE
were O O
independently O O
electroporated O O
into O O
YT O O
- O O
INDY O O
, O O
a O O
human O O
non O O
- O O
MHC B B_GENE/B_DISEASE
- O O
restricted O O
, O O
IL B B_GENE
- I I_GENE
2 I I_GENE
- O O
independent O O
, O O
cytotoxic O O
lymphocyte O O
. O O

When O O
expressed O O
in O O
Escherichia O O
coli O O
, O O
SH B B_GENE
- I I_GENE
PTP2 I I_GENE
displays O O
tyrosine B B_ENZYME[GENE]
- I I_ENZYME[GENE]
specific I I_ENZYME[GENE]
phosphatase I I_ENZYME[GENE]
activity O O
. O O

The O O
structure O O
elucidation O O
of O O
the O O
iridoid O O
compounds O O
2 O O
and O O
3 O O
are O O
discussed O O
in O O
detail O O
. O O

The O O
results O O
of O O
a O O
study O O
to O O
investigate O O
the O O
effectiveness O O
of O O
a O O
propolis O O
- O O
containing O O
mouthrinse O O
in O O
the O O
inhibition O O
of O O
de O O
novo O O
plaque O O
formation O O
are O O
presented O O
. O O

Effects O O
of O O
shosaikoto O O
, O O
an O O
oriental O O
herbal O O
medicinal O O
mixture O O
, O O
on O O
restraint O O
- O O
stressed O O
mice O O
. O O

The O O
region O O
surrounding O O
the O O
ZNF35 B B_DISEASE/B_GENE
zinc I I_DISEASE/I_GENE
finger I I_DISEASE/I_GENE
protein I I_DISEASE/I_GENE
gene I I_DISEASE/I_GENE
on O O
3p21 O O
is O O
of O O
particular O O
interest O O
, O O
as O O
this O O
region O O
of O O
chromosome O O
3 O O
is O O
frequently O O
involved O O
in O O
rearrangements O O
and O O
/ O O
or O O
deletions O O
associated O O
with O O
various O O
human O O
tumors O O
including O O
lung O O
and O O
renal O O
carcinoma O O
. O O

In O O
the O O
promoters O O
of O O
many O O
immediate B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
early I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
c B B_GENE
- I I_GENE
fos I I_GENE
, O O
CArG O O
DNA O O
regulatory O O
elements O O
mediate O O
basal O O
constituitive O O
expression O O
and O O
rapid O O
and O O
transient O O
serum O O
induction O O
. O O

The O O
biological O O
activity O O
of O O
these O O
mutants O O
was O O
tested O O
by O O
determining O O
their O O
capacity O O
to O O
( O O
i O O
) O O
reconstitute O O
RNA B B_ENZYME[GENE]/B_BIO
polymerase I I_ENZYME[GENE]/I_BIO
activity O O
in O O
vivo O O
by O O
cotransfection O O
with O O
proteins O O
NP B B_PROTEIN[GENE]/B_DISEASE
, O O
PB1 B B_PROTEIN[GENE]/B_LOCATION
, O O
and O O
PA B B_PROTEIN[GENE]/B_DISEASE
and O O
a O O
virion O O
- O O
like O O
RNA O O
encoding O O
the O O
cat B B_PROTEIN[GENE]/B_DISEASE
gene O O
into O O
vaccinia O O
virus O O
T7 O O
- O O
infected O O
COS O O
- O O
1 O O
cells O O
and O O
( O O
ii O O
) O O
complete O O
with O O
the O O
wild B B_GENE
- I I_GENE
type I I_GENE
PB2 I I_GENE
activity O O
. O O

Transient O O
thyrotoxicosis O O
in O O
primary O O
anti O O
- O O
phospholipid O O
syndrome O O
. O O

We O O
were O O
unable O O
to O O
construct O O
chvI B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
chvG B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
insertion I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
of O O
R O O
. O O
meliloti O O
, O O
whereas O O
mutants O O
carrying O O
insertions O O
outside O O
of O O
these O O
genes O O
were O O
readily O O
obtained O O
. O O

Western O O
blot O O
analyses O O
reveals O O
that O O
cJun B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
C B B_GENE/B_PERSON
/ I I_GENE/I_PERSON
EBP I I_GENE/I_PERSON
family I I_GENE/I_PERSON
member I I_GENE/I_PERSON
C B I_GENE/I_PERSON
/ I I_GENE/I_PERSON
EBP I I_GENE/I_PERSON
- I I_GENE/I_PERSON
beta I I_GENE/I_PERSON
are O O
physiologically O O
relevant O O
transcription O O
factors O O
whose O O
expression O O
corresponds O O
with O O
mda B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
7 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
. O O

In O O
isolated O O
olfactory O O
cilia O O
certain O O
odorants O O
elicit O O
a O O
rapid O O
and O O
transient O O
cAMP O O
response O O
, O O
terminated O O
by O O
a O O
concerted O O
process O O
which O O
requires O O
the O O
action O O
of O O
two O O
protein O O
kinases O O
, O O
protein B B_ENZYME[GENE]
kinase I I_ENZYME[GENE]
A I I_ENZYME[GENE]
( O O
PKA B B_GENE/B_LOCATION
) O O
and O O
a O O
receptor B B_GENE/B_PERSON
- I I_GENE/I_PERSON
specific I I_GENE/I_PERSON
kinase I I_GENE/I_PERSON
( O O
GRK3 B B_GENE/B_LOCATION
) O O
( O O
Schleicher O O
, O O
S O O
. O O
, O O
Boekhoff O O
, O O
I O O
. O O

Acetyl B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CoA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
carboxylase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
yeast O O
is O O
an O O
essential O O
enzyme O O
and O O
is O O
regulated O O
by O O
factors O O
that O O
control O O
phospholipid O O
metabolism O O
. O O

To O O
investigate O O
the O O
role O O
of O O
this O O
domain O O
in O O
the O O
incorporation O O
of O O
the O O
SIV B B_GENE
Env I I_GENE
into O O
virions O O
, O O
we O O
generated O O
a O O
series O O
of O O
SIV B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Env I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
carrying O O
small O O
in O O
- O O
frame O O
deletions O O
within O O
the O O
cytoplasmic O O
domain O O
. O O

Computer O O
analysis O O
, O O
simple O O
correlation O O
hypothesis O O
, O O
and O O
distribution O O
method O O
with O O
1 O O
degree O O
of O O
freedom O O
revealed O O
significant O O
correlation O O
between O O
vertical O O
root O O
fracture O O
and O O
the O O
technique O O
of O O
instrumentation O O
and O O
obturation O O
of O O
the O O
canal O O
( O O
p O O
= O O
0 O O
. O O
025 O O
) O O
, O O
the O O
length O O
of O O
the O O
post O O
( O O
p O O
= O O
0 O O
. O O
05 O O
) O O
, O O
and O O
the O O
existence O O
of O O
the O O
post O O
( O O
p O O
= O O
0 O O
. O O
05 O O
) O O
. O O

Minute B B_GENE/B_DISEASE
virus I I_GENE/I_DISEASE
of I I_GENE/I_DISEASE
mice I I_GENE/I_DISEASE
NS1 I I_GENE/I_DISEASE
, O O
an O O
83 O O
- O O
kDa O O
mainly O O
nuclear O O
phosphoprotein O O
, O O
is O O
the O O
only O O
viral O O
nonstructural O O
protein O O
required O O
in O O
all O O
cell O O
types O O
and O O
it O O
is O O
involved O O
in O O
multiple O O
processes O O
necessary O O
for O O
virus O O
propagation O O
. O O

The O O
TDx O O
assay O O
for O O
cyclosporine O O
and O O
its O O
metabolites O O
in O O
blood O O
samples O O
compared O O
with O O
HPLC O O
and O O
RIA O O
methods O O
. O O

However O O
, O O
the O O
sequence O O
of O O
mRAR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differs O O
from O O
that O O
of O O
mRAR B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
beta I I_PROTEIN[GENE]/I_MEASURE
1 I I_PROTEIN[GENE]/I_MEASURE
by O O
an O O
additional O O
27 O O
C O O
- O O
terminal O O
amino O O
acids O O
encoded O O
in O O
an O O
81 O O
nucleotide O O
- O O
long O O
putative O O
exon O O
which O O
is O O
spliced O O
in O O
between O O
the O O
exons O O
encoding O O
the O O
A B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regions I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRAR I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
propose O O
that O O
GCD7 B B_GENE
and O O
GCD2 B B_GENE
play O O
important O O
roles O O
in O O
the O O
regulatory O O
interaction O O
between O O
eIF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
and O O
eIF B B_GENE
- I I_GENE
2B I I_GENE
and O O
that O O
the O O
suppressor O O
mutations O O
we O O
isolated O O
in O O
these O O
genes O O
decrease O O
the O O
susceptibility O O
of O O
eIF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
2B I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O O
the O O
inhibitory O O
effects O O
of O O
phosphorylated O O
eIF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O O
impairing O O
the O O
essential O O
catalytic O O
function O O
of O O
eIF B B_GENE
- I I_GENE
2B I I_GENE
in O O
translation O O
initiation O O
. O O

The O O
3 O O
' O O
region O O
of O O
the O O
transcript O O
contained O O
a O O
fully O O
conserved O O
, O O
correctly O O
spliced O O
TCR B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
C I I_GENE/I_LOCATION
region I I_GENE/I_LOCATION
which O O
was O O
polyadenylated O O
at O O
the O O
3 O O
' O O
end O O
. O O

These O O
data O O
demonstrate O O
that O O
CCTalpha B B_GENE
can O O
be O O
regulated O O
by O O
lipids O O
by O O
two O O
independent O O
domains O O
: O O
( O O
i O O
) O O
the O O
three O O
amphipathic O O
alpha O O
- O O
helical O O
repeats O O
that O O
interact O O
with O O
both O O
neutral O O
and O O
anionic O O
lipid O O
mixtures O O
and O O
( O O
ii O O
) O O
the O O
last O O
57 O O
residues O O
that O O
interact O O
with O O
anionic O O
lipids O O
. O O

Sorting O O
information O O
to O O
the O O
chloroplastic O O
inner O O
envelope O O
is O O
contained O O
in O O
an O O
NH2 O O
- O O
proximal O O
part O O
of O O
mature B B_GENE
IEP110 I I_GENE
( O O
110N B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
. O O

Most O O
of O O
these O O
elements O O
are O O
adjacent O O
to O O
type O O
X O O
telomeric O O
repeats O O
, O O
and O O
regions O O
flanking O O
four O O
of O O
five O O
characterized O O
S O O
. O O
paradoxus O O
insertions O O
carry O O
autonomously O O
replicating O O
sequences O O
. O O

From O O
1981 O O
to O O
1989 O O
, O O
a O O
total O O
of O O
26 O O
women O O
with O O
locally O O
or O O
regionally O O
advanced O O
carcinoma O O
of O O
the O O
uterine O O
cervix O O
were O O
treated O O
with O O
radiotherapy O O
( O O
RT O O
) O O
and O O
pelvic O O
regional O O
hyperthermia O O
( O O
HT O O
) O O
, O O
in O O
the O O
Divisions O O
of O O
Radiation O O
Oncology O O
at O O
the O O
University O O
of O O
Utah O O
Medical O O
Center O O
( O O
UU O O
) O O
and O O
the O O
Kenneth O O
Norris O O
Jr O O
Cancer O O
Hospital O O
of O O
the O O
University O O
of O O
Southern O O
California O O
( O O
USC O O
) O O
. O O

The O O
ARE O O
is O O
loosely O O
defined O O
as O O
the O O
five O O
- O O
nucleotide O O
sequence O O
AUUUA O O
embedded O O
in O O
a O O
uracil O O
- O O
rich O O
region O O
. O O

Lack O O
of O O
changes O O
in O O
milk O O
production O O
and O O
milk O O
composition O O
suggest O O
that O O
acute O O
increases O O
in O O
somatotropin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O O
concomitant O O
increases O O
in O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O O
not O O
sufficient O O
to O O
stimulate O O
synthesis O O
of O O
milk O O
and O O
milk O O
components O O
by O O
cows O O
during O O
established O O
lactation O O
. O O

The O O
material O O
then O O
was O O
cut O O
with O O
a O O
diamond O O
saw O O
into O O
sheets O O
of O O
8 O O
x O O
10 O O
x O O
3 O O
mm O O
, O O
and O O
the O O
upper O O
surface O O
was O O
polished O O
by O O
colloidal O O
SiO2 O O
and O O
/ O O
or O O
covered O O
with O O
a O O
carbon O O
- O O
titanium O O
( O O
C O O
: O O
Ti O O
) O O
layer O O
( O O
3 O O
. O O
3 O O
microm O O
) O O
using O O
the O O
plasma O O
- O O
enhanced O O
physical O O
vapor O O
deposition O O
method O O
. O O

Iomazenil O O
- O O
SPECT O O
revealed O O
a O O
highly O O
significant O O
increase O O
in O O
the O O
benzodiazepine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
uptake O O
in O O
all O O
studied O O
cortical O O
regions O O
except O O
temporal O O
cortices O O
. O O

Both O O
in O O
the O O
Federal O O
Republic O O
of O O
Germany O O
and O O
in O O
some O O
neighbouring O O
countries O O
the O O
epizootic O O
situation O O
of O O
Aujeszky O O
' O O
s O O
disease O O
has O O
been O O
unsatisfactory O O
for O O
a O O
long O O
time O O
, O O
especially O O
in O O
areas O O
with O O
a O O
high O O
pig O O
density O O
. O O

Since O O
RIP140 B B_PROTEIN[GENE]/B_LOCATION
generally O O
down O O
- O O
regulates O O
receptor O O
activity O O
in O O
mammalian O O
cells O O
and O O
specifically O O
down O O
- O O
regulates O O
coactivation O O
mediated O O
by O O
SRC B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
, O O
we O O
propose O O
a O O
model O O
in O O
which O O
RIP140 B B_GENE
indirectly O O
regulates O O
nuclear B B_GENE/B_LOCATION
receptor I I_GENE/I_LOCATION
AF I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
activity O O
by O O
competition O O
for O O
coactivators O O
such O O
as O O
SRC B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
. O O

DIC O O
and O O
low O O
grade O O
fibrinolysis O O
may O O
account O O
for O O
the O O
coagulation O O
abnormalities O O
of O O
the O O
syndrome O O
. O O

As O O
in O O
the O O
case O O
of O O
the O O
chicken O O
homologue O O
, O O
there O O
are O O
two O O
hPR B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
forms O O
, O O
A O O
and O O
B O O
, O O
which O O
originate O O
from O O
translational O O
initiation O O
at O O
AUG2 O O
( O O
codon O O
165 O O
) O O
and O O
AUG1 O O
, O O
respectively O O
. O O

Fluctuations O O
of O O
the O O
measured O O
ECF O O
energy O O
- O O
related O O
substances O O
corresponded O O
to O O
various O O
clinical O O
events O O
presumably O O
involving O O
hypoxia O O
/ O O
ischemia O O
. O O

Using O O
lasers O O
in O O
diabetic O O
wound O O
healing O O
. O O

Furthermore O O
, O O
the O O
zincon O O
- O O
loaded O O
resin O O
was O O
applied O O
to O O
the O O
selective O O
concentration O O
of O O
trace O O
amounts O O
of O O
chalcophile O O
elements O O
in O O
natural O O
water O O
samples O O
prior O O
to O O
neutron O O
activation O O
analysis O O
. O O

In O O
cells O O
stably O O
transfected O O
with O O
G B B_GENE
alpha I I_GENE
i I I_GENE
- I I_GENE
2 I I_GENE
or O O
G B B_GENE/B_LOCATION
alpha I I_GENE/I_LOCATION
i I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
3 I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
5 O O
' O O
- O O
flanking O O
sequences O O
fused O O
to O O
firefly O O
luciferase B B_GENE/B_BIO
cDNA O O
reporter O O
, O O
temporal O O
10 O O
- O O
15 O O
- O O
fold O O
transcriptional O O
activation O O
of O O
both O O
genes O O
occurred O O
before O O
cellular O O
polarization O O
. O O

CONCLUSIONS O O
: O O
These O O
results O O
suggest O O
that O O
histamine B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
2 I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
mechanisms O O
may O O
not O O
be O O
involved O O
in O O
postoperative O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O O
. O O

In O O
resume O O
response O O
to O O
treatment O O
with O O
usual O O
regimens O O
, O O
doxycycline O O
plus O O
streptomycin O O
of O O
doxycycline O O
rifampicin O O
is O O
good O O
, O O
being O O
however O O
time O O
elapsed O O
until O O
pain O O
ceases O O
of O O
mean O O
length O O
in O O
hospital O O
stay O O
shorter O O
in O O
the O O
group O O
receiving O O
doxycycline O O
plus O O
streptomycin O O
. O O

Fibrosis O O
of O O
the O O
adjacent O O
myocardium O O
was O O
seen O O
in O O
five O O
cases O O
. O O

Purified O O
preparations O O
of O O
all O O
four O O
AGT O O
mutants O O
showed O O
an O O
approximately O O
similar O O
degree O O
( O O
74 O O
- O O
120 O O
- O O
fold O O
) O O
of O O
reduction O O
in O O
the O O
rate O O
of O O
reaction O O
with O O
O6 O O
- O O
benzylguanine O O
. O O

Identification O O
of O O
a O O
68 B B_GENE
- I I_GENE
kilodalton I I_GENE
nuclear I I_GENE
ATP I I_GENE
- I I_GENE
binding I I_GENE
phosphoprotein I I_GENE
encoded O O
by O O
bovine O O
papillomavirus O O
type O O
1 O O
. O O

It O O
is O O
suggested O O
that O O
biliary O O
secretion O O
of O O
both O O
TBZ O O
and O O
FBZ O O
and O O
their O O
metabolites O O
may O O
contribute O O
to O O
this O O
recycling O O
. O O

During O O
chordotonal O O
organ O O
development O O
, O O
the O O
3 O O
' O O
enhancer O O
directs O O
expression O O
in O O
proneural O O
clusters O O
; O O
whereas O O
successive O O
modular O O
enhancers O O
located O O
in O O
the O O
5 O O
' O O
region O O
drive O O
tissue O O
- O O
specific O O
expression O O
in O O
chordotonal O O
organ O O
precursors O O
in O O
the O O
embryo O O
and O O
larval O O
leg O O
, O O
wing O O
and O O
antennal O O
imaginal O O
discs O O
. O O

The O O
use O O
of O O
self O O
- O O
measured O O
blood O O
pressure O O
determinations O O
in O O
assessing O O
dynamics O O
of O O
drug O O
compliance O O
in O O
a O O
study O O
with O O
amlodipine O O
once O O
a O O
day O O
, O O
morning O O
versus O O
evening O O
. O O

Nucleocapsid O O
structure O O
and O O
thermostability O O
of O O
the O O
virion O O
, O O
nucleocapsid O O
and O O
polymerase O O
complex O O
. O O

A O O
vascular O O
component O O
to O O
impotence O O
was O O
shown O O
to O O
be O O
common O O
in O O
those O O
with O O
neurological O O
impairment O O
, O O
and O O
may O O
alter O O
management O O
. O O

RESULTS O O
- O O
- O O
The O O
maximal O O
early O O
asthmatic O O
response O O
after O O
allergen O O
with O O
placebo O O
treatment O O
was O O
18 O O
. O O
4 O O
% O O
( O O
SE O O
4 O O
. O O
4 O O
% O O
) O O
and O O
with O O
WEB O O
2086 O O
18 O O
. O O
9 O O
% O O
( O O
4 O O
. O O
4 O O
% O O
) O O
. O O

Column O O
chromatographic O O
determination O O
of O O
polymyxin O O
B O O
sulfate O O
. O O

Usefulness O O
of O O
computerized O O
tomography O O
in O O
hemodialysis O O
patients O O
. O O

The O O
aim O O
of O O
our O O
study O O
was O O
to O O
determine O O
whether O O
exercise O O
training O O
can O O
augment O O
left O O
ventricular O O
diastolic O O
filling O O
at O O
rest O O
and O O
during O O
exercise O O
in O O
patients O O
with O O
ischemic O O
cardiomyopathy O O
and O O
whether O O
any O O
correlation O O
exists O O
between O O
changes O O
in O O
diastolic O O
filling O O
and O O
changes O O
in O O
exercise O O
tolerance O O
. O O

On O O
the O O
pharmacology O O
of O O
9 O O
, O O
10 O O
- O O
dihydro O O
- O O
10 O O
- O O
( O O
1 O O
- O O
methyl O O
- O O
4 O O
- O O
piperidylidene O O
) O O
- O O
9 O O
- O O
anthrol O O
( O O
WA O O
335 O O
) O O
, O O
a O O
histamine O O
and O O
serotonin O O
antagonist O O

METHODOLOGY O O
: O O
A O O
case O O
control O O
study O O
of O O
survivors O O
with O O
gestational O O
age O O
( O O
GA O O
) O O
< O O
28 O O
weeks O O
or O O
birthweight O O
( O O
BW O O
) O O
< O O
1000 O O
g O O
using O O
data O O
collected O O
prospectively O O
in O O
our O O
Neonatal O O
Intensive O O
Care O O
Unit O O
database O O
. O O

There O O
are O O
two O O
regulatory O O
regions O O
between O O
the O O
US3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
US6 B B_GENE
transcription I I_GENE
units I I_GENE
. O O

4 O O
. O O
7 O O
+ O O
/ O O
- O O
0 O O
. O O
6 O O
micromol O O
. O O

kg O O
- O O
1 O O
. O O

min O O
- O O
1 O O
) O O
but O O
was O O
not O O
changed O O
by O O
training O O
. O O

We O O
established O O
that O O
, O O
in O O
unstimulated O O
lymphocytes O O
, O O
the O O
Src B B_GENE
homology I I_GENE
2 I I_GENE
( O O
SH2 B B_GENE/B_DISEASE
) O O
and O O
SH3 B B_GENE/B_PERSON
domain I I_GENE/I_PERSON
- I I_GENE/I_PERSON
containing I I_GENE/I_PERSON
protein I I_GENE/I_PERSON
Grb2 B I_GENE/I_PERSON
and O O
the O O
p85 B B_GENE
subunit O O
of O O
phosphatidylinositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
associate O O
constitutively O O
with O O
Cbl B B_GENE
via O O
their O O
SH3 B B_GENE/B_BIO
domains I I_GENE/I_BIO
. O O

Increased O O
gliadin B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
were O O
found O O
more O O
frequently O O
in O O
patients O O
with O O
subtotal O O
villous O O
atrophy O O
( O O
9 O O
out O O
of O O
17 O O
patients O O
, O O
or O O
53 O O
% O O
; O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
than O O
in O O
patients O O
with O O
partial O O
villous O O
atrophy O O
( O O
2 O O
out O O
of O O
13 O O
patients O O
, O O
or O O
15 O O
% O O
) O O
or O O
normal O O
villous O O
appearance O O
( O O
2 O O
out O O
of O O
10 O O
patients O O
, O O
or O O
20 O O
% O O
) O O
. O O

However O O
, O O
the O O
optimum O O
compressive O O
strength O O
reached O O
values O O
up O O
to O O
40 O O
% O O
higher O O
than O O
CC O O
- O O
free O O
samples O O
. O O

lin B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
49 I I_GENE/I_DISEASE
and O O
lin B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
59 I I_MEASURE/I_GENE
transgenes I I_MEASURE/I_GENE
are O O
expressed O O
widely O O
throughout O O
C O O
. O O
elegans O O
animals O O
. O O

Magnetic O O
field O O
influence O O
on O O
central O O
nervous O O
system O O
function O O
. O O

Eight O O
of O O
these O O
suppressors O O
for O O
into O O
two O O
complementation O O
groups O O
, O O
designated O O
KCS1 B B_GENE/B_DISEASE
and O O
KCS2 B B_PROTEIN[GENE]/B_DISEASE
. O O

These O O
results O O
point O O
towards O O
post O O
- O O
translational O O
steric O O
and O O
/ O O
or O O
allosteric O O
control O O
of O O
EKLF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O O
that O O
may O O
be O O
important O O
not O O
just O O
for O O
its O O
DNA O O
binding O O
ability O O
, O O
but O O
also O O
for O O
its O O
potential O O
to O O
interact O O
with O O
other O O
proteins O O
that O O
fully O O
establish O O
the O O
correct O O
stereospecific O O
array O O
leading O O
to O O
efficient O O
switching O O
of O O
beta B B_GENE
- I I_GENE
globin I I_GENE
transcription O O
during O O
development O O
. O O

Oxalates O O
and O O
the O O
digestive O O
tract O O

However O O
, O O
the O O
addition O O
of O O
intravenous O O
injection O O
of O O
FPFD O O
101 O O
resulted O O
in O O
a O O
marked O O
improvement O O
in O O
their O O
symptoms O O
. O O

Western O O
blot O O
experiments O O
detected O O
SMBP B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O O
a O O
70 O O
kDa O O
protein O O
that O O
may O O
be O O
further O O
cleaved O O
into O O
an O O
active O O
34 O O
kDa O O
N O O
- O O
terminal O O
polypeptide O O
. O O

The O O
aetiology O O
and O O
management O O
of O O
diabetic O O
impotence O O
is O O
well O O
- O O
documented O O
; O O
the O O
effects O O
of O O
diabetes O O
on O O
female O O
sexuality O O
are O O
not O O
so O O
clear O O
. O O

Treatment O O
of O O
diabetes O O
and O O
retinal O O
complications O O

The O O
activated O O
glucocorticoid B B_GENE/B_LOCATION
receptor I I_GENE/I_LOCATION
forms O O
a O O
complex O O
with O O
Stat5 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
enhances O O
Stat5 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mediated O O
transcriptional O O
induction O O
. O O

Taken O O
together O O
, O O
these O O
findings O O
demonstrate O O
that O O
ZNF76 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ZNF143 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
two O O
members O O
of O O
a O O
same O O
family O O
of O O
transactivator O O
proteins O O
. O O

For O O
example O O
, O O
the O O
presence O O
of O O
two O O
related O O
genes O O
, O O
b B B_PROTEIN[GENE]/B_DISEASE
and O O
b B B_PROTEIN[GENE]/B_DISEASE
' I I_PROTEIN[GENE]/I_DISEASE
, O O
in O O
the O O
cyanobacterium O O
suggests O O
that O O
its O O
ATP B B_GENE
synthase I I_GENE
is O O
a O O
complex O O
of O O
nine O O
polypeptides O O
, O O
and O O
that O O
it O O
may O O
have O O
single O O
copies O O
of O O
related O O
b B B_PROTEIN[GENE]/B_DISEASE
and O O
b B B_PROTEIN[GENE]
' I I_PROTEIN[GENE]
proteins I I_PROTEIN[GENE]
rather O O
than O O
two O O
copies O O
of O O
identical O O
b B B_GENE/B_LOCATION
subunits I I_GENE/I_LOCATION
as O O
found O O
in O O
the O O
E O O
. O O
coli O O
enzyme O O
. O O
4 O O
+ O O
off O O

Antiserum O O
raised O O
against O O
rat B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liver I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S6 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O O
immunoprecipitates O O
the O O
purified O O
32P O O
- O O
labeled O O
H4 O O
hepatoma O O
insulin O O
- O O
stimulated O O
S6 B B_ENZYME[GENE]/B_MEASURE
kinase I I_ENZYME[GENE]/I_MEASURE
. O O

CRKL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
an O O
SH2 B B_GENE/B_DISEASE
- O O
SH3 B B_LOCATION/B_GENE
- O O
SH3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adapter O O
protein O O
, O O
is O O
one O O
of O O
the O O
major O O
tyrosine B B_GENE/B_BIO
phosphoproteins I I_GENE/I_BIO
detected O O
in O O
primary O O
leukemic O O
neutrophils O O
from O O
patients O O
with O O
CML O O
. O O

KU O O
- O O
1257 O O
also O O
significantly O O
accelerated O O
the O O
healing O O
of O O
acetic O O
acid O O
- O O
induced O O
duodenal O O
ulcers O O
as O O
well O O
as O O
famotidine O O
and O O
roxatidine O O
acetate O O
. O O

To O O
further O O
identify O O
the O O
residues O O
responsible O O
for O O
the O O
activity O O
, O O
we O O
isolated O O
the O O
mutant O O
viruses O O
that O O
were O O
not O O
neutralized O O
with O O
the O O
soluble O O
form O O
of O O
MHV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
since O O
such O O
mutants O O
were O O
expected O O
to O O
have O O
mutations O O
in O O
amino O O
acids O O
responsible O O
for O O
receptor O O
- O O
binding O O
activity O O
. O O

It O O
is O O
suggested O O
that O O
death O O
of O O
S O O
. O O
mansoni O O
cercariae O O
during O O
penetration O O
of O O
mammalian O O
host O O
skin O O
is O O
probably O O
due O O
to O O
exhaustion O O
of O O
their O O
energy O O
reserves O O
. O O

Especially O O
if O O
the O O
number O O
of O O
dimensions O O
of O O
the O O
samples O O
is O O
large O O
, O O
it O O
can O O
be O O
said O O
that O O
BPN O O
is O O
better O O
than O O
k O O
- O O
NN O O
in O O
classification O O
ability O O
. O O

In O O
contrast O O
, O O
inactivation O O
of O O
the O O
Sir4p B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
interacting I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Rap1p I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
reduces O O
partitioning O O
by O O
a O O
LexA B B_GENE/B_BACTERIUM[BIO]
- O O
Sir4p B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
fusion O O
. O O

Nine O O
individuals O O
who O O
were O O
stable O O
after O O
1 O O
month O O
of O O
therapy O O
at O O
low O O
dosage O O
were O O
randomized O O
to O O
a O O
further O O
month O O
of O O
therapy O O
at O O
low O O
or O O
high O O
dosage O O
, O O
during O O
which O O
one O O
of O O
four O O
at O O
high O O
dosage O O
had O O
a O O
partial O O
response O O
, O O
and O O
none O O
of O O
five O O
at O O
low O O
dosage O O
manifested O O
response O O
. O O

( O O
4 O O
) O O
Expression O O
in O O
different O O
sites O O
in O O
the O O
central O O
nervous O O
system O O
is O O
driven O O
by O O
separable O O
elements O O
widely O O
dispersed O O
throughout O O
8 O O
kb O O
3 O O
' O O
of O O
the O O
gene O O
. O O

To O O
investigate O O
possible O O
roles O O
for O O
HCP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
during O O
late O O
erythroid O O
differentiation O O
, O O
effects O O
of O O
manipulating O O
HCP B B_PROTEIN[GENE]/B_BIO
expression O O
or O O
recruitment O O
on O O
EPO B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
hemoglobinization O O
in O O
erythroleukemic O O
SKT6 O O
cells O O
have O O
been O O
investigated O O
. O O

The O O
other O O
end O O
of O O
this O O
cluster O O
contained O O
the O O
human B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
type I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
I I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
cytokeratin I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
K20 B I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
K12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
loci O O
. O O

An O O
11 O O
. O O
5 O O
- O O
kb O O
intron O O
is O O
found O O
at O O
the O O
end O O
of O O
transmembrane O O
6 O O
, O O
and O O
the O O
rest O O
of O O
the O O
ORF O O
is O O
in O O
exon O O
3 O O
. O O

Are O O
there O O
any O O
lessons O O
to O O
be O O
learnt O O
? O O

We O O
provided O O
evidence O O
that O O
CaM B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
played O O
a O O
role O O
in O O
regulating O O
neurite O O
outgrowth O O
and O O
growth O O
cone O O
motility O O
in O O
these O O
cells O O
, O O
and O O
that O O
the O O
autophosphorylation O O
is O O
essential O O
for O O
the O O
kinase O O
to O O
sufficiently O O
exert O O
its O O
cellular O O
function O O
in O O
vivo O O
[ O O
Y O O
. O O

However O O
, O O
in O O
transient O O
transfection O O
assays O O
, O O
a O O
truncation O O
of O O
as O O
little O O
as O O
15 O O
Nurr1 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
COOH O O
- O O
terminal O O
amino O O
acids O O
diminished O O
transcriptional O O
activation O O
of O O
B1A B B_GENE/B_BIO
- O O
thymidine B B_GENE
kinase I I_GENE
- O O
chloramphenicol B B_GENE
acetyltransferase I I_GENE
reporter O O
. O O

All O O
sows O O
nursed O O
nine O O
pigs O O
. O O

In O O
the O O
second O O
group O O
the O O
untreated O O
fellow O O
eye O O
was O O
microscopically O O
intact O O
, O O
but O O
was O O
shown O O
( O O
as O O
the O O
treated O O
eye O O
) O O
to O O
alter O O
the O O
concentration O O
of O O
uronic O O
acid O O
in O O
different O O
parts O O
of O O
the O O
sclera O O
. O O

Effects O O
were O O
studied O O
of O O
extremely O O
high O O
- O O
frequency O O
electromagnetic O O
radiation O O
( O O
EHF O O
EMR O O
) O O
on O O
indices O O
for O O
the O O
immune O O
and O O
endocrine O O
systems O O
in O O
a O O
series O O
of O O
48 O O
patients O O
presenting O O
with O O
hyperplastic O O
processes O O
in O O
endometrium O O
. O O

Characterization O O
of O O
human B B_GENE
activating I I_GENE
transcription I I_GENE
factor I I_GENE
4 I I_GENE
, O O
a O O
transcriptional O O
activator O O
that O O
interacts O O
with O O
multiple O O
domains O O
of O O
cAMP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
responsive I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CREB B B_GENE/B_DISEASE
) O O
- O O
binding O O
protein O O
. O O

Effect O O
of O O
a O O
constant O O
magnetic O O
field O O
on O O
different O O
models O O
of O O
carcinogenesis O O

In O O
contrast O O
to O O
the O O
reciprocal O O
effects O O
of O O
Gab1 B B_GENE
and O O
Gab2 B B_GENE
in O O
mediating O O
Elk B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
induction O O
, O O
these O O
two O O
molecules O O
have O O
a O O
similar O O
function O O
in O O
extracellular B B_GENE
signal I I_GENE
- I I_GENE
regulated I I_GENE
kinase I I_GENE
activation O O
induced O O
by O O
either O O
oncogenic O O
Ras B B_GENE/B_DISEASE
or O O
growth O O
factor O O
stimulation O O
. O O

This O O
result O O
is O O
consistent O O
with O O
the O O
previous O O
observation O O
that O O
expression O O
of O O
the O O
hsp70 B B_GENE/B_BACTERIUM[BIO]
genes I I_GENE/I_BACTERIUM[BIO]
in I I_GENE/I_BACTERIUM[BIO]
T I I_GENE/I_BACTERIUM[BIO]
. I I_GENE/I_BACTERIUM[BIO]
brucei I I_GENE/I_BACTERIUM[BIO]
is O O
mainly O O
controlled O O
at O O
the O O
posttranscriptional O O
level O O
. O O

A O O
definition O O
of O O
bias O O
founded O O
on O O
the O O
concept O O
of O O
the O O
study O O
base O O
. O O

Chromaffin O O
cells O O
transfected O O
with O O
a O O
plasmid O O
with O O
the O O
entire O O
coding O O
sequence O O
of O O
c B B_GENE
- I I_GENE
Rabphilin3a I I_GENE
inserted O O
in O O
the O O
antisense O O
orientation O O
inhibited O O
secretion O O
of O O
co O O
- O O
expressed O O
GH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
approximately O O
30 O O
% O O
. O O

An O O
environmental O O
investigation O O
found O O
evidence O O
of O O
suboptimal O O
food O O
storage O O
and O O
cooking O O
temperatures O O
at O O
Restaurant O O
A O O
; O O
cross O O
contamination O O
of O O
foods O O
may O O
have O O
contributed O O
to O O
the O O
low O O
attributable O O
risk O O
identified O O
for O O
chile O O
rellenos O O
. O O

Evidence O O
from O O
four O O
areas O O
- O O
- O O
sensory O O
deprivation O O
, O O
enriched O O
environments O O
, O O
nervous O O
system O O
plasticity O O
, O O
and O O
sensitive O O
periods O O
of O O
neurodevelopment O O
- O O
- O O
suggests O O
that O O
sensory O O
stimulation O O
programs O O
are O O
potentially O O
beneficial O O
for O O
STR O O
patients O O
. O O

In O O
each O O
study O O
group O O
, O O
elevated O O
levels O O
of O O
serum O O
I O O
were O O
observed O O
. O O

With O O
repetitive O O
intermittent O O
exercise O O
, O O
gradual O O
increases O O
in O O
blood O O
lactate O O
concentration O O
[ O O
( O O
LA O O
] O O
b O O
) O O
occurred O O
, O O
whereas O O
its O O
rate O O
of O O
accumulation O O
( O O
delta O O
[ O O
LA O O
] O O
b O O
) O O
decreased O O
. O O

A O O
physical O O
and O O
genetic O O
map O O
covering O O
the O O
entire O O
RP12 B B_LOCATION/B_GENE
candidate I I_LOCATION/I_GENE
gene I I_LOCATION/I_GENE
region I I_LOCATION/I_GENE
was O O
constructed O O
. O O

An O O
atypical O O
form O O
of O O
juvenile O O
myasthenia O O
gravis O O
associated O O
with O O
severe O O
emaciation O O
, O O
muscle O O
atrophy O O
, O O
ophthalmoplegia O O
, O O
bulbar O O
signs O O
and O O
joint O O
contracture O O

Electron O O
microscopic O O
visualization O O
of O O
the O O
general O O
population O O
of O O
active O O
genes O O
in O O
flies O O
overexpressing O O
hnRNP B B_GENE
proteins I I_GENE
also O O
indicated O O
that O O
the O O
great O O
majority O O
of O O
genes O O
seemed O O
normal O O
in O O
terms O O
of O O
cotranscriptional O O
RNA O O
processing O O
events O O
, O O
although O O
there O O
were O O
a O O
few O O
abnormalities O O
consistent O O
with O O
rare O O
exon O O
- O O
skipping O O
events O O
. O O

Having O O
demonstrated O O
proper O O
localization O O
of O O
GFP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
calmodulin B B_GENE
in O O
budding O O
yeast O O
, O O
we O O
examined O O
the O O
localization O O
of O O
a O O
fusion O O
between O O
GFP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
calmodulin B B_GENE
( O O
GFP B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
Camlp I I_PROTEIN[GENE]/I_LOCATION
) O O
in O O
fission O O
yeast O O
, O O
where O O
calmodulin B B_GENE/B_BIO
had O O
not O O
been O O
localized O O
by O O
any O O
method O O
. O O

Sera O O
from O O
33 O O
newborn O O
infants O O
with O O
gestational O O
ages O O
ranging O O
from O O
27 O O
to O O
41 O O
weeks O O
were O O
tested O O
by O O
radioimmunoassay O O
for O O
IgG B B_GENE/B_MEASURE
antibodies O O
to O O
surface O O
antigens O O
of O O
group O O
B O O
streptococci O O
( O O
GBS O O
) O O
types O O
Ia O O
, O O
Ib O O
, O O
II O O
and O O
III O O
. O O

In O O
frozen O O
sections O O
the O O
spots O O
appear O O
as O O
blue O O
labelled O O
neurones O O
with O O
a O O
light O O
microscope O O
, O O
or O O
as O O
a O O
brilliant O O
red O O
neurones O O
surrounded O O
by O O
reddish O O
tissue O O
with O O
a O O
fluorescence O O
microscope O O
. O O

The O O
percentage O O
distribution O O
of O O
types O O
of O O
fixation O O
disparity O O
curves O O
was O O
found O O
to O O
be O O
similar O O
to O O
some O O
previous O O
studies O O
, O O
with O O
a O O
higher O O
prevalence O O
of O O
Type O O
I O O
curve O O
( O O
64 O O
. O O
3 O O
% O O
) O O
, O O
followed O O
by O O
Type O O
II O O
( O O
28 O O
. O O
6 O O
% O O
) O O
and O O
Type O O
III O O
( O O
7 O O
. O O
1 O O
% O O
) O O
curves O O
. O O

The O O
BUR O O
was O O
set O O
at O O
20 O O
/ O O
min O O
and O O
the O O
IT O O
at O O
. O O
5 O O
seconds O O
. O O

These O O
data O O
are O O
discussed O O
in O O
the O O
context O O
of O O
the O O
pathogenesis O O
and O O
differential O O
diagnosis O O
of O O
EEC O O
. O O

Seminal O O
prolactin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O O
were O O
significantly O O
elevated O O
in O O
all O O
infertile O O
males O O
. O O

Northern O O
blot O O
analysis O O
identified O O
retina O O
- O O
specific O O
transcripts O O
of O O
3 O O
. O O
0 O O
kb O O
for O O
rod B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
G I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
alpha I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
t I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
and O O
2 O O
. O O
6 O O
kb O O
for O O
cone B B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
G I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
alpha I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
t I I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O O

Adenovirus O O
- O O
mediated O O
gene O O
transfer O O
of O O
MMAC1 B B_GENE
/ O O
PTEN B B_PROTEIN[GENE]/B_MEASURE
to O O
glioblastoma O O
cells O O
inhibits O O
S O O
phase O O
entry O O
by O O
the O O
recruitment O O
of O O
p27Kip1 B B_GENE
into O O
cyclin B B_GENE
E I I_GENE
/ O O
CDK2 B B_GENE
complexes O O
. O O

Cost O O
analysis O O
and O O
the O O
HSA O O
: O O
a O O
framework O O
. O O

These O O
cells O O
also O O
showed O O
an O O
increase O O
in O O
cyclin B B_GENE
A I I_GENE
and O O
cyclin B B_GENE
A I I_GENE
- I I_GENE
and I I_GENE
E I I_GENE
- I I_GENE
associated I I_GENE
kinase I I_GENE
activities O O
characteristic O O
of O O
S O O
phase O O
induction O O
. O O

Characterization O O
of O O
a O O
tonB B B_GENE/B_BACTERIUM[BIO]
- O O
phoA B B_BACTERIUM[BIO]/B_GENE
gene O O
fusion O O
suggests O O
that O O
the O O
amino O O
- O O
terminal O O
41 O O
amino O O
acids O O
of O O
TonB B B_GENE/B_BACTERIUM[BIO]
are O O
sufficient O O
to O O
promote O O
export O O
of O O
the O O
fusion O O
protein O O
and O O
presumably O O
TonB B B_BACTERIUM[BIO]/B_GENE
as O O
well O O
. O O

Calcium O O
bilirubinate O O
crystals O O
were O O
seen O O
in O O
gallbladder O O
bile O O
or O O
wall O O
scrapings O O
of O O
7 O O
of O O
8 O O
TPN O O
animals O O
but O O
in O O
none O O
of O O
the O O
controls O O
( O O
P O O
less O O
than O O
0 O O
. O O
001 O O
) O O
. O O

This O O
domain O O
encompasses O O
the O O
region O O
of O O
ARP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
/ O O
COUP B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
TFII I I_PROTEIN[GENE]/I_MEASURE
corresponding O O
to O O
helices O O
3 O O
to O O
12 O O
in O O
the O O
recently O O
published O O
crystal O O
structure O O
of O O
other O O
members O O
of O O
the O O
nuclear B B_GENE/B_BIO
receptor I I_GENE/I_BIO
superfamily I I_GENE/I_BIO
. O O

Different O O
clinical O O
variants O O
of O O
the O O
empty O O
sella O O
turcica O O
syndrome O O
are O O
demonstrated O O
, O O
including O O
variants O O
resultant O O
from O O
substitution O O
therapy O O
of O O
thyroid O O
hypofunction O O
, O O
from O O
dopamine O O
agonist O O
therapy O O
for O O
hyperprolactinemic O O
hypogonadism O O
, O O
from O O
radiotherapy O O
of O O
hypophyseal O O
adenoma O O
. O O

Both O O
genes B B_GENE
ARO3 I I_GENE
and O O
ARO4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
strongly O O
regulated O O
under O O
the O O
general O O
control O O
regulatory O O
system O O
. O O

J O O
. O O
, O O
& O O
Olefsky O O
, O O
J O O
. O O

Importantly O O
, O O
a O O
single O O
base O O
change O O
in O O
the O O
fifth O O
position O O
of O O
the O O
c B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
fos I I_GENE/I_LOCATION
sequence I I_GENE/I_LOCATION
( O O
GGTCTnnnAGACC O O
to O O
GGTCA O O
/ O O
GnnnAGACC O O
) O O
produced O O
an O O
element O O
that O O
bound O O
the O O
estrogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
conferred O O
estrogen O O
- O O
dependent O O
transcriptional O O
activation O O
of O O
a O O
reporter O O
gene O O
. O O

Measuring O O
the O O
dim O O
light O O
melatonin O O
onset O O
( O O
DLMO O O
) O O
is O O
a O O
useful O O
and O O
practical O O
way O O
to O O
assess O O
circadian O O
phase O O
position O O
in O O
humans O O
. O O

Co O O
- O O
expression O O
of O O
a O O
gag B B_GENE
- O O
TRalpha B B_GENE
fusion O O
protein O O
in O O
AEV O O
- O O
transformed O O
cells O O
and O O
addition O O
of O O
ligand O O
derepresses O O
CAII B B_GENE/B_VIRUS[BIO]
transcription O O
. O O

The O O
IB2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HGMW O O
- O O
approved O O
symbol O O
MAPK8IP2 B B_GENE/B_TIME[MEASURE]
) O O
maps O O
to O O
human O O
chromosome O O
22q13 O O
and O O
contains O O
10 O O
coding O O
exons O O
. O O

Transcription O O
start O O
sites O O
of O O
sal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
salR B B_GENE
genes I I_GENE
were O O
determined O O
to O O
lie O O
30 O O
- O O
and O O
24 O O
- O O
bp O O
upstream O O
of O O
the O O
respective O O
initiation O O
codons O O
and O O
separated O O
from O O
each O O
other O O
by O O
78 O O
nucleotides O O
. O O

1 O O
. O O
23 O O
) O O
as O O
a O O
PPARalpha B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
interacting I I_MEASURE/I_GENE
protein I I_MEASURE/I_GENE
. O O

Here O O
we O O
demonstrate O O
that O O
the O O
T B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
zeta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ZAP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
70 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
T B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
zeta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
immunoreceptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
based I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motifs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
essential O O
for O O
the O O
membrane O O
recruitment O O
of O O
SOS B B_GENE/B_DISEASE
and O O
Vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
carried O O
out O O
two O O
experiments O O
to O O
investigate O O
this O O
problem O O
. O O

When O O
linked O O
to O O
the O O
herpes O O
simplex O O
thymidine B B_ENZYME[GENE]/B_VIRUS[BIO]
kinase I B_ENZYME[GENE]/I_VIRUS[BIO]
minimal O O
promoter O O
, O O
this O O
fragment O O
acts O O
as O O
an O O
enhancing O O
element O O
in O O
Rcho O O
but O O
not O O
GC O O
cells O O
. O O

A O O
mammalian O O
protein O O
called O O
RFX B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
NF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
X I I_GENE/I_DISEASE
binds O O
to O O
the O O
X O O
box O O
( O O
or O O
X1 O O
box O O
) O O
in O O
the O O
promoters O O
of O O
a O O
number O O
of O O
major B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MHC I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Site O O
- O O
directed O O
mutagenesis O O
was O O
conducted O O
to O O
investigate O O
the O O
functional O O
significance O O
of O O
this O O
element O O
and O O
the O O
3 O O
' O O
minus O O
- O O
strand O O
terminal O O
sequence O O
" O O
3 O O
' O O
- O O
OH O O
- O O
CCCUAU O O
, O O
" O O
which O O
contains O O
the O O
minus O O
- O O
strand O O
3 O O
' O O
- O O
end O O
sequence O O
" O O
3 O O
' O O
- O O
OH O O
- O O
CC O O
( O O
1 O O
- O O
2 O O
) O O
( O O
A O O
/ O O
U O O
) O O
( O O
A O O
/ O O
U O O
) O O
( O O
A O O
/ O O
U O O
) O O
" O O
found O O
in O O
all O O
carmovirus O O
RNAs O O
. O O

The O O
incidence O O
of O O
the O O
variability O O
of O O
the O O
free O O
PSA B B_PROTEIN[GENE]
/ O O
total O O
PSA B B_GENE
ratio O O
on O O
the O O
early O O
diagnosis O O
of O O
prostate O O
cancer O O

In O O
the O O
second O O
, O O
37 O O
students O O
were O O
given O O
trimethoprim O O
/ O O
sulphamethoxazole O O
( O O
160 O O
mg O O
TMP O O
- O O
SMX O O
800 O O
mg O O
) O O
, O O
38 O O
TMP O O
( O O
200 O O
mg O O
) O O
, O O
and O O
in O O
35 O O
a O O
placebo O O
was O O
given O O
b O O
. O O
i O O
. O O
d O O
. O O
for O O
five O O
days O O
. O O

Developmental O O
slot O O
blots O O
demonstrate O O
that O O
mRNAs O O
corresponding O O
to O O
the O O
three O O
LHM B B_GENE/B_LOCATION
cDNAs I I_GENE/I_LOCATION
are O O
transcribed O O
from O O
prophase O O
of O O
meiosis O O
I O O
to O O
the O O
uninucleate O O
microspore O O
stage O O
, O O
while O O
Northern O O
analysis O O
reveals O O
these O O
tapetally O O
expressed O O
cDNAs O O
to O O
correspond O O
with O O
transcripts O O
of O O
some O O
500 O O
bp O O
. O O

Other O O
recommendations O O
for O O
enhancing O O
the O O
safety O O
of O O
potent O O
antiplatelet O O
agents O O
in O O
a O O
variety O O
of O O
clinical O O
situations O O
are O O
provided O O
. O O

RESULTS O O
- O O
- O O
261 O O
patients O O
were O O
enrolled O O
into O O
this O O
study O O
; O O
of O O
these O O
, O O
138 O O
( O O
53 O O
% O O
) O O
patients O O
attended O O
for O O
repeat O O
colposcopy O O
and O O
cytology O O
at O O
one O O
year O O
. O O

Changes O O
in O O
the O O
greater O O
omentum O O
of O O
mice O O
of O O
different O O
strains O O
after O O
intraperitoneal O O
immunization O O
with O O
sheep O O
erythrocytes O O
. O O

In O O
this O O
study O O
, O O
we O O
sought O O
to O O
determine O O
the O O
specific O O
effect O O
of O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protease I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O O
on O O
patient O O
weight O O
. O O

However O O
massive O O
necrosis O O
of O O
the O O
renal O O
tubules O O
had O O
been O O
found O O
with O O
more O O
than O O
15mg O O
of O O
DSM O O
administration O O
. O O

The O O
characteristics O O
of O O
a O O
simple O O
apparatus O O
for O O
clinical O O
use O O
to O O
measure O O
DEOAEs O O
are O O
described O O
together O O
with O O
typical O O
examples O O
of O O
emissions O O
. O O

To O O
obtain O O
information O O
on O O
the O O
functional O O
role O O
of O O
the O O
Rac1 B B_GENE
/ O O
p38 B B_GENE
/ O O
MAPKAPK B B_GENE
- I I_GENE
2 I I_GENE
pathway O O
in O O
RA O O
signaling O O
, O O
the O O
effects O O
of O O
pharmacological O O
inhibition O O
of O O
p38 B B_GENE
on O O
RA O O
- O O
induced O O
gene O O
transcription O O
and O O
cell O O
differentiation O O
were O O
determined O O
. O O

The O O
cost O O
and O O
effectiveness O O
of O O
nurse O O
education O O
- O O
- O O
1 O O
. O O

The O O
ATF B B_LOCATION/B_GENE
/ O O
CRE O O
site O O
is O O
also O O
essential O O
for O O
CD4 B B_GENE/B_MEASURE
promoter I I_GENE/I_MEASURE
activation O O
by O O
forskolin O O
, O O
an O O
activator O O
of O O
adenylate B B_GENE
cyclase I I_GENE
. O O

YLL031c B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
an O O
essential O O
gene O O
. O O

Restricted O O
expression O O
of O O
a O O
novel O O
murine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
atonal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
undifferentiated O O
neural O O
precursors O O
. O O

Since O O
the O O
early O O
1900s O O
, O O
a O O
genetic O O
hypothesis O O
has O O
been O O
suggested O O
. O O

We O O
report O O
the O O
genomic O O
organization O O
of O O
the O O
mouse O O
orphan B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Ryk B B_GENE
) O O
, O O
a O O
structurally O O
unclassified O O
member O O
of O O
the O O
growth B B_GENE
factor I I_GENE
receptor I I_GENE
family O O
. O O

In O O
contrast O O
, O O
T229E B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p70s6k I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
migrated O O
more O O
slowly O O
in O O
SDS O O
- O O
polyacrylamide O O
gels O O
, O O
but O O
demonstrated O O
partial O O
kinase O O
activity O O
( O O
approximately O O
20 O O
% O O
compared O O
with O O
the O O
wild O O
type O O
) O O
. O O

The O O
structure O O
and O O
expression O O
of O O
the O O
murine B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
encoding I I_GENE/I_LOCATION
granulocyte I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
macrophage I I_GENE/I_LOCATION
colony I I_GENE/I_LOCATION
stimulating I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
: O O
evidence O O
for O O
utilisation O O
of O O
alternative O O
promoters O O
. O O

Thus O O
, O O
the O O
search O O
for O O
genetic O O
and O O
acquired O O
susceptibility O O
to O O
nontuberculous O O
mycobacteria O O
is O O
also O O
a O O
search O O
for O O
susceptibility O O
factors O O
for O O
MTB O O
as O O
well O O
as O O
an O O
opportunity O O
to O O
recognize O O
endogenous O O
pathways O O
that O O
can O O
be O O
exploited O O
therapeutically O O
. O O

Liver O O
disease O O
and O O
HCV O O
infection O O
after O O
transplantation O O
of O O
organs O O
from O O
hepatitis B B_DISEASE/B_GENE
C I I_DISEASE/I_GENE
antibody I I_DISEASE/I_GENE
positive O O
donors O O
. O O

Incubation O O
of O O
HeLa O O
cell O O
cytoplasmic O O
extracts O O
with O O
a O O
purified O O
recombinant O O
glutathione B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
S I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
raf B B_GENE/B_DISEASE
fusion O O
protein O O
in O O
the O O
presence O O
of O O
ATP O O
released O O
active O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
that O O
could O O
be O O
detected O O
by O O
electrophoretic O O
gel O O
mobility O O
shift O O
assay O O
. O O

Cross O O
- O O
species O O
characterization O O
of O O
the O O
promoter B B_GENE/B_LOCATION
region I I_GENE/I_LOCATION
of I I_GENE/I_LOCATION
the I I_GENE/I_LOCATION
cystic I I_GENE/I_LOCATION
fibrosis I I_GENE/I_LOCATION
transmembrane I I_GENE/I_LOCATION
conductance I I_GENE/I_LOCATION
regulator I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
reveals O O
multiple O O
levels O O
of O O
regulation O O
. O O

Pretreatment O O
with O O
lipid O O
X O O
was O O
not O O
necessary O O
to O O
improve O O
survival O O
: O O
16 O O
of O O
17 O O
( O O
94 O O
% O O
) O O
infected O O
and O O
visibly O O
ill O O
animals O O
that O O
received O O
lipid O O
X O O
and O O
ticarcillin O O
6 O O
h O O
after O O
thigh O O
inoculation O O
survived O O
versus O O
30 O O
of O O
44 O O
( O O
68 O O
% O O
) O O
control O O
animals O O
treated O O
with O O
ticarcillin O O
alone O O
( O O
P O O
less O O
than O O
0 O O
. O O
0001 O O
) O O
. O O

The O O
predicted O O
vav B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oncogene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exhibits O O
several O O
motifs O O
reminiscent O O
of O O
transcriptional O O
factors O O
. O O

The O O
pharmacokinetics O O
were O O
best O O
described O O
by O O
a O O
two O O
- O O
compartment O O
open O O
model O O
giving O O
distribution O O
half O O
- O O
lives O O
of O O
0 O O
. O O
31 O O
h O O
and O O
1 O O
. O O
53 O O
h O O
, O O
and O O
elimination O O
half O O
- O O
lives O O
of O O
69 O O
. O O
7 O O
h O O
and O O
60 O O
. O O
3 O O
h O O
for O O
oxolinic O O
acid O O
and O O
oxytetracycline O O
, O O
respectively O O
. O O

The O O
predictive O O
value O O
of O O
the O O
remotely O O
sensed O O
map O O
based O O
on O O
NDVI O O
data O O
appears O O
to O O
be O O
better O O
than O O
that O O
from O O
forecast O O
indices O O
based O O
only O O
on O O
climatic O O
data O O
. O O

It O O
has O O
been O O
confirmed O O
in O O
animal O O
experiments O O
that O O
the O O
number O O
of O O
microspheres O O
in O O
a O O
myocardial O O
sample O O
approximately O O
follows O O
a O O
Poisson O O
distribution O O
, O O
under O O
adequate O O
experimental O O
conditions O O
. O O

This O O
gene O O
is O O
divided O O
into O O
six O O
exons O O
spanning O O
about O O
3kb O O
, O O
and O O
encodes O O
a O O
175 O O
amino O O
acid O O
protein O O
with O O
40 O O
- O O
52 O O
% O O
identity O O
with O O
the O O
other O O
five O O
mouse B B_GENE/B_PERSON
Reg I I_GENE/I_PERSON
( O O
regenerating B B_PROTEIN[GENE]/B_LOCATION
gene I I_PROTEIN[GENE]/I_LOCATION
product I I_PROTEIN[GENE]/I_LOCATION
) O O
proteins O O
. O O

The O O
p63 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O O
features O O
an O O
acidic O O
domain O O
characteristic O O
of O O
transcriptional O O
activation O O
factors O O
, O O
as O O
well O O
as O O
sequence O O
blocks O O
displaying O O
limited O O
similarity O O
to O O
positionally O O
equivalent O O
regions O O
in O O
sigma B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
eubacteria O O
related O O
to O O
mitochondria O O
. O O

Thus O O
, O O
the O O
pathway O O
to O O
Fc B B_GENE
epsilonRI I I_GENE
- O O
mediated O O
MEK B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
ERK B B_GENE
and O O
ERK B B_GENE
activation O O
can O O
apparently O O
bypass O O
Ras B B_GENE/B_DISEASE
and O O
Raf B B_GENE
- I I_GENE
1 I I_GENE
. O O

Ftz B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
on O O
the O O
other O O
hand O O
, O O
influences O O
Ftz B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
F1 B B_GENE
activity O O
by O O
interacting O O
with O O
its O O
AF O O
- O O
2 O O
domain O O
in O O
a O O
manner O O
that O O
mimics O O
a O O
nuclear O O
receptor O O
coactivator O O
. O O

Successive O O
5 O O
' O O
deletions O O
of O O
the O O
[ O O
- O O
326 O O
; O O
+ O O
20 O O
] O O
type B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sPLA2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
indicated O O
that O O
the O O
region O O
upstream O O
of O O
position O O
- O O
195 O O
inhibits O O
the O O
transcription O O
activity O O
sixfold O O
in O O
HepG2 O O
cells O O
but O O
not O O
in O O
HeLa O O
cells O O
. O O

The O O
cloning O O
of O O
CWH43 B B_BIO/B_GENE
showed O O
that O O
it O O
corresponds O O
to O O
YCR017c B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
encodes O O
a O O
protein O O
with O O
14 O O
- O O
16 O O
transmembrane O O
segments O O
containing O O
several O O
putative O O
phosphorylation O O
and O O
glycosylation O O
sites O O
. O O

However O O
, O O
strains O O
in O O
which O O
both O O
of O O
the O O
two O O
most O O
highly O O
related O O
genes O O
, O O
DdPIK1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
DdPIK2 B B_GENE/B_DISEASE
, O O
were O O
disrupted O O
showed O O
both O O
growth O O
and O O
developmental O O
defects O O
, O O
while O O
double O O
knockouts O O
of O O
DdPIK1 B B_GENE/B_BIO
and O O
DdPIK3 B B_GENE
and O O
DdPIK2 B B_GENE
and O O
DdPIK3 B B_GENE/B_LOCATION
appear O O
to O O
be O O
lethal O O
. O O

Competition O O
and O O
methylation O O
interference O O
assays O O
showed O O
that O O
the O O
binding O O
site O O
for O O
the O O
novel O O
factor O O
was O O
limited O O
to O O
nucleotides O O
in O O
the O O
3 O O
' O O
half O O
of O O
the O O
kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
. O O

These O O
properties O O
prompted O O
us O O
to O O
investigate O O
Ets B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
in O O
32 O O
human O O
astroglial O O
tumors O O
of O O
WHO O O
grades O O
I O O
- O O
IV O O
and O O
to O O
correlate O O
the O O
data O O
with O O
the O O
expression O O
pattern O O
of O O
VEGF B B_GENE
, O O
Flt B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
, O O
and O O
KDR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
strongly O O
DNA O O
binding O O
p50 B B_PROTEIN[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit I B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
only O O
very O O
weak O O
, O O
if O O
any O O
, O O
induction O O
of O O
gene O O
expression O O
. O O

The O O
results O O
obtained O O
demonstrate O O
the O O
applicability O O
of O O
countercurrent O O
chromatography O O
to O O
the O O
determination O O
of O O
ultratrace O O
elements O O
. O O

E1A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
cHa B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ras I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transformed O O
rat O O
embryo O O
fibroblast O O
cells O O
are O O
characterized O O
by O O
high O O
and O O
constitutive O O
DNA O O
binding O O
activities O O
of O O
AP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
significantly O O
altered O O
composition O O
. O O

Nuclear O O
localization O O
of O O
this O O
SNF2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
like I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
putative O O
helicase B B_ENZYME[GENE]/B_LOCATION
is O O
dependent O O
on O O
a O O
nuclear O O
localization O O
sequence O O
located O O
in O O
the O O
NH2 O O
- O O
terminal O O
region O O
. O O

The O O
feasibility O O
of O O
creating O O
CR1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
Ig B B_GENE/B_LOCATION
chimeras O O
makes O O
possible O O
a O O
new O O
strategy O O
of O O
targeting O O
complement O O
inhibition O O
by O O
the O O
use O O
of O O
Ig B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partners I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O O
particular O O
antigenic O O
specificities O O
. O O

Morphological O O
- O O
functional O O
status O O
of O O
the O O
edentulous O O
mandible O O
and O O
selection O O
of O O
the O O
most O O
effective O O
method O O
for O O
functional O O
impression O O
- O O
taking O O

They O O
are O O
both O O
insensitive O O
to O O
inhibitors O O
of O O
serine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
aspartyl I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteinases I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
but O O
are O O
sensitive O O
to O O
sulfhydryl O O
reagents O O
and O O
0 O O
. O O
5 O O
mM O O
ZnCl2 O O
. O O

The O O
authors O O
investigate O O
in O O
a O O
group O O
of O O
211 O O
children O O
aged O O
2 O O
- O O
6 O O
years O O
, O O
incl O O
. O O
in O O
particular O O
a O O
group O O
of O O
33 O O
2 O O
- O O
year O O
- O O
old O O
ones O O
, O O
in O O
1990 O O
and O O
checked O O
in O O
1991 O O
at O O
two O O
sites O O
in O O
Bratislava O O
- O O
- O O
a O O
town O O
with O O
a O O
varying O O
concentration O O
of O O
NOX O O
, O O
SO2 O O
, O O
dustiness O O
and O O
dust O O
fallout O O
- O O
- O O
their O O
influence O O
on O O
the O O
incidence O O
, O O
type O O
and O O
course O O
of O O
relapsing O O
respiratory O O
disease O O
. O O

However O O
, O O
no O O
statistical O O
difference O O
in O O
the O O
Ca O O
/ O O
P O O
ratio O O
, O O
carbon O O
concentration O O
and O O
surface O O
energy O O
were O O
observed O O
with O O
different O O
heat O O
treatments O O
. O O

Here O O
we O O
show O O
that O O
inhibition O O
occurs O O
with O O
a O O
NS1 B B_GENE/B_BIO
- O O
Rev B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chimera O O
in O O
which O O
the O O
78 O O
amino O O
- O O
terminal O O
amino O O
acids O O
of O O
the O O
NS1A B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
comprising O O
its O O
entire O O
RNA O O
- O O
binding O O
domain O O
is O O
deleted O O
, O O
thereby O O
establishing O O
that O O
this O O
carboxyl O O
portion O O
of O O
the O O
NS1A B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
can O O
function O O
as O O
an O O
independent O O
effector O O
domain O O
. O O

Overall O O
, O O
it O O
appears O O
that O O
prenatal O O
exposure O O
to O O
androgen O O
- O O
based O O
synthetic O O
progestin O O
exerted O O
a O O
masculinizing O O
and O O
/ O O
or O O
defeminizing O O
influence O O
on O O
human O O
behavioral O O
development O O
, O O
whereas O O
prenatal O O
exposure O O
to O O
natural O O
progesterone O O
and O O
progesterone O O
- O O
based O O
synthetic O O
progestin O O
had O O
a O O
feminizing O O
and O O
/ O O
or O O
demasculinizing O O
influence O O
, O O
particularly O O
among O O
female O O
subjects O O
. O O

MTX O O
therapy O O
decreased O O
Ga O O
- O O
67 O O
uptake O O
in O O
liver O O
, O O
tumor O O
, O O
and O O
muscle O O
. O O

Encapsulation O O
of O O
sodium O O
fluorescein O O
for O O
dye O O
release O O
studies O O
. O O

Primer O O
extension O O
analysis O O
and O O
subcloning O O
of O O
the O O
virJ B B_SPECIES[BIO]/B_GENE
- O O
phoA B B_GENE/B_BACTERIUM[BIO]
fusion O O
indicate O O
that O O
the O O
acetosyringone O O
- O O
inducible O O
promoter O O
lies O O
directly O O
upstream O O
of O O
the O O
virJ B B_GENE/B_BIO
structural I I_GENE/I_BIO
gene I I_GENE/I_BIO
. O O

To O O
isolate O O
genes O O
that O O
contain O O
zinc O O
finger O O
motifs O O
, O O
a O O
human O O
brain O O
cDNA O O
library O O
was O O
screened O O
with O O
an O O
oligonucleotide O O
complementary O O
to O O
the O O
conserved O O
" O O
linker O O
" O O
sequence O O
between O O
adjacent O O
zinc O O
fingers O O
. O O

Percentage O O
incremental O O
18 O O
- O O
OHB O O
responses O O
to O O
metoclopramide O O
were O O
greater O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
in O O
the O O
subjects O O
after O O
5 O O
days O O
on O O
a O O
200 O O
- O O
meq O O
sodium O O
intake O O
than O O
after O O
5 O O
days O O
on O O
a O O
10 O O
- O O
meq O O
sodium O O
intake O O
. O O

Using O O
in O O
vivo O O
screening O O
, O O
we O O
first O O
identified O O
a O O
gene O O
that O O
appeared O O
to O O
interfere O O
with O O
the O O
His O O
- O O
Asp O O
phosphorelay O O
between O O
the O O
HPt O O
domain O O
and O O
the O O
receiver O O
domain O O
of O O
OmpR B B_GENE/B_BACTERIUM[BIO]
, O O
provided O O
that O O
the O O
gene O O
product O O
was O O
expressed O O
through O O
a O O
multicopy O O
plasmid O O
. O O

Quinethazone O O

Studies O O
on O O
nitrogen O O
- O O
containing O O
heterocyclic O O
compounds O O
. O O

We O O
found O O
that O O
RXR B B_GENE/B_LOCATION
and O O
VDR B B_GENE/B_LOCATION
transactivated O O
selectively O O
from O O
VDRE O O
- O O
linked O O
templates O O
exclusively O O
as O O
a O O
heterodimeric O O
complex O O
, O O
since O O
neither O O
receptor O O
alone O O
enhanced O O
transcription O O
in O O
vitro O O
. O O

METHODS O O
: O O
We O O
performed O O
nasal O O
mupirocin O O
treatment O O
on O O
10 O O
infants O O
who O O
were O O
MRSA O O
- O O
positive O O
either O O
in O O
the O O
nose O O
or O O
the O O
pharynx O O
and O O
evaluated O O
the O O
effect O O
of O O
mupirocin O O
on O O
the O O
eradication O O
of O O
MRSA O O
. O O

RESULTS O O
: O O
Of O O
10 O O
, O O
709 O O
, O O
701 O O
chemistry O O
specimens O O
submitted O O
to O O
the O O
participating O O
laboratories O O
during O O
the O O
data O O
collection O O
period O O
, O O
37 O O
, O O
208 O O
( O O
0 O O
. O O
35 O O
% O O
) O O
were O O
rejected O O
prior O O
to O O
testing O O
. O O

Administration O O
of O O
SnCl2 O O
and O O
ZnSO4 O O
( O O
group O O
V O O
) O O
resulted O O
in O O
a O O
decrease O O
of O O
ALA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
D I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
and O O
in O O
an O O
increase O O
in O O
CP O O
- O O
U O O
. O O

The O O
lack O O
of O O
chronically O O
depressed O O
LCBF O O
( O O
after O O
1 O O
day O O
) O O
may O O
be O O
related O O
to O O
the O O
quick O O
structural O O
repair O O
of O O
endothelium O O
. O O

In O O
this O O
study O O
, O O
to O O
elucidate O O
the O O
possible O O
mechanism O O
of O O
action O O
of O O
EM O O
, O O
we O O
examined O O
the O O
effect O O
of O O
the O O
drug O O
on O O
the O O
expression O O
of O O
neutrophil O O
adhesion O O
molecules O O
such O O
as O O
L B B_GENE
- I I_GENE
selectin I I_GENE
and O O
Mac B B_GENE
- I I_GENE
1 I I_GENE
. O O

Tissue O O
expansion O O
was O O
used O O
successfully O O
to O O
prepare O O
adequate O O
soft O O
tissue O O
for O O
closure O O
following O O
a O O
difficult O O
clubfoot O O
correction O O
. O O

The O O
transcription O O
start O O
site O O
was O O
identified O O
by O O
primer O O
extension O O
analysis O O
and O O
over O O
800 O O
bp O O
of O O
5 O O
' O O
flanking O O
DNA O O
was O O
sequenced O O
. O O

The O O
reporter O O
gene O O
with O O
two O O
copies O O
of O O
the O O
wild O O
- O O
type O O
Repeat O O
2 O O
+ O O
3 O O
sequence O O
was O O
transcribed O O
actively O O
in O O
sterol O O
- O O
deprived O O
cells O O
and O O
was O O
repressed O O
by O O
more O O
than O O
80 O O
% O O
when O O
sterols O O
were O O
present O O
. O O

Changes O O
in O O
tension O O
were O O
monitored O O
isometrically O O
on O O
spiral O O
strips O O
of O O
freshly O O
obtained O O
bovine O O
basilar O O
arteries O O
. O O

A O O
1 O O
. O O
5 O O
- O O
month O O
- O O
old O O
boy O O
with O O
Sandifer O O
' O O
s O O
syndrome O O
is O O
described O O
. O O

However O O
, O O
PC12 O O
cell O O
clones O O
which O O
expressed O O
p33rsu B B_GENE
- I I_GENE
1 I I_GENE
at O O
an O O
increased O O
level O O
in O O
a O O
regulatable O O
fashion O O
in O O
response O O
to O O
dexamethasone O O
were O O
isolated O O
. O O

In O O
this O O
study O O
, O O
we O O
verified O O
that O O
PI B B_GENE
3 I I_GENE
- I I_GENE
kinase I I_GENE
associates O O
with O O
the O O
CD4 B B_GENE/B_DISEASE
: O O
p56lck B B_GENE/B_LOCATION
complex I I_GENE/I_LOCATION
as O O
judged O O
by O O
the O O
presence O O
of O O
PI O O
3 O O
- O O
phosphate O O
generated O O
from O O
anti B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
CD4 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
immunoprecipitates O O
and O O
detected O O
by O O
high O O
- O O
pressure O O
liquid O O
chromatographic O O
analysis O O
. O O

The O O
clinical O O
picture O O
, O O
the O O
light O O
and O O
electron O O
microscopic O O
appearance O O
, O O
and O O
the O O
histochemical O O
findings O O
are O O
described O O
in O O
six O O
cases O O
of O O
fibroma O O
of O O
tendon O O
sheath O O
. O O

However O O
, O O
their O O
stability O O
was O O
low O O
as O O
already O O
reported O O
for O O
the O O
ARS O O
in O O
S O O
. O O
occidentalis O O
. O O

In O O
this O O
study O O
, O O
a O O
site O O
of O O
PDGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
tyrosine O O
phosphorylation O O
was O O
mapped O O
to O O
Tyr O O
138 O O
in O O
the O O
SH3 B B_GENE
domain I I_GENE
; O O
Tyr O O
138 O O
is O O
exposed O O
on O O
the O O
SH3 B B_PROTEIN[GENE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
peptide I B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
binding I B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
surface I B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
results O O
of O O
this O O
study O O
suggest O O
that O O
in O O
patients O O
with O O
syndrome O O
X O O
, O O
myocardial O O
ischemia O O
frequently O O
develops O O
during O O
daily O O
life O O
; O O
silent O O
ischemia O O
is O O
an O O
important O O
component O O
of O O
this O O
syndrome O O
; O O
and O O
increased O O
oxygen O O
demand O O
in O O
the O O
presence O O
of O O
impaired O O
coronary O O
vasodilatory O O
capacity O O
is O O
not O O
the O O
only O O
cause O O
of O O
myocardial O O
ischemia O O
. O O

We O O
also O O
identified O O
a O O
DNA O O
fragment O O
, O O
10 O O
. O O
7 O O
kbp O O
upstream O O
from O O
the O O
first O O
coding O O
exon O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
aFGF I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
whose O O
sequence O O
is O O
conserved O O
in O O
both O O
the O O
primate O O
and O O
rodent O O
genomes O O
. O O

These O O
events O O
were O O
only O O
weakly O O
stimulated O O
by O O
the O O
activated B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PDGF I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Buserelin O O
offers O O
an O O
effective O O
alternative O O
medical O O
treatment O O
of O O
carcinoma O O
of O O
the O O
prostate O O
and O O
, O O
apart O O
from O O
impotence O O
, O O
does O O
not O O
have O O
the O O
side O O
effects O O
of O O
oestrogens O O
. O O

Reduced O O
risk O O
of O O
upper O O
gastrointestinal O O
ulcer O O
complications O O
with O O
celecoxib O O
, O O
a O O
novel O O
COX B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
. O O

Moreover O O
, O O
our O O
recent O O
findings O O
on O O
the O O
Tc52 B B_GENE
encoding I I_GENE
gene I I_GENE
underline O O
the O O
interest O O
of O O
genetic O O
manipulation O O
of O O
T O O
. O O
cruzi O O
, O O
not O O
only O O
making O O
it O O
possible O O
to O O
use O O
more O O
closely O O
an O O
in O O
vitro O O
approach O O
to O O
find O O
out O O
how O O
genes O O
function O O
, O O
but O O
also O O
to O O
obtain O O
' O O
attenuated O O
' O O
strains O O
that O O
could O O
be O O
used O O
in O O
the O O
development O O
of O O
vaccinal O O
strategies O O
. O O

Infra O O
- O O
red O O
spectroscopy O O
of O O
tissues O O
in O O
the O O
700 O O
- O O
400 O O
cm O O
- O O
1 O O
region O O
. O O

YDL003w B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
also O O
termed O O
MCD1 B B_GENE/B_DISEASE
) O O
is O O
a O O
homologue O O
of O O
Schizosaccharomyces B B_GENE/B_BACTERIUM[BIO]
pombe I I_GENE/I_BACTERIUM[BIO]
rad21 I I_GENE/I_BACTERIUM[BIO]
, O O
an O O
essential O O
gene O O
implicated O O
in O O
DNA O O
double O O
- O O
strand O O
break O O
repair O O
and O O
nuclear O O
organization O O
in O O
fission O O
yeast O O
. O O

The O O
recent O O
concept O O
of O O
a O O
bioartificial O O
organ O O
is O O
an O O
attempt O O
to O O
avoid O O
such O O
disadvantages O O
. O O

The O O
objectives O O
of O O
this O O
study O O
were O O
1 O O
) O O
to O O
quantify O O
the O O
comparative O O
structural O O
static O O
and O O
fatigue O O
properties O O
of O O
the O O
pointe O O
shoe O O
toe O O
box O O
, O O
and O O
2 O O
) O O
to O O
evaluate O O
the O O
preferred O O
shoe O O
characteristics O O
as O O
determined O O
by O O
a O O
survey O O
of O O
local O O
dancers O O
. O O

In O O
the O O
postoperative O O
patient O O
with O O
tetralogy O O
of O O
Fallot O O
with O O
symptomatic O O
ventricular O O
arrhythmias O O
, O O
it O O
is O O
concluded O O
that O O
electrophysiologic O O
study O O
is O O
useful O O
in O O
reproducing O O
clinical O O
episodes O O
of O O
VT O O
and O O
in O O
selecting O O
effective O O
antiarrhythmic O O
medication O O
; O O
a O O
small O O
number O O
of O O
patients O O
with O O
ventricular O O
premature O O
complexes O O
alone O O
will O O
have O O
inducible O O
sustained O O
VT O O
during O O
electrophysiologic O O
study O O
; O O
prognosis O O
of O O
these O O
patients O O
may O O
be O O
improved O O
by O O
treatment O O
that O O
results O O
in O O
prevention O O
of O O
VT O O
induction O O
; O O
and O O
in O O
patients O O
with O O
right O O
ventricular O O
hypertension O O
, O O
VT O O
is O O
likely O O
to O O
be O O
refractory O O
to O O
drug O O
treatment O O
. O O

Indications O O
for O O
therapy O O
using O O
MAO B B_GENE
inhibitors O O

The O O
absorbance O O
of O O
the O O
eluent O O
was O O
monitored O O
at O O
254 O O
nm O O
. O O

Footprints O O
on O O
the O O
HPV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
18 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
show O O
five O O
protected O O
regions O O
with O O
homologies O O
to O O
NF1 B B_GENE/B_DISEASE
, O O
AP1 B B_GENE/B_DISEASE
and O O
EFII B B_GENE/B_LOCATION
transcription I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
motifs I I_GENE/I_LOCATION
. O O

Insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O O
to O O
the O O
alpha O O
- O O
subunit O O
of O O
its O O
receptor O O
stimulates O O
the O O
receptor B B_GENE
tyrosine I I_GENE
kinase I I_GENE
to O O
phosphorylate O O
the O O
beta O O
- O O
subunit O O
and O O
several O O
endogenous O O
protein O O
substrates O O
, O O
including O O
pp120 B B_GENE/B_LOCATION
/ O O
HA4 B B_MEASURE/B_GENE
, O O
a O O
liver O O
- O O
specific O O
plasma O O
membrane O O
glycoprotein O O
of O O
M O O
( O O
r O O
) O O
20 O O
, O O
000 O O
. O O

Motilin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
serum O O
levels O O
were O O
measured O O
for O O
one O O
hour O O
. O O

The O O
role O O
of O O
phosphorylation O O
on O O
receptor O O
desensitization O O
was O O
assessed O O
using O O
receptor O O
mutants O O
expressed O O
in O O
COS O O
cells O O
or O O
Chinese O O
hamster O O
lung O O
fibroblasts O O
. O O

First O O
aid O O
. O O

Improvement O O
of O O
some O O
pharmaceutical O O
properties O O
of O O
clofibrate O O
by O O
cyclodextrin O O
complexation O O
. O O

The O O
detection O O
limits O O
obtained O O
by O O
using O O
the O O
mixed O O
eluent O O
were O O
0 O O
. O O
05 O O
- O O
0 O O
. O O
13 O O
mg O O
/ O O
L O O
, O O
several O O
times O O
lower O O
than O O
those O O
obtained O O
by O O
using O O
single O O
KHPh O O
eluent O O
. O O

Early O O
diagnosis O O
and O O
early O O
surgical O O
division O O
of O O
the O O
biliary O O
tract O O
and O O
pancreatic O O
duct O O
is O O
recommended O O
for O O
children O O
with O O
AAPBD O O
. O O

We O O
have O O
analyzed O O
herein O O
the O O
roles O O
that O O
four O O
different O O
PIAS B B_GENE/B_BIO
proteins I I_GENE/I_BIO
( O O
ARIP3 B B_GENE/B_DISEASE
/ O O
PIASx B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Miz1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
PIASx B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
GBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
PIAS1 B B_GENE/B_DISEASE
, O O
and O O
PIAS3 B B_GENE
) O O
play O O
in O O
the O O
regulation O O
of O O
steroid B B_GENE
receptor I I_GENE
- O O
or O O
STAT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
mediated O O
transcriptional O O
activation O O
. O O

Comparison O O
of O O
the O O
predicted O O
amino O O
acid O O
sequence O O
with O O
that O O
of O O
the O O
Drosophila B B_GENE/B_BIO
virilis I I_GENE/I_BIO
gene I I_GENE/I_BIO
shows O O
that O O
several O O
blocks O O
of O O
amino O O
acid O O
sequence O O
have O O
been O O
very O O
highly O O
conserved O O
. O O

A O O
decrease O O
was O O
also O O
found O O
of O O
the O O
levels O O
of O O
total O O
cholesterol O O
and O O
LDL B B_GENE
- I I_GENE
cholesterol I I_GENE
. O O

Previously O O
, O O
we O O
had O O
shown O O
that O O
interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
constitutively O O
expressed O O
in O O
HTLV O O
- O O
I O O
- O O
infected O O
cells O O
and O O
in O O
cells O O
transiently O O
expressing O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Unlike O O
JNK B B_GENE/B_DISEASE
activation O O
, O O
ERK B B_GENE/B_LOCATION
activation O O
could O O
not O O
be O O
mapped O O
to O O
specific O O
reovirus O O
gene O O
segments O O
, O O
suggesting O O
that O O
ERK B B_GENE/B_LOCATION
activation O O
and O O
JNK B B_GENE/B_DISEASE
activation O O
are O O
triggered O O
by O O
different O O
events O O
during O O
virus O O
- O O
host O O
cell O O
interaction O O
. O O

Despite O O
the O O
same O O
decreases O O
or O O
increases O O
in O O
MAP O O
, O O
RSNA O O
was O O
attenuated O O
after O O
15 O O
and O O
30 O O
min O O
of O O
propofol O O
infusion O O
in O O
both O O
groups O O
compared O O
with O O
control O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
. O O

It O O
appears O O
to O O
be O O
useful O O
in O O
untreated O O
patients O O
with O O
stage O O
I O O
or O O
II O O
NHL O O
but O O
no O O
definite O O
radiographic O O
abnormalities O O
, O O
or O O
with O O
abnormal O O
radiographs O O
but O O
no O O
extrathoracic O O
spread O O
, O O
and O O
in O O
treated O O
patients O O
with O O
questionable O O
radiographs O O
. O O

B B B_PROTEIN[GENE]/B_DISEASE
and O O
C1 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
fusions I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
yeast B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GAL4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domains I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
also O O
found O O
to O O
interact O O
when O O
synthesized O O
and O O
assayed O O
in O O
yeast O O
. O O

Because O O
of O O
the O O
data O O
, O O
we O O
suggest O O
that O O
LAC9 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
contacts O O
positions O O
6 O O
, O O
7 O O
, O O
and O O
8 O O
, O O
both O O
plus O O
and O O
minus O O
, O O
of O O
the O O
UAS O O
, O O
which O O
are O O
separated O O
by O O
more O O
than O O
one O O
turn O O
of O O
the O O
DNA O O
helix O O
, O O
and O O
twists O O
part O O
way O O
around O O
the O O
DNA O O
, O O
thus O O
protecting O O
the O O
broad O O
region O O
of O O
the O O
minor O O
groove O O
between O O
the O O
major O O
- O O
groove O O
contacts O O
. O O

On O O
the O O
optic O O
tentacle O O
- O O
gonadal O O
axis O O
in O O
the O O
control O O
of O O
the O O
male O O
- O O
phase O O
ovotestis O O
in O O
the O O
slug O O
( O O
Ariolimax O O
californicus O O
) O O
. O O

Substitution O O
of O O
cholinergic O O
drugs O O
in O O
the O O
treatment O O
of O O
Alzheimer O O
type O O
dementia O O
( O O
AD O O
/ O O
SDAT O O
) O O
has O O
hitherto O O
not O O
been O O
very O O
successful O O
. O O

Here O O
we O O
show O O
that O O
the O O
nucleotide O O
in O O
the O O
middle O O
of O O
the O O
anticodon O O
( O O
i O O
. O O
e O O
. O O
, O O
psi O O
35 O O
) O O
also O O
contributes O O
to O O
the O O
suppressor O O
efficiency O O
displayed O O
by O O
cytoplasmic B B_GENE/B_DISEASE
tRNA I I_GENE/I_DISEASE
( I I_GENE/I_DISEASE
Tyr I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
. O O

The O O
root O O
- O O
mean O O
- O O
square O O
deviation O O
of O O
bond O O
lengths O O
from O O
the O O
ideal O O
values O O
is O O
0 O O
. O O
02 O O
A O O
. O O

Jet O O
lag O O
and O O
melatonin O O
. O O

In O O
addition O O
, O O
these O O
results O O
suggest O O
that O O
the O O
interactions O O
, O O
and O O
consequently O O
the O O
mechanisms O O
, O O
governing O O
transcriptional O O
activation O O
by O O
CTF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
are O O
distinct O O
from O O
those O O
mediating O O
DNA O O
replication O O
. O O

A O O
TAAATA O O
sequence O O
is O O
present O O
26 O O
nt O O
upstream O O
from O O
the O O
major O O
CAP O O
site O O
, O O
and O O
within O O
the O O
5 O O
' O O
- O O
flanking O O
region O O
there O O
are O O
several O O
putative O O
transcription O O
factor O O
binding O O
sites O O
. O O

The O O
reconstituted O O
enzyme O O
binds O O
DNA O O
with O O
an O O
affinity O O
that O O
is O O
approximately O O
20 O O
- O O
fold O O
lower O O
than O O
that O O
of O O
the O O
intact O O
topo70 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Treatment O O
with O O
KP O O
- O O
45 O O
preparation O O
usually O O
resulted O O
in O O
partial O O
regression O O
of O O
tumor O O
growth O O
, O O
accompanied O O
by O O
improvement O O
of O O
the O O
clinical O O
state O O
of O O
these O O
patients O O
, O O
as O O
well O O
as O O
reappearance O O
of O O
normal O O
values O O
of O O
blood O O
picture O O
and O O
biochemical O O
parameters O O
. O O

Istanbul O O
, O O
Turkey O O
. O O

We O O
propose O O
that O O
optimal O O
transcription O O
of O O
the O O
gD B B_GENE
gene I I_GENE
depends O O
on O O
the O O
interaction O O
of O O
ICP4 B B_GENE
with O O
multiple O O
binding O O
sites O O
across O O
the O O
gene O O
and O O
cellular O O
factors O O
that O O
recognize O O
specific O O
sequence O O
elements O O
in O O
the O O
promoter O O
. O O

The O O
human B B_GENE
Fc I I_GENE
gamma I I_GENE
receptor I I_GENE
gene I I_GENE
Fc B I_GENE
gamma I I_GENE
RIIA I I_GENE
is O O
expressed O O
in O O
platelets O O
, O O
neutrophils O O
, O O
monocytes O O
and O O
macrophages O O
. O O

This O O
dip O O
also O O
occurred O O
during O O
prednisone O O
and O O
vitamin O O
D O O
treatment O O
, O O
but O O
did O O
not O O
occur O O
when O O
calcium O O
was O O
added O O
to O O
prednisone O O
, O O
although O O
the O O
baseline O O
value O O
was O O
lower O O
at O O
the O O
start O O
of O O
combined O O
treatment O O
with O O
prednisone O O
and O O
calcium O O
. O O

E O O
. O O
granulosus O O
infection O O
has O O
been O O
confirmed O O
in O O
25 O O
patients O O
( O O
20 O O
. O O
6 O O
% O O
) O O
, O O
in O O
16 O O
cases O O
by O O
finding O O
parasite O O
protoscoleces O O
or O O
hooks O O
and O O
in O O
nine O O
cases O O
by O O
detection O O
of O O
an O O
antigen O O
specific O O
for O O
E B B_SPECIES[BIO]/B_GENE
. I I_SPECIES[BIO]/I_GENE
granulosus I I_SPECIES[BIO]/I_GENE
, I I_SPECIES[BIO]/I_GENE
antigen I I_SPECIES[BIO]/I_GENE
5 I I_SPECIES[BIO]/I_GENE
( O O
Ag5 B B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

The O O
effect O O
of O O
stimulation O O
of O O
the O O
entopeduncular O O
nucleus O O
( O O
EP O O
) O O
on O O
the O O
jaw O O
- O O
opening O O
reflex O O
( O O
JOR O O
) O O
was O O
studied O O
in O O
the O O
cat O O
anesthetized O O
with O O
sodium O O
pentobarbital O O
. O O

A O O
Premenstrual O O
Syndrome O O
, O O
the O O
late O O
luteal O O
phase O O
disorder O O
of O O
DSM O O
- O O
IIIR O O
criteria O O
, O O
was O O
identified O O
in O O
6 O O
% O O
of O O
the O O
women O O
. O O

025 O O
) O O
. O O

RESULTS O O
: O O
PET O O
revealed O O
wide O O
variations O O
in O O
CBF O O
between O O
regions O O
during O O
isoflurane O O
anaesthesia O O
, O O
particularly O O
in O O
comparison O O
with O O
propofol O O
anaesthesia O O
, O O
while O O
rCMRO2 O O
decreased O O
globally O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
during O O
both O O
isoflurane O O
and O O
propofol O O
anaesthesia O O
. O O

This O O
selective O O
squelching O O
activity O O
suggests O O
that O O
GRIM B B_GENE/B_DISEASE
can O O
interact O O
with O O
an O O
essential O O
component O O
of O O
the O O
RNA B B_SPECIES[BIO]/B_GENE
polymerase I I_SPECIES[BIO]/I_GENE
II I I_SPECIES[BIO]/I_GENE
transcription O O
machinery O O
. O O

This O O
is O O
the O O
first O O
description O O
of O O
an O O
integron O O
located O O
on O O
a O O
composite O O
transposon O O
. O O

The O O
nine O O
subjects O O
were O O
treated O O
in O O
random O O
sequence O O
with O O
cimetidine O O
0 O O
- O O
8 O O
- O O
1 O O
- O O
0 O O
g O O
on O O
one O O
day O O
and O O
placebo O O
capsules O O
on O O
the O O
other O O
. O O

Identification O O
and O O
characterization O O
of O O
a O O
yeast O O
gene O O
encoding O O
the O O
U2 B B_ENZYME[GENE]
small I I_ENZYME[GENE]
nuclear I I_ENZYME[GENE]
ribonucleoprotein I I_ENZYME[GENE]
particle I I_ENZYME[GENE]
B I I_ENZYME[GENE]
" I I_ENZYME[GENE]
protein I I_ENZYME[GENE]
. O O

Taking O O
into O O
account O O
certain O O
well O O
defined O O
conditions O O
( O O
frequent O O
feedings O O
, O O
no O O
supplementary O O
feeding O O
before O O
4 O O
- O O
6 O O
months O O
, O O
method O O
only O O
to O O
be O O
used O O
in O O
the O O
absence O O
of O O
menstruation O O
) O O
, O O
LAM O O
can O O
be O O
relied O O
on O O
for O O
contraceptive O O
protection O O
for O O
up O O
to O O
1 O O
year O O
post O O
partum O O
. O O

Nramp2 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contains O O
a O O
classical O O
iron O O
responsive O O
element O O
in O O
the O O
3 O O
' O O
untranslated O O
region O O
that O O
confers O O
iron O O
dependent O O
mRNA O O
stabilization O O
. O O

Likewise O O
, O O
epidural O O
morphine O O
does O O
not O O
modify O O
the O O
intraoperative O O
metabolic O O
and O O
hormonal O O
responses O O
. O O

CONCLUSIONS O O
- O O
- O O
Postlumbar O O
puncture O O
headache O O
may O O
be O O
mediated O O
by O O
the O O
release O O
of O O
substance B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
P I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
triggered O O
by O O
lumbar O O
puncture O O
, O O
in O O
patients O O
predisposed O O
to O O
headache O O
by O O
a O O
hypersensitivity O O
to O O
substance B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
P I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Continuous O O
arterial O O
blood O O
sampling O O
method O O
based O O
on O O
the O O
microsphere O O
model O O
was O O
used O O
as O O
a O O
quantitative O O
rCBF O O
measurement O O
. O O

A O O
mutated B B_DISEASE/B_PROTEIN[GENE]
ABF1 I B_DISEASE/I_PROTEIN[GENE]
site I B_DISEASE/I_PROTEIN[GENE]
that O O
displays O O
a O O
very O O
low O O
affinity O O
for O O
ABF1 B B_GENE
does O O
not O O
functionally O O
replace O O
the O O
ILV1 B B_GENE/B_LOCATION
REB1 B I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
. O O

Given O O
a O O
rapid O O
induction O O
of O O
Egr B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
on O O
stimulation O O
with O O
growth O O
factors O O
or O O
injury O O
, O O
these O O
findings O O
may O O
represent O O
at O O
least O O
one O O
of O O
the O O
molecular O O
mechanisms O O
underlying O O
phenotypic O O
modulation O O
of O O
smooth O O
muscles O O
after O O
vascular O O
injury O O
. O O

In O O
this O O
first O O
- O O
person O O
account O O
, O O
the O O
author O O
chronicles O O
her O O
experience O O
of O O
being O O
mentally O O
ill O O
and O O
homeless O O
in O O
New O O
York O O
and O O
New O O
Jersey O O
in O O
the O O
early O O
1980s O O
. O O

Rectal O O
temperatures O O
after O O
the O O
walk O O
were O O
greater O O
( O O
P O O
< O O
. O O
001 O O
) O O
in O O
native O O
Simmental O O
( O O
39 O O
. O O
87 O O
+ O O
/ O O
- O O
. O O
05 O O
degrees O O
C O O
) O O
than O O
in O O
Bos O O
indicus O O
( O O
39 O O
. O O
46 O O
+ O O
/ O O
- O O
. O O
05 O O
degrees O O
C O O
) O O
. O O

Dominant O O
- O O
negative O O
mutations O O
in O O
the O O
G B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
coupled I I_GENE/I_LOCATION
alpha I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
factor I I_GENE/I_LOCATION
receptor I I_GENE/I_LOCATION
map O O
to O O
the O O
extracellular O O
ends O O
of O O
the O O
transmembrane O O
segments O O
. O O

Such O O
simple O O
injuries O O
may O O
however O O
be O O
accompanied O O
by O O
far O O
reaching O O
consequences O O
. O O

This O O
is O O
the O O
first O O
report O O
which O O
clearly O O
proved O O
CEA B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O O
in O O
the O O
cells O O
of O O
HCC O O
. O O

By O O
screening O O
a O O
human O O
testis O O
cDNA O O
library O O
with O O
a O O
probe O O
containing O O
the O O
mouse B B_GENE
PEA3 I I_GENE
ETS B I_GENE
domain O O
, O O
we O O
isolated O O
a O O
2 O O
. O O
2 O O
kb O O
clone O O
containing O O
a O O
510 O O
AA O O
open O O
reading O O
frame O O
. O O

AU O O
- O O
rich O O
elements O O
in O O
the O O
3 O O
' O O
- O O
untranslated O O
region O O
of O O
a O O
new O O
mucin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family O O
of O O
Trypanosoma O O
cruzi O O
confers O O
mRNA O O
instability O O
and O O
modulates O O
translation O O
efficiency O O
. O O

These O O
findings O O
suggest O O
that O O
IL B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stimulated O O
, O O
Rho B B_GENE
- O O
dependent O O
cytoskeletal O O
reorganization O O
may O O
cluster O O
signaling O O
molecules O O
in O O
specific O O
architectures O O
that O O
are O O
necessary O O
for O O
persistent O O
cell O O
activation O O
in O O
chronic O O
inflammatory O O
disease O O
. O O

Changes O O
in O O
testicular O O
testosterone O O
and O O
acid O O
and O O
alkaline B B_ENZYME[GENE]
phosphatase I I_ENZYME[GENE]
activity O O
in O O
testis O O
and O O
accessory O O
sex O O
organs O O
after O O
induction O O
of O O
varicocele O O
in O O
Noble O O
rats O O
. O O

Alfalfa O O
phosphorus O O
release O O
kinetics O O
showed O O
high O O
bacterial O O
phosphorus O O
contamination O O
. O O

The O O
quantitative O O
analysis O O
of O O
1 O O
- O O
alpha O O
- O O
acetylmethadol O O
and O O
its O O
principal O O
metabolites O O
in O O
biological O O
specimens O O
by O O
gas O O
chromatography O O
- O O
chemical O O
ionization O O
- O O
multiple O O
ion O O
monitoring O O
mass O O
spectrometry O O
. O O

Effects O O
of O O
prolonged O O
inhibition O O
of O O
labour O O
pains O O
with O O
Th O O
1165a O O
and O O
Isoptin O O
on O O
the O O
heart O O
, O O
circulation O O
, O O
organ O O
- O O
and O O
metabolic O O
parameters O O
of O O
the O O
mother O O

Skytthe O O
, O O
and O O
K O O
. O O

In O O
the O O
Saccharomyces B B_BIO/B_GENE
cerevisiae I I_BIO/I_GENE
actin I I_BIO/I_GENE
intron I I_BIO/I_GENE
a O O
silent O O
branch O O
point O O
- O O
like O O
sequence O O
( O O
UACUAAG O O
) O O
is O O
located O O
7 O O
nt O O
upstream O O
of O O
the O O
canonical O O
sequence O O
. O O

The O O
requirement O O
for O O
an O O
essential O O
interaction O O
between O O
NPH B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
H4L B B_PROTEIN[GENE]/B_LOCATION
provides O O
an O O
explanation O O
for O O
the O O
observed O O
restriction O O
of O O
transcription O O
termination O O
to O O
early O O
viral O O
genes O O
. O O

After O O
birth O O
, O O
there O O
was O O
a O O
significantly O O
higher O O
increase O O
of O O
IgA B B_GENE
and O O
IgM B B_GENE/B_LOCATION
anti I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
M I I_GENE/I_LOCATION
. I I_GENE/I_LOCATION
leprae I I_GENE/I_LOCATION
antibody I I_GENE/I_LOCATION
activity O O
in O O
sera O O
taken O O
3 O O
- O O
6 O O
months O O
after O O
birth O O
from O O
babies O O
of O O
Group O O
1 O O
compared O O
to O O
Group O O
2 O O
, O O
but O O
the O O
IgA B B_GENE
and O O
IgM B B_GENE
activity O O
in O O
sera O O
taken O O
after O O
6 O O
months O O
of O O
age O O
showed O O
the O O
same O O
increase O O
in O O
the O O
two O O
groups O O
. O O

The O O
relation O O
between O O
the O O
changes O O
of O O
bone O O
density O O
and O O
the O O
level O O
of O O
blood O O
calcium O O
, O O
blood O O
phosphorus O O
and O O
alkaline B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphatase I B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
AKP B B_DISEASE/B_GENE
) O O
as O O
well O O
as O O
the O O
metabolism O O
of O O
vitamin O O
D O O
was O O
studied O O
. O O

These O O
results O O
demonstrate O O
the O O
extensive O O
homology O O
in O O
sequence O O
among O O
light O O
chains O O
of O O
IgM B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
autoantibodies I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
indicate O O
that O O
a O O
particular O O
V B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
germ I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
line I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
kappa B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
IIIb I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
expressed O O
as O O
a O O
phylogenetic O O
response O O
to O O
certain O O
self O O
antigens O O
or O O
as O O
part O O
of O O
a O O
selection O O
process O O
by O O
which O O
these O O
autoimmune O O
responses O O
are O O
regulated O O
. O O

In O O
addition O O
, O O
the O O
findings O O
confirmed O O
previous O O
studies O O
which O O
showed O O
that O O
monkeys O O
with O O
total O O
bilateral O O
striatectomies O O
could O O
require O O
the O O
ability O O
to O O
execute O O
accurate O O
visually O O
guided O O
reaches O O
. O O

Comparison O O
of O O
the O O
sequences O O
of O O
the O O
alpha B B_GENE/B_BIO
- I I_GENE/I_BIO
like I I_GENE/I_BIO
DNA I I_GENE/I_BIO
polymerases I I_GENE/I_BIO
including O O
E B B_GENE/B_PERSON
. I I_GENE/I_PERSON
coli I I_GENE/I_PERSON
DNA I I_GENE/I_PERSON
polymerase I I_GENE/I_PERSON
II I I_GENE/I_PERSON
showed O O
that O O
there O O
were O O
nine O O
highly O O
conserved O O
regions O O
, O O
and O O
we O O
constructed O O
an O O
unrooted O O
phylogenetic O O
tree O O
of O O
the O O
DNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
based O O
on O O
the O O
differences O O
in O O
these O O
conserved O O
regions O O
. O O

Four O O
experiments O O
examined O O
the O O
role O O
of O O
the O O
cholinergic O O
projections O O
from O O
the O O
septum O O
and O O
vertical O O
limb O O
nucleus O O
of O O
the O O
diagonal O O
band O O
of O O
Broca O O
( O O
VDB O O
) O O
in O O
acquisition O O
and O O
performance O O
of O O
a O O
conditional O O
visual O O
discrimination O O
. O O

trans O O
- O O
activation O O
of O O
the O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
the O O
HIV B B_GENE
- I I_GENE
1 I I_GENE
Tat I I_GENE
and O O
HTLV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Tax I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
mediated O O
by O O
different O O
cis O O
- O O
acting O O
sequences O O
. O O

For O O
more O O
detailed O O
mapping O O
, O O
we O O
constructed O O
mouse O O
A9 O O
cells O O
containing O O
STFs O O
derived O O
from O O
human O O
chromosome O O
2 O O
tagged O O
with O O
pSTneo O O
at O O
different O O
regions O O
in O O
2q31 O O
- O O
qter O O
. O O

Left O O
ventricular O O
insufficiency O O
requires O O
two O O
SP O O
/ O O
patient O O
, O O
with O O
good O O
results O O
in O O
approximately O O
81 O O
p O O
. O O
cent O O
. O O

However O O
, O O
there O O
are O O
some O O
cows O O
that O O
fail O O
to O O
produce O O
adequate O O
1 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D O O
at O O
the O O
onset O O
of O O
lactation O O
. O O

Acidic O O
carboxyl O O
- O O
terminal O O
domain O O
of O O
gene B B_GENE
2 I I_GENE
. I I_GENE
5 I I_GENE
protein I I_GENE
of I I_GENE
bacteriophage I I_GENE
T7 I I_GENE
is O O
essential O O
for O O
protein O O
- O O
protein O O
interactions O O
. O O

A O O
total O O
of O O
10 O O
, O O
763 O O
men O O
and O O
3 O O
, O O
118 O O
women O O
has O O
been O O
studied O O
, O O
of O O
whom O O
97 O O
% O O
and O O
89 O O
% O O
, O O
respectively O O
, O O
have O O
been O O
traced O O
and O O
36 O O
% O O
and O O
16 O O
% O O
have O O
died O O
. O O

EMG O O
- O O
based O O
measures O O
of O O
fatigue O O
during O O
a O O
repetitive O O
squat O O
exercise O O
. O O

We O O
have O O
introduced O O
the O O
same O O
change O O
in O O
a O O
yeast B B_GENE
tRNA I I_GENE
( I I_GENE
Trp I I_GENE
) I I_GENE
gene I I_GENE
and O O
demonstrated O O
that O O
the O O
tRNA O O
acts O O
as O O
an O O
efficient O O
amber O O
suppressor O O
in O O
vivo O O
. O O

This O O
evaluation O O
examines O O
several O O
analytical O O
and O O
cost O O
parameters O O
for O O
five O O
representative O O
assays O O
: O O
IgG B B_GENE/B_DISEASE
, O O
IgA B B_GENE
, O O
IgM B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
phenytoin O O
, O O
and O O
phenobarbital O O
. O O

These O O
results O O
suggest O O
that O O
UvrA B B_GENE/B_BACTERIUM[BIO]
is O O
involved O O
in O O
triplet O O
repeat O O
instability O O
in O O
cells O O
. O O

A O O
novel O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PKC B B_GENE
) O O
- O O
interacting O O
protein O O
was O O
identified O O
by O O
the O O
yeast O O
two O O
- O O
hybrid O O
screening O O
using O O
the O O
regulatory O O
domain O O
of O O
PKC B B_GENE
beta I I_GENE
I I I_GENE
as O O
a O O
bait O O
. O O

CONCLUSIONS O O
: O O
The O O
number O O
of O O
Spanish O O
articles O O
published O O
in O O
Anesthesiology O O
, O O
BJA O O
, O O
and O O
Anesth O O
Analg O O
is O O
low O O
, O O
although O O
the O O
comparison O O
of O O
our O O
productivity O O
with O O
that O O
of O O
other O O
EU O O
countries O O
in O O
function O O
of O O
GNPpc O O
places O O
us O O
in O O
an O O
intermediate O O
position O O
. O O

One O O
of O O
the O O
repeating O O
domains O O
( O O
Yheb1 B B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
consisting O O
of O O
67 O O
amino O O
acids O O
, O O
was O O
cloned O O
from O O
the O O
E O O
. O O
coli O O
chromosome O O
and O O
purified O O
by O O
metal O O
chelating O O
chromatography O O
. O O

Phosphorylation O O
at O O
Ser O O
( O O
670 O O
) O O
impairs O O
the O O
ability O O
of O O
GRK2 B B_GENE
to O O
phosphorylate O O
both O O
soluble O O
and O O
membrane O O
- O O
incorporated O O
receptor O O
substrates O O
and O O
dramatically O O
attenuates O O
Gbetagamma B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
mediated O O
activation O O
of O O
this O O
enzyme O O
. O O

METHODS O O
: O O
CD4 B B_GENE/B_MEASURE
cell O O
counts O O
and O O
interview O O
data O O
were O O
recorded O O
in O O
a O O
survey O O
of O O
136 O O
adult O O
patients O O
attending O O
a O O
community O O
hospital O O
- O O
based O O
HIV O O
outpatient O O
clinic O O
. O O

Biol O O
. O O

Inhibition O O
of O O
endogenous B B_GENE
Cdk2 I I_GENE
by O O
dominant B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
negative I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Cdk2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attenuated O O
phosphorylation O O
of O O
Thr447 O O
, O O
Thr490 O O
and O O
Thr497 O O
, O O
but O O
had O O
no O O
effect O O
upon O O
Ser581 O O
modification O O
. O O

A O O
rabbit O O
antiserum O O
raised O O
against O O
a O O
unique O O
( O O
V3 O O
domain O O
) O O
bacterially O O
expressed O O
PKC B B_GENE
theta I I_GENE
fragment I I_GENE
immunoprecipitated O O
specifically O O
an O O
82 O O
- O O
kDa O O
protein O O
from O O
Jurkat O O
cell O O
lysates O O
. O O

Histological O O
examination O O
revealed O O
variable O O
loss O O
of O O
motor O O
neurons O O
limited O O
to O O
the O O
injection O O
site O O
. O O

This O O
is O O
the O O
most O O
northern O O
and O O
, O O
at O O
the O O
same O O
time O O
largest O O
, O O
Q O O
fever O O
epidemic O O
recorded O O
in O O
Germany O O
over O O
the O O
last O O
28 O O
years O O
. O O

The O O
binding O O
of O O
PTB B B_GENE/B_DISEASE
was O O
antagonistic O O
to O O
the O O
binding O O
of O O
U2AF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
enhancer O O
- O O
located O O
pyrimidine O O
tract O O
. O O

VLA B B_GENE
- I I_GENE
4 I I_GENE
integrin I I_GENE
cross O O
- O O
linking O O
on O O
human O O
monocytic O O
THP O O
- O O
1 O O
cells O O
induces O O
tissue O O
factor O O
expression O O
by O O
a O O
mechanism O O
involving O O
mitogen B B_GENE
- I I_GENE
activated I I_GENE
protein I I_GENE
kinase I I_GENE
. O O

However O O
, O O
studies O O
using O O
the O O
A20 B B_GENE
promoter I I_GENE
demonstrated O O
that O O
LMP1 B B_GENE
transcriptionally O O
activates O O
the O O
A20 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
through O O
cis O O
- O O
acting O O
kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
sites I I_GENE/I_LOCATION
. O O

Southern O O
blot O O
analysis O O
revealed O O
that O O
CCaMK B B_GENE/B_PERSON
is O O
encoded O O
by O O
a O O
single O O
gene O O
. O O

Surgical O O
methods O O
in O O
the O O
treatment O O
of O O
rhinophyma O O
. O O

Phenazopyridine O O
- O O
induced O O
hemolytic O O
anemia O O
in O O
a O O
patient O O
with O O
G6PD B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficiency O O
. O O

Finally O O
, O O
we O O
demonstrated O O
that O O
although O O
the O O
DNA O O
- O O
binding O O
domain O O
of O O
c B B_GENE
- I I_GENE
myb I I_GENE
is O O
required O O
for O O
both O O
the O O
differentiation O O
block O O
and O O
the O O
shift O O
in O O
cell O O
cycle O O
after O O
PMA O O
treatment O O
, O O
phosphorylation O O
by O O
casein B B_GENE
kinase I I_GENE
II I I_GENE
and O O
mitogen B B_GENE
- I I_GENE
activated I I_GENE
protein I I_GENE
kinase I I_GENE
at O O
positions O O
11 O O
and O O
12 O O
or O O
532 O O
of O O
c B B_GENE
- I I_GENE
myb I I_GENE
, O O
respectively O O
, O O
are O O
not O O
. O O

The O O
activation O O
of O O
NF B B_GENE
- I I_GENE
kappaB I I_GENE
- O O
dependent O O
reporter O O
gene O O
transcription O O
by O O
E1A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
potently O O
suppressed O O
upon O O
coexpression O O
of O O
the O O
E1B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
19 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kDa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
19K I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
myeloid B B_GENE
zinc I I_GENE
finger I I_GENE
gene I I_GENE
1 I I_GENE
( O O
MZF1 B B_GENE/B_DISEASE
) O O
encodes O O
a O O
C B B_GENE/B_MEASURE
( I I_GENE/I_MEASURE
2 I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
H I I_GENE/I_MEASURE
( I I_GENE/I_MEASURE
2 I I_GENE/I_MEASURE
) I I_GENE/I_MEASURE
zinc I I_GENE/I_MEASURE
finger I I_GENE/I_MEASURE
transcription I I_GENE/I_MEASURE
factor I I_GENE/I_MEASURE
that O O
regulates O O
granulopoiesis O O
and O O
may O O
have O O
a O O
regulatory O O
role O O
in O O
cellular O O
proliferation O O
and O O
oncogenesis O O
. O O

Snails O O
infected O O
with O O
three O O
or O O
five O O
miracidia O O
produced O O
more O O
metacercariae O O
than O O
those O O
infected O O
with O O
a O O
single O O
miracidium O O
. O O

For O O
the O O
target O O
stimuli O O
, O O
P3 O O
amplitude O O
and O O
latency O O
were O O
negatively O O
correlated O O
and O O
most O O
tightly O O
coupled O O
over O O
the O O
frontal O O
- O O
central O O
and O O
right O O
medial O O
/ O O
lateral O O
recording O O
sites O O
. O O

Mitoxantrone O O
plus O O
ara O O
- O O
C O O
is O O
an O O
active O O
combination O O
with O O
great O O
promise O O
for O O
the O O
therapy O O
of O O
previously O O
untreated O O
patients O O
with O O
AML O O
. O O

In O O
the O O
renal O O
cortex O O
, O O
spleen O O
, O O
distal O O
colon O O
, O O
ileum O O
, O O
gallbladder O O
, O O
and O O
stomach O O
body O O
, O O
regional O O
O2 O O
delivery O O
was O O
significantly O O
decreased O O
with O O
hemodilution O O
to O O
20 O O
% O O
in O O
both O O
groups O O
. O O

( O O
A O O
short O O
account O O
of O O
Karl O O
Touton O O
' O O
s O O
life O O
is O O
also O O
included O O
. O O
) O O
After O O
reviewing O O
the O O
historical O O
development O O
of O O
the O O
concept O O
of O O
giant O O
cells O O
and O O
current O O
interpretations O O
of O O
their O O
nature O O
, O O
the O O
unitarian O O
view O O
of O O
polykaryons O O
now O O
favored O O
by O O
workers O O
in O O
the O O
field O O
is O O
extended O O
to O O
include O O
also O O
the O O
" O O
xanthelasmatic O O
giant O O
cell O O
" O O
of O O
Touton O O
, O O
whose O O
characteristic O O
appearance O O
is O O
determined O O
merely O O
by O O
the O O
presence O O
of O O
demonstrable O O
lipid O O
in O O
the O O
cytoplasm O O
. O O

Chronic O O
active O O
hepatitis O O
and O O
pregnancy O O
. O O

Influenza O O
virus O O
- O O
induced O O
NF B B_GENE
- I I_GENE
kappaB I I_GENE
- I I_GENE
dependent I I_GENE
gene I I_GENE
expression O O
is O O
mediated O O
by O O
overexpression O O
of O O
viral O O
proteins O O
and O O
involves O O
oxidative O O
radicals O O
and O O
activation O O
of O O
IkappaB B B_GENE
kinase I I_GENE
. O O

These O O
observed O O
changes O O
were O O
not O O
found O O
when O O
assessing O O
NPY B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O O
in O O
plasma O O
fluid O O
. O O

Reversible O O
topology O O
of O O
a O O
bifunctional O O
transmembrane O O
protein O O
depends O O
upon O O
the O O
charge O O
balance O O
around O O
its O O
transmembrane O O
domain O O
. O O

Protein B B_LOCATION/B_GENE
kinase I I_LOCATION/I_GENE
C I I_LOCATION/I_GENE
( O O
PKC B B_GENE
) O O
activation O O
after O O
treatment O O
of O O
human O O
neuroblastoma O O
SK O O
- O O
N O O
- O O
BE O O
( O O
2 O O
) O O
C O O
cells O O
with O O
phorbol O O
12 O O
- O O
myristate O O
13 O O
- O O
acetate O O
( O O
PMA O O
) O O
was O O
found O O
to O O
enhance O O
transcription O O
of O O
the O O
human O O
dopamine B B_ENZYME[GENE]
beta I I_ENZYME[GENE]
- I I_ENZYME[GENE]
hydroxylase I I_ENZYME[GENE]
( O O
DBH B B_GENE/B_LOCATION
) O O
in O O
those O O
cells O O
. O O

The O O
second O O
( O O
control O O
) O O
group O O
was O O
represented O O
by O O
cases O O
diagnosed O O
as O O
HSIL O O
by O O
cytology O O
. O O

The O O
illuminator O O
uses O O
a O O
grain O O
- O O
of O O
- O O
wheat O O
light O O
bulb O O
and O O
an O O
adjustable O O
bulb O O
holder O O
fashioned O O
from O O
bent O O
paper O O
clips O O
. O O

The O O
genomic O O
organization O O
in O O
this O O
region O O
is O O
similar O O
to O O
the O O
neural O O
- O O
restricted O O
family O O
members O O
, O O
Hel B B_PROTEIN[GENE]/B_DISEASE
- I I_PROTEIN[GENE]/I_DISEASE
N1 I I_PROTEIN[GENE]/I_DISEASE
( O O
ELAVL2 B B_GENE
) O O
and O O
mHuD B B_PROTEIN[GENE]/B_DISEASE
( O O
Elavl4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Synergistic O O
induction O O
of O O
apoptosis O O
in O O
human O O
leukemia O O
cells O O
( O O
U937 O O
) O O
exposed O O
to O O
bryostatin O O
1 O O
and O O
the O O
proteasome O O
inhibitor O O
lactacystin O O
involves O O
dysregulation O O
of O O
the O O
PKC B B_GENE
/ O O
MAPK B B_GENE
cascade O O
. O O

With O O
the O O
help O O
of O O
partially O O
overlapping O O
parenchymatous O O
sutures O O
, O O
different O O
renal O O
segments O O
were O O
devitalized O O
. O O

Promoter O O
elements O O
and O O
transcriptional O O
control O O
of O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acetylcholinesterase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
average O O
cumulative O O
UVA O O
dose O O
was O O
65 O O
J O O
/ O O
cm2 O O
; O O
40 O O
patients O O
had O O
received O O
more O O
than O O
200 O O
J O O
/ O O
cm2 O O
. O O

Malformations O O
of O O
the O O
regenerating O O
optic O O
tectum O O
of O O
larvae O O
of O O
the O O
Egyptian O O
toad O O
, O O
Bufo O O
regularis O O
Reuss O O
. O O

These O O
morphological O O
changes O O
are O O
associated O O
with O O
a O O
marked O O
induction O O
of O O
P450arom B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
. O O

The O O
immunoprofile O O
of O O
60 O O
adult O O
patients O O
of O O
pulmonary O O
tuberculosis O O
was O O
studied O O
and O O
compared O O
with O O
22 O O
normal O O
controls O O
. O O

Central O O
- O O
venous O O
- O O
catheter O O
- O O
related O O
infection O O
is O O
readily O O
diagnosed O O
by O O
comparing O O
simultaneous O O
quantitative O O
cultures O O
of O O
blood O O
samples O O
obtained O O
via O O
the O O
catheter O O
and O O
a O O
peripheral O O
vein O O
. O O

The O O
role O O
of O O
haptoglobin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
asphyxia O O
mechanism O O
( O O
II O O
) O O
- O O
- O O
Acute O O
drowning O O
and O O
hanging O O

Processing O O
MES O O
data O O
requires O O
large O O
bit O O
manipulations O O
and O O
heavy O O
memory O O
storage O O
requirements O O
. O O

Thus O O
, O O
BCR B B_GENE
ligation O O
initiates O O
a O O
PI B B_GENE
3 I I_GENE
- I I_GENE
kinase I I_GENE
/ O O
Akt B B_GENE
/ O O
GSK B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
3 I I_GENE/I_LOCATION
signaling O O
pathway O O
. O O

cDNA O O
cloning O O
and O O
transcriptional O O
properties O O
of O O
a O O
novel O O
GC B B_GENE/B_PERSON
box I I_GENE/I_PERSON
- I I_GENE/I_PERSON
binding I I_GENE/I_PERSON
protein I I_GENE/I_PERSON
, O O
BTEB2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
activity O O
creates O O
a O O
4 O O
- O O
bp O O
staggered O O
cut O O
with O O
3 O O
' O O
OH O O
overhangs O O
within O O
a O O
specific O O
sequence O O
of O O
the O O
21S B B_GENE/B_LOCATION
rRNA I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
of O O
omega O O
- O O
strains O O
. O O

The O O
two O O
ORFs O O
had O O
significant O O
similarity O O
with O O
the O O
putative O O
replication O O
protein O O
from O O
plasmid O O
pTiK12 O O
of O O
Thiobacillus O O
intermedius O O
and O O
other O O
CoIE2 O O
- O O
related O O
plasmids O O
. O O

In O O
contrast O O
SF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
GM B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CSF I I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O O
IL B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
3 I I_GENE/I_LOCATION
, O O
induced O O
tyrosine O O
phosphorylation O O
of O O
phospholipase B B_GENE
C I I_GENE
- I I_GENE
gamma I I_GENE
( O O
PLC B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
gamma I I_GENE/I_LOCATION
) O O
. O O

Phase O O
I O O
clinical O O
trial O O
with O O
a O O
combination O O
of O O
methotrexate O O
and O O
mitomycin O O
C O O
. O O

Replacement O O
of O O
Val20 O O
- O O
Leu21 O O
with O O
Ala O O
- O O
Ala O O
produced O O
a O O
dimeric B B_PROTEIN[GENE]
RII I I_PROTEIN[GENE]
beta I I_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
that O O
binds O O
AKAP75 B B_LOCATION/B_GENE
approximately O O
4 O O
% O O
as O O
avidly O O
as O O
wild B B_GENE
- I I_GENE
type I I_GENE
RII I I_GENE
beta I I_GENE
. O O

The O O
temporal O O
expression O O
of O O
CRAlBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
similar O O
to O O
IRBP B B_LOCATION/B_GENE
while O O
bFGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
expressed O O
until O O
after O O
photoreceptor O O
differentiation O O
is O O
complete O O
. O O

I O O
. O O

In O O
T O O
cells O O
these O O
two O O
signal O O
pathways O O
are O O
critical O O
for O O
interleukin B B_GENE
- I I_GENE
2 I I_GENE
production O O
. O O

Replacement O O
of O O
a O O
valine O O
( O O
V68 O O
) O O
in O O
the O O
ETS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
domain O O
of O O
SAP1a B B_GENE
by O O
aspartic O O
acid O O
( O O
as O O
found O O
in O O
c B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
Ets I I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
, O O
Elk B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
1 I I_PROTEIN[GENE]/I_MEASURE
, O O
and O O
Net B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
enhanced O O
ternary O O
complex O O
formation O O
by O O
more O O
than O O
60 O O
- O O
fold O O
. O O

In O O
order O O
to O O
investigate O O
the O O
effect O O
of O O
the O O
local O O
direct O O
action O O
of O O
danazol O O
upon O O
endometriosis O O
, O O
intravaginal O O
and O O
intrauterine O O
application O O
were O O
tried O O
. O O

The O O
NF B B_GENE
- I I_GENE
kappaB I I_GENE
/ O O
Rel B B_GENE/B_LOCATION
transcription O O
factors O O
participate O O
in O O
the O O
activation O O
of O O
immune O O
system O O
regulatory O O
genes O O
and O O
viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
early I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
including O O
the O O
human B B_DISEASE/B_GENE
immunodeficiency I B_DISEASE/I_GENE
virus I B_DISEASE/I_GENE
type I B_DISEASE/I_GENE
1 I B_DISEASE/I_GENE
long I B_DISEASE/I_GENE
terminal I B_DISEASE/I_GENE
repeat I B_DISEASE/I_GENE
. O O

A O O
total O O
of O O
4 O O
, O O
916 O O
children O O
were O O
examined O O
and O O
the O O
questionnaire O O
satisfactorily O O
completed O O
by O O
a O O
relative O O
or O O
guardian O O
( O O
usually O O
the O O
mother O O
) O O
of O O
4 O O
, O O
651 O O
. O O

cDNA O O
cloning O O
reveals O O
two O O
mouse B B_GENE
beta5 I I_GENE
integrin I I_GENE
transcripts I I_GENE
distinct O O
in O O
cytoplasmic O O
domains O O
as O O
a O O
result O O
of O O
alternative O O
splicing O O
. O O

Earlier O O
nonoptical O O
methods O O
probably O O
did O O
not O O
include O O
the O O
portion O O
of O O
the O O
film O O
that O O
contained O O
mucus O O
. O O

OBJECTIVE O O
: O O
To O O
summarise O O
quantitatively O O
the O O
association O O
between O O
moderate O O
alcohol O O
intake O O
and O O
biological O O
markers O O
of O O
risk O O
of O O
coronary O O
heart O O
disease O O
and O O
to O O
predict O O
how O O
these O O
changes O O
would O O
lower O O
the O O
risk O O
. O O

Like O O
other O O
known O O
GCD B B_GENE/B_BIO
genes I I_GENE/I_BIO
, O O
GCD14 B B_MEASURE/B_GENE
and O O
GCD15 B B_MEASURE/B_GENE
are O O
therefore O O
probably O O
required O O
for O O
general O O
translation O O
initiation O O
in O O
addition O O
to O O
their O O
roles O O
in O O
GCN4 B B_GENE
- O O
specific O O
translational O O
control O O
. O O

The O O
presence O O
of O O
highly O O
correlated O O
frequencies O O
provided O O
strong O O
evidence O O
of O O
a O O
medium O O
- O O
frequency O O
pattern O O
generator O O
which O O
may O O
remain O O
operative O O
beyond O O
the O O
neonatal O O
period O O
. O O

This O O
gene O O
is O O
named O O
PKNOX1 B B_GENE/B_LOCATION
by O O
the O O
Human O O
Nomenclature O O
Committee O O
. O O

Differentiation O O
of O O
porcine O O
mycoplasma O O
strains O O
by O O
means O O
of O O
a O O
simple O O
paper O O
chromatography O O
test O O
. O O

HIV O O
- O O
2 O O
in O O
Spain O O
. O O

No O O
effect O O
of O O
4 O O
beta O O
- O O
phorbol O O
12 O O
- O O
myristate O O
13 O O
- O O
acetate O O
was O O
observed O O
on O O
the O O
expression O O
of O O
hnRNP B B_GENE
H I I_GENE
. O O

Patients O O
commonly O O
considered O O
the O O
external O O
frame O O
cumbersome O O
. O O

D O O
. O O

The O O
atf1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Schizosaccharomyces I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pombe I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O O
a O O
bZIP B B_ENZYME[GENE]/B_MEASURE
transcription I I_ENZYME[GENE]/I_MEASURE
factor I I_ENZYME[GENE]/I_MEASURE
with O O
strong O O
homology O O
to O O
the O O
mammalian B B_GENE/B_BIO
factor I I_GENE/I_BIO
ATF I I_GENE/I_BIO
- I I_GENE/I_BIO
2 I I_GENE/I_BIO
. O O

The O O
effects O O
of O O
different O O
sources O O
of O O
commercial O O
rations O O
on O O
the O O
humoral O O
immune O O
response O O
of O O
broilers O O
to O O
Newcastle O O
disease O O
vaccination O O
. O O

Primary O O
TJRs O O
were O O
clinically O O
evaluated O O
for O O
degree O O
of O O
osteoarthrosis O O
. O O

Radiation O O
sensitivity O O
of O O
rats O O
irradiated O O
in O O
a O O
condition O O
of O O
hypoxia O O

The O O
activity O O
of O O
plasminogen B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
been O O
measured O O
in O O
tissue O O
sections O O
with O O
the O O
aid O O
of O O
a O O
modified O O
Todd O O
technique O O
. O O

The O O
complexity O O
of O O
some O O
of O O
the O O
reports O O
of O O
VACURG O O
studies O O
has O O
led O O
some O O
to O O
believe O O
that O O
this O O
group O O
was O O
opposed O O
to O O
estrogens O O
, O O
but O O
that O O
is O O
not O O
true O O
. O O

Up O O
to O O
1988 O O
, O O
145 O O
cases O O
had O O
been O O
reported O O
in O O
literature O O
and O O
32 O O
cases O O
in O O
our O O
country O O
. O O

Focal O O
glomerulosclerosis O O
- O O
like O O
disease O O
with O O
nephrotic O O
syndrome O O
in O O
a O O
horse O O
. O O

The O O
antihypertensive O O
action O O
corresponds O O
to O O
those O O
of O O
established O O
diuretics O O
. O O

Interconversions O O
between O O
haloperidol O O
and O O
reduced O O
haloperidol O O
in O O
schizophrenic O O
patients O O
and O O
guinea O O
pigs O O
: O O
a O O
steady O O
- O O
state O O
study O O
. O O

The O O
frequency O O
of O O
eating O O
dark O O
- O O
meat O O
fish O O
was O O
positively O O
associated O O
with O O
serum O O
eicosapentaenoic O O
acid O O
and O O
docosahexaenoic O O
acid O O
, O O
omega3 O O
fatty O O
acids O O
, O O
and O O
inversely O O
associated O O
with O O
serum O O
stearic O O
acid O O
and O O
linoleic O O
acid O O
. O O

Effect O O
of O O
food O O
on O O
hemodynamics O O
. O O

This O O
approach O O
allowed O O
examination O O
of O O
baseline O O
factors O O
as O O
well O O
as O O
the O O
effect O O
of O O
change O O
in O O
mileage O O
, O O
the O O
occurrence O O
of O O
a O O
musculoskeletal O O
problem O O
, O O
or O O
the O O
occurrence O O
of O O
another O O
health O O
problem O O
on O O
the O O
rate O O
of O O
dropout O O
. O O

Microalbuminuria O O
: O O
a O O
marker O O
of O O
systemic O O
disease O O
. O O

Coronary O O
arteries O O
were O O
found O O
in O O
the O O
biopsy O O
tissue O O
of O O
30 O O
( O O
76 O O
% O O
) O O
of O O
the O O
39 O O
patients O O
who O O
formed O O
the O O
study O O
group O O
. O O

Serum B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
amyloid I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
A I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
SAA B B_LOCATION/B_PROTEIN[GENE]
) O O
is O O
a O O
plasma O O
protein O O
which O O
has O O
been O O
associated O O
with O O
several O O
diseases O O
, O O
including O O
amyloidosis O O
, O O
arthritis O O
, O O
and O O
atherosclerosis O O
, O O
and O O
its O O
abnormal O O
expression O O
, O O
particularly O O
in O O
nonhepatic O O
cells O O
, O O
is O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
these O O
diseases O O
. O O

Phenacetin O O
nephritis O O

We O O
have O O
been O O
developing O O
a O O
digital O O
fluoroscopic O O
imaging O O
system O O
to O O
replace O O
the O O
portal O O
films O O
that O O
are O O
currently O O
used O O
to O O
verify O O
patient O O
positioning O O
during O O
radiotherapy O O
treatments O O
. O O

The O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p18 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
spans O O
at O O
least O O
7 O O
. O O
5 O O
kb O O
and O O
is O O
composed O O
of O O
three O O
exons O O
, O O
two O O
of O O
which O O
encode O O
the O O
p18 B B_GENE
protein I I_GENE
. O O

Serum O O
creatinine B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
was O O
7 O O
, O O
800 O O
- O O
17 O O
, O O
500 O O
U O O
/ O O
l O O
, O O
making O O
acute O O
muscle O O
damage O O
likely O O
, O O
probably O O
rhabdomyolysis O O
. O O

These O O
results O O
suggest O O
that O O
termination O O
is O O
a O O
highly O O
specific O O
event O O
, O O
and O O
not O O
merely O O
a O O
consequence O O
of O O
decreased O O
stability O O
of O O
the O O
EC O O
. O O

Like O O
Mdm2 B B_GENE/B_DISEASE
, O O
MdmX B B_GENE/B_BACTERIUM[BIO]
is O O
able O O
to O O
bind O O
p53 B B_GENE/B_DISEASE
and O O
inhibit O O
p53 B B_GENE/B_LOCATION
transactivation O O
; O O
however O O
, O O
the O O
ability O O
of O O
MdmX B B_GENE/B_BIO
to O O
degrade O O
p53 B B_GENE
has O O
yet O O
to O O
be O O
examined O O
. O O

PURPOSE O O
: O O
Second O O
malignant O O
neoplasms O O
( O O
SMNs O O
) O O
are O O
a O O
rare O O
occurrence O O
after O O
the O O
successful O O
treatment O O
of O O
childhood O O
cancer O O
. O O

Recent O O
geological O O
studies O O
focusing O O
on O O
the O O
Davie O O
Fracture O O
Zone O O
of O O
the O O
Mozambique O O
Channel O O
offer O O
a O O
resolution O O
to O O
this O O
situation O O
, O O
by O O
suggesting O O
the O O
presence O O
of O O
a O O
land O O
- O O
bridge O O
from O O
the O O
mid O O
- O O
Eocene O O
to O O
the O O
early O O
Miocene O O
, O O
an O O
interval O O
that O O
matches O O
the O O
ages O O
of O O
Madagascar O O
' O O
s O O
mammalian O O
groups O O
. O O

Mutant O O
p53 B B_GENE/B_DISEASE
DNA I B_GENE/I_DISEASE
clones O O
from O O
human O O
colon O O
carcinomas O O
cooperate O O
with O O
ras B B_GENE/B_DISEASE
in O O
transforming O O
primary O O
rat O O
cells O O
: O O
a O O
comparison O O
of O O
the O O
" O O
hot O O
spot O O
" O O
mutant O O
phenotypes O O
. O O

Gas O O
chromatographic O O
analysis O O
of O O
headspace O O
samples O O
of O O
alkalinized O O
vaginal O O
discharges O O
indicated O O
the O O
presence O O
of O O
trimethylamine O O
in O O
all O O
11 O O
samples O O
with O O
the O O
fishy O O
odor O O
but O O
not O O
in O O
the O O
other O O
samples O O
. O O

Standing O O
values O O
: O O
placebo O O
114 O O
/ O O
79 O O
; O O
BHT O O
- O O
933 O O
92 O O
/ O O
67 O O
. O O

The O O
SEC27 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
cloned O O
, O O
and O O
the O O
sequence O O
predicts O O
a O O
99 O O
. O O
4 O O
- O O
kDa O O
protein O O
with O O
45 O O
% O O
sequence O O
identity O O
to O O
mammalian O O
beta B B_GENE/B_PERSON
' I I_GENE/I_PERSON
- I I_GENE/I_PERSON
COP I I_GENE/I_PERSON
. O O

Studies O O
of O O
fetal O O
maturity O O

Fetal O O
arterial O O
and O O
sagittal O O
sinus O O
pH O O
, O O
base O O
excess O O
, O O
po2 O O
, O O
and O O
oxygen O O
saturation O O
decreased O O
, O O
and O O
hydrogen O O
ion O O
concentrations O O
and O O
pco2 O O
increased O O
during O O
asphyxia O O
alone O O
and O O
asphyxia O O
plus O O
isoflurane O O
- O O
oxygen O O
. O O

Therefore O O
, O O
it O O
appears O O
that O O
GCN2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
function O O
is O O
stimulated O O
posttranslationally O O
in O O
amino O O
acid O O
- O O
starved O O
cells O O
. O O

Although O O
paclitaxel O O
alone O O
failed O O
to O O
induce O O
p38 B B_GENE
MAPK O O
activation O O
, O O
subsequent O O
( O O
but O O
not O O
prior O O
) O O
exposure O O
to O O
PD98059 O O
induced O O
a O O
dramatic O O
increase O O
in O O
p38 B B_GENE
MAPK O O
phosphorylation O O
. O O

In O O
3 O O
of O O
the O O
5 O O
patients O O
with O O
AVNRT O O
and O O
AJR O O
, O O
junctional O O
beats O O
served O O
as O O
a O O
trigger O O
for O O
reentry O O
. O O

The O O
promoter O O
for O O
HMG B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CoA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
two O O
binding O O
sites O O
for O O
the O O
sterol B B_GENE/B_BIO
regulatory I I_GENE/I_BIO
element I I_GENE/I_BIO
- I I_GENE/I_BIO
binding I I_GENE/I_BIO
proteins I I_GENE/I_BIO
( O O
SREBPs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
curse O O
of O O
the O O
Pharaohs O O
. O O

Covariates O O
were O O
lower O O
extremity O O
range O O
of O O
motion O O
and O O
sensory O O
status O O
. O O

Characterization O O
and O O
targeted O O
disruption O O
of O O
murine B B_GENE
Nup50 I I_GENE
, O O
a O O
p27 B B_GENE
( O O
Kip1 B B_PROTEIN[GENE]/B_LOCATION
) O O
- O O
interacting O O
component O O
of O O
the O O
nuclear O O
pore O O
complex O O
. O O

p27 B B_GENE
( O O
Kip1 B B_GENE/B_LOCATION
) O O
is O O
a O O
member O O
of O O
the O O
Cip B B_DISEASE/B_GENE
- O O
Kip B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family O O
of O O
cyclin B B_GENE
- I I_GENE
dependent I I_GENE
kinase I I_GENE
( O O
Cdk B B_GENE/B_LOCATION
) O O
inhibitors O O
that O O
binds O O
to O O
cyclin B B_GENE
- O O
Cdk B B_GENE
complexes O O
and O O
inhibits O O
their O O
catalytic O O
activity O O
in O O
response O O
to O O
antiproliferative O O
stimuli O O
. O O

p27 B B_GENE
( O O
Kip1 B B_GENE/B_DISEASE
) O O
is O O
regulated O O
by O O
several O O
posttranscriptional O O
mechanisms O O
, O O
including O O
subcellular O O
localization O O
. O O

Therefore O O
, O O
the O O
Ogg1 B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
eukaryotic O O
DNA B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
glycosylase I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
AP B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lyase I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

One O O
patient O O
had O O
chronic O O
dysphoria O O
and O O
one O O
encephalopatia O O
toxica O O
. O O

Alveoli O O
- O O
capillary O O
diffusion O O
. O O

The O O
software O O
is O O
in O O
BASIC O O
adapted O O
for O O
the O O
Hewlett O O
- O O
Packard O O
calculators O O
HP O O
- O O
9845B O O
and O O
HP O O
- O O
85A O O
. O O

For O O
Thermus O O
strain O O
ZO5 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dihydroorotase I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DHOase B B_PROTEIN[GENE]
; O O
encoded O O
by O O
pyrC B B_GENE/B_BACTERIUM[BIO]
) O O
, O O
the O O
highest O O
similarity O O
scores O O
( O O
about O O
40 O O
% O O
identity O O
) O O
were O O
obtained O O
with O O
DHOases B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
B O O
. O O
caldolyticus O O
and O O
Bacillus O O
subtilis O O
. O O

Precision O O
of O O
data O O
from O O
models O O
of O O
sodium O O
kinetics O O
in O O
hemodialysis O O

These O O
data O O
suggest O O
that O O
the O O
fibrinogen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Gly190 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Val202 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
functions O O
as O O
a O O
minimal O O
recognition O O
sequence O O
for O O
the O O
leukocyte O O
integrin O O
CD11b B B_GENE
/ O O
CD18 B B_GENE/B_MEASURE
. O O

We O O
recently O O
described O O
the O O
isolation O O
and O O
characterization O O
of O O
nontoxic O O
PAP B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
NT123 O O
- O O
2 O O
, O O
which O O
has O O
a O O
point O O
mutation O O
( O O
E176V O O
) O O
in O O
the O O
active O O
site O O
that O O
abolishes O O
enzymatic O O
activity O O
, O O
and O O
NT124 O O
- O O
3 O O
, O O
which O O
has O O
a O O
nonsense O O
mutation O O
that O O
results O O
in O O
deletion O O
of O O
the O O
C O O
- O O
terminal O O
25 O O
aa O O
( O O
W237Stop O O
) O O
. O O

Toxicity O O
of O O
benzoyl O O
chloride O O
( O O
2 O O
, O O
4 O O
, O O
6 O O
- O O
trichlorophenyl O O
) O O
hydrazone O O
( O O
Banamite O O
) O O
and O O
potential O O
metabolites O O
to O O
twospotted O O
spider O O
mites O O
and O O
potency O O
as O O
inhibitors O O
of O O
rat B B_GENE
liver I I_GENE
monoamine I I_GENE
oxidase I I_GENE
. O O

The O O
genes O O
expressed O O
during O O
the O O
embryonic O O
( O O
zeta B B_PROTEIN[GENE]
) O O
or O O
fetal O O
and O O
adult O O
stage O O
( O O
alpha B B_PROTEIN[GENE]
2 I I_PROTEIN[GENE]
and O O
alpha B B_PROTEIN[GENE]
1 I I_PROTEIN[GENE]
) O O
can O O
be O O
modified O O
by O O
point O O
mutations O O
which O O
affect O O
either O O
the O O
processing O O
- O O
translation O O
of O O
mRNA O O
or O O
make O O
the O O
polypeptide O O
chains O O
extremely O O
unstable O O
. O O

In O O
a O O
study O O
in O O
Singapore O O
, O O
Chinese O O
, O O
Malay O O
and O O
Indian O O
patients O O
with O O
pulmonary O O
tuberculosis O O
received O O
2 O O
months O O
of O O
daily O O
treatment O O
with O O
streptomycin O O
, O O
isoniazid O O
, O O
rifampicin O O
, O O
and O O
pyrazinamide O O
followed O O
by O O
daily O O
isoniazid O O
, O O
and O O
rifampicin O O
either O O
with O O
pyrazinamide O O
( O O
SHRZ O O
/ O O
HRZ O O
) O O
or O O
without O O
it O O
( O O
SHRZ O O
/ O O
HR O O
) O O
, O O
allocated O O
at O O
random O O
. O O

Kaposi O O
' O O
s O O
sarcoma O O
- O O
associated O O
herpesvirus O O
/ O O
human O O
herpesvirus O O
- O O
8 O O
ORF50 B B_GENE
gene O O
product O O
contains O O
a O O
potent O O
C O O
- O O
terminal O O
activation O O
domain O O
which O O
activates O O
gene O O
expression O O
via O O
a O O
specific O O
target O O
sequence O O
. O O

NSAIDS O O
and O O
the O O
microcirculation O O
of O O
the O O
stomach O O
. O O

Genomic O O
Southern O O
blot O O
analysis O O
suggests O O
that O O
the O O
human O O
haploid O O
genome O O
contains O O
a O O
single O O
Gs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Evaluation O O
of O O
the O O
effects O O
of O O
chelation O O
therapy O O
with O O
time O O
following O O
strontium O O
exposure O O
to O O
mice O O
. O O

In O O
the O O
present O O
study O O
we O O
found O O
that O O
CD34 B B_GENE
downregulation O O
during O O
hematopoiesis O O
occured O O
at O O
the O O
level O O
of O O
transcriptional O O
initiation O O
. O O

Foreign O O
DNA O O
inserts O O
contained O O
within O O
the O O
fowlpox O O
virus O O
sequence O O
were O O
transferred O O
to O O
the O O
viral O O
genome O O
by O O
homologous O O
recombination O O
occurring O O
in O O
cells O O
infected O O
with O O
a O O
fowlpox O O
virus O O
temperature O O
- O O
sensitive O O
mutant O O
and O O
transfected O O
with O O
both O O
wild O O
- O O
type O O
viral O O
DNA O O
and O O
plasmid O O
DNA O O
. O O

Although O O
there O O
is O O
evidence O O
that O O
cone O O
ratios O O
do O O
determine O O
colour O O
appearance O O
under O O
many O O
conditions O O
, O O
the O O
site O O
or O O
sites O O
of O O
their O O
computation O O
is O O
unknown O O
. O O

Several O O
components O O
in O O
cytokine O O
signaling O O
remain O O
unidentified O O
. O O

This O O
is O O
the O O
first O O
report O O
demonstrating O O
specificity O O
at O O
the O O
level O O
of O O
the O O
energy O O
coupling O O
proteins O O
of O O
the O O
PTS O O
. O O

In O O
contrast O O
, O O
stem O O
- O O
loop O O
structures O O
2 O O
, O O
3 O O
, O O
and O O
4 O O
of O O
the O O
3 O O
' O O
domain O O
showed O O
great O O
variations O O
in O O
size O O
, O O
sequence O O
, O O
and O O
structure O O
. O O

A O O
spectrophotometric O O
method O O
for O O
the O O
microdetermination O O
of O O
periodate O O
. O O

Result O O
were O O
as O O
followed O O
: O O
1 O O
) O O
Early O O
cancer O O
- O O
like O O
advanced O O
cancers O O
were O O
consisted O O
of O O
133 O O
lesions O O
, O O
of O O
which O O
128 O O
lesions O O
( O O
96 O O
. O O
2 O O
% O O
) O O
had O O
peptic O O
ulcer O O
in O O
cancerous O O
lesion O O
( O O
73 O O
lesions O O
were O O
active O O
stage O O
and O O
55 O O
lesions O O
were O O
scarring O O
stage O O
) O O
. O O

Effect O O
of O O
hyperaemia O O
on O O
thallium O O
- O O
201 O O
redistribution O O
in O O
normal O O
canine O O
myocardium O O
. O O

Immunoblotting O O
showed O O
that O O
both O O
the O O
( O O
1 O O
- O O
404 O O
) O O
- O O
peptide O O
and O O
( O O
1 O O
- O O
506 O O
) O O
- O O
peptide O O
are O O
recognized O O
by O O
95J10 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
monoclonal O O
antibody O O
that O O
was O O
previously O O
raised O O
against O O
perlecan B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
24 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
404 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expressed O O
in O O
Escherichia O O
coli O O
. O O

The O O
anesthesiologist O O
and O O
the O O
cardiac O O
surgeon O O
. O O

To O O
gain O O
further O O
insights O O
into O O
these O O
events O O
, O O
the O O
porcine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
G I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
i I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
minimal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
characterized O O
and O O
found O O
67 O O
base O O
pairs O O
upstream O O
from O O
the O O
major O O
transcription O O
start O O
site O O
. O O

FDP O O
- O O
1 O O
( O O
200 O O
micrograms O O
. O O
kg O O
- O O
1 O O
) O O
of O O
intracoronary O O
injection O O
increased O O
collateral O O
flow O O
, O O
reduced O O
systemic O O
artery O O
resistance O O
, O O
and O O
coronary O O
systolic O O
pressure O O
in O O
infarcted O O
region O O
and O O
the O O
area O O
of O O
infarction O O
decreased O O
from O O
28 O O
. O O
9 O O
+ O O
/ O O
- O O
1 O O
. O O
3 O O
% O O
to O O
15 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
2 O O
% O O
( O O
P O O
< O O
0 O O
. O O
01 O O
, O O
n O O
= O O
6 O O
) O O
. O O

Pathophysiologic O O
mechanisms O O
underlying O O
spatial O O
disorientation O O
in O O
patients O O
with O O
Alzheimer O O
' O O
s O O
disease O O
. O O

Many O O
human O O
malignant O O
cells O O
lack O O
methylthioadenosine B B_GENE/B_DISEASE
phosphorylase I I_GENE/I_DISEASE
( O O
MTAP B B_LOCATION/B_GENE
) O O
enzyme O O
activity O O
. O O

Following O O
40 O O
min O O
" O O
ischemia O O
" O O
, O O
preparations O O
treated O O
with O O
PC O O
recovered O O
from O O
transmural O O
conduction O O
block O O
more O O
rapidly O O
( O O
PC1 O O
group O O
, O O
4 O O
min O O
, O O
P O O
less O O
than O O
0 O O
. O O
05 O O
; O O
PC2 O O
group O O
, O O
23 O O
min O O
, O O
ns O O
) O O
, O O
compared O O
to O O
control O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

The O O
novel O O
gene O O
spans O O
16 O O
. O O
7 O O
kb O O
of O O
genomic O O
sequence O O
and O O
it O O
is O O
formed O O
of O O
11 O O
exons O O
and O O
10 O O
intervening O O
introns O O
. O O

G B B_GENE/B_PERSON
- I I_GENE/I_PERSON
box I I_GENE/I_PERSON
binding I I_GENE/I_PERSON
factors I I_GENE/I_PERSON
( O O
GBFs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
constitute O O
a O O
family O O
of O O
plant O O
DNA O O
- O O
binding O O
proteins O O
that O O
bind O O
to O O
the O O
G O O
- O O
box O O
motif O O
, O O
a O O
regulatory O O
cis O O
element O O
present O O
in O O
many O O
plant O O
genes O O
with O O
a O O
palindromic O O
DNA O O
motif O O
of O O
CACGTG O O
. O O

CONCLUSION O O
: O O
In O O
an O O
acute O O
canine O O
model O O
of O O
progressive O O
LCX O O
coronary O O
stenosis O O
, O O
CFR O O
was O O
impaired O O
in O O
both O O
ischemic O O
and O O
remote O O
nonischemic O O
regions O O
in O O
association O O
with O O
mild O O
to O O
moderate O O
ischemic O O
- O O
induced O O
regional O O
myocardial O O
dysfunction O O
. O O

Late O O
results O O
in O O
the O O
treatment O O
of O O
urotuberculosis O O

Changes O O
in O O
the O O
frequency O O
of O O
X O O
- O O
chromatin O O
in O O
women O O
under O O
Prednisone O O
therapy O O

Other O O
toxicities O O
attributed O O
to O O
CPT O O
- O O
11 O O
included O O
dehydration O O
, O O
nausea O O
, O O
vomiting O O
, O O
and O O
asthenia O O
. O O

Proceedings O O
: O O
Influence O O
of O O
halothane O O
on O O
mortality O O
from O O
murine O O
hepatitis O O
virus O O
( O O
MHV3 O O
) O O
. O O

These O O
results O O
extend O O
our O O
knowledge O O
of O O
this O O
SNF2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
member I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
suggest O O
a O O
role O O
for O O
PASG B B_GENE/B_PERSON
in O O
leukemogenesis O O
. O O

Results O O
of O O
this O O
study O O
indicate O O
that O O
when O O
amniotic O O
fluid O O
samples O O
are O O
stored O O
frozen O O
and O O
strict O O
quality O O
control O O
is O O
maintained O O
in O O
analytic O O
procedures O O
, O O
only O O
minimal O O
changes O O
occur O O
in O O
phospholipid O O
concentrations O O
over O O
12 O O
months O O
. O O

Retinoic O O
acid O O
, O O
which O O
inhibits O O
the O O
progression O O
of O O
certain O O
cancers O O
, O O
repressed O O
v B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
src I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
MMP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O O
. O O

The O O
pattern O O
of O O
net B B_GENE/B_BACTERIUM[BIO]
RNA I I_GENE/I_BACTERIUM[BIO]
expression O O
in O O
adult O O
mouse O O
tissues O O
is O O
different O O
. O O

Immunoprecipitation O O
of O O
spinophilin B B_GENE/B_BACTERIUM[BIO]
or O O
neurabin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
crude O O
brain O O
extracts O O
selectively O O
coprecipitated O O
PP1gamma B B_GENE
( I I_GENE
1 I I_GENE
) I I_GENE
over O O
PP1beta B B_GENE/B_BIO
. O O

The O O
authors O O
discussed O O
their O O
experience O O
in O O
investigating O O
20 O O
patients O O
with O O
maxillary O O
malignant O O
tumors O O
using O O
routine O O
x O O
- O O
ray O O
studies O O
and O O
MR O O
- O O
tomography O O
, O O
and O O
13 O O
patients O O
, O O
investigated O O
in O O
the O O
same O O
way O O
plus O O
CT O O
. O O

Association O O
of O O
Syk B B_GENE
protein B I_GENE
tyrosine I I_GENE
kinase I I_GENE
( O O
PTK B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
with O O
LMP2A B B_GENE/B_DISEASE
occurs O O
at O O
the O O
two O O
tyrosines O O
of O O
the O O
LMP2A B B_GENE
immunoreceptor I I_GENE
tyrosine O O
- O O
based O O
activation O O
motif O O
, O O
and O O
it O O
is O O
hypothesized O O
that O O
Lyn B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PTK B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
associates O O
with O O
the O O
YEEA O O
amino O O
acid O O
motif O O
at O O
LMP2A B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
tyrosine O O
112 O O
( O O
Y112 O O
) O O
. O O

The O O
treatment O O
with O O
glucocorticoids O O
and O O
immunosuppressants O O
resulted O O
in O O
a O O
more O O
noticeable O O
decrease O O
in O O
the O O
levels O O
of O O
T3 O O
and O O
E B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RCF I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Four O O
of O O
these O O
fibroblast O O
clones O O
were O O
infected O O
with O O
a O O
retrovirus O O
containing O O
the O O
cDNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
encoding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
myoD I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
a O O
puromycin O O
selection O O
marker O O
. O O

Serum O O
estriol O O
levels O O
during O O
beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O O
infusion O O
in O O
the O O
third O O
trimester O O
of O O
pregnancy O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
mechanism O O
by O O
which O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activates O O
gene O O
expression O O
in O O
conjunction O O
with O O
members O O
of O O
the O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
CREB B B_GENE/B_LOCATION
family O O
. O O

Four O O
of O O
12 O O
patients O O
( O O
33 O O
% O O
) O O
were O O
initially O O
diagnosed O O
as O O
having O O
a O O
benign O O
disease O O
( O O
false O O
- O O
negatives O O
) O O
. O O

The O O
median O O
cumulative O O
incidence O O
rates O O
were O O
found O O
to O O
be O O
341 O O
per O O
million O O
for O O
males O O
and O O
296 O O
per O O
million O O
for O O
females O O
. O O

Similarly O O
, O O
antisense B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
TGF I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
type I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
II I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
oligodeoxynucleotides I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
40 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
microM I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
resulted O O
in O O
a O O
58 O O
% O O
increase O O
in O O
branching O O
, O O
compared O O
to O O
scrambled O O
and O O
mismatched O O
sequence O O
controls O O
, O O
while O O
TGF B B_GENE
- I I_GENE
beta I I_GENE
, I I_GENE
type I I_GENE
II I I_GENE
receptor I I_GENE
mRNA I I_GENE
and O O
its O O
protein O O
expression O O
levels O O
were O O
suppressed O O
by O O
95 O O
and O O
84 O O
% O O
, O O
respectively O O
. O O

Secretion O O
of O O
cuticle O O
over O O
and O O
between O O
the O O
domed O O
apical O O
surfaces O O
of O O
these O O
cells O O
leads O O
to O O
a O O
honeycomb O O
- O O
like O O
structure O O
and O O
gives O O
the O O
superficial O O
wart O O
- O O
like O O
phenotype O O
of O O
mitotic O O
clones O O
on O O
the O O
adult O O
. O O

Taken O O
together O O
, O O
these O O
results O O
indicate O O
that O O
ICSBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
critical O O
elements O O
for O O
IL B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
18 I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
expression O O
. O O

Based O O
on O O
these O O
results O O
, O O
it O O
has O O
been O O
concluded O O
that O O
an O O
IPFSA O O
can O O
promote O O
the O O
healing O O
process O O
in O O
the O O
avascular O O
zone O O
of O O
a O O
torn O O
meniscus O O
in O O
rabbits O O
and O O
that O O
systemic O O
vascularity O O
to O O
the O O
synovium O O
or O O
the O O
meniscus O O
is O O
not O O
essential O O
for O O
healing O O
to O O
occur O O
. O O

NASA O O
CR O O
- O O
1223 O O
. O O

The O O
magnitude O O
of O O
all O O
four O O
parameters O O
increased O O
in O O
an O O
exponential O O
fashion O O
with O O
increasing O O
sperm O O
number O O
up O O
to O O
400 O O
x O O
10 O O
( O O
6 O O
) O O
per O O
ejaculate O O
. O O

We O O
studied O O
about O O
the O O
histological O O
findings O O
of O O
the O O
kidneys O O
including O O
of O O
the O O
infiltrated O O
macrophages O O
in O O
one O O
hour O O
post O O
- O O
transplantation O O
kidney O O
biopsies O O
( O O
one O O
hour O O
biopsies O O
) O O
and O O
re O O
- O O
biopsies O O
on O O
11 O O
patients O O
. O O

An O O
additional O O
stimulation O O
of O O
D1 B B_PROTEIN[GENE]/B_BIO
receptors I B_PROTEIN[GENE]/I_BIO
by O O
giving O O
SKF38393 O O
30 O O
min O O
later O O
produced O O
an O O
almost O O
continuous O O
pattern O O
of O O
jaw O O
openings O O
but O O
less O O
closure O O
movements O O
from O O
the O O
rest O O
position O O
, O O
and O O
the O O
openings O O
were O O
accompanied O O
by O O
frequent O O
tongue O O
protrusions O O
. O O

( O O
control O O
hearts O O
) O O
. O O

The O O
( O O
0 O O
0 O O
2 O O
) O O
diffraction O O
of O O
the O O
synthesized O O
HAp O O
crystals O O
on O O
a O O
Col O O
fiber O O
showed O O
an O O
around O O
60 O O
arching O O
angle O O
, O O
while O O
that O O
on O O
a O O
ChS O O
fiber O O
showed O O
just O O
around O O
10 O O
degrees O O
. O O

During O O
4 O O
% O O
O2 O O
ventilation O O
, O O
baseline O O
pulmonary O O
vascular O O
resistance O O
( O O
PVR O O
) O O
and O O
the O O
dilator O O
response O O
to O O
both O O
ACh O O
and O O
SNP O O
were O O
greater O O
in O O
2D O O
lungs O O
. O O

To O O
determine O O
the O O
role O O
of O O
the O O
transmembrane O O
region O O
of O O
HN B B_PROTEIN[GENE]/B_DISEASE
on O O
fusion O O
- O O
promoting O O
activity O O
, O O
mutant B B_GENE/B_BIO
HN I I_GENE/I_BIO
proteins I I_GENE/I_BIO
were O O
expressed O O
and O O
their O O
biological O O
activities O O
examined O O
. O O

To O O
be O O
a O O
nurse O O
. O O

Synthesis O O
of O O
2 O O
- O O
( O O
2 O O
' O O
- O O
thiazolyl O O
) O O
alkanebenzimidazoles O O
- O O
- O O
potential O O
anthelmintics O O

Human B B_GENE
CR2 I I_GENE
has O O
a O O
restricted O O
cellular O O
distribution O O
, O O
being O O
expressed O O
on O O
B O O
lymphocytes O O
, O O
dendritic O O
cells O O
of O O
the O O
spleen O O
, O O
pharyngeal O O
epithelial O O
cells O O
, O O
and O O
at O O
low O O
levels O O
on O O
some O O
T O O
lymphocytes O O
. O O

ADR1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
extracts O O
made O O
from O O
glucose O O
- O O
repressed O O
and O O
- O O
derepressed O O
cells O O
bound O O
UAS1 O O
DNA O O
with O O
similar O O
affinities O O
despite O O
having O O
greatly O O
different O O
abilities O O
to O O
activate O O
ADH2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
in O O
vivo O O
. O O

Furthermore O O
, O O
agonist O O
action O O
at O O
a O O
5 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
HT1 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
antagonist O O
action O O
at O O
5 B B_GENE/B_PERSON
- I I_GENE/I_PERSON
HT2 I I_GENE/I_PERSON
receptors I I_GENE/I_PERSON
both O O
appear O O
to O O
contribute O O
to O O
antidepressant O O
- O O
like O O
activity O O
on O O
the O O
DRL O O
72 O O
- O O
s O O
schedule O O
. O O

MsEPV O O
genes O O
with O O
putative O O
functions O O
in O O
prevention O O
and O O
repair O O
of O O
DNA O O
damage O O
include O O
a O O
complete O O
base O O
excision O O
repair O O
pathway O O
( O O
uracil B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycosylase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
AP B B_ENZYME[GENE]
endonuclease I I_ENZYME[GENE]
, O O
DNA B B_GENE
polymerase I I_GENE
beta I I_GENE
, O O
and O O
an O O
NAD B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
+ I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
dependent I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
ligase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
a O O
photoreactivation O O
repair O O
pathway O O
( O O
cyclobutane B B_GENE/B_DISEASE
pyrimidine I I_GENE/I_DISEASE
dimer I I_GENE/I_DISEASE
photolyase I I_GENE/I_DISEASE
) O O
, O O
a O O
LINE B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
type I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
reverse I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transcriptase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
a O O
mutT B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
homologue I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Left O O
ventricle O O
to O O
coronary O O
sinus O O
fistula O O
. O O

In O O
this O O
report O O
we O O
describe O O
the O O
structure O O
and O O
DNA O O
sequence O O
of O O
transcriptional O O
control O O
regions O O
from O O
both O O
human B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Wistar I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rat I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
single I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
copy I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
EGF I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
their O O
functional O O
analysis O O
in O O
epithelial O O
cell O O
cultures O O
. O O

The O O
magnesium O O
content O O
in O O
leukocytes O O
could O O
not O O
be O O
estimated O O
because O O
of O O
interaction O O
between O O
the O O
ion O O
and O O
the O O
Percoll O O
( O O
R O O
) O O
media O O
. O O

The O O
sequence O O
of O O
three O O
of O O
them O O
revealed O O
pure O O
CAG O O
stretches O O
. O O

Furthermore O O
, O O
mutations O O
in O O
element O O
II O O
result O O
in O O
changes O O
in O O
the O O
RNA O O
structure O O
near O O
element O O
III O O
, O O
consistent O O
with O O
a O O
long O O
- O O
range O O
interaction O O
that O O
may O O
promote O O
translation O O
. O O

This O O
seems O O
to O O
take O O
place O O
in O O
the O O
same O O
nuclear O O
compartment O O
as O O
normal O O
cis O O
splicing O O
and O O
proceeds O O
through O O
Y O O
- O O
branched O O
intermediates O O
analogous O O
to O O
the O O
lariats O O
formed O O
in O O
cis O O
splicing O O
. O O

Chronic O O
, O O
recurrent O O
multifocal O O
osteomyelitis O O
. O O

Maximum O O
baroreceptor O O
activity O O
measured O O
at O O
140 O O
mm O O
Hg O O
and O O
the O O
slope O O
of O O
the O O
pressure O O
- O O
activity O O
curve O O
were O O
reduced O O
in O O
atherosclerotic O O
( O O
n O O
= O O
15 O O
) O O
compared O O
with O O
normal O O
( O O
n O O
= O O
13 O O
) O O
rabbits O O
( O O
425 O O
+ O O
/ O O
- O O
34 O O
versus O O
721 O O
+ O O
/ O O
- O O
30 O O
spikes O O
per O O
second O O
and O O
6 O O
. O O
2 O O
+ O O
/ O O
- O O
0 O O
. O O
6 O O
versus O O
10 O O
. O O
8 O O
+ O O
/ O O
- O O
0 O O
. O O
8 O O
spikes O O
per O O
second O O
per O O
mm O O
Hg O O
, O O
respectively O O
, O O
P O O
< O O
. O O
05 O O
) O O
. O O

A O O
pathogenetic O O
relation O O
with O O
the O O
Eisenmenger O O
' O O
s O O
syndrome O O
is O O
discussed O O
. O O

Located O O
between O O
the O O
3 O O
' O O
trans O O
- O O
spliced O O
leader O O
acceptor O O
site O O
and O O
the O O
translational O O
initiation O O
codon O O
of O O
the O O
GP63 B B_GENE
gene I I_GENE
is O O
an O O
area O O
of O O
conserved O O
hexanucleotide O O
direct O O
repeats O O
( O O
CTCGCC O O
) O O
which O O
vary O O
in O O
number O O
according O O
to O O
species O O
. O O

An O O
association O O
was O O
found O O
between O O
zafirlukast O O
plasma O O
concentrations O O
and O O
increases O O
in O O
PC8SRaw O O
10 O O
h O O
after O O
treatment O O
( O O
p O O
= O O
0 O O
. O O
001 O O
) O O
. O O

Insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
secreting O O
islet O O
- O O
cell O O
tumours O O
of O O
the O O
pancreas O O
. O O

Disruption O O
and O O
reconstruction O O
: O O
narrative O O
insights O O
into O O
the O O
experience O O
of O O
family O O
members O O
caring O O
for O O
a O O
relative O O
diagnosed O O
with O O
serious O O
mental O O
illness O O
. O O

The O O
results O O
suggest O O
that O O
the O O
posterior O O
wall O O
is O O
more O O
compliant O O
than O O
the O O
anterior O O
wall O O
( O O
that O O
is O O
, O O
for O O
a O O
given O O
difference O O
in O O
transmural O O
pressure O O
, O O
the O O
local O O
segment O O
length O O
change O O
of O O
the O O
posterior O O
wall O O
was O O
greater O O
) O O
. O O

Partial O O
characterization O O
of O O
the O O
CCAAT O O
box O O
in O O
the O O
promoter O O
of O O
the O O
hLGFBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
interaction O O
with O O
negatively O O
acting O O
transcription O O
factors O O
in O O
decidualized O O
human O O
endometrial O O
stromal O O
cells O O
. O O

We O O
conclude O O
that O O
transcription O O
of O O
both O O
SCD1 B B_GENE/B_LOCATION
and O O
SCD2 B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
is O O
responsive O O
to O O
cellular O O
sterol O O
levels O O
and O O
to O O
the O O
levels O O
of O O
nuclear O O
SREBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
ADD1 B B_PROTEIN[GENE]/B_LOCATION
and O O
that O O
transcriptional O O
induction O O
requires O O
three O O
spatially O O
conserved O O
cis O O
elements O O
, O O
that O O
bind O O
SREBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
NF B B_GENE
- I I_GENE
Y I I_GENE
. O O

Three O O
transcriptional O O
control O O
elements O O
within O O
300 O O
base O O
pairs O O
of O O
the O O
5 O O
' O O
- O O
flanking O O
region O O
of O O
the O O
rat B B_GENE/B_LOCATION
glucagon I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
interact O O
with O O
regulatory O O
cellular O O
proteins O O
and O O
direct O O
transcription O O
only O O
in O O
glucagon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
producing O O
islet O O
cells O O
. O O

A O O
role O O
for O O
phosphatidylinositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
regulation O O
of O O
beta B B_GENE
1 I I_GENE
integrin I I_GENE
activity O O
by O O
the O O
CD2 B B_GENE/B_PERSON
antigen O O
. O O

Relationship O O
between O O
age O O
- O O
associated O O
endocrine O O
deficiencies O O
and O O
muscle O O
function O O
in O O
elderly O O
women O O
: O O
a O O
cross O O
- O O
sectional O O
study O O
. O O

In O O
contrast O O
, O O
the O O
sequences O O
essential O O
for O O
the O O
transcription O O
of O O
EFT1 B B_GENE
were O O
localized O O
to O O
the O O
region O O
between O O
the O O
start O O
ATG O O
and O O
the O O
stop O O
codon O O
of O O
the O O
VPS17 B B_GENE
gene I I_GENE
that O O
terminates O O
267 O O
nt O O
upstream O O
on O O
the O O
same O O
strand O O
. O O

Exposure O O
of O O
raft O O
cultures O O
to O O
activators O O
of O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
such O O
as O O
phorbol O O
esters O O
, O O
results O O
in O O
the O O
further O O
induction O O
of O O
late B B_GENE
gene I I_GENE
expression O O
as O O
well O O
as O O
virion O O
assembly O O
. O O

A O O
case O O
of O O
2 O O
cancers O O
of O O
the O O
colon O O

The O O
" O O
Gregg O O
phenomenon O O
" O O
implies O O
that O O
myocardial O O
function O O
and O O
oxygen O O
consumption O O
( O O
MVO2 O O
) O O
increase O O
when O O
coronary O O
perfusion O O
is O O
enhanced O O
within O O
or O O
above O O
the O O
autoregulatory O O
range O O
. O O

We O O
have O O
mapped O O
the O O
specific O O
domains O O
within O O
each O O
of O O
the O O
proteins O O
responsible O O
for O O
this O O
interaction O O
. O O

In O O
each O O
of O O
the O O
studied O O
HPV O O
types O O
, O O
the O O
two O O
CDP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
Cut B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O O
sites O O
of O O
PSM B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
overlap O O
with O O
the O O
known O O
or O O
presumed O O
binding O O
sites O O
of O O
the O O
replication B B_PROTEIN[GENE]/B_BIO
initiator I I_PROTEIN[GENE]/I_BIO
protein I I_PROTEIN[GENE]/I_BIO
E1 I I_PROTEIN[GENE]/I_BIO
. O O

Reduced O O
cell O O
numbers O O
72 O O
h O O
after O O
insonation O O
were O O
recorded O O
when O O
the O O
cells O O
were O O
insonated O O
at O O
an O O
antinode O O
but O O
not O O
when O O
they O O
were O O
at O O
a O O
node O O
. O O

Hydroxyl O O
radical O O
footprinting O O
of O O
DNA O O
complexes O O
of O O
the O O
ets B B_GENE/B_LOCATION
domain I B_GENE/I_LOCATION
of O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
comparison O O
to O O
the O O
crystal O O
structure O O
. O O

ATF O O
is O O
formulated O O
from O O
the O O
prothrombin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time O O
( O O
PT O O
) O O
, O O
fibrinogen B B_MEASURE/B_PROTEIN[GENE]
transformation O O
rate O O
( O O
FTR O O
) O O
( O O
a O O
representation O O
of O O
thrombin B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
) O O
, O O
and O O
a O O
consideration O O
of O O
the O O
fibrinogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
FBG B B_PROTEIN[GENE]/B_LOCATION
) O O
content O O
of O O
blood O O
plasma O O
. O O

Phenotypic O O
and O O
molecular O O
analyses O O
of O O
patients O O
with O O
partial O O
chromosome O O
21 O O
monosomy O O
enabled O O
us O O
to O O
define O O
a O O
region O O
, O O
spanning O O
2 O O
. O O
4 O O
Mb O O
between O O
D21S190 B B_GENE
and O O
D21S226 B B_GENE/B_TIME[MEASURE]
, O O
associated O O
with O O
arthrogryposis O O
, O O
mental O O
retardation O O
, O O
hypertonia O O
, O O
and O O
several O O
facial O O
anomalies O O
. O O

The O O
Ca2 O O
+ O O
concentration O O
in O O
rats O O
serum O O
after O O
intragastrically O O
fenarimol O O
administration O O
( O O
doses O O
1 O O
/ O O
40 O O
, O O
1 O O
/ O O
20 O O
and O O
1 O O
/ O O
10 O O
LD50 O O
) O O
during O O
5 O O
days O O
was O O
investigated O O
. O O

In O O
Cos O O
7 O O
cells O O
transfected O O
with O O
oCRF1var B B_GENE
, O O
cAMP O O
accumulation O O
was O O
only O O
observed O O
at O O
the O O
highest O O
concentration O O
of O O
oCRF B B_PROTEIN[GENE]/B_DISEASE
utilized O O
( O O
100 O O
nM O O
) O O
. O O

Pyknotic O O
osteocytes O O
increased O O
at O O
12 O O
h O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
and O O
2 O O
days O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
of O O
ischemia O O
. O O

The O O
right O O
cornea O O
of O O
rats O O
was O O
cauterized O O
by O O
drops O O
of O O
1 O O
. O O
5 O O
N O O
HC1 O O
over O O
30 O O
s O O
; O O
the O O
left O O
one O O
served O O
as O O
a O O
control O O
. O O

Comparing O O
the O O
outcome O O
of O O
the O O
group O O
having O O
histologically O O
normal O O
biopsies O O
with O O
the O O
group O O
having O O
nonspecifically O O
abnormal O O
ones O O
it O O
is O O
concluded O O
that O O
frontal O O
biopsy O O
is O O
not O O
of O O
such O O
high O O
prognostic O O
value O O
as O O
has O O
been O O
claimed O O
in O O
previous O O
reports O O
. O O

He O O
presented O O
with O O
left O O
lower O O
abdominal O O
pain O O
and O O
hematoma O O
after O O
a O O
fall O O
. O O

Fusion O O
of O O
mouse B B_GENE
CD8 I I_GENE
+ I I_GENE
class B I_GENE
I I I_GENE
MHC I I_GENE
- O O
restricted O O
T O O
cells O O
with O O
the O O
BW5147 O O
thymoma O O
invariably O O
yields O O
CD8 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
hybridomas O O
in O O
which O O
RNA O O
transcribed O O
from O O
the O O
CD8 B B_GENE
alpha I I_GENE
( O O
Lyt B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
2 I I_PROTEIN[GENE]/I_MEASURE
) O O
gene O O
is O O
undetectable O O
. O O

Peak O O
plasma O O
ACTH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
responses O O
were O O
not O O
significantly O O
different O O
between O O
control O O
and O O
patient O O
groups O O
. O O

For O O
the O O
P B B_GENE/B_LOCATION
transcript I I_GENE/I_LOCATION
from O O
phage O O
with O O
the O O
G O O
( O O
- O O
) O O
orientation O O
, O O
full O O
termination O O
activity O O
required O O
both O O
the O O
region O O
containing O O
the O O
stem O O
- O O
loop O O
structure O O
and O O
upstream O O
sequences O O
. O O

Development O O
of O O
neural O O
control O O
of O O
alimentary O O
motor O O
function O O
in O O
the O O
vertebrates O O
. O O

Nb2 O O
- O O
11C O O
cells O O
expressed O O
three O O
PNR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
2 O O
. O O
5 O O
, O O
3 O O
. O O
0 O O
and O O
> O O
10 O O
kb O O
. O O

However O O
, O O
the O O
blend O O
of O O
Metanil O O
yellow O O
and O O
Orange O O
II O O
( O O
1 O O
: O O
1 O O
) O O
resulted O O
in O O
the O O
D1 O O
50 O O
. O O
value O O
of O O
288 O O
min O O
. O O

The O O
majority O O
of O O
these O O
cells O O
were O O
also O O
OKT4 B B_GENE
positive O O
( O O
helper O O
/ O O
inducer O O
T O O
lymphocytes O O
) O O
, O O
while O O
the O O
minority O O
were O O
OKT8 B B_GENE
positive O O
( O O
suppressor O O
/ O O
cytotoxic O O
T O O
lymphocytes O O
) O O
. O O

AIMS O O
: O O
We O O
postulated O O
that O O
perhexiline O O
, O O
a O O
novel O O
anti O O
- O O
ischaemic O O
agent O O
with O O
an O O
oxygen O O
- O O
sparing O O
metabolic O O
effect O O
in O O
the O O
myocardium O O
( O O
via O O
inhibition O O
of O O
carnitine B B_GENE
palmitoyltransferase I I_GENE
- I I_GENE
1 I I_GENE
) O O
and O O
no O O
adverse O O
haemodynamic O O
effects O O
, O O
may O O
improve O O
symptomatic O O
status O O
in O O
elderly O O
patients O O
with O O
severe O O
aortic O O
stenosis O O
. O O

The O O
IFNAR B B_GENE
chain I I_GENE
interacts O O
with O O
both O O
IFN B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IFN B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
demonstrated O O
by O O
cross O O
- O O
linking O O
. O O

To O O
clone O O
cDNAs O O
for O O
the O O
beta O O
subunit O O
of O O
rabbit B B_GENE
eIF I I_GENE
- I I_GENE
2B I I_GENE
, O O
amino O O
acid O O
sequence O O
data O O
was O O
first O O
obtained O O
and O O
used O O
to O O
design O O
redundant O O
oligonucleotide O O
primers O O
for O O
use O O
in O O
PCR O O
. O O

We O O
report O O
the O O
cloning O O
of O O
the O O
ade1 B B_GENE
gene I I_GENE
on O O
a O O
4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kb I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Sau3A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
insert I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
yeast O O
shuttle O O
vector O O
pWH5 O O
. O O

Nimodipine O O
( O O
5 O O
micrograms O O
/ O O
kg O O
) O O
followed O O
by O O
infusion O O
of O O
0 O O
. O O
75 O O
microgram O O
/ O O
kg O O
/ O O
min O O
lowered O O
the O O
blood O O
pressure O O
by O O
10 O O
% O O
in O O
both O O
normotensive O O
and O O
hypertensive O O
rats O O
; O O
the O O
same O O
dose O O
schedule O O
of O O
nifedipine O O
did O O
not O O
lower O O
MAP O O
. O O

Results O O
of O O
these O O
in O O
vitro O O
studies O O
may O O
be O O
relevant O O
to O O
the O O
pathogenesis O O
of O O
alveolitis O O
in O O
organic O O
dust O O
- O O
induced O O
lung O O
diseases O O
. O O

The O O
odds O O
of O O
atopy O O
( O O
defined O O
as O O
a O O
positive O O
test O O
for O O
at O O
least O O
one O O
of O O
the O O
antigens O O
) O O
were O O
5 O O
times O O
higher O O
( O O
odds O O
ratio O O
= O O
7 O O
. O O
0 O O
; O O
95 O O
% O O
confidence O O
interval O O
= O O
1 O O
. O O
6 O O
- O O
31 O O
. O O
1 O O
% O O
; O O
p O O
= O O
0 O O
. O O
01 O O
) O O
in O O
the O O
uninfected O O
group O O
, O O
after O O
taking O O
into O O
account O O
the O O
potential O O
influence O O
of O O
gender O O
and O O
age O O
. O O

A O O
selectable O O
marker O O
for O O
transformation O O
was O O
constructed O O
by O O
transcriptional O O
fusion O O
of O O
a O O
Ustilago B B_GENE
maydis I I_GENE
heat I I_GENE
shock I I_GENE
gene I I_GENE
promoter I I_GENE
with O O
the O O
hygromycin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphotransferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Escherichia I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coli I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
determine O O
the O O
response O O
properties O O
of O O
the O O
human O O
visual O O
cortex O O
to O O
chromatic O O
stimuli O O
using O O
magnetoencephalography O O
( O O
MEG O O
) O O
. O O

The O O
role O O
of O O
NUT1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
regulation O O
of O O
nitrogen O O
metabolism O O
in O O
the O O
disease O O
process O O
was O O
evaluated O O
by O O
pathogenicity O O
assays O O
. O O

These O O
three O O
phases O O
of O O
cyclin B B_GENE
E I I_GENE
association O O
with O O
chromatin O O
may O O
facilitate O O
the O O
diverse O O
activities O O
of O O
cyclin B B_GENE/B_DISEASE
E I I_GENE/I_DISEASE
- O O
- O O
Cdk2 B B_GENE/B_MEASURE
in O O
initiating O O
replication O O
, O O
blocking O O
rereplication O O
, O O
and O O
allowing O O
resetting O O
of O O
origins O O
after O O
mitosis O O
. O O

No O O
IORT O O
related O O
mortality O O
has O O
been O O
observed O O
. O O

Dermatophagoides O O
farinae O O
- O O
sensitized O O
lymphocytes O O
in O O
asthmatic O O
children O O
as O O
evaluated O O
by O O
interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IL B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
2 I I_GENE/I_MEASURE
) O O
production O O
and O O
acquisition O O
of O O
IL B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
2 I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
responsiveness O O

Enterotoxin O O
production O O
by O O
staphylococci O O
isolated O O
from O O
foods O O
in O O
France O O
. O O

Measurements O O
in O O
rats O O
given O O
a O O
dose O O
of O O
propranolol O O
that O O
partially O O
inhibited O O
the O O
NA O O
- O O
induced O O
increase O O
in O O
Q O O
to O O
IBAT O O
indicated O O
that O O
the O O
decline O O
in O O
ENAIBAT O O
was O O
attributable O O
primarily O O
to O O
the O O
increase O O
in O O
Q O O
rather O O
than O O
to O O
increasing O O
saturation O O
of O O
uptake O O
mechanisms O O
. O O

Plasma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
progesterone O O
levels O O
after O O
single O O
or O O
multiple O O
injections O O
of O O
synthetic O O
LH B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
RH B B_PROTEIN[GENE]/B_DISEASE
in O O
anoestrous O O
ewes O O
and O O
comparison O O
with O O
levels O O
during O O
the O O
oestrous O O
cycle O O
. O O

MATERIAL O O
AND O O
METHODS O O
: O O

But O O
, O O
when O O
mated O O
males O O
built O O
nests O O
in O O
the O O
absence O O
of O O
young O O
, O O
T O O
levels O O
were O O
higher O O
than O O
in O O
all O O
other O O
conditions O O
, O O
though O O
only O O
for O O
early O O
broods O O
. O O

Primers O O
were O O
developed O O
for O O
specific O O
amplification O O
of O O
9804 B B_GENE/B_DISEASE
gene I I_GENE/I_DISEASE
fragments I I_GENE/I_DISEASE
. O O

The O O
promyelocytic B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
leukemia I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
interacts O O
with O O
Sp1 B B_GENE
and O O
inhibits O O
its O O
transactivation O O
of O O
the O O
epidermal B B_GENE
growth I I_GENE
factor I I_GENE
receptor I I_GENE
promoter O O
. O O

The O O
mutants O O
retained O O
the O O
parental O O
ability O O
to O O
participate O O
in O O
intergeneric O O
coaggregation O O
with O O
human O O
oral O O
actinomyces O O
, O O
indicating O O
the O O
specificity O O
of O O
the O O
mutation O O
in O O
altering O O
intrageneric O O
coaggregations O O
. O O

The O O
Saccharomyces O O
cerevisiae O O
targets O O
of O O
rapamycin O O
, O O
TOR1 B B_GENE
and O O
TOR2 B B_GENE
, O O
signal O O
activation O O
of O O
cell O O
growth O O
in O O
response O O
to O O
nutrient O O
availability O O
. O O

Biology O O
of O O
Anopheles O O
quadrimaculatus O O
under O O
field O O
conditions O O
in O O
central O O
Florida O O
. O O

Immunogenicity O O
tested O O
in O O
experiments O O
on O O
guinea O O
pigs O O
and O O
rabbits O O
was O O
not O O
reduced O O
and O O
corresponded O O
to O O
that O O
of O O
the O O
reference O O
STI O O
- O O
1 O O
vaccine O O
. O O

In O O
addition O O
, O O
mutations O O
within O O
the O O
Ubx B B_GENE/B_BIO
unit I I_GENE/I_BIO
exons I I_GENE/I_BIO
are O O
known O O
and O O
most O O
of O O
these O O
behave O O
as O O
null O O
alleles O O
. O O

Taken O O
together O O
, O O
these O O
data O O
suggest O O
that O O
the O O
Smad3 B B_GENE
/ O O
Smad4 B B_GENE/B_MEASURE
complex O O
has O O
at O O
least O O
two O O
separable O O
nuclear O O
functions O O
: O O
it O O
forms O O
a O O
rapid O O
, O O
yet O O
transient O O
sequence O O
- O O
specific O O
DNA O O
binding O O
complex O O
, O O
and O O
it O O
potentiates O O
AP1 B B_GENE
- O O
dependent O O
transcriptional O O
activation O O
. O O

When O O
phentermine O O
was O O
mixed O O
with O O
other O O
unlabeled O O
reversible O O
MAO B B_ENZYME[GENE]
inhibitors O O
( O O
e O O
. O O
g O O
. O O
pseudoephedrine O O
, O O
ephedrine O O
, O O
norephedrine O O
; O O
estradiol O O
benzoate O O
) O O
, O O
the O O
degree O O
of O O
MAO B B_GENE
inhibition O O
was O O
additive O O
. O O

Here O O
we O O
report O O
that O O
point O O
mutations O O
of O O
the O O
Abd B B_GENE
- I I_GENE
B I I_GENE
gene I I_GENE
in O O
trans O O
suppress O O
the O O
Fab B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
7 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
phenotype I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
a O O
pairing O O
- O O
dependent O O
manner O O
and O O
thus O O
represent O O
a O O
type O O
of O O
transvection O O
. O O

4 O O
382 O O
new O O
mothers O O
were O O
examined O O
retrospectively O O
with O O
the O O
enzyme O O
- O O
linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
for O O
IgG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity O O
to O O
cytomegalovirus O O
( O O
CMV O O
) O O
during O O
pregnancy O O
. O O

Also O O
, O O
residues O O
273 O O
to O O
287 O O
, O O
which O O
are O O
identical O O
in O O
sequence O O
to O O
a O O
15 O O
- O O
amino O O
- O O
acid O O
segment O O
near O O
the O O
carboxy O O
terminus O O
of O O
the O O
simian B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
foamy I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Taf I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
can O O
independently O O
enhance O O
the O O
activity O O
of O O
the O O
minimal O O
activator O O
region O O
. O O

The O O
effect O O
of O O
pneumoperitoneum O O
on O O
dissemination O O
and O O
scar O O
implantation O O
of O O
intra O O
- O O
abdominal O O
tumor O O
cells O O
. O O

In O O
two O O
of O O
these O O
nine O O
patients O O
, O O
a O O
decrease O O
in O O
dyskinesia O O
score O O
was O O
observed O O
without O O
a O O
concomitant O O
worsening O O
of O O
parkinsonian O O
symptoms O O
, O O
whereas O O
in O O
the O O
remaining O O
seven O O
, O O
full O O
parkinsonian O O
akinesia O O
followed O O
THDL O O
administration O O
. O O

Alterations O O
in O O
TCR B B_GENE
- O O
MHC B B_GENE/B_DISEASE
contacts O O
subsequent O O
to O O
cross O O
- O O
recognition O O
of O O
class B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MHC I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
singly O O
substituted O O
peptide O O
variants O O
. O O

Two O O
patients O O
with O O
Ewing O O
' O O
s O O
sarcoma O O
relapsed O O
( O O
1 O O
patient O O
with O O
both O O
local O O
and O O
distant O O
failure O O
) O O
at O O
26 O O
and O O
58 O O
months O O
and O O
were O O
again O O
rendered O O
disease O O
- O O
free O O
with O O
surgery O O
, O O
total O O
body O O
irradiation O O
and O O
further O O
chemotherapy O O
. O O

The O O
cloning O O
of O O
human B B_GENE/B_SPECIES[BIO]
apo I B_GENE/I_SPECIES[BIO]
B I B_GENE/I_SPECIES[BIO]
- I B_GENE/I_SPECIES[BIO]
100 I B_GENE/I_SPECIES[BIO]
has O O
provided O O
new O O
insights O O
into O O
the O O
structure O O
and O O
physicochemical O O
properties O O
of O O
apo B B_GENE
B I I_GENE
- I I_GENE
100 I I_GENE
and O O
will O O
facilitate O O
studies O O
on O O
the O O
factors O O
modulating O O
apo B B_GENE
B I I_GENE
- I I_GENE
100 I I_GENE
biosynthesis O O
and O O
the O O
expression O O
of O O
the O O
apo B B_GENE/B_DISEASE
B I I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
100 I I_GENE/I_DISEASE
gene I I_GENE/I_DISEASE
in O O
patients O O
with O O
dyslipoproteinemias O O
. O O

Angiographic O O
follow O O
- O O
up O O
was O O
obtained O O
in O O
92 O O
% O O
of O O
patients O O
with O O
a O O
primary O O
success O O
of O O
angioplasty O O
. O O

Acceptability O O
of O O
home O O
monitoring O O
as O O
an O O
aid O O
to O O
conception O O
. O O

Repeated O O
interferon B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IFN B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
silencer O O
B O O
motifs O O
and O O
a O O
lysozyme B B_GENE/B_MEASURE
silencer I I_GENE/I_MEASURE
1 I I_GENE/I_MEASURE
motif I I_GENE/I_MEASURE
have O O
been O O
found O O
in O O
the O O
CD95 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
at O O
approximately O O
- O O
1 O O
, O O
600 O O
and O O
- O O
1 O O
, O O
100 O O
, O O
respectively O O
. O O

Action O O
against O O
Vibrio O O
cholerae O O
O1 O O
Tox B B_GENE/B_DISEASE
+ I B_GENE/I_DISEASE
of O O
chemical O O
products O O
used O O
in O O
the O O
lemon O O
production O O
. O O

When O O
patients O O
were O O
admitted O O
within O O
one O O
week O O
of O O
the O O
onset O O
of O O
dark O O
urine O O
, O O
45 O O
% O O
were O O
found O O
to O O
be O O
shedding O O
HAV O O
, O O
whereas O O
only O O
11 O O
% O O
of O O
specimens O O
obtained O O
from O O
patients O O
admitted O O
during O O
the O O
second O O
week O O
contained O O
virus O O
. O O

Biochemical O O
studies O O
have O O
identified O O
a O O
cellular O O
non B B_PROTEIN[GENE]/B_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
P I I_PROTEIN[GENE]/I_MEASURE
element I I_PROTEIN[GENE]/I_MEASURE
- I I_PROTEIN[GENE]/I_MEASURE
encoded I I_PROTEIN[GENE]/I_MEASURE
DNA I I_PROTEIN[GENE]/I_MEASURE
binding I I_PROTEIN[GENE]/I_MEASURE
protein I I_PROTEIN[GENE]/I_MEASURE
, O O
termed O O
the O O
inverted B B_GENE/B_MEASURE
repeat I I_GENE/I_MEASURE
binding I I_GENE/I_MEASURE
protein I I_GENE/I_MEASURE
( O O
IRBP B B_DISEASE/B_GENE
) O O
, O O
that O O
specifically O O
interacts O O
with O O
the O O
outer O O
half O O
of O O
the O O
31 O O
- O O
bp O O
terminal O O
inverted O O
repeats O O
. O O

Threefold O O
risks O O
were O O
observed O O
for O O
men O O
with O O
the O O
highest O O
level O O
of O O
intensity O O
and O O
for O O
those O O
with O O
the O O
highest O O
probability O O
of O O
EMF O O
exposure O O
, O O
although O O
women O O
with O O
heavy O O
EMF O O
exposure O O
did O O
not O O
experience O O
increased O O
risk O O
. O O

In O O
the O O
spontaneous O O
abortion O O
group O O
, O O
the O O
levels O O
of O O
PAPP B B_GENE
- I I_GENE
A I I_GENE
were O O
significantly O O
lower O O
than O O
in O O
normal O O
pregnancy O O
but O O
higher O O
than O O
in O O
non O O
- O O
pregnant O O
controls O O
. O O

We O O
report O O
the O O
sequence O O
of O O
a O O
7941 O O
bp O O
DNA O O
fragment O O
from O O
the O O
left O O
arm O O
of O O
chromosome O O
VII O O
of O O
Saccharomyces O O
cerevisiae O O
which O O
contains O O
four O O
open O O
reading O O
frames O O
( O O
ORFs O O
) O O
of O O
greater O O
than O O
100 O O
amino O O
acid O O
residues O O
. O O

A O O
4 O O
. O O
0 O O
- O O
kb O O
Nlk B B_GENE/B_LOCATION
message I I_GENE/I_LOCATION
is O O
also O O
present O O
during O O
embryogenesis O O
, O O
detectable O O
at O O
day O O
E10 O O
. O O

Promoting O O
fat O O
utilisation O O
by O O
reducing O O
the O O
carbohydrate O O
- O O
fat O O
ratio O O
of O O
the O O
TPN O O
reduces O O
free O O
radical O O
activity O O
to O O
a O O
similar O O
extent O O
as O O
fat O O
exclusion O O
. O O

In O O
cells O O
infected O O
with O O
a O O
recombinant O O
vaccinia O O
virus O O
expressing O O
HCV O O
structural O O
proteins O O
( O O
core B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
E1 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
E2 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
DDX3 B B_PROTEIN[GENE]/B_LOCATION
and O O
core B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colocalized O O
in O O
distinct O O
spots O O
in O O
the O O
perinuclear O O
region O O
of O O
the O O
cytoplasm O O
. O O

Mutating O O
this O O
sequence O O
eliminated O O
complex O O
formation O O
and O O
markedly O O
reduced O O
basal O O
and O O
cAMP O O
- O O
dependent O O
promoter O O
activity O O
of O O
transfected O O
reporter O O
genes O O
. O O

Due O O
to O O
significant O O
homology O O
to O O
the O O
C O O
- O O
terminus O O
of O O
the O O
Mutator B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transposase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
this O O
alternative O O
gene O O
product O O
was O O
named O O
Trap B B_GENE/B_DISEASE
( O O
transposon B B_PROTEIN[GENE]/B_LOCATION
- I I_PROTEIN[GENE]/I_LOCATION
associated I I_PROTEIN[GENE]/I_LOCATION
protein I I_PROTEIN[GENE]/I_LOCATION
) O O
. O O

Nonetheless O O
, O O
the O O
majority O O
were O O
located O O
within O O
three O O
short O O
sequences O O
at O O
the O O
N O O
terminus O O
, O O
middle O O
, O O
and O O
C O O
terminus O O
that O O
are O O
phylogenetically O O
conserved O O
among O O
all O O
known O O
eubacterial O O
and O O
chloroplast O O
versions O O
of O O
this O O
protein O O
. O O

The O O
c B B_GENE/B_BIO
- I I_GENE/I_BIO
raf I I_GENE/I_BIO
- I I_GENE/I_BIO
1 I I_GENE/I_BIO
proto I I_GENE/I_BIO
- I I_GENE/I_BIO
oncogene I I_GENE/I_BIO
is O O
the O O
cellular B B_GENE/B_PERSON
homologue I I_GENE/I_PERSON
of I I_GENE/I_PERSON
v I I_GENE/I_PERSON
- I I_GENE/I_PERSON
raf I I_GENE/I_PERSON
, O O
the O O
oncogene O O
of O O
the O O
acutely O O
transforming O O
retrovirus O O
3611 O O
- O O
MSV O O
. O O

Using O O
gel O O
retardation O O
analysis O O
, O O
four O O
binding O O
sites O O
for O O
Rap1p B B_GENE
have O O
been O O
identified O O
within O O
the O O
promoter O O
of O O
the O O
RAP1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
general O O
, O O
the O O
scallop O O
extract O O
potentiated O O
phototactic O O
suppression O O
. O O

Alcohol O O
abuse O O
and O O
treatment O O
resistance O O
in O O
skin O O
disease O O
. O O

The O O
mean O O
serum O O
CDT O O
increased O O
from O O
8 O O
. O O
5 O O
( O O
SD O O
2 O O
. O O
2 O O
) O O
U O O
/ O O
l O O
to O O
16 O O
. O O
6 O O
( O O
SD O O
7 O O
. O O
2 O O
) O O
U O O
/ O O
l O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

RT O O
- O O
PCR O O
analysis O O
of O O
FGFR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
the O O
presence O O
of O O
a O O
splice O O
variant O O
in O O
which O O
exons O O
7 O O
and O O
8 O O
are O O
deleted O O
. O O

In O O
human O O
myxoid O O
liposarcoma O O
, O O
a O O
chromosomal O O
rearrangement O O
leads O O
to O O
fusion O O
of O O
the O O
growth O O
- O O
arresting O O
and O O
DNA O O
- O O
damage O O
- O O
inducible O O
transcription O O
factor O O
CHOP B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
( O O
GADD153 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
to O O
a O O
peptide O O
fragment O O
encoded O O
by O O
the O O
TLS B B_GENE/B_DISEASE
gene I I_GENE/I_DISEASE
. O O

They O O
also O O
show O O
that O O
M O O
. O O
malmoense O O
can O O
be O O
isolated O O
from O O
the O O
environment O O
which O O
may O O
be O O
the O O
source O O
of O O
the O O
infection O O
. O O

The O O
monkeys O O
had O O
been O O
administered O O
a O O
common O O
lead O O
isotope O O
" O O
mix O O
" O O
at O O
the O O
rate O O
of O O
about O O
1300 O O
micrograms O O
Pb O O
/ O O
kg O O
body O O
wt O O
/ O O
day O O
from O O
age O O
10 O O
months O O
until O O
the O O
start O O
of O O
the O O
study O O
. O O

We O O
previously O O
described O O
the O O
upregulation O O
of O O
the O O
MT2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigen I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O O
urodele O O
limb O O
regeneration O O
and O O
characterized O O
the O O
MT2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
antigen I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
as O O
a O O
310 O O
- O O
to O O
325 O O
- O O
kDa O O
chondroitin O O
- O O
sulfated O O
glycoprotein O O
with O O
a O O
core O O
protein O O
of O O
285 O O
- O O
300 O O
kDa O O
. O O

Analysis O O
of O O
the O O
MCV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RPO1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
revealed O O
high O O
amino O O
acid O O
homologies O O
to O O
the O O
corresponding O O
polypeptides O O
of O O
vaccinia O O
and O O
variola O O
virus O O
. O O

The O O
effects O O
of O O
dopamine O O
and O O
of O O
dopamine B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D2 I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocker O O
haloperidol O O
on O O
the O O
activity O O
of O O
carotid O O
chemoreceptors O O
were O O
studied O O
in O O
24 O O
anesthetized O O
, O O
paralyzed O O
and O O
artificially O O
ventilated O O
newborn O O
kittens O O
aged O O
0 O O
- O O
17 O O
days O O
. O O

Fifty O O
- O O
seven O O
per O O
cent O O
of O O
the O O
primary O O
patients O O
reporting O O
mild O O
symptoms O O
had O O
abnormal O O
levels O O
of O O
leucocytes O O
in O O
their O O
CSF O O
. O O

When O O
proper O O
controls O O
were O O
used O O
, O O
the O O
psychophysical O O
data O O
and O O
computer O O
simulation O O
gave O O
remarkably O O
comparable O O
results O O
. O O

Patients O O
were O O
treated O O
with O O
either O O
4 O O
. O O
8 O O
million O O
units O O
of O O
procaine O O
penicillin O O
with O O
1 O O
g O O
probenecid O O
, O O
3 O O
. O O
5 O O
or O O
4 O O
. O O
5 O O
g O O
of O O
ampicillin O O
with O O
1 O O
g O O
probenecid O O
, O O
or O O
9 O O
. O O
5 O O
g O O
of O O
tetracycline O O
given O O
over O O
4 O O
days O O
. O O

The O O
results O O
of O O
this O O
study O O
indicate O O
that O O
the O O
Improved O O
Crest O O
Complete O O
with O O
longer O O
rippled O O
outer O O
bristles O O
provided O O
significantly O O
superior O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
interproximal O O
penetration O O
overall O O
and O O
at O O
the O O
gumline O O
than O O
the O O
Colgate O O
Total O O
and O O
Oral O O
- O O
B O O
Advantage O O
brushes O O
. O O

Cardiac O O
NE O O
spillover O O
was O O
higher O O
( O O
P O O
< O O
. O O
05 O O
) O O
at O O
baseline O O
in O O
the O O
patient O O
group O O
than O O
in O O
healthy O O
subjects O O
, O O
whereas O O
renal O O
and O O
whole O O
- O O
body O O
NE O O
spillovers O O
were O O
similar O O
between O O
the O O
study O O
groups O O
. O O

The O O
activity O O
of O O
platelet B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
plasma O O
of O O
healthy O O
and O O
high O O
risk O O
newborns O O
. O O

Plasma B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
renin I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activity O O
in O O
essential O O
arterial O O
hypertension O O
. O O

A O O
trend O O
was O O
observed O O
toward O O
increased O O
graft O O
half O O
- O O
life O O
in O O
era O O
2 O O
( O O
p O O
= O O
NS O O
) O O
. O O

The O O
proteins O O
encoded O O
by O O
these O O
genes O O
, O O
called O O
GF14 B B_GENE/B_BIO
proteins I I_GENE/I_BIO
, O O
participate O O
in O O
protein O O
/ O O
DNA O O
complexes O O
and O O
show O O
more O O
than O O
60 O O
% O O
identity O O
with O O
a O O
highly O O
conserved O O
, O O
widely O O
distributed O O
protein O O
family O O
, O O
collectively O O
referred O O
to O O
as O O
14 B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
3 I I_GENE/I_MEASURE
- I I_GENE/I_MEASURE
3 I I_GENE/I_MEASURE
proteins O O
. O O

The O O
p58 B B_GENE
( O O
PITSLRE B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
protein O O
kinase O O
( O O
PK O O
) O O
is O O
a O O
member O O
of O O
a O O
large O O
supergene O O
family O O
related O O
to O O
the O O
master B B_GENE
mitotic I I_GENE
protein I I_GENE
kinase I I_GENE
, O O
p34cdc2 B B_GENE
. O O

Maximal O O
exercise O O
duration O O
and O O
peak O O
oxygen O O
consumption O O
were O O
not O O
changed O O
. O O

In O O
contrast O O
, O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
activation O O
was O O
observed O O
in O O
these O O
cells O O
after O O
PMA O O
stimulation O O
. O O

A O O
simple O O
procedure O O
for O O
accurate O O
quantitation O O
of O O
factor B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
VIII I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O O
. O O

Low O O
serum B B_DISEASE/B_GENE
C3 I B_DISEASE/I_GENE
values O O
were O O
observed O O
in O O
all O O
11 O O
children O O
at O O
some O O
stage O O
of O O
their O O
illness O O
. O O

A O O
regression O O
analysis O O
showed O O
that O O
86 O O
% O O
of O O
the O O
variance O O
in O O
weight O O
gain O O
was O O
predicted O O
by O O
two O O
leading O O
indicators O O
in O O
the O O
middle O O
phase O O
of O O
treatment O O
. O O

OBJECTIVE O O
: O O
Respiratory O O
- O O
related O O
electromyographic O O
( O O
EMG O O
) O O
activity O O
of O O
the O O
superior O O
pharyngeal O O
constrictor O O
( O O
SPC O O
) O O
muscle O O
was O O
analyzed O O
during O O
the O O
early O O
stage O O
of O O
forced O O
breathing O O
. O O

Letter O O
: O O
Ballistocardiography O O
. O O

The O O
introduction O O
of O O
FWD1 B B_GENE
into O O
cells O O
significantly O O
promotes O O
ubiquitination O O
and O O
degradation O O
of O O
IkappaBalpha B B_GENE
in O O
concert O O
with O O
IkappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
resulting O O
in O O
nuclear O O
translocation O O
of O O
NF B B_GENE
- I I_GENE
kappaB I I_GENE
. O O

Fosinopril O O
decreased O O
blood O O
pressure O O
from O O
174 O O
/ O O
101 O O
mm O O
Hg O O
to O O
149 O O
/ O O
88 O O
mm O O
Hg O O
in O O
patients O O
with O O
diastolic O O
hypertension O O
and O O
from O O
182 O O
/ O O
86 O O
mm O O
Hg O O
to O O
151 O O
/ O O
80 O O
mm O O
Hg O O
in O O
patients O O
with O O
ISH O O
. O O

Although O O
CB O O
- O O
4 O O
isolates O O
were O O
less O O
resistant O O
to O O
chlorine O O
than O O
CB O O
- O O
5 O O
isolates O O
, O O
after O O
1 O O
, O O
000 O O
min O O
of O O
contact O O
0 O O
. O O
01 O O
% O O
of O O
the O O
input O O
virus O O
was O O
still O O
infectious O O
. O O

The O O
treatment O O
of O O
Sudeck O O
' O O
s O O
atrophy O O
in O O
the O O
upper O O
limb O O
by O O
sympathetic O O
blockade O O
. O O

To O O
assess O O
the O O
effect O O
on O O
thrombus O O
growth O O
, O O
we O O
determined O O
the O O
accretion O O
of O O
125I O O
- O O
labeled O O
fibrinogen B B_GENE
onto O O
autologous O O
non O O
- O O
radioactive O O
thrombi O O
preformed O O
in O O
the O O
jugular O O
veins O O
of O O
rabbits O O
. O O

Thallium O O
- O O
201 O O
scintigraphy O O
after O O
dipyridamole O O
infusion O O
with O O
low O O
level O O
exercise O O
. O O

A O O
kinetic O O
model O O
for O O
99mTc O O
- O O
DMSA O O
in O O
the O O
rat O O
. O O

Crude O O
drugs O O
from O O
aquatic O O
plants O O
. O O

Yet O O
testosterone O O
was O O
predominant O O
in O O
the O O
plasma O O
of O O
the O O
Type O O
II O O
male O O
morph O O
which O O
neither O O
courts O O
females O O
nor O O
nests O O
, O O
but O O
instead O O
parasitizes O O
Type O O
I O O
males O O
with O O
sneak O O
or O O
satellite O O
spawning O O
tactics O O
. O O

Comparison O O
of O O
the O O
therapeutic O O
effectiveness O O
of O O
membrane O O
and O O
centrifugation O O
plasmapheresis O O

Amino O O
- O O
terminal O O
polymorphisms O O
of O O
the O O
human B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
adrenergic I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
impart O O
distinct O O
agonist O O
- O O
promoted O O
regulatory O O
properties O O
. O O

Hence O O
, O O
it O O
is O O
perhaps O O
not O O
necessary O O
to O O
perform O O
spinal O O
puncture O O
if O O
the O O
only O O
purpose O O
is O O
to O O
determine O O
the O O
CSF O O
/ O O
serum O O
ratio O O
. O O

Biochemical O O
experiments O O
and O O
genome O O
sequencing O O
have O O
shown O O
that O O
, O O
despite O O
the O O
prokaryotic O O
cell O O
and O O
genome O O
organization O O
, O O
basal O O
transcriptional O O
elements O O
of O O
members O O
of O O
the O O
domain O O
Archaea O O
( O O
i O O
. O O
e O O
. O O
, O O
TATA O O
box O O
- O O
like O O
sequences O O
, O O
RNA B B_GENE
polymerase I I_GENE
, O O
and O O
transcription O O
factors O O
TBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
TFIIB B B_GENE/B_DISEASE
, O O
and O O
TFIIS B B_GENE/B_DISEASE
) O O
are O O
of O O
the O O
eukaryotic O O
type O O
. O O

Humoral O O
immunity O O
is O O
altered O O
with O O
the O O
drop O O
in O O
IgG B B_GENE
levels O O
. O O

Modified O O
Grocott O O
' O O
s O O
methenamine O O
silver O O
nitrate O O
method O O
for O O
quick O O
staining O O
of O O
Pneumocystis O O
carinii O O
. O O

Additionally O O
, O O
VAHS O O
is O O
often O O
associated O O
with O O
fatal O O
infectious O O
mononucleosis O O
( O O
IM O O
) O O
. O O

RESULTS O O
: O O
In O O
patients O O
with O O
necrotising O O
fasciitis O O
the O O
arterial O O
PO2 O O
rose O O
about O O
7 O O
- O O
fold O O
whereas O O
the O O
arterial O O
PCO2 O O
increased O O
only O O
slightly O O
during O O
exposure O O
to O O
2 O O
. O O
5 O O
absolute O O
atmospheres O O
( O O
ATA O O
) O O
of O O
oxygen O O
. O O

We O O
report O O
on O O
a O O
case O O
of O O
a O O
43 O O
- O O
old O O
- O O
male O O
with O O
a O O
bronchogenic O O
cyst O O
in O O
the O O
distal O O
esophagus O O
, O O
which O O
was O O
misdiagnosed O O
as O O
a O O
malignant O O
esophageal O O
tumor O O
based O O
on O O
preoperative O O
imaging O O
and O O
high O O
levels O O
of O O
the O O
tumor O O
markers O O
CA B B_GENE/B_DISEASE
19 I I_GENE/I_DISEASE
- I I_GENE/I_DISEASE
9 I I_GENE/I_DISEASE
and O O
CA B B_MEASURE/B_GENE
125 I I_MEASURE/I_GENE
. O O

100 O O
and O O
51 O O
p O O
. O O

A O O
plasma O O
cell O O
- O O
rich O O
infiltrate O O
was O O
present O O
in O O
the O O
connective O O
tissue O O
cores O O
of O O
the O O
papillae O O
. O O

Gene B B_GENE/B_DISEASE
GPR I B_GENE/I_DISEASE
51 I B_GENE/I_DISEASE
was O O
localized O O
by O O
radiation O O
hybrid O O
mapping O O
to O O
chromosome O O
9 O O
, O O
4 O O
. O O
81 O O
cR O O
from O O
the O O
WI O O
- O O
8684 O O
marker O O
, O O
and O O
proximal O O
to O O
the O O
hereditary B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sensory I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
neuropathy I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
type I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
locus I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

We O O
conclude O O
that O O
the O O
outcome O O
of O O
patients O O
with O O
uterine O O
MMMT O O
is O O
mainly O O
influenced O O
by O O
the O O
initial O O
stage O O
and O O
the O O
type O O
of O O
epithelial O O
component O O
. O O

Other O O
Fischer O O
- O O
344 O O
rats O O
were O O
also O O
exposed O O
for O O
1 O O
hr O O
to O O
0 O O
. O O
0 O O
or O O
to O O
0 O O
. O O
6 O O
ppm O O
O3 O O
. O O

A O O
computerized O O
database O O
of O O
veterans O O
discharged O O
from O O
the O O
military O O
after O O
1967 O O
was O O
selected O O
as O O
the O O
source O O
because O O
it O O
contains O O
about O O
50 O O
% O O
of O O
the O O
total O O
Vietnam O O
era O O
veteran O O
population O O
, O O
is O O
reasonably O O
unbiased O O
, O O
and O O
provides O O
a O O
feasible O O
method O O
for O O
identifying O O
twins O O
. O O

To O O
examine O O
the O O
functional O O
relationship O O
between O O
distinct O O
cis O O
- O O
active O O
elements O O
within O O
the O O
distal O O
enhancer O O
region O O
of O O
the O O
rat B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PRL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
have O O
used O O
deletional O O
and O O
mutational O O
analysis O O
of O O
that O O
region O O
in O O
transient O O
transfection O O
studies O O
in O O
GH3 O O
pituitary O O
tumor O O
cells O O
. O O

Alcohol O O
and O O
stomach O O
diseases O O

The O O
phosphatidylglycerol B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatidylinositol I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transfer I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PG B B_GENE/B_LOCATION
/ I I_GENE/I_LOCATION
PI I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
TP I I_GENE/I_LOCATION
) O O
is O O
a O O
new O O
and O O
original O O
phospholipid B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transfer I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PLTP B B_GENE/B_DISEASE
) O O
isolated O O
from O O
the O O
Deuteromycete O O
, O O
Aspergillus O O
oryzae O O
. O O

Blotting O O
analysis O O
of O O
intestinal O O
RNA O O
and O O
hybridization O O
of O O
the O O
blots O O
with O O
carboxy O O
apoB B B_GENE/B_MEASURE
cDNA O O
probes O O
produced O O
a O O
single O O
15 O O
- O O
kb O O
hybridization O O
band O O
whereas O O
hybridization O O
with O O
amino O O
terminal O O
probes O O
produced O O
two O O
hybridization O O
bands O O
of O O
15 O O
and O O
8 O O
kb O O
. O O

Influence O O
of O O
long O O
- O O
term O O
zimelidine O O
treatment O O
on O O
LSD O O
- O O
induced O O
behavioural O O
effects O O
. O O

We O O
have O O
determined O O
the O O
molecular O O
organization O O
and O O
transcription O O
start O O
points O O
( O O
tsp O O
) O O
for O O
the O O
murine O O
gene O O
( O O
TK B B_GENE/B_DISEASE
) O O
encoding O O
thymidine B B_GENE
kinase I I_GENE
. O O

Together O O
with O O
a O O
number O O
of O O
phase O O
II O O
trials O O
, O O
phase O O
I O O
trials O O
utilizing O O
escalating O O
doses O O
of O O
carboplatin O O
and O O
paclitaxel O O
with O O
growth O O
factor O O
or O O
growth O O
factor O O
and O O
blood O O
stem O O
- O O
cell O O
support O O
have O O
shown O O
that O O
substantial O O
increases O O
in O O
dose O O
intensity O O
can O O
be O O
achieved O O
. O O

It O O
is O O
an O O
untested O O
argument O O
that O O
conventional O O
beta B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adrenoceptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antagonists O O
possess O O
unwanted O O
metabolic O O
effects O O
that O O
may O O
counter O O
some O O
of O O
their O O
potential O O
cardiac O O
benefits O O
. O O

Genetic O O
polymorphisms O O
in O O
the O O
5 O O
' O O
- O O
flanking O O
region O O
change O O
transcriptional O O
regulation O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytochrome I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P450IIE1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Although O O
the O O
occurrence O O
of O O
any O O
ventricular O O
ectopic O O
activity O O
, O O
as O O
detected O O
by O O
either O O
or O O
both O O
methods O O
, O O
was O O
common O O
, O O
the O O
incidence O O
was O O
significantly O O
higher O O
( O O
P O O
less O O
than O O
0 O O
. O O
001 O O
) O O
in O O
patients O O
with O O
coronary O O
heart O O
disease O O
( O O
86 O O
percent O O
; O O
77 O O
/ O O
90 O O
) O O
, O O
as O O
compared O O
to O O
that O O
in O O
normal O O
subjects O O
( O O
40 O O
percent O O
; O O
12 O O
/ O O
30 O O
) O O
. O O

Increased O O
trabecular O O
spacing O O
, O O
such O O
as O O
it O O
occurs O O
in O O
osteoporosis O O
, O O
reduces O O
the O O
spatial O O
field O O
inhomogeneity O O
and O O
thus O O
prolongs O O
T2 O O
* O O
, O O
which O O
has O O
been O O
shown O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

Healthy O O
preterm O O
infants O O
of O O
gestational O O
age O O
26 O O
- O O
29 O O
weeks O O
showed O O
a O O
' O O
mature O O
' O O
pattern O O
of O O
permeability O O
at O O
birth O O
, O O
followed O O
by O O
a O O
temporary O O
period O O
of O O
enhanced O O
permeability O O
after O O
3 O O
- O O
4 O O
weeks O O
of O O
life O O
. O O

The O O
Brassica B B_GENE/B_BIO
BTH1 I I_GENE/I_BIO
gene I I_GENE/I_BIO
may O O
correspond O O
to O O
the O O
Arabidopsis B B_BIO/B_GENE
TH I I_BIO/I_GENE
- I I_BIO/I_GENE
1 I I_BIO/I_GENE
gene I I_BIO/I_GENE
. O O

The O O
same O O
pattern O O
of O O
firing O O
was O O
seen O O
with O O
saccades O O
in O O
light O O
and O O
in O O
complete O O
darkness O O
. O O

Mutation O O
of O O
the O O
HNF3 B B_GENE/B_MEASURE
element I I_GENE/I_MEASURE
significantly O O
reduced O O
promoter O O
activity O O
in O O
HepG2 O O
cells O O
, O O
whereas O O
this O O
element O O
in O O
isolation O O
conferred O O
HNF3beta B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
responsiveness O O
to O O
a O O
heterologous O O
promoter O O
. O O

The O O
mitochondrial B B_ENZYME[GENE]
tyrosyl I I_ENZYME[GENE]
- I I_ENZYME[GENE]
tRNA I I_ENZYME[GENE]
synthetase I I_ENZYME[GENE]
of O O
Podospora O O
anserina O O
is O O
a O O
bifunctional O O
enzyme O O
active O O
in O O
protein O O
synthesis O O
and O O
RNA O O
splicing O O
. O O

The O O
findings O O
in O O
the O O
human O O
multiple O O
myeloma O O
cell O O
lines O O
represent O O
the O O
first O O
examples O O
of O O
B O O
cells O O
with O O
downregulated O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
and O O
apparently O O
contradict O O
observations O O
in O O
the O O
murine O O
system O O
in O O
which O O
PU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
expressed O O
and O O
active O O
in O O
plasmacytoma O O
cell O O
lines O O
. O O

The O O
traW B B_GENE
gene I I_GENE
of I I_GENE
the I I_GENE
Escherichia I I_GENE
coli I I_GENE
K I I_GENE
- I I_GENE
12 I I_GENE
sex I I_GENE
factor I I_GENE
, O O
F O O
, O O
encodes O O
one O O
of O O
the O O
numerous O O
proteins O O
required O O
for O O
conjugative O O
transfer O O
of O O
this O O
plasmid O O
. O O

Mibefradil O O
( O O
Ro O O
40 O O
- O O
5967 O O
) O O
is O O
a O O
novel O O
nondihydropyridine O O
calcium O O
antagonist O O
. O O

However O O
, O O
technical O O
advances O O
have O O
shown O O
the O O
limitations O O
of O O
these O O
tests O O
as O O
tests O O
for O O
IgM B B_GENE/B_DISEASE
can O O
be O O
positive O O
because O O
of O O
residual O O
specific O O
IgM B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
even O O
in O O
subjects O O
free O O
of O O
acute O O
infection O O
due O O
to O O
the O O
existence O O
of O O
natural O O
interfering O O
IgM B B_GENE/B_BIO
. O O

Carcinogenic O O
action O O
of O O
groundnut O O
meal O O
containing O O
aflatoxin O O
in O O
rats O O
. O O

( O O
1991 O O
) O O
EMBO O O
J O O
. O O

We O O
have O O
utilized O O
transient O O
transfections O O
, O O
mutation O O
analysis O O
, O O
electromobility O O
gel O O
- O O
shifts O O
, O O
and O O
immunoblot O O
analysis O O
to O O
test O O
the O O
hypothesis O O
that O O
expression O O
of O O
the O O
CTalpha B B_GENE
gene I I_GENE
is O O
controlled O O
in O O
part O O
by O O
the O O
binding O O
of O O
three O O
trans O O
- O O
acting O O
nuclear O O
factors O O
, O O
Sp1 B B_GENE/B_LOCATION
, O O
Sp2 B B_GENE
, O O
and O O
Sp3 B B_GENE/B_DISEASE
. O O

AMPK B B_GENE
is O O
a O O
heterotrimer O O
composed O O
of O O
a O O
catalytic O O
subunit O O
( O O
alpha O O
) O O
and O O
two O O
regulatory O O
subunits O O
( O O
beta O O
and O O
gamma O O
) O O
. O O

The O O
evolutionary O O
significance O O
of O O
the O O
similarities O O
of O O
intron O O
secondary O O
structures O O
and O O
open O O
reading O O
frames O O
of O O
the O O
ND3 B B_GENE/B_BIO
, I I_GENE/I_BIO
4 I I_GENE/I_BIO
and I I_GENE/I_BIO
ATPase I I_GENE/I_BIO
6 I I_GENE/I_BIO
genes I I_GENE/I_BIO
is O O
discussed O O
, O O
including O O
the O O
possible O O
separate O O
evolution O O
of O O
structural O O
and O O
coding O O
sequences O O
. O O

Antinuclear O O
antibodies O O
, O O
rheumatoid B B_GENE/B_DISEASE
factor I I_GENE/I_DISEASE
and O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reactive I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
serum O O
of O O
normal O O
women O O
using O O
oral O O
contraceptives O O
. O O

The O O
destruction O O
of O O
the O O
mesometrium O O
did O O
not O O
lengthen O O
the O O
oestrous O O
cycle O O
. O O

Concentrations O O
of O O
platelet O O
nitrite O O
and O O
total O O
nitrate O O
/ O O
nitrite O O
were O O
determined O O
using O O
simple O O
and O O
sensitive O O
nitrate O O
/ O O
nitrite O O
fluorometric O O
assay O O
techniques O O
. O O

Power O O
deposition O O
by O O
inverse O O
- O O
bremsstrahlung O O
is O O
modeled O O
with O O
a O O
scheme O O
based O O
on O O
Gaussian O O
quadrature O O
to O O
accommodate O O
a O O
deposition O O
rate O O
whose O O
spatial O O
variation O O
is O O
highly O O
nonuniform O O
. O O

The O O
sulfur O O
species O O
could O O
be O O
separated O O
within O O
less O O
than O O
4 O O
min O O
by O O
CZE O O
with O O
a O O
pyromellitic O O
acid O O
electrolyte O O
at O O
pH O O
3 O O
. O O
5 O O
to O O
5 O O
. O O
0 O O
. O O

After O O
discharge O O
, O O
he O O
was O O
finally O O
given O O
a O O
diagnosis O O
of O O
PCH O O
because O O
a O O
Donath O O
- O O
Landsteiner O O
test O O
was O O
positive O O
. O O

The O O
second O O
intron O O
is O O
the O O
smallest O O
of O O
all O O
the O O
introns O O
( O O
116 O O
bp O O
) O O
. O O

Expression O O
of O O
the O O
gene O O
encoding O O
transcription B B_GENE
factor I I_GENE
cyclic I I_GENE
adenosine I I_GENE
3 I I_GENE
' I I_GENE
, I I_GENE
5 I I_GENE
' I I_GENE
- I I_GENE
monophosphate I I_GENE
( I I_GENE
cAMP I I_GENE
) I I_GENE
response I I_GENE
element I I_GENE
- I I_GENE
binding I I_GENE
protein I I_GENE
( O O
CREB B B_GENE/B_DISEASE
) O O
: O O
regulation O O
by O O
follicle B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulating I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
induced O O
cAMP O O
signaling O O
in O O
primary O O
rat O O
Sertoli O O
cells O O
. O O

Efficacy O O
was O O
evaluated O O
in O O
24 O O
patients O O
, O O
of O O
whom O O
eight O O
received O O
RD O O
and O O
16 O O
SD O O
. O O

A O O
silica O O
- O O
based O O
, O O
fluoride O O
- O O
free O O
placebo O O
containing O O
NaTPP O O
, O O
and O O
a O O
NaF O O
- O O
containing O O
silica O O
- O O
based O O
USP O O
reference O O
standard O O
toothpaste O O
were O O
used O O
as O O
negative O O
and O O
positive O O
control O O
toothpastes O O
, O O
respectively O O
. O O

The O O
overall O O
response O O
rate O O
including O O
CR O O
and O O
PR O O
was O O
23 O O
. O O
5 O O
% O O
( O O
4 O O
/ O O
17 O O
) O O
. O O

High O O
and O O
pathological O O
PAI B B_GENE
- I I_GENE
1 I I_GENE
levels O O
before O O
and O O
after O O
the O O
VO O O
test O O
were O O
consistent O O
with O O
a O O
defective O O
fibrinolytic O O
potential O O
due O O
to O O
the O O
inhibitory O O
effect O O
of O O
PAI B B_PROTEIN[GENE]/B_DISEASE
- I I_PROTEIN[GENE]/I_DISEASE
1 I I_PROTEIN[GENE]/I_DISEASE
on O O
plasminogen B B_GENE
activation O O
. O O

During O O
hexamethylene O O
bisactamide O O
( O O
HMBA O O
) O O
- O O
induced O O
differentiation O O
of O O
murine O O
erythroleukemia O O
( O O
MEL O O
) O O
cells O O
erythroid O O
genes O O
are O O
transcriptionally O O
activated O O
while O O
c B B_GENE
- I I_GENE
myb I I_GENE
and O O
several O O
other O O
nuclear O O
proto O O
- O O
oncogenes O O
are O O
down O O
- O O
regulated O O
. O O

The O O
recovery O O
of O O
adults O O
schistosomes O O
by O O
extracorporeal O O
filtration O O
. O O

Torsion O O
of O O
the O O
contralateral O O
testis O O
5 O O
years O O
after O O
orchiopexy O O
. O O

Frequency O O
of O O
recurrence O O
of O O
fibroids O O
after O O
myomectomy O O
has O O
been O O
evaluated O O
in O O
145 O O
women O O
( O O
median O O
age O O
38 O O
years O O
, O O
range O O
21 O O
- O O
52 O O
) O O
who O O
underwent O O
myomectomy O O
. O O

Ethanol O O
preference O O
in O O
strains O O
of O O
rats O O
selectively O O
bred O O
for O O
behavioral O O
characteristics O O
. O O

Nuclear O O
proteins O O
bound O O
the O O
cad B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
55 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
75 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
cell O O
cycle O O
- O O
dependent O O
manner O O
in O O
electromobility O O
shift O O
assays O O
; O O
antibodies O O
specific O O
to O O
USF B B_PERSON/B_GENE
and O O
Max B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
blocked O O
the O O
DNA O O
- O O
binding O O
activity O O
of O O
different O O
growth O O
- O O
regulated O O
protein O O
- O O
DNA O O
complexes O O
. O O

Thus O O
, O O
an O O
unmodified O O
threonine O O
at O O
position O O
169 O O
in O O
Cdc28 B B_GENE
is O O
important O O
for O O
interaction O O
with O O
G1 B B_GENE
cyclins I I_GENE
. O O

Additional O O
genetic O O
analyses O O
described O O
herein O O
suggest O O
that O O
Skb1 B B_GENE
is O O
a O O
component O O
of O O
the O O
morphology O O
control O O
branch O O
of O O
the O O
Ras B B_GENE/B_DISEASE
signaling O O
cascade O O
in O O
S O O
. O O
pombe O O
and O O
that O O
it O O
positively O O
modulates O O
Shk1 B B_GENE
function O O
. O O

Recent O O
studies O O
have O O
concentrated O O
on O O
the O O
methods O O
of O O
preparation O O
of O O
coffee O O
, O O
which O O
vary O O
from O O
country O O
to O O
country O O
. O O

In O O
this O O
report O O
, O O
we O O
investigated O O
whether O O
the O O
cleavage O O
of O O
the O O
RRKR O O
motif O O
of O O
MT B B_GENE
- I I_GENE
MMP1 I I_GENE
by O O
Golgi B B_GENE
- I I_GENE
associated I I_GENE
furin I I_GENE
is O O
analogous O O
to O O
a O O
similar O O
enzyme O O
activation O O
mechanism O O
observed O O
with O O
stromelysin B B_GENE
- I I_GENE
3 I I_GENE
. O O

Coexpression O O
of O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
altered O O
the O O
cell O O
specificity O O
. O O

A O O
preterm O O
formula O O
with O O
a O O
traditional O O
corn O O
oil O O
/ O O
MCT O O
blend O O
containing O O
38 O O
% O O
MCTs O O
( O O
MCT O O
group O O
) O O
was O O
compared O O
to O O
a O O
new O O
fat O O
blend O O
, O O
designed O O
to O O
resemble O O
human O O
milk O O
more O O
, O O
containing O O
6 O O
% O O
MCTs O O
( O O
LCT O O
group O O
) O O
. O O

Phenylalanine O O
and O O
tyrosine O O
levels O O
were O O
higher O O
in O O
those O O
who O O
received O O
Vamin O O
9 O O
glucose O O
but O O
55 O O
% O O
of O O
infants O O
given O O
Vamin O O
Infant O O
had O O
tyrosine O O
levels O O
below O O
the O O
lower O O
limit O O
of O O
the O O
target O O
range O O
. O O

We O O
sought O O
to O O
test O O
whether O O
a O O
prolonged O O
infusion O O
of O O
magnesium O O
sulfate O O
( O O
MgSO O O
( O O
4 O O
) O O
; O O
40 O O
mmol O O
/ O O
24 O O
hours O O
) O O
would O O
normalize O O
QT O O
interval O O
variability O O
in O O
patients O O
with O O
compensated O O
heart O O
failure O O
. O O

Escherichia O O
coli O O
strains O O
carrying O O
recA730 B B_GENE/B_LOCATION
( O O
or O O
other O O
recA B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
* I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
alleles I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) O O
exhibit O O
dramatic O O
increases O O
in O O
SOS O O
- O O
dependent O O
spontaneous O O
mutator O O
activity O O
. O O

Outlook O O
in O O
oral O O
and O O
cutaneous O O
Kaposi O O
' O O
s O O
sarcoma O O
. O O

We O O
report O O
the O O
complete O O
nucleotide O O
sequence O O
of O O
the O O
camC B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
along O O
with O O
155 O O
base O O
pairs O O
of O O
5 O O
' O O
and O O
175 O O
base O O
pairs O O
of O O
3 O O
' O O
flanking O O
sequence O O
. O O

However O O
, O O
it O O
is O O
only O O
loosely O O
associated O O
, O O
or O O
not O O
associated O O
, O O
with O O
viral O O
particles O O
. O O

gp170 B B_PROTEIN[GENE]/B_DISEASE
is O O
generated O O
by O O
an O O
alternatively O O
spliced O O
Env B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O O
a O O
splice O O
donor O O
and O O
splice O O
acceptor O O
pair O O
localized O O
within O O
the O O
env B B_GENE
open I I_GENE
reading I I_GENE
frame I I_GENE
( I I_GENE
ORF I I_GENE
) I I_GENE
, O O
which O O
is O O
normally O O
used O O
to O O
generate O O
Bell B B_GENE/B_LOCATION
and O O
Bet B B_GENE/B_BIO
transcripts I I_GENE/I_BIO
derived O O
from O O
the O O
internal O O
promoter O O
within O O
the O O
env B B_GENE/B_VIRUS[BIO]
ORF I I_GENE/I_VIRUS[BIO]
. O O

gp170 B B_GENE/B_DISEASE
is O O
expressed O O
at O O
a O O
level O O
30 O O
to O O
50 O O
% O O
of O O
the O O
Env B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
precursor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gp130 B B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Experimental O O
production O O
of O O
a O O
syndrome O O
analogous O O
to O O
hydramnios O O
in O O
the O O
rat O O
fetus O O

Total O O
cross O O
sections O O
for O O
electron O O
scattering O O
by O O
CO2 O O
molecules O O
in O O
the O O
energy O O
range O O
400 O O
- O O
5000 O O
eV O O
. O O

Thus O O
, O O
the O O
cognitive O O
performance O O
of O O
elderly O O
subjects O O
could O O
be O O
trained O O
to O O
a O O
large O O
extent O O
. O O

Partial O O
albinism O O
and O O
immunodeficiency O O
: O O
ultrastructural O O
study O O
of O O
haemophagocytosis O O
and O O
bone O O
marrow O O
erythroblasts O O
in O O
one O O
case O O
. O O

Residues O O
that O O
affect O O
PLCbeta B B_GENE
and O O
adenylyl B B_GENE
cyclase I I_GENE
II I I_GENE
activity O O
are O O
found O O
on O O
opposite O O
sides O O
of O O
the O O
central O O
tunnel O O
, O O
suggesting O O
that O O
PLC B B_GENE/B_DISEASE
and O O
adenylyl B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cyclase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
like O O
the O O
alpha O O
subunit O O
, O O
make O O
many O O
contacts O O
on O O
the O O
top O O
surface O O
. O O

The O O
dynamics O O
of O O
protozoa O O
were O O
studied O O
in O O
two O O
groups O O
of O O
rumen O O
- O O
fistulated O O
cattle O O
fed O O
on O O
a O O
basal O O
diet O O
of O O
molasses O O
ad O O
lib O O
. O O
, O O
with O O
oaten O O
chaff O O
given O O
at O O
6 O O
or O O
18 O O
g O O
/ O O
kg O O
live O O
weight O O
. O O

The O O
CBS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
mapped O O
to O O
human O O
chromosome O O
10p12 O O
between O O
markers O O
WI B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8535 I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
WI B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
4724 I I_MEASURE/I_GENE
, O O
and O O
is O O
tightly O O
linked O O
to O O
the O O
two O O
STRP O O
markers O O
of O O
D10S1789 B B_GENE/B_LOCATION
and O O
D10S550 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Value O O
of O O
bone O O
scintigraphy O O
with O O
Tc99MDP O O
in O O
the O O
early O O
diagnosis O O
of O O
mobilization O O
of O O
the O O
total O O
hip O O
prosthesis O O

Youssoufian O O
, O O
A O O
. O O

The O O
dipper O O
( O O
RONF O O
of O O
BP O O
( O O
or O O
HR O O
) O O
> O O
or O O
= O O
10 O O
% O O
2 O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
have O O
investigated O O
the O O
effects O O
of O O
SDZ O O
ENA O O
713 O O
on O O
spatial O O
learning O O
deficits O O
in O O
aged O O
rats O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
A O O
seven O O
- O O
wavelength O O
frequency O O
- O O
domain O O
photon O O
migration O O
probe O O
was O O
used O O
to O O
perform O O
noninvasive O O
NIR O O
measurements O O
in O O
the O O
breasts O O
of O O
28 O O
healthy O O
women O O
, O O
both O O
pre O O
- O O
and O O
postmenopausal O O
, O O
aged O O
18 O O
- O O
64 O O
years O O
. O O

YACs O O
, O O
BACs O O
, O O
cosmids O O
, O O
and O O
STSs O O
are O O
defined O O
to O O
aid O O
in O O
further O O
study O O
of O O
this O O
gene O O
. O O

The O O
MEF B B_GENE/B_BIO
- I I_GENE/I_BIO
2 I I_GENE/I_BIO
proteins I I_GENE/I_BIO
are O O
a O O
family O O
of O O
transcriptional O O
activators O O
that O O
have O O
been O O
detected O O
in O O
a O O
wide O O
variety O O
of O O
cell O O
types O O
. O O

The O O
ferric B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
uptake I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
regulation I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
fur B B_BIO/B_PROTEIN[GENE]
) O O
gene O O
product O O
participates O O
in O O
regulating O O
expression O O
of O O
the O O
manganese O O
- O O
and O O
iron O O
- O O
containing O O
superoxide B B_PROTEIN[GENE]/B_BACTERIUM[BIO]
dismutase I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
genes I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
of I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
Escherichia I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
coli I I_PROTEIN[GENE]/I_BACTERIUM[BIO]
. O O

To O O
date O O
, O O
6 O O
mammalian O O
GRKs B B_GENE/B_BIO
have O O
been O O
identified O O
by O O
molecular O O
cloning O O
. O O

The O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
investigate O O
the O O
influence O O
of O O
long O O
term O O
intravenous O O
administration O O
of O O
naftidrofuryl O O
( O O
Dusodril O O
- O O
Lipha O O
Arzn O O
) O O
twice O O
daily O O
in O O
a O O
dose O O
of O O
200 O O
mg O O
in O O
continuous O O
, O O
4 O O
- O O
hour O O
infusion O O
in O O
500 O O
ml O O
0 O O
. O O
9 O O
% O O
NaCl O O
to O O
the O O
patients O O
suffering O O
from O O
a O O
peripheral O O
arterial O O
occlusive O O
disease O O
( O O
PAOD O O
) O O
in O O
a O O
clinical O O
condition O O
with O O
special O O
attention O O
paid O O
to O O
transcutaneous O O
partial O O
oxygen O O
pressure O O
measurements O O
( O O
tcPO2 O O
) O O
and O O
rheographic O O
parameters O O
. O O

Judge O O
Christian O O
Byk O O
renders O O
service O O
to O O
the O O
Steering O O
Committee O O
on O O
Bioethics O O
of O O
the O O
Council O O
of O O
Europe O O
( O O
CDBI O O
) O O
by O O
proposing O O
a O O
draft O O
of O O
the O O
protocol O O
destined O O
to O O
fill O O
in O O
a O O
gap O O
in O O
international O O
law O O
on O O
the O O
status O O
of O O
the O O
human O O
embryo O O
. O O

We O O
found O O
both O O
the O O
v B B_PROTEIN[GENE]/B_LOCATION
- I B_PROTEIN[GENE]/I_LOCATION
Ras I B_PROTEIN[GENE]/I_LOCATION
- O O
and O O
PC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PLC I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
transformed O O
cells O O
to O O
be O O
insensitive O O
to O O
stimulation O O
with O O
platelet B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
derived I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PDGF B B_GENE
) O O
. O O

The O O
patient O O
groups O O
consisted O O
of O O
31 O O
with O O
dilated O O
cardiomyopathy O O
, O O
22 O O
with O O
hypertrophic O O
cardiomyopathy O O
, O O
38 O O
with O O
myocardial O O
infarction O O
, O O
15 O O
with O O
angina O O
pectoris O O
and O O
26 O O
with O O
rheumatic O O
valvular O O
disease O O
. O O

100 O O
. O O

Whereas O O
Sprague O O
- O O
Dawleys O O
displayed O O
lights O O
- O O
off O O
and O O
lights O O
- O O
on O O
peaks O O
of O O
ingestive O O
activity O O
, O O
only O O
a O O
minority O O
of O O
Fisher O O
- O O
344s O O
displayed O O
a O O
consistent O O
lights O O
- O O
on O O
peak O O
of O O
ingestive O O
activity O O
. O O

RESULTS O O
: O O
In O O
76 O O
trials O O
, O O
5 O O
, O O
351 O O
patients O O
received O O
24 O O
different O O
regimens O O
of O O
droperidol O O
. O O

The O O
tro B B_GENE/B_LOCATION
operon I I_GENE/I_LOCATION
is O O
flanked O O
by O O
a O O
Holliday B B_GENE
structure I I_GENE
DNA I I_GENE
helicase I I_GENE
homolog O O
( O O
upstream O O
) O O
and O O
two O O
ORFs O O
representing O O
a O O
purine B B_ENZYME[GENE]/B_SPECIES[BIO]
nucleoside I B_ENZYME[GENE]/I_SPECIES[BIO]
phosphorylase I B_ENZYME[GENE]/I_SPECIES[BIO]
homolog O O
and O O
tpp15 B B_GENE/B_LOCATION
, O O
a O O
previously O O
characterized O O
gene O O
encoding O O
a O O
membrane O O
lipoprotein O O
( O O
downstream O O
) O O
. O O

We O O
report O O
nine O O
consecutive O O
cases O O
of O O
ACB O O
, O O
which O O
occurred O O
in O O
five O O
males O O
and O O
four O O
females O O
and O O
were O O
detected O O
in O O
11 O O
, O O
159 O O
routine O O
spiral O O
CT O O
examinations O O
of O O
the O O
chest O O
, O O
performed O O
between O O
1994 O O
and O O
1998 O O
. O O

In O O
order O O
to O O
search O O
for O O
mutations O O
in O O
the O O
multicopy B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RBM I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
might O O
be O O
associated O O
with O O
male O O
infertility O O
, O O
we O O
have O O
used O O
sequence O O
data O O
from O O
the O O
reported O O
cDNA O O
clone O O
to O O
determine O O
the O O
intron O O
exon O O
boundaries O O
of O O
the O O
YRRM B B_GENE
1 I I_GENE
gene I I_GENE
. O O

98 O O
, O O
93 O O
- O O
98 O O
) O O
. O O

Studies O O
on O O
the O O
excretion O O
of O O
selenium O O
in O O
urine O O
and O O
feces O O
and O O
distribution O O
in O O
the O O
organs O O
of O O
rats O O
by O O
a O O
method O O
of O O
radioactivity O O
measurement O O

Gastric O O
secretory O O
inhibition O O
induced O O
by O O
three O O
methyl O O
analogs O O
of O O
prostaglandin O O
E2 O O
administered O O
intragastrically O O
to O O
man O O
. O O

By O O
RT O O
- O O
PCR O O
, O O
different O O
levels O O
of O O
E75 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
can O O
be O O
detected O O
in O O
the O O
epidermis O O
, O O
nerve O O
cord O O
and O O
the O O
eyestalk O O
of O O
early O O
pre O O
- O O
molt O O
shrimp O O
. O O

The O O
vicinity O O
of O O
large O O
industrial O O
emissions O O
of O O
lead O O
, O O
where O O
mean O O
Pb O O
- O O
B O O
concentrations O O
were O O
usually O O
twice O O
as O O
high O O
as O O
in O O
rural O O
areas O O
of O O
the O O
Katowice O O
voivodship O O
. O O

Forty O O
- O O
five O O
per O O
cent O O
of O O
the O O
dose O O
was O O
excreted O O
as O O
methyldopa O O
as O O
opposed O O
to O O
18 O O
% O O
normally O O
seen O O
after O O
oral O O
methyldopa O O
dosages O O
. O O

A O O
phylogenetic O O
comparison O O
of O O
32 O O
species O O
showed O O
minor O O
differences O O
in O O
the O O
apoB B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
apoB B B_GENE
mRNA I I_GENE
from O O
31 O O
species O O
was O O
robustly O O
edited O O
in O O
vitro O O
. O O

The O O
other O O
five O O
from O O
within O O
the O O
SRO O O
may O O
provide O O
an O O
entrance O O
point O O
for O O
the O O
cloning O O
of O O
candidate O O
genes O O
for O O
neuroblastoma O O
. O O

Sugar O O
analysis O O
was O O
performed O O
on O O
alpha B B_BIO/B_GENE
- I I_BIO/I_GENE
TM I I_BIO/I_GENE
to O O
investigate O O
a O O
possible O O
biosynthetic O O
mechanism O O
for O O
part O O
- O O
time O O
PGs O O
. O O

Pediatric O O
patients O O
- O O
- O O
handle O O
with O O
care O O
. O O

TRAF2 B B_GENE/B_DISEASE
has O O
previously O O
been O O
demonstrated O O
to O O
activate O O
both O O
transcription O O
factor O O
nuclear B B_PROTEIN[GENE]/B_MEASURE
factor I I_PROTEIN[GENE]/I_MEASURE
kappaB I I_PROTEIN[GENE]/I_MEASURE
( O O
NFkappaB B B_GENE/B_LOCATION
) O O
and O O
the O O
c B B_GENE
- I I_GENE
Jun I I_GENE
N I I_GENE
- I I_GENE
terminal I I_GENE
kinase I I_GENE
/ O O
stress B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
JNK B B_GENE/B_LOCATION
/ O O
SAPK B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
pathway O O
, O O
which O O
in O O
turn O O
stimulates O O
transcription B B_GENE
factor I I_GENE
activating I I_GENE
protein I I_GENE
1 I I_GENE
( O O
AP1 B B_GENE/B_DISEASE
) O O
mainly O O
via O O
phosphorylation O O
of O O
the O O
c B B_GENE
- I I_GENE
Jun I I_GENE
component O O
. O O

A O O
procaryotic O O
regulatory O O
factor O O
with O O
a O O
histone B B_GENE
H1 I I_GENE
- I I_GENE
like I I_GENE
carboxy I I_GENE
- I I_GENE
terminal I I_GENE
domain I I_GENE
: O O
clonal O O
variation O O
of O O
repeats O O
within O O
algP B B_GENE
, O O
a O O
gene O O
involved O O
in O O
regulation O O
of O O
mucoidy O O
in O O
Pseudomonas O O
aeruginosa O O
. O O

The O O
host O O
range O O
( O O
HR O O
) O O
of O O
poliovirus O O
is O O
thought O O
to O O
be O O
primarily O O
determined O O
by O O
a O O
cell O O
surface O O
molecule O O
that O O
functions O O
as O O
poliovirus B B_GENE/B_BIO
receptor I I_GENE/I_BIO
( O O
PVR B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
since O O
it O O
has O O
been O O
shown O O
that O O
transgenic O O
mice O O
are O O
made O O
poliovirus O O
sensitive O O
by O O
introducing O O
the O O
human B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
PVR I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
into O O
the O O
genome O O
. O O

Human B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
alcohol I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ADH B B_DISEASE/B_GENE
) O O
exists O O
as O O
a O O
heterogeneous O O
group O O
of O O
isozymes O O
capable O O
of O O
oxidizing O O
a O O
wide O O
variety O O
of O O
aliphatic O O
and O O
aromatic O O
alcohols O O
. O O

The O O
control O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
aromatase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
is O O
complex O O
in O O
that O O
several O O
promoters O O
drive O O
aromatase B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
in O O
a O O
tissue O O
- O O
specific O O
manner O O
. O O

In O O
addition O O
, O O
renal O O
sympathetic O O
activity O O
was O O
measured O O
in O O
a O O
separate O O
group O O
of O O
rats O O
. O O

Bodily O O
referents O O
and O O
the O O
experience O O
of O O
affect O O
. O O

The O O
effect O O
of O O
the O O
negative O O
regulatory O O
element O O
is O O
negated O O
by O O
the O O
viral B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IE2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
L O O
. O O

RXRalpha B B_GENE/B_LOCATION
/ O O
RARalpha B B_GENE
heterodimers O O
and O O
HNF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bind O O
to O O
DR O O
- O O
1 O O
motifs O O
on O O
elements O O
B O O
and O O
I4 O O
, O O
respectively O O
. O O

Evidence O O
for O O
involvement O O
of O O
proteins O O
HU B B_GENE/B_DISEASE
and O O
RpoS B B_PROTEIN[GENE]/B_LOCATION
in O O
transcription O O
of O O
the O O
osmoresponsive O O
proU B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
operon I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
Escherichia O O
coli O O
. O O

However O O
, O O
a O O
lesser O O
extent O O
effect O O
was O O
noticed O O
in O O
nonpregnant O O
than O O
seen O O
in O O
pregnant O O
rats O O
. O O

Morphine O O
administration O O
acutely O O
reduced O O
plasma O O
clearance O O
of O O
sulfobromophthalein O O
( O O
BSP O O
) O O
in O O
mice O O
and O O
increased O O
hepatic O O
retention O O
of O O
this O O
dye O O
. O O

Buchstein O O
, O O
L O O
. O O
- O O
L O O
. O O

Intraspinal O O
and O O
mediastinal O O
foregut O O
cyst O O
compressing O O
the O O
spinal O O
cord O O
. O O

The O O
nutraceuticals O O
of O O
specific O O
vitamins O O
, O O
minerals O O
, O O
phytoestrogens O O
, O O
and O O
essential O O
fatty O O
acid O O
supplementations O O
are O O
a O O
vital O O
component O O
of O O
the O O
risk O O
reduction O O
health O O
program O O
. O O

Characterization O O
of O O
a O O
unique O O
protein O O
component O O
of O O
yeast B B_SPECIES[BIO]/B_ENZYME[GENE]
RNase I I_SPECIES[BIO]/I_ENZYME[GENE]
MRP I I_SPECIES[BIO]/I_ENZYME[GENE]
: O O
an O O
RNA O O
- O O
binding O O
protein O O
with O O
a O O
zinc O O
- O O
cluster O O
domain O O
. O O

The O O
present O O
study O O
indicates O O
that O O
the O O
high O O
- O O
dose O O
5 O O
- O O
fluorouracil O O
regimen O O
shows O O
weak O O
activity O O
in O O
advanced O O
pancreatic O O
cancer O O
which O O
seems O O
comparable O O
to O O
gemcitabine O O
. O O

Like O O
the O O
nuclear O O
envelope O O
, O O
the O O
intranuclear O O
double O O
membrane O O
lamellae O O
enclosed O O
a O O
defined O O
cisterna O O
that O O
was O O
interrupted O O
by O O
pores O O
but O O
, O O
unlike O O
the O O
nuclear O O
envelope O O
pores O O
, O O
they O O
lacked O O
NPCs O O
. O O

The O O
22 O O
- O O
d O O
orbital O O
flight O O
of O O
rats O O
onboard O O
the O O
Cosmos O O
- O O
605 O O
biosatellite O O
was O O
followed O O
by O O
inhibition O O
of O O
erythroblastosis O O
, O O
alteration O O
in O O
the O O
morphology O O
of O O
megakaryocytes O O
, O O
and O O
stimulation O O
of O O
myelopoiesis O O
. O O

An O O
OD O O
650 O O
greater O O
than O O
0 O O
. O O
15 O O
appears O O
to O O
be O O
a O O
rapid O O
, O O
reliable O O
indicator O O
of O O
fetal O O
lung O O
maturity O O
. O O

The O O
role O O
of O O
PORT O O
in O O
the O O
treatment O O
of O O
N2 O O
tumours O O
is O O
not O O
clear O O
and O O
may O O
justify O O
further O O
research O O
. O O

We O O
concluded O O
that O O
RXR B B_GENE
- I I_GENE
gamma I I_GENE
induced O O
terminal O O
differentiation O O
in O O
SCC O O
lines O O
, O O
suggesting O O
a O O
potential O O
tumor O O
suppressor O O
function O O
for O O
this O O
transcription O O
factor O O
. O O

Phosphorylated O O
tyrosine O O
residues O O
were O O
subsequently O O
identified O O
by O O
sequencing O O
the O O
separated O O
phosphopeptides O O
by O O
matrix O O
assisted O O
laser O O
desorption O O
ionization O O
mass O O
spectrometry O O
( O O
MALDI O O
- O O
MS O O
) O O
and O O
Edman O O
degradation O O
. O O

The O O
infection O O
of O O
cells O O
with O O
Moloney O O
murine O O
leukemia O O
virus O O
( O O
M O O
- O O
MuLV O O
) O O
causes O O
an O O
increase O O
in O O
specific O O
cellular O O
gene O O
products O O
, O O
including O O
the O O
major B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MHC I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
data O O
demonstrate O O
that O O
oleosin B B_GENE
gene I I_GENE
transcription O O
is O O
regulated O O
in O O
a O O
tissue O O
- O O
specific O O
and O O
temporally O O
regulated O O
manner O O
and O O
clearly O O
indicate O O
that O O
oleosin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O O
is O O
co O O
- O O
ordinated O O
primarily O O
at O O
the O O
transcriptional O O
level O O
. O O

Myocardial O O
technetium O O
- O O
99m O O
- O O
teboroxime O O
uptake O O
during O O
adenosine O O
- O O
induced O O
hyperemia O O
in O O
dogs O O
with O O
either O O
a O O
critical O O
or O O
mild O O
coronary O O
stenosis O O
: O O
comparison O O
to O O
thallium O O
- O O
201 O O
and O O
regional O O
blood O O
flow O O
. O O

Although O O
immunoglobulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
CRP B B_GENE
concentration O O
increased O O
, O O
anemia O O
obviously O O
improved O O
with O O
hemoglobin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
levels O O
increasing O O
from O O
4 O O
. O O
8 O O
g O O
/ O O
dl O O
to O O
8 O O
. O O
5 O O
g O O
/ O O
dl O O
without O O
any O O
side O O
effects O O
. O O

Diff O O
- O O
Quik O O
stain O O
for O O
Tzanck O O
smears O O
. O O

Experience O O
in O O
using O O
the O O
Romashka O O
- O O
1 O O
laser O O
surgical O O
unit O O
in O O
treating O O
suppurative O O
wounds O O

At O O
D28 O O
, O O
149 O O
of O O
386 O O
patients O O
( O O
49 O O
% O O
) O O
had O O
had O O
episodes O O
of O O
automatic O O
mode O O
switch O O
prompted O O
by O O
atrial O O
arrhythmias O O
. O O

Together O O
, O O
these O O
results O O
implicate O O
Fal1p B B_GENE
in O O
the O O
18S B B_GENE
rRNA I I_GENE
maturation O O
pathway O O
rather O O
than O O
in O O
translation O O
initiation O O
. O O

Most O O
other O O
differences O O
between O O
these O O
two O O
Leporipoxviruses O O
are O O
located O O
in O O
the O O
telomeres O O
. O O

We O O
challenge O O
each O O
of O O
55 O O
consecutive O O
ragweed O O
( O O
RW O O
) O O
- O O
allergic O O
patients O O
with O O
hay O O
fever O O
and O O
with O O
graded O O
increasing O O
doses O O
of O O
ragweed O O
extract O O
to O O
investigate O O
the O O
frequency O O
and O O
relationship O O
between O O
the O O
early O O
( O O
ER O O
) O O
, O O
late O O
( O O
LPR O O
) O O
, O O
and O O
rechallenge O O
reactions O O
( O O
RCRs O O
) O O
to O O
nasal O O
challenge O O
. O O

The O O
expression O O
of O O
CAPL B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
second O O
protein O O
involved O O
in O O
calcium O O
metabolism O O
, O O
was O O
only O O
moderately O O
elevated O O
in O O
the O O
doxorubicin O O
- O O
resistant O O
cells O O
. O O

ANL O O
- O O
7535 O O
. O O

The O O
QCS O O
appears O O
comparable O O
with O O
the O O
MMSE O O
and O O
is O O
quicker O O
to O O
administer O O
. O O

We O O
used O O
high O O
- O O
resolution O O
ultrasound O O
to O O
characterize O O
postprandial O O
antral O O
excursion O O
characteristics O O
in O O
15 O O
healthy O O
volunteers O O
. O O

Copyright O O
1998 O O
Academic O O
Press O O
. O O

Human B B_GENE
PDNP3 I I_GENE
is O O
expressed O O
in O O
glioma O O
cells O O
, O O
prostate O O
, O O
and O O
uterus O O
, O O
but O O
not O O
in O O
the O O
alimentary O O
tract O O
. O O

Epithelial O O
cells O O
had O O
abnormal O O
and O O
accelerated O O
exfoliation O O
which O O
resulted O O
in O O
multifocal O O
epithelial O O
defects O O
. O O

Tight O O
- O O
binding O O
band O O
structure O O
calculations O O
for O O
beta O O
- O O
MNX O O
( O O
M O O
= O O
Zr O O
, O O
X O O
= O O
Cl O O
, O O
Br O O
; O O
M O O
= O O
Hf O O
, O O
X O O
= O O
Cl O O
) O O
, O O
ZrCl O O
, O O
and O O
Y O O
( O O
2 O O
) O O
C O O
( O O
2 O O
) O O
Br O O
( O O
2 O O
) O O
are O O
reported O O
. O O

The O O
psychosomatic O O
approach O O
to O O
temporomandibular O O
arthrosis O O

The O O
rate O O
of O O
decrease O O
of O O
PRA O O
after O O
REM O O
onset O O
closely O O
approximates O O
the O O
most O O
recent O O
estimations O O
of O O
PRA O O
half O O
- O O
life O O
, O O
which O O
suggests O O
that O O
REM O O
onset O O
is O O
associated O O
with O O
a O O
virtual O O
cessation O O
in O O
renin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O O
. O O

Similarly O O
, O O
interfering O O
with O O
MEKK B B_GENE
, O O
which O O
lies O O
upstream O O
of O O
JNK1 B B_GENE
, O O
using O O
a O O
dominant O O
negative O O
expression O O
vector O O
reduced O O
MMP B B_GENE
- I I_GENE
9 I I_GENE
promoter I I_GENE
activity O O
over O O
the O O
same O O
concentration O O
range O O
which O O
repressed O O
the O O
AP B B_GENE
- I I_GENE
1 I I_GENE
- O O
thymidine B B_GENE
kinase I I_GENE
CAT B I_GENE
reporter O O
construct O O
. O O

There O O
was O O
no O O
difference O O
in O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
albumin I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
transferrin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
levels O O
, O O
but O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
prealbumin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O O
in O O
the O O
group O O
fed O O
early O O
were O O
more O O
desirable O O
than O O
those O O
of O O
the O O
control O O
group O O
( O O
from O O
15 O O
. O O
8 O O
+ O O
/ O O
- O O
2 O O
. O O
5 O O
mg O O
/ O O
dl O O
to O O
28 O O
. O O
9 O O
+ O O
/ O O
- O O
3 O O
. O O
8 O O
mg O O
/ O O
dl O O
vs O O
from O O
18 O O
. O O
0 O O
+ O O
/ O O
- O O
2 O O
. O O
0 O O
mg O O
/ O O
dl O O
to O O
25 O O
. O O
9 O O
+ O O
/ O O
- O O
3 O O
. O O
9 O O
mg O O
/ O O
dl O O
) O O
. O O

The O O
repeats O O
are O O
highly O O
conserved O O
both O O
within O O
a O O
given O O
element O O
as O O
well O O
as O O
between O O
different O O
members O O
of O O
the O O
family O O
( O O
less O O
than O O
10 O O
% O O
divergence O O
) O O
. O O

Utility O O
of O O
thallium O O
- O O
201 O O
scintigraphy O O
in O O
detecting O O
right O O
ventricular O O
dysfunction O O
in O O
pulmonary O O
embolism O O
. O O

CONCLUSIONS O O
: O O
The O O
system O O
developed O O
in O O
this O O
study O O
can O O
be O O
used O O
as O O
a O O
method O O
to O O
detect O O
air O O
- O O
trapping O O
during O O
TGI O O
. O O

Pollinosis O O
in O O
the O O
U O O
. O O
A O O
. O O
R O O
. O O

Northern O O
blot O O
analysis O O
of O O
enoyl B B_GENE/B_BIO
- I I_GENE/I_BIO
ACP I I_GENE/I_BIO
reductase I I_GENE/I_BIO
mRNA I I_GENE/I_BIO
steady O O
- O O
state O O
levels O O
during O O
seed O O
development O O
suggests O O
that O O
the O O
increase O O
in O O
enzyme O O
activity O O
during O O
the O O
phase O O
of O O
storage O O
lipid O O
accumulation O O
is O O
regulated O O
at O O
the O O
level O O
of O O
gene O O
expression O O
. O O

The O O
sequences O O
at O O
- O O
10 O O
and O O
- O O
35 O O
relative O O
to O O
the O O
transcriptional O O
starting O O
site O O
showed O O
55 O O
% O O
homology O O
with O O
the O O
consensus O O
sequences O O
of O O
the O O
Escherichia B B_GENE/B_BIO
coli I I_GENE/I_BIO
sigma I I_GENE/I_BIO
70 I I_GENE/I_BIO
- I I_GENE/I_BIO
type I I_GENE/I_BIO
promoter I I_GENE/I_BIO
. O O

The O O
results O O
were O O
subjected O O
to O O
analysis O O
of O O
23 O O
autopsies O O
carried O O
out O O
in O O
children O O
dying O O
of O O
intoxication O O
with O O
Amanita O O
phalloides O O
. O O

METHODS O O
: O O
The O O
Die O O
Deutsche O O
Diabetes O O
Dialyse O O
Studie O O
is O O
a O O
prospective O O
randomized O O
placebo O O
- O O
controlled O O
trial O O
that O O
tests O O
the O O
hypothesis O O
that O O
atorvastatin O O
, O O
a O O
hydroxymethyl B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glutaryl I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coenzyme I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reductase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
, O O
decreases O O
the O O
rate O O
of O O
cardiovascular O O
mortality O O
and O O
of O O
nonfatal O O
myocardial O O
infarction O O
in O O
patients O O
with O O
type O O
2 O O
diabetes O O
who O O
have O O
been O O
on O O
hemodialysis O O
treatment O O
for O O
no O O
more O O
than O O
two O O
years O O
. O O

There O O
was O O
no O O
significant O O
correlation O O
between O O
serum O O
amiodarone O O
or O O
desethylamiodarone O O
levels O O
and O O
dosage O O
of O O
amiodarone O O
. O O

The O O
effect O O
of O O
monaural O O
middle O O
ear O O
destruction O O
on O O
postnatal O O
development O O
of O O
mouse O O
inferior O O
colliculus O O
. O O

This O O
unusual O O
behaviour O O
may O O
be O O
explained O O
by O O
the O O
18 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
long I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CDR I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
H3 I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
could O O
be O O
of O O
value O O
in O O
the O O
design O O
of O O
' O O
single O O
domain O O
' O O
antibodies O O
. O O

A O O
definitive O O
answer O O
to O O
the O O
question O O
must O O
come O O
from O O
large O O
scale O O
mortality O O
studies O O
of O O
patients O O
in O O
whom O O
the O O
risk O O
/ O O
benefit O O
ratio O O
of O O
thrombolysis O O
is O O
not O O
unacceptably O O
high O O
, O O
in O O
whom O O
electrocardiographic O O
criteria O O
of O O
infarction O O
are O O
unequivocal O O
, O O
and O O
in O O
whom O O
treatment O O
can O O
be O O
initiated O O
early O O
after O O
the O O
onset O O
of O O
symptoms O O
with O O
regimens O O
that O O
will O O
induce O O
not O O
only O O
early O O
recanalization O O
, O O
but O O
also O O
sustained O O
patency O O
in O O
infarct O O
- O O
related O O
arteries O O
. O O

Parameters O O
of O O
sperm O O
quality O O
were O O
evaluated O O
before O O
and O O
after O O
freezing O O
/ O O
thawing O O
. O O

It O O
has O O
also O O
been O O
previously O O
demonstrated O O
that O O
LPS O O
treatment O O
of O O
splenic O O
B O O
cells O O
from O O
athymic O O
mice O O
results O O
in O O
a O O
decrease O O
in O O
steady O O
state O O
mRNA O O
encoding O O
the O O
A B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Chemical O O
structure O O
of O O
antibiotic O O
SF O O
- O O
837 O O
. O O

Aspirin O O
therapy O O
in O O
the O O
rheumatic O O
diseases O O
. O O

Is O O
conventional O O
sperm O O
analysis O O
of O O
any O O
use O O
? O O

The O O
computerised O O
records O O
of O O
867 O O
couples O O
were O O
used O O
to O O
investigate O O
the O O
prognostic O O
significance O O
of O O
semen O O
volume O O
, O O
motility O O
, O O
density O O
and O O
morphology O O
. O O

Mutational O O
analysis O O
of O O
the O O
putative O O
effector O O
domain O O
of O O
the O O
GTP B B_GENE/B_BIO
- I I_GENE/I_BIO
binding I I_GENE/I_BIO
Ypt1 I I_GENE/I_BIO
protein I I_GENE/I_BIO
in O O
yeast O O
suggests O O
specific O O
regulation O O
by O O
a O O
novel O O
GAP B B_LOCATION/B_GENE
activity O O
. O O

The O O
interaction O O
obtained O O
with O O
DBM O O
scores O O
was O O
further O O
qualified O O
by O O
a O O
three O O
- O O
way O O
interaction O O
that O O
limited O O
this O O
pattern O O
to O O
participants O O
scoring O O
higher O O
on O O
self O O
- O O
deception O O
. O O

The O O
broad O O
range O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O O
genistein O O
and O O
the O O
phosphatidylinositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O O
wortmannin O O
and O O
LY O O
294002 O O
( O O
2 O O
- O O
( O O
4 O O
- O O
morpholinyl O O
) O O
- O O
8 O O
- O O
phenyl O O
- O O
4H O O
- O O
1 O O
- O O
benzopyran O O
- O O
4 O O
- O O
one O O
) O O
also O O
blocked O O
adenosine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
A3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation O O
of O O
p42 B B_GENE
/ O O
p44 B B_MEASURE/B_GENE
MAPK O O
. O O

Surprisingly O O
, O O
although O O
Mist1 B B_GENE/B_LOCATION
binds O O
to O O
E O O
- O O
boxes O O
in O O
vivo O O
, O O
the O O
Mist1 B B_GENE/B_BIO
protein I I_GENE/I_BIO
lacks O O
a O O
functional O O
transcription O O
activation O O
domain O O
. O O

As O O
exogenously O O
expressed O O
PKR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
form O O
heterodimers O O
with O O
endogenous B B_GENE
PKR I I_GENE
, O O
the O O
results O O
obtained O O
on O O
the O O
functional O O
characterization O O
of O O
mutant O O
forms O O
of O O
PKR B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
taken O O
with O O
caution O O
. O O

Orlistat O O
is O O
a O O
specific O O
lipase B B_GENE
inhibitor O O
that O O
impairs O O
fat O O
absorption O O
, O O
thereby O O
reducing O O
fat O O
uptake O O
. O O

The O O
metalloproteinase B B_ENZYME[GENE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mediating O O
Met B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cleavage O O
was O O
specifically O O
inhibited O O
by O O
the O O
tissue B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
metalloproteinases I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
TIMP I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
by O O
TIMP B B_GENE
- I I_GENE
1 I I_GENE
or O O
TIMP B B_GENE
- I I_GENE
2 I I_GENE
. O O

This O O
demonstrates O O
a O O
relative O O
independence O O
of O O
the O O
given O O
synchronizer O O
of O O
rhythmicity O O
at O O
a O O
tissue O O
level O O
from O O
any O O
influence O O
of O O
the O O
higher O O
regulatory O O
center O O
. O O

It O O
is O O
also O O
conceivable O O
that O O
elevated O O
insulin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
may O O
cause O O
hypertriglyceridaemia O O
and O O
possibly O O
other O O
abnormalities O O
of O O
lipid O O
metabolism O O
. O O

Flicker O O
thresholds O O
were O O
measured O O
from O O
1 O O
to O O
40 O O
Hz O O
with O O
a O O
vertical O O
- O O
line O O
target O O
used O O
for O O
the O O
asynchrony O O
thresholds O O
. O O

The O O
clr1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulates O O
the O O
expression O O
of O O
the O O
cryptic B B_GENE
mating I I_GENE
- I I_GENE
type I I_GENE
loci I I_GENE
of I I_GENE
fission I I_GENE
yeast I I_GENE
. O O

Use O O
of O O
ELISAs O O
for O O
the O O
diagnosis O O
of O O
canine O O
atopy O O
. O O

A O O
clinical O O
study O O
. O O

METHODS O O
. O O

Instead O O
, O O
HBx B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
shown O O
to O O
activate O O
the O O
cyclin B B_GENE/B_LOCATION
A I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
, O O
induce O O
cyclin B B_GENE
A I I_GENE
- O O
cyclin B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
dependent I I_GENE/I_DISEASE
kinase I I_GENE/I_DISEASE
2 I I_GENE/I_DISEASE
complexes O O
, O O
and O O
promote O O
cycling O O
of O O
growth O O
- O O
arrested O O
cells O O
into O O
G1 O O
through O O
a O O
pathway O O
involving O O
activation O O
of O O
Src B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Growth B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exerts O O
its O O
effects O O
on O O
the O O
ovarian O O
follicular O O
cycle O O
directly O O
or O O
by O O
local O O
production O O
of O O
insulin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IGF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
) O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
evaluate O O
the O O
impact O O
of O O
the O O
ESRD O O
treatment O O
modality O O
on O O
the O O
quality O O
of O O
life O O
in O O
patients O O
with O O
Type O O
I O O
( O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
dependent O O
) O O
diabetes O O
mellitus O O
. O O

The O O
subjects O O
were O O
started O O
on O O
indomethacin O O
25 O O
mg O O
thrice O O
daily O O
. O O

A O O
Buddhist O O
view O O
of O O
abortion O O
. O O

The O O
arterial O O
blood O O
pressure O O
was O O
measured O O
by O O
using O O
bloody O O
method O O
in O O
anesthizied O O
animals O O
. O O

After O O
15 O O
min O O
of O O
hemorrhage O O
the O O
cardiovascular O O
parameters O O
were O O
the O O
same O O
in O O
fed O O
and O O
starved O O
animals O O
, O O
but O O
at O O
45 O O
min O O
striking O O
differences O O
were O O
observed O O
. O O

Decidual B B_TIME[MEASURE]/B_GENE
/ I I_TIME[MEASURE]/I_GENE
trophoblast I I_TIME[MEASURE]/I_GENE
prolactin I I_TIME[MEASURE]/I_GENE
- I I_TIME[MEASURE]/I_GENE
related I I_TIME[MEASURE]/I_GENE
protein I I_TIME[MEASURE]/I_GENE
: O O
characterization O O
of O O
gene O O
structure O O
and O O
cell O O
- O O
specific O O
expression O O
. O O

Plasma O O
NE O O
and O O
E O O
increased O O
to O O
significantly O O
higher O O
values O O
after O O
15 O O
min O O
in O O
the O O
young O O
subjects O O
: O O
1 O O
. O O
68 O O
+ O O
/ O O
- O O
0 O O
. O O
18 O O
vs O O
. O O

An O O
insertion O O
sequence O O
element O O
( O O
IS1170 O O
) O O
was O O
identified O O
upstream O O
of O O
the O O
nimC B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gene I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Most O O
significantly O O
, O O
the O O
cyclin B B_GENE
E I I_GENE
- O O
Cdk2 B B_GENE
complex O O
is O O
maximally O O
active O O
at O O
the O O
G1 O O
/ O O
S O O
transition O O
, O O
and O O
overexpression O O
of O O
cyclin B B_GENE
E I I_GENE
decreases O O
the O O
time O O
it O O
takes O O
the O O
cell O O
to O O
complete O O
G1 O O
and O O
enter O O
S O O
phase O O
. O O

However O O
, O O
neither O O
SF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O O
NGF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IB I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O O
, O O
binding O O
as O O
monomers O O
, O O
increases O O
transcription O O
. O O

Satisfactory O O
correlation O O
was O O
also O O
obtained O O
between O O
the O O
in O O
vivo O O
and O O
the O O
in O O
vitro O O
results O O
. O O

Structural O O
organization O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Elk1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
processed O O
pseudogene B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Elk2 I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

After O O
cumulative O O
occlusions O O
of O O
15 O O
, O O
30 O O
, O O
45 O O
, O O
and O O
90 O O
min O O
, O O
transmural O O
needle O O
biopsies O O
were O O
taken O O
from O O
the O O
ischemic O O
area O O
to O O
be O O
analyzed O O
for O O
adenine O O
nucleotides O O
, O O
nucleosides O O
, O O
creatine O O
phosphate O O
, O O
and O O
ultrastructural O O
changes O O
. O O

The O O
prevalence O O
of O O
ocular O O
/ O O
adnexal O O
SCC O O
was O O
significantly O O
greater O O
for O O
all O O
hair O O
colors O O
when O O
compared O O
with O O
bay O O
, O O
brown O O
, O O
or O O
black O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
. O O

Seven O O
patients O O
were O O
without O O
a O O
syndromic O O
diagnosis O O
. O O

In O O
addition O O
, O O
while O O
GCN1 B B_GENE
is O O
required O O
in O O
vivo O O
for O O
phosphorylation O O
of O O
eIF B B_GENE
- I I_GENE
2 I I_GENE
alpha I I_GENE
by O O
GCN2 B B_GENE
, O O
cell O O
extracts O O
from O O
gcn1 B B_GENE/B_NUMBER[MEASURE]
delta I I_GENE/I_NUMBER[MEASURE]
strains O O
contained O O
wild O O
- O O
type O O
levels O O
of O O
GCN2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
eIF B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O O
kinase O O
activity O O
. O O

Polymorphisms O O
in O O
the O O
CCR5 B B_GENE/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
genes I B_GENE/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
of O O
African O O
green O O
monkeys O O
and O O
mice O O
implicate O O
specific O O
amino O O
acids O O
in O O
infections O O
by O O
simian O O
and O O
human O O
immunodeficiency O O
viruses O O
. O O

Furthermore O O
, O O
we O O
detect O O
hCoch B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
5B2 I I_GENE/I_DISEASE
on O O
three O O
overlapping O O
YACs O O
, O O
two O O
of O O
which O O
also O O
contain O O
one O O
of O O
the O O
markers O O
linked O O
to O O
DFNA9 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Absence O O
of O O
nitroso O O
formation O O
from O O
( O O
14C O O
) O O
methomyl O O
and O O
sodium O O
nitrite O O
under O O
simulated O O
stomach O O
conditions O O
. O O

Although O O
no O O
detectable O O
phenotypes O O
are O O
associated O O
with O O
a O O
disruption O O
allele O O
of O O
ABP1 B B_GENE
, O O
mutations O O
that O O
create O O
a O O
requirement O O
for O O
this O O
protein O O
have O O
now O O
been O O
isolated O O
in O O
the O O
previously O O
identified O O
gene B B_GENE/B_BIO
SAC6 I I_GENE/I_BIO
and O O
in O O
two O O
new O O
genes O O
, O O
SLA1 B B_PROTEIN[GENE]/B_LOCATION
and O O
SLA2 B B_GENE/B_DISEASE
. O O

Cross O O
- O O
talk O O
between O O
transcription O O
factors O O
NF B B_GENE
- I I_GENE
kappa I I_GENE
B I I_GENE
and O O
C B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
transcriptional O O
regulation O O
of O O
genes O O
. O O

Elective O O
replacement O O
of O O
the O O
aortic O O
root O O
in O O
Marfan O O
' O O
s O O
syndrome O O
. O O

The O O
detergent O O
- O O
solubilized O O
complex O O
oxidizes O O
caldariella O O
quinol O O
at O O
high O O
rates O O
and O O
is O O
completely O O
inhibited O O
by O O
cyanide O O
and O O
by O O
quinolone O O
analogs O O
, O O
potent O O
inhibitors O O
of O O
quinol B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidases I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
have O O
characterized O O
a O O
new O O
cDNA O O
, O O
33k O O
- O O
6 O O
, O O
potentially O O
encoding O O
a O O
tobacco B B_ENZYME[GENE]
33 I I_ENZYME[GENE]
kDa I I_ENZYME[GENE]
chloroplast I I_ENZYME[GENE]
RNP I I_ENZYME[GENE]
( I I_ENZYME[GENE]
cp33 I I_ENZYME[GENE]
) I I_ENZYME[GENE]
homologue I I_ENZYME[GENE]
. O O

The O O
regions O O
encoding O O
the O O
mature O O
proteinases O O
were O O
cloned O O
into O O
an O O
expression O O
vector O O
and O O
recombinant O O
protein O O
produced O O
in O O
Escherichia O O
coli O O
. O O

Between O O
1988 O O
and O O
1994 O O
, O O
data O O
from O O
3 O O
large O O
sites O O
revealed O O
a O O
3 O O
- O O
5 O O
fold O O
increase O O
in O O
the O O
prevalence O O
of O O
antidepressant O O
( O O
ATD O O
) O O
treatment O O
for O O
U O O
. O O
S O O
. O O
youths O O
aged O O
2 O O
- O O
19 O O
years O O
. O O

The O O
vaccinia O O
virus O O
D6R B B_GENE
open O O
reading O O
frame O O
encodes O O
the O O
small O O
subunit O O
of O O
the O O
heterodimeric O O
vaccinia B B_ENZYME[GENE]/B_LOCATION
virus I I_ENZYME[GENE]/I_LOCATION
early I I_ENZYME[GENE]/I_LOCATION
transcription I I_ENZYME[GENE]/I_LOCATION
factor I I_ENZYME[GENE]/I_LOCATION
( O O
VETF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
that O O
activates O O
transcription O O
of O O
early B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O O
. O O

The O O
Sensititre O O
MIC O O
panels O O
containing O O
meropenem O O
offer O O
a O O
convenient O O
and O O
valid O O
alternative O O
to O O
the O O
NCCLS O O
reference O O
method O O
for O O
the O O
susceptibility O O
testing O O
of O O
potential O O
pathogens O O
likely O O
to O O
be O O
recovered O O
from O O
mixed O O
infections O O
. O O

Recognition O O
of O O
DNA O O
by O O
single O O
- O O
chain O O
derivatives O O
of O O
the O O
phage O O
434 O O
repressor O O
: O O
high O O
affinity O O
binding O O
depends O O
on O O
both O O
the O O
contacted O O
and O O
non O O
- O O
contacted O O
base O O
pairs O O
. O O

The O O
paper O O
calls O O
for O O
standardized O O
question O O
formats O O
and O O
a O O
centralized O O
body O O
to O O
monitor O O
changes O O
in O O
these O O
parameters O O
of O O
sexual O O
behaviour O O
. O O

We O O
show O O
that O O
GCNF B B_GENE
binds O O
to O O
one O O
of O O
the O O
two O O
DRO O O
sequences O O
in O O
the O O
Prm1 B B_GENE/B_BIO
promoter I I_GENE/I_BIO
, O O
and O O
to O O
the O O
DRO O O
sequence O O
in O O
the O O
Prm2 B B_GENE/B_MEASURE
promoter I I_GENE/I_MEASURE
in O O
a O O
specific O O
manner O O
. O O

139La O O
NQR O O
relaxation O O
and O O
microSR O O
study O O
of O O
Zn O O
- O O
doping O O
effects O O
in O O
La2CuO4 O O
. O O

However O O
, O O
the O O
in O O
vivo O O
attachment O O
strength O O
of O O
the O O
CSTi O O
- O O
2 O O
coating O O
was O O
comparable O O
both O O
to O O
CSTi O O
- O O
1 O O
and O O
to O O
an O O
HA O O
- O O
coated O O
control O O
after O O
8 O O
weeks O O
. O O

Octamer O O
recognition O O
is O O
mediated O O
by O O
the O O
POU B B_GENE/B_DISEASE
domain O O
, O O
a O O
conserved O O
structural O O
motif O O
which O O
- O O
- O O
like O O
the O O
zinc O O
finger O O
and O O
leucine O O
zipper O O
- O O
- O O
defines O O
a O O
family O O
of O O
related O O
transcription O O
factors O O
. O O

All O O
testosterone O O
treatments O O
raised O O
plasma O O
testosterone O O
concentrations O O
above O O
control O O
and O O
pretreatment O O
levels O O
( O O
testosterone O O
and O O
synovex O O
+ O O
testosterone O O
> O O
synovex O O
> O O
control O O
; O O
all O O
P O O
< O O
0 O O
. O O
05 O O
) O O
. O O

Lifestyle O O
characteristics O O
were O O
ascertained O O
by O O
a O O
self O O
- O O
administered O O
questionnaire O O
. O O

The O O
major O O
promoter O O
element O O
of O O
the O O
Xenopus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
laevis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5S I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
located O O
within O O
the O O
transcribed O O
region O O
of O O
the O O
gene O O
and O O
forms O O
the O O
binding O O
site O O
for O O
the O O
transcription O O
initiation O O
factor O O
TFIIIA B B_GENE/B_LOCATION
. O O

During O O
each O O
step O O
of O O
the O O
pulse O O
infusion O O
the O O
osteocalcin B B_GENE
responses O O
to O O
changes O O
in O O
CaI O O
in O O
general O O
were O O
parallel O O
to O O
the O O
changes O O
in O O
PTH B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
r O O
= O O
0 O O
. O O
462 O O
; O O
P O O
= O O
0 O O
. O O
02 O O
) O O
and O O
were O O
inversely O O
correlated O O
to O O
CaI O O
( O O
r O O
= O O
- O O
0 O O
. O O
562 O O
; O O
P O O
= O O
0 O O
. O O
003 O O
) O O
. O O

The O O
gamma B B_GENE
- I I_GENE
GCS I I_GENE
gene I I_GENE
is O O
expressed O O
ubiquitously O O
and O O
induced O O
coordinately O O
with O O
NAD B B_GENE
( I I_GENE
P I I_GENE
) I I_GENE
H I I_GENE
: I I_GENE
quinone I I_GENE
oxidoreductase I I_GENE
( I I_GENE
1 I I_GENE
) I I_GENE
( O O
NQO1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
glutathione B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
S I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transferase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Ya I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GST B B_GENE
Ya I I_GENE
) O O
in O O
response O O
to O O
xenobiotics O O
and O O
antioxidants O O
. O O

Interestingly O O
, O O
the O O
expression O O
of O O
Id4 B B_GENE
in O O
Sertoli O O
cells O O
is O O
only O O
detectable O O
after O O
stimulation O O
with O O
FSH B B_GENE
or O O
cAMP O O
. O O

We O O
determined O O
their O O
N O O
- O O
terminal O O
amino O O
acid O O
sequence O O
and O O
found O O
that O O
these O O
polypeptides O O
were O O
CotT B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
YeeK B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
YxeE B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
CotF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
YrbA B B_LOCATION/B_GENE
( O O
31 O O
and O O
45 O O
kDa O O
) O O
, O O
and O O
SpoIVA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
. O O

Furthermore O O
, O O
it O O
is O O
also O O
established O O
that O O
serine O O
phosphorylation O O
of O O
STAT5a B B_GENE/B_PERSON
transactivation O O
domain O O
, O O
via O O
the O O
MAPK B B_GENE
pathway O O
, O O
is O O
a O O
means O O
of O O
modifying O O
GH B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
induced O O
transcriptional O O
activation O O
. O O

ES O O
cells O O
in O O
which O O
the O O
gene O O
for O O
the O O
erythroid O O
transcription O O
factor O O
GATA B B_GENE
- I I_GENE
1 I I_GENE
has O O
been O O
disrupted O O
fail O O
to O O
produce O O
mature O O
erythroid O O
cells O O
either O O
in O O
vivo O O
or O O
in O O
vitro O O
. O O

Two O O
conserved O O
motifs O O
, O O
W89RKRRY94 O O
and O O
P156KKIKP161 O O
, O O
seemed O O
to O O
act O O
as O O
nuclear O O
addressing O O
signals O O
. O O

It O O
is O O
concluded O O
that O O
the O O
predominant O O
action O O
of O O
LSD O O
on O O
the O O
female O O
copulatory O O
response O O
is O O
not O O
mediated O O
by O O
increased O O
dopamine B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
but O O
that O O
the O O
LSD O O
effect O O
might O O
be O O
modulated O O
by O O
decreased O O
dopaminergic O O
activity O O
. O O

Therefore O O
, O O
in O O
VDR B B_GENE
- O O
mediated O O
transcriptional O O
activation O O
, O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
binding O O
to O O
VDR B B_GENE/B_LOCATION
alters O O
the O O
conformation O O
of O O
the O O
ligand O O
binding O O
domain O O
such O O
that O O
it O O
: O O
( O O
i O O
) O O
engages O O
in O O
strong O O
heterodimerization O O
with O O
RXR B B_GENE/B_LOCATION
to O O
facilitate O O
VDRE O O
binding O O
, O O
( O O
ii O O
) O O
influences O O
the O O
RXR B B_GENE/B_LOCATION
ligand I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
domain I I_GENE/I_LOCATION
such O O
that O O
it O O
is O O
resistant O O
to O O
the O O
binding O O
of O O
9 O O
- O O
cis O O
RA O O
but O O
active O O
in O O
recruiting O O
coactivator O O
to O O
its O O
AF O O
- O O
2 O O
and O O
( O O
iii O O
) O O
presents O O
the O O
AF O O
- O O
2 O O
region O O
in O O
VDR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
for O O
coactivator O O
association O O
. O O

In O O
patients O O
, O O
750 O O
mL O O
of O O
saline O O
lowered O O
DL O O
( O O
CO O O
) O O
( O O
- O O
8 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
D O O
( O O
M O O
) O O
( O O
- O O
10 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
aldosterone O O
( O O
- O O
29 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
renin B B_GENE
( O O
- O O
52 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
and O O
hematocrit O O
( O O
- O O
6 O O
% O O
, O O
P O O
< O O
0 O O
. O O
05 O O
versus O O
baseline O O
) O O
and O O
increased O O
V O O
( O O
C O O
) O O
( O O
20 O O
% O O
, O O
P O O
< O O
0 O O
. O O
01 O O
versus O O
baseline O O
) O O
, O O
without O O
changing O O
rap O O
and O O
wpp O O
. O O

A O O
series O O
of O O
deletion O O
mutants O O
was O O
expressed O O
transiently O O
in O O
two O O
human O O
hepatocytes O O
, O O
HepG2 O O
and O O
PLC O O
. O O

The O O
predicted O O
amino O O
acid O O
sequence O O
of O O
the O O
FlaB2 B B_GENE
polypeptide I I_GENE
was O O
92 O O
% O O
identical O O
to O O
that O O
of O O
T B B_SPECIES[BIO]/B_GENE
. I B_SPECIES[BIO]/I_GENE
pallidum I B_SPECIES[BIO]/I_GENE
FlaB2 I B_SPECIES[BIO]/I_GENE
, O O
with O O
a O O
76 O O
% O O
identity O O
at O O
the O O
nucleotide O O
level O O
. O O

The O O
survival O O
of O O
patients O O
with O O
a O O
short O O
bowel O O
, O O
even O O
if O O
they O O
need O O
long O O
- O O
term O O
parenteral O O
nutrition O O
, O O
is O O
good O O
. O O

Thus O O
, O O
cross O O
- O O
resistance O O
between O O
fluoroquinolones O O
was O O
shown O O
for O O
both O O
enterococci O O
and O O
MRSA O O
. O O

The O O
5 O O
' O O
ends O O
of O O
the O O
P B B_OTHER/B_PROTEIN[GENE]
and O O
O B B_PROTEIN[GENE]/B_LOCATION
gene I I_PROTEIN[GENE]/I_LOCATION
mRNAs I I_PROTEIN[GENE]/I_LOCATION
are O O
separated O O
by O O
109 O O
nucleotide O O
pairs O O
in O O
the O O
DNA O O
template O O
. O O

Using O O
community O O
development O O
approaches O O
. O O

Biol O O
. O O

We O O
have O O
cloned O O
the O O
cDNA O O
for O O
the O O
SLBP B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
humans O O
, O O
mice O O
, O O
and O O
frogs O O
, O O
using O O
the O O
recently O O
developed O O
yeast O O
three O O
- O O
hybrid O O
system O O
. O O

Along O O
with O O
these O O
species O O
, O O
F O O
. O O
graminearum O O
group O O
2 O O
( O O
ZON O O
, O O
DON O O
and O O
/ O O
or O O
3AcDON O O
or O O
15AcDON O O
) O O
; O O
F O O
. O O
chlamydosporum O O
; O O
F O O
. O O
acuminatum O O
( O O
type O O
- O O
A O O
trichothecene O O
derivatives O O
) O O
; O O
and O O
F O O
. O O
semitectum O O
were O O
often O O
found O O
to O O
be O O
associated O O
. O O

TGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta1 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
phosphorylation O O
of O O
Smad2 B B_GENE
and O O
Smad3 B B_GENE
in O O
Mv1Lu O O
mink O O
lung O O
epithelial O O
cells O O
. O O

There O O
is O O
little O O
supportive O O
evidence O O
that O O
ACE B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibitors O O
( O O
captopril O O
or O O
enalapril O O
) O O
are O O
teratogenic O O
. O O

Thus O O
, O O
the O O
potential O O
induction O O
of O O
this O O
gene O O
rearrangement O O
by O O
E1A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
is O O
unlikely O O
to O O
be O O
clinically O O
significant O O
in O O
the O O
treatment O O
of O O
advanced O O
malignant O O
disease O O
. O O

Although O O
the O O
cDNAs O O
of O O
HMG B B_GENE
- I I_GENE
14 I I_GENE
and O O
HMG B B_MEASURE/B_GENE
- I I_MEASURE/I_GENE
17 I I_MEASURE/I_GENE
do O O
not O O
cross O O
- O O
hybridize O O
, O O
they O O
have O O
several O O
similar O O
structural O O
features O O
: O O
the O O
open O O
reading O O
frame O O
comprises O O
only O O
23 O O
% O O
of O O
the O O
transcripts O O
, O O
the O O
5 O O
' O O
- O O
untranslated O O
region O O
is O O
extremely O O
GC O O
rich O O
whereas O O
the O O
3 O O
' O O
- O O
untranslated O O
region O O
is O O
unusually O O
long O O
and O O
AT O O
rich O O
. O O

Previously O O
, O O
we O O
reported O O
the O O
identification O O
of O O
a O O
23 O O
- O O
kD O O
protein O O
that O O
interacts O O
with O O
zyxin B B_GENE/B_BACTERIUM[BIO]
in O O
vitro O O
( O O
Sadler O O
et O O
al O O
. O O
, O O
1992 O O
) O O
. O O

If O O
vascular O O
induction O O
between O O
a O O
vascular O O
carrier O O
and O O
the O O
selected O O
jejunal O O
segment O O
is O O
done O O
as O O
a O O
kind O O
of O O
flap O O
prefabrication O O
, O O
the O O
jejunal O O
interposition O O
flap O O
can O O
be O O
used O O
without O O
the O O
need O O
for O O
complex O O
microsurgery O O
. O O

In O O
gel O O
mobility O O
shift O O
assays O O
, O O
high O O
binding O O
activities O O
of O O
ATPC B B_GENE
- I I_GENE
2 I I_GENE
and O O
low O O
binding O O
activities O O
of O O
CBF B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
observed O O
with O O
nuclear O O
extracts O O
from O O
tissue O O
with O O
low O O
AtpC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
levels O O
, O O
and O O
the O O
opposite O O
was O O
observed O O
with O O
extracts O O
from O O
tissues O O
with O O
high O O
AtpC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O O
levels O O
. O O

Activation O O
of O O
tyrosine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
containing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
heterotrimeric B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
G I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhanced O O
the O O
activities O O
of O O
both O O
MEK B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
isoforms I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
293 O O
and O O
PC12 O O
cells O O
. O O

The O O
Fugu O O
rubripes O O
( O O
Fugu O O
) O O
gene O O
fragment O O
was O O
used O O
to O O
isolate O O
the O O
GH B B_GENE/B_BIO
gene I B_GENE/I_BIO
from O O
a O O
Fugu O O
genomic O O
library O O
. O O

An O O
in O O
vitro O O
' O O
glass O O
stomach O O
' O O
( O O
containing O O
various O O
volumes O O
of O O
hydrochloric O O
acid O O
[ O O
HCl O O
] O O
and O O
ammonium O O
chloride O O
[ O O
NH4Cl O O
] O O
) O O
was O O
used O O
to O O
evaluate O O
the O O
means O O
of O O
increasing O O
' O O
gastric O O
' O O
pH O O
to O O
that O O
of O O
the O O
NH4 O O
+ O O
- O O
- O O
> O O
NH3 O O
transition O O
that O O
occurs O O
significantly O O
at O O
pH O O
9 O O
. O O
24 O O
. O O

Acyclovir O O
( O O
3 O O
% O O
ointment O O
) O O
used O O
topically O O
one O O
to O O
five O O
times O O
a O O
day O O
on O O
acute O O
ocular O O
HSV O O
infection O O
gave O O
beneficial O O
results O O
as O O
measured O O
by O O
a O O
reduction O O
in O O
corneal O O
involvement O O
, O O
conjunctivitis O O
, O O
iritis O O
, O O
and O O
corneal O O
clouding O O
. O O

Partial O O
proteolysis O O
of O O
cell O O
surface O O
- O O
iodinated O O
B B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
G I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
generates O O
extremely O O
similar O O
patterns O O
of O O
spots O O
, O O
both O O
within O O
and O O
between O O
haplotypes O O
. O O

SETTING O O
: O O
University O O
research O O
laboratory O O
. O O

There O O
was O O
a O O
57 O O
% O O
reduction O O
in O O
IGF B B_GENE
IR I I_GENE
mRNA I I_GENE
levels O O
in O O
clone O O
CA9 O O
after O O
confluence O O
compared O O
with O O
clone O O
ME10 O O
. O O

Similar O O
tissue O O
- O O
specific O O
patterns O O
are O O
observed O O
with O O
a O O
fusion O O
between O O
the O O
caufliflower B B_GENE/B_BIO
mosaic I I_GENE/I_BIO
virus I I_GENE/I_BIO
35S I I_GENE/I_BIO
RNA I I_GENE/I_BIO
promotor I I_GENE/I_BIO
and O O
the O O
GUS B B_GENE
gene I I_GENE
. O O

One O O
function O O
of O O
p53 B B_GENE
is O O
in O O
regulating O O
cell O O
cycle O O
check O O
- O O
point O O
control O O
after O O
DNA O O
damage O O
. O O

We O O
used O O
event O O
- O O
related O O
functional O O
magnetic O O
resonance O O
imaging O O
( O O
fMRI O O
) O O
during O O
a O O
cued O O
spatial O O
- O O
attention O O
task O O
to O O
dissociate O O
brain O O
activity O O
related O O
to O O
attentional O O
control O O
from O O
that O O
related O O
to O O
selective O O
processing O O
of O O
target O O
stimuli O O
. O O

BACKGROUND O O
: O O
The O O
extract O O
of O O
medicinal O O
plants O O
containing O O
curcumin O O
is O O
traditionally O O
believed O O
to O O
have O O
a O O
positive O O
contraction O O
effect O O
on O O
the O O
human O O
gall O O
- O O
bladder O O
. O O

Apoptosis O O
triggered O O
through O O
Fas B B_GENE
and O O
F B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
inhibited O O
by O O
coexpression O O
of O O
CrmA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
p35 B B_GENE
, O O
but O O
not O O
Bcl B B_GENE
- I I_GENE
xL I I_GENE
. O O

The O O
product O O
of O O
one O O
gene O O
, O O
Bv80 B B_GENE/B_LOCATION
, O O
has O O
a O O
single O O
divergent O O
copy O O
of O O
a O O
sequence O O
of O O
149 O O
amino O O
acids O O
( O O
approx O O
. O O

The O O
1031 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bp I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
wild I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HIT1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
contained O O
an O O
open O O
reading O O
frame O O
encoding O O
a O O
protein O O
of O O
164 O O
amino O O
acids O O
and O O
the O O
AGG B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
arginine I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complemented O O
all O O
hit1 B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
1 I I_DISEASE/I_GENE
mutant I I_DISEASE/I_GENE
phenotypes I I_DISEASE/I_GENE
, O O
indicating O O
that O O
the O O
mutant O O
phenotypes O O
were O O
caused O O
by O O
the O O
deletion O O
of O O
these O O
genes O O
. O O

Tilisolol O O
and O O
carboxymethylcellulose O O
sodium O O
salt O O
( O O
CMC O O
) O O
were O O
used O O
as O O
the O O
model O O
ophthalmic O O
drug O O
and O O
viscous O O
polymer O O
, O O
respectively O O
. O O

These O O
results O O
are O O
discussed O O
in O O
the O O
context O O
of O O
a O O
model O O
of O O
the O O
myogenic O O
lineage O O
that O O
is O O
based O O
on O O
the O O
expression O O
of O O
desmin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
identified O O
two O O
potential O O
phosphorylation O O
sites O O
at O O
serine49 O O
and O O
serine133 O O
, O O
both O O
of O O
which O O
seem O O
to O O
be O O
necessary O O
for O O
Myf B B_GENE/B_MEASURE
- I I_GENE/I_MEASURE
5 I I_GENE/I_MEASURE
activity O O
. O O

CVO2 O O
saturation O O
is O O
a O O
reliable O O
and O O
sensitive O O
method O O
for O O
detecting O O
blood O O
loss O O
. O O

The O O
gene O O
encoding O O
the O O
Neisseria B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
lactamica I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
III I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
DNA I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
methyltransferase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
M B B_SPECIES[BIO]/B_GENE
. I B_SPECIES[BIO]/I_GENE
NlaIII I B_SPECIES[BIO]/I_GENE
) O O
which O O
recognizes O O
the O O
sequence O O
CATG O O
has O O
been O O
cloned O O
and O O
expressed O O
in O O
Escherichia O O
coli O O
. O O

This O O
latter O O
complex O O
reacts O O
with O O
an O O
antibody O O
to O O
serum B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
SRF B B_GENE/B_LOCATION
) O O
and O O
exhibits O O
the O O
same O O
binding O O
characteristics O O
as O O
purified O O
SRF B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
second O O
patient O O
was O O
successfully O O
treated O O
with O O
intravenous O O
prostaglandin O O
F2 O O
alpha O O
( O O
PGF2 O O
alpha O O
) O O
. O O

Alignment O O
of O O
the O O
rat B B_GENE
and I I_GENE
human I I_GENE
WIN I I_GENE
cDNAs I I_GENE
and O O
their O O
comparison O O
with O O
mouse O O
genomic O O
sequence O O
revealed O O
that O O
the O O
WIN B B_GENE/B_MEASURE
DNA I I_GENE/I_MEASURE
binding I I_GENE/I_MEASURE
domain I I_GENE/I_MEASURE
is O O
encoded O O
by O O
four O O
exons O O
, O O
two O O
of O O
which O O
( O O
exons O O
4 O O
and O O
6 O O
) O O
are O O
alternatively O O
spliced O O
to O O
generate O O
at O O
least O O
three O O
classes O O
of O O
mRNA O O
transcripts O O
. O O

In O O
a O O
pilot O O
study O O
in O O
which O O
two O O
dogs O O
were O O
given O O
parenteral O O
rifampin O O
before O O
and O O
after O O
operation O O
and O O
grafts O O
were O O
preclotted O O
with O O
blood O O
that O O
contained O O
rifampin O O
, O O
it O O
was O O
suggested O O
that O O
there O O
was O O
a O O
slight O O
increase O O
in O O
inhibition O O
at O O
24 O O
hours O O
( O O
93 O O
% O O
) O O
. O O

A O O
flow O O
probe O O
for O O
direct O O
measurement O O
of O O
blood O O
flow O O
of O O
the O O
mitral O O
valve O O
was O O
devised O O
. O O

Here O O
, O O
we O O
analyzed O O
the O O
interaction O O
of O O
the O O
Lactococcus B B_PROTEIN[GENE]
lactis I I_PROTEIN[GENE]
Ll I I_PROTEIN[GENE]
. I I_PROTEIN[GENE]
LtrB I I_PROTEIN[GENE]
group I I_PROTEIN[GENE]
II I I_PROTEIN[GENE]
intron I I_PROTEIN[GENE]
endonuclease I I_PROTEIN[GENE]
with O O
its O O
DNA O O
target O O
site O O
by O O
DNA O O
footprinting O O
and O O
modification O O
- O O
interference O O
approaches O O
. O O

Clinical O O
trials O O
bring O O
informations O O
for O O
pharmacology O O
and O O
epidemiology O O
. O O

In O O
several O O
steps O O
we O O
converted O O
the O O
retinoid O O
specific O O
response O O
element O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
retinoic I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
into O O
the O O
vitamin O O
D O O
/ O O
retinoic O O
acid O O
response O O
element O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
osteocalcin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
immediate O O
5 O O
' O O
- O O
flanking O O
region O O
was O O
GC O O
- O O
rich O O
with O O
3 O O
SP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
- I I_GENE/I_LOCATION
like I I_GENE/I_LOCATION
and O O
2 O O
AP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
2 I I_GENE/I_LOCATION
sites I I_GENE/I_LOCATION
identified O O
in O O
close O O
proximity O O
to O O
the O O
transcription O O
start O O
site O O
. O O

Akt B B_GENE
- O O
dependent O O
antiapoptotic O O
action O O
of O O
insulin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O O
sensitive O O
to O O
farnesyltransferase O O
inhibitor O O
. O O

For O O
all O O
samples O O
, O O
the O O
sensitivity O O
of O O
the O O
blast O O
flag O O
on O O
the O O
CD3500 O O
was O O
85 O O
% O O
with O O
a O O
specificity O O
of O O
91 O O
% O O
( O O
STKS O O
: O O
sensitivity O O
, O O
75 O O
% O O
; O O
specificity O O
, O O
85 O O
% O O
) O O
; O O
the O O
sensitivity O O
of O O
the O O
CD3500 O O
IG O O
flag O O
was O O
72 O O
% O O
with O O
a O O
specificity O O
of O O
76 O O
% O O
( O O
STKS O O
: O O
sensitivity O O
, O O
75 O O
% O O
: O O
specificity O O
, O O
73 O O
% O O
) O O
; O O
and O O
the O O
sensitivity O O
of O O
the O O
NRBC O O
flag O O
was O O
43 O O
% O O
with O O
a O O
specificity O O
of O O
94 O O
% O O
( O O
STKS O O
sensitivity O O
, O O
37 O O
% O O
; O O
specificity O O
, O O
88 O O
% O O
) O O
. O O

Control O O
of O O
ovulation O O
in O O
mares O O
in O O
the O O
early O O
breeding O O
season O O
with O O
ovarian O O
steroids O O
and O O
prostaglandin O O
. O O

Reasons O O
are O O
given O O
for O O
suggesting O O
that O O
tiapamil O O
warrants O O
further O O
clinical O O
evaluation O O
, O O
after O O
which O O
it O O
may O O
join O O
the O O
more O O
established O O
calcium O O
antagonists O O
as O O
a O O
valuable O O
therapeutic O O
agent O O
. O O

The O O
central O O
venous O O
O2 O O
saturation O O
test O O
in O O
acute O O
pulmonary O O
fat O O
embolism O O
. O O

Two O O
of O O
the O O
proteins O O
UPRF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
1 I I_GENE/I_DISEASE
and O O
UPRF B B_GENE
- I I_GENE
2 I I_GENE
( O O
which O O
is O O
apparently O O
a O O
proteolytic O O
degradation O O
product O O
of O O
UPRF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
) O O
bind O O
inefficiently O O
to O O
mutant O O
versions O O
of O O
the O O
UPR O O
that O O
are O O
unable O O
to O O
confer O O
responsiveness O O
to O O
unfolded O O
proteins O O
to O O
the O O
( O O
CYC1 B B_GENE/B_SPECIES[BIO]
) O O
promoter O O
. O O

Identification O O
of O O
domains O O
mediating O O
transcription O O
activation O O
, O O
repression O O
, O O
and O O
inhibition O O
in O O
the O O
paired B B_GENE/B_BIO
- I I_GENE/I_BIO
related I I_GENE/I_BIO
homeobox I I_GENE/I_BIO
protein I I_GENE/I_BIO
, O O
Prx2 B B_GENE
( O O
S8 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Analytical O O
scanning O O
isoelectrofocusing O O
. O O

Upstream B B_GENE
stimulatory I I_GENE
factor I I_GENE
USF B I_GENE
is O O
a O O
human O O
transcriptional O O
activation O O
factor O O
, O O
which O O
uses O O
a O O
basic O O
/ O O
helix O O
- O O
loop O O
- O O
helix O O
/ O O
leucin O O
zipper O O
( O O
b O O
/ O O
HLH O O
/ O O
Z O O
) O O
motif O O
to O O
homodimerize O O
and O O
recognize O O
specific O O
sequences O O
in O O
the O O
promoter O O
region O O
of O O
both O O
nuclear O O
and O O
viral O O
genes O O
transcribed O O
by O O
RNA B B_GENE/B_VIRUS[BIO]
polymerase I B_GENE/I_VIRUS[BIO]
II I B_GENE/I_VIRUS[BIO]
. O O

43 O O
% O O
, O O
6 O O
/ O O
14 O O
; O O
P O O
= O O
0 O O
. O O
013 O O
) O O
, O O
whereas O O
, O O
in O O
RCC O O
samples O O
with O O
VHL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
methylation O O
or O O
mutation O O
, O O
the O O
frequency O O
of O O
3p14 O O
- O O
p21 O O
LOH O O
did O O
not O O
differ O O
from O O
that O O
of O O
sp25 O O
- O O
p26 O O
( O O
72 O O
% O O
, O O
18 O O
/ O O
25 O O
vs O O
. O O

Sequences O O
homologous O O
to O O
the O O
consensus O O
TUF B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
binding I I_GENE/I_LOCATION
UAS I I_GENE/I_LOCATION
boxes I I_GENE/I_LOCATION
are O O
present O O
in O O
the O O
5 O O
' O O
flanking O O
regions O O
of O O
both O O
genes O O
. O O

The O O
analysis O O
predicted O O
that O O
progressive O O
increases O O
in O O
serum O O
creatinine O O
or O O
aspartate B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
transaminase I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
activity O O
will O O
result O O
in O O
only O O
a O O
50 O O
% O O
reduction O O
of O O
clearance O O
. O O

RESULTS O O
: O O
Although O O
low O O
levels O O
of O O
vIRF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
detected O O
in O O
the O O
HHV O O
- O O
8 O O
- O O
positive O O
BCBL O O
- O O
1 O O
tumor O O
cell O O
line O O
, O O
12 O O
- O O
0 O O
- O O
tetradecanoylphorbol O O
- O O
13 O O
- O O
acetate O O
( O O
TPA O O
) O O
treatment O O
does O O
not O O
stimulate O O
expression O O
of O O
vIRF B B_GENE/B_DISEASE
- I I_GENE/I_DISEASE
2 I I_GENE/I_DISEASE
gene I I_GENE/I_DISEASE
together O O
with O O
primary O O
lytic O O
cycle O O
genes O O
. O O

Central O O
projections O O
of O O
gastric O O
afferent O O
vagal O O
inputs O O
. O O

DNA O O
sequence O O
of O O
the O O
UL6 B B_PROTEIN[GENE]/B_DISEASE
to O O
UL20 B B_MEASURE/B_GENE
genes I I_MEASURE/I_GENE
of O O
infectious O O
laryngotracheitis O O
virus O O
and O O
characterization O O
of O O
the O O
UL10 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
product I I_GENE/I_LOCATION
as O O
a O O
nonglycosylated O O
and O O
nonessential O O
virion O O
protein O O
. O O

Coimmunoprecipitation O O
analysis O O
suggests O O
that O O
these O O
residues O O
likely O O
contribute O O
to O O
the O O
multimerization O O
function O O
required O O
for O O
homomeric O O
complex O O
formation O O
or O O
heteromeric O O
complex O O
formation O O
with O O
p50 B B_GENE
in O O
that O O
no O O
association O O
of O O
p65 B B_GENE
delta I I_GENE
with O O
itself O O
or O O
with O O
p50 B B_GENE
was O O
evident O O
. O O

A O O
yeast O O
mitochondrial O O
translation O O
initiation O O
codon O O
mutation O O
affecting O O
the O O
gene O O
for O O
cytochrome B B_GENE
oxidase I I_GENE
subunit I I_GENE
III I I_GENE
( O O
COX3 B B_PROTEIN[GENE]/B_LOCATION
) O O
was O O
partially O O
suppressed O O
by O O
a O O
spontaneous O O
nuclear O O
mutation O O
. O O

Only O O
the O O
27 O O
- O O
kDa O O
protein O O
was O O
detected O O
after O O
N B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glycosidase I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O O
, O O
indicating O O
that O O
PLP B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
H I I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
glycoprotein O O
. O O

Moreover O O
, O O
we O O
studied O O
the O O
relationship O O
between O O
initial O O
percentage O O
of O O
bone O O
marrow O O
plasma O O
cells O O
and O O
prognosis O O
. O O

These O O
results O O
demonstrate O O
that O O
GGTase B B_GENE
- I I_GENE
I I I_GENE
inhibitors O O
arrest O O
cells O O
in O O
G0 O O
/ O O
G1 O O
and O O
induce O O
accumulation O O
of O O
p21WAF B B_GENE
in O O
a O O
p53 B B_GENE/B_MEASURE
- O O
independent O O
manner O O
and O O
that O O
FTase B B_GENE/B_PERSON
inhibitors O O
can O O
interfere O O
with O O
cell O O
cycle O O
events O O
by O O
a O O
mechanism O O
that O O
involves O O
neither O O
p21WAF B B_GENE
nor O O
p27KIP B B_GENE
. O O

We O O
report O O
here O O
on O O
an O O
eight O O
- O O
year O O
- O O
old O O
boy O O
who O O
first O O
developed O O
acute O O
intravascular O O
hemolysis O O
following O O
therapy O O
with O O
amphotericin O O
B O O
( O O
AmB O O
) O O
and O O
subsequently O O
a O O
delayed O O
hemolytic O O
transfusion O O
reaction O O
due O O
to O O
alloantibodies O O
. O O

The O O
temporal O O
sequence O O
of O O
organ O O
failure O O
was O O
lung O O
, O O
clotting O O
system O O
, O O
kidney O O
, O O
and O O
liver O O
. O O

The O O
potential O O
biological O O
significance O O
of O O
the O O
identified O O
structural O O
motif O O
shared O O
by O O
the O O
human B B_GENE
CCR5 I I_GENE
, O O
CCR3 B B_GENE
, O O
CCR2B B B_GENE
and O O
other O O
GPCRs B B_GENE/B_BIO
is O O
discussed O O
. O O

The O O
papers O O
provide O O
a O O
broad O O
perspective O O
of O O
MPAs O O
and O O
include O O
social O O
, O O
economic O O
, O O
cultural O O
, O O
biological O O
and O O
statistical O O
components O O
. O O

Management O O
of O O
patients O O
with O O
Ewing O O
' O O
s O O
sarcoma O O
has O O
been O O
discussed O O
with O O
reference O O
to O O
the O O
need O O
to O O
achieve O O
an O O
excellent O O
local O O
result O O
from O O
radiation O O
therapy O O
now O O
that O O
patients O O
are O O
experiencing O O
long O O
- O O
term O O
survival O O
. O O

Since O O
1985 O O
the O O
combination O O
of O O
chlorambucil O O
( O O
10 O O
mg O O
daily O O
, O O
initially O O
for O O
six O O
weeks O O
, O O
then O O
alternating O O
fortnights O O
for O O
12 O O
weeks O O
) O O
and O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2b I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
Schering O O
- O O
Plough O O
; O O
2 O O
x O O
10 O O
( O O
6 O O
) O O
U O O
/ O O
m2 O O
three O O
times O O
weekly O O
by O O
subcutaneous O O
injection O O
for O O
18 O O
weeks O O
) O O
has O O
been O O
compared O O
in O O
a O O
randomised O O
trial O O
with O O
chlorambucil O O
alone O O
in O O
previously O O
untreated O O
patients O O
with O O
stage O O
III O O
or O O
IV O O
follicular O O
lymphoma O O
. O O

Serum O O
concentrations O O
of O O
hormones O O
in O O
patients O O
classified O O
as O O
C O O
were O O
characteristically O O
and O O
inclined O O
to O O
be O O
hypergonadotropic O O
and O O
hypoestrogenic O O
. O O

Incorporation O O
of O O
this O O
information O O
in O O
the O O
data O O
brought O O
about O O
a O O
revised O O
five O O
- O O
year O O
survival O O
estimate O O
of O O
55 O O
percent O O
. O O

These O O
motifs O O
, O O
and O O
their O O
cognate O O
transcription O O
factors O O
, O O
appear O O
to O O
act O O
in O O
concert O O
, O O
with O O
partial O O
redundancy O O
, O O
so O O
that O O
discrete O O
mutations O O
were O O
only O O
partially O O
effective O O
in O O
reducing O O
transcriptional O O
activity O O
. O O

Statistical O O
conservation O O
laws O O
in O O
turbulent O O
transport O O
. O O

Expression O O
of O O
the O O
bacteriophage B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T4 I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
terminase I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
16 I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
17 I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
yields O O
multiple O O
proteins O O
. O O

Erdheim O O
- O O
Chester O O
disease O O
: O O
a O O
distinct O O
lipoidosis O O
or O O
part O O
of O O
the O O
spectrum O O
of O O
histiocytosis O O
? O O

Erdheim O O
- O O
Chester O O
disease O O
has O O
always O O
been O O
considered O O
a O O
distinct O O
lipoidosis O O
based O O
on O O
clinical O O
and O O
radiographic O O
criteria O O
. O O

Self O O
- O O
consistent O O
calculation O O
of O O
the O O
surface O O
electronic O O
structure O O
of O O
the O O
( O O
1 O O
x O O
2 O O
) O O
reconstructed O O
Au O O
( O O
110 O O
) O O
surface O O
. O O

The O O
plasmid O O
was O O
found O O
to O O
confer O O
drug O O
resistance O O
specifically O O
to O O
LMB O O
. O O

Two O O
pharmacokinetic O O
models O O
were O O
compared O O
. O O

A O O
higher O O
median O O
proportion O O
of O O
spirochaetes O O
was O O
observed O O
in O O
sites O O
after O O
diagnosis O O
of O O
loss O O
of O O
attachment O O
. O O

Ocular O O
injuries O O
during O O
general O O
anesthesia O O
. O O

Of O O
81 O O
girls O O
cured O O
from O O
the O O
bacteriuria O O
24 O O
recurred O O
, O O
5 O O
with O O
a O O
symptomatic O O
pyelonephritis O O
and O O
3 O O
with O O
cystitis O O
. O O

The O O
performances O O
of O O
two O O
tests O O
, O O
the O O
ProstAsure O O
index O O
and O O
the O O
percent O O
free O O
PSA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
test O O
, O O
were O O
evaluated O O
in O O
detecting O O
cancer O O
. O O

The O O
protein O O
encoded O O
by O O
the O O
NF2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
a O O
similarity O O
to O O
ezrin B B_GENE/B_BACTERIUM[BIO]
, O O
radixin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
moesin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ERM B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
proteins O O
that O O
link O O
membrane O O
proteins O O
to O O
the O O
cytoskeleton O O
. O O

PATIENTS O O
- O O
- O O
125 O O
women O O
consulting O O
the O O
general O O
practitioner O O
for O O
symptomatic O O
bacterial O O
vaginosis O O
. O O

In O O
the O O
healing O O
tendons O O
, O O
the O O
rate O O
of O O
collagen B B_GENE/B_DISEASE
synthesis O O
decreased O O
and O O
the O O
rate O O
of O O
noncollagen O O
protein O O
synthesis O O
remained O O
unchanged O O
. O O

From O O
our O O
own O O
investigations O O
on O O
phantoms O O
, O O
the O O
smallest O O
signal O O
- O O
to O O
- O O
noise O O
ratio O O
( O O
delta O O
S O O
min O O
/ O O
delta O O
R O O
) O O
was O O
obtained O O
which O O
determines O O
the O O
minimal O O
contrast O O
, O O
given O O
the O O
film O O
properties O O
( O O
film O O
response O O
S O O
, O O
film O O
gradient O O
gamma O O
) O O
and O O
the O O
amount O O
of O O
scatter O O
. O O

However O O
, O O
one O O
activity O O
binds O O
preferentially O O
to O O
G O O
+ O O
C O O
- O O
rich O O
promoters O O
, O O
and O O
another O O
activity O O
appears O O
to O O
bind O O
preferentially O O
to O O
only O O
two O O
of O O
the O O
promoters O O
tested O O
. O O

Cardiovascular O O
effects O O
in O O
man O O
of O O
intravenous O O
prizidilol O O
hydrochloride O O
( O O
SK O O
& O O
F O O
92657 O O
) O O
; O O
a O O
new O O
antihypertensive O O
agent O O
. O O

From O O
the O O
Centers O O
for O O
Disease O O
Control O O
and O O
Prevention O O
. O O

Expression O O
of O O
a O O
cDNA O O
clone O O
in O O
yeast O O
containing O O
a O O
large O O
portion O O
of O O
the O O
open O O
reading O O
frame O O
produced O O
cAMP B B_GENE
PDEase I I_GENE
activity O O
identical O O
in O O
properties O O
to O O
the O O
Drosophila O O
enzyme O O
affected O O
by O O
the O O
dnc B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

FdsR B B_GENE
purified O O
to O O
homogeneity O O
after O O
overexpression O O
of O O
fdsR B B_GENE
in O O
E O O
. O O
coli O O
is O O
a O O
130 O O
kDa O O
homotetramer O O
binding O O
to O O
the O O
fds B B_GENE/B_BIO
control O O
region O O
located O O
between O O
the O O
fdsR B B_GENE
and O O
fdsG B B_GENE/B_LOCATION
genes I I_GENE/I_LOCATION
. O O

ZNS O O
, O O
in O O
the O O
mmolar O O
range O O
, O O
scavenged O O
hydroxyl O O
and O O
nitric O O
oxide O O
radicals O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O

Binding O O
of O O
ZAP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
70 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
phospho O O
- O O
TAMs O O
is O O
notable O O
for O O
the O O
high O O
level O O
of O O
cooperativity O O
between O O
the O O
two O O
SH2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
domains I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
individually O O
demonstrate O O
low O O
affinity O O
interaction O O
with O O
the O O
ligand O O
. O O

The O O
benzo O O
- O O
pyrone O O
drug O O
Venalot O O
had O O
a O O
considerable O O
effect O O
in O O
reducing O O
the O O
protein O O
concentration O O
in O O
the O O
air O O
spaces O O
and O O
the O O
interstitial O O
tissue O O
, O O
and O O
of O O
the O O
oedema O O
in O O
the O O
latter O O
. O O

Radiation O O
was O O
delivered O O
in O O
a O O
single O O
4 O O
- O O
mJ O O
pulse O O
of O O
200 O O
microseconds O O
duration O O
by O O
means O O
of O O
an O O
articulated O O
zirconium O O
fluoride O O
optical O O
fibre O O
and O O
a O O
320 O O
- O O
microns O O
quartz O O
- O O
fibre O O
tip O O
. O O

Perception O O
of O O
sweetness O O
cannot O O
be O O
used O O
to O O
accurately O O
meter O O
the O O
metabolizable O O
energy O O
or O O
nutritive O O
value O O
of O O
a O O
food O O
. O O

The O O
leader O O
peptide O O
was O O
hypothesized O O
to O O
inhibit O O
ribosome O O
release O O
at O O
the O O
tnaC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
stop I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
codon I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
thereby O O
blocking O O
Rho B B_GENE
' O O
s O O
access O O
to O O
the O O
transcript O O
. O O

Response O O
properties O O
of O O
single O O
units O O
in O O
the O O
accessory O O
optic O O
system O O
of O O
the O O
dark O O
- O O
reared O O
cat O O
. O O

Excretion O O
of O O
radiopharmaceuticals O O
into O O
breast O O
milk O O
. O O

The O O
leukotriene B B_GENE
receptor I I_GENE
antagonist O O
zafirlukast O O
inhibits O O
sulfur O O
dioxide O O
- O O
induced O O
bronchoconstriction O O
in O O
patients O O
with O O
asthma O O
. O O

This O O
sequence O O
was O O
sufficient O O
to O O
confer O O
p53 B B_GENE
- O O
dependent O O
activation O O
to O O
a O O
heterologous O O
promoter O O
and O O
p53 B B_GENE/B_LOCATION
was O O
capable O O
of O O
binding O O
to O O
this O O
sequence O O
as O O
assessed O O
by O O
gel O O
shift O O
analysis O O
. O O

The O O
embryology O O
of O O
the O O
vertebral O O
column O O
is O O
reviewed O O
briefly O O
, O O
and O O
the O O
origin O O
of O O
each O O
anomaly O O
of O O
the O O
C2 O O
vertebra O O
is O O
traced O O
to O O
one O O
of O O
the O O
two O O
early O O
stages O O
in O O
development O O
as O O
follows O O
: O O
1 O O
) O O
the O O
formation O O
of O O
the O O
mesenchymal O O
vertebra O O
or O O
2 O O
) O O
its O O
induction O O
to O O
cartilage O O
. O O

Parathyroid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hormone I B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
responses O O
of O O
cyclic O O
AMP O O
- O O
, O O
serum O O
- O O
and O O
phorbol O O
ester O O
- O O
responsive O O
reporter O O
genes O O
in O O
osteoblast O O
- O O
like O O
UMR O O
- O O
106 O O
cells O O
. O O

Our O O
results O O
strongly O O
suggest O O
that O O
activation O O
of O O
the O O
beta O O
origin O O
by O O
a O O
distant O O
replication O O
enhancer O O
element O O
requires O O
a O O
small O O
target O O
sequence O O
essential O O
for O O
initiator O O
protein O O
- O O
mediated O O
DNA O O
looping O O
. O O

HNF4alpha7 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
also O O
found O O
in O O
totipotent O O
embryonic O O
stem O O
cells O O
. O O

Penicillamine O O
- O O
induced O O
myasthenia O O
gravis O O
associated O O
with O O
antibodies O O
to O O
acetylcholine B B_GENE
receptor I I_GENE
. O O

A O O
. O O

A O O
significant O O
increase O O
of O O
gastric O O
mucosal O O
permeability O O
was O O
observed O O
in O O
six O O
normal O O
human O O
subjects O O
after O O
instillation O O
of O O
ethanol O O
( O O
20 O O
percent O O
v O O
/ O O
v O O
) O O
. O O

Using O O
a O O
simulated O O
cough O O
machine O O
, O O
we O O
analyzed O O
the O O
effect O O
of O O
adding O O
tensio O O
- O O
active O O
liquids O O
as O O
sol O O
phase O O
simulant O O
on O O
the O O
clearance O O
of O O
gel O O
mucus O O
simulant O O
by O O
cough O O
. O O

First O O
, O O
the O O
amino O O
- O O
terminal O O
regulatory O O
arm O O
of O O
the O O
GDI B B_ENZYME[GENE]/B_BIO
binds O O
to O O
the O O
switch O O
I O O
and O O
II O O
domains O O
of O O
Cdc42 B B_GENE
leading O O
to O O
the O O
inhibition O O
of O O
both O O
GDP O O
dissociation O O
and O O
GTP O O
hydrolysis O O
. O O

By O O
a O O
combination O O
of O O
alternative O O
promoter O O
usage O O
and O O
exon O O
splicing O O
, O O
each O O
ROR B B_GENE
gene I I_GENE
generates O O
several O O
isoforms O O
that O O
differ O O
only O O
in O O
their O O
amino O O
terminus O O
. O O

Electrophoretic O O
mobility O O
- O O
shift O O
assays O O
showed O O
a O O
rapid O O
induction O O
of O O
nuclear O O
proteins O O
that O O
bound O O
to O O
the O O
consensus B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motif I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Analysis O O
of O O
larger O O
cDNA O O
clones O O
demonstrates O O
that O O
there O O
are O O
at O O
least O O
two O O
isoforms O O
of O O
RIP14 B B_GENE
that O O
differ O O
in O O
the O O
N O O
- O O
terminal O O
( O O
A O O
and O O
B O O
) O O
and O O
hinge O O
( O O
D O O
) O O
domains O O
. O O

Multiple O O
copies O O
of O O
this O O
binding O O
site O O
are O O
found O O
in O O
the O O
viral O O
genomes O O
. O O

In O O
contrast O O
, O O
the O O
tail O O
deviated O O
ipsilaterally O O
in O O
cats O O
with O O
a O O
hemisection O O
, O O
and O O
the O O
tail O O
was O O
ventroflexed O O
in O O
cats O O
with O O
a O O
transection O O
. O O

The O O
major O O
open O O
reading O O
frame O O
of O O
the O O
cDNA O O
predicts O O
a O O
protein O O
of O O
59 O O
kD O O
, O O
with O O
a O O
leucine O O
zipper O O
situated O O
adjacent O O
to O O
an O O
myc B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
has O O
been O O
proposed O O
to O O
assume O O
a O O
helix O O
- O O
loop O O
- O O
helix O O
structure O O
. O O

This O O
residue O O
, O O
although O O
located O O
55 O O
rather O O
than O O
35 O O
residues O O
NH2 O O
- O O
terminal O O
of O O
the O O
essential O O
glutamate O O
, O O
is O O
undoubtedly O O
the O O
analog O O
of O O
the O O
second O O
aspartate O O
of O O
the O O
Asp O O
- O O
Asp O O
- O O
35 O O
- O O
Glu O O
motif O O
found O O
in O O
other O O
family O O
members O O
. O O

The O O
PEP4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
isolated O O
from O O
a O O
genomic O O
DNA O O
library O O
by O O
complementation O O
of O O
the O O
pep4 B B_GENE/B_TIME[MEASURE]
- I I_GENE/I_TIME[MEASURE]
3 I I_GENE/I_TIME[MEASURE]
mutation O O
. O O

A O O
gene O O
with O O
a O O
high O O
degree O O
of O O
sequence O O
identity O O
with O O
mammalian B B_GENE/B_BIO
ADP I I_GENE/I_BIO
- I I_GENE/I_BIO
ribosylation I I_GENE/I_BIO
factors I I_GENE/I_BIO
( O O
ARFs B B_DISEASE/B_GENE
) O O
, O O
believed O O
to O O
be O O
important O O
in O O
vesicular O O
transport O O
, O O
was O O
identified O O
. O O

Off O O
- O O
shell O O
effect O O
in O O
Rydberg O O
- O O
atom O O
- O O
alkali O O
- O O
metal O O
- O O
atom O O
scattering O O
. O O

Short O O
- O O
term O O
growth O O
: O O
rhythms O O
, O O
chaos O O
, O O
or O O
noise O O
? O O

Association O O
between O O
diaphragm O O
use O O
and O O
asymptomatic O O
bacteriuria O O
. O O

The O O
effect O O
of O O
iron O O
on O O
the O O
toxigenicity O O
of O O
Vibrio O O
cholerae O O
. O O

The O O
Tat B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coded O O
by O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
is O O
a O O
strong O O
activator O O
of O O
viral O O
gene O O
expression O O
from O O
the O O
long O O
terminal O O
repeat O O
( O O
LTR O O
) O O
. O O

Is O O
it O O
time O O
for O O
a O O
wine O O
trial O O
? O O

The O O
average O O
coefficient O O
of O O
variation O O
between O O
assays O O
for O O
gas O O
chromatography O O
mass O O
spectrometry O O
was O O
5 O O
. O O
8 O O
% O O
and O O
for O O
radioimmunoassay O O
was O O
12 O O
. O O
3 O O
% O O
, O O
while O O
the O O
average O O
coefficient O O
of O O
variation O O
within O O
assays O O
for O O
gas O O
chromatography O O
mass O O
spectrometry O O
was O O
4 O O
. O O
9 O O
% O O
and O O
for O O
radioimmunoassay O O
6 O O
. O O
9 O O
% O O
. O O

Macrophages O O
: O O
modulators O O
of O O
immunity O O
. O O

Production O O
of O O
VT O O
was O O
also O O
examined O O
retrospectively O O
in O O
32 O O
E O O
. O O
coli O O
strains O O
of O O
serotype O O
O26 O O
: O O
H11 O O
isolated O O
from O O
children O O
with O O
diarrhoea O O
; O O
eight O O
( O O
25 O O
% O O
) O O
of O O
them O O
produced O O
moderate O O
to O O
high O O
levels O O
of O O
verotoxin B B_DISEASE/B_PROTEIN[GENE]
1 I B_DISEASE/I_PROTEIN[GENE]
despite O O
several O O
years O O
storage O O
in O O
vitro O O
. O O

Serum O O
pituitary O O
and O O
steroid O O
hormone O O
levels O O
in O O
the O O
adult O O
male O O
: O O
one O O
value O O
is O O
as O O
good O O
as O O
the O O
mean O O
of O O
three O O
. O O

The O O
sections O O
were O O
stained O O
with O O
anti O O
- O O
polymorphonuclear O O
leukocyte O O
antibody O O
, O O
the O O
endothelial O O
marker O O
factor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
VIII I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
related I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antigen I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
with O O
hematoxylin O O
and O O
eosin O O
. O O

Mapping O O
of O O
the O O
region O O
in O O
KAP B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
1 I I_GENE/I_LOCATION
required O O
for O O
HP1 B B_GENE/B_MEASURE
interaction O O
showed O O
that O O
amino O O
acid O O
substitutions O O
which O O
abolish O O
HP1 B B_GENE/B_BIO
binding O O
in O O
vitro O O
reduce O O
KAP B B_GENE/B_PERSON
- I I_GENE/I_PERSON
1 I I_GENE/I_PERSON
mediated O O
repression O O
in O O
vivo O O
. O O

Promoter O O
activity O O
of O O
the O O
proliferating B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
cell I I_GENE/I_LOCATION
nuclear I I_GENE/I_LOCATION
antigen I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
is O O
associated O O
with O O
inducible O O
CRE B B_GENE
- I I_GENE
binding I I_GENE
proteins I I_GENE
in O O
interleukin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
stimulated O O
T O O
lymphocytes O O
. O O

METHODS O O
: O O
Levels O O
of O O
sIL B B_GENE
- I I_GENE
2R I I_GENE
were O O
measured O O
simultaneously O O
in O O
plasma O O
and O O
pleural O O
fluid O O
in O O
111 O O
patients O O
with O O
pleural O O
effusions O O
of O O
unknown O O
causes O O
. O O

The O O
GIS O O
software O O
program O O
, O O
ArcView O O
, O O
was O O
used O O
for O O
spatial O O
analysis O O
and O O
distance O O
calculations O O
. O O

chi2 O O
Tests O O
were O O
used O O
to O O
compare O O
the O O
distribution O O
of O O
the O O
characteristics O O
between O O
intersection O O
and O O
midblock O O
collisions O O
. O O

A O O
phase O O
II O O
study O O
was O O
initiated O O
to O O
evaluate O O
the O O
effect O O
of O O
a O O
combination O O
of O O
the O O
pure O O
L O O
- O O
isomer O O
of O O
LV O O
and O O
5 O O
- O O
FU O O
along O O
with O O
epirubicin O O
in O O
patients O O
with O O
advanced O O
pancreatic O O
cancer O O
. O O

RESULTS O O
: O O
After O O
3 O O
weeks O O
of O O
therapy O O
, O O
the O O
patient O O
had O O
an O O
increase O O
in O O
platelet O O
count O O
from O O
a O O
baseline O O
of O O
5 O O
, O O
000 O O
to O O
8 O O
, O O
000 O O
/ O O
microliter O O
to O O
a O O
maximal O O
level O O
of O O
33 O O
, O O
000 O O
/ O O
microliter O O
. O O

In O O
another O O
patient O O
, O O
IRPF O O
recurred O O
in O O
the O O
ureter O O
of O O
a O O
living O O
related O O
renal O O
graft O O
6 O O
months O O
after O O
transplantation O O
. O O

These O O
mutants O O
, O O
assayed O O
by O O
injection O O
into O O
Xenopus O O
oocyte O O
nuclei O O
, O O
delimit O O
the O O
promoter O O
to O O
36 O O
bp O O
of O O
DNA O O
upstream O O
of O O
the O O
cap O O
site O O
and O O
73 O O
bp O O
of O O
the O O
untranslated O O
mRNA O O
leader O O
. O O

Upstream O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
metalloproteinases I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TIMP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
novel O O
and O O
essential O O
regulatory O O
DNA O O
motif O O
in O O
the O O
human B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
TIMP I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
1 I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
promoter I B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
directly O O
interacts O O
with O O
a O O
30 O O
- O O
kDa O O
nuclear O O
protein O O
. O O

The O O
results O O
of O O
these O O
experiments O O
indicated O O
that O O
charcoal O O
, O O
imbiber O O
beads O O
, O O
and O O
the O O
anion O O
exchanges O O
resins O O
, O O
Dowex O O
XFS O O
- O O
4022 O O
and O O
Dowex O O
SBR O O
- O O
C1 O O
, O O
would O O
not O O
be O O
useful O O
agents O O
for O O
increasing O O
the O O
amount O O
of O O
dieldrin O O
eliminated O O
via O O
feces O O
( O O
droppings O O
) O O
of O O
chickens O O
. O O

The O O
receptor O O
for O O
CSF B B_GENE
- I I_GENE
1 I I_GENE
, O O
c B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Fms I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
expressed O O
in O O
osteoclasts O O
, O O
possesses O O
intrinsic O O
tyrosine B B_ENZYME[GENE]
- I I_ENZYME[GENE]
kinase I I_ENZYME[GENE]
activity O O
, O O
and O O
signals O O
via O O
rapid O O
phosphorylation O O
of O O
selected O O
proteins O O
. O O

Adaptive O O
effects O O
of O O
repeated O O
immersion O O
exposure O O
on O O
the O O
human O O
body O O

To O O
this O O
end O O
we O O
generated O O
a O O
detailed O O
physical O O
map O O
of O O
the O O
genomic O O
region O O
spanning O O
between O O
sequence O O
- O O
tagged O O
site O O
markers O O
D16S518 B B_GENE
and O O
D16S516 B B_GENE
. O O

We O O
have O O
found O O
that O O
pro B B_GENE
- I I_GENE
IGF I I_GENE
- I I_GENE
2 I I_GENE
can O O
initially O O
form O O
two O O
disulfide O O
isomers O O
that O O
undergo O O
rearrangement O O
to O O
a O O
single O O
conformation O O
in O O
vivo O O
. O O

While O O
working O O
on O O
the O O
toxicity O O
of O O
war O O
gases O O
. O O

The O O
existence O O
of O O
a O O
TFIIIB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
assembly O O
pathway O O
leading O O
to O O
the O O
faithful O O
transcription O O
of O O
natural O O
eukaryotic O O
tRNA O O
genes O O
in O O
the O O
absence O O
of O O
TFIIIC B B_GENE
provides O O
novel O O
insights O O
into O O
the O O
functional O O
flexibility O O
of O O
the O O
eukaryotic O O
tRNA O O
gene O O
transcription O O
machinery O O
and O O
on O O
its O O
evolution O O
from O O
an O O
ancestral O O
RNA B B_GENE
polymerase I I_GENE
III I I_GENE
system O O
relying O O
on O O
upstream O O
, O O
TATA O O
- O O
centered O O
control O O
elements O O
. O O

Ectopic O O
Xbra B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O O
induce O O
Xegr B B_GENE
- I I_GENE
1 I I_GENE
transcription O O
by O O
an O O
indirect O O
mechanism O O
that O O
appears O O
to O O
operate O O
via O O
primary O O
activation O O
of O O
fibroblast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
growth I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
secretion O O
. O O

A O O
rapid O O
mixing O O
device O O
for O O
quasielastic O O
light O O
scattering O O
studies O O
of O O
reacting O O
systems O O
. O O

These O O
aa O O
residues O O
correspond O O
to O O
codons O O
59 O O
and O O
108 O O
in O O
the O O
P B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
falciparum I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DHFR I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
active I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
site I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
which O O
similar O O
aa O O
substitutions O O
( O O
Cys O O
Arg O O
- O O
59 O O
and O O
Ser O O
Asn O O
- O O
108 O O
) O O
are O O
associated O O
with O O
pyrimethamine O O
resistance O O
. O O

Of O O
all O O
YASR O O
syndromes O O
, O O
the O O
highest O O
stability O O
was O O
for O O
the O O
Anxious O O
/ O O
Depressed O O
scale O O
. O O

Here O O
we O O
investigate O O
the O O
mechanism O O
of O O
TPA O O
induction O O
of O O
FGF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BP I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O O
expression O O
in O O
the O O
human O O
ME O O
- O O
180 O O
SCC O O
cell O O
line O O
. O O

Between O O
the O O
RNA O O
initiation O O
site O O
and O O
the O O
coding O O
region O O
is O O
a O O
GC O O
- O O
rich O O
hairpin O O
structure O O
followed O O
by O O
8 O O
T O O
residues O O
that O O
looks O O
like O O
a O O
rho B B_GENE/B_LOCATION
- I I_GENE/I_LOCATION
independent I I_GENE/I_LOCATION
transcription I I_GENE/I_LOCATION
terminator I I_GENE/I_LOCATION
. O O

Conversely O O
the O O
rate O O
of O O
bioavailability O O
was O O
significantly O O
different O O
, O O
because O O
from O O
the O O
Reference O O
patch O O
the O O
release O O
rate O O
is O O
fast O O
in O O
the O O
first O O
24 O O
h O O
, O O
leading O O
to O O
an O O
E2 O O
peak O O
at O O
8 O O
h O O
and O O
to O O
a O O
Cmax O O
in O O
average O O
at O O
23 O O
h O O
. O O

3 O O
) O O
The O O
progress O O
of O O
fibrinolysis O O
was O O
observed O O
by O O
serial O O
collection O O
of O O
middle O O
ear O O
fluid O O
in O O
the O O
same O O
side O O
ear O O
of O O
5 O O
cases O O
out O O
of O O
17 O O
cases O O
having O O
much O O
activity O O
for O O
fibrin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
degradation O O
, O O
and O O
lowering O O
of O O
fibrinolytic O O
activity O O
was O O
revealed O O
in O O
4 O O
out O O
of O O
these O O
5 O O
cases O O
as O O
the O O
result O O
. O O

Thus O O
G17 B B_GENE
targets O O
the O O
c B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
fos I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
promoter I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
CArG I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
sequence I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
via O O
Rho B B_GENE
A I I_GENE
- O O
dependent O O
pathways O O
, O O
and O O
Rho B B_GENE/B_TIME[MEASURE]
A I I_GENE/I_TIME[MEASURE]
appears O O
to O O
play O O
an O O
important O O
role O O
in O O
the O O
regulation O O
of O O
the O O
trophic O O
action O O
of O O
G17 B B_GENE
. O O

In O O
each O O
patient O O
, O O
MBF O O
was O O
quantified O O
in O O
the O O
three O O
major O O
vascular O O
territories O O
: O O
the O O
left O O
anterior O O
descending O O
and O O
left O O
circumflex O O
coronary O O
artery O O
territories O O
and O O
the O O
right O O
coronary O O
artery O O
( O O
control O O
region O O
) O O
territory O O
. O O

These O O
results O O
demonstrate O O
that O O
m2 B B_GENE
receptors I I_GENE
couple O O
to O O
both O O
G B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
i2 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
G B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
i3 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O O
and O O
that O O
this O O
interaction O O
is O O
integral O O
to O O
both O O
positive O O
and O O
negative O O
regulatory O O
pathways O O
leading O O
to O O
activation O O
of O O
PLC B B_GENE/B_DISEASE
and O O
desensitization O O
of O O
receptor O O
signaling O O
. O O

Platelet O O
count O O
and O O
plasma O O
volume O O
were O O
significantly O O
higher O O
in O O
group O O
A O O
than O O
in O O
group O O
B O O
throughout O O
pregnancy O O
. O O

The O O
fru B B_GENE/B_MEASURE
gene I I_GENE/I_MEASURE
has O O
seven O O
exons O O
spanning O O
15 O O
- O O
kb O O
encoding O O
two O O
transcripts O O
with O O
ORFs O O
of O O
841 O O
and O O
695 O O
amino O O
acids O O
. O O

The O O
human O O
RIL B B_GENE
gene I I_GENE
: O O
mapping O O
to O O
human O O
chromosome O O
5q31 O O
. O O
1 O O
, O O
genomic O O
organization O O
and O O
alternative O O
transcripts O O
. O O

